

000950170-25-01583910-Q Canopy Growth Corp 2025020720250207064533064534064534 0 0000950170-25-015839 10-Q 132 20241231 20250207 20250207 Canopy Growth Corp
0001737927 2833 000000000 Qa 0331 10-Q 34-001-38496 25599233 1 HERSHEY DRIVE SMITH FALLS A6 K7A0A8 855-558-9333 1 HERSHEY DRIVE SMITH FALLS A6 K7A0A8 10-Q 1 cgc-
20241231.htm 10-Q 10-Q 0001737927falseQ3--03-31202500-
00000000.1http://www.canopygrowth.com/20241231#ComprehensiveIncomeLossNetOfTaxFromDiscontinuedOperationsIncludingPortionAttributableToNoncontrollingInteresthttp://www.canopyg
12-092024-12-090001737927cgc:PaydownAgreementMembercgc:CreditFacilityMember2023-04-172023-04-170001737927cgc:AcreegeDebtOptionAgreementMember2024-12-
310001737927cgc:InternationalMarketsCannabisMember2024-10-012024-12-310001737927cgc:RangeTwoMember2024-12-
310001737927srt:MaximumMembercgc:OmnibusEquityIncentivePlanMember2023-09-252023-09-250001737927cgc:WanaMember2024-04-300001737927cgc:WanaMember2024-10-242022-10-
240001737927cgc:InternationalMarketsCannabisMember2023-10-012023-12-3100017379272022-10-242022-10-240001737927cgc:CanopyUsaMember2024-04-302024-04-
300001737927cgc:JettyMemberus-gaap:StockOptionMember2024-03-3100017379272023-03-310001737927cgc:AcreegeTaxReceivableAgreementMembercgc:OtherMember2024-04-012024-12-
310001737927cgc:JettyMemberus-gaap:StockOptionMember2024-04-012024-12-310001737927cgc:AcreegeHoldingsIncMember2022-11-152022-11-
150001737927cgc:CanadaCannabisMember2024-10-012024-12-3100017379272020-08-102020-09-0900017379272024-04-012024-06-300001737927us-
gaap:AccumulatedOtherComprehensiveIncomeMember2024-04-012024-12-310001737927cgc:CanadianMedicalCannabisNetRevenueMembercgc:CanadianAdultUseCannabisMember2024-10-
012024-12-310001737927us-gaap:OfficeEquipmentMember2024-12-310001737927cgc:AcreegeDebtOptionAgreementMembercgc:OtherLenderMember2024-12-310001737927us-
gaap:EmployeeStockOptionMember2023-10-012023-12-310001737927cgc:CredifacilityMember2021-03-180001737927cgc:OtherIssuesAndShareIssueCostsMember2024-04-012024-12-
310001737927cgc:AtTheMarketEquityProgramMember2023-10-012023-12-310001737927us-gaap:EmployeeStockOptionMember2024-10-012024-12-3100017379272024-03-310001737927us-
gaap:FairValueInputsLevel3Membercgc:CanopyUsaEquityMethodInvestmentExpectedFutureCashFlowsMember2024-04-012024-12-310001737927us-gaap:RetainedEarningsMember2023-10-
012023-12-310001737927us-gaap:NoncontrollingInterestMember2024-03-310001737927cgc:CanopyUsaMember2024-04-012024-12-310001737927us-
gaap:AccumulatedGainLossFinancialLiabilityFairValueOptionAttributableToParentMember2023-03-3100017379272022-06-222022-06-220001737927cgc:CredifacilityMember2024-10-162024-
10-160001737927us-gaap:CommonStockMember2023-03-310001737927cgc:StorzbickelMember2024-04-012024-12-310001737927cgc:AtTheMarketEquityProgramMember2024-12-
310001737927cgc:SharebasedReserveMemberus-gaap:AdditionalPaidInCapitalMember2023-12-310001737927cgc:BioSteelMember2024-03-310001737927cgc:OwnershipChangesMemberus-
gaap:AdditionalPaidInCapitalMember2024-09-3000017379272023-09-252023-09-250001737927cgc:OwnershipChangesMemberus-gaap:AdditionalPaidInCapitalMember2023-03-
310001737927us-gaap:CommonStockMembercgc:AcreegeAcquisitionMember2024-12-090001737927cgc:CanadianAdultUseCannabisMembercountry:CA2024-10-012024-12-
310001737927cgc:BioSteelMember2023-12-310001737927cgc:EntityOtherMembercgc:VariousMember2024-04-012024-12-310001737927us-gaap:WarrantMemberus-
gaap:AdditionalPaidInCapitalMember2024-09-300001737927cgc:InternationalMarketsCannabisMember2023-04-012023-12-310001737927cgc:SoftwareAndDomainNamesMember2024-12-
310001737927country:DE2023-04-012023-12-310001737927us-gaap:AssetUnderConstructionMember2024-03-310001737927cgc:DistributionChannelMember2024-03-
310001737927cgc:CanopyUsaMember2024-04-300001737927us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-07-012024-09-300001737927us-gaap:WarrantMemberus-
gaap:AdditionalPaidInCapitalMember2023-09-300001737927cgc:ThirdQuarterTwoThousandAndTwentyFourPaydownsMembercgc:CredifacilityMember2023-10-012023-12-
310001737927cgc:AtTheMarketEquityProgramMember2024-04-012024-12-310001737927us-gaap:FairValueInputsLevel3Membercgc:ElevateLoanReceivableMember2024-04-012024-12-
310001737927cgc:ExchangeableSharesMember2024-03-310001737927cgc:April2024ExchangeAgreementMember2024-04-1800017379272023-10-012023-12-310001737927country:DE2024-
03-310001737927us-gaap:FairValueMeasurementsRecurringMember2024-12-310001737927cgc:CanopyUSAAssetsMember2023-04-012023-12-310001737927cgc:BioSteelMember2023-09-
140001737927cgc:SupremeConvertibleDebenturesMember2024-12-310001737927cgc:OtherNoncontrollingInterestMember2024-04-012024-12-
310001737927cgc:AcreegeTaxReceivableAgreementMembercgc:OtherMember2024-03-310001737927us-gaap:CommonStockMembercgc:AcreegeAcquisitionMember2024-12-092024-12-
090001737927cgc:BioSteelUSMember2024-12-310001737927cgc:StockOptionSubjectToPerformanceConditionsMember2024-04-012024-12-
310001737927cgc:AcreegeHoldingsIncMember2022-10-242022-10-240001737927us-gaap:LandMember2024-12-310001737927cgc:OwnershipChangesMemberus-
gaap:AdditionalPaidInCapitalMember2024-03-310001737927srt:MaximumMember2023-04-012023-12-310001737927us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-10-012023-
12-310001737927cgc:ReorganizationAmendmentsMembersr:MinimumMemberus-gaap:CommonClassBMember2023-05-192023-05-190001737927country:CA2024-03-
310001737927cgc:TerrAscendCommonSharesMember2024-06-040001737927cgc:StorzbickelMember2024-10-012024-12-310001737927cgc:InternationalMarketsCannabisMember2023-04-
012023-12-3100017379272020-09-082020-09-090001737927cgc:DebentureMembercgc:AcreegeHempcoI Member2024-04-012024-12-310001737927country:US2024-04-012024-12-
310001737927cgc:RedeemableNonControllingInterestsMemberus-gaap:AdditionalPaidInCapitalMember2023-03-310001737927us-gaap:FairValueInputsLevel3Member2024-04-012024-12-
310001737927srt:MaximumMember2020-08-102020-09-090001737927cgc:OtherNoncontrollingInterestMember2023-03-310001737927us-gaap:EmployeeStockOptionMember2023-04-012023-
12-310001737927cgc:HSCPHoldersPursuantToAmendedTRAMemberus-gaap:CommonStockMember2022-10-242022-10-240001737927cgc:CanadianMedicalCannabisMembercountry:CA2023-
04-012023-12-310001737927cgc:WanaMemberus-gaap:StockOptionMember2024-03-310001737927cgc:RangeOneMember2024-04-012024-12-310001737927cgc:OwnershipChangesMemberus-
gaap:AdditionalPaidInCapitalMember2023-07-012023-09-3000017379272024-04-012024-12-310001737927cgc:TerrAscendCommonSharesMember2024-12-
310001737927cgc:TerrAscendWarrantsMember2024-06-040001737927cgc:OtherNoncontrollingInterestMember2023-12-310001737927cgc:CredifacilityMember2023-07-
130001737927cgc:MaiTwoThousandAndTwentyFourConvertible

\$ 15,822,414, \$ 23,332,414 Total current assets \$ 341,085,414 \$ 371,180,414 Equity method investments \$ 49,834,414 \$ - Other financial assets \$ 321,368,414 \$ 437,629,414
 Property, plant and equipment \$ 299,604,414 \$ 320,103,414 Intangible assets \$ 89,791,414 \$ 104,053,414 Goodwill \$ 44,093,414 \$ 43,239,414 Other assets \$ 18,444,414 \$ 24,126,414
 Total assets \$ 1,164,219,414 \$ 1,300,330,414 \$ - \$ - LIABILITIES AND SHAREHOLDERS' EQUITY Current liabilities: \$ - \$ - Accounts payable \$ 28,918,414 \$ 28,673,414
 Other accrued expenses and liabilities \$ 37,191,414 \$ 54,039,414 Current portion of long-term debt \$ 3,167,414 \$ 103,935,414 Other liabilities \$ 27,740,414 \$ 48,068,414
 Total current liabilities \$ 97,016,414 \$ 234,715,414 Long-term debt \$ 438,404,414 \$ 493,294,414 Other liabilities \$ 37,324,414 \$ 71,814,414 Total liabilities \$ 572,744,414 \$ 799,823,414
 Commitments and contingencies \$ - \$ - Canopy Growth Corporation shareholders' equity: \$ - \$ - Share capital \$ - \$ - Common shares - \$nil par value; Authorized - unlimited; Issued and \$ - outstanding - 129,153,014 shares and 91,115,501 shares, respectively. \$ - \$ - Exchangeable shares - \$nil par value; Authorized - unlimited; Issued \$ - and \$ - outstanding - 26,261,474 shares and nil shares, respectively. \$ - \$ - 8,670,494 \$ - \$ 8,244,301 Additional paid-in capital \$ 2,637,337 \$ 2,602,148 Accumulated other comprehensive loss \$ (8,999) \$ (16,051) Deficit \$ (10,707,357) \$ (10,330,030) Total Canopy Growth Corporation shareholders' equity \$ 591,475 \$ 500,368
 Noncontrolling interests \$ - \$ 139 Total shareholders' equity \$ 591,475 \$ 500,507 Total liabilities and shareholders' equity \$ 1,164,219 \$ 1,300,330 The accompanying notes are an integral part of these condensed interim consolidated financial statements. 1 CANOPY GROWTH CORPORATION CONDENSED INTERIM CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (in thousands of Canadian dollars, except number of shares and per share data, unaudited) \$ - Three months ended December 31, \$ - Nine months ended December 31, \$ - \$ 2024 \$ 2023 \$ 2024 \$ 2023 \$ 2024 \$ 2023 Revenue \$ 86,244 \$ 90,061 \$ 235,985 \$ 260,781 Excise taxes \$ 11,483 \$ 11,556 \$ 32,021 \$ 36,423 Net revenue \$ 74,761 \$ 78,505 \$ 203,964 \$ 224,358 Cost of goods sold \$ 50,663 \$ 50,279 \$ 134,997 \$ 158,944 Gross margin \$ 24,098 \$ 28,226 \$ 68,967 \$ 65,414 Operating expenses \$ - \$ - \$ - \$ - Selling, general and administrative expenses \$ 41,476 \$ 54,436 \$ 131,174 \$ 174,810 Share-based compensation \$ 5,159 \$ 3,693 \$ 14,531 \$ 10,127 Loss on asset impairment and restructuring \$ 1,858 \$ 30,413 \$ 22,135 \$ 2,452 Total operating expenses \$ 47,920 \$ 88,542 \$ 167,840 \$ 187,389 Operating loss from continuing operations \$ (23,822) \$ (60,316) \$ (98,873) \$ (121,975) Other income (expense), net \$ (97,758) \$ (171,037) \$ (276,952) \$ (253,270) Loss from continuing operations before income taxes \$ (121,580) \$ (231,353) \$ (375,825) \$ (439,007) Income tax (expense) recovery \$ (316) \$ 1,077 \$ (6,812) \$ (13,762) Net loss from continuing operations \$ (121,896) \$ (230,276) \$ (382,637) \$ (439,007) Discontinued operations, net of income tax \$ - \$ - \$ 13,479 \$ 5,310 \$ (194,451) Net loss \$ (121,896) \$ (216,797) \$ (377,327) \$ (583,458) Discontinued operations attributable to noncontrolling interests and redeemable noncontrolling interest \$ - \$ - \$ - \$ - \$ - \$ - \$ - \$ - Net loss attributable to Canopy Growth Corporation \$ (121,896) \$ (216,797) \$ (377,327) \$ (583,458) \$ - \$ - \$ - \$ - Basic and diluted loss per share \$ - \$ - \$ - \$ - Continuing operations \$ (1.11) \$ (2.78) \$ (4.15) \$ (5.56) Discontinued operations \$ - \$ - \$ - \$ - \$ 0.16 \$ 0.06 \$ (2.52) Basic and diluted loss per share \$ (1.11) \$ (2.62) \$ (4.09) \$ (5.08) Basic and diluted weighted average common shares \$ 110,306,430 \$ 82,919,190 \$ 92,172,660 \$ 69,918,744 \$ - \$ - \$ - \$ - Comprehensive income (loss): \$ - \$ - \$ - \$ - Net loss from continuing operations \$ (121,896) \$ (230,276) \$ (382,637) \$ (439,007) Other comprehensive income (loss), net of income tax \$ - \$ - \$ - \$ - Fair value changes of own credit risk of financial liabilities \$ - \$ - \$ (1,354) \$ (1,354) \$ - \$ - \$ (1,324) Foreign currency translation \$ (1,162) \$ 10,104 \$ 3,586 \$ 575 Total other comprehensive income (loss), net of income tax \$ (1,162) \$ 8,750 \$ 3,586 \$ 575 \$ (1,249) Comprehensive loss from continuing operations \$ (123,058) \$ (221,526) \$ (379,051) \$ (402,256) Comprehensive income (loss) from discontinued operations \$ - \$ - \$ - \$ - \$ (13,479) \$ 5,310 \$ (194,451) Comprehensive loss \$ (123,058) \$ (221,526) \$ (379,051) \$ (402,256) Comprehensive loss attributable to Canopy Growth Corporation \$ (123,058) \$ (221,526) \$ (379,051) \$ (402,256) \$ - \$ - \$ - \$ - Comprehensive loss attributable to noncontrolling interests and redeemable noncontrolling interest \$ - \$ - \$ - \$ - \$ - \$ - \$ - \$ - Comprehensive loss attributable to Canopy Growth Corporation \$ (123,058) \$ (221,526) \$ (379,051) \$ (402,256) \$ - \$ - \$ - \$ - The accompanying notes are an integral part of these condensed interim consolidated financial statements. 2 CANOPY GROWTH CORPORATION CONDENSED INTERIM CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY (in thousands of Canadian dollars, unaudited) \$ - Nine months ended December 31, 2024 \$ - \$ - \$ - Additional paid-in capital \$ - \$ - \$ - Accumulated \$ - \$ - \$ - \$ - Share capital \$ - \$ - \$ - Share-based reserve \$ - \$ - Warrants \$ - \$ - Ownership changes \$ - \$ - other comprehensive income (loss) \$ - \$ - Deficit \$ - \$ - Noncontrolling interests \$ - \$ - Total \$ - \$ - Balance at March 31, 2024 \$ 8,244,301 \$ 514,578 \$ 2,610,519 \$ (522,949) \$ (16,051) \$ (10,330,030) \$ 139 \$ 500,507 Common shares issued from ATM Program \$ 46,291 \$ - \$ - \$ - \$ - \$ - \$ - \$ - Exercise of warrants \$ 10,265 \$ - \$ - \$ (2,702) \$ - \$ - \$ - \$ - Share-based compensation \$ 4,151 \$ - \$ - \$ - \$ - \$ - \$ - \$ - Issuance and vesting of restricted share units and performance share units \$ 2,596 \$ - \$ - \$ (2,596) \$ - \$ - \$ - \$ - Extinguishment of promissory note and issuance of exchangeable shares \$ 8,220 \$ 8,005 \$ - \$ - \$ - \$ - \$ - \$ - Canopy USA Transaction \$ 12,452 \$ - \$ - \$ - \$ - \$ - \$ - \$ - Comprehensive loss \$ - \$ - \$ - \$ - \$ - \$ - \$ - \$ - Comprehensive loss \$ - \$ - \$ - \$ - \$ - \$ - \$ - \$ - Balance at June 30, 2024 \$ 8,393,936 \$ 524,138 \$ 2,616,514 \$ (522,949) \$ (21,548) \$ (10,457,168) \$ - \$ 532,923 Common shares issued from ATM Program \$ 92,185 \$ - \$ - \$ - \$ - \$ - \$ - \$ - Exercise of warrants \$ 1,207 \$ - \$ - \$ (316) \$ - \$ - \$ - \$ - Exercise of Previous Equity Incentive Plan stock options \$ 238 \$ - \$ - \$ (126) \$ - \$ - \$ - \$ - Share-based compensation \$ 112 \$ - \$ - \$ 5,221 \$ - \$ - \$ - \$ - Issuance and vesting of restricted share units and performance share units \$ 2,635 \$ - \$ - \$ (2,635) \$ - \$ - \$ - \$ - Comprehensive loss \$ - \$ - \$ - \$ - \$ - \$ - \$ - \$ - Balance at September 30, 2024 \$ 8,490,670 \$ 527,242 \$ 2,616,198 \$ (522,949) \$ (16,032) \$ (10,585,461) \$ - \$ 509,668 Common shares issued from ATM Program \$ 117,513 \$ - \$ - \$ - \$ - \$ - \$ - \$ - Exercise of Previous Equity Incentive Plan stock options \$ 70 \$ - \$ - \$ (70) \$ - \$ - \$ - \$ - Issuance and vesting of restricted share units and performance share units \$ 182 \$ - \$ - \$ - \$ - \$ - \$ - \$ - Disposal and liquidation of consolidated entities \$ 8,195 \$ - \$ - \$ - \$ - \$ - \$ - \$ - Comprehensive loss \$ - \$ - \$ - \$ - \$ - \$ - \$ - \$ - Balance at December 31, 2024 \$ 8,670,494 \$ 532,149 \$ 2,628,137 \$ (522,949) \$ (8,999) \$ (10,707,357) \$ - \$ 591,475 The accompanying notes are an integral part of these condensed interim consolidated financial statements. 3 CANOPY GROWTH CORPORATION CONDENSED INTERIM CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY (in thousands of Canadian dollars, unaudited) \$ - Nine months ended December 31, 2023 \$ - \$ - \$ - Additional paid-in capital \$ - \$ - \$ - Accumulated \$ - \$ - \$ - \$ - Share capital \$ - \$ - \$ - Share-based reserve \$ - \$ - Warrants \$ - \$ - Ownership changes \$ - \$ - Redeemable noncontrolling interest \$ - \$ - other comprehensive income (loss) \$ - \$ - Deficit \$ - \$ - Noncontrolling interests \$ - \$ - Total \$ - \$ - Balance at March 31, 2023 \$ 7,938,571 \$ 498,150 \$ 2,581,788 \$ (521,961) \$ (51,492) \$ (13,860) \$ (9,672,761) \$ 1,587 \$ 760,022 Other issuances of common shares and warrants \$ 120,470 \$ - \$ - \$ - \$ - \$ - \$ - \$ - Share-based compensation \$ - \$ - \$ - \$ 3,716 \$ - \$ - \$ - \$ - Issuance and vesting of restricted share units and performance share units \$ 2,718 \$ - \$ - \$ - \$ - \$ - \$ - \$ - Changes in redeemable noncontrolling interest \$ - \$ - \$ - \$ - \$ - \$ - \$ - \$ - Redemption of redeemable noncontrolling interest \$ - \$ - \$ - \$ - \$ - \$ - \$ - \$ - Comprehensive income (loss) \$ - \$ - \$ - \$ - \$ - \$ - \$ - \$ - Balance at June 30, 2023 \$ 8,065,281 \$ 495,626 \$ 2,581,788 \$ (522,142) \$ (55,232) \$ (8,509) \$ (9,710,882) \$ 1,575 \$ 847,505 Private Placement, net of issuance costs \$ 12,836 \$ - \$ - \$ 9,820 \$ 8,977 \$ - \$ - \$ - Other issuances of common shares and warrants \$ 132,553 \$ (80) \$ - \$ - \$ - \$ - \$ - \$ - Exercise of Previous Equity Incentive Plan stock options \$ 165 \$ (165) \$ - \$ - \$ - \$ - \$ - \$ - Share-based compensation \$ - \$ - \$ - \$ 2,718 \$ - \$ - \$ - \$ - Issuance and vesting of restricted share units and performance share units \$ 561 \$ - \$ - \$ - \$ - \$ - \$ - \$ - Changes in redeemable noncontrolling interest \$ - \$ - \$ - \$ - \$ - \$ - \$ - \$ - Ownership changes relating to noncontrolling interests, net \$ - \$ - \$ - \$ - \$ - \$ - \$ - \$ - Redemption of redeemable noncontrolling interest \$ 8,450 \$ - \$ - \$ (807) \$ - \$ - \$

Company’s ability to continue as a going concern for at least twelve months from the issuance of those condensed interim consolidated financial statements, due to certain material debt obligations coming due in the short-term, recurring losses from operations and additional required financing to fund its business and operations.As of the filing of the Annual Report, the Company had been able to successfully mitigate the substantial doubt by completing several balance sheet actions as further described in the Annual Report. During the nine months ended December 31, 2024, the Company completed additional actions and established the ATM Program (as defined below), issued and sold an aggregate of 39,519,029 common shares for gross proceeds of \$255,989 under the ATM Program (see Note 19), amended the terms of the Credit Facility (as defined below) thereby extending the maturity date of the Credit Facility, made a mandatory US\$100,000 prepayment of the Credit Facility, which significantly reduced the Company’s short-term debt obligation, received additional proceeds from the liquidation and sale of assets of BioSteel Canada (as defined below), and entered into an amended facility lease, which is expected to reduce the Company’s potential lease payment obligation.The Company continues to evaluate different strategies and may pursue additional actions that are expected to further increase its liquidity position, including, but not limited to, pursuing additional actions to find cost-savings and seeking additional financing from both the public and private markets through the issuance of equity and/or debt securities. As a result of management’s plans 7 A above and the financial results of the Company at December 31, 2024, management concludes that the substantial doubt about the Company’s ability to continue as a going concern continues to be alleviated.Principles of consolidationThese condensed interim consolidated financial statements include the accounts of the Company and all entities in which the Company either has a controlling voting interest or is the primary beneficiary of a variable interest entity. All intercompany accounts and transactions have been eliminated on consolidation.Variable interest entitiesA variable interest entity (a“VIE”) is an entity that does not have sufficient equity at risk to finance its activities without additional subordinated financial support or is structured such that equity investors lack the ability to control the entity’s activities or do not substantially participate in the gains and losses of the entity. Upon inception of a contractual agreement, and thereafter, if a reconsideration event occurs, the Company performs an assessment to determine whether the arrangement contains a variable interest in an entity and whether that entity is a VIE. The primary beneficiary of a VIE is the party that has both the power to direct the activities that most significantly impact the VIE’s economic performance and the obligation to absorb losses or the right to receive benefits from the VIE that could potentially be significant to the VIE. Under ASC 810 “Consolidations, where the Company concludes that it is the primary beneficiary of a VIE, the Company consolidates the accounts of that VIE.Equity method investmentsEquity method investments include those investments where the Company: (i) can exercise significant influence over the other entity and (ii) holds common stock and/or in-substance common stock of the other entity. Unless the fair value method is elected, equity method investments are accounted for under the equity method. Under the equity method, investments are carried at cost, and subsequently adjusted for the Company’s share of net income (loss), comprehensive income (loss) and distributions received from the investee. If the current fair value of an investment falls below its carrying amount, this may indicate that an impairment loss should be recorded. Any impairment losses recognized are not reversed in subsequent periods.Use of estimatesThe preparation of these condensed interim consolidated financial statements and accompanying notes in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported. Actual results could differ from those estimates. Financial statement areas that require significant judgements and estimates are as follows:Allowance for credit losses - The assessment involves judgement and incorporates estimates of loss based on available information relevant to considering the collectability and includes consideration of economic and business conditions, default trends and other internal and external factors. The amount is subject to change based on experience and new information which could result in outcomes that require adjustment to the carrying amounts affecting future periods.Inventory reserves - The Company records inventory reserves based on the Company’s estimated forecast of product demand, production requirements, market conditions and regulatory environment. Actual losses may differ from management’s estimates.Estimated useful lives, impairment considerations, and amortization of property, plant and equipment and intangible assets - Amortization of capital and intangible assets is dependent upon estimates of useful lives based on management’s judgment.Goodwill and indefinite lived intangible asset impairment testing requires management to make estimates in the impairment testing model. On at least an annual basis, the Company tests whether goodwill and indefinite lived intangible assets are impaired. The reporting unit’s fair value is determined using a discounted future cash flow model, which incorporate assumptions regarding future events, specifically future cash flows, growth rates and discount rates.Impairment of long-lived assets is influenced by judgment in defining an asset group and determining the indicators of impairment, and estimates used to measure impairment losses.Legal proceedings - Judgement is used in determining the probability of incurring a loss in addition to determining the estimated amount. Amounts recorded are based on management’s judgement and actual amounts recorded may not be realized.Fair value measurement of financial instruments - The use of various valuation approaches described in Note 23 may involve uncertainties and determinations based on the Company’s judgment and any value estimated from these techniques may not be realized or realizable.Consolidation of variable interest entities - The determination of whether the Company is the primary beneficiary of a variable interest entity requires significant judgement. The assessment requires a qualitative analysis of power and benefits of the variable interest entity. 8 A Share ConsolidationOn December 13, 2023, the Company announced that the Company’s board of directors (the “Board”) had approved the consolidation of the Company’s issued and outstanding common shares on the basis of one post-consolidation common share for every 10 pre-consolidation common shares (the “Share Consolidation”). The Share Consolidation was implemented to ensure that the Company continues to comply with the listing requirements of the Nasdaq Global Select Market.The Share Consolidation was approved by the Company’s shareholders at the annual general and special meeting of shareholders held on September 25, 2023. The Share Consolidation became effective on December 15, 2023. No fractional common shares were issued in connection with the Share Consolidation. Any fractional common shares arising from the Share Consolidation were deemed to have been tendered by its registered owner to the Company for cancellation for no consideration. In addition, the exercise or conversion price and/or the number of common shares issuable under any of the Company’s outstanding convertible securities, were proportionately adjusted in connection with the Share Consolidation.All issued and outstanding common shares, per share amounts, and outstanding equity instruments and awards exercisable into common shares, as well as the exchange ratios for the Fixed Shares (as defined below) and the Floating Shares (as defined below) in connection with the Acreage Amended Arrangement (as defined below) and the Floating Share Arrangement (as defined below), respectively, contained in these condensed interim consolidated financial statements of the Company and notes thereto have been retroactively adjusted to reflect the Share Consolidation for all prior periods presented.New accounting policiesAccounting Guidance Not Yet AdoptedSegment ReportingIn November 2023, the Financial Accounting Standards Board (the “FASB”) issued ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures (a“ASU 2023-07”), which expands reportable segment disclosure requirements, primarily through enhanced disclosures about significant segment expenses that are regularly provided to the chief operating decision maker and included within each reported measure of segment profit or loss. ASU 2023-07 is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. The Company is evaluating the impact on the consolidated financial statements and expects to implement the provisions of ASU 2023-07 for its fiscal year ending March 31, 2025.Income TaxesIn December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures (a“ASU 2023-09”), which enhances income tax disclosures, primarily through changes to the rate reconciliation and disaggregation of income taxes paid. ASU 2023-09 is effective for annual periods beginning after December 15, 2024, with early adoption permitted. The Company is evaluating the impact on the consolidated financial statements and expects to implement the provisions of ASU 2023-09 for its fiscal year ending March 31, 2026.Disaggregation of Income Statement ExpensesIn November 2024, the FASB issued ASU 2024-03, Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses (a“ASU 2024-03”), which requires the disclosure of additional information related to certain costs and expenses, including amounts of inventory purchases, employee compensation, and depreciation and amortization included in each income statement line item. ASU 2024-03 is effective for annual periods beginning after December 15, 2026, and interim periods within fiscal years beginning after December 15, 2027. The Company is evaluating the impact on the consolidated financial statements and expects to implement the provisions of ASU 2024-03 for its fiscal year ending March 31, 2028. 3 CANOPY USACanopy USAOn October 24, 2022, Canopy Growth completed a number of strategic transactions (the “Reorganization”) in connection with the creation of Canopy USA, LLC (a“Canopy USA”), a U.S.-domiciled holding company wherein, as of October 24, 2022, Canopy USA, holds certain U.S. cannabis investments previously held by Canopy Growth.Following the creation of Canopy USA, the Nasdaq Stock Market LLC (a“Nasdaq”) communicated its position to the Company stating that companies that consolidate the assets and revenues generated from activities in violation under federal law cannot continue to list on Nasdaq. Since the Company is committed to compliance with the listing requirements of the Nasdaq, the Company and Canopy USA effectuated certain changes to the initial structure of the Company’s interest in Canopy USA that were intended to facilitate the deconsolidation of the financial results of Canopy USA within the Company’s financial statements. These changes included, among other things, modifying the terms of the Protection Agreement (as defined below) between the Company, its 9 A wholly-owned subsidiary and Canopy USA as well as the terms of Canopy USA’s limited liability company agreement and amending the terms of certain agreements with third-party investors in Canopy USA to eliminate any rights to guaranteed returns (collectively, the “Reorganization Amendments”). On May 19, 2023, the Company and Canopy USA implemented the Reorganization Amendments, which included, entering into the First A&R Protection Agreement (as defined below) and amending and restating Canopy USA’s limited liability company agreement (the “A&R LLC Agreement”) in order to: (i) eliminate certain negative covenants that were previously granted by Canopy USA in favor of the Company as well as delegating to the managers of the Canopy USA Board (as defined below) not appointed by Canopy Growth the authority to approve the following key decisions (collectively, the “Key Decisions”): (a) the annual business plan for Canopy USA; (b) decisions regarding the executive officers of Canopy USA and any of its subsidiaries; (c) increasing the compensation, bonus levels or other benefits payable to any current, former or future employees or managers of Canopy USA or any of its subsidiaries; (d) any other executive compensation plan matters of Canopy USA or any of its subsidiaries; and (e) the exercise of the Wana Options (as defined below) or the Jetty Options (as defined below), which for greater certainty means that the Company’s nominee on the Canopy USA Board will not be permitted to vote on any Key Decisions while the Company owns Non-Voting Shares (as defined below); (ii) reduce the number of managers on the Canopy USA Board from four to three, including, reducing the Company’s nomination right to a single manager; (iii) amend the share capital of Canopy USA to, among other things, (a) create a new class of Canopy USA Class B Shares (as defined below), which may not be issued prior to the conversion of the Non-Voting Shares or the Class A shares of Canopy USA (the “Canopy USA Common Shares”) into Canopy USA Class B Shares; (b) amend the terms of the Non-Voting Shares such that the Non-Voting Shares will be convertible into Canopy USA Class B Shares (as opposed to Canopy USA Common Shares); and (c) amend the terms of the Canopy USA Common Shares such that upon conversion of all of the Non-Voting Shares into Canopy USA Class B Shares, the Canopy USA Common Shares will, subject to their terms, automatically convert into Canopy USA Class B Shares, provided that the number of Canopy USA Class B Shares to be issued to the former holders of the Canopy USA Common Shares will be equal to no less than 10% of the total issued and outstanding Canopy USA Class B Shares following such issuance. Accordingly, as a result of the Reorganization Amendments, in no circumstances will the Company, at the time of such conversions, own more than 90% of the Canopy USA Class B Shares.In connection with the Reorganization Amendments, on May 19, 2023, Canopy USA and Huneus 2017 Irrevocable Trust (the “Trust”) entered into a share purchase agreement (the “Trust SPA”), which sets out the terms of the Trust’s investment in Canopy USA in the aggregate amount of up to US\$20 million (the “Trust Transaction”). Agustin Huneus, Jr. is the trustee of the Trust and is an affiliate of a shareholder of Jetty (as defined below). Pursuant to the terms of the Trust SPA, the Trust was entitled, subject to certain terms and conditions contained in the Trust SPA, to be issued Canopy USA Common Shares in two tranches with an aggregate value of up to US\$10 million along with warrants of Canopy USA to acquire additional Canopy USA Common Shares. In addition, subject to the terms of the Trust SPA, the Trust has also been granted options to acquire additional Voting Shares (as defined in the A&R LLC Agreement) with a value of up to an additional US\$10 million and one such additional option includes the issuance of additional warrants of Canopy USA. On April 26, 2024, Canopy USA completed the first tranche closing of the Trust Transaction in accordance with the Trust SPA and pursuant to the Trust SPA, the timeline to complete the second tranche closing has lapsed. As of February 6, 2025, the Trust holds an aggregate 28,571,429 Canopy USA Common Shares and warrants to acquire up to 85,714,284 Voting Shares expiring on April 26, 2031.In addition, subject to the terms and conditions of the A&R Protection Agreement (as defined below) and the terms of the option agreements to acquire Wana (as defined below) and Jetty, as applicable, Canopy Growth may be required to issue additional common shares in satisfaction of certain deferred and/or option exercise payments to the shareholders of Wana and Jetty. Canopy Growth will receive additional Non-Voting Shares from Canopy USA as consideration for any Company common shares issued in the future to the shareholders of Wana and Jetty.On November 3, 2023, the Company received a letter from the staff of the SEC (the “Staff”) in which the Staff indicated that, despite the Reorganization Amendments, it would object to the deconsolidation of the financial results of Canopy USA from the Company’s financial statements in accordance with U.S. GAAP once Canopy USA acquires Wana, Jetty or the Fixed Shares of Acreage Holdings, Inc. (a“Acreage”). The Company subsequently had discussions with the Office of Chief Accountant of the SEC (the “OCA”) and determined to make certain additional amendments to the structure of Canopy USA (the “Additional Reorganization Amendments”) to facilitate the deconsolidation of Canopy USA from the financial results of Canopy Growth in accordance with U.S. GAAP upon Canopy USA’s acquisition of Wana, Jetty or Acreage. In connection with the Additional Reorganization Amendments, Canopy USA and its members entered into a second amended and restated limited liability company agreement (the “Second A&R LLC Agreement”). In accordance with the terms of the Second A&R LLC Agreement, the terms of the Non-Voting Shares have been amended such that the Non-Voting Shares are only convertible into Canopy USA Class B Shares following the date that the NASDAQ Stock Market or The New York Stock Exchange permit the listing of companies that consolidate the financial statements of companies that cultivate, distribute or possess marijuana (as defined in 21 U.S.C 802) in the United States (the “Stock Exchange Permissibility Date”). Based on the Company’s discussions with the OCA, upon effectuating the Additional Reorganization Amendments, the Company believes that the Staff would not object to the deconsolidation of the financial results of Canopy USA from the Company’s financial statements in accordance with U.S. GAAP.Following the Reorganization, Reorganization Amendments and Additional Reorganization Amendments, on May 6, 2024, Canopy USA exercised the options (the “Wana Options”) to acquire Mountain High Products, LLC, Wana Wellness, LLC and The 10 A Cima Group, LLC (collectively, a“Wana”), a leading cannabis edibles brand in North America, and subsequently closed the transactions to acquire Wana Wellness, LLC and The Cima Group, LLC. On October 8, 2024, Canopy USA closed the acquisition of Mountain High Products, LLC. In addition, Canopy USA exercised the options (the “Jetty Options”) to acquire Lemurian, Inc. (a“Jetty”) a California-based producer of high-quality cannabis extracts and pioneer of clean vape technology and subsequently completed the first tranche closing to acquire Jetty. On June 4, 2024, the option to acquire the issued and outstanding Class E subordinate voting shares (the “Fixed Shares”) of Acreage, a leading vertically-integrated multi-state cannabis operator, with its main operations in densely populated states across the Northeast U.S., including New Jersey and New York (the “Acreage Option”) was exercised and on December 9, 2024, Canopy USA completed the acquisition of all of the issued and outstanding Fixed Shares and Class D subordinate voting shares (the “Floating Shares”) of Acreage (the “Acreage Acquisition”). Canopy USA also holds direct and indirect interests in the capital of TerrAscend Corp. (a“TerrAscend”), a leading North American cannabis operator with vertically integrated operations and a presence in Pennsylvania, New Jersey, Michigan and California as well as licensed cultivation and processing operations in Maryland.Canopy USA currently holds an ownership interest in the following assets, among others:a“Wana” 100% of the membership interests of Wana Wellness, LLC, The Cima Group, LLC, and Mountain High Products, LLC.a“Jetty” approximately 77% of the shares of Jetty.a“Acreage” 100% of the issued and outstanding shares of Acreage.a“TerrAscend” Canopy USA beneficially holds an aggregate of 64,564,487 TerrAscend common shares (the “TerrAscend Common Shares”) on an as-converted basis and 22,474,130 TerrAscend Common Share purchase warrants with a weighted average exercise price of \$6.07 per TerrAscend Common Share and expiring on December 31, 2032 (the “TerrAscend Warrants”). Assuming full exercise of the TerrAscend Warrants, Canopy USA will beneficially hold an aggregate of 87,038,617 TerrAscend Common Shares on an as-converted basis assuming conversion of the TerrAscend exchangeable shares (the “TerrAscend Exchangeable Shares”) beneficially held by Canopy USA.Following the implementation of the Reorganization, Canopy USA was determined to be a variable interest entity pursuant to ASC 810 - Consolidations (a“ASC 810”) and prior to the completion of the Reorganization Amendments and the Additional Reorganization Amendments, Canopy Growth was determined to be the primary beneficiary of Canopy USA. As a result of such determination and in accordance with ASC 810, Canopy Growth consolidated the financial results of Canopy USA up to April 30, 2024.Ownership of U.S. Cannabis InvestmentsFollowing the implementation of the Reorganization, the shares and interests in Acreage, Wana, Jetty and TerrAscend are held,

directly or indirectly, by Canopy USA, and Canopy Growth no longer holds a direct interest in any shares or interests in such entities. Canopy Growth holds non-voting and non-participating shares (the “Non-Voting Shares”) in the capital of Canopy USA. The Non-Voting Shares do not carry voting rights, rights to receive dividends or other rights upon dissolution of Canopy USA. Following the Reorganization Amendments, the Non-Voting Shares are convertible into Class B shares of Canopy USA (the “Canopy USA Class B Shares”), provided that such conversion shall only be permitted following the Stock Exchange Permissibility Date. The Company also has the right (regardless of the fact that its Non-Voting Shares are non-voting and non-participating) to appoint one member to the Canopy USA Board of managers (the “Canopy USA Board”). On October 24, 2022, Canopy USA and the Company also entered into an agreement with, among others, Nancy Whiteman, the controlling shareholder of Wana, which was amended and restated on May 19, 2023 and on April 30, 2024, whereby subsidiaries of Canopy USA agreed to pay additional consideration in order to acquire the Wana Options and the future payments owed in connection with the exercise of the Wana Options were reduced to US\$3.00 in exchange for the issuance of Canopy USA Common Shares and Canopy Growth common shares (the “Wana Amending Agreement”). In accordance with the terms of the Wana Amending Agreement, on April 30, 2024, (i) Canopy USA issued 60,955,929 Canopy USA Common Shares and (ii) Canopy Growth issued 1,086,279 Canopy Growth common shares to the shareholders of Wana. The Canopy USA Common Shares issued to Ms. Whiteman, or entities controlled by Ms. Whiteman, are subject to a repurchase right exercisable at any time after April 30, 2027, being the 36 month anniversary of the closing of the transaction contemplated by the Wana Amending Agreement (the “Wana Repurchase Right”) to repurchase all Canopy USA Common Shares that have been issued at a price per Canopy USA Common Share equal to the fair market value as determined by an appraiser. As part of this agreement, Canopy USA has granted Ms. Whiteman the right to appoint one member to the Canopy USA Board and a put right on the same terms and conditions as the Wana Repurchase Right. As of February 6, 2025, the Trust holds 28,571,429 Canopy USA Common Shares, the shareholders of Wana collectively hold 60,955,929 Canopy USA Common Shares and a wholly-owned subsidiary of the Company holds all of the issued and outstanding Non-Voting Shares in the capital of Canopy USA, representing approximately 84.4% of the issued and outstanding shares in Canopy USA on an as-converted basis. 11 Canopy Growth and Canopy USA are also party to a protection agreement (the “Protection Agreement”) to provide for certain covenants in order to preserve the value of the Non-Voting Shares held by Canopy Growth until such time as the Non-Voting Shares are converted in accordance with their terms, provided that, such conversion shall only be permitted following the Stock Exchange Permissibility Date, but does not provide Canopy Growth with the ability to direct the business, operations or activities of Canopy USA. The Protection Agreement was amended and restated in connection with: (a) the Reorganization Amendments (the “First A&R Protection Agreement”); and (b) the Additional Reorganization Amendments (the “Second A&R Protection Agreement” and together with the First A&R Protection Agreement, the “A&R Protection Agreement”). Until such time as Canopy Growth converts the Non-Voting Shares into Canopy USA Class B Shares following the Stock Exchange Permissibility Date, Canopy Growth will have no economic or voting interest in Canopy USA, Wana, Jetty, TerrAscend, or Acreage. Canopy USA, Wana, Jetty, TerrAscend, and Acreage will continue to operate independently of Canopy Growth. Acreage Agreements On October 24, 2022, Canopy Growth entered into an arrangement agreement with Canopy USA and Acreage, as amended (the “Floating Share Arrangement Agreement”), pursuant to which Canopy USA acquired all of the issued and outstanding Floating Shares by way of a court-approved plan of arrangement (the “Floating Share Arrangement”) in exchange for 0.045 of a Company common share for each Floating Share held. In connection with the Floating Share Arrangement Agreement, Canopy Growth irrevocably waived the Acreage Floating Option (as defined below) existing under the Existing Acreage Arrangement Agreement. On October 24, 2022, the Company and Canopy USA entered into a third amendment to tax receivable agreement (the “Amended TRA”) with, among others, certain current or former unitholders (the “Holders”) of High Street Capital Partners, LLC, a subsidiary of Acreage (“HSCP”), pursuant to HSCP’s amended tax receivable agreement (the “TRA”) and related tax receivable bonus plans with Acreage. Pursuant to the Amended TRA, the Company, on behalf of Canopy USA, agreed to issue common shares of the Company with a value of US\$30.4 million to certain Holders as consideration for the assignment of such Holder’s rights under the TRA to Canopy USA. As a result of the Amended TRA, Canopy USA is the sole member and beneficiary under the TRA. In connection with the foregoing, the Company issued: (i) 564,893 common shares with a value of \$20.6 million (US\$15.2 million) to certain Holders on November 4, 2022 as the first installment under the Amended TRA; and (ii) 710,208 common shares with a value of \$20.6 million (US\$15.2 million) to certain Holders on March 17, 2023, as the second installment under the Amended TRA. In connection with the Acreage Acquisition, the Company, on behalf of Canopy USA, issued 5,118,426 common shares of the Company to an eligible participant pursuant to HSCP’s existing tax receivable bonus plans. In addition to shareholder and court approvals, completion of the Floating Share Arrangement was subject to applicable regulatory approvals including, but not limited to, Toronto Stock Exchange (“TSX”) approval and the satisfaction of certain other closing conditions, including the conditions set forth in the Acreage Amended Arrangement. The Floating Share Arrangement received the requisite approval from the holders of Floating Shares at the special meeting of Acreage shareholders held on March 15, 2023 and on March 20, 2023 Acreage obtained a final order from the Supreme Court of British Columbia approving the Floating Share Arrangement. The Floating Share Arrangement was implemented on December 9, 2024 in connection with the closing of the Acreage Acquisition. On June 4, 2024, the Acreage Option was exercised in accordance with the terms of the arrangement agreement dated April 18, 2019, as amended on May 15, 2019, September 23, 2020 and November 17, 2020 (the “Existing Acreage Arrangement Agreement”). Concurrently with the closing of the acquisition of the Fixed Shares pursuant to the exercise of the Acreage Option, on December 9, 2024, the Fixed Shares were issued to Canopy USA upon closing of the Acreage Acquisition. Accordingly, Canopy Growth does not hold any Fixed Shares or Floating Shares. The acquisition of the Floating Shares pursuant to the Floating Share Arrangement occurred immediately prior to the acquisition of the Fixed Shares pursuant to the Existing Acreage Arrangement Agreement such that 100% of the issued and outstanding shares of Acreage are owned by Canopy USA. For additional details, see Acreage Acquisition below. On June 3, 2024, the Company exercised its option to acquire certain outstanding debt of Acreage (the “Debt Acquisition”) in connection with the option agreement dated November 15, 2022 (the “Option Agreement”) among a wholly-owned subsidiary of Canopy Growth (the “Optionor”) and the lenders (the “Lenders”) party to Acreage’s credit agreement dated as of December 16, 2021, as amended by the first amendment to credit agreement dated as of October 24, 2022 and the second amendment to credit agreement dated as of April 28, 2023. The Optionor entered into various agreements in connection with the Debt Acquisition in order to acquire approximately \$136,567 (US\$99,837) of Acreage’s outstanding debt (the “Acquired Debt”) from certain Lenders in exchange for \$95,460 (US\$69,786) in cash and the release of approximately \$41,107 (US\$30,051) (the “Option Premium”) that was held in escrow pursuant to the Option Agreement. As reported in the Annual Report, the Option Premium was not included in Canopy Growth’s cash and cash equivalents as of March 31, 2024. The Optionor subsequently transferred approximately \$2,972 (US\$2,173) of the Acquired Debt to the other Lender (the “Rolling Lender”) and entered into a series of agreements with the Rolling Lender and Acreage, among others, including an amended and restated credit agreement (the “First ARCA”), which provided for, among other things, the Acquired Debt, certain interest payments to be paid-in-kind, revisions to certain financial covenants and, following certain events, an extension to the maturity date. 12 On September 13, 2024, the Optionor entered into a series of transactions with, among others, Acreage, the Rolling Lender and an arm’s length third-party lender (the “Other Lender”). Pursuant to such transactions, all of Acreage’s indebtedness held by the Rolling Lender was acquired by the Other Lender. Following the acquisition by the Other Lender, the Optionor, the Other Lender and Acreage, among others, amended and restated the First ARCA pursuant to a second amended and restated credit agreement dated as of September 13, 2024 (the “Second ARCA”). Pursuant to the Second ARCA and an agreement among lenders entered into on September 13, 2024 between, among others, the Optionor and the Other Lender, all interest owing to the Optionor under the Second ARCA is, subject to the consent of the Other Lender, to be paid-in-kind and not in cash. Under the Second ARCA, as of September 13, 2024, the Optionor was owed an aggregate principal amount equal to approximately \$137,955 (US\$102,000), which is subordinate to approximately \$87,913 (US\$65,000) owed to the Other Lender. Deconsolidation of Canopy USAAs of April 30, 2024, as a result of the series of transactions related to the Additional Reorganization Amendments described above (the “Canopy USA Transactions”), Canopy Growth has deconsolidated the financial results of Canopy USA and has a non-controlling interest in Canopy USA as of such date. The deconsolidation of Canopy USA occurred after completion of the following structural amendments: (i) execution of the Second A&R LLC Agreement, (ii) execution of the Second A&R Protection Agreement and (iii) completion of the initial tranche closing of the Trust Transaction, which included the election of a third member to the Canopy USA Board such that the Canopy USA Board is comprised of an appointee of the Trust, Ms. Whiteman, and the Company. Canopy Growth’s deconsolidation of Canopy USA resulted in recognition of an equity method investment (see Note 11) and a loan receivable recorded at fair value (see Note 12). The deconsolidation of Canopy USA from the financial results of Canopy Growth resulted in the derecognition of the following assets and liabilities: Cash \$ 6,968 Other financial assets \$ 386,045 Other assets \$ 1,315 Other liabilities \$ (20,067) Cumulative translation adjustment \$ 10,398 Net assets disposed \$ 384,659 \$ Derecognition of non-controlling interest in Canopy USA \$ 139 \$ Equity method investment \$ 227,119 Elevate loan receivable \$ 174,864 Total retained non-controlling interest in the former subsidiaries \$ 401,983 \$ Issuance of common shares \$ (12,452) \$ Consideration received in cash \$ - Total consideration \$ - \$ Gain on disposal of consolidated entity \$ 5,011 The gain on derecognition of Canopy USA is the differences between the carrying amounts of the derecognized assets, liabilities and non-controlling interest, value of common shares issued, and the fair value of the retained non-controlling interest in Canopy USA, being the equity method investment and the Canopy Elevate I LLC, Canopy Elevate II LLC and Canopy Elevate III LLC (collectively, “Elevate”) loan receivable. The gain on derecognition is reflected in other income (expense), net. Acreage Acquisition On December 9, 2024, Canopy USA completed the Acreage Acquisition and now owns 100% of the issued and outstanding shares of Acreage. In connection with: (i) the Existing Acreage Arrangement Agreement and the Acreage Amended Arrangement; and (ii) the Floating Share Arrangement Agreement, Canopy USA acquired all of the issued and outstanding Floating Shares of Acreage on the terms and conditions set forth in Floating Share Arrangement. Immediately following the implementation of the Floating Share Arrangement, Canopy USA acquired all of the issued and outstanding Fixed Shares of Acreage (the “Fixed Share Acquisition”). In accordance with the Floating Share Arrangement, registered holders of Floating Shares received 0.045 of a common share of Canopy Growth for each Floating Share (the “Floating Share Exchange Ratio”). In connection with the Fixed Share Acquisition, each of the outstanding Fixed Shares was exchanged for 0.0000000617 of a common share of Canopy Growth for each Fixed Share, as adjusted pursuant to the terms and conditions set forth in the Existing Acreage Arrangement Agreement (the “Fixed Share Exchange Ratio”). In aggregate, Canopy Growth issued 5,888,291 common shares to former shareholders of Acreage. 13 Pursuant to the Floating Share Arrangement, (i) each outstanding stock option to acquire Floating Shares was exchanged for a replacement option exercisable for Canopy Growth common shares, with the number of underlying Canopy Growth common shares and exercise price of such options adjusted by the Floating Share Exchange Ratio; (ii) each outstanding warrant to acquire Floating Shares was exchanged for a replacement warrant to acquire Canopy Growth common shares, with the number of underlying Canopy Growth common shares and exercise price of such warrants adjusted by the Floating Share Exchange Ratio; and (iii) each restricted share unit and performance share unit, as applicable, that vested into Fixed Shares was exchanged for a replacement restricted share unit or performance share unit, as applicable, that vested into Canopy Growth common shares, with the number of underlying Canopy Growth common shares adjusted by the Fixed Share Exchange Ratio. In addition, Canopy Growth: (i) issued 5,118,426 common shares of the Company to an eligible participant pursuant to HSCP’s existing tax receivable bonus plans; and (ii) 306,151 common shares of the Company were issuable in connection with Canopy USA’s acquisition of the minority interests of certain subsidiaries of Acreage, of which 236,960 common shares of the Company have been issued. Immediately following the closing of the Acreage Acquisition, Canopy Growth issued an aggregate of 1,315,553 common shares and 1,197,658 common share purchase warrants to certain securityholders of Acreage in order to satisfy an outstanding liability. Each common share purchase warrant entitles the holder thereof to acquire one common share of Canopy Growth at an exercise price of US\$3.66 until June 6, 2029. In exchange for the issuances of Canopy Growth common shares, warrants and other replacement securities in connection with the Acreage Acquisition, Canopy Growth received additional Non-Voting Shares with a value of \$50,786 and Canopy USA delivered guarantees in respect of the obligations owing pursuant to the Elevate loan receivable. Refer to Note 11 and 12 for more information on Canopy USA investment balances and refer to Note 19 for more information on the share and warrant issuances as part of the Acreage Acquisition. 4. BIOTEEL On September 14, 2023, following a review of the strategic options for the BioSteel business unit, Canopy Growth ceased funding the operations of BioSteel Sports Nutrition Inc. (“BioSteel Canada”). BioSteel Canada commenced proceedings (the “CCAA Proceedings”) under the Companies’ Creditors Arrangement Act (the “CCAA”) in the Ontario Superior Court of Justice (Commercial List) (the “CCAA Court”) and sought and obtained recognition of that proceeding under Chapter 15 of the United States Bankruptcy Code. To assist with the sale process, the CCAA Court approved the appointment of a monitor as required under the CCAA. As a result of the CCAA Proceedings, the most relevant activity of BioSteel Canada became the liquidation and sale of assets. Management concluded that Canopy Growth ceased to have the power to direct the relevant activity of BioSteel Canada because the liquidation and sale transactions required approval from the CCAA Court. Thus, Canopy Growth no longer had a controlling interest in BioSteel Canada and had deconsolidated the entity effective September 14, 2023. The deconsolidation of BioSteel Canada and related impairment charges were classified under losses from discontinued operations. The strategic decisions made encompassed all operations of the BioSteel business unit, including those of BioSteel Canada. For this reason, the BioSteel segment results for all periods prior to the September 14, 2023 deconsolidation of BioSteel Canada, including costs to exit, were classified as discontinued operations. On November 16, 2023, BioSteel Sports Nutrition USA LLC (“BioSteel US”) and BioSteel Manufacturing LLC (“BioSteel Manufacturing”) and collectively with BioSteel Canada and BioSteel US, the “BioSteel Entities”) were added as additional applicants in the CCAA Proceedings. As a result, the most relevant activity of both entities became the liquidation and sale of assets and distribution of cash and proceeds to their respective stakeholders and management concluded that Canopy Growth ceased to have the power to direct the relevant activities of BioSteel US and BioSteel Manufacturing because those activities required approval from the CCAA Court. As a result of the conclusion of the sale of assets and distribution of the cash and proceeds of the BioSteel Entities, on July 31, 2024, the CCAA Court granted an order which provided, among other things, for the termination of the CCAA Proceedings upon service of a certificate (the “CCAA Termination Certificate”) and authorization for the BioSteel Entities to file assignments in bankruptcy pursuant to the Bankruptcy and Insolvency Act. The BioSteel Entities were assigned into bankruptcy as of October 2, 2024. The bankruptcy of the BioSteel Entities will deal with any remaining nominal assets of the BioSteel Entities. The CCAA Termination Certificate was served on October 22, 2024. 14 As a result of the foregoing, Canopy Growth no longer has a controlling interest in BioSteel US and BioSteel Manufacturing and has deconsolidated both entities effective November 16, 2023. The deconsolidation of BioSteel US and BioSteel Manufacturing and related impairment charges were classified under losses from discontinued operations. A Three months ended A Nine months ended A December 31, A December 31, A December 31, A December 31, A December 31, A 2024 A 2023 A 2024 A 2023 A Net revenue \$ - A \$ 172 A \$ - A \$ 56,610 A Cost of goods sold A - A \$ 1,900 A A - A \$ 145,625 A Operating expenses A - A A (726) A - A \$ 97,851 A Operating loss A - A A (1,002) A A - A (186,866) Other income (expense), net 1 A - A A 14,481 A A 5,310 A A (8,521) Income tax (expense) recovery A - A A - A A - A A 936 A Net income (loss) on discontinued operations, net of tax A \$ - A \$ 13,479 A A \$ 5,310 A A (194,451) 1 Included in Other income (expense), net for the three and nine months ended December 31, 2023 is a gain/loss on deconsolidation of \$nil and \$nil, respectively (three and nine months ended December 31, 2023 - gain on deconsolidation of \$12,417 and loss on deconsolidation of \$9,820, respectively). Investment in BioSteel Entities The CCAA Proceedings for the BioSteel Entities have been completed. Canopy Growth continues to have a 100% ownership interest in each of BioSteel US and BioSteel Manufacturing but has deconsolidated both entities because it no longer has a controlling interest in them. Since the estimated amount of the liabilities of BioSteel US and BioSteel Manufacturing exceeds the estimated fair value of the assets available for distribution to its creditors, the fair value of Canopy Growth’s equity investment in BioSteel US and BioSteel Manufacturing approximates zero. Canopy Growth’s Amounts Receivable from BioSteel Entities Prior to Canopy Growth’s deconsolidation of BioSteel Canada, Canopy Growth made

significant secured loans to BioSteel Canada for purposes of funding its operations. The secured loans and corresponding interest were considered intercompany transactions and eliminated in Canopy Growth's consolidated financial statements prior to September 14, 2023, being the deconsolidation date. As of the deconsolidation date, the secured loans and corresponding interest are now considered related party transactions and have been recognized in Canopy Growth's consolidated financial statements at their estimated fair value of \$29,000. As of the deconsolidation date for BioSteel US and BioSteel Manufacturing, Canopy Growth has recorded remaining amounts legally receivable from BioSteel US and BioSteel Manufacturing at their estimated fair value. The remaining amounts legally receivable from the BioSteel Entities are measured at their expected recoverable amounts. As of December 31, 2024, the receivable balance from the BioSteel Entities is \$nil. The assets and liabilities related to the BioSteel Entities business units are classified as discontinued operations and the major categories are as follows: 4. December 31, 5. March 31, 6. 2024 7. 2024 8. Receivable from BioSteel Entities 9. \$ - 10. \$ 8,038 11. Total assets of discontinued operations 12. \$ - 13. \$ 8,038 14. Total liabilities of discontinued operations 15. \$ - 16. 5. LOSS ON ASSET IMPAIRMENT AND RESTRUCTURING In the three months ended December 31, 2024, the Company recorded a loss on asset impairment and restructuring which primarily related to the employee restructuring costs and other costs associated with previous restructuring actions. In the nine months ended December 31, 2024, the Company recorded a loss on asset impairment and restructuring which primarily related to the non-cash impairment of divestiture-related assets, employee restructuring costs and other costs associated with previous restructuring actions. This was partially offset by a gain related to the remeasurement of a restructured lease facility upon execution of the related exit agreement. As a result, in the three and nine months ended December 31, 2024, the Company recognized a loss on asset impairment and restructuring of \$1,285 and \$22,135, respectively (three and nine months ended December 31, 2023 â€ loss of \$30,413 and \$2,452, respectively). 15. 6. CASH AND CASH EQUIVALENTS The components of cash and cash equivalents are as follows: 7. December 31, 8. March 31, 9. 2024 10. 2024 11. Cash 12. \$ 145,599 13. \$ 115,427 14. Cash equivalents 15. \$ 16,310 16. \$ 54,873 17. \$ 161,909 18. \$ 170,300 19. 7. SHORT-TERM INVESTMENTS The components of short-term investments are as follows: 8. December 31, 9. March 31, 10. 2024 11. 2024 12. Term deposits 13. \$ 16,435 14. \$ 33,161 15. 2024 16. \$ 16,435 17. \$ 33,161 18. The amortized cost of short-term investments at December 31, 2024 is \$16,435 (March 31, 2024 â€ \$33,161). 8. AMOUNTS RECEIVABLE, NET The components of amounts receivable, net are as follows: 9. December 31, 10. March 31, 11. 2024 12. 2024 13. Accounts receivable, net 14. \$ 44,393 15. \$ 44,943 16. Indirect taxes receivable 17. \$ 3,655 18. 2,517 19. Interest receivable 20. \$ 1,004 21. 876 22. Other receivables 23. \$ 6 24. 3,511 25. \$ 49,058 26. \$ 51,847 27. Included in the accounts receivable, net balance at December 31, 2024 is an allowance for doubtful accounts of \$8,161 (March 31, 2024 â€ \$9,903). 9. INVENTORY The components of inventory are as follows: 10. December 31, 11. March 31, 12. 2024 13. 2024 14. Raw materials, packaging supplies and consumables 15. \$ 15,980 16. \$ 18,872 17. Work in progress 18. \$ 42,733 19. 31,367 20. Finished goods 21. \$ 32,040 22. 27,053 23. \$ 90,753 24. \$ 77,292 25. In the three and nine months ended December 31, 2024, the Company recorded write-downs related to inventory in cost of goods sold of \$1,225 and \$3,130, respectively (three and nine months ended December 31, 2023 â€ \$859 and \$8,362, respectively). 10. PREPAID EXPENSES AND OTHER ASSETS The components of prepaid expenses and other assets are as follows: 11. December 31, 12. March 31, 13. 2024 14. 2024 15. Prepaid expenses 16. \$ 5,609 17. \$ 6,621 18. Deposits 19. \$ 5,254 20. 2,365 21. Other assets 22. \$ 4,959 23. 14,246 24. \$ 15,822 25. \$ 23,232 26. 16 27. 11. EQUITY METHOD INVESTMENTS The components of equity method investments are as follows: 12. December 31, 13. March 31, 14. 2024 15. 2024 16. Canopy USA 17. \$ 49,834 18. \$ - 19. \$ 49,834 20. \$ - 21. Through its ownership in the Non-Voting Shares, the Company has a non-participating and non-voting interest in Canopy USA and classifies such interest in Canopy USA as an equity method investment. The Company has elected to account for its investment in Canopy USA at fair value. Refer to Note 23 for information on the valuation technique and inputs used in determining the fair value of the Canopy USA investment and Note 25 for information on fair value movements. 17. 12. OTHER FINANCIAL ASSETS The following table outlines changes in other financial assets. Additional details on how the fair value of significant investments is calculated are included in Note 23. 2. 3. 4. 5. 6. 7. 8. 9. 10. 11. 12. 13. 14. Foreign 15. 16. Balance at 17. 18. 19. currency 20. 21. Balance at 22. 23. March 31, 24. 25. Fair value 26. translation 27. 28. December 31, 29. 30. Entity 31. Instrument 32. 2024 33. Additions 34. 35. changes 36. adjustments 37. Other 38. 2024 39. Acreege 1 40. Fixed Shares option and Floating Shares agreement 41. \$ 10,000 42. \$ - 43. \$ (31,808) 44. \$ (35) 45. \$ 21,843 46. \$ - 47. TerrAscend Exchangeable Shares 48. Exchangeable shares 49. \$ 120,000 50. \$ - 51. \$ 17,291 52. \$ 2,109 53. \$ (139,400) 54. \$ - 55. TerrAscend - December 2022 56. Warrants 57. \$ 32,500 58. \$ - 59. 7,929 60. \$ 571 61. \$ (41,000) 62. \$ - 63. TerrAscend 64. Option 65. \$ 2,000 66. \$ - 67. \$ 265 68. \$ 35 69. \$ (2,300) 70. \$ - 71. Wana 72. Option 73. \$ 149,766 74. \$ - 75. 1,537 76. \$ (151,303) 77. \$ - 78. Jetty 79. Options 80. \$ 59,915 81. \$ - 82. \$ - 83. 615 84. \$ (60,530) 85. \$ - 86. Acreege Hempco 87. Debenture 88. \$ 11,780 89. \$ - 90. 121 91. \$ (11,901) 92. \$ - 93. Acreege Debt Option Premium 94. Option 95. \$ 37,574 96. \$ - 97. \$ 3,147 98. \$ 386 99. \$ (41,107) 100. \$ - 101. Acreege Tax Receivable Agreement 102. Other 103. \$ 1,287 104. \$ - 105. \$ 13 106. \$ (1,300) 107. \$ - 108. Acreege Debt 109. Loan receivable 110. \$ - 111. \$ 133,595 112. \$ (1,239) 113. \$ 6,512 114. \$ - 115. \$ 138,868 116. Elevate loan receivable 117. 2 118. Loan receivable 119. \$ - 120. \$ 174,864 121. \$ 24,804 122. \$ 4,137 123. \$ (24,622) 124. \$ 179,183 125. Other 126. Various 127. \$ 12,807 128. \$ - 129. \$ (2,915) 130. \$ 24 131. \$ (6,599) 132. \$ 3,317 133. \$ 437,629 134. \$ 308,459 135. \$ 17,474 136. \$ 16,025 137. \$ (458,219) 138. \$ 321,368 139. 1 See Note 27 for information regarding the Acreege Amended Arrangement. 2 Upon deconsolidation of the financial results of Canopy USA within the Company's financial statements, the Elevate loan receivable, which was previously recorded at amortized cost, is now recorded at fair value. The remeasurement of this retained non-controlling interest from the deconsolidation of Canopy USA is part of the gain on disposal of consolidated entity described in Note 3. For information regarding the deconsolidation of the financial results of Canopy USA within the Company's financial statements, see Note 3. Following the deconsolidation of Canopy USA on April 30, 2024, the Company derecognized certain U.S. cannabis investments above, including, among others, interests in the Floating Shares of Acreege, Wana, Jetty, TerrAscend, and the Universal Hemp, LLC debenture. Acreege Debt On June 3, 2024, the Company closed the Debt Acquisition in connection with the Option Agreement among the Optionor and the Lenders party to Acreege â€s credit agreement dated as of December 16, 2021, as amended by the first amendment to credit agreement dated as of October 24, 2022 and the second amendment to credit agreement dated as of April 28, 2023. The Optionor entered into various agreements in connection with the Debt Acquisition in order to acquire the Acquired Debt from certain Lenders in exchange for \$95,460 (US\$69,786) in cash and the release of the Option Premium that was held in escrow pursuant to the Option Agreement. As reported in the Annual Report, the Option Premium was not included in the Company's cash and cash equivalents as of March 31, 2024. The Optionor subsequently transferred approximately \$2,972 (US\$2,173) of the Acquired Debt to the Rolling Lender and entered into a series of agreements with the Rolling Lender and Acreege, among others, including the First ARCA, which provided for, among other things, the Acquired Debt, certain interest payments to be paid-in-kind, revisions to certain financial covenants and, following certain events, an extension to the maturity date. On September 13, 2024, the Optionor entered into a series of transactions with, among others, Acreege, the Rolling Lender and the Other Lender. Pursuant to such transactions, all of Acreege's indebtedness held by the Rolling Lender was acquired by the Other Lender. Following the acquisition by the Other Lender, the Optionor, the Other Lender and Acreege, among others, entered into the Second ARCA. Pursuant to the Second ARCA and an agreement among lenders entered into on September 13, 2024 between, among others, the Optionor and the Other Lender, all interest owing to the Optionor under the Second ARCA is, subject to the consent of the Other Lender, to be paid-in-kind and not in cash. Under the Second ARCA, as of September 13, 2024, the Optionor was owed an aggregate principal amount equal to approximately \$137,955 (US\$102,000), which is subordinate to approximately \$87,913 (US\$65,000) owed to the Other Lender. As of December 31, 2024, the aggregate principal amount owing to the Optionor was approximately \$152,421 (US\$105,966) and the aggregate principal amount owing to the Other Lender was approximately \$93,496 (US\$65,000). 18. Elevate Loan Receivable On December 9, 2024, Canopy USA delivered guarantees in respect of the obligations owing pursuant to the Elevate loan receivable. Upon delivery thereof, each guarantee is now factored into the fair value consideration of the Elevate loan receivable. Refer to Note 23 for information on the valuation technique and other inputs used in determining the fair value. 13. PROPERTY, PLANT AND EQUIPMENT The components of property, plant and equipment are as follows: 4. December 31, 5. March 31, 6. 2024 7. 2024 8. Buildings and greenhouses 9. \$ 304,356 10. \$ 305,606 11. Production and warehouse equipment 12. \$ 60,685 13. \$ 62,026 14. Leasehold improvements 15. \$ 3,160 16. \$ 7,787 17. Office and lab equipment 18. \$ 10,389 19. \$ 11,041 20. Computer equipment 21. \$ 7,119 22. \$ 7,784 23. Land 24. \$ 4,923 25. \$ 5,323 26. Right-of-use assets 27. \$ 4 28. Buildings and greenhouses 29. \$ 11,822 30. \$ 17,697 31. Assets in process 32. \$ 4,910 33. \$ 1,019 34. \$ 407,364 35. \$ 418,283 36. Less: Accumulated depreciation 37. \$ (107,760) 38. \$ (98,180) 39. \$ 299,604 40. \$ 320,103 41. Depreciation expense included in cost of goods sold for the three and nine months ended December 31, 2024 is \$4,298 and \$13,554, respectively (three and nine months ended December 31, 2023 â€ \$5,091 and \$19,589, respectively). Depreciation expense included in selling, general and administrative expenses for the three and nine months ended December 31, 2024 is \$644 and \$2,016, respectively (three and nine months ended December 31, 2023 â€ \$826 and \$2,896, respectively). 14. INTANGIBLE ASSETS The components of intangible assets are as follows: 5. December 31, 6. March 31, 7. 2024 8. 2024 9. Gross 10. Net 11. Gross 12. Net 13. Carrying 14. Carrying 15. Carrying 16. Carrying 17. Amount 18. Amount 19. Amount 20. Finite lived intangible assets 21. \$ 4 22. \$ 4 23. Intellectual property 24. \$ 83,977 25. \$ 32,974 26. \$ 82,423 27. \$ 38,571 28. Distribution channel 29. \$ 46,112 30. \$ 2,317 31. \$ 45,981 32. \$ 3,029 33. Operating licenses 34. \$ 24,400 35. \$ 13,674 36. \$ 24,400 37. \$ 15,964 38. Software and domain names 39. \$ 33,002 40. \$ 3,124 41. \$ 32,262 42. \$ 7,010 43. Brands 44. \$ 14,498 45. \$ 8,307 46. \$ 14,493 47. \$ 10,850 48. Amortizable intangibles in process 49. \$ 256 50. \$ 256 51. \$ 29 52. \$ 29 53. Total 54. \$ 202,245 55. \$ 60,652 56. \$ 199,588 57. \$ 75,453 58. \$ 4 59. \$ 4 60. Indefinite lived intangible assets 61. \$ 4 62. \$ 4 63. Acquired brands 64. \$ 29,139 65. \$ 28,600 66. Total intangible assets 67. \$ 89,791 68. \$ 104,053 69. Amortization expense included in cost of goods sold for the three and nine months ended December 31, 2024 is \$5 and \$29, respectively (three and nine months ended December 31, 2023 â€ \$13 and \$41, respectively). Amortization expense included in selling, general and administrative expenses for the three and nine months ended December 31, 2024 is \$5,367 and \$16,052, respectively (three and nine months ended December 31, 2023 â€ \$6,310 and \$19,355, respectively). 19. 15. GOODWILL The changes in the carrying amount of goodwill are as follows: Balance, March 31, 2023 8. \$5,563 9. Impairment losses 10. \$ (42,081) 11. Foreign currency translation adjustments 12. \$ (243) 13. Balance, March 31, 2024 14. \$ 43,239 15. Foreign currency translation adjustments 16. \$ 854 17. Balance, December 31, 2024 18. \$ 44,093 19. The Company does not believe that an event occurred or circumstances changed during the nine months ended December 31, 2024 that would, more likely than not, reduce the fair value of the Storz & Bickel (â€Storz & Bickelâ€) reporting unit below its carrying value. Therefore, the Company concluded that the quantitative goodwill impairment assessment was not required for the Storz & Bickel reporting unit at December 31, 2024. The carrying value of goodwill associated with the Storz & Bickel reporting unit was \$44,093 at December 31, 2024. The Company is required to perform its next annual goodwill impairment analysis on March 31, 2025, or earlier should there be an event that occurs or circumstances change that would more likely than not reduce the fair value of a reporting unit below its carrying amount. 16. OTHER ACCRUED EXPENSES AND LIABILITIES The components of other accrued expenses and liabilities are as follows: 4. December 31, 5. March 31, 6. 2024 7. 2024 8. Employee compensation 9. \$ 10,822 10. \$ 21,468 11. Taxes and government fees 12. \$ 11,337 13. \$ 10,519 14. Professional fees 15. \$ 3,120 16. \$ 5,849 17. Other 18. \$ 11,912 19. \$ 16,203 20. \$ 37,191 21. \$ 54,039 22. 17. DEBT The components of debt are as follows: 4. December 31, 5. March 31, 6. 2024 7. Maturity Date 8. 2024 9. Credit facility 10. December 18, 2026 11. \$ 4 12. Principal amount 13. \$ 4 14. \$ 360,481 15. \$ 486,935 16. Accrued interest 17. \$ 4 18. \$ 284 19. \$ 831 20. Deferred financing costs 21. \$ (10,410) 22. \$ (17,948) 23. \$ 4 24. \$ 350,355 25. \$ 469,818 26. Supreme convertible debentures 27. September 10, 2025 28. \$ 2,267 29. \$ 30,654 30. Accretion debentures 31. September 10, 2025 32. \$ 417 33. \$ 4 34. \$ 6,390 35. May 2024 Convertible Debenture 36. May 14, 2029 37. \$ 88,067 38. \$ - 39. Promissory note 40. December 31, 2024 41. \$ - 42. \$ 89,224 43. Other revolving debt facility, loan, and financings 44. \$ 465 45. \$ 1,143 46. \$ 4 47. \$ 441,571 48. \$ 597,229 49. Less: current portion 50. \$ (3,167) 51. \$ (103,935) 52. Long-term portion 53. \$ 438,404 54. \$ 493,294 55. Credit Facility On March 18, 2021, the Company entered into a term loan credit agreement (the â€Credit Agreementâ€) providing for a five-year, first lien senior secured term loan facility in an aggregate principal amount of US\$750,000 (the â€Credit Facilityâ€). The Company had the ability to obtain up to an additional US\$500,000 of incremental senior secured debt pursuant to the Credit Agreement. On October 24, 2022, in connection with the balance sheet actions completed as part of the creation of Canopy USA, the Company entered into agreements with certain of its lenders under the Credit Agreement to tender US\$187,500 of the principal amount outstanding thereunder at a discounted price of US\$930 per US\$1,000 or US\$174,375 in the aggregate. The first payment, which was oversubscribed, in the amount of \$117,528 (US\$87,852) was made on November 10, 2022 to reduce the principal indebtedness by \$126,324 (US\$94,427). The second payment of \$116,847 (US\$87,213) was made on April 17, 2023 to reduce principal indebtedness 20. under the Credit Agreement by \$125,606 (US\$93,750). Additionally, on October 24, 2022, the Company and certain of its lenders agreed to make certain amendments to the Credit Agreement which, among other things, resulted in: (i) a reduction to the minimum liquidity covenant to no less than US\$100,000 following completion of the second principal repurchase on April 17, 2023; (ii) certain changes to the application of net proceeds from asset sales; (iii) the establishment of a new committed delayed draw term credit facility in an aggregate principal amount of US\$100,000; and (iv) the elimination of the additional US\$500,000 incremental term loan facility. On July 13, 2023, as part of the Company's balance sheet deleveraging initiatives, the Company entered into agreements with certain of its lenders under the Credit Agreement pursuant to which certain additional amendments were made to the Credit Agreement (the â€Credit Agreement, as amended as of July 13, 2023, is referred to herein as the â€Amended Credit Agreementâ€). The Amended Credit Agreement required the Company to prepay or repurchase principal indebtedness under the Credit Facility in an amount equal to the US dollar equivalent of \$93,000 at a discounted price of US\$930 per US\$1,000 (the â€July 2023 Paydownâ€). In addition, the Amended Credit Agreement requires the Company to apply certain net proceeds from asset sales to prepay or repurchase principal indebtedness under the Credit Facility and receive principal reductions at, in certain circumstances, a discounted price of US\$950 per US\$1,000. The Amended Credit Agreement also includes, among other things, amendments to the minimum liquidity covenant such that the US\$100,000 minimum liquidity covenant ceased to apply concurrently with the July 2023 Paydown. The Company made the July 2023 Paydown on July 21, 2023. On each of August 11, 2023 and September 14, 2023, pursuant to the terms of the Amended Credit Agreement, the Company repurchased additional outstanding principal amounts under the Credit Facility using certain net proceeds from completed asset sales (the â€Second Quarter 2024 Paydownsâ€). The Second Quarter 2024 Paydowns resulted in an aggregate principal reduction of \$73,313 (US\$54,491) for a cash payment of \$69,647 (US\$51,766). On each of November 28, 2023 and December 27, 2023, pursuant to the terms of the Amended Credit Agreement, the Company repurchased and repaid, as applicable, additional outstanding principal amounts under the Credit Facility using certain net proceeds from completed asset sales (the â€Third Quarter 2024 Paydownsâ€). The Third Quarter 2024 Paydowns resulted in an aggregate principal reduction of \$65,379 (US\$48,532) for a cash payment of \$63,167 (US\$46,902). On February 21, 2024, the Company repurchased additional outstanding principal amounts under the Credit Facility (the â€Fourth Quarter 2024 Paydownâ€). The Fourth Quarter 2024 Paydown resulted in an aggregate principal reduction of \$31,078 (US\$23,000) for a cash payment of \$27,970 (US\$20,700). On April 29, 2024 and June 28, 2024, the Company repurchased additional outstanding principal amounts under the Credit Facility (the â€First Quarter 2025 Paydownsâ€). The First Quarter 2025 Paydowns resulted in an aggregate principal reduction of \$11,159 (US\$8,165) for a cash payment of \$11,159 (US\$8,165). On August 8, 2024, the Company entered into an amendment (the â€Amending Agreementâ€) with all of the lenders to the Credit Facility under the Credit Agreement dated March 18, 2021, as amended on October 24, 2022 and July 13, 2023, among the Company and 11065220 Canada Inc., as borrowers, the lenders party thereto and Wilmington Trust, National Association, as administrative and collateral agent. Pursuant to the terms of the Amending Agreement, the maturity date of the Credit Facility was extended to December 18, 2026 and a mandatory US\$97,500 prepayment of the Credit Facility at 97.5% of par thereby reducing the outstanding amount of the Credit Facility by US\$100,000 was required to be made by December 31, 2024. In addition, the maturity date of the Credit Facility will be further extended to September 18, 2027 if an optional prepayment on the same terms is made on or before March 31, 2025. The Amending Agreement also includes changes to certain negative covenants, repayment provisions in the event of divestitures and events of default. Through August 8, 2024, the Credit Facility matured on March 18, 2026 and through December 26, 2023, had an interest rate of LIBOR + 8.50%. After August 8, 2024, the Credit Facility matures on December 18, 2026, and after December 26, 2023, interest on amounts outstanding under the Credit Facility is calculated at either the applicable prime rate plus 7.50% per annum, subject to a prime rate floor of 2.00%, or adjusted term SOFR plus 8.50% per annum, subject to an adjusted term SOFR floor of 1.00%. The Company's obligations under the Credit Facility are guaranteed by material wholly-owned Canadian and U.S. subsidiaries of the Company. The Credit Facility is secured by substantially all of the assets of the Company and its material wholly-owned Canadian and U.S. subsidiaries, including material real property. The Amended Credit Agreement contains representations and warranties, and affirmative and negative covenants. On

September 27, 2024, the Company repurchased additional outstanding principal amounts under the Credit Facility (the “Second Quarter 2025 Paydown”). The Second Quarter 2025 Paydown resulted in an aggregate principal reduction of \$1,148 (US\$851) for a cash payment of \$1,148 (US\$851). In accordance with the Amending Agreement, on October 16, 2024, the Company made an early prepayment under its Credit Facility in an aggregate principal amount equal to US\$100,000 of the principal amount outstanding thereunder at a discounted price of US\$97,500 (the “Third Quarter 2025 Paydown”). The Third Quarter 2025 Paydown resulted in an aggregate principal reduction of \$137,710 (US\$100,000) for a cash payment of \$134,267 (US\$97,500). 21. A Promissory Note On April 13, 2023, the Company entered into an exchange agreement (the “April 2023 Exchange Agreement”) with Greenstar Canada Investment Limited Partnership (the “Greenstar”), an affiliate of Constellation Brands, Inc. (the “CBI”), in order to acquire and cancel \$100,000 aggregate principal amount of the 4.25% unsecured senior notes due in 2023 (the “Canopy Notes”). Pursuant to the April 2023 Exchange Agreement, the Company agreed to acquire and cancel \$100,000 aggregate principal amount of the Canopy Notes held by Greenstar in exchange for: (i) a cash payment to Greenstar in the amount of the unpaid and accrued interest owing under the Canopy Notes held by Greenstar; and (ii) a promissory note (the “CBI Note”) issuable to Greenstar in the aggregate amount of \$100,000 payable on December 31, 2024. The CBI Note bears interest at a rate of 4.25% per year, payable on maturity of the CBI Note. On April 18, 2024, the Company entered into an exchange agreement (the “April 2024 Exchange Agreement”) with Greenstar, pursuant to which Greenstar converted approximately \$81,220 of the principal amount of the \$100,000 principal amount of the CBI Note into 9,111,549 exchangeable shares of the Company (the “Exchangeable Shares”), calculated based on a price per Exchangeable Share equal to \$8.91 (the “Note Exchange”). Pursuant to the terms of the April 2024 Exchange Agreement, all accrued but unpaid interest on the CBI Note together with the remaining principal amount of the CBI Note was cancelled and forgiven for no additional consideration by Greenstar. Following the closing of the Note Exchange, there is no outstanding balance owing under the CBI Note and the CBI Note has been cancelled. Supreme Cannabis Convertible Debentures and Accretion Debentures On October 19, 2018, The Supreme Cannabis Company, Inc. (the “Supreme Cannabis”) entered into an indenture with Computershare Trust Company of Canada (the “Trustee”) pursuant to which Supreme Cannabis issued 6.0% senior unsecured convertible debentures (the “Supreme Debentures”) for gross proceeds of \$100,000. On September 9, 2020, Supreme Cannabis and the Trustee entered into a supplemental indenture to effect certain amendments to the Supreme Debentures, which included among other things: (i) the cancellation of \$63,500 of principal amount of the Supreme Debentures; (ii) an increase in the interest rate to 8% per annum; (iii) the extension of the maturity date to September 10, 2025; and (iv) a reduction in the conversion price to \$2.85. In addition, on September 9, 2020, Supreme Cannabis issued new senior unsecured non-convertible debentures (the “Accretion Debentures”). The principal amount began at nil and accreted at a rate of 11.06% per annum based on the remaining principal amount of the Supreme Debentures of \$36,500 to a maximum of \$13,500, compounding on a semi-annual basis commencing on September 9, 2020, and ending on September 9, 2023. As of September 9, 2023, the principal amount of the Accretion Debentures was finalized as \$10,434. The Accretion Debentures are payable in cash, but do not bear cash interest and are not convertible into the common shares of Supreme Cannabis (the “Supreme Shares”). The principal amount of the Accretion Debentures will amortize, or be paid, at 1.0% per month over the 24 months prior to maturity. As a result of the completion of an arrangement on June 22, 2021 by the Company and Supreme Cannabis, pursuant to which the Company acquired 100% of the issued and outstanding Supreme Shares (the “Supreme Arrangement”), the Supreme Debentures remain outstanding as securities of Supreme Cannabis, which, upon conversion will entitle the holder thereof to receive, in lieu of the number of Supreme Shares to which such holder was theretofore entitled, the consideration payable under the Supreme Arrangement that such holder would have been entitled to be issued and receive if, immediately prior to the effective time of the Supreme Arrangement, such holder had been the registered holder of the number of Supreme Shares to which such holder was theretofore entitled. In connection with the Supreme Arrangement, the Company, Supreme Cannabis and the Trustee entered into a supplemental indenture whereby the Company agreed to issue common shares upon conversion of any Supreme Debenture. In addition, the Company may force conversion of the Supreme Debentures outstanding with 30 days’ notice if the daily volume weighted average trading price of the Company’s common shares is greater than \$385.90 for any 10 consecutive trading days. The Company, Supreme Cannabis and the Trustee entered into a further supplemental indenture whereby the Company agreed to guarantee the obligations of Supreme Cannabis pursuant to the Supreme Debentures and the Accretion Debentures. Prior to September 9, 2023, the Supreme Debentures were not redeemable. Beginning on and after September 9, 2023, Supreme Cannabis may from time to time, upon providing 60 days prior written notice to the Trustee, redeem the Supreme Debentures outstanding, provided that the Accretion Debentures have already been redeemed in full. During the three and nine months ended December 31, 2024, principal payments on Accretion Debentures totaled \$530 and \$1,207, respectively, and approximately \$nil and \$30,227, respectively, of aggregate principal amount of outstanding Supreme Debentures and Accretion Debentures were settled through the August 2024 Supreme Convertible Debt Exchange (as defined below) and the Exchange and Subscription Agreement (as defined below). On August 20, 2024, the Company entered into an exchange and subscription agreement (the “August 2024 Supreme Convertible Debt Exchange”) with a single institutional investor (the “August 2024 Investor”) pursuant to which, among other things, the August 2024 Investor delivered to the Company approximately 2,664 of aggregate principal amount of outstanding Supreme 22 A Debentures held by the August 2024 Investor in exchange for 291,351 common shares of the Company and \$29 in cash for accrued interest. May 2024 Convertible Debenture On May 2, 2024, the Company entered into an exchange and subscription agreement (the “Exchange and Subscription Agreement”) with a single institutional investor (the “May 2024 Investor”) pursuant to which, among other things, the May 2024 Investor delivered to the Company approximately 27,563 aggregate principal amount of outstanding Supreme Debentures and Accretion Debentures held by the May 2024 Investor and paid the Company \$68,255 (US\$50,000) in exchange for the Company issuing to the May 2024 Investor (i) a new senior unsecured convertible debenture of the Company (the “May 2024 Convertible Debenture”) with an aggregate principal amount of \$96,358 maturing five years from the closing date (the “Closing Date”) of the transaction and (ii) 3,350,430 common share purchase warrants (the “May 2024 Investor Warrants”) of the Company. Each May 2024 Investor Warrant entitles the holder to acquire one Canopy Growth common share at an exercise price equal to \$16.18 per Canopy Growth common share for a period of five years from the Closing Date. The May 2024 Convertible Debenture bears interest at a rate of 7.50% per annum, payable in semi-annual payments in cash or, at the option of the Company, in Canopy Growth common shares for the first four semi-annual interest payments after the Closing Date, subject to satisfaction of certain conditions, including the prior approval of the TSX. The May 2024 Convertible Debenture is convertible into Canopy Growth common shares at the option of the May 2024 Investor at a conversion price equal to \$14.38 per share. The May 2024 Convertible Debenture is subject to a forced conversion feature upon notice from the Company in the event that the average closing trading price of the Canopy Growth common shares on the TSX exceeds \$21.57 for a period of 10 consecutive trading days. In addition, pursuant to the terms of the May 2024 Convertible Debenture, for so long as the principal amount under the May 2024 Convertible Debenture remains outstanding (the “Debenture ROFR Term”), the Company granted the May 2024 Investor a right of first refusal to subscribe for, and to be issued, as an investor in any debt or equity financing that the Company wishes to complete during the Debenture ROFR Term (the “Proposed Financing”); provided, however, that the May 2024 Investor shall subscribe for 25% of the Proposed Financing on the same terms and conditions contemplated in the Proposed Financing. 18. OTHER LIABILITIES The components of other liabilities are as follows: A A As at December 31, 2024 A A As at March 31, 2024 A A Current A A Long-term A A Total A A Current A A Long-term A A Total A Lease liabilities A \$ 18,579 A A \$ 29,524 A A \$ 48,103 A A \$ 15,173 A A \$ 55,597 A A \$ 70,770 A Acquisition consideration A A and other investment A A related liabilities A A - A A 4,265 A A \$ 4,265 A A \$ 12,809 A A \$ 10,558 A A \$ 23,367 A Refund liability A A 2,727 A A - A A 2,727 A A 4,169 A A - A A 4,169 A Settlement liabilities and A A other A A 6,434 A A \$ 3,535 A A \$ 9,969 A A \$ 15,917 A A \$ 5,659 A A \$ 21,576 A A \$ 27,740 A A \$ 37,324 A A \$ 65,064 A A \$ 48,068 A A \$ 71,814 A A \$ 119,882 A In December 2024, the Company renegotiated the terms of a facility lease, resulting in a short-term to long-term reclassification of its lease liabilities. The renegotiated terms result in changes to future cashflows associated with the lease. 19. SHARE CAPITAL CANOPY GROWTH Authorized An unlimited number of common shares. (i) Equity financings On June 6, 2024, the Company established an at-the-market equity program that allows it to sell up to US\$250,000 of common shares of the Company from treasury to the public from time to time at the Company’s discretion (the “ATM Program”). The ATM Program will be effective until the earlier of (i) the issuance and sale of all of the common shares issuable pursuant to the ATM Program (ii) the date on which the Company receives notice from a securities regulatory authority that the Company’s Canadian short form base shelf prospectus dated June 5, 2024 and/or the Company’s registration statement on Form S-3ASR has ceased to be effective and (iii) July 5, 2026, unless terminated earlier in accordance with the terms of the equity distribution agreement entered into between the Company and BMO Nesbitt Burns Inc., as Canadian agent, and BMO Capital Markets Corp., as U.S. agent. As part of the ATM Program, during the three and nine months ended December 31, 2024, the Company sold 22,713,177 and 39,519,029 common 23 A shares, respectively, for gross proceeds of \$117,513 and \$255,989, respectively. Refer to Note 30 for additional information on common shares sold after December 31, 2024 as part of the ATM Program. For the three and nine months ended December 31, 2023, the Company issued nil and 2,292,947 common shares, respectively, for aggregate gross proceeds of \$nil and \$33,745, respectively, relating to the private placement unit offering completed by the Company pursuant to the terms of the subscription agreements entered into between the Company and certain institutional investors on September 18, 2023. (ii) Other issuances of common shares and share capital transactions During the nine months ended December 31, 2024, the Company had the following other issuances and share capital transactions: A Number of common shares A A Share capital A A Share and warrants reserve A A Settlement of Acreage Acquisition A \$ 12,559,230 A A \$ 63,915 A A \$ 11,939 A Other issuances and share issue costs A A - A A (6,567) A A - A Total A \$ 12,559,230 A A \$ 57,348 A A \$ 11,939 A During the nine months ended December 31, 2023, the Company had the following other issuances and share capital transactions: A Number of common shares A A Share capital A A Share based reserve A A Settlement of convertible debentures A \$ 8,445,894 A A \$ 108,055 A A - A Settlement of Canopy Notes A \$ 11,477,366 A A \$ 57,084 A A - A Settlement of debentures A \$ 7,341,818 A A \$ 87,754 A A - A Other issuances and share issue costs A \$ 6,165 A A (317) A A (80) Total A \$ 27,271,243 A A \$ 252,576 A A \$ (80) (iii) Warrants A Number of whole warrants A A Average exercise price A A Warrant value A Balance outstanding at March 31, 2024 A \$ 10,451,457 A A \$ 9.12 A A \$ 2,610,519 A Issuance of warrants A \$ 4,548,088 A A \$ 13.31 A A \$ 13,525 A Issuance of replacement warrants resulting from the Acreage Acquisition A \$ 1,845,843 A A \$ 10.72 A A \$ 7,111 A Exercise of warrants A (1,279,660) A A 6.60 A A (3,018) Balance outstanding at December 31, 2024 A \$ 15,565,728 A A \$ 11.09 A A \$ 2,628,137 A A Number of whole warrants A A Average exercise price A A Warrant value A Balance outstanding at March 31, 2023 A \$ 12,819,305 A A \$ 580.40 A A \$ 2,581,788 A Issuance of warrants from private placement A \$ 2,292,947 A A \$ 18.33 A A \$ 8,977 A Expiry of Warrants A (12,692,731) A A 583.62 A A - A Balance outstanding at December 31, 2023 A \$ 2,419,521 A A \$ 30.34 A A \$ 2,590,765 A 1 This balance excludes warrants previously issued by the Company to CBG (as defined below) which were exercisable to acquire 1,281,815 common shares at an exercise price equal to the 5-day volume-weighted average price of the Company common shares immediately prior to exercise (the “Tranche C Warrants”). The Tranche C Warrants represent a derivative liability and have nominal value. As of November 1, 2023, the Tranche C Warrants are considered expired in accordance with their terms. (iv) Issuances of exchangeable shares On April 18, 2024, Greenstar and CBG Holdings LLC (the “CBG”), indirect, wholly-owned subsidiaries of CBI exchanged all 17,149,925 Canopy Growth common shares they collectively held for 17,149,925 Exchangeable Shares for no consideration. In addition, an additional 9,111,549 Exchangeable Shares were issued to Greenstar as part of the Note Exchange. The Exchangeable Shares are convertible at any time, at the option of the holder, into Canopy Growth common shares on a one for one basis. See Note 17 for additional details relating to the Note Exchange. 24 A 20. SHARE-BASED COMPENSATION CANOPY GROWTH CORPORATION SHARE-BASED COMPENSATION PLAN On September 25, 2023, the Company’s shareholders approved a new Omnibus Equity Incentive Plan (the “Omnibus Equity Incentive Plan”) pursuant to which the Company can issue share-based long-term incentives. The Omnibus Equity Incentive Plan replaces the Company’s previous equity incentive plan, which was originally approved by the Company’s shareholders on July 30, 2018 (the “Previous Equity Incentive Plan”), together with the Omnibus Equity Incentive Plan, the “Incentive Plans”). The approval of the Omnibus Equity Incentive Plan and replacement of the Previous Equity Incentive Plan are detailed in the Company’s definitive proxy statement filed with the Securities and Exchange Commission on August 9, 2023. All directors, employees and consultants of the Company are eligible to receive awards of common share purchase options (the “Options”), restricted share units (the “RSUs”), deferred share units or shares-based awards (collectively, the “Awards”) under the Omnibus Equity Incentive Plan, subject to certain limitations. The Omnibus Equity Incentive Plan allows for a maximum term of each Option to be ten years from the date of grant and the maximum number of common shares available for issuance under the Omnibus Equity Incentive Plan remains at 10% of the issued and outstanding common shares from time to time, less the number of common shares issuable pursuant to other security-based compensation arrangements of the Company (including common shares reserved for issuance under the Previous Equity Incentive Plan). The Omnibus Equity Incentive Plan was adopted on September 25, 2023. No further awards will be granted under the Previous Equity Incentive Plan and any new Awards will be issued by the Company pursuant to the terms of the Omnibus Equity Incentive Plan. However, outstanding and unvested awards granted under the Previous Equity Incentive Plan will continue to be governed in accordance with the terms of such plan. The maximum number of common shares reserved for issuance upon the exercise or vesting, as applicable, of Awards granted pursuant to the Incentive Plans is 12,915,301 as at December 31, 2024. As of December 31, 2024, the only Awards issued have been Options, RSUs and performance share units (the “PSUs”) under the Previous Equity Incentive Plan, and Options and RSUs under the Omnibus Equity Incentive Plan. The Omnibus Equity Incentive Plan is administered by the Corporate Governance, Compensation and Nominating Committee of the Board, which establishes in its discretion, among other things, exercise prices, at not less than the Fair Market Value (as defined in the Omnibus Equity Incentive Plan) at the date of grant, vesting terms and expiry dates (set at up to ten years from issuance) for Awards, subject to the limits contained in the Omnibus Equity Incentive Plan. The following is a summary of the changes in the Options outstanding during the nine months ended December 31, 2024: A A Options issued A A Weighted average exercise price A Balance outstanding at March 31, 2024 A \$ 2,883,922 A A \$ 70.01 A Options granted A \$ 765,107 A A \$ 10.37 A Replacement options issued resulting from the Acreage Acquisition A \$ 93,383 A A \$ 85.67 A Options exercised A (18,621) A A 6.05 A Options expired/forfeited A (243,483) A A 226.05 A Balance outstanding at December 31, 2024 A \$ 3,480,308 A A \$ 37.84 A The following is a summary of the Options outstanding as at December 31, 2024: A A Options Outstanding A A Options Exercisable A A A A Weighted Average A A A A Weighted Average A A A A Remaining A A A A Remaining A A A A Outstanding at A A Contractual Life A A Exercisable at A A Contractual Life A Range of Exercise Prices A December 31, 2024 A (years) A A December 31, 2024 A (years) A \$ 0.60A - \$ 7.50 A A 2,030,678 A A 4.50 A A 668,981 A A 4.50 A \$ 7.51A - \$ 56.10 A A 1,040,200 A A 4.96 A A 183,390 A A 3.64 A \$ 56.11A - \$ 585.10 A A 409,430 A A 1.08 A A 301,556 A A 1.16 A A 3,480,308 A A 4.32 A A 1,153,927 A A 3.69 A 1 Prior period Options and exercise price amounts have been retrospectively adjusted to reflect the Share Consolidation, which became effective on December 15, 2023. See Note 2 for details. At December 31, 2024, the weighted average exercise price of the Options outstanding and Options exercisable was \$37.84 and \$75.56, respectively (March 31, 2024 at \$70.01 and \$312.68, respectively). 25 A The Company recorded \$3,262 and \$9,484 in share-based compensation expense related to Options issued to employees and contractors for the three and nine months ended December 31, 2024, respectively (three and nine months ended December 31, 2023 at \$2,671 and \$7,637, respectively). The share-based compensation expense for the nine months ended December 31, 2024, includes an amount related to 107,874 Options being provided in exchange for services which are subject to performance conditions (for the nine months ended December 31, 2023 at \$107,874). The Company uses the Black-Scholes option pricing model to establish the fair value of Options granted during the three months ended December 31, 2024 and 2023, on their measurement date by applying the following assumptions: A A December 31, A December 31, A A 2024 A 2023 Risk-free interest rate A - A 3.95% Expected life of options (years) A - A 3A - 5 Expected volatility A - A 101% Expected forfeiture rate A - A 21% Expected dividend yield A - A nil Black-Scholes value of each Option A - A \$5.33 Volatility was estimated by using the historical volatility of the Company. The expected life in years represents the period of time that Options granted are expected to be outstanding. The risk-free rate was based on zero coupon Canada government bonds with a remaining term equal to the expected life of the Options. For the three and nine months ended December 31, 2024, the Company recorded \$1,897 and \$5,047, respectively, in share-based compensation expense related to RSUs and PSUs (for the three and nine months ended December 31, 2023 at \$1,022 and \$2,490, respectively). The following is a summary of the changes in the Company’s RSUs and PSUs during the nine months ended December 31, 2024: A A Number of RSUs and PSUs A Balance outstanding at March 31, 2024 A \$ 1,272,299 A RSUs and PSUs granted A \$ 720,873 A Replacement RSUs issued resulting from the Acreage Acquisition A \$ 6,627 A RSUs and PSUs released A (433,268) RSUs and PSUs cancelled and forfeited A (130,257) Balance outstanding at December 31, 2024 A \$ 1,436,274 A 21. ACCUMULATED OTHER

risk of financial liabilities. Accumulated other comprehensive income (loss) As at March 31, 2024 \$ (31,178) \$ 15,127 \$ (16,051) Disposal and liquidation of consolidated entities \$ 18,593 \$ 18,593 Extinguishment of promissory note and issuance of exchangeable shares \$ - \$ (15,127) \$ (15,127) Other comprehensive income \$ 3,586 \$ 3,586 As at December 31, 2024 \$ (8,999) \$ (8,999) \$ - Foreign currency translation adjustments \$ - \$ - \$ - Changes of own credit risk of financial liabilities Accumulated other comprehensive income (loss) As at March 31, 2023 \$ (30,261) \$ 16,401 \$ (13,860) Settlement of unsecured senior notes, net of deferred income tax \$ - \$ 11,060 \$ 11,060 Other comprehensive income (loss) \$ 575 \$ (13,824) \$ (13,249) As at December 31, 2023 \$ (29,686) \$ 13,637 \$ (16,049) 26.22. NONCONTROLLING INTERESTS The net change in the noncontrolling interests is as follows: \$ - \$ - \$ - Other \$ - \$ - \$ - Total As at March 31, 2024 \$ 139 \$ 139 \$ 139 Comprehensive income (loss) \$ - \$ - \$ - Canopy USA Transaction \$ (139) \$ (139) \$ - As at December 31, 2024 \$ - \$ - \$ - BioSteel \$ - \$ - \$ - Other \$ - \$ - \$ - Total As at March 31, 2023 \$ 1,447 \$ 140 \$ 1,587 Comprehensive loss \$ (18,526) \$ (18,526) \$ - Net loss attributable to redeemable noncontrolling interest \$ 18,526 \$ 18,526 \$ 18,526 Share-based compensation \$ 148 \$ 148 \$ 148 Ownership changes \$ (1,595) \$ (1,595) \$ (1,595) As at December 31, 2023 \$ - \$ 139 \$ 139 23. FAIR VALUE OF FINANCIAL INSTRUMENTS Fair value measurements are made using a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value: Level 1 defined as observable inputs such as quoted prices in active markets; Level 2 defined as inputs other than quoted prices in active markets that are either directly or indirectly observable; and Level 3 defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions. The fair value measurement is categorized in its entirety by reference to its lowest level of significant input. The Company records cash, accounts receivable, interest receivable and accounts payable, and other accrued expenses and liabilities at cost. The carrying values of these instruments approximate their fair value due to their short-term maturities. Unless otherwise noted, it is management's opinion that the Company is not exposed to significant interest or credit risks arising from these financial instruments. Assets and liabilities recognized or disclosed at fair value on a nonrecurring basis may include items such as property, plant and equipment, goodwill and other intangible assets, equity and other investments and other assets. The Company determines the fair value of these items using Level 3 inputs, as described in the related sections below. The following table represents the Company's financial assets and liabilities measured at estimated fair value on a recurring basis: \$ Fair value measurement using \$ Quoted \$ Significant \$ prices in \$ other \$ Significant \$ active \$ observable \$ unobservable \$ markets \$ inputs \$ (Level 1) \$ (Level 2) \$ (Level 3) \$ Total December 31, 2024 \$ Assets: \$ Short-term investments \$ 16,435 \$ 16,435 \$ 16,435 \$ Restricted short-term investments \$ 7,108 \$ 7,108 \$ 7,108 \$ Equity method investments \$ 49,834 \$ 49,834 \$ 49,834 \$ Other financial assets \$ 46 \$ 46 \$ 318,051 \$ 318,097 \$ 318,097 \$ As at March 31, 2024 \$ Assets: \$ Short-term investments \$ 33,161 \$ 33,161 \$ 33,161 \$ Restricted short-term investments \$ 7,310 \$ 7,310 \$ 7,310 \$ Other financial assets \$ 2,957 \$ 426,306 \$ 429,263 \$ Liabilities: \$ Long-term debt \$ 89,224 \$ 89,224 \$ 89,224 \$ Other liabilities \$ 18,983 \$ 18,983 \$ 27 \$ The following table summarizes the valuation techniques and significant unobservable inputs in the fair value measurement of significant level 3 financial instruments: \$ Financial asset / financial liability \$ Valuation techniques \$ Significant unobservable inputs \$ Relationship of unobservable inputs to fair value \$ Canopy USA Equity Method Investment \$ Asset based approach \$ Probability and timing of US legalization \$ Increase or decrease in probability of US legalization will result in an increase or decrease in fair value \$ Discount rate \$ Increase or decrease in discount rate will result in a decrease or increase in fair value \$ Expected future cash flows \$ Increase or decrease in expected future cash flows will result in an increase or decrease in fair value \$ Volatility of Wana and Jetty equity \$ Increase or decrease in volatility will result in an increase or decrease in fair value \$ Elevate Loan Receivable \$ Lesser of discounted cash flow and debtor net assets \$ Equity value of Canopy USA \$ Increase or decrease in equity value will result in an increase or decrease in fair value \$ Acreage Debt \$ Discounted cash flow \$ Discount rate \$ Increase or decrease in discount rate will result in a decrease or increase in fair value 24. REVENUE Revenue is disaggregated as follows: \$ Three months ended \$ Nine months ended \$ December 31, \$ December 31, \$ December 31, \$ December 31, \$ 2024 \$ 2023 \$ 2024 \$ 2023 \$ Canada cannabis \$ 21,153 \$ 23,490 \$ 58,424 \$ 71,848 \$ Canadian medical cannabis \$ 19,575 \$ 16,894 \$ 57,059 \$ 48,695 \$ \$ 40,728 \$ 40,384 \$ 115,483 \$ 120,543 \$ International markets cannabis \$ 12,024 \$ 10,527 \$ 32,166 \$ 29,666 \$ Storz & Bickel \$ 22,009 \$ 18,453 \$ 56,315 \$ 48,517 \$ This Works \$ 8,165 \$ 21,256 \$ Other \$ 976 \$ 4,376 \$ 74,761 \$ 78,505 \$ \$ 203,964 \$ 224,358 \$ 1 Canadian adult-use net revenue during the three and nine months ended December 31, 2024 reflects excise taxes of \$9,335 and \$25,755, respectively (three and nine months ended December 31, 2023) \$9,741 and \$31,596, respectively. 2 Canadian medical cannabis net revenue for the three and nine months ended December 31, 2024 reflects excise taxes of \$2,148 and \$6,266, respectively (three and nine months ended December 31, 2023) \$1,815 and \$4,827, respectively). The Company recognizes variable consideration related to estimated future product returns and price adjustments as a reduction of the transaction price at the time revenue for the corresponding product sale is recognized. Net revenue reflects actual returns and variable consideration related to estimated returns and price adjustments in the amount of \$986 and \$3,486 for the three and nine months ended December 31, 2024, respectively (three and nine months ended December 31, 2023) \$1,430 and \$2,937, respectively). As of December 31, 2024, the liability for estimated returns and price adjustments was \$2,727 (March 31, 2024) \$4,169. 25. OTHER INCOME (EXPENSE), NET Other income (expense), net is disaggregated as follows: \$ Three months ended \$ Nine months ended \$ December 31, \$ December 31, \$ December 31, \$ December 31, \$ 2024 \$ 2023 \$ 2024 \$ 2023 \$ Fair value changes on Canopy USA related assets \$ (148,734) \$ (209,643) \$ (164,985) \$ Fair value changes on other financial assets \$ (50) \$ 2,062 \$ (2,915) \$ 1,125 \$ Fair value changes on debt \$ (5,400) \$ (30,614) \$ Fair value changes on acquisition related contingent \$ consideration and other \$ 8,629 \$ (33,472) \$ 19,146 \$ Gain (charges) related to settlement of debt \$ (571) \$ 22,439 \$ (13,124) \$ Interest income \$ 1,941 \$ 2,548 \$ 6,415 \$ 13,833 \$ Interest expense \$ (16,766) \$ (24,623) \$ (59,187) \$ (84,223) \$ Foreign currency gain (loss) \$ 723 \$ (4,069) \$ 1,430 \$ 529 \$ Other income (expense), net \$ (7,355) \$ (879) \$ (2,019) \$ 5,043 \$ \$ (97,758) \$ (171,037) \$ \$ (276,952) \$ (253,270) \$ 1 Included in fair value changes on Canopy USA assets are fair value changes on other financial assets of \$64,143 and \$20,389 for the three and nine months ended December 31, 2024, respectively (\$148,734) and (\$164,985) for the three and nine months ended December 31, 2023, respectively. 2 Included in fair value changes on Canopy USA assets are fair value changes on equity method investments of (\$140,394) and (\$230,032) for the three and nine months ended December 31, 2024, respectively (\$nil and \$nil for the three and nine months ended December 31, 2023, respectively). 26. INCOME TAXES There have been no material changes to income tax matters in connection with normal course operations during the nine months ended December 31, 2024. The Company is subject to income tax in numerous jurisdictions with varying income tax rates. During the most recent period ended and the fiscal year to date, there were no material changes to the statutory income tax rates in the taxing jurisdictions where the majority of the Company's income for tax purposes was earned, or where its temporary differences or losses are expected to be realized or settled. Although statutory income tax rates remain stable, the Company's effective income tax rate may fluctuate, arising as a result of the Company's evolving footprint, discrete transactions and other factors that, to the extent material, are disclosed in these financial statements. The Company continues to believe that the amount of unrealized tax benefits appropriately reflects the uncertainty of items that are or may in the future be under discussion, audit, dispute or appeal with a tax authority or which otherwise result in uncertainty in the determination of income for tax purposes. If appropriate, an unrealized tax benefit will be realized in the reporting period in which the Company determines that realization is not in doubt. Where the final determined outcome is different from the Company's estimate, such difference will impact the Company's income taxes in the reporting period during which such determination is made. 27. ACREAGE ARRANGEMENT On December 9, 2024, Canopy USA completed the Acreage Acquisition and now owns 100% of the issued and outstanding shares of Acreage. In connection with: (i) the Existing Acreage Arrangement Agreement and the amended and restated plan of arrangement (the "Acreage Amended Arrangement") implemented by Canopy Growth and Acreage on September 23, 2020 in connection with the Existing Acreage Arrangement Agreement; and (ii) the Floating Share Arrangement Agreement, Canopy USA acquired all of the issued and outstanding Floating Shares of Acreage on the terms and conditions set forth in Floating Share Arrangement. Immediately following the implementation of the Floating Share Arrangement, Canopy USA completed the Fixed Share Acquisition. In aggregate, Canopy Growth issued 5,888,291 common shares to former shareholders of Acreage. Pursuant to the Floating Share Arrangement, (i) each outstanding stock option to acquire Floating Shares was exchanged for a replacement option exercisable for Canopy Growth common shares, with the number of underlying Canopy Growth common shares and exercise price of such options adjusted by the Floating Share Exchange Ratio; (ii) each outstanding warrant to acquire Floating Shares was exchanged for a replacement warrant to acquire Canopy Growth common shares, with the number of underlying Canopy Growth common shares and exercise price of such warrants adjusted by the Floating Share Exchange Ratio; and (iii) each outstanding restricted share unit, performance share and performance unit, as applicable, that vested into Floating Shares was exchanged for a replacement restricted share unit, performance share or performance unit, as applicable, that vests into Canopy Growth common shares, with the number of underlying Canopy Growth common shares adjusted by the Floating Share Exchange Ratio. In connection with the Fixed Share Acquisition, (i) each outstanding stock option to acquire Fixed Shares was exchanged for a replacement option exercisable for Canopy Growth common shares, with the number of underlying Canopy Growth common shares and exercise price of such options adjusted by the Fixed Share Exchange Ratio; (ii) each outstanding warrant to acquire Fixed Shares was exchanged for a replacement warrant to acquire Canopy Growth common shares, with the number of underlying Canopy Growth common shares and exercise price of such warrants adjusted by the Fixed Share Exchange Ratio; and (iii) each restricted share unit and performance share unit, as applicable, that vested into Fixed Shares was exchanged for a replacement restricted share unit or performance share unit, as applicable, that vests into Canopy Growth common shares, with the number of underlying Canopy Growth common shares adjusted by the Fixed Share Exchange Ratio. See Note 3 for information regarding the Reorganization. In connection with the Reorganization and the Floating Share Arrangement Agreement, Canopy Growth irrevocably waived the Acreage Floating Option. Following the implementation of the Reorganization, Canopy USA, holds certain U.S. cannabis investments previously held by the Company, which enabled Canopy USA to consummate the acquisition of Acreage. See Note 3 for more details related to the Acreage Acquisition. 28. COMMITMENTS AND CONTINGENCIES Legal proceedings In the ordinary course of business, the Company is at times subject to various legal proceedings and disputes, including the proceedings specifically discussed below. The Company assesses the liabilities and contingencies in connection with outstanding legal proceedings utilizing the latest information available. Where it is probable that the Company will incur a loss and the amount of the loss can be reasonably estimated, a liability is recorded in the consolidated financial statements. Where a loss is only reasonably possible or the amount of the loss cannot be reasonably estimated, no liability is recorded in the consolidated financial statements, but disclosures, as necessary, are provided. For the three months ended December 31, 2024 there have been no material changes with respect to provisions relating to legal proceedings for the Company. 29. SEGMENT INFORMATION Reportable segments The Company reports its financial results for the following four reportable segments: \$ Canada cannabis - includes the production, distribution and sale of a diverse range of cannabis, hemp and cannabis-related products in Canada pursuant to the Cannabis Act and cannabis-related areas such as merchandise and clinics; \$ International markets cannabis - includes the production, distribution and sale of a diverse range of cannabis and hemp products internationally pursuant to applicable international legislation, regulations and permits. Priority markets include medical cannabis in Australia and Europe where the Company offers branded high-quality flower, oil and extract products under the Company's recognized Spectrum Therapeutics, Canopy Medical and Tweed brands, as well as the Company's Storz & Bickel line of medically approved vaporizers in Australia; \$ Storz & Bickel - includes the production, distribution and sale of vaporizers and accessories; and \$ This Works - includes the production, distribution and sale of beauty, skincare, wellness and sleep products, some of which have been blended with hemp-derived CBD isolate. On December 18, 2023, the Company completed the sale of This Works and as of such date, the results of This Works are no longer included in the Company's financial results. These segments reflect how the Company's operations are managed, how the Company's Chief Executive Officer, who is the Chief Operating Decision Maker (CODM), allocates resources and evaluates performance, and how the Company's internal management financial reporting is structured. The Company's CODM evaluates the performance of these segments, with a focus on (i

Interim Financial Statements in accordance with accounting principles generally accepted in the United States of America (“US GAAP”). Our Interim Financial Statements and the financial information contained herein, are reported in thousands of Canadian dollars, except share and per share amounts or as otherwise stated. We have determined that the Canadian dollar is the most relevant and appropriate reporting currency as, despite continuing shifts in the relative size of our operations across multiple geographies, the majority of our operations are conducted in Canadian dollars and our financial results are prepared and reviewed internally by management in Canadian dollars. Special Note Regarding Forward-Looking Statements This Quarterly Report contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) and other applicable securities laws, which involve certain known and unknown risks and uncertainties. Forward-looking statements predict or describe our future operations, business plans, business and investment strategies and the performance of our investments. These forward-looking statements are generally identified by their use of such terms and phrases as “intend,” “goal,” “strategy,” “estimate,” “expect,” “project,” “projections,” “forecasts,” “plans,” “seek,” “anticipates,” “opportunity,” “propose,” “will,” “should,” “could,” “would,” “may,” “likely,” “designed to,” “foreseeable future,” “believe,” “scheduled,” and other similar expressions. Our actual results or outcomes may differ materially from those anticipated. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date the statement was made. Forward-looking statements include, but are not limited to, statements with respect to: “laws and regulations and any amendments thereto applicable to our business and the impact thereof, including uncertainty regarding the application of U.S. state and federal law to cannabis and hemp (including CBD) products and the scope of any regulations by the U.S. Food and Drug Administration, the U.S. Drug Enforcement Administration, the U.S. Federal Trade Commission, the U.S. Patent and Trademark Office, the U.S. Department of Agriculture and any state equivalent regulatory agencies over cannabis and hemp (including CBD) products; “expectations regarding the amount or frequency of impairment losses, including as a result of the write-down of intangible assets, including goodwill; “our ability to refinance debt as and when required on terms favorable to us and comply with covenants contained in our debt facilities and debt instruments; “the impacts of the Company’s strategy to accelerate entry into the U.S. cannabis market through the creation of Canopy USA, LLC (“Canopy USA”); “expectations for Canopy USA to capitalize on the opportunity for growth in the United States cannabis sector and the anticipated benefits of such strategy; “the timing and occurrence of the final tranche closing in connection with the acquisition of Jetty (as defined below) pursuant to the exercise of the Jetty Options (as defined below); “the issuance of additional common shares of the Company (each whole share, a “Canopy Share” or a “Share”) to satisfy any deferred and/or option exercise payments to the shareholders of Wana (as defined below) and Jetty and the issuance of additional Non-Voting Shares (as defined below) issuable to Canopy Growth from Canopy USA in consideration thereof; 32 “the acquisition of additional Canopy USA Common Shares (as defined below) in connection with the Trust Transaction (as defined below), including any warrants of Canopy USA issued to the Trust (as defined below) in accordance with the Trust SPA (as defined below); “the potential further extension to the maturity date of the Credit Facility (as defined below) and the timing and occurrence of the optional prepayment of the Credit Facility in connection with the Amending Agreement (as defined below); “expectations regarding the potential success of, and the costs and benefits associated with, our acquisitions, equity investments and dispositions; “the grant, renewal and impact of any license or supplemental license to conduct activities with cannabis or any amendments thereof; “our international activities, including required regulatory approvals and licensing, anticipated costs and timing, and expected impact; “our ability to successfully create and launch brands and further create, launch and scale products in jurisdictions where such products are legal and that we currently operate in; “the benefits, viability, safety, efficacy, dosing and social acceptance of cannabis, including CBD and other cannabinoids; “our ability to continue as a going concern; “our ability to maintain effective internal control over financial reporting; “expectations regarding the use of proceeds of equity financings; “the legalization of the use of cannabis for medical or adult-use in jurisdictions outside of Canada, the related timing and impact thereof and our intentions to participate in such markets, if and when such use is legalized; “our ability to execute on our strategy and the anticipated benefits of such strategy; “the ongoing impact of the legalization of additional cannabis product types and forms for adult-use in Canada, including federal, provincial, territorial and municipal regulations pertaining thereto, the related timing and impact thereof and our intentions to participate in such markets; “the ongoing impact of developing provincial, state, territorial and municipal regulations pertaining to the sale and distribution of cannabis, the related timing and impact thereof, as well as the restrictions on federally regulated cannabis producers participating in certain retail markets and our intentions to participate in such markets to the extent permissible; “the timing and nature of legislative changes in the U.S. regarding the regulation of cannabis including tetrahydrocannabinol (“THC”); “the future performance of our business and operations; “our competitive advantages and business strategies; “the competitive conditions of the industry; “the expected growth in the number of customers using our products; “expectations regarding revenues, expenses and anticipated cash needs; “expectations regarding cash flow, liquidity and sources of funding; “expectations regarding capital expenditures; “the expansion of our production and manufacturing, the costs and timing associated therewith and the receipt of applicable production and sale licenses; “expectations with respect to our growing, production and supply chain capacities; “expectations regarding the resolution of litigation and other legal and regulatory proceedings, reviews and investigations; “expectations with respect to future production costs; “expectations with respect to future sales and distribution channels and networks; “the expected methods to be used to distribute and sell our products; “our future product offerings; “the anticipated future gross margins of our operations; “accounting standards and estimates; “expectations regarding our distribution network; “expectations regarding the costs and benefits associated with our contracts and agreements with third parties, including under our third-party supply and manufacturing agreements; “our ability to comply with the listing requirements of the Nasdaq Stock Market LLC (“Nasdaq”) and the Toronto Stock Exchange (“TSX”); and “expectations on price changes for products in cannabis markets. Certain of the forward-looking statements contained herein concerning the industries in which we conduct our business are based on estimates prepared by us using data from publicly available governmental sources, market research, industry analysis and on assumptions based on data and knowledge of these industries, which we believe to be reasonable. However, although generally indicative of relative market positions, market shares and performance characteristics, such data is inherently imprecise. The industries in which we conduct our business involve risks and uncertainties that are subject to change based on various factors, which are described further below. 33 “The forward-looking statements contained herein are based upon certain material assumptions, including: (i) management’s perceptions of historical trends, current conditions and expected future developments; (ii) our ability to generate cash flow from operations; (iii) general economic, financial market, regulatory and political conditions in which we operate; (iv) the production and manufacturing capabilities and output from our facilities, strategic alliances and equity investments; (v) consumer interest in our products; (vi) competition; (vii) anticipated and unanticipated costs; (viii) government regulation of our activities and products including but not limited to the areas of taxation and environmental protection; (ix) the timely receipt of any required regulatory authorizations, approvals, consents, permits and/or licenses; (x) our ability to obtain qualified staff, equipment and services in a timely and cost-efficient manner; (xi) our ability to conduct operations in a safe, efficient and effective manner; (xii) our ability to realize anticipated benefits, synergies or generate revenue, profits or value from our recent acquisitions into our existing operations; and (xiii) other considerations that management believes to be appropriate in the circumstances. While our management considers these assumptions to be reasonable based on information currently available to management, there is no assurance that such expectations will prove to be correct. By their nature, forward-looking statements are subject to inherent risks and uncertainties that may be general or specific and which give rise to the possibility that expectations, forecasts, predictions, projections or conclusions will not prove to be accurate, that assumptions may not be correct and that objectives, strategic goals and priorities will not be achieved. A variety of factors, including known and unknown risks, many of which are beyond our control, could cause actual results to differ materially from the forward-looking statements in this Quarterly Report and other reports we file with, or furnish to, the Securities and Exchange Commission (the “SEC”) and other regulatory agencies and made by our directors, officers, other employees and other persons authorized to speak on our behalf. Such factors include, without limitation, our limited operating history; our ability to continue as a going concern; risks that we may be required to write down intangible assets, including goodwill, due to impairment; the adequacy of our capital resources and liquidity, including but not limited to, availability of sufficient cash flow to execute our business plan (either within the expected timeframe or at all); our ability to maintain an effective system of internal control; the diversion of management time on matters related to Canopy USA; the risks that the Trust’s future ownership interest in Canopy USA is not quantifiable, and the Trust may have significant ownership and influence over Canopy USA; the risks related to the financial statements of Acreage Holdings, Inc. (“Acreage”) expressing doubt about its ability to continue as a going concern; the risks in the event that Acreage cannot satisfy its debt obligations as they become due; volatility in and/or degradation of general economic, market, industry or business conditions; risks relating to the overall macroeconomic environment, which may impact customer spending, our costs and our margins, including tariffs (and related retaliatory measures), the levels of inflation, and interest rates; risks relating to our current and future operations in emerging markets; compliance with applicable environmental, economic, health and safety, energy and other policies and regulations and in particular health concerns with respect to vaping and the use of cannabis products in vaping devices; risks and uncertainty regarding future product development; changes in regulatory requirements in relation to our business and products; our reliance on licenses issued by and contractual arrangements with various federal, state and provincial governmental authorities; inherent uncertainty associated with projections; future levels of revenues and the impact of increasing levels of competition; third-party manufacturing risks; third-party transportation risks; our exposure to risks related to an agricultural business, including wholesale price volatility and variable product quality; changes in laws, regulations and guidelines and our compliance with such laws, regulations and guidelines; risks relating to inventory write downs; risks relating to our ability to refinance debt as and when required on terms favorable to us and to comply with covenants contained in our debt facilities and debt instruments; risks associated with jointly owned investments; our ability to manage disruptions in credit markets or changes to our credit ratings; the success or timing of completion of ongoing or anticipated capital or maintenance projects; risks related to the integration of acquired businesses; the timing and manner of the legalization of cannabis in the United States; business strategies, growth opportunities and expected investment; counterparty risks and liquidity risks that may impact our ability to obtain loans and other credit facilities on favorable terms; the potential effects of judicial, regulatory or other proceedings, litigation or threatened litigation or proceedings, or reviews or investigations, on our business, financial condition, results of operations and cash flows; risks associated with divestment and restructuring; the anticipated effects of actions of third parties such as competitors, activist investors or federal, state, provincial, territorial or local regulatory authorities, self-regulatory organizations, plaintiffs in litigation or persons threatening litigation; consumer demand for cannabis and hemp products; the implementation and effectiveness of key personnel changes; risks related to stock exchange restrictions; risks related to the protection and enforcement of our intellectual property rights; the risks related to our exchangeable shares (the “Exchangeable Shares”) having different rights from our common shares and there may never be a trading market for the Exchangeable Shares; future levels of capital, environmental or maintenance expenditures, general and administrative and other expenses; and the factors discussed under the heading “Risk Factors” in the Annual Report and in Item 1A of Part II of this Quarterly Report. Readers are cautioned to consider these and other factors, uncertainties and potential events carefully and not to put undue reliance on forward-looking statements. Forward-looking statements are provided for the purposes of assisting the reader in understanding our financial performance, financial position, and cash flows as of and for periods ended on certain dates and to present information about management’s current expectations and plans relating to the future, and the reader is cautioned that the forward-looking statements may not be appropriate for any other purpose. While we believe that the assumptions and expectations reflected in the forward-looking statements are reasonable based on information currently available to management, there is no assurance that such assumptions and expectations will prove to have been correct. Forward-looking statements are made as of the date they are made and are based on the beliefs, estimates, “expectations, and opinions of management on that date. We undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, estimates or opinions, future events or results or otherwise or to explain any material difference between subsequent actual events and such forward-looking statements, except as required by law. The forward-looking statements contained in this Quarterly Report and other reports we file with, or furnish to, the SEC and other regulatory agencies and made by our directors, officers, other employees, and other persons authorized to speak on our behalf are expressly qualified in their entirety by these cautionary statements. Part I - Business Overview We are a world-leading cannabis company which produces, distributes, and sells a diverse range of cannabis and cannabis related products. Cannabis products are principally sold for adult-use and medical purposes under a portfolio of distinct brands. Our core operations are in Canada, Europe and Australia and we hold a significant non-controlling, non-voting interest in an entity that participates in the sale of cannabis and hemp derived products in the United States. Using a consumer-driven approach, our portfolio delivers diverse products that offer experiences for occasions our consumers seek. Our mainstream and premium branded product portfolio includes multiple cannabis formats, such as high-quality dried flower, oils, softgel capsules, infused beverages, edibles and topical formats, as well as vaporizer devices, in addition to cannabis accessories, designed to meet the needs of consumers worldwide. Our cannabis cultivation operations are focused in two facilities, our greenhouse facility in Kincardine, Ontario and the DOJA facility in Kelowna, British Columbia. We believe that the cultivation capacity in the Kincardine facility and the DOJA facility, as well as externally sourced cannabis flower supply can meet the current demand for our premium dried flower. The receipt of our European Union Good Manufacturing Practices (“EU GMP”) certification at the Kincardine facility enables us to continue exporting certified medical cannabis to medical markets in Europe as well as other medical cannabis markets around the world. Our licensed operational capacity in Canada includes advanced manufacturing capability for oil and softgel encapsulation, pre-rolled joints (“PRJ”) (infused and non-infused), and hash production, which is primarily completed at our Smiths Falls, Ontario facility. Through our in-house manufacturing capabilities of adult-use cannabis products, we can process and package bulk cannabis flower, PRJ and vape products, whether internally or externally sourced, into high quality cannabis products. Our remaining products are manufactured through an adaptive third-party sourcing model for all cannabis beverages, edibles, and extracts. We are confident that our production and manufacturing capabilities and know-how are sufficient to meet the diverse needs of our adult-use and medical cannabis consumers in Canada. Today, we offer a broad portfolio of brands and products and continue to expand our portfolio to include new innovative cannabis products and formats. We maintain agreements to supply all Canadian provinces and territories with our adult-use products for sale through their established retail distribution systems. Through our Spectrum Therapeutics website, patients who have registered with Spectrum Therapeutics are able to purchase products online and have them shipped directly to the address indicated on their registration document. We have developed several programs to improve access to medical cannabis for authorized patients through income-tested compassionate pricing program whereby eligible low-income patients may obtain a 20% discount on regular prices of medical cannabis. We also provide support through our customer care team to help patients identify if their medication is covered under the growing number of private health plans that have a medical cannabis component. Our Canopy Medical, Spectrum Therapeutics and Tweed brands serve the medical market in Europe and Australia. Our European medical cannabis business operates in accordance with the specific regulatory framework in place in the relevant jurisdictions, including supplying EU GMP compliant pharmaceutical products. In Australia, Spectrum Therapeutics and Tweed continue to support Australian medical patients through imported products. We also offer premier herbal vaporizer products under the Storz & Bickel® (“Storz & Bickel”) brand. Our cannabis products contain THC, CBD, or a combination of these two cannabinoids which are found in the cannabis sativa plant species. THC is the primary psychoactive or intoxicating cannabinoid found in cannabis. We also refer throughout this MD&A to “cannemp,” which is a term used to classify varieties of the cannabis sativa plant that contain CBD and 0.3% or less THC content (by dry weight). Conversely, references to the term “marijuana” refers to varieties of the cannabis sativa plant with more than 0.3% THC. Segment Reporting We report our financial results for the following four reportable segments: “Canada cannabis - includes the production, distribution and sale of a diverse range of cannabis, hemp and cannabis-related products in Canada pursuant to the Cannabis Act and cannabis-related areas such as merchandise and clinics; “International markets cannabis - includes the production, distribution and sale of a diverse range of cannabis and hemp products internationally pursuant to applicable international legislation, regulations and permits. Priority markets include medical cannabis in Australia and Europe where the Company offers branded high-quality flower, oil and extract products under our recognized Spectrum Therapeutics, Canopy Medical and Tweed brands, as well as the Company’s Storz & Bickel line of medically approved vaporizers in Australia; 35 “Storz & Bickel - includes the production, distribution and sale of vaporizers and accessories; and “This Works - includes the production, distribution and sale of beauty, skincare, wellness and sleep products, some of which have been blended with hemp-derived CBD isolate. On December 18, 2023, the Company completed the sale of This Works and as of such date, the results of This Works are no longer included in the Company’s financial results. These segments reflect how our

operations are managed, how our Chief Executive Officer, who is the Chief Operating Decision Maker (the “CODM”), allocates resources and evaluates performance, and how our internal management financial reporting is structured. Our CODM evaluates the performance of these segments, with a focus on (i) segment net revenue, and (ii) segment gross margin as the measure of segment profit or loss. The remainder of our operations include revenue derived from, and cost of sales associated with, our non-cannabis extraction activities and other ancillary activities; these are included within “other.” Canopy USA On October 24, 2022, Canopy Growth completed a number of strategic transactions (the “Reorganization”) in connection with the creation of Canopy USA, a U.S.-domiciled holding company wherein, as of October 24, 2022, Canopy USA, holds certain U.S. cannabis investments previously held by Canopy Growth. Following the creation of Canopy USA, the Nasdaq communicated its position to the Company stating that companies that consolidate the assets and revenues generated from activities in violation under federal law cannot continue to list on Nasdaq. Since the Company is committed to compliance with the listing requirements of the Nasdaq, the Company and Canopy USA effectuated certain changes to the initial structure of the Company’s interest in Canopy USA that were intended to facilitate the deconsolidation of the financial results of Canopy USA within the Company’s financial statements. These changes included, among other things, modifying the terms of the Protection Agreement (as defined below) between the Company, its wholly-owned subsidiary and Canopy USA as well as the terms of Canopy USA’s limited liability company agreement and amending the terms of certain agreements with third-party investors in Canopy USA to eliminate any rights to guaranteed returns (collectively, the “Reorganization Amendments”). On May 19, 2023, the Company and Canopy USA implemented the Reorganization Amendments, which included, entering into the First A&R Protection Agreement (as defined below) and amending and restating Canopy USA’s limited liability company agreement (the “A&R LLC Agreement”) in order to: (i) eliminate certain negative covenants that were previously granted by Canopy USA in favor of the Company as well as delegating to the managers of the Canopy USA Board (as defined below) not appointed by Canopy Growth the authority to approve the following key decisions (collectively, the “Key Decisions”): (a) the annual business plan of Canopy USA; (b) decisions regarding the executive officers of Canopy USA and any of its subsidiaries; (c) increasing the compensation, bonus levels or other benefits payable to any current, former or future employees or managers of Canopy USA or any of its subsidiaries; (d) any other executive compensation plan matters of Canopy USA or any of its subsidiaries; and (e) the exercise of the Wana Options (as defined below) or the Jetty Options, which for greater certainty means that the Company’s nominee on the Canopy USA Board will not be permitted to vote on any Key Decisions while the Company owns Non-Voting Shares; (ii) reduce the number of managers on the Canopy USA Board from four to three, including, reducing the Company’s nomination right to a single manager; (iii) amend the share capital of Canopy USA to, among other things, (a) create a new class of Canopy USA Class B Shares (as defined below), which may not be issued prior to the conversion of the Non-Voting Shares or the Class A shares of Canopy USA (the “Canopy USA Common Shares”) into Canopy USA Class B Shares; (b) amend the terms of the Non-Voting Shares such that the Non-Voting Shares will be convertible into Canopy USA Class B Shares (as opposed to Canopy USA Common Shares); and (c) amend the terms of the Canopy USA Common Shares such that upon conversion of all of the Non-Voting Shares into Canopy USA Class B Shares, the Canopy USA Common Shares will, subject to their terms, automatically convert into Canopy USA Class B Shares, provided that the number of Canopy USA Class B Shares to be issued to the former holders of the Canopy USA Common Shares will be equal to no less than 10% of the total issued and outstanding Canopy USA Class B Shares following such issuance. Accordingly, as a result of the Reorganization Amendments, in no circumstances will the Company, at the time of such conversions, own more than 90% of the Canopy USA Class B Shares. In connection with the Reorganization Amendments, on May 19, 2023, Canopy USA and Huneus 2017 Irrevocable Trust (the “Trust”) entered into a share purchase agreement (the “Trust SPA”), which sets out the terms of the Trust’s investment in Canopy USA in the aggregate amount of up to US\$20 million (the “Trust Transaction”). Agustin Huneus, Jr. is the trustee of the Trust and is an affiliate of a shareholder of Jetty. Pursuant to the terms of the Trust SPA, the Trust was entitled, subject to certain terms and conditions contained in the Trust SPA, to be issued Canopy USA Common Shares in two tranches with an aggregate value of up to US\$10 million along with warrants of Canopy USA to acquire additional Canopy USA Common Shares. In addition, subject to the terms of the Trust SPA, the Trust has also been granted options to acquire additional Voting Shares (as defined in the A&R LLC Agreement) with a value of up to an additional US\$10 million and one such additional option includes the issuance of additional warrants of Canopy USA. On April 26, 2024, Canopy USA completed the first tranche closing of the Trust Transaction in accordance with the Trust SPA and pursuant to the Trust SPA, the timeline to complete the second tranche closing has lapsed. As of February 6, 2025, the Trust holds an aggregate 28,571,429 Canopy USA Common Shares and warrants to acquire up to 85,714,284 Voting Shares expiring on April 26, 2031. In addition, subject to the terms and conditions of the A&R Protection Agreement (as defined below) and the terms of the option agreements to acquire Wana and Jetty, as applicable, Canopy Growth may be required to issue additional common shares in 36 A satisfaction of certain deferred and/or option exercise payments to the shareholders of Wana and Jetty. Canopy Growth will receive additional Non-Voting Shares from Canopy USA as consideration for any Company common shares issued in the future to the shareholders of Wana and Jetty. On November 3, 2023, the Company received a letter from the staff of the SEC (the “Staff”) in which the Staff indicated that, despite the Reorganization Amendments, it would object to the deconsolidation of the financial results of Canopy USA from the Company’s financial statements in accordance with U.S. GAAP once Canopy USA acquires Wana, Jetty or the Fixed Shares (as defined below) of Acreage. The Company subsequently had discussions with the Office of Chief Accountant of the SEC (the “OCA”) and determined to make certain additional amendments to the structure of Canopy USA (the “Additional Reorganization Amendments”) to facilitate the deconsolidation of Canopy USA from the financial results of Canopy Growth in accordance with U.S. GAAP upon Canopy USA’s acquisition of Wana, Jetty or Acreage. In connection with the Additional Reorganization Amendments, Canopy USA and its members entered into a second amended and restated limited liability company agreement (the “Second A&R LLC Agreement”). In accordance with the terms of the Second A&R LLC Agreement, the terms of the Non-Voting Shares have been amended such that the Non-Voting Shares are only convertible into Canopy USA Class B Shares following the date that the NASDAQ Stock Market or The New York Stock Exchange permit the listing of companies that consolidate the financial statements of companies that cultivate, distribute or possess marijuana (as defined in 21 U.S.C 802) in the United States (the “Stock Exchange Permissibility Date”). Based on the Company’s discussions with the OCA, upon effectuating the Additional Reorganization Amendments, the Company believes that the Staff would not object to the deconsolidation of the financial results of Canopy USA from the Company’s financial statements in accordance with U.S. GAAP. Following the Reorganization, Reorganization Amendments and Additional Reorganization Amendments, on May 6, 2024, Canopy USA exercised the options (the “Wana Options”) to acquire Mountain High Products, LLC, Wana Wellness, LLC and The Cima Group, LLC (collectively, “Wana”), a leading cannabis edibles brand in North America, and subsequently closed the transactions to acquire Wana Wellness, LLC and The Cima Group, LLC. On October 8, 2024, Canopy USA closed the acquisition of Mountain High Products, LLC. In addition, Canopy USA exercised the options (the “Jetty Options”) to acquire Lemurian, Inc. (“Jetty”) a California-based producer of high-quality cannabis extracts and pioneer of clean vape technology and subsequently completed the first tranche closing to acquire Jetty. On June 4, 2024, the option to acquire the issued and outstanding Class E subordinate voting shares (the “Fixed Shares”) of Acreage, a leading vertically-integrated multi-state cannabis operator, with its main operations in densely populated states across the Northeast U.S., including New Jersey and New York (the “Acreage Option”) was exercised and on December 9, 2024, Canopy USA completed the acquisition of all of the issued and outstanding Fixed Shares and Class D subordinate voting shares (the “Floating Shares”) of Acreage (the “Acreage Acquisition”). Canopy USA also holds direct and indirect interests in the capital of TerrAscend Corp. (the “TerrAscend”), a leading North American cannabis operator with vertically integrated operations and a presence in Pennsylvania, New Jersey, Michigan and California as well as licensed cultivation and processing operations in Maryland. Canopy USA currently holds an ownership interest in the following assets, among others: “Wana” 100% of the membership interests of Wana Wellness, LLC, The Cima Group, LLC, and Mountain High Products, LLC. “Jetty” approximately 77% of the shares of Jetty. “Acreage” 100% of the issued and outstanding shares of Acreage. “TerrAscend” Canopy USA beneficially holds an aggregate of 64,564,487 TerrAscend common shares (the “TerrAscend Common Shares”) on an as-converted basis and 22,474,130 TerrAscend Common Share purchase warrants with a weighted average exercise price of \$6.07 per TerrAscend Common Share and expiring on December 31, 2032 (the “TerrAscend Warrants”). Assuming full exercise of the TerrAscend Warrants, Canopy USA will beneficially hold an aggregate of 87,038,617 TerrAscend Common Shares on an as-converted basis assuming conversion of the TerrAscend exchangeable shares (the “TerrAscend Exchangeable Shares”) beneficially held by Canopy USA. Following the implementation of the Reorganization, Canopy USA was determined to be a variable interest entity pursuant to ASC 810 - Consolidations (the “ASC 810”) and prior to the completion of the Reorganization Amendments and the Additional Reorganization Amendments, Canopy Growth was determined to be the primary beneficiary of Canopy USA. As a result of such determination and in accordance with ASC 810, Canopy Growth consolidated the financial results of Canopy USA up to April 30, 2024. Ownership of U.S. Cannabis Investments Following the implementation of the Reorganization, the shares and interests in Acreage, Wana, Jetty and TerrAscend are held, directly or indirectly, by Canopy USA, and Canopy Growth no longer holds a direct interest in any shares or interests in such entities. Canopy Growth holds non-voting and non-participating shares (the “Non-Voting Shares”) in the capital of Canopy USA. The Non-Voting Shares do not carry voting rights, rights to receive dividends or other rights upon dissolution of Canopy USA. Following the Reorganization Amendments, the Non-Voting Shares are convertible into Class B shares of Canopy USA (the “Canopy USA Class B Shares”), provided that such conversion shall only be permitted following the Stock Exchange Permissibility Date. The Company also has the right (regardless of the fact that its Non-Voting Shares are non-voting and non-participating) to appoint one member to the Canopy USA board of managers (the “Canopy USA Board”). On October 24, 2022, Canopy USA and the Company also entered into an agreement with, among others, Nancy Whiteman, the controlling shareholder of Wana, which was amended and restated on May 19, 2023 and on April 30, 2024, whereby subsidiaries of Canopy USA agreed to pay additional consideration in order to acquire the Wana Options and the future payments owed in connection with the exercise of the Wana Options were reduced to US\$3.00 in exchange for the issuance of Canopy USA Common Shares and Canopy Growth common shares (the “Wana Amending Agreement”). In accordance with the terms of the Wana Amending Agreement, on April 30, 2024, (i) Canopy USA issued 60,955,929 Canopy USA Common Shares and (ii) Canopy Growth issued 1,086,279 Canopy Growth common shares to the shareholders of Wana. The Canopy USA Common Shares issued to Ms. Whiteman, or entities controlled by Ms. Whiteman, are subject to a repurchase right exercisable at any time after April 30, 2027, being the 36 month anniversary of the closing of the transaction contemplated by the Wana Amending Agreement (the “Wana Repurchase Right”) to repurchase all Canopy USA Common Shares that have been issued at a price per Canopy USA Common Share equal to the fair market value as determined by an appraiser. As part of this agreement, Canopy USA has granted Ms. Whiteman the right to appoint one member to the Canopy USA Board and a put right on the same terms and conditions as the Wana Repurchase Right. As of February 6, 2025, the Trust holds 28,571,429 Canopy USA Common Shares, the shareholders of Wana collectively hold 60,955,929 Canopy USA Common Shares and a wholly-owned subsidiary of the Company holds all of the issued and outstanding Non-Voting Shares in the capital of Canopy USA, representing approximately 84.4% of the issued and outstanding shares in Canopy USA on an as-converted basis. Canopy Growth and Canopy USA are also party to a protection agreement (the “Protection Agreement”) to provide for certain covenants in order to preserve the value of the Non-Voting Shares held by Canopy Growth until such time as the Non-Voting Shares are converted in accordance with their terms, provided that, such conversion shall only be permitted following the Stock Exchange Permissibility Date, but does not provide Canopy Growth with the ability to direct the business, operations or activities of Canopy USA. The Protection Agreement was amended and restated in connection with: (a) the Reorganization Amendments (the “First A&R Protection Agreement”); and (b) the Additional Reorganization Amendments (the “Second A&R Protection Agreement” and together with the First A&R Protection Agreement, the “A&R Protection Agreement”). Upon Canopy USA completing the Acreage Acquisition, Canopy Growth received additional Non-Voting Shares from Canopy USA in consideration for the issuance of common shares of the Company that shareholders of Acreage received in accordance with the terms of the Existing Acreage Arrangement Agreement (as defined below) and the Floating Share Arrangement Agreement (as defined below). Until such time as Canopy Growth converts the Non-Voting Shares into Canopy USA Class B Shares following the Stock Exchange Permissibility Date, Canopy Growth will have no economic or voting interest in Canopy USA, Wana, Jetty, TerrAscend, or Acreage. Canopy USA, Wana, Jetty, TerrAscend, and Acreage will continue to operate independently of Canopy Growth. Acreage Agreements On October 24, 2022, Canopy Growth entered into an arrangement agreement with Canopy USA and Acreage, as amended (the “Floating Share Arrangement Agreement”), pursuant to which Canopy USA acquired all of the issued and outstanding Floating Shares by way of a court-approved plan of arrangement (the “Floating Share Arrangement”) in exchange for 0.045 of a Company common share for each Floating Share held. In connection with the Floating Share Arrangement Agreement, Canopy Growth irrevocably waived the right to acquire all of the issued and outstanding Floating Shares existing under the Existing Acreage Arrangement Agreement. On October 24, 2022, the Company and Canopy USA entered into a third amendment to tax receivable agreement (the “Amended TRA”) with, among others, certain current or former unitholders (the “Holders”) of High Street Capital Partners, LLC, a subsidiary of Acreage (the “HSCP”), pursuant to HSCP’s amended tax receivable agreement (the “TRA”) and related tax receivable bonus plans with Acreage. Pursuant to the Amended TRA, the Company, on behalf of Canopy USA, agreed to issue common shares of the Company with a value of US\$30.4 million to certain Holders as consideration for the assignment of such Holder’s rights under the TRA to Canopy USA. As a result of the Amended TRA, Canopy USA is the sole member and beneficiary under the TRA. In connection with the foregoing, the Company issued: (i) 564,893 common shares with a value of \$20.6 million (US\$15.2 million) to certain Holders on November 4, 2022 as the first installment under the Amended TRA; and (ii) 710,208 common shares with a value of \$20.6 million (US\$15.2 million) to certain Holders on March 17, 2023, as the second installment under the Amended TRA. In connection with the Acreage Acquisition, the Company, on behalf of Canopy USA, issued 5,118,426 common shares of the Company to an eligible participant pursuant to HSCP’s existing tax receivable bonus plans. In addition to shareholder and court approvals, completion of the Floating Share Arrangement was subject to applicable regulatory approvals including, but not limited to, TSX approval and the satisfaction of certain other closing conditions, including the conditions set forth in the amended and restated plan of arrangement (the “Acreage Amended Arrangement”) implemented by Canopy Growth and Acreage on September 23, 2020 in connection with the Existing Acreage Arrangement Agreement. The Floating Share 38 A Arrangement received the requisite approval from the holders of Floating Shares at the special meeting of Acreage shareholders held on March 15, 2023 and on March 20, 2023 Acreage obtained a final order from the Supreme Court of British Columbia approving the Floating Share Arrangement. The Floating Share Arrangement was implemented on December 9, 2024 in connection with the closing of the Acreage Acquisition. On June 4, 2024, the Acreage Option was exercised in accordance with the terms of the arrangement agreement dated April 18, 2019, as amended on May 15, 2019, September 23, 2020 and November 17, 2020 (the “Existing Acreage Arrangement Agreement”), with such exercise being completed in advance of the Exercise Outside Date (as defined in the Floating Share Arrangement Agreement). Concurrently with the closing of the acquisition of the Fixed Shares pursuant to the exercise of the Acreage Option, on December 9, 2024, the Fixed Shares were issued to Canopy USA upon closing of the Acreage Acquisition. Accordingly, Canopy Growth does not hold any Fixed Shares or Floating Shares. The acquisition of the Floating Shares pursuant to the Floating Share Arrangement occurred immediately prior to the acquisition of the Fixed Shares pursuant to the Existing Acreage Arrangement Agreement such that 100% of the issued and outstanding shares of Acreage are owned by Canopy USA. For additional details, see “Acreage Acquisition” below. On June 3, 2024, the Company exercised its option to acquire certain outstanding debt of Acreage (the “Debt Acquisition”) in connection with the option agreement dated November 15, 2022 (the “Option Agreement”) among a wholly-owned subsidiary of Canopy Growth (the “Optionor”) and the lenders (the “Lenders”) party to Acreage’s credit agreement dated as of December 16, 2021, as amended by the first amendment to credit agreement dated as of October 24, 2022 and the second amendment to credit agreement dated as of April 28, 2023. The Optionor entered into various agreements in connection with the Debt Acquisition in order to acquire approximately US\$99.8 million of Acreage’s outstanding debt (the “Acquired Debt”) from certain Lenders in exchange for US\$69.8 million in cash and the release of approximately US\$30.1 million (the “Option Premium”) that was held in escrow pursuant to the Option Agreement. As reported in the Annual Report, the Option Premium was not included in Canopy Growth’s cash and cash equivalents as of March 31, 2024. The Optionor subsequently transferred approximately US\$2.2 million of the Acquired Debt to the other Lender (the “Rolling Lender”) and entered into a series of agreements with the Rolling Lender and Acreage, among others, including an amended and restated credit agreement (the “First ARCA”), which provided for, among other things, the Acquired Debt, certain interest payments to be paid-in-kind, revisions to certain financial covenants and, following certain events, an extension to the maturity date. On September 13, 2024, the Optionor entered into a series of transactions with, among others, Acreage, the Rolling Lender and an arm’s length third-party lender (the “Other Lender”). Pursuant to such transactions, all of Acreage’s indebtedness held by the Rolling Lender was acquired by the Other Lender. Following the acquisition by the Other Lender, the Optionor, the Other Lender and Acreage, among others, amended and restated the First

ARCA pursuant to a second amended and restated credit agreement dated as of September 13, 2024 (the "Second ARCA"). Pursuant to the Second ARCA and an agreement among lenders entered into on September 13, 2024 between, among others, the Optionor and the Other Lender, all interest owing to the Optionor under the Second ARCA is, subject to the consent of the Other Lender, to be paid-in-kind and not in cash. Under the Second ARCA, as of September 13, 2024, the Optionor was owed an aggregate principal amount equal to approximately US\$102 million which is subordinate to approximately US\$65 million owed to the Other Lender. As of December 31, 2024, the aggregate principal amount owing to the Optionor was approximately US\$106 million and the aggregate principal amount owing to the Other Lender was approximately US\$65 million. Recent Developments Canopy USA As described above, Canopy Growth has implemented the Reorganization Amendments and the Additional Reorganization Amendments and Canopy USA subsequently completed the first tranche closing of the Trust Transaction and exercised the Wana Options and the Jetty Options, such that we will not consolidate the financial results of Canopy USA as of April 30, 2024. Following the implementation of the Reorganization, Canopy USA was determined to be a variable interest entity pursuant to ASC 810 and prior to the completion of the Reorganization Amendments and the Additional Reorganization Amendments, Canopy Growth was determined to be the primary beneficiary of Canopy USA. As a result of such determination and in accordance with ASC 810, Canopy Growth consolidated the financial results of Canopy USA up to April 30, 2024. Deconsolidation of Canopy USA As of April 30, 2024, as a result of the series of transactions related to the Additional Reorganization Amendments described above, Canopy Growth has deconsolidated the financial results of Canopy USA and has a non-controlling interest in Canopy USA as of such date. The deconsolidation of Canopy USA occurred after completion of the following structural amendments: (i) execution of the Second A&R LLC Agreement, (ii) execution of the Second A&R Protection Agreement and (iii) completion of the initial tranche 39 A closing of the Trust Transaction, which included the election of a third member to the Canopy USA Board such that the Canopy USA Board is comprised of an appointee from the Trust, Ms. Whiteman, and the Company. Canopy Growth's deconsolidation of Canopy USA resulted in recognition of an equity method investment and a loan receivable recorded at fair value. Acreage Acquisition On December 9, 2024, Canopy USA completed the Acreage Acquisition and now owns 100% of the issued and outstanding shares of Acreage. In connection with: (i) the Existing Acreage Arrangement Agreement and the Acreage Amended Arrangement; and (ii) the Floating Share Arrangement Agreement, Canopy USA acquired all of the issued and outstanding Floating Shares of Acreage on the terms and conditions set forth in Floating Share Arrangement. Immediately following the implementation of the Floating Share Arrangement, Canopy USA acquired all of the issued and outstanding Fixed Shares of Acreage (the "Fixed Share Acquisition"). In accordance with the Floating Share Arrangement, registered holders of Floating Shares received 0.045 of a common share of Canopy Growth for each Floating Share (the "Floating Share Exchange Ratio"). In connection with the Fixed Share Acquisition, each of the outstanding Fixed Shares was exchanged for 0.00000000617 of a common share of Canopy Growth for each Fixed Share, as adjusted pursuant to the terms and conditions set forth in the Existing Acreage Arrangement Agreement (the "Fixed Share Exchange Ratio"). In aggregate, Canopy Growth issued 5,888,291 common shares to former shareholders of Acreage. Pursuant to the Floating Share Arrangement, (i) each outstanding stock option to acquire Floating Shares was exchanged for a replacement option exercisable for Canopy Growth common shares, with the number of underlying Canopy Growth common shares and exercise price of such options adjusted by the Floating Share Exchange Ratio; (ii) each outstanding warrant to acquire Floating Shares was exchanged for a replacement warrant to acquire Canopy Growth common shares, with the number of underlying Canopy Growth common shares and exercise price of such warrants adjusted by the Floating Share Exchange Ratio; and (iii) each outstanding restricted share unit, performance share and performance unit, as applicable, that vested into Floating Shares was exchanged for a replacement restricted share unit, performance share or performance unit, as applicable, that vests into Canopy Growth common shares, with the number of underlying Canopy Growth common shares adjusted by the Floating Share Exchange Ratio. In connection with the Fixed Share Acquisition, (i) each outstanding stock option to acquire Fixed Shares was exchanged for a replacement option exercisable for Canopy Growth common shares, with the number of underlying Canopy Growth common shares and exercise price of such options adjusted by the Fixed Share Exchange Ratio; (ii) each outstanding warrant to acquire Fixed Shares was exchanged for a replacement warrant to acquire Canopy Growth common shares, with the number of underlying Canopy Growth common shares and exercise price of such warrants adjusted by the Fixed Share Exchange Ratio; and (iii) each restricted share unit and performance share unit, as applicable, that vested into Fixed Shares was exchanged for a replacement restricted share unit or performance share unit, as applicable, that vests into Canopy Growth common shares, with the number of underlying Canopy Growth common shares adjusted by the Fixed Share Exchange Ratio. In addition, Canopy Growth: (i) issued 5,118,426 common shares of the Company to an eligible participant pursuant to HSCP's existing tax receivable bonus plans; and (ii) 306,151 common shares of the Company were issuable in connection with Canopy USA's acquisition of the minority interests of certain subsidiaries of Acreage, of which 236,960 common shares of the Company have been issued. Immediately following the closing of the Acreage Acquisition, Canopy Growth issued an aggregate of 1,315,553 common shares and 1,197,658 common share purchase warrants to certain securityholders of Acreage in order to satisfy an outstanding liability. Each common share purchase warrant entitles the holder thereof to acquire one common share of Canopy Growth at an exercise price of US\$3.66 until June 6, 2029. Balance Sheet Deleveraging Initiatives On April 18, 2024, the Company entered into an exchange agreement (the "April 2024 Exchange Agreement") with Greenstar Canada Investment Limited Partnership (the "Greenstar"), an affiliate of Constellation Brands, Inc. (the "CBI"), pursuant to which Greenstar converted approximately \$81.2 million of the principal amount of the \$100 million principal amount of a promissory note (the "CBI Note") into 9,111,549 Exchangeable Shares (the "Note Exchange"), calculated based on a price per Exchangeable Share equal to \$8.91. Pursuant to the terms of the April 2024 Exchange Agreement, all accrued but unpaid interest on the CBI Note together with the remaining principal amount of the CBI Note was cancelled and forgiven for no additional consideration by Greenstar. Following the closing of the Note Exchange, there is no outstanding balance owing under the CBI Note and the CBI Note has been cancelled. On April 29, 2024 and June 28, 2024, the Company repurchased additional outstanding principal amounts under the Credit Facility (the "First Quarter 2025 Paydowns"). The First Quarter 2025 Paydowns resulted in an aggregate principal reduction of \$11.2 million (US\$8.2 million) for a cash payment of \$11.2 million (US\$8.2 million). On August 20, 2024, the Company entered into an exchange and subscription agreement (the "August 2024 Supreme Convertible Debt Exchange") with a single institutional investor (the "August 2024 Investor") pursuant to which, among other things, the August 2024 Investor delivered to the Company approximately \$2.7 million of aggregate principal amount of outstanding Supreme 40 A Debentures (as defined below) in exchange for 291,351 common shares of the Company and \$0.03 million in cash for accrued interest. On September 27, 2024, the Company repurchased additional outstanding principal amounts under the Credit Facility (the "Second Quarter 2025 Paydowns"). The Second Quarter 2025 Paydown resulted in an aggregate principal reduction of \$1.1 million (US\$0.9 million) for a cash payment of \$1.1 million (US\$0.9 million). On October 16, 2024, the Company made an early prepayment under the Credit Facility in an aggregate principal amount equal to US\$100.0 million of the principal amount outstanding thereunder at a discounted price of US\$97.5 million (the "Third Quarter 2025 Paydown"). Pursuant to the Amending Agreement, the US\$100.0 million prepayment of the Credit Facility was required to be made by December 31, 2024. May 2024 Convertible Debenture On May 2, 2024, the Company entered into an exchange and subscription agreement (the "Exchange and Subscription Agreement") with a single institutional investor (the "May 2024 Investor") pursuant to which, among other things, the May 2024 Investor delivered to the Company approximately \$27.5 million aggregate principal amount of outstanding Supreme Debentures and Accretion Debentures (as defined below) held by the May 2024 Investor and paid the Company approximately US\$50 million in exchange for the Company issuing to the May 2024 Investor (i) a new senior unsecured convertible debenture of the Company (the "May 2024 Convertible Debenture") with an aggregate principal amount of approximately \$96.4 million maturing five years from the closing date (the "Closing Date") of the transaction (the "Transaction") and (ii) 3,350,430 common share purchase warrants (the "May 2024 Investor Warrants") of the Company. Each May 2024 Investor Warrant entitles the holder to acquire one Canopy Share at an exercise price equal to \$16.18 per Canopy Share for a period of five years from the Closing Date. The May 2024 Convertible Debenture bears interest at a rate of 7.50% per annum, payable in semi-annual payments in cash or, at the option of the Company, in Canopy Shares for the first four semi-annual interest payments after the Closing Date, subject to satisfaction of certain conditions, including the prior approval of the TSX. The May 2024 Convertible Debenture is convertible into Canopy Shares at the option of the May 2024 Investor at a conversion price equal to \$14.38 per share. The May 2024 Convertible Debenture is subject to a forced conversion feature upon notice from the Company in the event that the average closing trading price of the Canopy Shares on the TSX exceeds \$21.57 for a period of 10 consecutive trading days. In addition, pursuant to the terms of the May 2024 Convertible Debenture, for so long as the principal amount under the May 2024 Convertible Debenture remains outstanding (the "Debenture ROFR Term"), the Company granted the May 2024 Investor a right of first refusal to subscribe for, and to be issued, as an investor in any debt or equity financing that the Company wishes to complete during the Debenture ROFR Term (the "Proposed Financing"); provided, however, that the May 2024 Investor shall subscribe for 25% of the Proposed Financing on the same terms and conditions contemplated in the Proposed Financing. Canadian Federal Income Tax Proposals Proposed amendments to the Income Tax Act (Canada) originally released on June 10, 2024 with revised proposals released on August 12, 2024 and September 23, 2024, (collectively the "Capital Gains Proposals"), would, if enacted, generally increase the capital gains inclusion rate from one-half to two-thirds for corporations and trusts, and from one-half to two-thirds for individuals on the portion of capital gains realized, including capital gains realized indirectly through a trust or partnership, in a taxation year that exceed \$250,000. The Capital Gains Proposals further propose to adjust the value of capital losses realized in previous years so that two-thirds of capital losses realized prior to June 25, 2024 will be deductible against capital gains included in income at the two-thirds inclusion rate such that a capital loss will offset an equivalent capital gain regardless of the inclusion rate (additional adjustments would be required where the capital gains have been subjected to an effective inclusion rate of one-half rather than the basic inclusion rate of two-thirds). Revised alternative minimum tax rules were enacted on June 20, 2024, which may increase a shareholder's liability for such tax. On January 31, 2025, the Department of Finance announced a deferral in the implementation of the Capital Gains Proposals to January 1, 2026. At the present time, it is uncertain if the Capital Gains Proposals will be re-introduced and enacted in its current form or at all. Facility Lease Renegotiation In December 2024, the Company renegotiated the terms of a facility lease, resulting in a short-term to long-term reclassification of its lease liabilities (the "Lease Renegotiation"). The renegotiated terms result in changes to future cashflows associated with the lease. Part 2 - Results of Operations The results of operations presented below reports the financial performance of the continuing operations of Canopy Growth for the three and nine months ended December 31, 2024. Further to Note 4 in the Company's accompanying financial statements, the BioSteel segment results for all periods prior to September 14, 2023 and November 16, 2023, being the effective dates of deconsolidation as a result of the CCAA Proceedings (as defined below), are classified as discontinued operations and therefore are excluded from continuing operations. 41 A On September 14, 2023, Canopy Growth ceased funding the operations of BioSteel Sports Nutrition Inc. (the "BioSteel Canada") and commenced proceedings (the "CCAA Proceedings") under the Companies' Creditors Arrangement Act (the "CCAA") in the Ontario Superior Court of Justice (Commercial List) and obtained recognition of that proceeding under Chapter 15 of the United States Bankruptcy Code. Discussion of Results of Operations for the Three Months Ended December 31, 2024 A Three months ended December 31, A A A A A A (in thousands of Canadian dollars, except share amounts and A A A A A A where otherwise indicated) A 2024 A A 2023 A A \$ Change A A % Change A Selected consolidated financial information: A A A A A A A A A A Net revenue A \$ 74,761 A A \$ 78,505 A A \$ (3,744) A A (5 %) Gross margin percentage A A 32 % A A 36 % A A - A A (400) bps A Net loss from continuing operations A \$ (121,896) A A \$ (230,276) A A 108,380 A A 47 % Basic and diluted loss per share from A A continuing operations1 A A \$ (1.11) A A \$ (2.78) A A \$ 1.67 A A 60 % A A A A A A A A 1 For the three months ended December 31, 2024, the weighted average number of outstanding common shares, basic and diluted, totaled 110,306,430 (three months ended December 31, 2023 - 82,919,190). A A Revenue We report net revenue in four segments: (i) Canada cannabis; (ii) international markets cannabis; (iii) Storz & Bickel; and (iv) This Works. Revenue derived from the remainder of our operations are included within "other". The following table presents segmented net revenue for the three months ended December 31, 2024 and 2023: Net Revenue A Three months ended December 31, A A A A A A (in thousands of Canadian dollars) A 2024 A A 2023 A A \$ Change A A % Change A Canada cannabis A A A A A A A A Canadian adult-use cannabis1 A \$ 21,153 A A \$ 23,490 A A \$ (2,337) A A (10 %) Canadian medical cannabis2 A \$ 19,575 A A \$ 16,894 A A \$ 2,681 A A 16 % A A \$ 40,728 A A \$ 40,384 A A \$ 344 A A 1 % A A A A A A A A International markets cannabis3 A \$ 12,024 A A \$ 10,527 A A \$ 1,497 A A 14 % Storz & Bickel A \$ 22,009 A A \$ 18,453 A A \$ 3,556 A A 19 % This Works A \$ - A A \$ 8,165 A A \$ (8,165) A A (100 %) Other A A - A A 976 A A \$ (976) A A (100 %) A A A A A A A A Net revenue A \$ 74,761 A A \$ 78,505 A A \$ (3,744) A A (5 %) A A A A A A A A 1A Reflects excise taxes of \$9,335 and other revenue adjustments, representing our determination of returns and pricing adjustments, of \$924 for the three months ended December 31, 2024 (three months ended December 31, 2023 - excise taxes of \$9,741 and other revenue adjustments of \$1,113). A 2 Reflects excise taxes of \$2,148 for the three months ended December 31, 2024 (three months ended December 31, 2023 - \$1,815). A 3A Reflects other revenue adjustments of \$62 for the three months ended December 31, 2024 (three months ended December 31, 2023 - \$317). A Net revenue was \$74.8 million in the third quarter of fiscal 2025, a decrease of \$3.7 million as compared to \$78.5 million in the third quarter of fiscal 2024. Canada cannabis Net revenue from our Canada cannabis segment was \$40.7 million in the third quarter of fiscal 2025, as compared to \$40.4 million in the third quarter of fiscal 2024. Canadian adult-use cannabis net revenue was \$21.2 million in the third quarter of fiscal 2025, as compared to \$23.5 million in the third quarter of fiscal 2024. The year-over-year decrease is primarily attributable to lower sales volumes and sales velocity on our core flower and PRJ offerings due to continued increase in price competition, partially offset by contributions from new product launches and opportunistic bulk sales. Canadian medical cannabis net revenue was \$19.6 million in the third quarter of fiscal 2025, as compared to \$16.9 million in the third quarter of fiscal 2024. The year-over-year increase is primarily attributable to an increase in the average size of medical orders placed by our customers due largely to an increase in the percentage of insured customers, and a larger assortment of cannabis product choices offered to our customers. 42 A International markets cannabis International markets cannabis revenue was \$12.0 million in the third quarter of fiscal 2025, as compared to \$10.5 million in the third quarter of fiscal 2024. The year-over-year increase is primarily attributable to the increased shipments of flower products in Europe, driven by Poland and Germany, which was offset by a decline in our Australian medical business. Storz & Bickel Revenue from Storz & Bickel was \$22.0 million in the third quarter of fiscal 2025, as compared to \$18.5 million in the third quarter of fiscal 2024. The year-over-year increase is primarily attributable to strong growth in Germany, the U.S., and the United Kingdom and sales of Venty, our newest portable vaporizer. This Works Revenue from This Works was \$nil in the third quarter of fiscal 2025, as compared to \$8.2 million in the third quarter of fiscal 2024. The year-over-year decrease is due to the completion of the divestiture of This Works on December 18, 2023. Cost of Goods Sold and Gross Margin The following table presents cost of goods sold, gross margin and gross margin percentage on a consolidated basis for the three months ended December 31, 2024 and 2023: A A Three months ended December 31, A A A A A A (in thousands of Canadian dollars except where indicated) 2024 A A 2023 A A \$ Change A A % Change A A Canada cannabis segment A A A A A A A A Net revenue A \$ 40,728 A A \$ 40,384 A A \$ 344 A A 1 % A Cost of goods sold A \$ 30,547 A A \$ 29,078 A A \$ 1,469 A A 5 % A Gross margin A \$ 10,181 A A \$ 11,306 A A A (1,125) A A (10 %) A Gross margin percentage A \$ 25 % A A 28 % A A A (300) bps A A A A A A A A International markets cannabis segment A A A A A A A A A Revenue A \$ 12,024 A A \$ 10,527 A A \$ 1,497 A A 14 % A Cost of goods sold A \$ 7,092 A A \$ 6,335 A A \$ 757 A A 12 % A Gross margin A \$ 4,932 A A \$ 4,192 A A \$ 740 A A 18 % A Gross margin percentage A \$ 41 % A A 40 % A A A 100 bps A A A A A A A A A Storz & Bickel segment A A A A A A A A A Revenue A \$ 22,009 A A \$ 18,453 A A \$ 3,556 A A 19 % A Cost of goods sold A \$ 13,024 A A \$ 9,004 A A \$ 4,020 A A 45 % A Gross margin A \$ 8,985 A A \$ 9,449 A A

A \$ (5) % A Gross margin percentage A \$ 41 % A \$ 51 % A \$ (1,000) bps A A A A A A A A A A A A A A A A This Works segment A A A A A A A A Revenue A \$ 8,165 A \$ (8,165) A (100 %) A Cost of goods sold A - A A 3,912 A A (3,912) A (100 %) A Gross margin A A - A A 4,253 A A (4,253) A (100 %) A Gross margin percentage A - % A 52 % A A (5,200) bps A A A A A A A A A A Other A A A A A A A A Revenue A \$ - A \$ 976 A A (976) A (100 %) A Cost of goods sold A - A A 1,950 A A (1,950) A (100 %) A Gross margin A A - A A (974) A A 974 A A 100 % A Gross margin percentage A - % A (100 %) A A A 10,000 bps A Canada cannabis Gross margin for our Canada cannabis segment was \$10.2 million in the third quarter of fiscal 2025, or 25% of net revenue, as compared to \$11.3 million in the third quarter of fiscal 2024, or 28% of net revenue. The year-over-year decrease in the gross margin percentage was primarily attributable to lower adult-use sales and costs related to new product launches, partially offset by increased sales in higher-margin medical business. International markets cannabis Gross margin for our international markets cannabis segment was \$4.9 million in the third quarter of fiscal 2025, or 41% of net revenue, as compared to \$4.2 million in the third quarter of fiscal 2024, or 40% of net revenue. The year-over-year increase in the gross margin percentage is primarily attributable to the shift in sales mix to higher-margin Poland. Storz & Bickel Gross margin for our Storz & Bickel segment was \$9.0 million in the third quarter of fiscal 2025, or 41% of net revenue, as compared to \$9.4 million in the third quarter of fiscal 2024, or 51% of net revenue. The year-over-year decrease in the gross margin percentage is primarily attributable to increases in indirect costs. 44 This Works Gross margin for our This Works segment was \$nil in the third quarter of fiscal 2025, or 0% of net revenue, as compared to \$4.3 million in the third quarter of fiscal 2024, or 52% of net revenue. The year-over-year decrease in the gross margin percentage is due to the completion of the divestiture of This Works on December 18, 2023. Operating Expenses The following table presents operating expenses for the three months ended December 31, 2024 and 2023:

	December 31, 2024 (in thousands of Canadian dollars)	December 31, 2023 (in thousands of Canadian dollars)	% Change
Selling, general and administrative	\$ 16,984	\$ 24,046	(7,062) A (29%)
Sales and marketing	\$ 15,445	\$ 18,326	(2,881) A (16%)
Acquisition, divestiture, and other costs	\$ 3,036	\$ 4,981	(1,945) A (39%)
Depreciation and amortization	\$ 6,011	\$ 7,083	(1,072) A (15%)
Selling, general and administrative expenses	\$ 41,476	\$ 54,436	(12,960) A (24%)
Share-based compensation expense	\$ 5,159	\$ 3,693	\$ 1,466 A 40%
Loss on asset impairment and restructuring	\$ 1,285	\$ 30,413	(29,128) A (96%)
Total operating expenses	\$ 47,920	\$ 88,542	(40,622) A (46%)

Selling, general and administrative expenses Selling, general and administrative expenses were \$41.5 million in the third quarter of fiscal 2025, as compared to \$54.4 million in the third quarter of fiscal 2024. General and administrative expense was \$17.0 million in the third quarter of fiscal 2025, as compared to \$24.0 million in the third quarter of fiscal 2024. The year-over-year decrease is primarily attributable to: (i) the divestiture of This Works on December 18, 2023 and (ii) the impact of the restructuring actions and cost savings program initiated in the fourth quarter of fiscal 2023. Sales and marketing expense was \$15.4 million in the third quarter of fiscal 2025, as compared to \$18.3 million in the third quarter of fiscal 2024. The year-over-year decrease is primarily attributable to: (i) the divestiture of This Works on December 18, 2023 and (ii) the impact of the restructuring actions and cost savings program initiated in the fourth quarter of fiscal 2023. Acquisition, divestiture, and other costs were \$3.0 million in the third quarter of fiscal 2025, as compared to \$5.0 million in the third quarter of fiscal 2024. In the third quarter of fiscal 2025, costs were incurred primarily in relation to: continued legal costs arising from the restatement of our consolidated financial statements in connection with the review of the financial reporting matters related to the BioSteel business unit; and the Reorganization of Canopy USA. Comparatively, in the third quarter of fiscal 2024, costs were incurred primarily in relation to: costs relating to the modification of the Credit Agreement (as defined below) that occurred in July 2023; legal and audit costs arising from the restatement of our consolidated financial statements in connection with the review of the financial reporting matters related to the BioSteel business unit; the Reorganization of Canopy USA. Depreciation and amortization expense was \$6.0 million in the third quarter of fiscal 2025, as compared to \$7.1 million in the third quarter of fiscal 2024. The year-over-year decrease is primarily attributable to the previously-noted restructuring actions and cost savings programs, including the closure of certain of our Canadian facilities and other operational changes to implement cultivation-related efficiencies and improvements in the Canadian adult-use cannabis business. Share-based compensation expense Share-based compensation expense was \$5.2 million in the third quarter of fiscal 2025, as compared to \$3.7 million in the third quarter of fiscal 2024. The year-over-year increase is primarily attributable to: (i) the first quarter of fiscal 2025 grant of 0.8 million options and 0.7 million restricted share units, and (ii) higher forfeitures in the third quarter of fiscal 2024 due to previously-noted restructuring actions. 45 Loss on asset impairment and restructuring Loss on asset impairment and restructuring recorded in operating expenses was \$1.3 million in the third quarter of fiscal 2025, as compared to \$30.4 million in the third quarter of fiscal 2024. Loss on asset impairment and restructuring recorded in the third quarter of fiscal 2025 related primarily to employee restructuring costs, and ongoing holding costs to maintain previously restructured sites. Comparatively, in the third quarter of fiscal 2024, the loss on asset impairment and restructuring was primarily related to the charges associated with the completion of the This Works Divestiture (as defined below), as \$28.1 million of write-downs occurred due to the sale. In addition, there were various incremental impairment losses and other costs associated with the restructuring of our Canadian cannabis operations that were initiated in the three months ended March 31, 2023. Other The following table presents other income (expense), net, and income tax (expense) recovery for the three months ended December 31, 2024 and 2023:

	December 31, 2024 (in thousands of Canadian dollars)	December 31, 2023 (in thousands of Canadian dollars)	% Change
Other income (expense), net	\$ (97,758)	\$ (171,037)	\$ 73,279 A 43%
Income tax (expense) recovery	\$ (316)	\$ 1,077	(1,393) A (129%)

Other income (expense), net Other income (expense), net was an expense amount of \$97.8 million in the third quarter of fiscal 2025, as compared to an expense amount of \$171.0 million in the third quarter of fiscal 2024. The year-over-year change of \$73.3 million is primarily attributable to: Change of \$70.4 million related to non-cash fair value changes on our Canopy USA related and other financial assets, from an expense amount of \$146.7 million in the third quarter of fiscal 2024 to an expense amount of \$76.3 million in the third quarter of fiscal 2025. The expense amount recognized in the third quarter of fiscal 2025 is primarily attributable to fair value decreases relating to our investment in: the Canopy USA equity method investment in the amount of \$140.4 million. These fair value decreases were partially offset by a fair value increase related to our investment in: the Canopy Elevate I LLC, Canopy Elevate II LLC and Canopy Elevate III LLC (collectively, "Elevate") loan receivable, in the amount of \$59.4 million relating to fair value movements in consideration of the debtor's net assets; and the Acreage Debt (as defined below) loan receivable, in the amount of \$4.7 million, primarily attributable to changes in market conditions and assumptions. Comparatively, the expense amount in the third quarter of fiscal 2024 was primarily attributable to fair value decreases relating to our investments in: the Wana financial instrument, in the amount of \$62.6 million, which was attributable primarily to changes in expectations of the future cash flows to be generated by Wana; the Acreage financial instrument, in the amount of \$43.6 million. On a quarterly basis, we determine the fair value of the Acreage financial instrument using a probability-weighted expected return model, incorporating several potential scenarios and outcomes associated with the Acreage Amended Arrangement. The fair value decrease in the third quarter of fiscal 2024 is primarily attributable to a decrease of approximately 36% in our share price during the third quarter of fiscal 2024, relative to a decrease of approximately 54% in Acreage's share price during that same period. As a result, the model at December 31, 2023 reflects both a lower estimated value of the Canopy Growth common shares expected to be issued upon Canopy USA's acquisition of Acreage, and a lower estimated value of the Acreage shares expected to be acquired at that time. In the third quarter of fiscal 2024, the relative share price movements resulted in a decrease in the value of the Acreage financial instrument; the TerrAscend Exchangeable Shares, in the amount of \$22.9 million, primarily attributable to a decrease of approximately 21% in TerrAscend's share price during the third quarter of fiscal 2024; the TerrAscend Warrants, in the amount of \$10.5 million, primarily attributable to a decrease of approximately 21% in TerrAscend's share price during the third quarter of fiscal 2024; and the Jetty financial instrument, in the amount of \$9.9 million, which was attributable primarily to changes in the expectations of the future cash flows to be generated by Jetty. 46 These fair value decreases were partially offset by a fair value increase related to our investment in: the Universal Hemp, LLC ("Acreage Hempco") debenture, in the amount of \$2.1 million, which was attributable primarily to changes in expected future cash flows to be received. Decrease in expense of \$5.4 million related to non-cash fair value changes on our debt, from \$5.4 million in the third quarter of fiscal 2024 to nil in the third quarter of fiscal 2025. The year-over-year change is driven primarily by the fair value change of the CBI Note in the third quarter of fiscal 2024. In the third quarter of fiscal 2025 there are no debt balances recorded at fair value. Change of \$8.6 million related to fair value changes on acquisition related contingent consideration and other, from an income amount of \$8.6 million in the third quarter of fiscal 2024 to nil in the third quarter of fiscal 2025. No fair value changes occurred in the third quarter of fiscal 2025. Comparatively, the fair value change in the third quarter of fiscal 2024, related primarily to the estimated deferred payments associated with our investment in Wana. Change of \$0.6 million related to charges associated with the settlement of our debt, from an expense amount of \$0.6 million in the third quarter of fiscal 2024 to nil in the third quarter of fiscal 2025. In the third quarter of fiscal 2025, settlement of debt balances did not result in any gains or losses. In the third quarter of fiscal 2024, we recognized a charge in the amount of \$0.6 million which is primarily due to principal repayments on the Credit Facility. Decrease in interest income of \$0.6 million, from \$2.5 million in the third quarter of fiscal 2024 to \$1.9 million in the third quarter of fiscal 2025. The year-over-year decrease is attributable to lower cash and cash equivalents and short-term investment balances. Decrease in interest expense of \$7.9 million, from \$24.6 million in the third quarter of fiscal 2024 to \$16.8 million in the third quarter of fiscal 2025. The year-over-year decrease is primarily attributable to the reduction of our debt balances. Income tax (expense) recovery Income tax expense in the third quarter of fiscal 2025 was \$0.3 million, compared to income tax recovery of \$1.1 million in the third quarter of fiscal 2024. In the third quarter of fiscal 2025, income tax expense consisted of deferred income tax expense of \$0.2 million (compared to a recovery of \$0.6 million in the third quarter of fiscal 2024) and current income tax expense of \$0.1 million (compared to a recovery of \$0.5 million in the third quarter of fiscal 2024). The increase of \$0.8 million in the deferred income tax expense is primarily a result of the utilization of losses for tax purposes, where the accounting criteria for recognition of an asset has been met. The increase of \$0.6 million in current income tax expense arose primarily in connection with tax on income for tax purposes that could not be reduced by the group's tax attributes in the current taxation year. Net Loss from Continuing Operations The net loss from continuing operations in the third quarter of fiscal 2025 was \$121.9 million, as compared to a net loss of \$230.3 million in the third quarter of fiscal 2024. The year-over-year decrease in the net loss is primarily attributable to: (i) the year-over-year change in other income (expense), net, of \$73.3 million; and (ii) the decrease in operating loss from continuing operations. These variances are described above. Adjusted EBITDA (Non-GAAP Measure) Our Adjusted EBITDA is a non-GAAP measure used by management that is not defined by U.S. GAAP and may not be comparable to similar measures presented by other companies. Management calculates Adjusted EBITDA as the reported net income (loss), adjusted to exclude income tax recovery (expense); other income (expense), net; loss on equity method investments; share-based compensation expense; depreciation and amortization expense; asset impairment and restructuring costs; restructuring costs recorded in cost of goods sold; and charges related to the flow-through of inventory step-up on business combinations, and further adjusted to remove acquisition, divestiture, and other costs. Asset impairments related to periodic changes to our supply chain processes are not excluded from Adjusted EBITDA given their occurrence through the normal course of core operational activities. Accordingly, management believes that Adjusted EBITDA provides meaningful and useful financial information, as this measure demonstrates the operating performance of businesses. 47 A The following table

percentage 34 % 29 % - 500 bps Cost of goods sold was \$135.0 million in the nine months ended December 31, 2024, as compared to \$158.9 million in the nine months ended December 31, 2023. Our gross margin was \$69.0 million in the nine months ended December 31, 2024, or 34% of net revenue, as compared to a gross margin of \$65.4 million and gross margin percentage of 29% of net revenue in the nine months ended December 31, 2023. The year-over-year increase in the gross margin percentage is primarily attributable to: (i) improvement in our Canada cannabis segment, primarily attributable to: (i) the realized benefit of our cost savings program and strategic changes to our business that were initiated in the fourth quarter of fiscal 2023; (ii) a year-over-year decrease in write-downs of excess inventory; and (iii) a shift in channel mix to higher margin medical sales; and (ii) improvement in our international markets cannabis segment, primarily due to an increase in sales mix to higher-margin Poland as well as a lower overall cost structure. Partially offset by costs related to new product launches, increased price competition and indirect costs. 49 We report gross margin and gross margin percentage in four segments: (i) Canada cannabis; (ii) international markets cannabis; (iii) Storz & Bickel; and (iv) This Works. Cost of sales associated with the remainder of our operations are included within "other". The following table presents segmented gross margin and gross margin percentage for the nine months ended December 31, 2024 and 2023:

	Nine months ended December 31, 2024	(in thousands of Canadian dollars except where indicated)	2023	% Change	% Change	Canada cannabis segment	Net revenue	\$ 115,483	\$ 120,543	\$ (5,060)	(4 %)	Cost of goods sold	\$ 81,258	\$ 95,203	(13,945)	(15 %)	Gross margin	\$ 34,225	\$ 25,340	\$ 8,885	\$ 35 %	Gross margin percentage	30 %	21 %	\$ 900 bps	\$ 1,869	\$ 19,302	(433)	(2 %)	Gross margin	\$ 13,297	\$ 10,364	\$ 2,933	\$ 28 %	Gross margin percentage	41 %	35 %	600 bps	\$ 7,798	\$ 16 %	Cost of goods sold	\$ 34,870	\$ 27,443	\$ 7,427	\$ 27 %	Gross margin	\$ 21,445	\$ 21,074	\$ 371	\$ 2 %	Gross margin percentage	38 %	43 %	(500) bps	(100) %	Cost of goods sold	\$ 10,722	\$ (10,722)	(100) %	Gross margin	\$ -	\$ 10,534	\$ (10,534)	(100) %	Gross margin percentage	- %	50 %	(5,000) bps	(6,274)	(100) %	Gross margin	\$ (1,898)	\$ 1,898	100 %	Gross margin percentage	- %	(43 %)	\$ 4,300 bps
Canada cannabis Gross margin for our Canada cannabis segment was \$34.2 million in the nine months ended December 31, 2024, or 30% of net revenue, as compared to \$25.3 million in the nine months ended December 31, 2023, or 21% of net revenue. The year-over-year increase in the gross margin percentage was primarily attributable to: (i) the realized benefit of our cost savings program and strategic changes to our business that were initiated in the fourth quarter of fiscal 2023; (ii) a year-over-year decrease in write-downs of excess inventory; and (iii) strong Canadian medical cannabis sales. Offset by costs related to new product launches and increased price competition. International markets cannabis Gross margin for our international markets cannabis segment was \$13.3 million in the nine months ended December 31, 2024, or 41% of net revenue, as compared to \$10.4 million in the nine months ended December 31, 2023, or 35% of net revenue. The year-over-year increase in the gross margin percentage is primarily attributable to the shift in sales mix to higher-margin Poland as well as a lower cost structure relating to our overall international cannabis operations. Storz & Bickel Gross margin for our Storz & Bickel segment was \$21.4 million in the nine months ended December 31, 2024, or 38% of net revenue, as compared to \$21.1 million in the nine months ended December 31, 2023, or 43% of net revenue. The year-over-year decrease in the gross margin percentage is driven primarily by a shift in product mix as additional rebates were provided to clear out remaining stock of a previously planned discontinued product and increases in indirect costs. 50 This Works Gross margin for our This Works segment was \$nil in the nine months ended December 31, 2024, or 0% of net revenue, as compared to \$10.5 million in the nine months ended December 31, 2023, or 50% of net revenue. The year-over-year decrease in the gross margin percentage is due to the completion of the divestiture of This Works (the "This Works Divestiture") on December 18, 2023. Operating Expenses The following table presents operating expenses for the nine months ended December 31, 2024 and 2023:																																																																														
	2024	2023	% Change	% Change	Operating expenses	General and administrative	\$ 52,689	\$ 69,667	\$ (16,978)	(24 %)	Sales and marketing	\$ 45,676	\$ 58,678	(13,002)	(22 %)	Acquisition, divestiture, and other costs	\$ 14,741	\$ 24,373	(9,632)	(40 %)	Depreciation and amortization	\$ 18,068	\$ 22,092	(4,024)	(18 %)	Selling, general and administrative expenses	\$ 131,174	\$ 174,810	(43,636)	(25 %)	Share-based compensation expense	\$ 14,531	\$ 10,127	\$ 4,404	43 %	Total operating expenses	\$ 167,840	\$ 187,389	(19,549)	(10 %)	Selling, general and administrative expenses	\$ 131.2 million in the nine months ended December 31, 2024, as compared to \$174.8 million in the nine months ended December 31, 2023. General and administrative expense was \$52.7 million in the nine months ended December 31, 2024, as compared to \$69.7 million in the nine months ended December 31, 2023. The year-over-year decrease is primarily attributable to: (i) the divestiture of This Works on December 18, 2023 and (ii) the impact of the restructuring actions and cost savings program initiated in the fourth quarter of fiscal 2023. Sales and marketing expense was \$45.7 million in the nine months ended December 31, 2024, as compared to \$58.7 million in the nine months ended December 31, 2023. The year-over-year decrease is primarily attributable to: (i) the divestiture of This Works on December 18, 2023 and (ii) the impact of the restructuring actions and cost savings program initiated in the fourth quarter of fiscal 2023. Acquisition, divestiture, and other costs were \$14.7 million in the nine months ended December 31, 2024, as compared to \$24.4 million in the nine months ended December 31, 2023. In the nine months ended December 31, 2024, costs were incurred primarily in relation to: continued legal costs arising from the restatement of our consolidated financial statements in connection with the review of the financial reporting matters related to the BioSteel business unit; the Reorganization of Canopy USA; costs associated with the Debt Acquisition of Acreage; and costs relating to the modification of the Credit Agreement that occurred in August 2024. Comparatively, in the nine months ended December 31, 2023, costs were incurred primarily in relation to: costs relating to the modification of the Credit Agreement that occurred in July 2023; legal and audit costs arising from the restatement of our consolidated financial statements in connection with the review of the financial reporting matters related to the BioSteel business unit; the Reorganization of Canopy USA; and evaluating other potential acquisition opportunities. Depreciation and amortization expense was \$18.1 million in the nine months ended December 31, 2024, as compared to \$22.1 million in the nine months ended December 31, 2023. The year-over-year decrease is primarily attributable to the previously-noted restructuring actions and cost savings programs, including the closure of certain of our Canadian facilities and other operational changes to implement cultivation-related efficiencies and improvements in the Canadian adult-use cannabis business. 51 Share-based compensation expense Share-based compensation expense was \$14.5 million in the nine months ended December 31, 2024, as compared to \$10.1 million in the nine months ended December 31, 2023. The year-over-year increase is primarily attributable to: (i) the first quarter of fiscal 2025 grant of 0.8 million options and 0.7 million restricted share units, and (ii) higher forfeitures in the first three quarters of fiscal 2024 due to previously-noted restructuring actions. Loss on asset impairment and restructuring Loss on asset impairment and restructuring recorded in operating expenses were \$22.1 million in the nine months ended December 31, 2024, as compared to \$2.5 million in the nine months ended December 31, 2023. Loss on asset impairment and restructuring recorded in the nine months ended December 31, 2024 related primarily to the non-cash impairment of divestiture-related assets, employee restructuring costs, and ongoing holding costs to maintain previously restructured sites. These amounts were offset by a gain related to remeasurement of a lease liability upon execution of the surrender agreement. Comparatively, in the nine months ended December 31, 2023, the loss on asset impairment and restructuring was primarily related to charges associated with the completion of the This Works Divestiture, as \$28.1 million of write-downs occurred due to the sale. In addition, there were various incremental impairment losses and other costs associated with the restructuring of our Canadian cannabis operations that were initiated in the three months ended March 31, 2023. These charges were offset by a gain on the sale of our production facility at 1 Hershey Drive in Smiths Falls, Ontario. The gain is due to the sale proceeds exceeding the carrying value that was previously impaired at March 31, 2023. Other The following table presents other income (expense), net, and income tax expense for the nine months ended December 31, 2024 and 2023:																																				
	2024	2023	% Change	% Change	Other income (expense), net	(276,952)	(253,270)	(23,682)	(9 %)	Income tax expense	(6,812)	(13,762)	(6,950)	(51 %)	Other income (expense), net	\$ 277.0 million in the nine months ended December 31, 2024, as compared to an expense amount of \$253.3 million in the nine months ended December 31, 2023. The year-over-year change of \$23.7 million is primarily attributable to: Change of \$48.7 million related to non-cash fair value changes on our Canopy USA related and other financial assets, from an expense amount of \$163.9 million in the nine months ended December 31, 2023 to an expense amount of \$212.6 million in the nine months ended December 31, 2024. The expense amount recognized in the nine months ended December 31, 2024 is primarily attributable to fair value decreases relating to our investments in: the Canopy USA equity method investment in the amount of \$230.0 million; the Acreage Debt loan receivable, in the amount of \$1.2 million, primarily attributable to changes in market conditions and assumptions; the Acreage financial instrument, in the amount of \$31.8 million. On a quarterly basis, we determine the fair value of the Acreage financial instrument using a probability-weighted expected return model, incorporating several potential scenarios and outcomes associated with the Acreage Amended Arrangement. The fair value decrease in the nine months ended December 31, 2024 is primarily attributable to an increase of approximately 75% in our share price up to the Deconsolidation Date (as defined below), relative to an increase of approximately 46% in Acreage's share price during that same period. As a result, the model at the Deconsolidation Date reflects both a higher estimated value of the Canopy Growth common shares that were expected to be issued upon Canopy USA's acquisition of Acreage, and a higher estimated value of the Acreage shares that were expected to be acquired at that time. In the period up to the Deconsolidation Date, the relative share price movements resulted in a decrease in the value of the Acreage financial instrument; and olndiva Limited ("olndiva") shares, in the amount of \$2.8 million due to a decrease in their share price as a result of their CCAA proceedings. These fair value decreases were partially offset by fair value increases related to our investments in: the Elevate loan receivable, in the amount of \$24.8 million relating to fair value movements in consideration of the debtor's net assets; 52 the TerrAscend Exchangeable Shares, in the amount of \$17.3 million, which was primarily attributable to an increase of approximately 16% in TerrAscend's share price up to April 30, 2024, being the date that Canopy Growth deconsolidated the financial results of Canopy USA (the "Deconsolidation Date"); the TerrAscend Warrants, in the amount of \$7.9 million, which was primarily attributable to an increase of approximately 16% in TerrAscend's share price up to the Deconsolidation Date; and the Acreage debt Option Premium, in the amount of \$3.1 million related to closing of the Acreage Debt Acquisition and release of the amount that was previously held in escrow pursuant to the Option Agreement. Comparatively, the expense amount in the nine months ended December 31, 2023 was primarily attributable to fair value decreases relating to our investments in: (i) the Wana financial instrument (\$11.8 million); (ii) the Jetty financial instrument (\$27.2 million); (iii) the Acreage financial instrument (\$22.3 million); and (iv) the Acreage Hempco debenture (\$15.8 million). The fair value decreases were partially offset by fair value increases associated with our investments in: (i) the TerrAscend Exchangeable Shares (\$10.2 million); and (ii) the TerrAscend Warrants (\$2.7 million). Decrease in expense of \$30.6 million related to non-cash fair value changes on our debt, from \$30.6 million in the nine months ended December 31, 2023 to \$nil in the nine months ended December 31, 2024. The year-over-year change is driven primarily by the fair value change of the CBI Note in the nine months ended December 31, 2023. In the nine months ended December 31, 2024 there are no debt balances recorded at fair value. A Change of \$52.6 million related to fair value changes on acquisition related contingent consideration and other, from an income amount of \$19.1 million in the nine months ended December 31, 2023 to an expense amount of \$33.5 million in the nine months ended December 31, 2024. The fair value change in the nine months ended December 31, 2024 relates primarily to various acquisition related contingent consideration. Comparatively, the fair value change in the nine months ended December 31, 2023, related primarily to the estimated deferred payments associated with our investment in Wana. A Change of \$35.6 million related to charges associated with the settlement of our debt, from an expense amount of \$13.1 million in the nine months ended December 31, 2023 to an income amount of \$22.4 million in the nine months ended December 31, 2024. In the nine months ended December 31, 2024 we recognized a gain of \$22.4 million, primarily in connection with the exchange of the CBI Note. Comparatively, in the nine months ended December 31, 2023, we recognized a charge in the amount of \$13.1 million which is primarily due to the settlement of our unsecured senior notes and principal repayments on the Credit Facility. A Decrease in interest income of \$7.4 million, from \$13.8 million in the nine months ended December 31, 2023 to \$6.4 million in the nine months ended December 31, 2024. The year-over-year decrease is attributable to lower cash and cash equivalents and short-term investment balances. A Decrease in interest expense of \$25.0 million, from \$84.2 million in the nine months ended December 31, 2023 to \$59.2 million in the nine months ended December 31, 2024. The year-over-year decrease is primarily attributable to the reduction of our debt balances. Income tax expense Income tax expense in the nine months ended December 31, 2024 was \$6.8 million, compared to income tax expense of \$13.8 million in the nine months ended December 31, 2023. In the nine months ended December 31, 2024, income tax expense consisted of deferred income tax expense of \$6.4 million (compared to an expense of \$13.4 million in the nine months ended December 31, 2023) and current income tax expense of \$0.4 million (compared to an expense of \$0.4 million in the nine months ended December 31, 2023). The decrease of \$7.0 million in the deferred income tax expense is primarily a result of: (i) a decrease due to the settlements of the Canopy Notes (as defined below) in fiscal 2024 relative to the settlements of the CBI Note in fiscal 2025; and (ii) an increase due to the realization of deferred taxes for entities that historically did not meet the deferred tax asset recognition criteria. The current income tax expense remained consistent period over period and arose primarily in connection with tax on income for tax purposes that could not be reduced by the group's tax attributes in the current taxation year. Net Loss from Continuing Operations The net loss from continuing operations in the nine months ended December 31, 2024 was \$382.6 million, as compared to a net loss of \$389.0 million in the nine months ended December 31, 2023. The year-over-year decrease in the net loss is primarily attributable to: (i) the decrease in selling, general and administrative expenses and improvement in gross margins; (ii) reduction in income tax expense; and (iii) offset by the year-over-year change in other income (expense), net of \$23.7 million. These variances are described above. 53 Adjusted EBITDA (Non-GAAP Measure) Our Adjusted EBITDA is a non-GAAP measure used by management that is not defined by U.S. GAAP and may not be comparable to similar measures presented by other companies. Management calculates Adjusted EBITDA as the reported net income (loss), adjusted to exclude income tax recovery (expense); other income (expense), net; loss on equity method investments; share-based compensation expense; depreciation and amortization expense; asset impairment and restructuring costs; restructuring costs recorded in cost of goods sold; and charges related to the flow-through of inventory step-up on business combinations, and further adjusted to remove acquisition, divestiture, and other costs. Asset impairments related to periodic changes to our supply chain processes are not excluded from Adjusted EBITDA given their occurrence through the normal course of core operational activities. Accordingly, management believes that Adjusted EBITDA provides meaningful and useful financial information, as this measure demonstrates the operating performance of businesses. The following table presents Adjusted EBITDA for the nine months ended December 31, 2024 and 2023:																																																														
	2024	2023	% Change	% Change	Net loss from continuing operations	(382,637)	(389,007)	(6,370)	(2 %)	Income tax expense	(6,812)	(13,762)	(6,950)	(51 %)	Other (income) expense, net	(276,952)	(253,270)	(23,682)	(9 %)	Share-based compensation	(14,531)	(10,127)	(4,404)	43 %	Acquisition, divestiture, and other costs	(16,300)	(24,373)	(8,073)	(33 %)	Depreciation and amortization	(31,651)	(41,881)	(10,230)	(24 %)	Loss on asset impairment and restructuring	(22,135)	(2,452)	(19,683)	(803 %)	Restructuring costs recorded in cost of goods sold	(41,881)	(689)	(41,192)	(598 %)	Adjusted EBITDA	(14,256)	(43,831)	(29,575)	(67 %)	The Adjusted EBITDA loss in the nine months ended December 31, 2024 was \$14.3 million, as compared to an Adjusted EBITDA loss of \$43.8 million in the nine months ended December 31, 2023. The year-over-year decrease in Adjusted EBITDA loss is primarily attributable to the year-over-year increase in our gross margin and the year-over-year decrease in our selling, general and administrative expenses. Part 3 Financial Liquidity and Capital Resources The Interim Financial Statements have been prepared in accordance with generally accepted accounting principles on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. In our condensed interim consolidated financial statements for the quarterly period ended December 31, 2023, we raised substantial doubt about our ability to continue as a going concern for at least twelve months from the issuance of those condensed interim consolidated financial statements,																												

due to certain material debt obligations coming due in the short-term, recurring losses from operations and additional required financing to fund our business and operations. As of the filing of the Annual Report, we were able to successfully mitigate the substantial doubt by completing several balance sheet actions as further described in the Annual Report. During the nine months ended December 31, 2024, we completed additional actions and established our at-the-market equity program (the “at-ATM Program”), issued and sold an aggregate of 39,519,029 common shares for gross proceeds of \$256.0 million under the ATM Program, amended the terms of the Credit Facility thereby extending the maturity date of the Credit Facility, made a mandatory US\$100.0 million prepayment of the Credit Facility (as defined below), which significantly reduced our short-term debt obligation, received additional proceeds from the liquidation and sale of assets of BioSteel Canada, and completed the Lease Renegotiation, which is expected to reduce our potential lease payment obligation. We continue to evaluate different strategies and may pursue additional actions that are expected to further increase our liquidity position, including, but not limited to, pursuing additional actions to find cost-savings and seeking additional financing from both the public and private markets through the issuance of equity and/or debt securities. We have access to further liquidity through public offerings of equity and debt securities. To facilitate such offerings, in June 2024, we filed (a) a shelf registration statement with the SEC that is effective for a term of three years and expires in June 2027 (the “Shelf Registration Statement”); and (b) a short form base shelf prospectus dated June 5, 2024 that is effective for a 25 month period (the “Canadian Shelf Prospectus”). The amount of securities to be issued pursuant to the Shelf Registration Statement was not specified when it was filed and there is no specific dollar limit on the amount of securities we may issue. Pursuant to the Canadian Shelf Prospectus we may sell securities up to an aggregate total offering price of US\$500 million (or the equivalent thereof in other currencies). The securities covered by the Shelf Registration Statement and the Canadian Shelf Prospectus include: (i) common shares; (ii) exchangeable shares; (iii) debt securities; (iv) subscription receipts; (v) warrants; and (vi) units consisting of one or more of such securities or any combination of these securities. The specifics of any future offerings, along with the use of proceeds of any securities offered, will be described in detail in a prospectus supplement, or other offering materials, at the time of any offering. 54 Å We may also access liquidity through the ATM Program, pursuant to which we may sell, from time to time, up to US\$22.5 million of additional common shares of the Company as of the date hereof. Refer to Notes 19 and 30 to the Interim Financial Statements. As a result of our plans above and our financial results at December 31, 2024, we conclude that the substantial doubt about our ability to continue as a going concern continues to be alleviated. As of December 31, 2024, we had cash and cash equivalents of \$161.9 million and short-term investments of \$16.4 million. We have recently completed the following debt and equity financings and repayments: Å On April 18, 2024, we entered into the April 2024 Exchange Agreement with Greenstar, pursuant to which Greenstar completed the Note Exchange, calculated based on a price per Exchangeable Share equal to \$8.91. Pursuant to the terms of the April 2024 Exchange Agreement, all accrued but unpaid interest on the CBI Note together with the remaining principal amount of the CBI Note was cancelled and forgiven for no additional consideration by Greenstar. Following the closing of the Note Exchange, there is no outstanding balance owing under the CBI Note and the CBI Note has been cancelled. Å On May 2, 2024, we entered into the Exchange and Subscription Agreement with the May 2024 Investor pursuant to which, among other things, the May 2024 Investor delivered to us approximately \$27.5 million aggregate principal amount of outstanding Supreme Debentures and Accretion Debentures held by the May 2024 Investor and paid us approximately \$68.3 million (US\$50.0 million) in exchange for us issuing to the May 2024 Investor (i) the May 2024 Convertible Debenture with an aggregate principal amount of approximately \$96.4 million maturing five years from the Closing Date and (ii) 3,350,430 May 2024 Investor Warrants. Each May 2024 Investor Warrant entitles the holder to acquire one Canopy Share at an exercise price equal to \$16.18 per Canopy Share for a period of five years from the Closing Date. The May 2024 Convertible Debenture bears interest at a rate of 7.50% per annum, payable in semi-annual payments in cash or, at our option, in Canopy Shares for the first four semi-annual interest payments after the Closing Date, subject to satisfaction of certain conditions, including the prior approval of the TSX. The May 2024 Convertible Debenture is convertible into Canopy Shares at the option of the May 2024 Investor at a conversion price equal to \$14.38 per share. The May 2024 Convertible Debenture is subject to a forced conversion feature upon notice from us in the event that the average closing trading price of the Canopy Shares on the TSX exceeds \$21.57 for a period of 10 consecutive trading days. In addition, pursuant to the terms of the May 2024 Convertible Debenture, during Debenture ROFR Term, we granted the May 2024 Investor a right of first refusal to subscribe for, and to be issued, as an investor in a Proposed Financing; provided, however, that the May 2024 Investor shall subscribe for 25% of the Proposed Financing on the same terms and conditions contemplated in the Proposed Financing. Å On June 6, 2024, we established the ATM Program that allows us to sell up to US\$250 million of common shares of the Company from treasury to the public from time to time at the Company’s discretion. As part of the ATM Program, during the three months ended December 31, 2024 we sold an aggregate of 22,713,177 common shares at an average price of \$5.17 per common share, for gross proceeds of \$117.5 million and net proceeds, inclusive of commissions and fees, of \$115.7 million. During the three months ended December 31, 2024, we paid an aggregate amount of \$1.8 million as compensation to the agents involved in the sale of our common shares under the ATM Program. During the nine months ended December 31, 2024, we sold an aggregate of 39,519,029 common shares at an average price of \$6.48 per common share, for gross proceeds of \$256.0 million and net proceeds, inclusive of commissions and fees, of \$252.1 million. During the nine months ended December 31, 2024, we paid an aggregate amount of \$3.9 million as compensation to the agents involved in the sale of our common shares under the ATM Program. As of February 6, 2025, we can sell up to US\$22.5 million of our common shares under the ATM Program. Å On August 20, 2024, we entered into the August 2024 Supreme Convertible Debt Exchange with the August 2024 Investor pursuant to which, among other things, the August 2024 Investor delivered to the Company approximately \$2.7 million of aggregate principal amount of outstanding Supreme Debentures held by the August 2024 Investor in exchange for 291,351 common shares of the Company and \$0.03 million in cash for accrued interest. In addition to the above, we continue to review and pursue selected external financing sources to ensure adequate financial resources. These potential sources include, but are not limited to: (i) obtaining financing from traditional or non-traditional investment capital organizations; (ii) obtaining funding from the sale of our common shares or other equity or debt instruments; and (iii) obtaining debt financing with lending terms that more closely match our business model and capital needs. We may from time to time seek to retire our outstanding debt through cash purchases and/or exchanges for equity securities, and open market purchases, privately negotiated transactions or otherwise. Such repurchases or exchanges, if any, will depend on prevailing market conditions, our liquidity requirements, contractual restrictions and other factors. The amounts involved may be material. 55 Å Cash Flows The following table presents cash flows for the nine months ended December 31, 2024 and 2023: Å Nine months ended December 31, Å (in thousands of Canadian dollars) Å 2024 Å Å 2023 Å Net cash (used in) provided by: Å Å Å Å Operating activities1 Å \$ (132,598) Å \$ (259,891) Investing activities2 Å \$ (46,787) Å \$ 202,106 Å Financing activities Å \$ 164,618 Å \$ (473,524) Effect of exchange rate changes on cash and cash equivalents Å \$ 6,376 Å \$ (2,953) Net decrease in cash and cash equivalents Å \$ (8,391) Å \$ (534,262) Cash and cash equivalents, beginning of period3 Å \$ 170,300 Å \$ 677,007 Å Cash and cash equivalents, end of period4 Å \$ 161,909 Å \$ 142,745 1 Å Includes net cash used in operating activities from discontinued operations of \$nil and \$(53,930) for the nine months ended December 31, 2024 and 2023, respectively. 2 Å Includes net cash provided by (used in) investing activities from discontinued operations of \$13,414 and \$(2,600) for the nine months ended December 31, 2024 and 2023, respectively. 3 Å Includes cash of our discontinued operations of \$nil and \$9,314 for March 31, 2024 and 2023, respectively. 4 Å Includes cash of our discontinued operations of \$nil and \$nil for December 31, 2024 and 2023, respectively. Å Operating activities Cash used in operating activities totaled \$132.6 million in the nine months ended December 31, 2024, as compared to cash used of \$259.9 million in the nine months ended December 31, 2023. The decrease in the cash used in operating activities is primarily due to: (i) the year-over-year decrease in our working capital spending, resulting from our previously-noted restructuring actions and cost savings programs, including the closure of certain of our Canadian facilities and other operational changes to implement cultivation-related efficiencies and improvements in the Canadian adult-use cannabis business; and (ii) a reduction in the cash interest paid resulting from a reduction in our debt balances. Investing activities The cash used in investing activities totaled \$46.8 million in the nine months ended December 31, 2024, as compared to cash provided of \$202.1 million in the nine months ended December 31, 2023. In the nine months ended December 31, 2024, purchases of property, plant and equipment were \$7.7 million, primarily related to building improvements and production equipment enhancements made at certain of our Canadian cultivation and production facilities. Comparatively, in the nine months ended December 31, 2023, we invested \$3.2 million in production equipment enhancements made at certain of our Canadian cultivation and production facilities, and at our Storz & Bickel facilities. In the nine months ended December 31, 2024, our strategic investments in other financial assets were \$95.3 million and related primarily to the cash payment to acquire the outstanding principal, including all accrued and unpaid interest thereon, of Acreeage’s debt, being an amount up to US\$150.0 million (the “Acreeage Debt”). Comparatively, in the nine months ended December 31, 2023, our strategic investments in other financial assets were \$0.5 million and related primarily to our investment in Indiva. Net redemptions of short-term investments in the nine months ended December 31, 2024 were \$17.0 million, as compared to net redemptions of \$68.3 million in the nine months ended December 31, 2023. The year-over-year decrease in the net redemptions reflects the continued redemption of our short-term investments, largely to fund operations and investing activities as described above. As at December 31, 2024, we had short-term investments remaining of \$16.4 million. Net cash flow on sale or deconsolidation of subsidiaries in the nine months ended December 31, 2024 was an outflow of \$7.0 million and related to the deconsolidation of Canopy USA, refer to Note 3 in the Company’s accompanying financial statements for details. Comparatively, net cash flow in the nine months ended December 31, 2023 was an outflow of \$3.7 and related to the completion of the This Works Divestiture. Additional cash inflows during the nine months ended December 31, 2024 include proceeds of \$4.9 million from the sale of property, plant and equipment, primarily in relation to previous restructuring actions. Comparatively, additional cash inflows during the nine months ended December 31, 2023 include proceeds of \$153.8 million from the sale of property, plant and equipment, primarily relating to facilities sold in connection with the restructuring actions associated with our Canadian cannabis operations and transition to an asset-light model. Finally, net cash flow on loan receivable and other investing activities resulted in a cash inflow of \$28.4 million in the nine months ended December 31, 2024, primarily related to cash receipts from various loan repayments. Comparatively, net cash flow on loan receivable and other investing activities in the nine months ended December 31, 2023 of \$9.2 million primarily related to completing the purchase of the remaining 45% of the common shares of Les Serres Vert Cannabis Inc., in connection with the restructuring actions related to our Canadian cannabis operations initiated in the fourth quarter of fiscal 2023. 56 Å Financing activities The cash provided by financing activities in the nine months ended December 31, 2024 was \$164.6 million, as compared to cash used of \$473.5 million in the nine months ended December 31, 2023. In the nine months ended December 31, 2024, \$256.0 million in gross proceeds were received from the sale of common shares as part of the ATM Program and \$8.5 million in gross proceeds were received from the exercise of warrants, these amounts were offset by share issuance costs of \$6.6 million. In addition, \$68.3 million was received relating to the Exchange and Subscription Agreement, offset by long-term debt repayments of \$148.2 million which related primarily to the First Quarter 2025 Paydowns, Second Quarter 2025 Paydown, and the Third Quarter 2025 Paydown. Other financing activities resulted in a cash outflow of \$19.9 million, which related primarily to: (i) finance lease payments and (ii) share issuance costs, as noted above. Comparatively, in the nine months ended December 31, 2023, we made repayments of long-term debt in the amount of \$480.1 million, which related to the various paydowns of our Credit Facility and settlement of the 4.25% unsecured senior notes due in 2023 (the “Canopy Notes”). Other financing activity cash outflow of \$27.2 million related primarily to payments made in connection with terminating the finance lease for the cultivation facility in Mirabel, Quebec. In addition, debt extinguishment and issuance costs, and share issue costs contributed to the cash outflow. The cash outflows were offset by proceeds from the issuance of common shares. Free Cash Flow (Non-GAAP Measure) Free cash flow is a non-GAAP measure used by management that is not defined by U.S. GAAP and may not be comparable to similar measures presented by other companies. Management believes that free cash flow presents meaningful information regarding the amount of cash flow required to maintain and organically expand our business, and that the free cash flow measure provides meaningful information regarding our liquidity requirements. The following table presents free cash flows for the three and nine months ended December 31, 2024, and 2023: Å Å Three months ended December 31, Å Å Nine months ended December 31, Å (in thousands of Canadian dollars) Å 2024 Å Å 2023 Å Å 2024 Å Å 2023 Å Net cash used in operating activities - continuing Å \$ (26,966) Å \$ (33,348) Å \$ (132,598) Å \$ (205,961) Purchases of and deposits on property, plant Å \$ (140,322) Å \$ (209,161) 1 Free cash flow is a non-GAAP measure, and is calculated as net cash provided by (used in) operating activities, less purchases of and deposits on property, plant and equipment. Å Free cash flow in the three months ended December 31, 2024 was an outflow of \$28.2 million, as compared to an outflow of \$33.9 million in the three months ended December 31, 2023. The year-over-year decrease in the free cash outflow primarily reflects the decrease in cash used in operating activities, as described above. Free cash flow in the nine months ended December 31, 2024 was an outflow of \$140.3 million, as compared to an outflow of \$209.2 million in the nine months ended December 31, 2023. The year-over-year decrease in the free cash outflow primarily reflects the decrease in cash used in operating activities, as described above. Debt Since our formation, we have financed our cash requirements primarily through the issuance of common shares of Canopy Growth, including the \$5.1 billion investment by CBI in the third quarter of fiscal 2019, and debt. Total debt outstanding as of December 31, 2024 was \$441.6 million, a decrease from \$597.2 million as of March 31, 2024. The total principal amount owing was \$459.8 million at December 31, 2024, a decrease from \$622.0 million at March 31, 2024. The decreases were primarily due to: (i) the April 2024 Exchange Agreement, which resulted in the settlement of all amounts owing under the CBI Note; (ii) the First Quarter 2025 Paydowns resulting in an aggregate principal reduction of \$11.2 million; (iii) the Second Quarter 2025 Paydown resulting in an aggregate principal reduction of \$1.1 million; (iv) the Third Quarter 2025 Paydown resulting in an aggregate principal reduction of \$137.7 million and (v) the August 2024 Supreme Convertible Debt Exchange (as defined below) and offset by the Exchange and Subscription Agreement where a cash payment of approximately US\$50 million was received and approximately \$27.5 million of aggregate principal amount outstanding Supreme Debentures and Accretion Debentures were settled in exchange for a new senior unsecured convertible debenture with an aggregate principal amount of \$96.4 million. 57 Å Credit Facility On March 18, 2021, the Company entered into a term loan credit agreement (the “Credit Agreement”) providing for a five-year, first lien senior secured term loan facility in an aggregate principal amount of US\$750.0 million (the “Credit Facility”). The Company had the ability to obtain up to an additional US\$500.0 million of incremental senior secured debt pursuant to the Credit Agreement. Pursuant to the balance sheet actions completed in connection with the Reorganization, on October 24, 2022, we entered into agreements with certain of our lenders under the Credit Agreement pursuant to which we agreed to purchase in the aggregate US\$187.5 million of the principal amount outstanding under the Credit Facility at a discounted price of US\$930 per US\$1,000 or US\$174.4 million in the aggregate. The first payment, which was oversubscribed, in the amount of approximately \$117.5 million (US\$87.9 million) was made on November 10, 2022 to reduce the principal indebtedness under the Credit Facility by approximately \$126.3 million (US\$94.4 million). The second payment of approximately \$116.8 million (US\$87.2 million) was made on April 17, 2023 to reduce principal indebtedness under the Credit Facility by approximately \$125.6 million (US\$93.8 million). Additionally, on October 24, 2022, we and certain of our lenders agreed to make certain amendments to the Credit Agreement which, among other things, resulted in: (i) a reduction to the minimum liquidity covenant to no less than US\$100.0 million following completion of the second principal repurchase on April 17, 2023; (ii) certain changes to the application of net proceeds from asset sales; (iii) the establishment of a new committed delayed draw term credit facility in an aggregate principal amount of US\$100.0 million; and (iv) the elimination of the additional US\$500.0 million incremental term loan facility. On July 13, 2023, we entered into an amended Credit Agreement (the “Amended Credit Agreement”). The Amended Credit Agreement required the Company to prepay or repurchase principal indebtedness under the Credit Facility in an amount equal to the U.S. dollar equivalent of \$93,000 at a discounted price of US\$930 per US\$1,000 (the “July 2023 Paydown”). In addition, pursuant to the Amended Credit Agreement we agreed to apply certain net proceeds from asset sales to prepay or repurchase principal indebtedness under the Credit Facility and receive principal reductions at, in certain circumstances, a discounted price of US\$950 per US\$1,000. The Amended Credit Agreement also includes, among other things, amendments to the minimum liquidity covenant such that the US\$100.0 million minimum ceased to apply concurrently with the July 2023 Paydown. The July 2023 Paydown was made on July 21, 2023. On each of August 11, 2023 and September 14, 2023, pursuant to the terms of the Amended Credit Agreement, we repurchased additional outstanding principal amounts under the Credit Facility using certain net proceeds from completed asset sales (the “Second Quarter 2024 Paydowns”). The Second Quarter 2024 Paydowns resulted in an aggregate principal reduction of \$73.3 million (US\$54.5 million) for a cash payment of \$69.6 million (US\$51.8 million). On each of November 28, 2023 and December 27, 2023, pursuant to the terms of the Amended Credit Agreement, we repurchased and repaid, as applicable, additional outstanding principal amounts under the Credit Facility using certain net proceeds from completed asset sales (the “Third Quarter 2024 Paydowns”). The Third Quarter 2024 Paydowns resulted in an aggregate principal reduction of \$65.4 million (US\$48.5 million) for a cash payment of \$63.2 million (US\$46.9 million). On February 21, 2024,

repurchased and repaid, as applicable, additional outstanding principal amounts under the Credit Facility (the "Fourth Quarter 2024 Paydowns"). The Fourth Quarter 2024 Paydowns resulted in an aggregate principal reduction of \$31.1 million (US\$23.0 million) for a cash payment of \$28.0 million (US\$20.7 million). On April 29, 2024 and June 28, 2024, we made the First Quarter 2025 Paydowns. The First Quarter 2025 Paydowns resulted in an aggregate principal reduction of \$11.2 million (US\$8.2 million) for a cash payment of \$11.2 million (US\$8.2 million). On August 8, 2024, we entered into an amendment (the "Amending Agreement") with all of the lenders to the Credit Facility under the Amended Credit Agreement. Pursuant to the terms of the Amending Agreement, the maturity date of the Credit Facility was extended to December 18, 2026 and a mandatory US\$97.5 million prepayment of the Credit Facility at 97.5% of par thereby reducing the outstanding amount of the Credit Facility by US\$100 million was required to be made by December 31, 2024. We made the mandatory prepayment on October 16, 2024. In addition, the maturity date of the Credit Facility will be further extended to September 18, 2027 if an optional prepayment on the same terms is made on or before March 31, 2025. Borrowings under the Credit Facility are available by either prime rate advances or SOFR advances. Prime rate advances bear interest at the applicable prime rate plus 7.50% per annum and are subject to a prime rate floor of 2.00%. SOFR advances bear interest at the adjusted term SOFR rate plus 8.50% per annum and are subject to an adjusted term SOFR rate floor of 1.00%. Our obligations under the Credit Facility are guaranteed by our material wholly-owned Canadian and U.S. subsidiaries. The Credit Facility is secured by substantially all of our assets and our material wholly-owned Canadian and U.S. subsidiaries, including material real property. The Amended Credit Agreement, as amended by the Amending Agreement contains representations and warranties, and affirmative and negative covenants. On September 27, 2024, we made the Second Quarter 2025 Paydown. The Second Quarter 2025 Paydown resulted in an aggregate principal reduction of \$1.1 million (US\$0.9 million) for a cash payment of \$1.1 million (US\$0.9 million). On October 16, 2024, we made the Third Quarter 2025 Paydown. The Third Quarter 2025 Paydown resulted in an aggregate principal reduction of \$137.7 million (US\$100.0 million) for a cash payment of \$134.3 million (US\$97.5 million). 58 A Supreme Cannabis Convertible Debentures and Accretion Debentures On October 19, 2018, The Supreme Cannabis Company, Inc. (the "Supreme Cannabis") issued 6.0% senior unsecured convertible debentures (the "Supreme Debentures") for gross proceeds of \$100.0 million. On September 9, 2020, the Supreme Debentures were amended to effect, among other things: (i) the cancellation of \$63.5 million of principal amount of the Supreme Debentures; (ii) an increase in the interest rate to 8% per annum; (iii) the extension of the maturity date to September 10, 2025; and (iv) a reduction in the conversion price to \$2.85. In addition, on September 9, 2020, Supreme Cannabis issued new senior unsecured non-convertible debentures (the "Accretion Debentures"). The principal amount began at \$nil and accretes at a rate of 11.06% per annum based on the remaining principal amount of the Supreme Debentures of \$36.5 million to a maximum of \$13.5 million, compounding on a semi-annual basis commencing on September 9, 2020, and ending on September 9, 2023. As of September 9, 2023, the principal amount of the Accretion Debentures was finalized as \$10.4 million. The Accretion Debentures are payable in cash, but do not bear cash interest and are not convertible into Supreme Shares (as defined below). The principal amount of the Accretion Debentures will amortize, or be paid, at 1.0% per month over the 24 months prior to maturity. As a result of the arrangement (the "Supreme Arrangement") we completed with Supreme Cannabis on June 22, 2021 pursuant to which we acquired 100% of the issued and outstanding common shares of Supreme Cannabis (the "Supreme Shares"), the Supreme Debentures remain outstanding as securities of Supreme Cannabis, which, upon conversion will entitle the holder thereof to receive, in lieu of the number of Supreme Shares to which such holder was theretofore entitled, the consideration payable under the Supreme Arrangement that such holder would have been entitled to be issued and receive if, immediately prior to the effective time of the Supreme Arrangement, such holder had been the registered holder of the number of Supreme Shares to which such holder was theretofore entitled. In connection with the Supreme Arrangement, we, Supreme Cannabis and Computershare Trust Company of Canada (the "Trustee") entered into a supplemental indenture whereby we agreed to issue common shares upon conversion of any Supreme Debenture. In addition, we may force conversion of the Supreme Debentures outstanding with 30 days' notice if the daily volume weighted average trading price of our common shares is greater than \$385.90 for any 10 consecutive trading days. We, Supreme Cannabis and the Trustee entered into a further supplemental indenture whereby we agreed to guarantee the obligations of Supreme Cannabis pursuant to the Supreme Debentures and the Accretion Debentures. Prior to September 9, 2023, the Supreme Debentures were not redeemable. Beginning on and after September 9, 2023, Supreme Cannabis may from time to time, upon providing 60 days prior written notice to the Trustee, redeem the Supreme Debentures outstanding, provided that the Accretion Debentures have already been redeemed in full. Refer to the May 2024 Convertible Debenture details below for details on partial settlement of the Supreme Debentures and Accretion Debentures. On August 20, 2024, we entered into the August 2024 Supreme Convertible Debt Exchange with the August 2024 Investor pursuant to which, among other things, the August 2024 Investor delivered to the Company approximately \$2.7 million of aggregate principal amount of outstanding Supreme Debentures held by the August 2024 Investor in exchange for 291,351 common shares of the Company and \$0.03 million in cash for accrued interest. May 2024 Convertible Debenture On May 2, 2024, we entered into the Exchange and Subscription Agreement with the May 2024 Investor pursuant to which, among other things, the May 2024 Investor delivered to us approximately \$27.5 million aggregate principal amount of outstanding Supreme Debentures and Accretion Debentures held by the May 2024 Investor and paid us approximately US\$50 million in exchange for us issuing to the May 2024 Investor (i) the May 2024 Convertible Debenture with an aggregate principal amount of \$96.4 million maturing five years from the Closing Date of the Transaction and (ii) 3,350,430 May 2024 Investor Warrants of Canopy Growth. Each May 2024 Investor Warrant entitles the holder to acquire one Canopy Share at an exercise price equal to \$16.18 per Canopy Share for a period of five years from the Closing Date. The May 2024 Convertible Debenture bears interest at a rate of 7.50% per annum, payable in semi-annual payments in cash or, at our option, in Canopy Shares for the first four semi-annual interest payments after the Closing Date, subject to satisfaction of certain conditions, including the prior approval of the TSX. The May 2024 Convertible Debenture is convertible into Canopy Shares at the option of the May 2024 Investor at a conversion price equal to \$14.38 per share. The May 2024 Convertible Debenture is subject to a forced conversion feature upon notice from us in the event that the average closing trading price of the Canopy Shares on the TSX exceeds \$21.57 for a period of 10 consecutive trading days. In addition, pursuant to the terms of the May 2024 Convertible Debenture, during the Debenture ROFR Term, we granted the May 2024 Investor a right of first refusal to subscribe for, and to be issued, as an investor in a Proposed Financing; provided, however, that the May 2024 Investor shall subscribe for 25% of the Proposed Financing on the same terms and conditions contemplated in the Proposed Financing. 59 A Contractual Obligations and Commitments Other than changes to our Supreme Cannabis Convertible Debentures and Accretion Debentures, the May 2024 Convertible Debenture, the CBI Note, the First Quarter 2025 Paydowns, the Second Quarter 2025 Paydown, the Third Quarter 2025 Paydown, the Lease Renegotiation and certain agreements entered into in connection with the Reorganization, the Reorganization Amendments and the Additional Reorganization Amendments, as described above under "Recent Developments", there have been no material changes to our contractual obligations and commitments from the information provided in the MD&A section in the Annual Report. Off-Balance Sheet Arrangements We have no off-balance sheet arrangements that have, or are reasonably likely to have, a material current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that are material to investors. Critical Accounting Policies and Estimates There have been no material changes to our critical accounting policies and estimates from the information provided in the MD&A section in the Annual Report. Impairment of goodwill We do not believe that an event occurred or circumstances changed during the third quarter of fiscal 2025 that would, more likely than not, reduce the fair value of the Storz & Bickel reporting unit below its carrying value. Therefore, we concluded that the quantitative goodwill impairment assessment was not required for the Storz & Bickel reporting unit at December 31, 2024. The carrying value of goodwill associated with the Storz & Bickel reporting unit was \$44,093 at December 31, 2024. We are required to perform our next annual goodwill impairment analysis on March 31, 2025, or earlier should there be an event that occurs or circumstances change that would more likely than not reduce the fair value of a reporting unit below its carrying amount. Item 3. Quantitative and Qualitative Disclosures About Market Risk. Market risk is the potential economic loss arising from adverse changes in market factors. As a result of our global operating, acquisition and financing activities, we are exposed to market risk associated with changes in foreign currency exchange rates, interest rates and equity prices. To manage the volatility relating to these risks, we may periodically purchase derivative instruments including foreign currency forwards. We do not enter into derivative instruments for trading or speculative purposes. Foreign currency risk Our Interim Financial Statements are presented in Canadian dollars. We are exposed to foreign currency exchange rate risk as the functional currencies of certain subsidiaries, including those in the United States and Europe, are not in Canadian dollars. The translation of foreign currencies to Canadian dollars is performed for balance sheet accounts using exchange rates in effect at the balance sheet date, and for revenues and expense using an average exchange rate for the period. Therefore, fluctuations in the value of the Canadian dollar affect the reported amounts of net revenue, expenses, assets and liabilities. The resulting translation adjustments are reported as a component of accumulated other comprehensive income or loss on the consolidated balance sheet. A hypothetical 10% change in the U.S. dollar against the Canadian dollar compared to the exchange rate at December 31, 2024, would affect the carrying value of net assets by approximately \$9.4 million, with a corresponding impact to the foreign currency translation account within accumulated other comprehensive income (loss). A hypothetical 10% change in the euro against the Canadian dollar compared to the exchange rate at December 31, 2024, would affect the carrying value of net assets by approximately \$20.5 million, with a corresponding impact to the foreign currency translation account within accumulated other comprehensive income (loss). We also have exposure to changes in foreign exchange rates associated with transactions which are undertaken by our subsidiaries in currencies other than their functional currency. As a result, we have been impacted by changes in exchange rates and may be impacted for the foreseeable future. Foreign currency derivative instruments may be used to hedge existing foreign currency denominated assets and liabilities, forecasted foreign currency denominated sales/purchases to/from third parties as well as intercompany sales/purchases, intercompany principal and interest payments, and in connection with acquisitions, divestitures or investments outside of Canada. Historically, while we have purchased derivative instruments to mitigate the foreign exchange risks associated with certain transactions, the impact of these hedging transactions on our financial statements has been immaterial. Interest rate risk Our cash equivalents and short-term investments are held in both fixed-rate and adjustable-rate securities. Investments in fixed-rate instruments carry a degree of interest rate risk. The fair value of fixed-rate securities may be adversely impacted due to a rise in 60 A interest rates. Additionally, a falling-rate environment creates reinvestment risk because as securities mature, the proceeds are reinvested at a lower rate, generating less interest income. As at December 31, 2024, our cash and cash equivalents, and short-term investments consisted of \$32.7 million in interest rate sensitive instruments (March 31, 2024: \$88.0 million). Our financial liabilities consist of long-term fixed rate debt and floating-rate debt. Fluctuations in interest rates could impact our cash flows, primarily with respect to the interest payable on floating-rate debt. A Aggregate Notional Value A Fair Value A Decrease in Fair Value - Hypothetical 1% Rate Increase A December 31, 2024 A March 31, 2024 A December 31, 2024 A March 31, 2024 A December 31, 2024 A March 31, 2024 A Promissory note A \$ - A \$ 100,000 A \$ - A \$ 89,224 A \$ - A \$ (523) Fixed interest rate debt A 99,356 A A 38,186 A A N/A A N/A A N/A A Variable interest rate debt A 360,481 A A 469,819 A A N/A A N/A A N/A A Equity price risk We hold other financial assets and liabilities in the form of investments in shares, warrants, options, put liabilities, and convertible debentures that are measured at fair value and recorded through either net income (loss) or other comprehensive income (loss). We are exposed to price risk on these financial assets, which is the risk of variability in fair value due to movements in equity or market prices. Information regarding the fair value of financial instrument assets and liabilities that are measured at fair value on a recurring basis, and the relationship between the unobservable inputs used in the valuation of these financial assets and their fair value is presented in Note 23 of the Interim Financial Statements. 61 A Item 4. Controls and Procedures. Evaluation of Disclosure Controls and Procedures. We maintain disclosure controls and procedures (as that term is defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) that are designed to ensure that information required to be disclosed in our reports under the Exchange Act is recorded, processed, and summarized and reported within the time periods specified in the SEC's rules and forms, and that such information is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosures. Any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives. An evaluation of the effectiveness of the design and operation of our disclosure controls and procedures as of the end of the period covered by this Quarterly Report was made under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer. Based upon this evaluation, our Chief Executive Officer and Chief Financial Officer have concluded that, as of December 31, 2024, our disclosure controls and procedures (a) are effective to ensure that information required to be disclosed by us in reports filed or submitted under the Exchange Act is timely recorded, processed, summarized and reported and (b) include, without limitation, controls and procedures designed to ensure that information required to be disclosed by us in reports filed or submitted under the Exchange Act is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate to allow timely decisions regarding required disclosure. Changes in Internal Control over Financial Reporting. There have been no changes in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) that occurred during the period covered by this Quarterly Report that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting. 62 A PART II A OTHER INFORMATION Item 1. Legal Proceedings. Other than as disclosed below, we are not aware of: (a) any legal proceedings to which we are a party, or to which any of our properties is subject, which would be material to us or of any such proceedings being contemplated, (b) any penalties or sanctions imposed by a court relating to securities legislation, or other penalties or sanctions imposed by a court or regulatory body against us that would likely be considered important to a reasonable investor

prejudicial to the proposed class members by failing to remedy alleged deficiencies in the Company’s internal controls, and that all of the defendants are liable for damages to the putative class. The action seeks an unspecified amount of damages, interest, legal fees, and the costs of administering a plan of distribution of the recovery. The Company was also named in two other putative class proceedings that were commenced between May 2023 and July 2023 in the Ontario Superior Court of Justice alleging that the Company’s disclosures contained misrepresentations. However, on November 10, 2023, the Ontario Superior Court of Justice decided a carriage motion staying those actions (Leonard v. Canopy Growth Corporation et al., Court File No. CV-23-00702281-00CP and Twidale v. Canopy Growth Corporation et al., Court File No. CV-23-00700135-00CP), and allowing Dziedziejko v. Canopy Growth Corporation et al., Court File No. CV-23-00701769-00CP to proceed to a class certification hearing. On June 15, 2023, an ostensible shareholder commenced a putative class action (Asmaro v. Canopy Growth Corporation et al., Court File No. VLC-S-S-234351) against the Company and two of its officers in the Supreme Court of British Columbia on behalf of a putative class of all persons and entities who purchased or otherwise acquired securities of the Company between August 6, 2021 and May 10, 2023. The lawsuit alleges that the Company’s disclosures contained misrepresentations within the meaning of the 63 Securities Act (British Columbia), that certain officers authorized, permitted, or acquiesced in the release of the impugned disclosures, and that all of the defendants are liable for damages to the putative class. The plaintiff seeks an unspecified amount of damages. In May 2023, in connection with the Company’s internal review of the financial reporting matters related to BioSteel Canada, as previously disclosed in the Annual Report (the BioSteel Review), the Company voluntarily self-reported to the SEC that the timing and amount of revenue recognition in the BioSteel Canada segment were under review. As a result of self-reporting the BioSteel Review, the Company is the subject of an ongoing investigation by the SEC. Although the Company is fully cooperating with the SEC and continues to voluntarily respond to requests in connection with this matter, it cannot predict when such matters will be completed or the outcome and potential impact. Any remedial measures, sanctions, fines or penalties, including, but not limited to, financial penalties and awards, injunctive relief and compliance conditions, imposed on the Company in connection with this matter could have a material adverse impact on our business, financial condition and results of operations. See Risk Factors “Risks Relating to the Restatement of the Prior Financial Statements” As a result of self-reporting the BioSteel Review, the Company is the subject of an investigation by the SEC and an ongoing informal inquiry by regulatory authorities in Canada, and it cannot predict the timing of developments, and any adverse outcome of these continuing matters could have a material adverse effect on the Company under Item 1A of the Annual Report. The Company denies any alleged misconduct and liability for each of the claims asserted in the above-noted Court proceedings, believes that the defendants/respondents have meritorious defenses to the claims, and expects to vigorously defend the claims, although the Company cannot predict when or how they will be resolved or estimate what the potential loss or range of loss would be, if any. From time to time, we may become involved in legal proceedings arising in the ordinary course of our business. We are not currently a party to any other legal proceedings other than described above, the outcome of which, if determined adversely to us, would individually or in the aggregate have a material adverse effect on our business, financial condition, results of operations or prospects. Please refer to Risk Factors under Item 1A of the Annual Report for further discussion. Item 1A. Risk Factors. For information regarding factors that could affect our results of operations, financial condition and liquidity, see the risk factors discussed in Part I, Item 1A in the Annual Report. Except as set forth below, there have been no material changes to the risk factors previously disclosed in Part I, Item 1A in our Annual Report. Acreege’s financial statements express doubt about its ability to continue as a going concern, which could have a negative impact on Canopy USA’s business, financial results and operations and have an adverse impact on the Company’s United States strategy, and, ultimately, the Company’s financial results and operations, and, in the event Acreege cannot satisfy its debt obligations as they become due, the Acquired Debt may not be repaid and the Company may lose the entirety of its investment. Acreege’s publicly available financial statements as of and for three and nine months ended September 30, 2024 filed with the SEC on November 14, 2024 (the Acreege’s September 30, 2024 Financial Statements) express doubt about Acreege’s ability to continue as a going concern. In particular, Acreege’s September 30, 2024 Financial Statements state: Acreege had an accumulated deficit as of September 30, 2024, as well as a net loss and negative cash flow from operating activities for the nine months ended September 30, 2024. These factors raise substantial doubt about Acreege’s ability to continue as a going concern for at least one year from the issuance of these financial statements. In the event Acreege is unable to continue as a going concern, this would have a negative impact on Canopy USA’s business, financial results and operations and have an adverse impact on the Company’s United States strategy, and, ultimately, the Company’s financial results and operations. On June 3, 2024, the Company closed the Debt Acquisition pursuant to the credit agreement dated as of December 16, 2021, as amended by the first amendment to credit agreement dated as of on October 24, 2022, and the second amendment to credit agreement dated as of April 28, 2023. The Company entered into various agreements in connection with the Debt Acquisition in order to, among other things, acquire the Acquired Debt in exchange for US\$69.8 million in cash and the release of approximately US\$30.1 million that was held in escrow pursuant to the Option Agreement. As of December 31, 2024, an aggregate principal amount of approximately US\$171 million was outstanding pursuant to the Second ARCA, of which approximately US\$106 million is owing to the Company and such amount is subordinate to approximately US\$65 million owed to the Other Lender. In view of the foregoing, Acreege’s continuation as a going concern is dependent upon its continued operations, which in turn is dependent upon, among other things, Acreege’s ability to meet its financial requirements. There is no assurance that Acreege will be successful in its plans to fund its operations and debt obligations as they become due and payable, which for greater certainty includes its debt obligations in favor of the Company in connection with the Acquired Debt. In addition, should an event of default occur under the Second ARCA, the portion of the Acquired Debt owing to the Other Lender would rank in priority to the portion of the Acquired Debt owing to the Company. Accordingly, in the event Acreege cannot satisfy its debt obligations as they become due, the Acquired Debt may not be repaid and the Company may lose the entirety of its investment. In addition, Acreege may be required to terminate or significantly curtail its operations or enter into arrangements with third parties that may require Acreege to relinquish rights to certain 64 aspects of its business and/or dispose of certain assets, which would have a negative impact on Canopy USA’s business, financial results and operations and have an adverse impact on the Company’s United States strategy, and, ultimately, the Company’s financial results and operations. Item 2. Unregistered Sales of Equity Securities and Use of Proceeds. None. Item 3. Defaults Upon Senior Securities. None. Item 4. Mine Safety Disclosures. Not applicable. Item 5. Other Information. Rule 10b5-1 Trading Arrangements During the three months ended December 31, 2024, no director or officer (as defined in Rule 16b-1(f) of the Exchange Act) informed us of the adoption or termination of a Rule 10b5-1 trading arrangement or a non-Rule 10b5-1 trading arrangement, as each term is defined in Item 408(c) of Regulation S-K. Item 6. Exhibits. ExhibitNumber Description 3.1 A 3.1 A Certificate of Incorporation and Articles of Amendment of Canopy Growth Corporation (incorporated by reference to Exhibit 3.1 to the Company’s Annual Report on Form 10-K for the year ended March 31, 2020, filed with the SEC on June 1, 2020). 3.2 A Amendment to Articles of Canopy Growth Corporation, filed on December 15, 2023 (incorporated by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K, filed with the SEC on December 18, 2023). 3.3 A Articles of Amendment to Articles of Incorporation of Canopy Growth Corporation, filed on April 12, 2024 (incorporated by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K, filed with the SEC on April 16, 2024). 3.4 Bylaws of Canopy Growth Corporation (incorporated by reference to Exhibit 3.2 to the Company’s Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2021, filed with the SEC on November 8, 2021). 10.1 Employment Agreement, effective as of November 26, 2024, by and between Canopy Growth Corporation and Luc Mongeau (incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K, filed with the SEC on November 26, 2024). 31.1 Certification of Principal Executive Officer pursuant to Rules 13a-14(a) and 15d-14(a) of the Securities Exchange Act of 1934, as amended, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. 31.2 Certification of Principal Financial Officer pursuant to Rules 13a-14(a) and 15d-14(a) of the Securities Exchange Act of 1934, as amended, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. 32.1 Certification of Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. 32.2 Certification of Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. 101.INS XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document 101.SCH 101.INS XBRL Taxonomy Extension Schema With Embedded Linkbase Documents 104 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) * Filed herewith. * This exhibit shall not be deemed fled for purposes of Section 18 of the Exchange Act or otherwise subject to the liability of that Section. Such exhibit shall not be deemed incorporated into any filing under the Securities Act or the Exchange Act. # This document has been identified as a management contract or compensatory plan or arrangement. 65 The agreements and other documents filed as exhibits to this report are not intended to provide factual information or other disclosure other than with respect to the terms of the agreements or other documents themselves, and you should not rely on them for that purpose. In particular, any representations and warranties made by us in these agreements or other documents were made solely within the specific context of the relevant agreement or document and may not describe the actual state of affairs as of the date they were made or at any other time. 66 SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. CANOPY GROWTH CORPORATION Date: February 7, 2025 By: /s/ Luc Mongeau Luc Mongeau Chief Executive Officer(Principal Executive Officer) Date: February 7, 2025 By: /s/ Judy Hong Judy Hong Chief Financial Officer(Principal Financial Officer and Principal Accounting Officer) 67 EX-31.1 2 cgc-ex31 1.htm EX-31.1 EX-31.1 Exhibit 31.1 CERTIFICATION PURSUANT TO RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Luc Mongeau, certify that: 1.I have reviewed this Quarterly Report on Form 10-Q of Canopy Growth Corporation; 2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; 3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; 4.The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: a.Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; b.Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; c.Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and d.Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and 5.The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s board of directors (or persons performing the equivalent functions): a.All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and b.Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting. Date: February 7, 2025 By: /s/ Luc Mongeau Luc Mongeau Chief Executive Officer(Principal Executive Officer) EX-31.2 3 cgc-ex31 2.htm EX-31.2 EX-31.2 CERTIFICATION PURSUANT TO RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Judy Hong, certify that: 1.I have reviewed this Quarterly Report on Form 10-Q of Canopy Growth Corporation; 2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; 3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; 4.The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: a.Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; b.Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; c.Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and d.Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and 5.The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s board of directors (or persons performing the equivalent functions): a.All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and b.Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting. Date: February 7, 2025 By: /s/ Judy Hong Judy Hong Chief Financial Officer(Principal Financial Officer) EX-32.1 4 cgc-ex32 1.htm EX-32.1 EX-32.1 Exhibit 32.1 A CERTIFICATION PURSUANT TO 18 U.S.C. 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 In connection with the Quarterly Report of Canopy Growth Corporation (the Company) on Form 10-Q for the period ended December 31, 2024 as filed with the Securities and Exchange Commission on the date hereof (the Report), I, Luc Mongeau, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that: (1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and (2) The information contained in this Report fairly presents, in all material respects, the financial condition and results of operations of the Company. February 7, 2025 /s/ Luc Mongeau A Luc Mongeau A Chief Executive Officer A (Principal Executive Officer) A A signed original of this written statement required by Section 906 has been provided to Canopy Growth Corporation and will be retained by Canopy Growth Corporation and furnished to the Securities and Exchange Commission or its staff upon request. A EX-32.2 5 cgc-ex32 2.htm EX-32.2 EX-32.2 Exhibit 32.2 A CERTIFICATION PURSUANT TO 18 U.S.C. 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 In connection with the Quarterly Report of Canopy Growth Corporation (the Company) on Form 10-Q for the period ended December 31, 2024 as filed with the Securities and Exchange Commission on the date hereof (the Report), I, Judy Hong, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that: (1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and (2) The information contained in this Report fairly presents, in all material respects, the financial condition and results of operations of the Company. February 7, 2025 /s/ Judy Hong A Judy Hong A Chief Financial Officer A (Principal Financial Officer) A A signed original of this written statement required by Section 906 has been provided to Canopy Growth Corporation and will be retained by Canopy Growth Corporation and furnished to the Securities and Exchange Commission or its staff upon request. A EX-101.SCH 6 cgc-20241231.xsd XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT 100000 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 100010 - Statement - Condensed Interim Consolidated Balance Sheets (Unaudited) link:presentationLink link:calculationLink

link:definitionLink 100020 - Statement - Condensed Interim Consolidated Balance Sheets (Parenthetical) (Unaudited) link:presentationLink link:calculationLink link:definitionLink 100030 - Statement - Condensed Interim Consolidated Statements of Cash Flows (Unaudited) 2 link:presentationLink link:calculationLink link:definitionLink 100040 - Statement - Condensed Interim Consolidated Statements of Operations and Comprehensive Loss (Unaudited) 2 link:presentationLink link:calculationLink link:definitionLink 100050 - Statement - Condensed Interim Consolidated Statements of Operations and Comprehensive Loss (Unaudited) link:presentationLink link:calculationLink link:definitionLink 100060 - Statement - Condensed Interim Consolidated Statements of Shareholder's Equity (Unaudited) link:presentationLink link:calculationLink link:definitionLink 100070 - Statement - Condensed Interim Consolidated Statements of Cash Flows (Unaudited) link:presentationLink link:calculationLink link:definitionLink 100080 - Statement - Condensed Interim Consolidated Statements of Cash Flows (Parenthetical) (Unaudited) link:presentationLink link:calculationLink link:definitionLink 995455 - Disclosure - Description of Business link:presentationLink link:calculationLink link:definitionLink 995465 - Disclosure - Basis of Presentation link:presentationLink link:calculationLink link:definitionLink 995475 - Disclosure - Canopy USA link:presentationLink link:calculationLink link:definitionLink 995485 - Disclosure - Biosteel link:presentationLink link:calculationLink link:definitionLink 995495 - Disclosure - Loss on Asset Impairment and Restructuring link:presentationLink link:calculationLink link:definitionLink 995505 - Disclosure - Cash and Cash Equivalents link:presentationLink link:calculationLink link:definitionLink 995515 - Disclosure - Short-term Investments link:presentationLink link:calculationLink link:definitionLink 995525 - Disclosure - Amounts Receivable, Net link:presentationLink link:calculationLink link:definitionLink 995535 - Disclosure - Inventory link:presentationLink link:calculationLink link:definitionLink 995545 - Disclosure - Prepaid Expenses and Other Assets link:presentationLink link:calculationLink link:definitionLink 995555 - Disclosure - Equity Method Investments link:presentationLink link:calculationLink link:definitionLink 995565 - Disclosure - Other Financial Assets link:presentationLink link:calculationLink link:definitionLink 995575 - Disclosure - Property, Plant and Equipment link:presentationLink link:calculationLink link:definitionLink 995585 - Disclosure - Intangible Assets link:presentationLink link:calculationLink link:definitionLink 995595 - Disclosure - Goodwill link:presentationLink link:calculationLink link:definitionLink 995605 - Disclosure - Other Accrued Expenses and Liabilities link:presentationLink link:calculationLink link:definitionLink 995615 - Disclosure - Debt link:presentationLink link:calculationLink link:definitionLink 995625 - Disclosure - Other Liabilities link:presentationLink link:calculationLink link:definitionLink 995635 - Disclosure - Redeemable Noncontrolling Interest link:presentationLink link:calculationLink link:definitionLink 995645 - Disclosure - Share Capital link:presentationLink link:calculationLink link:definitionLink 995655 - Disclosure - Share-Based Compensation link:presentationLink link:calculationLink link:definitionLink 995665 - Disclosure - Accumulated Other Comprehensive Income (Loss) link:presentationLink link:calculationLink link:definitionLink 995675 - Disclosure - Noncontrolling Interests link:presentationLink link:calculationLink link:definitionLink 995685 - Disclosure - Fair Value of Financial Instruments link:presentationLink link:calculationLink link:definitionLink 995695 - Disclosure - Revenue link:presentationLink link:calculationLink link:definitionLink 995705 - Disclosure - Other Income (Expense), Net link:presentationLink link:calculationLink link:definitionLink 995715 - Disclosure - Income Taxes link:presentationLink link:calculationLink link:definitionLink 995725 - Disclosure - Earnings (Loss) Per Share link:presentationLink link:calculationLink link:definitionLink 995735 - Disclosure - Acquisition link:presentationLink link:calculationLink link:definitionLink 995745 - Disclosure - Acreage Arrangement link:presentationLink link:calculationLink link:definitionLink 995755 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 995765 - Disclosure - Segment Information link:presentationLink link:calculationLink link:definitionLink 995775 - Disclosure - Subsequent Events link:presentationLink link:calculationLink link:definitionLink 995785 - Disclosure - Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 995795 - Disclosure - Canopy USA (Tables) link:presentationLink link:calculationLink link:definitionLink 995805 - Disclosure - Biosteel (Tables) link:presentationLink link:calculationLink link:definitionLink 995815 - Disclosure - Cash and Cash Equivalents (Tables) link:presentationLink link:calculationLink link:definitionLink 995825 - Disclosure - Short-term Investments (Tables) link:presentationLink link:calculationLink link:definitionLink 995835 - Disclosure - Amounts Receivable, Net (Tables) link:presentationLink link:calculationLink link:definitionLink 995845 - Disclosure - Inventory (Tables) link:presentationLink link:calculationLink link:definitionLink 995855 - Disclosure - Prepaid Expenses and Other Assets (Tables) link:presentationLink link:calculationLink link:definitionLink 995865 - Disclosure - Equity Method Investments (Tables) link:presentationLink link:calculationLink link:definitionLink 995875 - Disclosure - Other Financial Assets (Tables) link:presentationLink link:calculationLink link:definitionLink 995885 - Disclosure - Property, Plant and Equipment (Tables) link:presentationLink link:calculationLink link:definitionLink 995895 - Disclosure - Intangible Assets (Tables) link:presentationLink link:calculationLink link:definitionLink 995905 - Disclosure - Goodwill (Tables) link:presentationLink link:calculationLink link:definitionLink 995915 - Disclosure - Other Accrued Expenses and Liabilities (Tables) link:presentationLink link:calculationLink link:definitionLink 995925 - Disclosure - Debt (Tables) link:presentationLink link:calculationLink link:definitionLink 995935 - Disclosure - Other Liabilities (Tables) link:presentationLink link:calculationLink link:definitionLink 995945 - Disclosure - Redeemable Noncontrolling Interest (Tables) link:presentationLink link:calculationLink link:definitionLink 995955 - Disclosure - Share Capital (Tables) link:presentationLink link:calculationLink link:definitionLink 995965 - Disclosure - Share-Based Compensation (Tables) link:presentationLink link:calculationLink link:definitionLink 995975 - Disclosure - Accumulated Other Comprehensive Income (Loss) (Tables) link:presentationLink link:calculationLink link:definitionLink 995985 - Disclosure - Noncontrolling Interests (Tables) link:presentationLink link:calculationLink link:definitionLink 995995 - Disclosure - Fair Value of Financial Instruments (Tables) link:presentationLink link:calculationLink link:definitionLink 996005 - Disclosure - Revenue (Tables) link:presentationLink link:calculationLink link:definitionLink 996015 - Disclosure - Other Income (Expense), Net (Tables) link:presentationLink link:calculationLink link:definitionLink 996025 - Disclosure - Earnings (Loss) Per Share (Tables) link:presentationLink link:calculationLink link:definitionLink 996035 - Disclosure - Acquisition (Tables) link:presentationLink link:calculationLink link:definitionLink 996045 - Disclosure - Segment Information (Tables) link:presentationLink link:calculationLink link:definitionLink 996055 - Disclosure - Basis of Presentation - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 996065 - Disclosure - Canopy USA - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 996075 - Disclosure - Canopy USA - Acreage Agreements - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 996085 - Disclosure - Canopy USA - Summary of Derecognized Assets and Liabilities Transferred (Details) link:presentationLink link:calculationLink link:definitionLink 996095 - Disclosure - Biosteel - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 996105 - Disclosure - Biosteel - Summary of Deconsolidation and Costs to Exit Classified as Discontinued Operations (Details) link:presentationLink link:calculationLink link:definitionLink 996115 - Disclosure - Biosteel - Summary of Deconsolidation and Costs to Exit Classified as Discontinued Operations (Parenthetical) (Details) link:presentationLink link:calculationLink link:definitionLink 996125 - Disclosure - Biosteel - Summary of Assets and Liabilities Classified as Discontinued Operations and Major Categories (Details) link:presentationLink link:calculationLink link:definitionLink 996135 - Disclosure - Loss on Asset Impairment and Restructuring - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 996145 - Disclosure - Cash and Cash Equivalents - Components of Cash and Cash Equivalents (Details) link:presentationLink link:calculationLink link:definitionLink 996155 - Disclosure - Short-term Investments - Components of Short-term Investments (Details) link:presentationLink link:calculationLink link:definitionLink 996165 - Disclosure - Short-term Investments - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 996175 - Disclosure - Amounts Receivable, Net - Components of Amounts Receivable, Net (Details) link:presentationLink link:calculationLink link:definitionLink 996185 - Disclosure - Amounts Receivable, Net - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 996195 - Disclosure - Inventory - Components of Inventory (Details) link:presentationLink link:calculationLink link:definitionLink 996205 - Disclosure - Inventory - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 996215 - Disclosure - Prepaid Expenses and Other Assets - Components of Prepaid Expenses and Other Assets (Details) link:presentationLink link:calculationLink link:definitionLink 996225 - Disclosure - Equity Method Investments - Components of Equity Method Investments (Details) link:presentationLink link:calculationLink link:definitionLink 996235 - Disclosure - Other Financial Assets - Summary of Changes in Other Financial Assets (Details) link:presentationLink link:calculationLink link:definitionLink 996245 - Disclosure - Other Financial Assets - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 996255 - Disclosure - Property, Plant and Equipment - Schedule of Components of Property, Plant and Equipment (Details) link:presentationLink link:calculationLink link:definitionLink 996265 - Disclosure - Property, Plant and Equipment - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 996275 - Disclosure - Intangible Assets - Summary of Components of Intangible Assets (Details) link:presentationLink link:calculationLink link:definitionLink 996285 - Disclosure - Intangible Assets - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 996295 - Disclosure - Goodwill - Changes in Carrying Amount of Goodwill (Details) link:presentationLink link:calculationLink link:definitionLink 996305 - Disclosure - Goodwill - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 996315 - Disclosure - Other Accrued Expenses and Liabilities - Components of Other Accrued Expenses and Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 996325 - Disclosure - Debt - Summary of Components of Debt (Details) link:presentationLink link:calculationLink link:definitionLink 996335 - Disclosure - Debt - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 996345 - Disclosure - Other Liabilities - Components of Other Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 996355 - Disclosure - Redeemable Noncontrolling Interest - Summary of Net Changes in Redeemable Noncontrolling Interests (Details) link:presentationLink link:calculationLink link:definitionLink 996365 - Disclosure - Redeemable Noncontrolling Interest - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 996375 - Disclosure - Share Capital - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 996385 - Disclosure - Share Capital - Summary of Issuances of Stock Other (Details) link:presentationLink link:calculationLink link:definitionLink 996395 - Disclosure - Share Capital - Summary of Warrants (Details) link:presentationLink link:calculationLink link:definitionLink 996405 - Disclosure - Share Capital - Summary of Warrants (Parenthetical) (Details) link:presentationLink link:calculationLink link:definitionLink 996415 - Disclosure - Share-Based Compensation - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 996425 - Disclosure - Share-Based Compensation - Summary of the Changes in Options Outstanding (Details) link:presentationLink link:calculationLink link:definitionLink 996435 - Disclosure - Share-Based Compensation - Summary of Options Outstanding (Details) link:presentationLink link:calculationLink link:definitionLink 996445 - Disclosure - Share-Based Compensation - Summary of Assumptions Applied to Establish Fair Value of Options Granted Using Black-Scholes Option Pricing Model (Details) link:presentationLink link:calculationLink link:definitionLink 996455 - Disclosure - Share-Based Compensation - Summary of the Changes in RSUs and PSUs (Details) link:presentationLink link:calculationLink link:definitionLink 996465 - Disclosure - Accumulated Other Comprehensive Income (Loss) - Accumulated Other Comprehensive Income (Details) link:presentationLink link:calculationLink link:definitionLink 996475 - Disclosure - Noncontrolling Interests - Summary of Net Change in Noncontrolling Interests (Details) link:presentationLink link:calculationLink link:definitionLink 996485 - Disclosure - Fair Value of Financial Instruments - Summary of Financial Assets and Liabilities Measured at Estimated Fair Value on a Recurring Basis (Details) link:presentationLink link:calculationLink link:definitionLink 996495 - Disclosure - Fair Value of Financial Instruments - Summary of Valuation Techniques and Significant Unobservable Inputs in the Fair Value Measurement of Significant Level 2 Financial Instruments (Details) link:presentationLink link:calculationLink link:definitionLink 996505 - Disclosure - Fair Value of Financial Instruments - Summary of Valuation Techniques and Significant Unobservable Inputs in the Fair Value Measurement of Significant Level 3 Financial Instruments (Details) link:presentationLink link:calculationLink link:definitionLink 996515 - Disclosure - Revenue - Summary of Disaggregation of Revenue (Details) link:presentationLink link:calculationLink link:definitionLink 996525 - Disclosure - Revenue - Summary of Disaggregation of Revenue (Parenthetical) (Details) link:presentationLink link:calculationLink link:definitionLink 996535 - Disclosure - Revenue - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 996545 - Disclosure - Other Income (Expense), Net - Schedule of Other Income (Expense), Net (Details) link:presentationLink link:calculationLink link:definitionLink 996555 - Disclosure - Other Income (Expense), Net - Schedule of Other Income (Expense), Net (Parenthetical) (Details) link:presentationLink link:calculationLink link:definitionLink 996565 - Disclosure - Acquisition - Summary of Consolidated Balance Sheet Impact at Acquisition of Company's Business Combination (Details) link:presentationLink link:calculationLink link:definitionLink 996575 - Disclosure - Acquisition - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 996585 - Disclosure - Acreage Arrangement - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 996595 - Disclosure - Commitments and Contingencies - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 996605 - Disclosure - Segment Information - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 996615 - Disclosure - Segment Information - Summary of Reconciliation of Operating Profit (Loss) from Segments to Consolidated (Details) link:presentationLink link:calculationLink link:definitionLink 996625 - Disclosure - Segment Information - Summary of Disaggregation of Net Revenue by Geographic Area (Details) link:presentationLink link:calculationLink link:definitionLink 996635 - Disclosure - Segment Information - Summary of Disaggregation of Property, Plant and Equipment by Geographic Area (Details) link:presentationLink link:calculationLink link:definitionLink 996645 - Disclosure - Subsequent Events - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink Statement [Line Items] Statement [Line Items] Floating Shares Floating Shares [Member] Floating share. Range of Exercise Prices, Lower Range Share-Based Payment Arrangement, Option, Exercise Price Range, Lower Range Limit Share Consolidation Share Consolidation [Policy Text Block] Share consolidation. Decrease in lease payment obligation and cash operating costs Increase (Decrease) In Lease Payment Obligation and Cash Operating Costs Increase (decrease) in lease payment obligation and cash operating costs. Decrease in lease payment obligation and cash operating costs Liabilities: Liabilities, Fair Value Disclosure [Abstract] Land Land [Member] Arise Bioscience term loan Arise Bioscience Term Loan [Member] Arise bioscience term loan member. Comprehensive income (loss) from discontinued operations Comprehensive income (loss), net of tax, from discontinued operations including portion attributable to noncontrolling interest. Comprehensive income (loss), net of tax, from discontinued operations including portion attributable to noncontrolling interest Debt Instrument Debt Instrument [Axis] Amounts receivable Increase (Decrease) in Accounts Receivable Plan Name Plan Name [Domain] Subscription Agreementt with Institutional Investors Subscription Agreementt With Institutional Investors [Member] Subscription agreementt with institutional investors. Disposal group including discontinued operation issuance of common shares. Disposal Group Including Discontinued Operation Issuance Of Common Shares Issuance of common shares Canopy USA Transaction Canopy USA equity method investment expected future cash flows. Canopy USA Equity Method Investment Expected Future Cash Flows [Member] Canopy USA Equity Method Investment Expected Future Cash Flows Summary of Warrants Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block] Entity Address, Postal Zip Code Entity Address, Postal Zip Code Disposal Group Name [Axis] Percentage non voting shares in capital. Percentage Non-Voting Shares in Capital Percentage non-voting shares in capital Office and Lab Equipment Office Equipment [Member] Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table] Fair Value, Recurring and Nonrecurring [Table] Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Interest Interest Paid, Excluding Capitalized Interest, Operating Activities Number of operating segments Number of Operating Segments Share-based Payment Arrangement, Tranche One Share-Based Payment Arrangement, Tranche One [Member] Business Combination Disclosure [Text Block] Acquisition Other Other Geographical Area [Member] Other geographical area member. Weighted average exercise price of options exercisable Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price Issuance And Vesting Of Restricted Issuance and vesting of restricted share units. Issuance and vesting of restricted share units and performance share units Intangible Assets Net Excluding Goodwill [Line Items] Intangible Assets Net Excluding Goodwill [Line Items] Intangible assets net excluding goodwill line items. Share consolidation, description Stockholders' Equity, Reverse Stock Split TerrAscend Terr Ascend [Member] TerrAscend. Redeemable non controlling interests. Redeemable Non Controlling Interests [Member] Redeemable Noncontrolling Interest Fair Value Hierarchy and NAV Fair Value Hierarchy and NAV [Axis] Option Indexed to Issuer's Equity, Type Option Indexed to Issuer's Equity, Type [Axis] Percentage of outstanding shares purchased Business Acquisition, Percentage of Voting Interests Acquired Class E Subordinated Voting Shares Class E Subordinated Voting Shares [Member] Class E subordinated voting shares. Acreage Tax Receivable Agreement Probability-weighted Expected Return Model Acreage Tax Receivable Agreement Probability Weighted Expected Return Model [Member] Acreage tax receivable agreement probability weighted expected return model. Level 2 Fair Value, Inputs, Level 2 [Member] Share Based Compensation Arrangement By Share Based Payment Award [Line Items] Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Long-Term Debt, Type Long-Term Debt, Type [Domain] Wana Financial Instrument Volatility of Wana Equity Wana Financial Instrument Volatility Of Wana Equity [Member] Wana financial instrument volatility of wana equity. Going Concern Going Concern [Policy Text Block] Disclosure of accounting policy for going concern. Long-Term Debt, Current Maturities, Total Less: current portion Long-Term Debt, Current Maturities Current portion of long-term

debt Disposal Group, Including Discontinued Operation, Deferred Tax Liabilities Deferred income tax liabilities Debt Instrument, Call Date, Latest Latest date to call Commitments and Contingencies Commitments and Contingencies Disclosure [Text Block] Schedule Of Restructuring And Related Costs [Table] Restructuring Cost [Table] Derivative liability Derivative Liability, Subject to Master Netting Arrangement, before Offset Stock, Class of Stock [Table] Canopy USA equity method investment probability and timing of US legalization. Canopy USA Equity Method Investment Probability and Timing of US Legalization [Member] Canopy USA Equity Method Investment Probability and Timing of US Legalization Product and Service Product and Service [Axis] Deferred Income Tax Liabilities, Net Deferred income tax liabilities Basis Of Presentation [Table] Basis Of Presentation [Table] Basis of presentation. Indefinite-Lived Intangible Assets (Excluding Goodwill), Ending Balance Indefinite-Lived Intangible Assets (Excluding Goodwill), Beginning Balance Indefinite-Lived Intangible Assets (Excluding Goodwill), Total Indefinite lived intangible assets Indefinite-Lived Intangible Assets (Excluding Goodwill) Finite-Lived Intangible Assets by Major Class Finite-Lived Intangible Assets by Major Class [Axis] Investment, Name Investment, Name [Domain] Percentage of options vest on each anniversaries from date of grant Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage Loss on Asset Impairment and Restructuring (Gain)/loss on asset impairment and restructuring. (Gain) loss on asset impairment and restructuring [Text Block] Maximum discount to last reported sales price Maximum Discount To Last Reported Sales Price Maximum discount to last reported sales price. Collaborative Arrangement and Arrangement Other than Collaborative Collaborative Arrangement and Arrangement Other than Collaborative [Domain] Schedule Of Goodwill [Table] Goodwill [Table] Cumulative Effect, Period of Adoption Cumulative Effect, Period of Adoption [Domain] Noncash investing and financing activities Noncash Investing and Financing Items [Abstract] Class Of Treasury Stock [Table] Class of Treasury Stock [Table] Percentage ownership of wholly owned subsidiaries. Percentage Ownership Of Wholly Owned Subsidiaries Percentage ownership of wholly owned subsidiaries Promissory Note Promissory Note [Member] Promissory note. Convertible conversion price Debt Instrument Convertible Conversion Price Measurement Period Debt instrument convertible conversion price measurement period. Concentration Risk Benchmark Concentration Risk Benchmark [Axis] Debenture Debenture [Member] Debenture Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Replacement RSUs Issued Resulting From The Acreage Acquisition Share based compensation arrangement by share based payment award equity instruments other than options replacement RSUs issued resulting from the acreage acquisition. Replacement RSUs issued resulting from the Acreage Acquisition Net income (loss) on discontinued operations, net of tax Discontinued Operation, Gain (Loss) on Disposal of Discontinued Operation, Net of Tax Debt instrument acquired Debt Instrument Acquired Debt instrument acquired. Share Capital Equity [Text Block] Class of Warrant or Right Class of Warrant or Right [Axis] New TerrAscend Securities New TerrAscend Securities [Member] New TerrAscend Securities. Revenue Revenue from Contract with Customer [Text Block] Loss (gain) on asset impairment and restructuring (Gain)/loss on asset impairment and restructuring. Gain Loss On Asset Impairment And Restructuring Common stock shares conversion ratio Common Stock Shares Conversion Ratio Common stock shares conversion ratio. Sale of Stock [Domain] Income (Loss) from Discontinued Operations, Net of Tax, Attributable to Noncontrolling Interest Discontinued operations attributable to noncontrolling interests and redeemable noncontrolling interest Storz & Bickel reporting unit member. Storz Bickel Reporting Unit [Member] Storz & Bickel Reporting Unit Initial principal amount Initial Principal Amount Initial Principal Amount CBI Exchange member. CBI Exchange [Member] CBI Exchange Terr Ascend December2022. Terr Ascend December2022 [Member] TerrAscend - December 2022 Entity Central Index Key Entity Central Index Key Noncontrolling Interest, Increase from Subsidiary Equity Issuance Ownership changes relating to noncontrolling interests, net Debt Instrument, Annual Principal Payment Aggregate principal payment amount Summary of Issuances of Stock Other Schedule of Business Acquisitions by Acquisition, Equity Interest Issued or Issuable [Table Text Block] Changes of Own Credit Risk of Financial Liabilities Accumulated Gain (Loss), Financial Liability, Fair Value Option, Attributable to Parent [Member] Cash Equivalents, at Carrying Value, Total Cash equivalents Cash Equivalents, at Carrying Value Tranche A Warrants Tranche A Warrants [Member] Tranche A warrants. Warrant Warrants Warrant [Member] This Works This Works [Member] This Works. TerrAscend Canada Term Loan - October 2019 March 2020 Terr Ascend Canada Term Loan October2019 March2020 [Member] TerrAscend Canada Term Loan October 2019, March 2020. Change in operating assets and liabilities, net of effects from purchases of businesses: Increase (Decrease) in Operating Capital [Abstract] Gain (loss) on deconsolidation Deconsolidation, Gain (Loss), Amount Redemption Agreements Redemption Agreements [Member] Redemption Agreements. Proceeds from Divestiture of Businesses Consideration received in cash Proceeds from divestiture of businesses Common stock, shares issued Common Stock, Shares, Issued Additional common stock issued Excise taxes Excise and Sales Taxes Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Table] Fair Value Measurement Inputs and Valuation Techniques [Table] Acreage Financial Instrument Market Access Premium Acreage Financial Instrument Market Access Premium [Member] Acreage financial instrument market access premium. Prepaid expenses and other assets Increase (Decrease) in Prepaid Expense and Other Assets Disposal Group, Including Discontinued Operation, Operating Expense Operating expenses Four point two five percent unsecured senior notes. Four Point Two Five Percent Unsecured Senior Notes [Member] 4.25% Unsecured Senior Notes [Member] Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest Net loss from continuing operations Net loss Net loss from continuing operations Basis of Presentation Business Description and Basis of Presentation [Text Block] Gain (Loss) on Sale of Assets and Asset Impairment Charges (Gain)/loss on asset impairment and restructuring Loss on asset impairment and restructuring Loss on asset impairment and restructuring Senior Notes Senior Notes, Total Income Statement [Abstract] Cash received during the period: Cash Received During Year [Abstract] Cash received during the year abstract Options granted to acquire additional voting shares, value Options Granted To Acquire Additional Voting Shares, Value Options granted to acquire additional voting shares, value. Entity Address, State or Province Entity Address, State or Province Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Loss from continuing operations before income taxes Lease liabilities, long-term Operating And Finance Lease Liability Noncurrent Operating and finance lease liability, noncurrent. Conversion price percentage Debt Instrument, Convertible, Threshold Percentage of Stock Price Trigger Vert Mirabel redeemable noncontrolling interest future wholesale price and production levels. Vert Mirabel Redeemable Noncontrolling Interest Future Wholesale Price And Production Levels [Member] Vert Mirabel Redeemable Noncontrolling Interest Future Wholesale Price and Production Levels Liability for estimated returns and price adjustments Liability For Estimated Sales Returns And Price Adjustments Liability for estimated sales returns and price adjustments. Receivable from BioSteel Entities Receivable from BioSteel Disposal group including discontinued operation receivable. Disposal group including discontinued operation receivable Redeemable Noncontrolling Interest [Line Items] Redeemable Noncontrolling Interest [Line Items] Debt to be exchanged. Debt to be Exchanged Debt to be exchanged Refund liability, current Refund Liability Current Refund liability current. Adjustments to redemption amount Redeemable Noncontrolling Interest Change In Redemption Value Redeemable noncontrolling interest change in redemption value. Concentration Risk Type Concentration Risk Type [Domain] Equity Class Of Treasury Stock [Line Items] Equity, Class of Treasury Stock [Line Items] Loss Contingencies [Table] Accounting Standards Update [Extensible Enumeration] Accounting Standards Update [Extensible Enumeration] Acreage Hempco1 Acreage Hempco1 [Member] Acreage Hempco1. Omnibus equity incentive plan. Omnibus Equity Incentive Plan [Member] Omnibus Equity Incentive Plan Schedule Of Investments [Table] Schedule of Investments [Table] Customer Concentration Risk Customer Concentration Risk [Member] Reduced liquidity requirement Reduced liquidity requirement Reduced liquidity requirement. Common share purchase warrants in the capital Warrant Issued Warrant issued. Common share purchase warrants Third Quarter 2024 Payouts Third Quarter Two Thousand And Twenty Four Payouts [Member] Third quarter two thousand and twenty four payouts. Jetty Financial Instrument - Deferred Payments Jetty Financial Instrument Deferred Payments [Member] Jetty financial instrument deferred payments. Equity Method Investments and Joint Ventures Disclosure [Text Block] Equity Method Investments Discontinued operations, net of income tax Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest, Total Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest Gain (loss) from discontinued operations, net of income tax Number of whole warrants on issuance of warrants. Number Of Whole Warrants On Issuance Of Warrants Number of whole warrants, Issuance of warrants Liability Class Liability Class [Axis] Principal redemption Debt Instrument Principal Redemption Debt instrument principal redemption. Aggregate purchase price Debt Instrument Aggregate Purchase Price Debt instrument aggregate purchase price. Significant unobservable inputs Key inputs Fair Value Measurements Significant Unobservable Input Description Fair value measurements significant unobservable input description. Ownership Changes Ownership Changes [Member] Ownership changes. Percentage price of rolling interest amount at which debt can be purchased. Rolling Interest, Purchase Price, Percentage Purchase price of rolling interest Valuation techniques Valuation Allowance, Methodologies and Assumptions Cover Cover [Abstract] Subsequent Event [Line Items] Basic loss per share Earnings Per Share, Basic, Total Basic (loss) earnings per share Earnings Per Share, Basic Options extended period Extended Period Of Option From Grant Date Maximum period of option from grant date. Schedule Of Share Based Compensation Shares Authorized Under Stock Option Plans By Exercise Price Range [Table] Share-Based Payment Arrangement, Option, Exercise Price Range [Table] Operating expenses Operating Expenses [Abstract] Lease liabilities, current Operating And Finance Lease Liability Current Operating and finance lease liability, current. Debt instrument, redemption threshold consecutive trading days Debt Instrument Redemption Threshold Consecutive Trading Period Debt instrument redemption threshold consecutive trading period. Private placement unit offering completed. Private Placement Unit Offering Completed Private placement unit offering completed Wana Financial Instrument - Call Options, Discount Rate Wana Financial Instrument Call Options Discount Rate [Member] Wana financial instrument - Call Options, Discount rate. Cancellation of Debt Cancellation Of Debt Cancellation of Debt. Other liabilities Other Liabilities Tranche B Warrants Tranche B Warrants [Member] Tranche B Warrants. Warrant value, Beginning balance Warrant value, Ending balance Warrant Value Warrant value. Jetty Jetty [Member] Jetty member. Jetty Financial Instrument - Call Options, Discount Rate Jetty Financial Instrument Call Options Discount Rate [Member] Jetty financial instrument call options discount rate. Disposal Group, Including Discontinued Operation, Inventory Inventory Canopy USA equity method investment intrinsic value of acreage. Canopy USA Equity Method Investment Intrinsic Value of Acreage [Member] Canopy USA Equity Method Investment Intrinsic Value of Acreage Debt instrument discounted price per us dollar Debt Instrument Discounted Price Per Us Dollar Debt instrument discounted price per us dollar. Disposal of consolidated entities Disposal of consolidated entities Disposal Group, Including Discontinued Operation, Goodwill Goodwill Components of Cash and Cash Equivalents Schedule of Cash and Cash Equivalents [Table Text Block] Summary of Changes in Other Financial Assets Schedule Of Other Financial Assets Table [Text Block] Schedule of other financial assets. Share-based compensation expense Share-Based Payment Arrangement, Expense Schedule of Business Acquisitions, by Acquisition [Table Text Block] Summary of Consolidated Balance Sheet Impact at Acquisition of Company's Business Combination Long-term debt Total debt Long-Term Debt Consumer Products and Other Consumer Products And Other [Member] Consumer products and other member. Retained Earnings (Accumulated Deficit), Total Accumulated deficit Deficit Retained Earnings (Accumulated Deficit) Plan Name Plan Name [Axis] Acreage Financial Instrument Probability and Timing of US Legalization Acreage Financial Instrument Probability And Timing Of U S Legalization [Member] Acreage financial instrument probability and timing of us legalization. Segment Reporting [Abstract] Stock options outstanding Options Outstanding Options outstanding, beginning balance Options outstanding, ending balance Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number Current assets: Assets, Current [Abstract] United States UNITED STATES Net cash used in operating activities Net Cash Provided by (Used in) Operating Activities Assets in Process Asset under Construction [Member] Number of whole warrants, Expiry of warrants Number Of Whole Warrants On Expiry Of Warrants Number of whole warrants on Expiry of warrants. Number of whole warrants, Expiry of warrants Product and Service Product and Service [Domain] Accumulated Other Comprehensive Income (Loss), Net of Tax, Total Accumulated other comprehensive loss Accumulated Other Comprehensive Income (Loss), Net of Tax Debt Instrument [Line Items] Debt Instrument [Line Items] Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment, Total Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment Property, plant and equipment Property, plant and equipment Operating Licenses Operating Licenses [Member] Operating licenses. Property, plant and equipment, net Property, plant and equipment Property, Plant and Equipment, Net Cash flows from operating activities: Net Cash Provided by (Used in) Operating Activities [Abstract] Debentures bear interest rate per annum Debentures Bear Interest Rate Per Annum Debentures bear interest rate per annum. Fair Value Measurements Recurring Fair Value, Recurring [Member] Proceeds from Sale of Treasury Stock Gross proceed from sale of common stock Other Income and Expenses [Abstract] Convertible measurement period threshold trading days Debt Instrument Convertible Measurement Threshold Trading Period Debt instrument convertible measurement threshold trading period. Senior credit facility Additional Incremental Senior Secured Debt Additional incremental debt. Restructuring and Related Activities [Abstract] Summary of Financial Assets and Liabilities Measured at Estimated Fair Value on a Recurring Basis Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block] Vesting Vesting [Axis] Common stock, par value Common Stock, Par or Stated Value Per Share Aggregate principal amount of debentures Aggregate principal amount of debentures Aggregate principal amount of debentures. Debt instrument, redemption threshold trading days Debt Instrument Redemption Threshold Trading Period Debt instrument redemption threshold trading period. Facility Sale Facility Sale [Member] Facility sale. Change in the noncontrolling interests of owner. Change In Noncontrolling Interests Of Owner Canopy USA Transaction Intangible Assets Intangible Assets Disclosure [Text Block] Disposal Groups, Including Discontinued Operations [Table] Comprehensive income (loss): Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract] Senior secured debt, Term Long-Term Debt, Term Comprehensive income (loss) Comprehensive Income Loss Net Of Tax Including Portion Attributable To Noncontrolling Interest Comprehensive income (loss), net of tax, including portion attributable to noncontrolling interest. Statement of Cash Flows [Abstract] Warrants to acquire shares Class of Warrant or Right, Unissued Term Deposits Deposits [Member] Foreign Currency Translation Adjustments Accumulated Foreign Currency Adjustment Attributable to Parent [Member] Equity Method Investments Equity method investments Summary of Reconciliation of Operating Profit (Loss) from Segments to Consolidated Segment, Reconciliation of Other Items from Segments to Consolidated [Table Text Block] Long-term debt/ Unsecured senior notes Long-Term Debt, Fair Value Long-term debt Accounts, Notes, Loans and Financing Receivable [Line Items] Class of Warrant or Right, Number of Securities Called by Warrants or Rights Warrants exercisable Selling, General and Administrative Expenses Selling, General and Administrative Expenses [Member] Supreme debt exchange. Supreme Debt Exchange [Member] Supreme Debt Exchange Taxes and government fees payable€€ current. Taxes And Government Fees Payable Current Taxes and government fees Equity Components Equity Components [Axis] Entity Address, Address Line One Entity Address, Address Line One Earnings (Loss) Per Share Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Employee-related Liabilities, Current, Total Employee compensation Employee-related Liabilities, Current RSUs and PSUs granted Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period Schedule Of Finite Lived Intangible Assets [Table] Intangible Asset, Finite-Lived [Table] Share capital other Issuances Of Common Shares Net Of Share Issuance Cost Other issuances of common shares net of share issuance cost. Employee Stock Purchase Plan Employee Stock Option Plan [Member] Employee stock option plan. July 2023 Payoutdown July Two Thousand and Twenty Three Pay Down [Member] July two thousand and twenty three pay down. Computer Equipment Computer Equipment [Member] Property Plant And Equipment [Line Items] Property, Plant and Equipment [Line Items] Other financial assets Other Financial Assets Other financial assets. Subsequent Event Type [Axis] Equity Option Equity Option [Member] Share Based Compensation Arrangement By Share Based Payment Award Replacement Options Issued Resulting From The Acreage Acquisition Weighted Average Exercise Price Share based compensation arrangement by share based payment award replacement options issued resulting from the acreage acquisition weighted average exercise price. Weighted average exercise price, Replacement options issued resulting from the Acreage Acquisition Risk-free interest rate Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate Settlement of Debentures [Member] Settlement of debentures. Expected forfeiture rate Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Forfeiture Rate Share-based compensation arrangement by share-based payment award fair value assumptions expected forfeiture rate. Options maximum period Maximum Period Of Option From Grant Date Maximum period of option from grant date. Beginning balance Ending balance Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number Amendment Amendment Flag Amendment Flag Net Income (Loss) Attributable to Noncontrolling Interest, Total Net Income (Loss) Attributable to Noncontrolling Interest Net loss from continuing operations attributable tononcontrolling interests and redeemable noncontrollinginterest Comprehensive income (loss) Concentration risk customer number of customers Concentration Risk Customer Number Of Customers Concentration risk customer number of customers. Amount of floating shares issued in first installment Amount Of Floating Shares Issued In First Installment Amount of floating shares issued in first installment. Share Purchase Agreement Share Purchase Agreement [Member] Share purchase agreement. Cmmn Satock Additional Shares Issued Cmmn satock additional Shares issued. Additional shares issued Debt Instrument, Name Debt Instrument, Name [Domain] Additional paid-in capital Additional Paid in Capital, Common Stock Change in noncontrolling interests due to issuance of warrants. Change In Noncontrolling Interests Due To Issuance Of Warrants Warrants This Work This Work

[Member] This work. Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate [Member] SOFR Plus Receivables [Abstract] Net loss attributable to Canopy Growth Corporation Net loss attributable to Canopy Growth Corporation Additions Other Financial Assets Additions Other financial assets additions. Options exercised Options exercised Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period Equity shares issued to shareholders Share-Based Compensation Arrangement by Share-Based Payment Award, Shares Issued in Period Options Exercisable Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number Minority Interest [Line Items] Noncontrolling Interest [Line Items] Summary of Components of Debt Schedule of Debt [Table Text Block] Other rest-of-world cannabis Other rest-of-world cannabis [Member] Other rest-of-world cannabis. Equity Component Equity Component [Domain] Statistical Measurement Statistical Measurement [Domain] VIRGINIA Verona, Virginia Non Voting Shares Value Non voting shares value. Non voting shares, value Proceeds on sale of property, plant and equipment Proceeds from Sale of Property, Plant, and Equipment Proceeds from Sale of Property, Plant, and Equipment, Total Recreational Cannabis Revenue Recreational Revenue [Member] Recreational revenue. Other income (expense), net Other income (expense), net Other Nonoperating Income (Expense) Other income (expense), net Options expiration period Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period Debt instrument, change in fair value of notes from contractual interest Debt Instrument, Increase, Accrued Interest Redeemable Noncontrolling Interest, Equity, Carrying Amount, Total Redeemable noncontrolling interest Beginning balance Ending balance Redeemable Noncontrolling Interest, Equity, Carrying Amount Disaggregation Of Revenue [Table] Disaggregation of Revenue [Table] Disposal Group, Including Discontinued Operation, Other Liabilities, Noncurrent Other liabilities Net loss Net Income (Loss), Including Portion Attributable to Noncontrolling Interest Net loss from continuing operations Acquisition consideration and other investment related liabilities, current Acquisition Consideration Related Liabilities Current Acquisition consideration related liabilities current. Proceeds from exercise of stock options Proceeds from Stock Options Exercised Comprehensive income (loss), net of tax, from continuing operations including portion attributable to noncontrolling interest. Comprehensive income (loss), net of tax, from continuing operations including portion attributable to noncontrolling interest Comprehensive loss from continuing operations Comprehensive income (loss), net of tax, from continuing operations including portion attributable to noncontrolling interest, Total Net cash provided by (used in) investing activities - discontinued operations Cash Provided by (Used in) Investing Activities, Discontinued Operations BioSteel US Bio Steel U S [Member] BioSteel US. Settlement of Acreage Acquisition [Member] Settlement of acreage acquisition. Disposal Group, Including Discontinued Operation, Description and Timing of Disposal Discontinued operations, description Short-Term Investments, Total Short-term investments Short-Term Investments Summary of Options Outstanding Share-Based Payment Arrangement, Option, Exercise Price Range [Table Text Block] Percentage of purchase price for Rolling Interest. Percentage of Purchase Price for Rolling Interest Percentage of purchase price for Rolling Interest Disposal group including discontinued operation short term investments. Disposal group including discontinued operation short term investments Short-term investments Vert Mirabel Redeemable Noncontrolling Interest Future Wholesale Price and Production Levels Discount Rate [Member] Vert Mirabel Redeemable Noncontrolling Interest Future Wholesale Price And Production Levels Discount Rate [Member] Vert Mirabel Redeemable Noncontrolling Interest Future Wholesale Price and Production Levels Discount Rate Prepaid and other assets Prepaid expenses and other assets Prepaid Expense and Other Assets, Current Other Income and Expenses [Line Items] Other income and expenses line items. First Quarter 2025 Paydowns. First Quarter Two Thousand And Twenty Five Paydowns [Member] First Quarter 2025 Paydowns Collaborative Arrangement and Arrangement Other than Collaborative Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Class of Stock Class of Stock [Domain] Other Comprehensive Income (Loss), Net of Tax Total other comprehensive income (loss), net of income tax Cumulative effect from adoption of ASU 2020-06 Cumulative Effect, Period of Adoption, Adjustment [Member] Derivative liability related to settlement of convertible senior notes, long term Derivative Liability Related To Settlement Of Convertible Senior Notes Long Term Derivative liability related to settlement of convertible senior notes long term. Comprehensive loss attributable to Canopy Growth Corporation Comprehensive Income (Loss), Net of Tax, Attributable to Parent Common stock, shares outstanding Common Stock, Shares, Outstanding Common Stock, Shares, Outstanding, Ending Balance Common Stock, Shares, Outstanding, Beginning Balance Payments to Acquire Investments, Total Payments to acquire investments Payments to Acquire Investments Finite-Lived Intangible Assets, Major Class Name Finite-Lived Intangible Assets, Major Class Name [Domain] Short-Term Investments [Abstract] Deposits Prepaid Deposits Current Prepaid deposits current. Payments to Acquire Businesses and Interest in Affiliates, Total Aggregate payment Payments to Acquire Businesses and Interest in Affiliates Accounts Payable and Accrued Liabilities, Current [Abstract] Medical Cannabis Revenue Medical Cannabis Revenue [Member] Medical cannabis revenue. Monthly Interest Rate Debt Instrument Monthly Interest Rate Percentage Debt Instrument Monthly Interest Rate Percentage. Reorganizations [Abstract] Fixed Shares Fixed Shares [Member] Fixed shares. Damages Loss Contingency, Damages Awarded, Value Cash Cash Summary of Changes in RSUs and PSUs Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block] Wana Financial Instrument - Call Options Wana Financial Instrument Call Options [Member] Wana financial instrument - Call Options. Finite Lived Intangible Assets [Line Items] Finite-Lived Intangible Assets [Line Items] Intellectual Property Intellectual Property [Member] Discontinued Operations and Disposal Groups [Abstract] Entity Interactive Data Current Entity Interactive Data Current Equity Method Investments [Policy Text Block] Equity method investments Cash Acquired from Acquisition Less: Cash and cash equivalents acquired Costs Recorded in Cost of Goods Sold Cost of Sales [Member] Disposal group, including discontinued operation, cumulative translation adjustment. Disposal Group Including Discontinued Operation Cumulative Translation Adjustment Cumulative translation adjustment Number of common shares issued Number of common shares Business Acquisition, Equity Interest Issued or Issuable, Number of Shares Gain (Loss) on Disposition of Business Gain on disposal of consolidated entity Loss on disposal of consolidated entity Gain on disposal of consolidated entity August 2024 Supreme Convertible Debt Exchange August Twenty Two Four Supreme Convertible Debt Exchange [Member] August 2024 Supreme Convertible Debt Exchange. Total Other Liabilities [Abstract] Marketable Securities [Table] Marketable Securities [Table] Debt instrument, redemption price, percentage Debt Instrument, Redemption Price, Percentage Document Quarterly Report Document Quarterly Report Goodwill [Line Items] Goodwill [Line Items] Consolidated Entities Consolidated Entities [Axis] Number of shares to be issued on completion of acquisition and asset purchase milestones Share Based Compensation Number Of Shares To Be Issued On Completion Of Acquisition And Asset Purchase Milestones Share based compensation number of shares to be issued on completion of acquisition and asset purchase milestones. Balance Sheet Location Statement of Financial Position Location, Balance [Axis] Statistical Measurement Statistical Measurement [Axis] Equity Method Investment [Table] Cost of Goods and Services Sold, Total Cost of goods sold Cost of Goods and Services Sold Share-based Payment Arrangement, Tranche Three Share-Based Payment Arrangement, Tranche Three [Member] Debt Instrument Fair Value Debt Instrument Fair Value Of Common Shares Debt instrument fair value of common shares. Related Party Related and Nonrelated Parties [Domain] Wana Wana [Member] Wana member. Summary of Disaggregation of Revenue Disaggregation of Revenue [Table Text Block] Income tax (expense) recovery Discontinued Operation, Tax Effect of Discontinued Operation Amortization, Total Loan amortization payment Amortization Prepaid Expenses and Other Assets Prepaid Expense And Other Assets Disclosure [Text Block] Prepaid expense and other assets disclosure. Finite-Lived Intangible Assets, Gross, Total Gross Carrying Amount Finite-Lived Intangible Assets, Gross Accrued interest Interest Payable Canopy USA. Canopy USA [Member] Canopy USA Payments to Acquire Businesses, Net of Cash Acquired Net cash outflow (inflow) Net cash outflow Reorganization, Chapter 11 Reorganization, Chapter 11 [Domain] Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant Number of common shares reserved for issuance upon exercise or vesting of Awards Relationship of unobservable inputs to fair value Relationship Of Unobservable Inputs To Fair Value Description Relationship of unobservable inputs to fair value description. Proceeds from Issuance of Private Placement Proceeds from private placement unit offering Acreage Financial Instrument Intrinsic Value of Acreage Acreage Financial Instrument Intrinsic Value Of Acreage [Member] Acreage financial instrument intrinsic value of acreage. Canada Cannabis Canada cannabis [Member] Canada cannabis. Summary of Disaggregation of Property, Plant and Equipment by Geographic Area Long-Lived Assets by Geographic Areas [Table Text Block] Effect of exchange rate changes on cash and cash equivalents Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations Terr Ascend Warrants December 2022. Terr Ascend Warrants December 2022 [Member] TerrAscend warrants - December 2022 Threshold consecutive trading days Debt Instrument, Convertible, Threshold Consecutive Trading Days Income Statement Location Statement of Income Location, Balance [Axis] Canopy Rivers Canopy Rivers [Member] Canopy Rivers. Other Non-material Interests Other Non Material Interests [Member] Other non-material interests. Average exercise price, Beginning balance Average exercise price, Ending balance Warrants Average Exercise Price Warrant average exercise price. Total assets Assets Expected life of options (years) Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term Various Various [Member] Various. Disposal Group, Including Discontinued Operation, Prepaid and Other Assets Prepaid expenses and other assets Number of floating shares issued in first installment, Number Of Floating Shares Issued In First Installment Number Of Floating Shares Issued In First Installment Verona Manufacturing Facility. Verona Manufacturing Facility [Member] Verona Manufacturing Facility Debt Instrument [Table] Schedule of Long-Term Debt Instruments [Table] Accretion debentures Accretion Debentures Accretion debentures. Settlement liabilities and other, current Settlement Liabilities And Other Current Settlement liabilities and other current. RSUs and PSUs released Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period Senior Secured Term Loan Facility Senior Secured Term Loan Facility [Member] Senior secured term loan facility. Refund liability Refund Liability Refund liability. Business Acquisition [Line Items] Business Acquisition [Line Items] Acreage debt. Acreage Debt [Member] Acreage Debt BioSteel US and BioSteel Manufacturing Bio Steel U S and Bio Steel Manufacturing [Member] BioSteel US and BioSteel Manufacturing. New accounting policies New Accounting Pronouncements, Policy [Policy Text Block] Entity Address, City or Town Entity Address, City or Town Accumulated Other Comprehensive Income (Loss) AOCI Attributable to Parent [Member] Equity [Abstract] Share of loss on equity method investments Income (Loss) from Equity Method Investments Segments Segments [Axis] Current Other Liabilities, Current [Abstract] Beginning balance Ending balance Other Noncurrent Financial Asset Other noncurrent financial asset. Assets: Assets, Fair Value Disclosure [Abstract] CANADA CANADA Debt Conversion, Description Debt Conversion, Description Option premium payment Option Premium Payment Option premium payment. RSUs and PSUs cancelled and forfeited Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period Transfer of acquired debt to lenders. Transfer Of Acquired Debt To Lenders Amount of debt transferred Supreme Convertible Debentures Long-Term Debt, Maturity Date Maturity date Germany GERMANY Business combination consideration transferred related to repayment of debt and retirement of certain lease obligations. Business Combination Consideration Transferred Related to Repayment of Debt and Retirement of Certain Lease Obligations Consideration transferred related to repayment of debt and retirement of certain lease obligations Disposal Group, Including Discontinued Operation, Property, Plant and Equipment Property, plant and equipment Principal amount Debt Instrument, Face Amount Other. Other [Member] Other Unsecured Senior Notes [Member] Unsecured Senior Notes Long-Term Debt [Member] Principal amount of accretion debentures Principal Amount Of Accretion Debentures Principal amount of accretion debentures. Restructuring Cost And Reserve [Line Items] Restructuring Cost and Reserve [Line Items] Depreciation, Total Depreciation of property, plant and equipment Depreciation Other, including non-cash foreign currency Increase Decrease In Other Non Cash Foreign Currency Other, including non-cash foreign currency. Share Price Share price Price per exchangeable share Other financial assets Other Assets, Fair Value Disclosure Schedule Of Segment Reporting Information By Segment [Table] Schedule of Segment Reporting Information, by Segment [Table] Disposal Group, Including Discontinued Operation, Assets, Current, Total Disposal Group, Including Discontinued Operation, Assets, Current Current assets Assets of discontinued operations Average exercise price, Issuance of warrants Average Exercise Price On Issuance Of Warrants Average exercise price on issuance of warrants. Tranche C Warrants Tranche C Warrants [Member] Tranche C Warrants. Amount due relating to facility sale Nontrade Receivables Nontrade Receivables, Total Acreage Financial Instrument Value and Number of Canopy Shares Issued Acreage Financial Instrument Value And Number Of Canopy Shares Issued [Member] Acreage financial instrument value and number of canopy shares issued. Payments For Proceeds From Divestiture Of Interest In deconsolidation of subsidiaries And Affiliates Payments For Proceeds From Divestiture Of Interest In deconsolidation of subsidiaries And Affiliates Net cash outflow on sale or deconsolidation of subsidiaries Net cash outflow on sale or deconsolidation of subsidiaries Private Placement [Member] Private Placement Unit Offering Share-Based Compensation Share-Based Payment Arrangement [Text Block] Acreage Financial Instrument Estimated Premium on US Legalization Acreage Financial Instrument Estimated Premium On U S Legalization [Member] Acreage financial instrument estimated premium on us legalization. Range Two Range Two [Member] Rangeâ€ two. Aggregate number of common shares authorized Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture, Total Share-based compensation expense, options subject to performance conditions Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture Prepaid Expense and Other Assets, Current [Abstract] Business acquisition additional number of shares issuable Business Acquisition Equity Interests Additional Number Of Shares Issuable Business acquisition equity interests additional number of shares issuable. TerrAscend Common Shares Terr Ascend Common Shares [Member] TerrAscend common shares. Discontinued Operation, Income (Loss) from Discontinued Operation, Net of Tax, Per Diluted Share Diluted loss per share discontinued operations Convertible Debentures [Member] Convertible Debentures Accumulated Other Comprehensive Income Loss [Line Items] Accumulated Other Comprehensive Income (Loss) [Line Items] Fair Value Disclosures [Abstract] Number of Whole Warrants on Issuance of Replacement Warrants Resulting from Acreage Transaction Number of whole warrants on issuance of replacement warrants resulting from acreage transaction. Number of whole warrants, Issuance of replacement warrants resulting from the Acreage Transaction Interest income Interest Income Interest income. Weighted average exercise price, Options expired/forfeited Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price Right-of-Use Assets Right Of Use Assets [Member] Right of use assets. Stock Issued During Period, Value, New Issues Sale of common stock Common shares issued from ATM Program Disposal Group Including Discontinued Operation Equity Method Investments Disposal group including discontinued operation equity method investments. Equity method investment Canopy USA Assets [Member] Canopy USA assets member. Canopy USA Assets Stock Issued During Period, Value, Stock Options Exercised Exercise of Previous Equity Incentive Plan stock options Current liabilities: Liabilities, Current [Abstract] Canopy USA equity method investment discount rate. Canopy USA Equity Method Investment Discount Rate [Member] Canopy USA Equity Method Investment Discount Rate Expected credit losses on financial assets and related charges. Expected Credit Losses On Financial Assets And Related Charges Expected credit losses on financial assets and related charges Estimated fair value of notes using discounted cash flow Estimated fair value of notes using discounted cash flow Estimated fair value of notes using discounted cash flow. Document Type Document Type Summary of Components of Intangible Assets Schedule of Intangible Assets and Goodwill [Table Text Block] Other investing activities Payments for (Proceeds from) Other Investing Activities Title of 12(b) Security Title of 12(b) Security BioSteel Bio Steel [Member] BioSteel. Elevate loan receivable, Elevate Loan Receivable [Member] Elevate Loan Receivable Disposal Group, Including Discontinued Operation, Intangible Assets Intangible assets Cash and cash equivalents Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Canopy USA equity method investment probability of each acreage scenario. Canopy USA Equity Method Investment Probability of Each Acreage Scenario [Member] Canopy USA Equity Method Investment Probability of Each Acreage Scenario Restricted short-term investments Restricted Short Term Investments Fair Value Disclosure Restricted Short Term Investments Fair Value Disclosure. Balance Sheet Location Statement of Financial Position Location, Balance [Domain] Disposal Group, Including Discontinued Operation, Other Liabilities, Current Other current liabilities Components of Other Liabilities Other Liabilities [Table Text Block] Statement of Stockholders' Equity [Abstract] Document Fiscal Period Focus Document Fiscal Period Focus Long-Term Debt, Excluding Current Maturities, Total Long-term portion Long-term debt Long-Term Debt, Excluding Current Maturities Options granted Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross Changes in Carrying Amount of Goodwill Schedule of Goodwill [Table Text Block] Acquisition date Business Acquisition, Effective Date of Acquisition Number of whole warrants, Issuance of warrants from private placement Number Of Whole Warrants On Issuance Of Warrants From Private Placement Number of whole warrants on issuance of warrants from private placement. Amount of floating shares issued for second payment Amount Of Floating Shares Issued For Second Payment Amount of floating shares issued for second payment. Vesting date description Share-based Compensation Arrangement By Share-based Payment Award Option Vesting Date Description Share-based Compensation Arrangement By Share-based Payment Award Option Vesting Date Description Property, Plant and Equipment, Gross, Ending Balance Property, Plant and Equipment, Gross, Beginning Balance Property, Plant and Equipment, Gross, Total Property, plant and equipment, gross Property, Plant and Equipment, Gross C3 C Three [Member] C three. Principles of consolidation Consolidation, Policy [Policy Text Block] Canopy USA equity method investment control premium. Canopy USA Equity Method Investment Control Premium [Member] Canopy USA Equity Method Investment Control Premium Adjustments to additional paid in capital private placement. Adjustments to additional paid in capital private placement Private Placement Subsequent Event Type [Domain] Amounts Receivable, Net Loans,

Notes, Trade and Other Receivables Disclosure [Text Block] Basis Of Presentation [Line Items] Basis Of Presentation [Line Items] Basis of presentation. Summary of Assumptions Applied to Establish Fair Value of Options Granted Using Black-Scholes Option Pricing Model Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] Issuance and vesting of restricted and performance share units. Issuance And Vesting Of Restricted And Performance Issuance and vesting of restricted share units and performance share units Government debt securities. Government Debt Securities [Member] Government securities BioSteel Canada Bio Steel Canada [Member] BioSteel Canada. This Works Divestiture Disposal Groups, Including Discontinued Operations, Disclosure [Text Block] Biosteel Prepaid inventory Prepaid Inventory Current Prepaid inventory current. Exercise price of warrants Class of Warrant or Right, Exercise Price of Warrants or Rights Weighted average exercise price of warrants Financial Instruments Financial Instruments [Domain] L I B O R Plus L I B O R Plus [Member] LIBOR Plus [Member]. Canopy USA equity method investment volatility of wana and jetty equity. Canopy USA Equity Method Investment Volatility of Wana and Jetty Equity [Member] Canopy USA Equity Method Investment Volatility of Wana and Jetty Equity Less: valuation allowance Disposal Group, Including Discontinued Operation, Assets, Noncurrent, Total Disposal Group, Including Discontinued Operation, Assets, Noncurrent Noncurrent assets of discontinued operations Buildings and Greenhouses Buildings And Greenhouses [Member] Buildings and greenhouses. Sale of Stock [Axis] Cash flows from investing activities: Net Cash Provided by (Used in) Investing Activities [Abstract] Stock Option Subject To Performance Conditions Stock Option Subject To Performance Conditions [Member] Stock option subject to performance conditions. Reorganization under Chapter 11 of US Bankruptcy Code Disclosure [Text Block] Canopy USA Reorganization, Chapter 11 Reorganization, Chapter 11 [Axis] Supreme Cannabis Supreme Cannabis [Member] Supreme cannabis member. Aggregate investment amount Aggregate Investment Amount Aggregate investment amount. April 2024 exchange agreement. April 2024 Exchange Agreement [Member] April 2024 Exchange Agreement Exercise of warrants. Exercise Of Warrants Exercise of warrants Net revenue Net revenue Revenue from Contract with Customer, Excluding Assessed Tax Acreage Financial Instrument Acreage Financial Instrument [Member] Acreage financial instrument. Disposal Groups, Including Discontinued Operations [Table Text Block] Summary of Derecognized Assets and Liabilities Transferred Summary of Discontinued Operations Accumulated Other Comprehensive Income Loss [Table] Accumulated Other Comprehensive Income (Loss) [Table] Income Taxes Income Tax Disclosure [Text Block] Replacement options issued resulting from the Acreage Acquisition Share Based Compensation Arrangement By Share Based Payment Award Replacement Options Issued Resulting From The Acreage Acquisition Share based compensation arrangement by share based payment award replacement options issued resulting from the acreage acquisition. Other noncontrolling interest. Other Noncontrolling Interest [Member] Other Investment, Issuer Affiliation [Axis] Consolidated Entities Consolidated Entities [Domain] Other Long-Term Debt, Total Other revolving debt facility, loan, and financings Other Long-Term Debt Warrants and Rights Note Disclosure [Abstract] Total assets of discontinued operations Disposal Group, Including Discontinued Operation, Assets Net assets disposed Selling, General and Administrative Expense, Total Selling, general and administrative expenses Selling, General and Administrative Expense Finite-Lived Intangible Assets, Net, Ending Balance Finite-Lived Intangible Assets, Net, Beginning Balance Finite-Lived Intangible Assets, Net, Total Net Carrying Amount Finite-Lived Intangible Assets, Net Supreme debt settlement Warrant value issuance of warrants. Warrant Value Issuance Of Warrants Warrant value, Issuance of warrants Percentage of common shares to be issued to former holders Percentage Of Common Shares To Be Issued To Former Holders Percentage of common shares to be issued to former holders. Proceeds from Sale and Collection of Loans Receivable, Total Proceeds from Sale and Collection of Loans Receivable Net cash inflow on loan receivable Terr Ascend Warrants October2019 March2020 [Member] TerrAscend Warrants October 2019 March 2020. TerrAscend Warrants - December 2022 Frequency of periodic payment team Debt Instrument, Frequency of Periodic Payment Other Other Accrued Liabilities, Current Canopy USA equity method investment number of acreage common shares to be issued. Canopy USA Equity Method Investment Number of Acreage Common Shares to Be Issued [Member] Canopy USA Equity Method Investment Number of Acreage Common Shares to Be Issued Other financing activities Proceeds from (Payments for) Other Financing Activities Canadian Cannabis Net Revenue Canadian Cannabis Net Revenue [Member] Canadian cannabis net revenue. Schedule Of Intangible Assets Net Excluding Goodwill [Table] Schedule Of Intangible Assets Net Excluding Goodwill [Table] Schedule of intangible assets net excluding goodwill. LIABILITIES AND SHAREHOLDERS' EQUITY Liabilities and Equity [Abstract] Document Period End Date Document Period End Date Promissory note Promissory note. Net Cash Provided by (Used in) Financing Activities Net cash provided by (used in) financing activities Redeemable Noncontrolling Interest Redeemable Noncontrolling Interest [Text Block] Redeemable noncontrolling interest. Reorganization. Reorganization [Table] SOFR Floor. Secured Overnight Financing Rate Sofr OvernightIndex Swap Floor Rate [Member] SOFR Floor APIC, Share-Based Payment Arrangement, Increase for Cost Recognition, Total Share-based compensation APIC, Share-Based Payment Arrangement, Increase for Cost Recognition Class B Shares Common Class B [Member] Ownership percentage Equity Method Investment, Ownership Percentage Goodwill Goodwill Disclosure [Text Block] 4.25% Senior Notes [Member] Four Point Two Five Percent Senior Notes [Member] Four point two five percent senior notes. Disposal Group, Including Discontinued Operation, Other Liabilities Other liabilities Business Combination, Consideration Transferred, Other Other consideration Total [Member] Total [Member] Total [Member]. Income Tax Expense (recovery) Income Tax Expense (Benefit), Total Income tax expense Income tax (expense) recovery Net Cash Provided by (Used in) Investing Activities, Continuing Operations Net cash (used in) provided by investing activities - continuing operations Trading Symbol Trading Symbol Business Combinations [Abstract] Entity Other [Member] Entity other member. Other Stockholders' Equity Attributable to Parent, Ending Balance Stockholders' Equity Attributable to Parent, Beginning Balance Total Canopy Growth Corporation shareholders' equity Equity, Attributable to Parent Net income (loss) attributable to redeemable noncontrolling interest Net Income (Loss) Attributable to Redeemable Noncontrolling Interest, Total Net income (loss) attributable to redeemable noncontrolling interest Net Income (Loss) Attributable to Redeemable Noncontrolling Interest Net loss attributable to redeemable noncontrolling interest Schedule of Investments [Abstract] Acquisition consideration and other investment related liabilities, long term Acquisition Consideration Related Liabilities Noncurrent Acquisition consideration related liabilities noncurrent. Warrant value, Exercise of warrants Warrant Value Exercise Of Warrants Warrant value exercise of warrants. Purchase and sale of aggregate principal amount of senior unsecured convertible debentures Purchase and sale of aggregate principal amount of senior unsecured convertible debentures Purchase and sale of aggregate principal amount of senior unsecured convertible debentures. Purchased initial amount of convertible debentures Purchased initial amount of convertible debentures Purchased initial amount of convertible debentures. Aggregate redemption amount Debt Instrument Aggregate Redemption Amount Debt instrument aggregate redemption amount. Disposal Group, Including Discontinued Operation, Liabilities Total liabilities of discontinued operations Long-Lived Tangible Asset Long-Lived Tangible Asset [Axis] Number of whole warrants, Beginning balance Number of whole warrants, Ending balance Class of Warrant or Right, Outstanding Additions to property, plant and equipment Increase Decrease Capital Expenditures Incurred But Not Yet Paid Increase (decrease) capital expenditures incurred but not yet paid. Other liabilities, long-term Other liabilities Other Liabilities, Noncurrent Allowance for estimated returns and price adjustments Allowance For Estimated Returns And Price Adjustments Allowance for estimated returns and price adjustments. Conversion price Debt Instrument, Convertible, Conversion Price Payments to Acquire Businesses, Gross Consideration paid in cash SOFR Adjusted Floor Secured Overnight Financing Rate Sofr OvernightIndex Swap Adjusted Floor Rate [Member] SOFR Adjusted Floor Global Cannabis Net Revenue Global Cannabis Net Revenue [Member] Global cannabis net revenue. RSUs Restricted Stock Units (RSUs) [Member] Number of common shares issued and sold Sale of Stock, Number of Shares Issued in Transaction Number of units sold Other Liabilities Disclosure [Abstract] Acreage Disclosure [Text Block] The entire disclosure for acreage. Acreage Arrangement Schedule Of Property Plant And Equipment [Table] Property, Plant and Equipment [Table] Goodwill, Total Goodwill Beginning Balance Ending Balance Goodwill Option Indexed to Issuer's Equity, Type Option Indexed to Issuer's Equity, Type [Domain] Average exercise price, Expiry of warrants Average Exercise Price On Warrant Expiry Average Exercise Price On Warrant Expiry. Canadian adult-use cannabis. Canadian Adult-use Cannabis [Member] Canadian Adult-use Cannabis Disposal group including discontinued operation other financial assets. Disposal Group Including Discontinued Operation Other Financial Assets Other financial assets BioSteel Manufacturing Bio Steel Manufacturing [Member] BioSteel Manufacturing. Cash and Cash Equivalents Cash and Cash Equivalents Disclosure [Text Block] Principal amount of newly issued unsecured non-interest bearing convertible debentures Principal Amount Of Newly Issued Unsecured Non-Interest Bearing Convertible Debentures Principal amount of newly issued unsecured non-interest bearing convertible debentures. Share Repurchase Program Share Repurchase Program [Axis] Other Lender Rolling Lender. Rolling Lender [Member] Rolling Lender Vert Mirabel Vert Mirabel [Member] Vert Mirabel. Components of Amounts Receivable, Net Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block] Share-based compensation Share Based Compensation Including Amounts Recorded In Selling General And Administrative Expenses Share based compensation including amounts recorded in selling, general and administrative expenses. Refund liability, long-term Refund Liability Noncurrent Refund liability noncurrent. Geographical Geographical [Axis] Settlement liabilities and other, long term Settlement Liabilities And Other Non Current Settlement liabilities and other noncurrent. Retained non-controlling investment interest in subsidiaries. Retained Non-controlling Investment Interest In Subsidiaries Total retained non-controlling interest in the former subsidiaries Use of estimates Use of Estimates, Policy [Policy Text Block] Other - Classified as Held for Investment Other Classified As Held For Investment [Member] Other classified as held for investment. Average exercise price, Issuance of warrants from private placement Average Exercise Price On Issuance Of Warrants From Private Placement Average exercise price on issuance of warrants from private placement. Proceeds from Issuance of Long-Term Debt, Total Issuance of long-term debt Proceeds from Issuance of Long-Term Debt Issuance of long-term debt and convertible debentures Interest Proceeds from Interest Received Share Capital Share Capital [Member] Share capital. Other income (expense), net Other Operating Income (Expense), Net Settlement of convertible senior notes Stock Issued During Period, Value, Conversion of Convertible Securities Conversion of loans from related company into shares of Common Stock Exercise Price Range Exercise Price Range [Domain] Class Of Stock [Line Items] At-the-market equity program. At The Market Equity Program [Member] ATM Program Debt and other liabilities Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Debt And Other Liabilities Business combination recognized identifiable assets acquired and liabilities assumed debt and other liabilities. Other income (expense), net Other income (expense), net Disposal Group, Including Discontinued Operation, Other Income (Expense) Disposal group, including discontinued operation, other income (expense). Debt instrument, redemption, description Debt Instrument, Redemption, Description Schedule Of Business Acquisitions By Acquisition [Table] Schedule of Business Acquisitions, by Acquisition [Table] Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range [Line Items] Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items] Range of Exercise Prices, Upper Range Share-Based Payment Arrangement, Option, Exercise Price Range, Upper Range Limit Acreage1 Acreage One [Member] Acreage1 member. Scenario [Axis] Expected dividend yield Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate Average Exercise Price On Issuance of Replacement Warrants Resulting from Acreage Acquisition Average exercise price, Issuance of replacement warrants resulting from the Acreage Acquisition Average exercise price on issuance of replacement warrants resulting from acreage acquisition. Security Exchange Name Security Exchange Name Income (Loss) from Continuing Operations, Per Basic Share Basic loss per share continuing operations Fair Value by Liability Class Fair Value by Liability Class [Domain] Business Acquisition, Acquiree Business Acquisition, Acquiree [Domain] Total operating expenses Operating Expenses Equity Method Investments, Fair Value Disclosure Fair value of equity investments Equity method investments Other liabilities Other Liabilities, Fair Value Disclosure Summary of Disaggregation of Net Revenue by Geographic Area Revenue from External Customers by Geographic Areas [Table Text Block] TerrAscend Exchangeable Shares Terr Ascend Exchangeable Shares [Member] TerrAscend exchangeable shares. Cumulative Effect, Period of Adoption Cumulative Effect, Period of Adoption [Axis] Long-Lived Tangible Asset Long-Lived Tangible Asset [Domain] Class of Stock Class of Stock [Axis] Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Ending Balance Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Beginning Balance Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Total Less: Accumulated depreciation Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Fair Value of Financial Instruments Fair Value Disclosures [Text Block] Gain (loss) and charges related to settlement of debt. Gain (Loss) And Charges Related To Settlement Of Debt Gain (charges) related to settlement of debt Disposal and liquidation of consolidated entities Disposal and liquidation of consolidated entities. Disposal and liquidation of consolidated entities Black-Scholes value of each option Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value Warrant value, Issuance of replacement warrants resulting from Acreage Acquisition Issuance of Replacement Warrants Resulting from Acreage Acquisition, Warrants Value Issuance of replacement warrants resulting from acreage acquisition, warrants value. Interest receivable Interest Receivable, Current Subsequent Event Subsequent Event [Member] Maximum Maximum [Member] Total liabilities and shareholders' equity Liabilities and Equity Business to Business Business To Business [Member] Business to business. Omnibus Incentive Plan Omnibus Incentive Plan [Member] Omnibus incentive plan. Prepaid Expense, Current, Total Prepaid expenses Prepaid Expense, Current Adjustments to additional paid in capital other issuances of common shares and share issue costs. Adjustments To Additional Paid In Capital Other Issuances Of Common Shares And Share Issue Costs Other issuances of common shares warrants and share issue costs Supplemental disclosure of cash flow information Supplemental Cash Flow Information [Abstract] Prime Rate [Member] Prime Rate Convertible measurement period threshold consecutive trading days Debt Instrument Convertible Measurement Threshold Consecutive Trading Period Debt instrument convertible measurement threshold consecutive trading period. Canopy USA equity method investment market access premium. Canopy USA Equity Method Investment Market Access Premium [Member] Canopy USA Equity Method Investment Market Access Premium Elevate loan receivable equity value of wana and canopy USA. Elevate Loan Receivable Equity value of Wana and Canopy USA [Member] Elevate Loan Receivable Equity Value of Wana And Canopy USA Diluted loss per share Earnings Per Share, Diluted, Total Diluted (loss) earnings per share Earnings Per Share, Diluted Leasehold Improvements Leasehold Improvements [Member] Jetty Financial Instrument Volatility of Jetty Equity and Revenue Jetty Financial Instrument Volatility Of Jetty Equity And Revenue [Member] Jetty financial instrument volatility of jetty equity and revenue. Total liabilities Liabilities Average Exercise Price On Issuance of Replacement Warrants Resulting from Acreage Transaction Average exercise price on issuance of replacement warrants resulting from acreage transaction. Average exercise price, Issuance of replacement warrants resulting from the Acreage Transaction Fair Value Hierarchy and NAV Fair Value Hierarchy and NAV [Domain] Acreage debt option agreement. Acreage Debt Option Agreement [Member] Acreage Debt Option Agreement Range Three Range Three [Member] Rangeâ€ three. Total current assets Assets, Current Net Cash Provided by (Used in) Investing Activities Net cash (used in) provided by investing activities Second Amended and Restated Investor Rights Agreement and Consent Agreement Second Amended And Restated Investor Rights Agreement And Consent Agreement [Member] Second amended and restated investor rights agreement and consent agreement. Forecast [Member] Scenario Forecast Issuance of common shares Stock Issued During Period, Shares, New Issues Investment, Issuer Affiliation [Domain] Vesting period Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period Disposal Group, Including Discontinued Operation, Costs of Goods Sold Cost of goods sold Entity Filer Category Entity Filer Category Supreme convertible debentures Convertible debentures Convertible Debentures Convertible debentures. Other Comprehensive Income (Loss), before Tax, Total Other Comprehensive Income (Loss), before Tax Other comprehensive income (loss) Property, Plant and Equipment [Abstract] Settlement of canopy notes. Settlement of Canopy Notes [Member] Settlement of Canopy Notes [Member] Replacement equity instruments from the acquisition of Supreme Cannabis Replacement Equity Instruments Replacement equity instruments. May 2024 Convertible Debenture. May Two Thousand and Twenty Four Convertible Debenture [Member] May 2024 Convertible Debenture Total shareholders' equity Beginning balance Ending balance Equity, Including Portion Attributable to Noncontrolling Interest May 2024 Convertible Debenture. May Two Thousand and Twenty Four Convertible Debenture [Member] May 2024 Convertible Debenture Description of Business Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block] Fair value changes on equity method investments. Equity Method Investments Fair Value Adjustment Fair value changes on equity method investments Fair value changes on equity method investments Percentage of number of shares issuable from treasury pursuant to awards Percentage Of Options Exercisable On Each Anniversaries From Date Of Grant Percentage of options exercisable on each anniversaries from date of grant. Current Fiscal Year End Date Current Fiscal Year End Date Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Number of trading days to provide notice of redemption Trading Period To Provide Notice Of Redemption Trading period to provide notice of redemption. Jetty Financial Instrument - Call Options Jetty Financial Instrument Call Options [Member] Jetty financial instrument call options. Noncontrolling Interests Noncontrolling Interest [Member] Exchangeable Shares Exchangeable Shares [Member] Exchangeable shares CBI Exchange Agreement member. CBI Exchange Agreement [Member] CBI Exchange Agreement Prime rate floor. Prime Rate Floor [Member] Prime Rate Floor Proceeds from issuance of common shares and warrants. Proceeds From Issuance Of Common Shares And Warrants Proceeds from issuance of common shares and warrants Share-Based Payment Arrangement, Noncash Expense, Total Share-based compensation Share-Based Payment Arrangement, Noncash Expense Disposal of consolidated entities

Disposal Of Consolidated Entities Disposal of consolidated entities. Related Party Related and Nonrelated Parties [Axis] BioSteel Redeemable Noncontrolling Interest Discount Rate Bio Steel Redeemable Noncontrolling Interest Discount Rate [Member] Bio Steel redeemable noncontrolling interest discount rate. Foreign currency translation adjustments Goodwill, Foreign Currency Translation Gain (Loss) Issuance of debenture shares in excess percentage of issued common shares Issuance Of Debenture Shares In Excess Percentage Of Issued Common Shares Issuance of debenture shares in excess percentage of issued common shares. Aggregate value of shares issued in two tranches Aggregate Value Of Shares Issued In Two Tranches Aggregate value of shares issued in two tranches. Settlement of unsecured senior notes Stock issued during period, value, settlement of unsecured senior notes Stock issued during period, value, settlement of unsecured senior notes. Settlement of unsecured senior notes, net of tax Disposal Group, Including Discontinued Operation, Revenue Net revenue Entity Registrant Name Entity Registrant Name Bio Steel Sports Nutrition Inc Biosteel Sports Nutrition Inc1 [Member] Biosteel sports nutrition inc 1 Member. Share-based Reserve Sharebased Reserve [Member] Share-based reserve. L I B O R Floor L I B O R Floor [Member] LIBOR Floor [Member]. TerrAscend Option Terr Ascend Option [Member] TerrAscend Option. Gross margin Gross margin Gross Profit Fourth Quarter 2024 Paydown. Fourth Quarter Two Thousand And Twenty Four Paydowns [Member] Fourth Quarter 2024 Paydowns Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table] Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Earnings (Loss) Per Share Earnings Per Share [Text Block] Maturity date Debenture maturity date Debt Instrument, Maturity Date Entity Emerging Growth Company Entity Emerging Growth Company International and Other Revenue International And Other Revenue [Member] International and other revenue member. Equity Method Investments and Joint Ventures [Abstract] Purchases of intangible assets Payments to Acquire Intangible Assets Other Liabilities Current Other liabilities Other Liabilities. Current Subscription percentage for proposed financing. Subscription percentage for proposed financing. Subscription percentage for proposed financing Weighted Average Number of Shares Outstanding, Basic, Total Weighted average number of common shares outstanding Basic weighted average common shares outstanding Weighted Average Number of Shares Outstanding, Basic Consolidation, Variable Interest Entity, Policy [Policy Text Block] Variable interest entities Vesting Vesting [Domain] Loss Contingencies [Line Items] Noncontrolling Interests Noncontrolling Interest Disclosure [Text Block] Conversion Of Outstanding Debentures Description Conversion Of Outstanding Debentures Description Conversion Of Outstanding Debentures Description Credit Facility Credit Facility [Member] Credit facility. Schedule of Equity Method Investments [Line Items] Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] Other Other Operating Segment [Member] Fair value changes on acquisition related contingent consideration and other Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability Share Repurchase Program Share Repurchase Program [Domain] Number of common shares released on completion of acquisition milestones Number Of Common Shares Issued Relating To Completion Of Acquisition Milestones Number of common shares issued relating to completion of acquisition milestones. Fixed Shares Option And Floating Shares Agreement [Member] Fixed shares option and floating shares agreement. Fixed Shares Option and Floating Shares Agreement Proceeds from Issuance of Common Stock Gross proceeds from common shares Noncontrolling Interest, Period Increase (Decrease), Total Changes in redeemable noncontrolling interest Noncontrolling Interest, Period Increase (Decrease) Concentration Risk Type Concentration Risk Type [Axis] Cash and Cash Equivalents [Abstract] Number of whole warrants, Issuance of replacement warrants resulting from the Acreage Acquisition Number of Whole Warrants on Issuance of Replacement Warrants Resulting from Acreage Acquisition Number of whole warrants on issuance of replacement warrants resulting from acreage acquisition. Level 1 Fair Value, Inputs, Level 1 [Member] Long-term Other Liabilities, Noncurrent [Abstract] Debt Instrument, Call Feature Description of call feature Increase (Decrease) in Accounts Payable and Accrued Liabilities, Total Accounts payable and accrued liabilities Increase (Decrease) in Accounts Payable and Accrued Liabilities Debt Disclosure [Abstract] Weighted average exercise price, Options granted Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Disposal Group, Including Discontinued Operation, Accounts Payable, Current Accounts payable Amortization of intangible assets Amortization of Intangible Assets Canadian Recreational Cannabis Net Revenue [Member] Canadian recreational cannabis net revenue member. Canadian adult-use Cannabis Net Revenue Exercise Price Range Exercise Price Range [Axis] Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Replacement RSUs Issued Resulting From The Acreage Transaction Share based compensation arrangement by share based payment award equity instruments other than options replacement rsus issued resulting from the acreage transaction. Replacement RSUs issued resulting from the Acreage Transaction Financial Instrument Financial Instrument [Axis] Options Outstanding, Weighted Average Remaining Contractual Life Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term Other Other Financial Assets Other Other financial assets, other. Consideration Business Combination, Consideration Transferred, Including Equity Interest in Acquiree Held before Combination Total consideration Total consideration Number of equity financings Number Of Equity Financing Number of equity financings. Production and Warehouse Equipment Production And Warehouse Equipment [Member] Production and warehouse equipment. Stock Issued During Period Shares Acquisitions and cancellation of Notes Stock issued during period shares acquisitions and cancellation of notes. Net revenue Long-Lived Assets Share-Based Payment Arrangement [Abstract] Other Receivables, Net, Current, Total Other receivables Other Receivables, Net, Current Accumulated Other Comprehensive Income (Loss) Comprehensive Income (Loss) Note [Text Block] Purchase accounting allocations Goodwill, Measurement Period Adjustment Earliest date when the issuer can put the outstanding debt instrument for repayment or conversion to equity. Debt Instrument Put Date Earliest Earliest date to put Impairment losses Goodwill impairment loss Goodwill, Impairment Loss Aggregate exercise price of common shares Aggregate Exercise Price of Common Shares Aggregate exercise price of common shares. Average exercise price, Exercise of warrants Average Exercise Price On Warrant Exercised Average exercise price on warrants exercised. Disposal Group, Including Discontinued Operation, Cash and Cash Equivalents Cash Accumulated Other Comprehensive Income Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block] Paydown Agreement [Member] Paydown agreement. Other Issuances and Share Issue Costs [Member] Other issuances and share issue costs. Accounting Policies [Abstract] Summary of Changes in Options Outstanding Share-Based Payment Arrangement, Option, Activity [Table Text Block] Percentage of shares acquired Debt Instrument Shares Acquired Percentage Debt instrument shares acquired percentage. Long-Term Line of Credit, Total Long-Term Line of Credit Principal amount Income Tax Disclosure [Abstract] Other Income And Expenses [Table] Other income and expenses table. Canopy Growth Corporation shareholders' equity: Equity, Attributable to Parent [Abstract] Schedule Of Investments [Line Items] Schedule of Investments [Line Items] Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations, Total Foreign currency translation adjustments Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations CBI Promissory Note CBI Promissory Note [Member] CBI promissory note. Accretion Rate Accretion Rate Accretion Rate Inventory, Raw Matrials and Supplies, Gross, Total Raw materials, packaging supplies and consumables Inventory, Raw Materials and Supplies, Gross Disposal Group Name [Domain] TerrAscend Arrangement TerrAscend Arrangement [Member] TerrAscend Arrangement. Statement [Table] Statement [Table] TerrAscend warrants - December 2020 Terr Ascend Warrants December2020 [Member] TerrAscend warrants december 2020 member. Summary of Expected Useful Life of Property, Plant and Equipment Property, Plant and Equipment [Table Text Block] Conversion price percentage Debt Instrument Convertible Conversion Price percentage Debt instrument convertible conversion price percentage. Inventory write-downs Inventory Write-down Debt Instruments [Abstract] Subsequent Event [Table] Cannabis operations reporting unit member. Cannabis Operations Reporting Unit [Member] Cannabis Operations Reporting Unit Disposal Group, Including Discontinued Operation, Other Assets Other assets Gross revenue Revenue Revenue from Contract with Customer, Including Assessed Tax Entity File Number Securities Act File Number Segment Information Segment Reporting Disclosure [Text Block] Asset-backed Securities Asset-Backed Securities [Member] Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Disposal Group, Including Discontinued Operations Cash and cash equivalents, including discontinued operations Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Net decrease in cash and cash equivalents Revenue from Contract with Customer [Abstract] Earnings Per Share [Abstract] Basic and diluted loss per share Minimum liquidity covenant Minimum liquidity, each fiscal quarter Liquidity Requirement Liquidity requirement. Outstanding principal of acreage's debt Outstanding Principal Of Acreage's Debt Outstanding principal of acreage's debt. Inventory Disclosure [Abstract] Statement of Financial Position [Abstract] Equity Method Investments [Table Text Block] Schedule of Equity Method Investments TerrAscend Warrants Terr Ascend Warrants [Member] TerrAscend warrants. Interest Expense, Total Interest expense Interest Expense, Operating and Nonoperating Other income (expense), net Other Miscellaneous Non Operating Income Expense Net Other miscellaneous non operating income (expense) net. Operating Income (Loss) Operating loss from continuing operations Purchase price of shares Aggregate purchase price of stock options Notional price per share Expected volatility Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate Aggregate cash payment Redemption of Notes, Aggregate Cash Payment Redemption of notes, aggregate cash payment. Entity Shell Company Entity Shell Company Professional fees Accrued Professional Fees, Current Summary of Valuation Techniques and Significant Unobservable Inputs in the Fair Value Measurement of Significant Level 2 and Level 3 Financial Instruments Fair Value Measurement Inputs and Valuation Techniques [Table Text Block] Entity Tax Identification Number Entity Tax Identification Number ASSETS Assets [Abstract] Tax impact on aggregated principal amount Accumulated other comprehensive income into income tax expense, Tax Accumulated other comprehensive income into income tax expense, Tax. Comprehensive Income (Loss), Net of Tax, from discontinued operations attributable to noncontrolling interests and redeemable noncontrolling interest. Comprehensive Income (Loss), Net of Tax, from discontinued operations attributable to noncontrolling interests and redeemable noncontrolling interest Comprehensive loss from discontinued operations attributable to noncontrolling interests and redeemable noncontrolling interest Class of Warrant or Right Class of Warrant or Right [Domain] Debt Instrument, Call Date, Earliest Earliest date to call Credit facility Credit Facility Credit facility Entity Current Reporting Status Entity Current Reporting Status Options Exercisable, Weighted Average Remaining Contractual Life Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term Debt instrument principal reduction. Debt instrument principal reduction Principal reduction Components of Other Accrued Expenses and Liabilities Schedule of Accounts Payable and Accrued Liabilities [Table Text Block] Property, Plant and Equipment Property, Plant and Equipment Disclosure [Text Block] Long-Term Debt, Type Long-Term Debt, Type [Axis] Canadian medical cannabis. Canadian medical cannabis [Member] Canadian Medical Cannabis Subsequent Events [Abstract] Inventory Inventory Disclosure [Text Block] Geographical Geographical [Domain] Document Fiscal Year Focus Document Fiscal Year Focus Trust SPA Trust S P A [Member] Trust SPA. Acreage Tax Receivable Agreement Discounted Cash Flow Acreage Tax Receivable Agreement Discounted Cash Flow [Member] Acreage tax receivable agreement discounted cash flow. Income taxes Income Taxes Received Income taxes received. Cash and cash equivalents and short-term investments Cash, Cash Equivalents, and Short-Term Investments Cash, Cash Equivalents, and Short-Term Investments, Total Derivative liability related to settlement of convertible senior notes Derivative Liability Related To Settlement Of Convertible Senior Notes Derivative liability related to settlement of convertible senior notes. Share Based Compensation Arrangement By Share Based Payment Award Replacement Options Issued Resulting From The Acreage Transaction Weighted Average Exercise Price Share based compensation arrangement by share based payment award replacement options issued resulting from the acreage transaction weighted average exercise price. Weighted average exercise price, Replacement options issued resulting from the Acreage Transaction Additional convertible debentures amount purchased in the event of certain conditions are satisfied or waived Additional convertible debentures amount purchased in the event of certain conditions are satisfied or waived. Share-based Payment Arrangement, Tranche Two Share-Based Payment Arrangement, Tranche Two [Member] Disposal Group, Including Discontinued Operation, Accounts Payable and Accrued Liabilities, Current, Total Disposal Group, Including Discontinued Operation, Accounts Payable and Accrued Liabilities, Current Other accrued expenses and liabilities Options expired/forfeited Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Total Cash Provided by (Used in) Operating Activities, Discontinued Operations Net cash used in operating activities - discontinued operations Equity Settled Convertible Debentures Equity settled convertible debentures [Member] Equity settled convertible debentures. Acreage Debt Option Premium. Acreage Debt Option Premium [Member] Acreage Debt Option Premium Redemption of redeemable noncontrolling interests, net Stock Issued During Period Value, Redemption of Redeemable Noncontrolling Interest. Stock Issued During Period Value Redemption Of Redeemable Noncontrolling Interest Redemption of redeemable noncontrolling interest Repayments of Long-Term Debt, Total Repayment of long-term debt Repayments of Long-Term Debt Repayment of debt Mandatory prepayment of senior secured term loan facility Redeemable Noncontrolling Interest [Member] Redeemable Noncontrolling Interest [Member] Redeemable noncontrolling interest. Cash payment or any other property payable Cash Payment Or Any Other Property Payable Cash payment or any other property payable. Acreage Financial Instrument Control Premium Acreage Financial Instrument Control Premium [Member] Acreage financial instrument control premium. Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations, Total Cash and cash equivalents, beginning of period Cash and cash equivalents, end of period Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations Business Acquisition Business Acquisition [Axis] City Area Code City Area Code Value of transaction including cash Disposal Group, Including Discontinued Operation, Consideration Total consideration Total consideration Business combination consideration transferred in remediation and indemnity holdbacks. Business Combination Consideration Transferred in Remediation and Indemnity Holdbacks Consideration transferred in remediation and indemnity holdbacks Commercial Paper and Other Commercial Paper And Other [Member] Commercial paper and other [Member] Cash acquired from lenders. Cash Acquired From Lenders Cash acquired from lenders Total current liabilities Liabilities, Current Debt instrument, change in fair value of notes Liabilities, Fair Value Adjustment Net Cash Provided by (Used in) Operating Activities, Continuing Operations Net cash used in operating activities - continuing operations Class D Subordinated Voting Shares Class D Subordinated Voting Shares [Member] Class D subordinated voting shares. Other accrued expenses and liabilities Other accrued expenses and liabilities Accrued Liabilities and Other Liabilities Minority Interest [Table] Noncontrolling Interest [Table] Adjustments to additional paid in capital private placement net of issuance costs. Adjustments To Additional Paid In Capital Private Placement Net Of Issuance Costs Private Placement, net of issuance costs Inventory Inventory Inventory, Net Disposal group including discontinued operation deconsolidation of noncontrolling interest. Disposal Group Including Discontinued Operation Deconsolidation Of Noncontrolling Interest Derecognition of non-controlling interest in Canopy A Finished goods Inventory, Finished Goods, Gross Accrued and unpaid interest Debt Securities, Available-for-Sale, Accrued Interest Writetoff Ownership percentage exercised. Ownership Percentage Exercised Ownership percentage exercised Settlement of convertible senior notes, shares Conversion of loans from related company into shares of Common Stock, shares Exchangeable shares Principal redeemed fair value Debt Instrument Fair Value Redeemed Debt instrument fair value redeemed. Organization, Consolidation and Presentation of Financial Statements [Abstract] Local Phone Number Local Phone Number SOFR Prime Secured Overnight Financing Rate Sofr OvernightIndex Swap Prime Rate [Member] SOFR Prime Additional Paid in Capital, Total Additional paid in capital Additional Paid in Capital Replacement options issued resulting from the Acreage Transaction Share Based Compensation Arrangement By Share Based Payment Award Replacement Options Issued Resulting From The Acreage Transaction Share based compensation arrangement by share based payment award replacement options issued resulting from the acreage transaction. Fair Value Changes on Related Assets Fair value changes on related assets. Fair value changes on Canopy A related assets Proceeds from exercise of warrants Proceeds from Warrant Exercises Amounts receivable, net Amounts receivable, net Accounts and Financing Receivable, after Allowance for Credit Loss, Current Hempco debenture. Hempco Debenture [Member] Hempco Debenture Change in noncontrolling interests due to acquisition and ownership. Change In Noncontrolling Interests Due To Acquisition And Ownership Ownership changes Issuance of debenture shares in excess percentage of outstanding common shares Issuance Of Debenture Shares In Excess Percentage Of Outstanding Common Shares Issuance of debenture shares in excess percentage of outstanding common shares. Commitments and Contingencies Disclosure [Abstract] Shares issued Shares, Issued Exchangeable shares in the capital Subscription percentage for proposed private placement. Subscription percentage for proposed private placement Subscription percentage for proposed financing Acquired Brands Acquired Brands [Member] Acquired brands. Shares Acquired, Average Cost Per Share Shares acquired, price per share Debt Issuance Costs, Net, Total Debt Issuance Costs, Net Deferred financing costs Debt Securities, Available-for-Sale, Amortized Cost, Total Amortized cost of short-term investments Debt Securities, Available-for-Sale, Amortized Cost Warrant value, Issuance of warrants from private placement Warrant Value Issuance Of Warrants From Private Placement Warrant value issuance of warrants from private placement. Temporary Equity Disclosure [Abstract] Discontinued Operation, Gain (Loss) on Disposal, Statement of Income or Comprehensive Income [Extensible Enumeration] Debt instrument discounted price Debt Instrument Discounted Price Debt instrument discounted price. Other

issuances of common shares and warrants Adjustments To Additional Paid In Capital Other Issuances Of Common Shares And Warrants Value Adjustments to additional paid in capital other issuances of common shares and warrants value. Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Total Foreign currency translation Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax Debt instrument interest rate stated percentage Interest at a rate Annual interest rate Cash paid during the period: Cash Paid During The Year [Abstract] Cash paid during the year. Discontinued Operation, Income (Loss) from Discontinued Operation, Net of Tax, Per Basic Share Basic loss per share discontinued operations Fair value changes on debt Debt Fair Value Adjustment Debt fair value adjustment. Deficit Retained Earnings [Member] Payments to Acquire Property, Plant, and Equipment, Total Purchases of and deposits on property, plant and equipment Payments to Acquire Property, Plant, and Equipment Schedule of Other Income (Expense), Net Schedule of Other Nonoperating Income (Expense) [Table Text Block] Storz Bickel [Member] Storz & Bickel. Storz & Bickel Settlement liabilities and other Settlement Liabilities And Other Settlement liabilities and other. Document Transition Report Document Transition Report Rest-of-world Cannabis Rest-of-world Cannabis [Member] Rest-of-world Cannabis. Third Quarter 2025 Paydown Third Quarter Two Thousand And Twenty Five Paydowns [Member] Third quarter two thousand and twenty five paydowns. Business to Consumer Business To Consumer [Member] Business to consumer. Components of Short-term Investments Schedule Of Short Term Investments Table [Text Block] Schedule of short term investments. Second Quarter 2025 Paydown Second Quarter Two Thousand And Twenty Five Paydowns [Member] Second quarter two thousand and twenty five paydowns. Additional incremental term loan facility Additional Incremental Term Loan Facility Additional incremental term loan facility. Exercise price Weighted average exercise price, Options exercised Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price Warrant Derivative Liability Volatility of Canopy Growth Share Price Warrant Derivative Liability Volatility Of Canopy Growth Share Price [Member] Warrant derivative liability volatility of canopy growth share price. Minimum [Member] Minimum Lease liabilities Operating And Finance Lease Liability Operating and finance lease liability. Convertible Debenture Agreement [Member] Convertible debenture agreement. Common Stock Common Shares Common Stock [Member] Acquisition consideration and other investment related liabilities Acquisition Consideration Related Liabilities Acquisition consideration related liabilities. Investment, Name Investment, Name [Axis] Additional Paid-in capital Additional Paid-in Capital [Member] Other Other Revenue [Member] Other revenue. Redemption of redeemable noncontrolling interest Net Income (Loss) Attributable to Nonredeemable Noncontrolling Interest Net Income (Loss) Attributable to Nonredeemable Noncontrolling Interest, Total Adjustments to reconcile net loss to net cash used in operating activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Restricted short-term investments Restricted Investments, Current Other Comprehensive Income (Loss), Net of Tax [Abstract] Other comprehensive income (loss), net of income tax Income Statement Location Statement of Income Location, Balance [Domain] Other assets Other Assets, Noncurrent Gross proceeds from exchange and subscription agreement of debt. Gross Proceeds From Exchange and Subscription Agreement of Debt Gross proceeds from exchange and subscription agreement of debt Number Of Fixed And Floating Shares Issued Number Of Fixed And Floating Shares Issued Number of fixed and floating shares issued. Amortizable Intangibles in Process Amortizable Intangibles In Process [Member] Amortizable intangibles in process. Percentage of shares owned Percentage Of Shares Owned At Conversion Percentage of shares owned at conversion. Percentage of issued and outstanding shares. Percentage of issued and outstanding shares Percentage of issued and outstanding shares Segments [Domain] Components of Inventory Schedule of Inventory, Current [Table Text Block] Other At Fair Value Through Net Income (Loss) Other At Fair Value Through Net Income Loss [Member] Other - at fair value through net income (loss) Other assets Other Assets, Current Debt instrument cancelled Debt Instrument Cancelled Debt instrument cancelled. Goodwill and Intangible Assets Disclosure [Abstract] Foreign currency gain (loss) Realized Gain (Loss), Foreign Currency Transaction, before Tax Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Other Income (Expense), Net Other Income and Other Expense Disclosure [Text Block] Common Stock Shares Issued to Minority Interests Common stock shares issued to minority interests. Common shares issued to minority interests Disaggregation Of Revenue [Line Items] Disaggregation of Revenue [Line Items] Income (Loss) from Continuing Operations, Per Diluted Share Diluted loss per share continuing operations Accounts and Financing Receivables [Table] Schedule Of Revenues From External Customers And Long Lived Assets [Table] Schedule of Revenues from External Customers and Long-Lived Assets [Table] Number of shares exchanged Number of canopy shares exchanged Number Of Canopy Shares Exchanged Number of canopy shares exchanged. Stockholders' Equity Attributable to Noncontrolling Interest, Ending Balance Stockholders' Equity Attributable to Noncontrolling Interest, Beginning Balance Stockholders' Equity Attributable to Noncontrolling Interest, Total Noncontrolling interests Equity, Attributable to Noncontrolling Interest Remaining interest in Acreeageaē™'s debt. Remaining Interest in Acreeage's debt Remaining interest in Acreeage's debt BioSteel Redeemable Noncontrolling Interest Future Wholesale Price and Production Levels Bio Steel Redeemable Noncontrolling Interest Future Wholesale Price And Production Levels [Member] Bio Steel redeemable noncontrolling interest future wholesale price and production levels. Scenario [Domain] Indirect taxes receivable Value Added Tax Receivable Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Less Noncontrolling Interest Net assets acquired Net assets acquired International markets cannabis. International Markets Cannabis [Member] International Markets Cannabis Redeemable Noncontrolling Interest By Legal Entity [Table] Redeemable Noncontrolling Interest [Table] Second Quarter 2024 Paydowns Second Quarter Two Thousand And Twenty Four Paydowns [Member] Second quarter two thousand and twenty four paydowns. Cancellation consideration Common stock value Common shares - \$nil par value; Authorized - unlimited; Issued and outstanding - 129,153,014 shares and 91,115,501 shares, respectively. Exchangeable shares - \$nil par value; Authorized - unlimited; Issued and outstanding - 26,261,474 shares and nil shares, respectively. Principal payments of accretion debentures Principal Payments Of Accretion Debentures Principal payments of accretion debentures. Fair Value Measurements, Nonrecurring Value Measurement [Abstract] Right to call over rolling lender's remaining interest in acreeage's debt. Call Right Over Rolling Lenders Remaining Interest In Acreeages Debt Remaining acreage debt of rolling lender's Revenue from Contract with Customer Benchmark Revenue from Contract with Customer Benchmark [Member] Proceeds from the Credit Facility Proceeds From Credit Facility Proceeds from the Credit Facility. Measurement Frequency Measurement Frequency [Axis] Acreage Tax Receivable Agreement. Acreage Tax Receivable Agreement [Member] Acreage Tax Receivable Agreement Commitments and contingencies Commitments and Contingencies TerrAscend Exchangeable Shares, TerrAscend Option Terr Ascend Exchangeable Shares Terr Ascend Option [Member] TerrAscend exchangeable shares TerrAscend option. Marketable Securities [Line Items] Marketable Securities [Line Items] Income taxes Income Taxes Paid Acreage Tax Receivable Agreement Probability and Timing of US Legalization Acreage tax receivable agreement probability and timing of U S legalization [Member] Acreage tax receivable agreement probability and timing of US legalization. Acreage Financial Instrument Probability of Each Scenario Acreage Financial Instrument Probability Of Each Scenario [Member] Acreage financial instrument probability of each scenario. Short-term Investments Short Term Investments Disclosure [Text Block] Short term investments disclosure. Weighted Average Number of Shares Outstanding, Diluted, Total Diluted weighted average common shares outstanding Weighted Average Number of Shares Outstanding, Diluted Accounts Receivable, after Allowance for Credit Loss, Current, Total Accounts receivable, net Accounts Receivable, after Allowance for Credit Loss, Current Increase (Decrease) in Inventories, Total Inventory Increase (Decrease) in Inventories Debt instrument final closing trading days Debt Instrument Final Closing Trading Days Debt instrument final closing trading days. Reorganization. Reorganization [Line Items] Exchangeable Shares Acceleration Of Share Based Compensation Expense Related To Acquisition Milestones [Member] Acceleration of share-based compensation expense related to acquisition milestones. Reorganization Amendments Reorganization Amendments [Member] Reorganization Amendments. Extinguishment of promissory note and issuance of exchangeable shares. Extinguishment Of Promissory Note And Issuance Of Exchangeable Shares Extinguishment of promissory note and issuance of exchangeable shares Concentration Risk Benchmark Concentration Risk Benchmark [Domain] Warrant expiration date Warrants and Rights Outstanding, Maturity Date Comprehensive loss Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest Entity Small Business Entity Small Business Segment Reporting Information [Line Items] Segment Reporting Information [Line Items] Debt Instrument, Basis Spread on Variable Rate Credit agreement borrowing rate Debt Debt Disclosure [Text Block] Summary of Net Change in Noncontrolling Interests Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Table Text Block] Consolidated Entities Consolidated Entities [Member] H S C P Holders Pursuant To Amended T R A Member HSCP Holders pursuant to Amended TRA. HSCP Share consolidation ratio Stockholders' Equity Note, Stock Split, Conversion Ratio Storz & Bickel Storz and Bickel [Member] Storz and Bickel. Derivative Liability, Total Derivative liability Derivative Liability Disposal Group, Including Discontinued Operation, Liabilities, Current, Total Disposal Group, Including Discontinued Operation, Liabilities, Current Current liabilities Current liabilities Liabilities of discontinued operations Treasury Stock, Shares, Acquired Aggregate common shares acquired Summary of Net Changes in Redeemable Noncontrolling Interests Redeemable Noncontrolling Interest [Table Text Block] Average closing trading price of common shares. Average Closing Trading Price of Common Shares Average closing trading price of common shares Minimum call price Minimum Call Price Per Share Minimum call price per share. Intangible Assets, Net (Excluding Goodwill) [Abstract] Canadian Medical Cannabis Net Revenue Canadian Medical Cannabis Net Revenue [Member] Canadian medical cannabis net revenue. Warrant Value Expiry Of Warrants. Warrant Value Expiry Of Warrants Warrant value, Expiry of warrants Revenues From External Customers And Long Lived Assets [Line Items] Revenues from External Customers and Long-Lived Assets [Line Items] Revolving Credit Facility Revolving Credit Facility [Member] Exchange and subscription agreement terms. Exchange and Subscription Agreement Terms Exchange and subscription agreement terms Other Liabilities Other Liabilities Disclosure [Text Block] Acreage acquisition. Acreage acquisition [Member] Acreage Acquisition Accretion Debentures Accretion Debentures [Member] Accretion debentures [Member]. Software and Domain Names Software And Domain Names [Member] Software and domain names. Non-cash fair value adjustments and charges related to settlement of long-term debt Non-cash fair value adjustments and charges related to settlement of long-term debt Non-cash fair value adjustments and charges related to settlement of long-term debt Non-cash fair value adjustments and charges related to settlement of long-term debt. Debt instrument, redemption period, start date Debt Instrument, Redemption Period, Start Date Range One Range One [Member] Rangeaē one. Other Comprehensive Income (Loss), Financial Liability, Fair Value Option, after Tax and Reclassification Adjustment, Attributable to Parent, Total Fair value changes of own credit risk of financial liabilities Other Comprehensive Income (Loss), Financial Liability, Fair Value Option, after Tax and Reclassification Adjustment, Attributable to Parent Fair value changes of own credit risk of financial liabilities Cash flows from financing activities: Net Cash Provided by (Used in) Financing Activities [Abstract] Weighted average exercise price of options outstanding Weighted average exercise price outstanding, beginning balance Weighted average exercise price outstanding, ending balance Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price Other Accrued Expenses and Liabilities Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block] Other Financial Assets Other Financial Assets [Text Block] Other financial assets. Adjustments to additional paid in capital extinguishment of promissory note and issuance of exchangeable shares. Adjustments To Additional Paid In Capital Extinguishment Of Promissory Note And Issuance Of Exchangeable Shares Extinguishment of promissory note and issuance of exchangeable shares Disposal Group, Including Discontinued Operation, Accounts, Notes and Loans Receivable, Net Amounts receivable, net Distribution Channel Distribution Channel [Member] Relationships with distribution channels obtained through acquisitions. Supreme Convertible Debentures Supreme convertible debentures [Member] Supreme convertible debentures. Intangible Assets, Net (Excluding Goodwill), Total Total intangible assets Intangible assets Intangible Assets, Net (Excluding Goodwill) Other Lender Other Lender [Member] Other Lender. Measurement Frequency Measurement Frequency [Domain] Second quarter two thousand and twenty three pay downs. Second Quarter Two Thousand and Twenty Three Pay Downs [Member] Second Quarter 2023 Paydowns Tranche B and C Warrants Tranche B And C Warrants [Member] Tranche B and C warrants. Acreage Acreage Holdings Inc [Member] Acreage Holdings Inc. Noncontrolling Interest [Abstract] Brands Brands [Member] Brands. Schedule Of Prepaid Expense And Other Assets Table [Text Block] Schedule of prepaid expense and other assets. Components of Prepaid Expenses and Other Assets Work in progress Inventory, Work in Process, Gross Settlement of unsecured senior notes, net of deferred income tax Stock issued during period, value, settlement of unsecured senior notes, net of deferred income tax Stock issued during period, value, settlement of unsecured senior notes, net of deferred income tax. Level 3 Fair Value, Inputs, Level 3 [Member] Wana financial instrument - Deferred Payments. Wana Financial Instrument Deferred Payments [Member] Wana Financial Instrument - Deferred Payments Number of whole warrants, Exercise of warrants Number Of Whole Warrants On Exercise Of Warrants Number of whole warrants on exercise of warrants. Disposal group including discontinued operation elevate loan receivable. Disposal Group Including Discontinued Operation Elevate Loan Receivable Elevate loan receivable Subsequent Events Subsequent Events [Text Block] Loan Receivable Loan Receivable [Member] Loan receivable. Accounts Payable, Current, Total Accounts payable Accounts Payable, Current Common stock shares on hold. Common stock shares on hold Common stock shares on hold Short-term investments Short Term Investments Fair Value Disclosure Short term investments fair value disclosure. Disposal Group, Including Discontinued Operation, Operating Income (Loss) Operating loss Operating loss Settlement of convertible debentures [Member] Settlement of convertible debentures. Settlement of Convertible Debentures [Member] Fair value changes Changes In Other Financial Asset Fair Value Through Profit Or Loss Changes in other financial asset fair value through profit or loss. Other Financial Assets Fair Value Adjustment Amount of expense (income) related to adjustment to fair value of other financial assets. Fair value changes on other financial assets Fair value changes on other financial assets Business Acquisition Share Based Compensation Reserve Business acquisition share based compensation reserve. Share and warrant reserve Allowance for doubtful accounts Accounts Receivable, Allowance for Credit Loss, Current Senior Unsecured Convertible Debenture. Senior Unsecured Convertible Debenture [Member] Payments For Proceeds From Other Financial Assets Payments for proceeds from other financial assets. Investment in other financial assets (Investment in) sale of other financial assets Payments for (Proceeds from) Short-Term Investments, Total Redemption of short-term investments XML 8 R.1.htm IDEA: XBRL DOCUMENT v3.25.0.1 Document and Entity Information - shares 9 Months Ended Dec. 31, 2024 Feb. 06, 2025 Cover [Abstract] A A Document Type 10-Q A Amendment Flag false A Document Period End Date Dec. 31, 2024 A Document Fiscal Year Focus 2025 A Document Fiscal Period Focus Q3 A Entity Registrant Name Canopy Growth Corporation A Entity Central Index Key 0001737927 A Entity Current Reporting Status Yes A Entity Interactive Data Current Yes A Current Fiscal Year End Date --03-31 A Entity Filer Category Accelerated Filer A Entity Common Stock, Shares Outstanding A 147,120,088 Entity Shell Company false A Entity Small Business false A Entity Emerging Growth Company false A Title of 12(b) Security Common shares, no par value A Trading Symbol CGC A Security Exchange Name NASDAQ A Entity File Number 001-38496 A Entity Incorporation, State or Country Code Z4 A Entity Tax Identification Number 00-0000000 A Entity Address, Address Line One 1 Hershey Drive A Entity Address, City or Town Smiths Falls A Entity Address, State or Province ON A Entity Address, Postal Zip Code K7A 0A8 A City Area Code 855 A Local Phone Number 558-9333 A Document Quarterly Report true A Document Transition Report false A X - DefinitionBoolean flag that is true when the XBRL content amends previously-filed or accepted submission. + ReferencesNo definition available. + Details Name: dei AmendmentFlag Namespace Prefix: dei Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionArea code of city + ReferencesNo definition available. + Details Name: dei CityAreaCode Namespace Prefix: dei Data Type: xbrli:normalizedStringItem Type Balance Type: na Period Type: duration X - DefinitionCover page. + ReferencesNo definition available. + Details Name: dei CoverAbstract Namespace Prefix: dei Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration X - DefinitionEnd date of current fiscal year in the format --MM-DD. + ReferencesNo definition available. + Details Name: dei CurrentFiscalYearEndDate Namespace Prefix: dei Data Type: xbrli:gMonthDayItem Type Balance Type: na Period Type: duration X - DefinitionFiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY. + ReferencesNo definition available. + Details Name: dei DocumentFiscalPeriodFocus Namespace Prefix: dei Data Type: dei:fiscalPeriodItem Type Balance Type: na Period Type: duration X - DefinitionThis is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006. + ReferencesNo definition available. + Details Name: dei DocumentFiscalYearFocus Namespace Prefix: dei Data Type: xbrli:gYearItem Type Balance Type: na Period Type: duration X - DefinitionFor the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD. + ReferencesNo definition available. + Details Name: dei DocumentPeriodEndDate Namespace Prefix: dei Data Type: xbrli:dateItem Type Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true only for a form used as an quarterly report. + ReferencesReference 1: http://www.xbrli.org/2003/role/presentationRef -Publisher SEC -Name Form 10-Q -Number 240 -Section 308 -Subsection a + Details Name: dei DocumentQuarterlyReport Namespace Prefix: dei Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true only for a form used as a transition report. + ReferencesReference 1: http://www.xbrli.org/2003/role/presentationRef -Publisher SEC -Name Forms 10-K, 10-Q, 20-F -Number 240 -Section 13 -Subsection a-1 + Details Name: dei DocumentTransitionReport Namespace Prefix: dei Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionThe type of document being provided

(such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other', + ReferencesNo definition available. + Details Name: dei_DocumentType Namespace Prefix: dei_ Data Type: dei:submissionTypeItemType Balance Type: na Period Type: duration X - DefinitionAddress Line 1 such as Attn, Building Name, Street Name + ReferencesNo definition available. + Details Name: dei_EntityAddressAddressLine1 Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionName of the City or Town + ReferencesNo definition available. + Details Name: dei_EntityAddressCityOrTown Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionCode for the postal or zip code + ReferencesNo definition available. + Details Name: dei_EntityAddressPostalZipCode Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionName of the state or province. + ReferencesNo definition available. + Details Name: dei_EntityAddressStateOrProvince Namespace Prefix: dei_ Data Type: dei:stateOrProvinceItemType Balance Type: na Period Type: duration X - DefinitionA unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK. + ReferencesReference 1: <http://www.xbrl.org/2003/role/presentationRef> -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityCentralIndexKey Namespace Prefix: dei_ Data Type: dei:centralIndexKeyItemType Balance Type: na Period Type: duration X - DefinitionIndicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument. + ReferencesNo definition available. + Details Name: dei_EntityCommonStockSharesOutstanding Namespace Prefix: dei_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionIndicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure. + ReferencesNo definition available. + Details Name: dei_EntityCurrentReportingStatus Namespace Prefix: dei_ Data Type: dei:yesNoItemType Balance Type: na Period Type: duration X - DefinitionIndicate if registrant meets the emerging growth company criteria. + ReferencesReference 1: <http://www.xbrl.org/2003/role/presentationRef> -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityEmergingGrowthCompany Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionCommission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen. + ReferencesNo definition available. + Details Name: dei_EntityFileNumber Namespace Prefix: dei_ Data Type: dei:fileNumberItemType Balance Type: na Period Type: duration X - DefinitionIndicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure. + ReferencesReference 1: <http://www.xbrl.org/2003/role/presentationRef> -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityFilerCategory Namespace Prefix: dei_ Data Type: dei:filerCategoryItemType Balance Type: na Period Type: duration X - DefinitionTwo-character EDGAR code representing the state or country of incorporation. + ReferencesNo definition available. + Details Name: dei_EntityIncorporationStateCountryCode Namespace Prefix: dei_ Data Type: dei:edgarStateCountryItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). + ReferencesReference 1: <http://www.xbrl.org/2003/role/presentationRef> -Publisher SEC -Name Regulation S-T -Number 232 -Section 405 + Details Name: dei_EntityInteractiveDataCurrent Namespace Prefix: dei_ Data Type: dei:yesNoItemType Balance Type: na Period Type: duration X - DefinitionThe exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC. + ReferencesReference 1: <http://www.xbrl.org/2003/role/presentationRef> -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityRegistrantName Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act. + ReferencesReference 1: <http://www.xbrl.org/2003/role/presentationRef> -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityShellCompany Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionIndicates that the company is a Smaller Reporting Company (SRC). + ReferencesReference 1: <http://www.xbrl.org/2003/role/presentationRef> -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntitySmallBusiness Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionThe Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS. + ReferencesReference 1: <http://www.xbrl.org/2003/role/presentationRef> -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityTaxIdentificationNumber Namespace Prefix: dei_ Data Type: dei:employerIdItemType Balance Type: na Period Type: duration X - DefinitionLocal phone number for entity. + ReferencesNo definition available. + Details Name: dei_LocalPhoneNumber Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionTitle of a 12(b) registered security. + ReferencesReference 1: <http://www.xbrl.org/2003/role/presentationRef> -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b + Details Name: dei_Security12bTitle Namespace Prefix: dei_ Data Type: dei:securityTitleItemType Balance Type: na Period Type: duration X - DefinitionName of the Exchange on which a security is registered. + ReferencesReference 1: <http://www.xbrl.org/2003/role/presentationRef> -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection d1-1 + Details Name: dei_SecurityExchangeName Namespace Prefix: dei_ Data Type: dei:edgarExchangeCodeItemType Balance Type: na Period Type: duration X - DefinitionTrading symbol of an instrument as listed on an exchange. + ReferencesNo definition available. + Details Name: dei_TradingSymbol Namespace Prefix: dei_ Data Type: dei:tradingSymbolItemType Balance Type: na Period Type: duration XML 9 R2.htm IDEA: XBRL DOCUMENT v3.25.0.1 Condensed Interim Consolidated Balance Sheets (Unaudited) - CAD (\$) in Thousands Dec. 31, 2024 Mar. 31, 2024 Current assets: Á Á Cash and cash equivalents \$ 161,909 \$ 170,300 Short-term investments 16,435 33,161 Restricted short-term investments 7,108 7,310 Amounts receivable, net 49,058 51,847 Inventory 90,753 77,292 Assets of discontinued operations Á 8,038 Prepaid expenses and other assets 15,822 23,232 Total current assets 341,085 371,180 Equity Method Investments 49,834 Á Other financial assets 321,368 437,629 Property, plant and equipment 299,604 320,103 Intangible assets 89,791 104,053 Goodwill 44,093 43,239 Other assets 18,444 24,126 Total assets 1,164,219 1,300,330 Current liabilities: Á Á Accounts payable 28,918 28,673 Other accrued expenses and liabilities 37,191 54,039 Current portion of long-term debt 3,167 103,935 Other liabilities 27,740 48,068 Total current liabilities 97,016 234,715 Long-term debt 438,404 493,294 Other liabilities 37,324 71,814 Total liabilities 572,744 799,823 Commitments and contingencies Canopy Growth Corporation shareholders' equity: Á Á Common shares - \$nil par value; Authorized - unlimited; Issued and outstanding - 129,153,014 shares and 91,115,501 shares, respectively. Exchangeable shares - \$nil par value; Authorized - unlimited; Issued and outstanding - 26,261,474 shares and nil shares, respectively. 8,670,494 8,244,301 Additional paid-in capital 2,637,337 2,602,148 Accumulated other comprehensive loss (8,999) (16,051) Deficit (10,707,357) (10,330,030) Total Canopy Growth Corporation shareholders' equity 591,475 500,368 Noncontrolling interests Á 139 Total shareholders' equity 591,475 500,507 Total liabilities and shareholders' equity \$ 1,164,219 \$ 1,300,330 X - DefinitionOther financial assets. + ReferencesNo definition available. + Details Name: cgc_OtherFinancialAssets Namespace Prefix: cgc_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount, after allowance for credit loss, of accounts and financing receivables, classified as current. Includes, but is not limited to, notes and loan receivable. + ReferencesReference 1: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481990/310-10-45-2> + Details Name: us-gaap_AccountsNotesAndLoansReceivableNetCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionCarrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)(a)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1>Reference 2: <http://www.xbrl.org/2003/role/exampleRef> -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481372/852-10-55-10> + Details Name: us-gaap_AccountsPayableCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other. + ReferencesNo definition available. + Details Name: us-gaap_AccruedLiabilitiesAndOtherLiabilities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 14A -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482790/220-10-45-14A>Reference 2: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482790/220-10-45-11>Reference 3: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(2)(ii) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480016/944-40-65-2>Reference 4: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480016/944-40-65-2>Reference 5: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(4)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1>Reference 6: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(23)(a)(3)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147478777/944-210-S99-1>Reference 7: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 14 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482790/220-10-45-14> + Details Name: us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionValue received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(1)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1> + Details Name: us-gaap_AdditionalPaidInCapitalCommonStock Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of asset recognized for present right to economic benefit. + ReferencesReference 1: <http://www.xbrl.org/2003/role/exampleRef> -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482785/280-10-55-48>Reference 2: <http://www.xbrl.org/2003/role/exampleRef> -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 49 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482785/280-10-55-49>Reference 3: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482964/270-10-50-1>Reference 4: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482810/280-10-50-32>Reference 5: <http://fasb.org/us-gaap/role/ref/otherTransitionRef> -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (d) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482810/280-10-50-32>Reference 6: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482810/280-10-50-22>Reference 7: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481203/810-10-50-3>Reference 8: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481231/810-10-45-25>Reference 9: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(iii)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480678/235-10-S99-1>Reference 10: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481687/323-10-50-3>Reference 11: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482907/825-10-50-28>Reference 12: <http://www.xbrl.org/2003/role/exampleRef> -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481372/852-10-55-10>Reference 13: <http://www.xbrl.org/2003/role/exampleRef> -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479168/946-830-55-12>Reference 14: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(12)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147478777/944-210-S99-1>Reference 15: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(8)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479170/946-210-S99-1>Reference 16: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(18)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1>Reference 17: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1A>Reference 18: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1A>Reference 19: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1A>Reference 20: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1A>Reference 21: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1A>Reference 22: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1A>Reference 23: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1B>Reference 24: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1B>Reference 25: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1B>Reference 26: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1B>Reference 27: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1B>Reference 28: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 852 -SubTopic 10 -Name Accounting Standards

Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 30: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(11)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1 + Details Name: us-gaap Assets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of asset recognized for present right to economic benefit, classified as current, + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(iii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 6: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 10: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7 + Details Name: us-gaap AssetsCurrentNamespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap AssetsCurrentAbstractNamespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount classified as assets attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 10 -SubTopic 20 -Topic 205 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-10Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5C -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5CReference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482130/360-10-45-9Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5BReference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-3Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-11 + Details Name: us-gaap AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrentNamespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4 + Details Name: us-gaap CashAndCashEquivalentsAtCarryingValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionRepresents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(15)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1 + Details Name: us-gaap CommitmentsAndContingencies Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1 + Details Name: us-gaap CommonStockValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionThis item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481664/323-10-45-1Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(10)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 25 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-25 + Details Name: us-gaap EquityMethodInvestments Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount, after accumulated impairment loss, of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 49 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482548/350-20-55-24Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 100 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(15)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482598/350-20-45-1Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(10)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1 + Details Name: us-gaap Goodwill Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionSum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482686/350-30-45-1 + Details Name: us-gaap IntangibleAssetsNetExcludingGoodwill Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap InventoryNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(24)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(26)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(21)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI

common stock, shares issued 26,261,474 Common stock, shares outstanding 26,261,474 X - DefinitionTotal number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.5-02\(29\)\)](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.5-02(29))) - Publisher FASB -URI [http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Section 50-Paragraph 2-SubTopic 10-Topic 505-Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.5-02\(29\)\)](https://asc.fasb.org/1943274/2147480566/210-10-S99-1+Details Name: us-gaap CommonStockSharesIssued Namespace Prefix: us-gaap_ Data Type: xbrli:shareItem Type Balance Type: na Period Type: instant X - DefinitionNumber of shares of common stock outstanding. Common stock represent the ownership interest in a corporation. + ReferencesReference 1: <a href=) - Publisher FASB -URI [https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 210-Name Accounting Standards Codification-Section S99-Paragraph 2-Subparagraph \(SX 210.6-05\(4\)\)](https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 210-Name Accounting Standards Codification-Section S99-Paragraph 2-Subparagraph (SX 210.6-05(4))) - Publisher FASB -URI [https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef-Topic 946-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 3-Subparagraph \(SX 210.6-09\(4\)\(b\)\)](https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef-Topic 946-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 3-Subparagraph (SX 210.6-09(4)(b))) - Publisher FASB -URI [https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 210-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.6-04\(16\)\(a\)\)](https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 210-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.6-04(16)(a))) - Publisher FASB -URI [https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef-Topic 946-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 3-Subparagraph \(SX 210.6-09\(7\)\)](https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef-Topic 946-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 3-Subparagraph (SX 210.6-09(7))) - Publisher FASB -URI [http://www.xbrl.org/2003/role/disclosureRef-Topic 220-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 2-Subparagraph \(SX 210.5-03\(24\)\)](https://asc.fasb.org/1943274/2147479134/946-220-S99-3+Details Name: us-gaap CommonStockSharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:shareItem Type Balance Type: na Period Type: instant X - Details Name: us-gaap InvestmentIssuerAffiliationAxis=cgc ExchangeableSharesMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 11 R4.htm IDEA: XBRL DOCUMENT v3.25.0.1 Condensed Interim Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - CAD ($) $ in Thousands 3 Months Ended 9 Months Ended Dec. 31, 2024 Dec. 31, 2023 Dec. 31, 2023 Dec. 31, 2023 Income Statement [Abstract] A A A Revenue $ 86,244 $ 90,061 $ 235,985 $ 260,781 Excise taxes 11,483 11,556 32,021 36,423 Net revenue 74,761 78,505 203,964 224,358 Cost of goods sold 50,663 50,279 134,997 158,944 Gross margin 24,098 28,226 68,967 65,414 Operating expenses 4 A A Selling, general and administrative expenses 41,476 54,436 131,174 174,810 Share-based compensation 5,159 3,693 14,531 10,127 Loss on asset impairment and restructuring 1,285 30,413 22,135 2,452 Total operating expenses 47,920 88,542 167,840 187,389 Operating loss from continuing operations (23,822) (60,316) (98,873) (121,975) Other income (expense), net (97,758) (171,037) (276,952) (253,720) Loss from continuing operations before income taxes (121,580) (231,353) (375,825) (375,245) Income tax (expense) recovery (316) 1,077 (6,812) (13,762) Net loss from continuing operations (121,896) (230,276) (382,637) (389,007) Discontinued operations, net of income tax 0 13,479 5,310 (194,451) Net loss (121,896) (216,797) (377,327) (583,458) Discontinued operations attributable to noncontrolling interests and redeemable noncontrolling interest A 0 A (18,526) Net loss attributable to Canopy Growth Corporation $ (121,896) $ (216,797) $ (377,327) $ (583,458) Basic and diluted loss per share A A A Basic loss per share continuing operations $ (1.11) $ (2.78) $ (4.15) $ (5.56) Diluted loss per share continuing operations (1.11) (2.78) (4.15) (5.56) Basic loss per share discontinued operations 0.16 0.06 (2.52) Diluted loss per share discontinued operations 0.16 0.06 (2.52) Basic loss per share (1.11) (2.78) (4.15) (5.56) Diluted loss per share (1.11) (2.78) (4.15) (5.56) Basic weighted average common shares outstanding 110,306,430 82,919,190 92,172,660 69,918,744 Comprehensive income (loss): A A A Net loss from continuing operations $ (121,896) $ (230,276) $ (382,637) $ (389,007) Other comprehensive income (loss), net of income tax A A A Fair value changes of own credit risk of financial liabilities A (1,354) A (13,824) Foreign currency translation (1,162) 10,104 3,586 575 Total other comprehensive income (loss), net of income tax (1,162) 10,104 3,586 575 Comprehensive income (loss), net of tax, from continuing operations including portion attributable to noncontrolling interest, Total (123,058) (221,526) (379,051) (402,256) Comprehensive income (loss) from discontinued operations 0 13,479 5,310 (194,451) Comprehensive loss (123,058) (208,047) (373,741) (596,707) Comprehensive loss from discontinued operations attributable to noncontrolling interests and redeemable noncontrolling interest A 0 A (18,526) Comprehensive loss attributable to Canopy Growth Corporation $ (123,058) $ (208,047) $ (373,741) $ (596,707) X - DefinitionComprehensive income (loss), net of tax, from continuing operations including portion attributable to noncontrolling interest. + ReferencesNo definition available. + Details Name: cgc ComprehensiveIncomeLossNetOfTaxFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest Namespace Prefix: cgc_ Data Type: xbrli:monetaryItem Type Balance Type: credit Period Type: duration X - DefinitionComprehensive Income (Loss), Net of Tax, from discontinued operations attributable to noncontrolling interests and redeemable noncontrolling interest. + ReferencesNo definition available. + Details Name: cgc ComprehensiveIncomeLossNetOfTaxFromDiscontinuedOperationsAttributableToNoncontrollingInterestsAndRedeemableNoncontrollingInterest Namespace Prefix: cgc_ Data Type: xbrli:monetaryItem Type Balance Type: debit Period Type: duration X - DefinitionComprehensive income (loss), net of tax, from discontinued operations including portion attributable to noncontrolling interest. + ReferencesNo definition available. + Details Name: cgc ComprehensiveIncomeLossNetOfTaxFromDiscontinuedOperationsIncludingPortionAttributableToNoncontrollingInterest Namespace Prefix: cgc_ Data Type: xbrli:monetaryItem Type Balance Type: credit Period Type: duration X - DefinitionAmount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners. + ReferencesReference 1: <a href=) - Publisher FASB -URI [https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef-Topic 942-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.9-04\(26\)\)](https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef-Topic 942-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.9-04(26))) - Publisher FASB -URI [https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef-Topic 944-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.7-04\(22\)\)](https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef-Topic 944-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.7-04(22))) - Publisher FASB -URI

Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 21>: [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph \(SX 210.6-09\(1\)\(d\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 22](http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 22): [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(4\)\(i\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23): [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(4\)\(ii\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24): [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(4\)\(iii\)\(A\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 25](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 25): [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(4\)\(iv\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 26](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 26): [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(5\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 27](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 27): [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(4\)\(i\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28): [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(4\)\(iii\)\(A\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29): [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(4\)\(iii\)\(B\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 30](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 30): [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(4\)\(iv\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 31](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 31): [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(5\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 32](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 32): [http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 33](http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 33): <http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 34>: <http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 35>: [http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 36](http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 36): [http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 37](http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 37): [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.9-04\(22\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionGenerally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense. + ReferencesNo definition available. + Details Name: us-gaap_OperatingExpenses Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_OperatingExpensesAbstract Namespace Prefix: us-gaap_Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe net result for the period of deducting operating expenses from operating revenues. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 2](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionGenerally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense. + ReferencesNo definition available. + Details Name: us-gaap_OperatingExpenses Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_OperatingExpensesAbstract Namespace Prefix: us-gaap_Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe net result for the period of deducting operating expenses from operating revenues. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 2): [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph \(f\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 3](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 3): [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 4](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 4): [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph \(i\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 5](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 5): [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph \(ee\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6): [http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph \(c\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 7](http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 7): [http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31 + Details Name: us-gaap_OperatingIncomeLoss Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount, after tax and reclassification adjustment, of gain \(loss\) from increase \(decrease\) in instrument-specific credit risk of financial liability measured under fair value option, attributable to parent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph \(c\)\(3\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1AReference 2](http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31 + Details Name: us-gaap_OperatingIncomeLoss Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount, after tax and reclassification adjustment, of gain (loss) from increase (decrease) in instrument-specific credit risk of financial liability measured under fair value option, attributable to parent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (c)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1AReference 2): [http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 19 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19 + Details Name: us-gaap_OtherComprehensiveIncomeLossFinancialLiabilityFairValueOptionAfterTaxAndReclassificationAdjustmentAttributableToParent Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount after tax and reclassification adjustments of gain \(loss\) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term investment nature. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 10A -Subparagraph \(a\) -SubTopic 10 -Topic 220 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10AReference 2](http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 19 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19 + Details Name: us-gaap_OtherComprehensiveIncomeLossFinancialLiabilityFairValueOptionAfterTaxAndReclassificationAdjustmentAttributableToParent Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term investment nature. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 10A -Subparagraph (a) -SubTopic 10 -Topic 220 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10AReference 2): [http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.7-04\(19\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1 + Details Name: us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOffTax Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount after tax and reclassification adjustments of other comprehensive income \(loss\). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/214748112/505-10-50-2Reference 2](http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1 + Details Name: us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOffTax Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount after tax and reclassification adjustments of other comprehensive income (loss). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/214748112/505-10-50-2Reference 2): <http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 3>: <http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481674/830-30-50-1Reference 4>: <http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 17 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481694/830-30-45-17Reference 5>: [http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.7-04\(19\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 6](http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 6): <http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-4Reference 7>: <http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-5Reference 8>: <http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 20 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20Reference 9>: [http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph \(SX 210.5-03\(21\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 10](http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(21)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 10): [http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.9-04\(23\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 11](http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 11): [http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 12](http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 12): <http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 55 -Paragraph 15 -SubTopic 10 -Topic 220 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482739/220-10-55-15Reference 13>: [http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph \(SX 210.5-03\(9\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_OtherNonoperatingIncomeExpense Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2](http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A + Details Name: us-gaap_OtherComprehensiveIncomeLossNetOffTax Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_OtherComprehensiveIncomeLossNetOffTaxPeriodIncreaseDecreaseAbstract Namespace Prefix: us-gaap_Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of income (expense) related to nonoperating activities, classified as other. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_OtherNonoperatingIncomeExpense Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2): <http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3>: [http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph \(g\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4](http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4): [http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph \(g\)\(3\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5](http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5): [http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.4-08\(g\)\(1\)\(iii\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 6](http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(iii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 6): [http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph \(c\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 7](http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 7): [http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph \(f\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 8](http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 8): [http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph \(b\)\(2\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 9](http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 9): [http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph \(f\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 10](http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 10): <http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 11>: [http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic](http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11Reference 12)

standards Codification -Section 55 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4KReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 34: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-2Reference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1AReference 37: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (c)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A + Details Name: us-gaap_ProfitLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 924 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4 + Details Name: us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 924 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4 + Details Name: us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_SellingGeneralAndAdministrativeExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of noncash expense for share-based payment arrangement. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_ShareBasedCompensation Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 16 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16 + Details Name: us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10 + Details Name: us-gaap_WeightedAverageNumberOfSharesOutstanding Basic Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration XML 12 R5.htm ID&A: XBRL DOCUMENT V.23.5.0.1 Condensed Interim Consolidated Statements of Shareholder's Equity (Unaudited) - CAD (\$) \$ in Thousands Total Common Shares Additional Paid-in capital Share-based Reserve Additional Paid-in capital Warrants Additional Paid-in capital Ownership Changes Additional Paid-in capital Redeemable Noncontrolling Interest Accumulated Other Comprehensive Income (Loss) Deficit Noncontrolling Interests Beginning balance at Mar. 31, 2023 \$ 760,022 \$ 7,938,571 \$ 498,150 \$ 2,581,788 \$ (521,961) \$ (51,492) \$ (13,860) \$ (9,672,761) \$ 1,587 Other issuances of common shares and warrants 118,803 120,470 \$ (1,667) \$ A Share-based compensation 3,716 \$ A A A A A Issuance and vesting of restricted share units and performance share units 6,240 (6,240) \$ A A A A Changes in redeem

https://asc.fasb.org/1943274/2147481089/718-20-55-12 + Details Name: us-gaap AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionNet Increase or Decrease in balance of noncontrolling interest in the subsidiary during the reporting period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 45 - Paragraph 16 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-16 + Details Name: us-gaap MinorityInterestPeriodIncreaseDecrease Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: na Period Type: duration X - DefinitionAmount of increase in noncontrolling interest from subsidiary issuance of equity interests to noncontrolling interest holders. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 23 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-23Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section S99 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (c)(2) -SubTopic 10 -Topic 810 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A + Details Name: us-gaap NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionEquity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 205 -Name Accounting Standards Codification -Section 45 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap StockIssuedDuringPeriodValueNewIssues Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionValue of stock issued as a result of the exercise of stock options. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(31)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap StockIssuedDuringPeriodValueStockOptionsExercised Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (d)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 848 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (a)(3)(iii)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483550/848-10-65-2Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 8 -Subparagraph (c)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479832/842-10-65-8Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483421/250-10-45-24Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 23 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483421/250-10-45-23Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 5 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483421/250-10-45-5Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 5 -Subparagraph (c)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479654/326-10-65-5Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (h)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (h)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (h)(1)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (h)(1)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (i)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 105 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479343/105-10-65-6Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 105 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479343/105-10-65-6Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (f)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (f)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 8 -Subparagraph (d)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482615/740-10-65-8Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 8 -Subparagraph (d)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482615/740-10-65-8Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 4 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479654/326-10-65-4Reference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7Reference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-5Reference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481674/830-30-50-1Reference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 17 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481694/830-30-45-17Reference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 20 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20Reference 34: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 205 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3Reference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-3Reference 37: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 38: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 39: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 40: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 41: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 44: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 45: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 46: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 45 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-15Reference 47: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 45 -Paragraph 16 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-16Reference 48: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 55 -Paragraph 41 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481175/810-10-55-41Reference 49: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476166/350-60-65-1 + Details Name: us-gaap StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant XML 13 R6.htm IDEA: XBRL DOCUMENT v3.25.0.1 Condensed Interim Consolidated Statements of Cash Flows (Unaudited) \$ in Thousands, \$ in Thousands 9 Months Ended Dec. 31, 2024 CAD (\$) Dec. 31, 2023 CAD (\$) Cash flows from operating activities: Á Á Net loss \$ (377,327) \$ (583,458) Gain (loss) from discontinued operations, net of income tax 5,310 (194,451) Net loss from continuing operations (382,637) (389,007) Adjustments to reconcile net loss to net cash used in operating activities: Á Á Depreciation of property, plant and equipment 15,570 22,485 Amortization of intangible assets 16,081 19,396 Share-based compensation 14,531 10,127 Loss (gain) on asset impairment and restructuring 18,971 (816) Income tax expense 6,812 13,762 Non-cash fair value adjustments and charges related to settlement of long-term debt 223,591 188,452 Change in operating assets and liabilities, net of effects from purchases of businesses: Á Á Amounts receivable (3,163) (14,460) Inventory (12,924) (8,047) Prepaid expenses and other assets (641) (843) Accounts payable and accrued liabilities (17,000) 891 Other, including non-cash foreign currency (11,789) (47,901) Net cash used in operating activities - continuing operations (132,598) (205,961) Net cash used in operating activities - discontinued operations Á (53,930) Net cash used in operating activities (132,598) (259,891) Cash flows from investing activities: Á Á Purchases of and deposits on property, plant and equipment (7,724) (3,200) Purchases of intangible assets (409) (716) Proceeds on sale of property, plant and equipment 4,932 153,753 Redemption of short-term investments 16,950 68,294 Net cash outflow on sale or deconsolidation of subsidiaries (6,968) (3,719) Net cash inflow on loan receivable 28,353 1,279 Investment in other financial assets (95,335) (472) Other investing activities Á (10,513) Net cash (used in) provided by investing activities - continuing operations (60,201) 204,706 Net cash provided by (used in) investing activities - discontinued operations 13,414 (2,600) Net cash (used in) provided by investing activities (46,787) 202,106 Cash flows from financing activities: Á Á Proceeds from issuance of common shares and warrants 255,989 33,795 Proceeds from exercise of stock options 112 Á Proceeds from exercise of warrants 8,454 Á Issuance of long-term debt and convertible debentures 68,255 Á Repayment of long-term debt (148,249) (480,080) Other financing activities (19,943) (27,239) Net cash provided by (used in) financing activities 164,618 (473,524) Effect of exchange rate changes on cash and cash equivalents 6,376 (2,953) Net decrease in cash and cash equivalents (8,391) (534,262) Cash and cash equivalents, beginning of period 170,300 677,007 Cash and cash equivalents, end of period 161,909 142,745 Cash received during the period: Á Á Income taxes 101,402 Interest 2,040 14,230 Cash paid during the period: Á Á Income taxes 476 1,551 Interest 53,193 80,108 Noncash investing and financing activities Á Á Additions to property, plant and equipment \$ 339 \$ 199 X - DefinitionCash paid during the year. + ReferencesNo definition available. + Details Name: cgc CashPaidDuringTheYearAbstract Namespace Prefix: cgc Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionCash received during the year abstract + ReferencesNo definition available. + Details Name: cgc CashReceivedDuringYearAbstract Namespace Prefix: cgc Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Definition(Gain)/loss on asset impairment and restructuring. + ReferencesNo definition available. + Details Name: cgc GainLossOnAssetImpairmentAndRestructuring Namespace Prefix: cgc Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionIncome taxes received. + ReferencesNo definition available. + Details Name: cgc IncomeTaxesReceived

Namespace Prefix: cgc_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionIncrease (decrease) capital expenditures incurred but not yet paid. + ReferencesNo definition available. + Details Name: cgc_IncreaseDecreaseCapitalExpendituresIncurredButNotYetPaid Namespace Prefix: cgc_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionOther, including non-cash foreign currency. + ReferencesNo definition available. + Details Name: cgc_IncreaseDecreaseInOtherNonCashForeignCurrency Namespace Prefix: cgc_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionNon-cash fair value adjustments and charges related to settlement of long-term debt. + ReferencesNo definition available. + Details Name: cgc_NonCashFairValueAdjustmentsAndChargesRelatedToSettlementOfLongTermDebt Namespace Prefix: cgc_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionPayments For Proceeds From Divestiture Of Interest In deconsolidation of subsidiaries And Affiliates + ReferencesNo definition available. + Details Name: cgc_PaymentsForProceedsFromDivestitureOfInterestInDeconsolidationOfSubsidiariesAndAffiliates Namespace Prefix: cgc_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionPayments for proceeds from other financial assets. + ReferencesNo definition available. + Details Name: cgc_PaymentsForProceedsFromOtherFinancialAssets Namespace Prefix: cgc_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionProceeds from issuance of common shares and warrants. + ReferencesNo definition available. + Details Name: cgc_ProceedsFromIssuanceOfCommonSharesAndWarrants Namespace Prefix: cgc_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionShare based compensation including amounts recorded in selling, general and administrative expenses. + ReferencesNo definition available. + Details Name: cgc_ShareBasedCompensationIncludingAmountsRecordedInSellingGeneralAndAdministrativeExpenses Namespace Prefix: cgc_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration X - DefinitionThe aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> - Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482740/230-10-45-28>Reference 2: <http://www.xbrl.org/2003/role/exampleRef> -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 40 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482640/350-30-55-40>Reference 3: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(2) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482665/350-30-50-2>Reference 4: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482686/350-30-45-2> + Details Name: us-gaap_AmortizationOfIntangibleAssets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482913/230-10-50-8>Reference 2: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482740/230-10-45-24>Reference 3: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482740/230-10-45-4> + Details Name: us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482740/230-10-45-24>Reference 2: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Subparagraph (c)(1) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483499/205-20-50-5B> + Details Name: us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of cash inflow (outflow) of operating activities of discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482740/230-10-45-24>Reference 2: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Subparagraph (c)(1) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483499/205-20-50-5B> + Details Name: us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482740/230-10-45-28>Reference 2: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482099/360-10-50-1> + Details Name: us-gaap_Depreciation Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 830 -SubTopic 230 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147477401/830-230-45-1> + Details Name: us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount after tax of income (loss) from continuing operations including portion attributable to the noncontrolling interest. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 19 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481231/810-10-45-19>Reference 2: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482810/280-10-50-22>Reference 3: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482810/280-10-50-32>Reference 4: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482810/280-10-50-30>Reference 5: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482964/270-10-50-1>Reference 6: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (e) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482810/280-10-50-32>Reference 7: <http://fasb.org/us-gaap/role/ref/otherTransitionRef> -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (c) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482810/280-10-50-32>Reference 8: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483443/250-10-50-6>Reference 9: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147476176/805-60-65-1>Reference 10: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147478666/740-323-65-2>Reference 11: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480678/235-10-S99-1>Reference 12: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481687/323-10-50-3>Reference 13: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482907/825-10-50-28>Reference 14: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483443/250-10-50-1>Reference 15: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480175/815-40-65-1>Reference 16: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(11)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147477250/944-220-S99-1>Reference 17: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1A>Reference 18: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1A>Reference 19: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1A>Reference 20: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1A>Reference 21: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1A>Reference 22: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1B>Reference 23: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1B>Reference 24: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1B>Reference 25: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1B>Reference 26: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1B>Reference 27: <http://www.xbrl.org/2003/role/exampleRef> -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482810/280-10-50-31> + Details Name: us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount after tax of income (loss) from a discontinued operation including the portion attributable to the noncontrolling interest. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(12)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147477250/944-220-S99-1>Reference 2: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 740 -SubTopic 270 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147477349/740-270-45-3>Reference 3: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483499/205-20-50-7>Reference 4: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 3A -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483475/205-20-45-3A>Reference 5: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5C -Subparagraph (b)(2) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483499/205-20-50-5C>Reference 6: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 3B -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483475/205-20-45-3B>Reference 7: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 4 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483475/205-20-45-4>Reference 8: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482964/270-10-50-1>Reference 9: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483499/205-20-50-31> + Details Name: us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482964/270-10-50-1>Reference 2: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (e) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482810/280-10-50-32>Reference 3: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482685/740-10-50-12>Reference 4: <http://www.xbrl.org/2003/role/exampleRef> -Topic 740 -SubTopic 10 -Name

Accounting Standards Codification -Section 55 -Paragraph 231 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482663/740-10-55-231>Reference 5: <http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9>Reference 6: [http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 599 -Paragraph 1 -Subparagraph \(SAB Topic 6.1.7\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479360/740-10-599-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 599 -Paragraph 1 -Subparagraph (SAB Topic 6.1.7) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479360/740-10-599-1)Reference 7: <http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8>Reference 8: <http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10>Reference 9: [http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph \(h\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22](http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22)Reference 10: [http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section 599 -Paragraph 1 -Subparagraph \(SX 210.7-04\(9\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-599-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section 599 -Paragraph 1 -Subparagraph (SX 210.7-04(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-599-1)Reference 11: [http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Subparagraph \(a\) -SubTopic 20 -Topic 740 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2](http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Subparagraph (a) -SubTopic 20 -Topic 740 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2)Reference 12: [http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 599 -Paragraph 1 -Subparagraph \(SX 210.4-08\(h\)\) -SubTopic 10 -Topic 235 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-599-1](http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 599 -Paragraph 1 -Subparagraph (SX 210.4-08(h)) -SubTopic 10 -Topic 235 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-599-1) + Details Name: us-gaap_IncomeTaxExpenseBenefit Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount, before refund, of cash paid to foreign, federal, state, and local jurisdictions as income tax. + ReferencesReference 1: <http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2A -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2A>Reference 2: <http://www.xbrl.org/2009/role/commonPracticeRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 23 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-23>Reference 3: <http://www.xbrl.org/2009/role/commonPracticeRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-22>Reference 4: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph \(f\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25)Reference 5: <http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2> + Details Name: us-gaap_IncomeTaxesPaid Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph \(a\) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28](http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28) + Details Name: us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph \(a\) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28](http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28) + Details Name: us-gaap_IncreaseDecreaseInAccountsReceivable Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph \(a\) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28](http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28) + Details Name: us-gaap_IncreaseDecreaseInInventories Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_IncreaseDecreaseInOperatingCapitalAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of increase (decrease) in prepaid expenses, and assets classified as other. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph \(a\) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28](http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28) + Details Name: us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 17 -Subparagraph \(d\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-17](http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 17 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-17)Reference 2: [http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph \(e\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25](http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25)Reference 3: <http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2> + Details Name: us-gaap_InterestPaidNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24> + Details Name: us-gaap_NetCashProvidedByUsedInFinancingActivities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24> + Details Name: us-gaap_NetCashProvidedByUsedInInvestingActivities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of cash inflow (outflow) from investing activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28>Reference 2: <http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24>Reference 3: <http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25> + Details Name: us-gaap_NetCashProvidedByUsedInOperatingActivities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28>Reference 2: <http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24>Reference 3: <http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25> + Details Name: us-gaap_NetCashProvidedByUsedInOperatingActivities Continuing Operations Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28>Reference 2: <http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24>Reference 3: <http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25> + Details Name: us-gaap_NetCashProvidedByUsedInOperatingActivities Continuing Operations Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NoncashInvestingAndFinancingItemsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of cash (inflow) outflow from investing activities classified as other. + ReferencesReference 1: <http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 13 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13>Reference 2: <http://www.xbrl.org/2009/role/commonPracticeRef -Name Accounting Standards Codification -Section 45 -Paragraph 12 -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-12> + Details Name: us-gaap_PaymentsForProceedsFromOtherInvestingActivities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe net amount paid (received) by the reporting entity through acquisition or sale and maturities of short-term investments with an original maturity that is three months or less which qualify for treatment as an investing activity based on management's intention and intended by management to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term. + ReferencesReference 1: [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 12 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-12](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 12 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-12)Reference 2: [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 13 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13)Reference 3: [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 9 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-9](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 9 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-9) + Details Name: us-gaap_PaymentsForProceedsFromShortTermInvestments Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 13 -Subparagraph \(c\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 13 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13) + Details Name: us-gaap_PaymentsToAcquireIntangibleAssets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 13 -Subparagraph \(c\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 13 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13) + Details Name: us-gaap_PaymentsToAcquirePropertyPlantAndEquipment Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionInterest received on loans and other debt instruments during the current period. + ReferencesReference 1: [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 16 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-16](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 16 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-16) + Details Name: us-gaap_ProceedsFromInterestReceived Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section 599 -Paragraph 3 -Subparagraph \(SX 210.6-03\(i\)\(1\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-599-3](http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section 599 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-599-3)Reference 2: [http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 14 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14](http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 14 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14) + Details Name: us-gaap_ProceedsFromIssuanceOfLongTermDebt Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of cash inflow (outflow) from financing activities classified as other. + ReferencesReference 1: <http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14>Reference 2: <http://www.xbrl.org/2009/role/commonPracticeRef -Name Accounting Standards Codification -Section 45 -Paragraph 15 -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15> + Details Name: us-gaap_ProceedsFromPaymentsForOtherFinancingActivities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe cash inflow associated with the sale and collection of loans receivables arising from the financing of goods and services. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 12 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-12](http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 12 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-12) + Details Name: us-gaap_ProceedsFromSaleAndCollectionOfLoansReceivable Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 12 -Subparagraph \(c\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-12](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 12 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-12) + Details Name: us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of cash inflow from exercise of option under share-based payment arrangement. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph \(a\) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14](http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14)Reference 2: [http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2A -Subparagraph \(a\) -SubTopic 10 -Topic 718 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2A](http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2A -Subparagraph (a) -SubTopic 10 -Topic 718 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2A) + Details Name: us-gaap_ProceedsFromStockOptionsExercised Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe cash inflow associated with the amount received from holders exercising their stock warrants. + ReferencesReference 1: [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14) + Details Name: us-gaap_ProceedsFromWarrantExercises Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6>Reference 2: <http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9>Reference 3: [http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph](http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1)

4:

duration XML 16 R9.htm IDEA: XBRL DOCUMENT v3.25.0.1 Insider Trading Arrangements 3 Months Ended Dec. 31, 2024 Trading Arrangements, by Individual X - Rule 10b5-1 Arrangement Adopted false Non-Rule 10b5-1 Arrangement Adopted false Rule 10b5-1 Arrangement Terminated false Non-Rule 10b5-1 Arrangement Terminated false X - ReferencesReference 1:

other executive compensation plan matters of Canopy USA or any of its subsidiaries; and (e) the exercise of the Wana Options (as defined below) or the Jetty Options (as defined below), which for greater certainty means that the Company’s nominee on the Canopy USA Board will not be permitted to vote on any Key Decisions while the Company owns Non-Voting Shares (as defined below); (ii) reduce the number of managers on the Canopy USA Board from four to three, including, reducing the Company’s nomination right to a single manager; (iii) amend the share capital of Canopy USA to, among other things, (a) create a new class of Canopy USA Class B Shares (as defined below), which may not be issued prior to the conversion of the Non-Voting Shares or the Class A shares of Canopy USA (the “Canopy USA Common Shares”) into Canopy USA Class B Shares; (b) amend the terms of the Non-Voting Shares such that the Non-Voting Shares will be convertible into Canopy USA Class B Shares (as opposed to Canopy USA Common Shares); and (c) amend the terms of the Canopy USA Common Shares such that upon conversion of all of the Non-Voting Shares into Canopy USA Class B Shares, the Canopy USA Common Shares will, subject to their terms, automatically convert into Canopy USA Class B Shares, provided that the number of Canopy USA Class B Shares to be issued to the former holders of the Canopy USA Common Shares will be equal to no less than 10% of the total issued and outstanding Canopy USA Class B Shares following such issuance. Accordingly, as a result of the Reorganization Amendments, in no circumstances will the Company, at the time of such conversions, own more than 90% of the Canopy USA Class B Shares. In connection with the Reorganization Amendments, on May 19, 2023, Canopy USA and Huneus 2017 Irrevocable Trust (the “Trust”) entered into a share purchase agreement (the “Trust SPA”), which sets out the terms of the Trust’s investment in Canopy USA in the aggregate amount of up to US\$20 million (the “Trust Transaction”). Agustín Huneus, Jr. is the trustee of the Trust and is an affiliate of a shareholder of Jetty (as defined below). Pursuant to the terms of the Trust SPA, the Trust was entitled, subject to certain terms and conditions contained in the Trust SPA, to be issued Canopy USA Common Shares in two tranches with an aggregate value of up to US\$10 million along with warrants of Canopy USA to acquire additional Canopy USA Common Shares. In addition, subject to the terms of the Trust SPA, the Trust has also been granted options to acquire additional Voting Shares (as defined in the A&R LLC Agreement) with a value of up to an additional US\$10 million and one such additional option includes the issuance of additional warrants of Canopy USA. On April 26, 2024, Canopy USA completed the first tranche closing of the Trust Transaction in accordance with the Trust SPA and pursuant to the Trust SPA, the timeline to complete the second tranche closing has lapsed. As of February 6, 2025, the Trust holds an aggregate 28,571,429 Canopy USA Common Shares and warrants to acquire up to 85,714,284 Voting Shares expiring on April 26, 2031. In addition, subject to the terms and conditions of the A&R Protection Agreement (as defined below) and the terms of the option agreements to acquire Wana (as defined below) and Jetty, as applicable, Canopy Growth may be required to issue additional common shares in satisfaction of certain deferred and/or option exercise payments to the shareholders of Wana and Jetty. Canopy Growth will receive additional Non-Voting Shares from Canopy USA as consideration for any Company common shares issued in the future to the shareholders of Wana and Jetty. On November 3, 2023, the Company received a letter from the staff of the SEC (the “Staff”) in which the Staff indicated that, despite the Reorganization Amendments, it would object to the deconsolidation of the financial results of Canopy USA from the Company’s financial statements in accordance with U.S. GAAP once Canopy USA acquires Wana, Jetty or the Fixed Shares of Acreage Holdings, Inc. (the “Acreage”). The Company subsequently had discussions with the Office of Chief Accountant of the SEC (the “OCA”) and determined to make certain additional amendments to the structure of Canopy USA (the “Additional Reorganization Amendments”) to facilitate the deconsolidation of Canopy USA from the financial results of Canopy Growth in accordance with U.S. GAAP upon Canopy USA’s acquisition of Wana, Jetty or Acreage. In connection with the Additional Reorganization Amendments, Canopy USA and its members entered into a second amended and restated limited liability company agreement (the “Second A&R LLC Agreement”). In accordance with the terms of the Second A&R LLC Agreement, the terms of the Non-Voting Shares have been amended such that the Non-Voting Shares are only convertible into Canopy USA Class B Shares following the date that the NASDAQ Stock Market or The New York Stock Exchange permit the listing of companies that consolidate the financial statements of companies that cultivate, distribute or possess marijuana (as defined in 21 U.S.C 802) in the United States (the “Stock Exchange Permissibility Date”). Based on the Company’s discussions with the OCA, upon effectuating the Additional Reorganization Amendments, the Company believes that the Staff would not object to the deconsolidation of the financial results of Canopy USA from the Company’s financial statements in accordance with U.S. GAAP. Following the Reorganization, Reorganization Amendments and Additional Reorganization Amendments, on May 6, 2024, Canopy USA exercised the options (the “Wana Options”) to acquire Mountain High Products, LLC, Wana Wellness, LLC and The Cima Group, LLC (collectively, “Wana”), a leading cannabis edibles brand in North America, and subsequently closed the transactions to acquire Wana Wellness, LLC and The Cima Group, LLC. On October 8, 2024, Canopy USA closed the acquisition of Mountain High Products, LLC. In addition, Canopy USA exercised the options (the “Jetty Options”) to acquire Lemurian, Inc. (the “Jetty”) a California-based producer of high-quality cannabis extracts and pioneer of clean vape technology and subsequently completed the first tranche closing to acquire Jetty. On June 4, 2024, the option to acquire the issued and outstanding Class E subordinate voting shares (the “Fixed Shares”) of Acreage, a leading vertically-integrated multi-state cannabis operator, with its main operations in densely populated states across the Northeast U.S., including New Jersey and New York (the “Acreage Option”) was exercised and on December 9, 2024, Canopy USA completed the acquisition of all of the issued and outstanding Fixed Shares and Class D subordinate voting shares (the “Floating Shares”) of Acreage (the “Acreage Acquisition”). Canopy USA also holds direct and indirect interests in the capital of TerrAscend Corp. (the “TerrAscend”), a leading North American cannabis operator with vertically integrated operations and a presence in Pennsylvania, New Jersey, Michigan and California as well as licensed cultivation and processing operations in Maryland. Canopy USA currently holds an ownership interest in the following assets, among others: “Wana” 100% of the membership interests of Wana Wellness, LLC, The Cima Group, LLC, and Mountain High Products, LLC. “Jetty” approximately 77% of the shares of Jetty. “Acreage” 100% of the issued and outstanding shares of Acreage. “TerrAscend” Canopy USA beneficially holds an aggregate of 64,564,487 TerrAscend common shares (the “TerrAscend Common Shares”) on an as-converted basis and 22,474,130 TerrAscend Common Share purchase warrants with a weighted average exercise price of \$6.07 per TerrAscend Common Share and expiring on December 31, 2032 (the “TerrAscend Warrants”). Assuming full exercise of the TerrAscend Warrants, Canopy USA will beneficially hold an aggregate of 87,038,617 TerrAscend Common Shares on an as-converted basis assuming conversion of the TerrAscend exchangeable shares (the “TerrAscend Exchangeable Shares”) beneficially held by Canopy USA. Following the implementation of the Reorganization, Canopy USA was determined to be a variable interest entity pursuant to ASC 810 - Consolidations (the “ASC 810”) and prior to the completion of the Reorganization Amendments and the Additional Reorganization Amendments, Canopy Growth was determined to be the primary beneficiary of Canopy USA. As a result of such determination and in accordance with ASC 810, Canopy Growth consolidated the financial results of Canopy USA up to April 30, 2024. Ownership of U.S. Cannabis Investments Following the implementation of the Reorganization, the shares and interests in Acreage, Wana, Jetty and TerrAscend are held, directly or indirectly, by Canopy USA, and Canopy Growth no longer holds a direct interest in any shares or interests in such entities. Canopy Growth holds non-voting and non-participating shares (the “Non-Voting Shares”) in the capital of Canopy USA. The Non-Voting Shares do not carry voting rights, rights to receive dividends or other rights upon dissolution of Canopy USA. Following the Reorganization Amendments, the Non-Voting Shares are convertible into Class B shares of Canopy USA (the “Canopy USA Class B Shares”), provided that such conversion shall only be permitted following the Stock Exchange Permissibility Date. The Company also has the right (regardless of the fact that its Non-Voting Shares are non-voting and non-participating) to appoint one member to the Canopy USA board of managers (the “Canopy USA Board”). On October 24, 2022, Canopy USA and the Company also entered into an agreement with, among others, Nancy Whiteman, the controlling shareholder of Wana, which was amended and restated on May 19, 2023 and on April 30, 2024, whereby subsidiaries of Canopy USA agreed to pay additional consideration in order to acquire the Wana Options and the future payments owed in connection with the exercise of the Wana Options were reduced to US\$3.00 in exchange for the issuance of Canopy USA Common Shares and Canopy Growth common shares (the “Wana Amending Agreement”). In accordance with the terms of the Wana Amending Agreement, on April 30, 2024, (i) Canopy USA issued 60,955,929 Canopy USA Common Shares and (ii) Canopy Growth issued 1,086,279 Canopy Growth common shares to the shareholders of Wana. The Canopy USA Common Shares issued to Ms. Whiteman, or entities controlled by Ms. Whiteman, are subject to a repurchase right exercisable at any time after April 30, 2027, being the 36 month anniversary of the closing of the transaction contemplated by the Wana Amending Agreement (the “Wana Repurchase Right”) to repurchase all Canopy USA Common Shares that have been issued at a price per Canopy USA Common Share equal to the fair market value as determined by an appraiser. As part of this agreement, Canopy USA has granted Ms. Whiteman the right to appoint one member to the Canopy USA Board and a put right on the same terms and conditions as the Wana Repurchase Right. As of February 6, 2025, the Trust holds 28,571,429 Canopy USA Common Shares, the shareholders of Wana collectively hold 60,955,929 Canopy USA Common Shares and a wholly-owned subsidiary of the Company holds all of the issued and outstanding Non-Voting Shares in the capital of Canopy USA, representing approximately 84.4% of the issued and outstanding shares in Canopy USA on an as-converted basis. Canopy Growth and Canopy USA are also party to a protection agreement (the “Protection Agreement”) to provide for certain covenants in order to preserve the value of the Non-Voting Shares held by Canopy Growth until such time as the Non-Voting Shares are converted in accordance with their terms, provided that, such conversion shall only be permitted following the Stock Exchange Permissibility Date, but does not provide Canopy Growth with the ability to direct the business, operations or activities of Canopy USA. The Protection Agreement was amended and restated in connection with: (a) the Reorganization Amendments (the “First A&R Protection Agreement”); and (b) the Additional Reorganization Amendments (the “Second A&R Protection Agreement”) and together with the First A&R Protection Agreement, the “A&R Protection Agreement”). Until such time as Canopy Growth converts the Non-Voting Shares into Canopy USA Class B Shares following the Stock Exchange Permissibility Date, Canopy Growth will have no economic or voting interest in Canopy USA, Wana, Jetty, TerrAscend, or Acreage. Canopy USA, Wana, Jetty, TerrAscend, and Acreage will continue to operate independently of Canopy Growth. Acreage Agreements On October 24, 2022, Canopy Growth entered into an arrangement agreement with Canopy USA and Acreage, as amended (the “Floating Share Arrangement Agreement”), pursuant to which Canopy USA acquired all of the issued and outstanding Floating Shares by way of a court-approved plan of arrangement (the “Floating Share Arrangement”) in exchange for 0.045 of a Company common share for each Floating Share held. In connection with the Floating Share Arrangement Agreement, Canopy Growth irrevocably waived the Acreage Floating Option (as defined below) existing under the Existing Acreage Arrangement Agreement. On October 24, 2022, the Company and Canopy USA entered into a third amendment to tax receivable agreement (the “Amended TRA”) with, among others, certain current or former unitholders (the “Holders”) of High Street Capital Partners, LLC, a subsidiary of Acreage (the “HSCP”), pursuant to HSCP’s amended tax receivable agreement (the “TRA”) and related tax receivable bonus plans with Acreage. Pursuant to the Amended TRA, the Company, on behalf of Canopy USA, agreed to issue common shares of the Company with a value of US\$30.4 million to certain Holders as consideration for the assignment of such Holder’s rights under the TRA to Canopy USA. As a result of the Amended TRA, Canopy USA is the sole member and beneficiary under the TRA. In connection with the foregoing, the Company issued: (i) 564,893 common shares with a value of \$20.6 million (US\$15.2 million) to certain Holders on November 4, 2022 as the first installment under the Amended TRA; and (ii) 710,208 common shares with a value of \$20.6 million (US\$15.2 million) to certain Holders on March 17, 2023, as the second installment under the Amended TRA. In connection with the Acreage Acquisition, the Company, on behalf of Canopy USA, issued 5,118,426 common shares of the Company to an eligible participant pursuant to HSCP’s existing tax receivable bonus plans. In addition to shareholder and court approvals, completion of the Floating Share Arrangement was subject to applicable regulatory approvals including, but not limited to, Toronto Stock Exchange (the “TSX”) approval and the satisfaction of certain other closing conditions, including the conditions set forth in the Acreage Amended Arrangement. The Floating Share Arrangement received the requisite approval from the holders of Floating Shares at the special meeting of Acreage shareholders held on March 15, 2023 and on March 20, 2023. Acreage obtained a final order from the Supreme Court of British Columbia approving the Floating Share Arrangement. The Floating Share Arrangement was implemented on December 9, 2024 in connection with the closing of the Acreage Acquisition. On June 4, 2024, the Acreage Option was exercised in accordance with the terms of the arrangement agreement dated April 18, 2019, as amended on May 15, 2019, September 23, 2020 and November 17, 2020 (the “Existing Acreage Arrangement Agreement”). Concurrently with the closing of the acquisition of the Fixed Shares pursuant to the exercise of the Acreage Option, on December 9, 2024, the Fixed Shares were issued to Canopy USA upon closing of the Acreage Acquisition. Accordingly, Canopy Growth does not hold any Fixed Shares or Floating Shares. The acquisition of the Floating Shares pursuant to the Floating Share Arrangement occurred immediately prior to the acquisition of the Fixed Shares pursuant to the Existing Acreage Arrangement Agreement such that 100% of the issued and outstanding shares of Acreage are owned by Canopy USA. For additional details, see “Acreage Acquisition” below. On June 3, 2024, the Company exercised its option to acquire certain outstanding debt of Acreage (the “Debt Acquisition”) in connection with the option agreement dated November 15, 2022 (the “Option Agreement”) among a wholly-owned subsidiary of Canopy Growth (the “Optionor”) and the lenders (the “Lenders”) party to Acreage’s credit agreement dated as of December 16, 2021, as amended by the first amendment to credit agreement dated as of October 24, 2022 and the second amendment to credit agreement dated as of April 28, 2023. The Optionor entered into various agreements in connection with the Debt Acquisition in order to acquire approximately \$136,567 (US\$99,837) of Acreage’s outstanding debt (the “Acquired Debt”) from certain Lenders in exchange for \$95,460 (US\$69,786) in cash and the release of approximately \$41,107 (US\$30,051) (the “Option Premium”) that was held in escrow pursuant to the Option Agreement. As reported in the Annual Report, the Option Premium was not included in Canopy Growth’s cash and cash equivalents as of March 31, 2024. The Optionor subsequently transferred approximately \$2,972 (US\$2,173) of the Acquired Debt to the other Lender (the “Rolling Lender”) and entered into a series of agreements with the Rolling Lender and Acreage, among others, including an amended and restated credit agreement (the “First ARCA”), which provided for, among other things, the Acquired Debt, certain interest payments to be paid-in-kind, revisions to certain financial covenants and, following certain events, an extension to the maturity date. On September 13, 2024, the Optionor entered into a series of transactions with, among others, Acreage, the Rolling Lender and an arm’s length third-party lender (the “Other Lender”). Pursuant to such transactions, all of Acreage’s indebtedness held by the Rolling Lender was acquired by the Other Lender. Following the acquisition by the Other Lender, the Optionor, the Other Lender and Acreage, among others, amended and restated the First ARCA pursuant to a second amended and restated credit agreement dated as of September 13, 2024 (the “Second ARCA”). Pursuant to the Second ARCA and an agreement among lenders entered into on September 13, 2024 between, among others, the Optionor and the Other Lender, all interest owing to the Optionor under the Second ARCA is, subject to the consent of the Other Lender, to be paid-in-kind and not in cash. Under the Second ARCA, as of September 13, 2024, the Optionor was owed an aggregate principal amount equal to approximately \$137,955 (US\$102,000), which is subordinate to approximately \$87,913 (US\$65,000) owed to the Other Lender. Deconsolidation of Canopy USA As of April 30, 2024, as a result of the series of transactions related to the Additional Reorganization Amendments described above (the “Canopy USA Transactions”), Canopy Growth has deconsolidated the financial results of Canopy USA and has a non-controlling interest in Canopy USA as of such date. The deconsolidation of Canopy USA occurred after completion of the following structural amendments: (i) execution of the Second A&R LLC Agreement, (ii) execution of the Second A&R Protection Agreement and (iii) completion of the initial tranche closing of the Trust Transaction, which included the election of a third member to the Canopy USA Board such that the Canopy USA Board is comprised of an appointee of the Trust, Ms. Whiteman, and the Company. Canopy Growth’s deconsolidation of Canopy USA resulted in recognition of an equity method investment (see Note 11) and a loan receivable recorded at fair value (see Note 12). The deconsolidation of Canopy USA from the financial results of Canopy Growth resulted in the derecognition of the following assets and liabilities: Cash \$ 6,968 \$ Other financial assets \$ A 386,045 \$ Other assets \$ A 1,315 \$ Other liabilities \$ A (20,067) Cumulative translation adjustment \$ A 10,398 \$ Net assets disposed \$ 384,659 \$ Total retained non-controlling interest in the former subsidiaries \$ 401,983 \$ Issuance of common shares \$ (12,452) Consideration received in cash \$ - \$ Total consideration \$ - \$ Gain on disposal of consolidated entity \$ 5,011 \$ The gain on derecognition of Canopy USA is the differences between the carrying amounts of the derecognized assets, liabilities and non-controlling interest, value of common shares issued, and the fair value of the retained non-controlling interest in Canopy USA, being the equity method investment and the Canopy Elevate I LLC, Canopy Elevate II LLC and Canopy Elevate III LLC (collectively, “Elevate”) loan receivable. The gain on derecognition is reflected in other income (expense), net. Acreage Acquisition On December 9, 2024, Canopy USA completed the Acreage Acquisition and now owns 100% of the issued and outstanding shares of Acreage. In connection with: (i) the Existing Acreage Arrangement Agreement and the Acreage Amended Arrangement; and (ii) the Floating Share Arrangement Agreement, Canopy USA acquired all of the issued and outstanding Floating Shares of Acreage on the terms and conditions set forth in Floating Share Arrangement. Immediately following the implementation of the Floating Share Arrangement, Canopy USA acquired all

[illegible]

of the Company's balance sheet deleveraging initiatives, the Company entered into agreements with certain of its lenders under the Credit Agreement pursuant to which certain additional amendments were made to the Credit Agreement (the Credit Agreement, as amended as of July 13, 2023, is referred to herein as the "Amended Credit Agreement"). The Amended Credit Agreement required the Company to prepay or repurchase principal indebtedness under the Credit Facility in an amount equal to the US dollar equivalent of \$93,000 at a discounted price of US\$930 per US\$1,000 (the "July 2023 Paydown"). In addition, the Amended Credit Agreement requires the Company to apply certain net proceeds from asset sales to prepay or repurchase principal indebtedness under the Credit Facility and receive principal reductions at, in certain circumstances, a discounted price of US\$950 per US\$1,000. The Amended Credit Agreement also includes, among other things, amendments to the minimum liquidity covenant such that the US\$100,000 minimum liquidity covenant ceased to apply concurrently with the July 2023 Paydown. The Company made the July 2023 Paydown on July 21, 2023. On each of August 11, 2023 and September 14, 2023, pursuant to the terms of the Amended Credit Agreement, the Company repurchased additional outstanding principal amounts under the Credit Facility using certain net proceeds from completed asset sales (the "Second Quarter 2024 Paydowns"). The Second Quarter 2024 Paydowns resulted in an aggregate principal reduction of \$73,313 (US\$54,491) for a cash payment of \$69,647 (US\$51,766). On each of November 28, 2023 and December 27, 2023, pursuant to the terms of the Amended Credit Agreement, the Company repurchased and repaid, as applicable, additional outstanding principal amounts under the Credit Facility using certain net proceeds from completed asset sales (the "Third Quarter 2024 Paydowns"). The Third Quarter 2024 Paydowns resulted in an aggregate principal reduction of \$65,379 (US\$48,532) for a cash payment of \$63,167 (US\$46,902). On February 21, 2024, the Company repurchased additional outstanding principal amounts under the Credit Facility (the "Fourth Quarter 2024 Paydown"). The Fourth Quarter 2024 Paydown resulted in an aggregate principal reduction of \$31,078 (US\$23,000) for a cash payment of \$27,970 (US\$20,700). On April 29, 2024 and June 28, 2024, the Company repurchased additional outstanding principal amounts under the Credit Facility (the "First Quarter 2025 Paydowns"). The First Quarter 2025 Paydowns resulted in an aggregate principal reduction of \$11,159 (US\$8,165) for a cash payment of \$11,159 (US\$8,165). On August 8, 2024, the Company entered into an amendment (the "Amending Agreement") with all of the lenders to the Credit Facility under the Credit Agreement dated March 18, 2021, as amended on October 24, 2022 and July 13, 2023, among the Company and 11065220 Canada Inc., as borrowers, the lenders party thereto and Wilmington Trust, National Association, as administrative and collateral agent. Pursuant to the terms of the Amending Agreement, the maturity date of the Credit Facility was extended to December 18, 2026 and a mandatory US\$97,500 prepayment of the Credit Facility at 97.5% of par thereby reducing the outstanding amount of the Credit Facility by US\$100,000 was required to be made by December 31, 2024. In addition, the maturity date of the Credit Facility will be further extended to September 18, 2027 if an optional prepayment on the same terms is made on or before March 31, 2025. The Amending Agreement also includes changes to certain negative covenants, repayment provisions in the event of divestitures and events of default. Through August 8, 2024, the Credit Facility matured on March 18, 2026 and through December 26, 2023, had an interest rate of LIBOR + 8.50%. After August 8, 2024, the Credit Facility matures on December 18, 2026, and after December 26, 2023, interest on amounts outstanding under the Credit Facility is calculated at either the applicable prime rate plus 7.50% per annum, subject to a prime rate floor of 2.00%, or adjusted term SOFR plus 8.50% per annum, subject to an adjusted term SOFR floor of 1.00%. The Company's obligations under the Credit Facility are guaranteed by material wholly-owned Canadian and U.S. subsidiaries of the Company. The Credit Facility is secured by substantially all of the assets of the Company and its material wholly-owned Canadian and U.S. subsidiaries, including material real property. The Amended Credit Agreement contains representations and warranties, and affirmative and negative covenants. On September 27, 2024, the Company repurchased additional outstanding principal amounts under the Credit Facility (the "Second Quarter 2025 Paydown"). The Second Quarter 2025 Paydown resulted in an aggregate principal reduction of \$1,148 (US\$851) for a cash payment of \$1,148 (US\$851). In accordance with the Amending Agreement, on October 16, 2024, the Company made an early prepayment under its Credit Facility in an aggregate principal amount equal to US\$100,000 of the principal amount outstanding thereunder at a discounted price of US\$97,500 (the "Third Quarter 2025 Paydown"). The Third Quarter 2025 Paydown resulted in an aggregate principal reduction of \$137,710 (US\$100,000) for a cash payment of \$134,267 (US\$97,500). Promissory Note On April 13, 2023, the Company entered into an exchange agreement (the "April 2023 Exchange Agreement") with Greenstar Canada Investment Limited Partnership (the "Greenstar"), an affiliate of Constellation Brands, Inc. (the "CBI"), in order to acquire and cancel \$100,000 aggregate principal amount of the 4.25% unsecured senior notes due in 2023 (the "Canopy Notes"). Pursuant to the April 2023 Exchange Agreement, the Company agreed to acquire and cancel \$100,000 aggregate principal amount of the Canopy Notes held by Greenstar in exchange for: (i) a cash payment to Greenstar in the amount of the unpaid and accrued interest owing under the Canopy Notes held by Greenstar; and (ii) a promissory note (the "CBI Note") issuable to Greenstar in the aggregate amount of \$100,000 payable on December 31, 2024. The CBI Note bears interest at a rate of 4.25% per year, payable on maturity of the CBI Note. On April 18, 2024, the Company entered into an exchange agreement (the "April 2024 Exchange Agreement") with Greenstar, pursuant to which Greenstar converted approximately \$81,220 of the principal amount of the \$100,000 principal amount of the CBI Note into 9,111,549 exchangeable shares of the Company (the "Exchangeable Shares"), calculated based on a price per Exchangeable Share equal to \$8.91 (the "Note Exchange"). Pursuant to the terms of the April 2024 Exchange Agreement, all accrued but unpaid interest on the CBI Note together with the remaining principal amount of the CBI Note was cancelled and forgiven for no additional consideration by Greenstar. Following the closing of the Note Exchange, there is no outstanding balance owing under the CBI Note and the CBI Note has been cancelled. Supreme Cannabis Convertible Debentures and Accretion Debentures On October 19, 2018, The Supreme Cannabis Company, Inc. (the "Supreme Cannabis") entered into an indenture with Computershare Trust Company of Canada (the "Trustee") pursuant to which Supreme Cannabis issued 6.0% senior unsecured convertible debentures (the "Supreme Debentures") for gross proceeds of \$100,000. On September 9, 2020, Supreme Cannabis and the Trustee entered into a supplemental indenture to effect certain amendments to the Supreme Debentures, which included among other things: (i) the cancellation of \$63,500 of principal amount of the Supreme Debentures; (ii) an increase in the interest rate to 8% per annum; (iii) the extension of the maturity date to September 10, 2025; and (iv) a reduction in the conversion price to \$2.85. In addition, on September 9, 2020, Supreme Cannabis issued new senior unsecured non-convertible debentures (the "Accretion Debentures"). The principal amount began at \$nil and accreted at a rate of 11.06% per annum based on the remaining principal amount of the Supreme Debentures of \$36,500 to a maximum of \$13,500, compounding on a semi-annual basis commencing on September 9, 2020, and ending on September 9, 2023. As of September 9, 2023, the principal amount of the Accretion Debentures was finalized as \$10,434. The Accretion Debentures are payable in cash, but do not bear cash interest and are not convertible into the common shares of Supreme Cannabis (the "Supreme Shares"). The principal amount of the Accretion Debentures will amortize, or be paid, at 1.0% per month over the 24 months prior to maturity. As a result of the completion of an arrangement on June 22, 2021 by the Company and Supreme Cannabis, pursuant to which the Company acquired 100% of the issued and outstanding Supreme Shares (the "Supreme Arrangement"), the Supreme Debentures remain outstanding as securities of Supreme Cannabis, which, upon conversion will entitle the holder thereof to receive, in lieu of the number of Supreme Shares to which such holder was theretofore entitled, the consideration payable under the Supreme Arrangement that such holder would have been entitled to be issued and receive if, immediately prior to the effective time of the Supreme Arrangement, such holder had been the registered holder of the number of Supreme Shares to which such holder was theretofore entitled. In connection with the Supreme Arrangement, the Company, Supreme Cannabis and the Trustee entered into a supplemental indenture whereby the Company agreed to issue common shares upon conversion of any Supreme Debenture. In addition, the Company may force conversion of the Supreme Debentures outstanding with 30 days' notice if the daily volume weighted average trading price of the Company's common shares is greater than \$385.90 for any 10 consecutive trading days. The Company, Supreme Cannabis and the Trustee entered into a further supplemental indenture whereby the Company agreed to guarantee the obligations of Supreme Cannabis pursuant to the Supreme Debentures and the Accretion Debentures. Prior to September 9, 2023, the Supreme Debentures were not redeemable. Beginning on and after September 9, 2023, Supreme Cannabis may from time to time, upon providing 60 days prior written notice to the Trustee, redeem the Supreme Debentures outstanding, provided that the Accretion Debentures have already been redeemed in full. During the three and nine months ended December 31, 2024, principal payments on Accretion Debentures totaled \$530 and \$1,207, respectively, and approximately \$nil and \$30,227, respectively, of aggregate principal amount of outstanding Supreme Debentures and Accretion Debentures were settled through the August 2024 Supreme Convertible Debt Exchange (as defined below) and the Exchange and Subscription Agreement (as defined below). On August 20, 2024, the Company entered into an exchange and subscription agreement (the "August 2024 Supreme Convertible Debt Exchange") with a single institutional investor (the "August 2024 Investor") pursuant to which, among other things, the August 2024 Investor delivered to the Company approximately \$2,664 of aggregate principal amount of outstanding Supreme Debentures held by the August 2024 Investor in exchange for 291,351 common shares of the Company and \$29 in cash for accrued interest. May 2024 Convertible Debenture On May 2, 2024, the Company entered into an exchange and subscription agreement (the "Exchange and Subscription Agreement") with a single institutional investor (the "May 2024 Investor") pursuant to which, among other things, the May 2024 Investor delivered to the Company approximately \$27,563 aggregate principal amount of outstanding Supreme Debentures and Accretion Debentures held by the May 2024 Investor and paid the Company \$68,255 (US\$50,000) in exchange for the Company issuing to the May 2024 Investor (i) a new senior unsecured convertible debenture of the Company (the "May 2024 Convertible Debenture") with an aggregate principal amount of \$96,358 maturing five years from the closing date (the "Closing Date") of the transaction and (ii) 3,350,430 common share purchase warrants (the "May 2024 Investor Warrants") of the Company. Each May 2024 Investor Warrant entitles the holder to acquire one Canopy Growth common share at an exercise price equal to \$16.18 per Canopy Growth common share for a period of five years from the Closing Date. The May 2024 Convertible Debenture bears interest at a rate of 7.50% per annum, payable in semi-annual payments in cash or, at the option of the Company, in Canopy Growth common shares for the first four semi-annual interest payments after the Closing Date, subject to satisfaction of certain conditions, including the prior approval of the TSX. The May 2024 Convertible Debenture is convertible into Canopy Growth common shares at the option of the May 2024 Investor at a conversion price equal to \$14.38 per share. The May 2024 Convertible Debenture is subject to a forced conversion feature upon notice from the Company in the event that the average closing trading price of the Canopy Growth common shares on the TSX exceeds \$21.57 for a period of 10 consecutive trading days. In addition, pursuant to the terms of the May 2024 Convertible Debenture, for so long as the principal amount under the May 2024 Convertible Debenture remains outstanding (the "Debenture ROFR Term"), the Company granted the May 2024 Investor a right of first refusal to subscribe for, and to be issued, as an investor in any debt or equity financing that the Company wishes to complete during the Debenture ROFR Term (the "Proposed Financing"); provided, however, that the May 2024 Investor shall subscribe for 25% of the Proposed Financing on the same terms and conditions contemplated in the Proposed Financing. X - References No definition available. + Details Name: us-gaap DebtDisclosureAbstract Namespace Prefix: us-gaap Data Type: xbrl:stringItem Type Balance Type: na Period Type: duration X - Definition The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants. + References Reference 1: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6Reference 2:](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6Reference 2:) [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 405 -SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph \(d\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 405 -SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph \(a\)\(1\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 405 -SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph \(h\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.4-08\(c\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 470 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/470/tableOfContentReference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph \(g\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph \(i\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1C -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1CReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1C -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1CReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1C -Subparagraph \(c\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1CReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1I -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1IReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1I -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1IReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1I -Subparagraph \(d\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I + Details Name: us-gaap DebtDisclosureTextBlock Namespace Prefix: us-gaap Data Type: dtr-types:textBlock Item Type Balance Type: na Period Type: duration XML 34 R27.htm IDEA: XBRL DOCUMENT v3.25.01 Other Liabilities 9 Months Ended Dec. 31, 2024 Other Liabilities Disclosure \[Abstract\] A Other Liabilities 18. OTHER LIABILITIES The components of other liabilities are as follows: A As at December 31, 2024 A As at March 31, 2024 A As at Current A Long-term A Total A Current A Long-term A Total A Lease liabilities A \\$ 18,579 A \\$ 29,524 A \\$ 48,103 A \\$ 15,173 A \\$ 55,597 A \\$ 70,770 Acquisition consideration A A and other investment A A related liabilities A A A 4,265 A A 4,265 A A 12,809 A A 10,558 A A 23,367 Refund liability A 2,727 A A - A A 2,727 A A 4,169 A A - A A 4,169 A Settlement liabilities and A A other A 6,434 A A 3,355 A A 9,969 A A 15,917 A A 5,659 A A 21,576 A A 27,740 A A 37,324 A A 65,064 A A \\$ 71,814 A A \\$ 119,882 A In December 2024, the Company renegotiated the terms of a facility lease, resulting in a short-term to long-term reclassification of its lease liabilities. The renegotiated terms result in changes to future cashflows associated with the lease. X - References No definition available. + Details Name: us-gaap OtherLiabilitiesDisclosureAbstract Namespace Prefix: us-gaap Data Type: xbrl:stringItem Type Balance Type: na Period Type: duration X - Definition The entire disclosure for other liabilities. + References Reference 1: \[http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \\(SX 210.5-02\\(20\\)\\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -\]\(http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(20\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -\)](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 405 -SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 405 -SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1Reference 5:)

Paragraph 1 - Subparagraph (SX 210.5-02(24)) - Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef - Topic 405 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/405/tableOfContent + Details Name: us-gaap OtherLiabilitiesDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 35 R28.htm IDEA: XBRL DOCUMENT v.325.0.1 Share Capital 9 Months Ended Dec. 31, 2024 Equity [Abstract] A Share Capital 19. SHARE CAPITALCANOPY GROWTHAuthorizedAn unlimited number of common shares.(i) Equity financingsOn June 6, 2024, the Company established an at-the-market equity program that allows it to sell up to US\$250,000 of common shares of the Company from treasury to the public from time to time at the Company's discretion (the "ATM Program"). The ATM Program will be effective until the earlier of (i) the issuance and sale of all of the common shares issuable pursuant to the ATM Program (ii) the date on which the Company receives notice from a securities regulatory authority that the Company's Canadian short form base shelf prospectus dated June 5, 2024 and/or the Company's registration statement on Form S-3ASR has ceased to be effective and (iii) July 5, 2026, unless terminated earlier in accordance with the terms of the equity distribution agreement entered into between the Company and BMO Nesbitt Burns Inc., as Canadian agent, and BMO Capital Markets Corp., as U.S. agent. As part of the ATM Program, during the three and nine months ended December 31, 2024, the Company sold 22,713,177 and 39,519,029 common shares, respectively, for gross proceeds of \$117,513 and \$255,989, respectively. Refer to Note 30 for additional information on common shares sold after December 31, 2024 as part of the ATM Program.For the three and nine months ended December 31, 2023, the Company issued nil and 2,292,947 common shares, respectively, for aggregate gross proceeds of \$nil and \$33,745, respectively, relating to the private placement unit offering completed by the Company pursuant to the terms of the subscription agreements entered into between the Company and certain institutional investors on September 18, 2023.(ii) Other issuances of common shares and share capital transactionsDuring the nine months ended December 31, 2024, the Company had the following other issuances and share capital transactions: A Number of common shares A Sharecapital A Share andwarrantreserve A Settlement of Acreage Acquisition A 12,559,230 A \$ 63,915 A \$ 11,939 A Other issuances and share issue costs A - A (6,567) A A Total A 12,559,230 A \$ 57,348 A \$ 11,939 A During the nine months ended December 31, 2023, the Company had the following other issuances and share capital transactions: A Number of common shares A Sharecapital A Sharebasedreserve A Settlement of convertible debentures A 8,445,894 A \$ 108,055 A \$ - A Settlement of Canopy Notes A 11,477,366 A \$ 57,084 A A Settlement of debentures A 7,341,818 A \$ 87,754 A A Other issuances and share issue costs A 6,165 A A (317) A (80) Total A 27,271,243 A \$ 252,576 A \$ (80) (iii) Warrants A Number ofwholewarrants A Averageexerciseprice A Warrantvalue A Balance outstanding at March 31, 2024 A 10,451,457 A \$ 9.12 A \$ 2,610,519 A Issuance of warrants A 4,548,088 A A 13.31 A A 13.525 A Issuance of replacement warrants resulting from the Acreage Acquisition A 1,845,843 A A 10.72 A A 7,111 A Exercise of warrants A (1,279,660) A A 6.60 A A (3,018) Balance outstanding at December 31, 2024 A 15,565,728 A \$ 11.09 A \$ 2,628,137 A A Number ofwholewarrants A Averageexerciseprice A Warrantvalue A Balance outstanding at March 31, 2023 A 12,819,305 A \$ 580.40 A \$ 2,581,788 A Issuance of warrants from private placement A 2,292,947 A A 18.33 A A 8,977 A Expiry of Warrants A (12,692,731) A 583.62 A A Balance outstanding at December 31, 2023 A 2,419,521 A \$ 30.34 A \$ 2,590,765 A 1 This balance excludes warrants previously issued by the Company to CBG (as defined below) which were exercisable to acquire 1,281,815 common shares at an exercise price equal to the 5-day volume-weighted average price of the Company common shares immediately prior to exercise (the "Tranche C Warrants"). The Tranche C Warrants represent a derivative liability and have nominal value. As of November 1, 2023, the Tranche C Warrants are considered expired in accordance with their terms.(iv) Issuances of exchangeable sharesOn April 18, 2024, Greenstar and CBG Holdings LLC (the "CBG"), indirect, wholly-owned subsidiaries of CBI exchanged all 17,149,925 Canopy Growth common shares they collectively held for 17,149,925 Exchangeable Shares for no consideration. In addition, an additional 9,111,549 Exchangeable Shares were issued to Greenstar as part of the Note Exchange. The Exchangeable Shares are convertible at any time, at the option of the holder, into Canopy Growth common shares on a one for one basis. See Note 17 for additional details relating to the Note Exchange. X - ReferencesNo definition available. + Details Name: us-gaap EquityAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for equity. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 235 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 235 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-6Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480237/815-40-50-6Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 599 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-599-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section 599 -Paragraph 1 -Subparagraph (SX 210.4-08(e)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-599-1Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/505/tableOfContentReference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 16 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-16Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18 + Details Name: us-gaap StockholdersEquityNoteDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 36 R29.htm IDEA: XBRL DOCUMENT v.325.0.1 Share-Based Compensation 9 Months Ended Dec. 31, 2024 Share-Based Payment Arrangement [Abstract] A Share-Based Compensation 20. SHARE-BASED COMPENSATIONA CANOPY GROWTH CORPORATION SHARE-BASED COMPENSATION PLANOn September 25, 2023, the Company's shareholders approved a new Omnibus Equity Incentive Plan (the "Omnibus Equity Incentive Plan") pursuant to which the Company can issue share-based long-term incentives. The Omnibus Equity Incentive Plan replaces the Company's previous equity incentive plan, which was originally approved by the Company's shareholders on July 30, 2018 (the "Previous Equity Incentive Plan", together with the Omnibus Equity Incentive Plan, the "Incentive Plans"). The approval of the Omnibus Equity Incentive Plan and replacement of the Previous Equity Incentive Plan are detailed in the Company's definitive proxy statement filed with the Securities and Exchange Commission on August 9, 2023.All directors, employees and consultants of the Company are eligible to receive awards of common share purchase options (the "Options"), restricted share units (the "RSUs"), deferred share units or shares-based awards (collectively, the "Awards") under the Omnibus Equity Incentive Plan, subject to certain limitations. The Omnibus Equity Incentive Plan allows for a maximum term of each Option to be ten years from the date of grant and the maximum number of common shares available for issuance under the Omnibus Equity Incentive Plan remains at 10% of the issued and outstanding common shares from time to time, less the number of common shares issuable pursuant to other security-based compensation arrangements of the Company (including common shares reserved for issuance under the Previous Equity Incentive Plan).The Omnibus Equity Incentive Plan was adopted on September 25, 2023. No further awards will be granted under the Previous Equity Incentive Plan and any new Awards will be issued by the Company pursuant to the terms of the Omnibus Equity Incentive Plan. However, outstanding and unvested awards granted under the Previous Equity Incentive Plan will continue to be governed in accordance with the terms of such plan.The maximum number of common shares reserved for issuance upon the exercise or vesting, as applicable, of Awards granted pursuant to the Incentive Plans is 12,915,301 as at December 31, 2024. As of December 31, 2024, the only Awards issued have been Options, RSUs and performance share units (the "PSUs") under the Previous Equity Incentive Plan, and Options and RSUs under the Omnibus Equity Incentive Plan.The Omnibus Equity Incentive Plan is administered by the Corporate Governance, Compensation and Nominating Committee of the Board, which establishes in its discretion, among other things, exercise prices, at not less than the Fair Market Value (as defined in the Omnibus Equity Incentive Plan) at the date of grant, vesting terms and expiry dates (set at up to ten years from issuance) for Awards, subject to the limits contained in the Omnibus Equity Incentive Plan.The following is a summary of the changes in the Options outstanding during the nine months ended December 31, 2024: A Optionsissued A Weightedaverageexercise price A Balance outstanding at March 31, 2024 A 2,883,922 A \$ 70.01 A Options granted A 765,107 A A 10.37 A Replacement options issued resulting from the Acreage Acquisition A 93,383 A A 85.67 A Options exercised A (18,621) A A 6.05 A Options expired/forfeited A (243,483) A A 226.05 A Balance outstanding at December 31, 2024 A 3,480,308 A A 37.84 A The following is a summary of the Options outstanding as at December 31, 2024: A Options Outstanding A Options Exercisable A A A Weighted Average A A A Weighted Average A A A Remaining A A A Remaining A A Outstanding at A Contractual Life A Exercisable at A Contractual Life A Range of Exercise Prices A December 31, 2024 A (years) A December 31, 2024 A (years) A \$0.60A - \$7.50 A 2,030,678 A A 4.50 A A 668,981 A A 4.50 A \$7.51A - \$56.10 A 1,040,200 A A 4.96 A A 183,390 A A 3.64 A \$56.11A - \$585.10 A 409,430 A A 1.08 A A 301,556 A A 1.16 A A 3,480,308 A A 4.32 A A 1,153,927 A A 3.69 A 1 Prior period Options and exercise price amounts have been retrospectively adjusted to reflect the Share Consolidation, which became effective on December 15, 2023. See Note 2 for details.At December 31, 2024, the weighted average exercise price of the Options outstanding and Options exercisable was \$37.84 and \$75.56, respectively (March 31, 2024 " \$70.01 and \$312.68, respectively).The Company recorded \$3,262 and \$9,484 in share-based compensation expense related to Options issued to employees and contractors for the three and nine months ended December 31, 2024, respectively (three and nine months ended December 31, 2023 " \$2,671 and \$7,637, respectively). The share-based compensation expense for the nine months ended December 31, 2024, includes an amount related to 107,874 Options being provided in exchange for services which are subject to performance conditions (for the nine months ended December 31, 2023 " 107,874).The Company uses the Black-Scholes option pricing model to establish the fair value of Options granted during the three months ended December 31, 2024 and 2023, on their measurement date by applying the following assumptions: A December 31, A December 31, A 2024 A 2023 Risk-free interest rate A - 3.95% Expected life of options (years) A - 3A - 5 Expected volatility A - 101% Expected forfeiture rate A - 21% Expected dividend yield A - nil Black-Scholes value of each Option A - \$5.33 Volatility was estimated by using the historical volatility of the Company. The expected life in years represents the period of time that Options granted are expected to be outstanding. The risk-free rate was based on zero coupon Canada government bonds with a remaining term equal to the expected life of the Options.For the three and nine months ended December 31, 2024, the Company recorded \$1,897 and \$5,047, respectively, in share-based compensation expense related to RSUs and PSUs (for the three and nine months ended December 31, 2023 " \$1,022 and \$2,490, respectively).The following is a summary of the changes in the Company's RSUs and PSUs during the nine months ended December 31, 2024: A Number of RSUsand PSUs A Balance outstanding at March 31, 2024 A 1,272,299 A RSUs and PSUs granted A 720,873 A Replacement RSUs issued resulting from the Acreage Acquisition A 6,627 A RSUs and PSUs released A (433,268) RSUs and PSUs cancelled and forfeited A (130,257) Balance outstanding at December 31, 2024 A 1,436,274 A X - DefinitionThe entire disclosure for share-based payment arrangement. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/718/tableOfContentReference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (l) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap DisclosureOfCompensationRelatedCostsShareBasedPaymentsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 37 R30.htm IDEA: XBRL DOCUMENT v.325.0.1 Accumulated Other Comprehensive Income (Loss) 9 Months Ended Dec. 31, 2024 Equity [Abstract] A Accumulated Other Comprehensive Income (Loss) 21. ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS)Accumulated other comprehensive income includes the following components: A A Foreign currency translation adjustments A Changes of own credit risk of financial liabilities A Accumulated other comprehensive income (loss) A As at March 31, 2024 A \$ (31,178) A \$ 15,127 A \$ (16,051) Disposal and liquidation of consolidated entities A 18,593 A A - A A 18,593 A Extinguishment of promissory note and issuance of exchangeable shares A - A A (15,127) A (15,127) Other comprehensive income A 3,586 A A - A A 3,586 A As at December 31, 2024 A \$ (8,999) A \$ - A A (8,999) A A Foreign currency translation adjustments A Changes of own credit risk of financial liabilities A Accumulated other comprehensive income (loss) A As at March 31, 2023 A \$ (30,261) A \$ 16,401 A A (13,860) Settlement of unsecured senior notes, net of deferred income tax A - A A 11,060 A A 11,060 A Other comprehensive income (loss) A 575 A A (13,824) A (13,249) As at December 31, 2023 A \$ (29,686) A \$ 13,637 A A (16,049) X - DefinitionThe entire disclosure for comprehensive income, which includes, but is not limited to, 1) the amount of income tax expense or benefit allocated to each component of other comprehensive income, including reclassification adjustments, 2) the reclassification adjustments for each classification of other comprehensive income and 3) the ending accumulated balances for each component of comprehensive income. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section 599 -Paragraph 1 -Subparagraph (SX 210.7-04(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-599-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 599 -Paragraph 2 -Subparagraph (SX 210.5-03(21)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-599-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section 599 -Paragraph 1 -Subparagraph (SX 210.9-04(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-599-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/220/tableOfContent + Details Name: us-gaap ComprehensiveIncomeNoteTextBlock Namespace

Prefix: us-gaap Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_EquityAbstract Namespace Prefix: us-gaap Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 38 R31.htm IDEA: XBRL DOCUMENT v3.25.0.1 Noncontrolling Interests 9 Months Ended Dec. 31, 2024 Noncontrolling Interest [Abstract] A Noncontrolling Interests 22. NONCONTROLLING INTERESTSThe net change in the noncontrolling interests is as follows: A A Other A A Total A As at March 31, 2024 A A \$ 139 A A \$ 139 A Comprehensive income (loss) A A - A A A - A Canopy USA Transaction A A (139) A A (139) A As at December 31, 2024 A A \$ - A A \$ - A A A BioSteel A A Other A A Total A As at March 31, 2023 A A \$ 1,447 A A \$ 140 A A \$ 1,587 A Comprehensive loss A A (18,526) A A - A A (18,526) Net loss attributable to redeemable noncontrolling interest A A 18,526 A A - A A 18,526 A Share-based compensation A A 148 A A - A A 148 A Ownership changes A A (1,595) A A (1) A A (1,596) A As at December 31, 2023 A A \$ - A A \$ 139 A A \$ 139 A X - DefinitionThe entire disclosure for noncontrolling interest in consolidated subsidiaries, which could include the name of the subsidiary, the ownership percentage held by the parent, the ownership percentage held by the noncontrolling owners, the amount of the noncontrolling interest, the location of this amount on the balance sheet (when not reported separately), an explanation of the increase or decrease in the amount of the noncontrolling interest, the noncontrolling interest share of the net income or loss of the subsidiary, the location of this amount on the income statement (when not reported separately), the nature of the noncontrolling interest such as background information and terms, the amount of the noncontrolling interest represented by preferred stock, a description of the preferred stock, and the dividend requirements of the preferred stock. + ReferencesReference 1:

Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 231 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12C -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12B -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12BReference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 270 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477891/740-270-50-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 6.1.5.Q1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480990/946-20-50-13Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(h)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/740/tableOfContentReference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-14Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 21 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-21Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 17 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 11.C) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-2Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482603/740-30-50-2 + Details Name: us-gaap IncomeTaxDisclosureTextBlock Namespace Prefix: us-gaap Data Type: dtr-types:textBlockItem Type: Balance Type: na Period Type: duration XML 43 R36.htm IDEA: XBRL DOCUMENT v3.25.0.1 Acreage Arrangement 9 Months Ended Dec. 31, 2024 Business Combinations [Abstract] A Acreage Arrangement 27. ACREAGE ARRANGEMENT On December 9, 2024, Canopy USA completed the Acreage Acquisition and now owns 100% of the issued and outstanding shares of Acreage. In connection with: (i) the Existing Acreage Arrangement Agreement and the amended and restated plan of arrangement (the “Acreage Amended Arrangement”) implemented by Canopy Growth and Acreage on September 23, 2020 in connection with the Existing Acreage Arrangement Agreement; and (ii) the Floating Share Arrangement Agreement, Canopy USA acquired all of the issued and outstanding Floating Shares of Acreage on the terms and conditions set forth in Floating Share Arrangement. Immediately following the implementation of the Floating Share Arrangement, Canopy USA completed the Fixed Share Acquisition. In aggregate, Canopy Growth issued 5,888,291 common shares to former shareholders of Acreage. Pursuant to the Floating Share Arrangement, (i) each outstanding stock option to acquire Floating Shares was exchanged for a replacement option exercisable for Canopy Growth common shares, with the number of underlying Canopy Growth common shares and exercise price of such options adjusted by the Floating Share Exchange Ratio; (ii) each outstanding warrant to acquire Floating Shares was exchanged for a replacement warrant to acquire Canopy Growth common shares, with the number of underlying Canopy Growth common shares and exercise price of such warrants adjusted by the Floating Share Exchange Ratio; and (iii) each outstanding restricted share unit, performance share and performance unit, as applicable, that vested into Floating Shares was exchanged for a replacement restricted share unit, performance share or performance unit, as applicable, that vests into Canopy Growth common shares, with the number of underlying Canopy Growth common shares adjusted by the Floating Share Exchange Ratio. In connection with the Fixed Share Acquisition, (i) each outstanding stock option to acquire Fixed Shares was exchanged for a replacement option exercisable for Canopy Growth common shares, with the number of underlying Canopy Growth common shares and exercise price of such options adjusted by the Fixed Share Exchange Ratio; (ii) each outstanding warrant to acquire Fixed Shares was exchanged for a replacement warrant to acquire Canopy Growth common shares, with the number of underlying Canopy Growth common shares and exercise price of such warrants adjusted by the Fixed Share Exchange Ratio; and (iii) each restricted share unit and performance share unit, as applicable, that vested into Fixed Shares was exchanged for a replacement restricted share unit or performance share unit, as applicable, that vests into Canopy Growth common shares, with the number of underlying Canopy Growth common shares adjusted by the Fixed Share Exchange Ratio. See Note 3 for information regarding the Reorganization. In connection with the Reorganization and the Floating Share Arrangement Agreement, Canopy Growth irrevocably waived the Acreage Floating Option. Following the implementation of the Reorganization, Canopy USA, holds certain U.S. cannabis investments previously held by the Company, which enabled Canopy USA to consummate the acquisition of Acreage. See Note 3 for more details related to the Acreage Acquisition. X - Definition The entire disclosure for acreage. + References No definition available. + Details Name: cgc AcreageDisclosureTextBlock Namespace Prefix: cgc Data Type: dtr-types:textBlockItem Type: Balance Type: na Period Type: duration X - References No definition available. + Details Name: us-gaap BusinessCombinationsAbstract Namespace Prefix: us-gaap Data Type: xbrli:stringItem Type: Balance Type: na Period Type: duration XML 44 R37.htm IDEA: XBRL DOCUMENT v3.25.0.1 Commitments and Contingencies 9 Months Ended Dec. 31, 2024 Commitments and Contingencies Disclosure [Abstract] A Commitments and Contingencies 28. COMMITMENTS AND CONTINGENCIES Legal proceedings In the ordinary course of business, the Company is at times subject to various legal proceedings and disputes, including the proceedings specifically discussed below. The Company assesses the liabilities and contingencies in connection with outstanding legal proceedings utilizing the latest information available. Where it is probable that the Company will incur a loss and the amount of the loss can be reasonably estimated, a liability is recorded in the consolidated financial statements. Where a loss is only reasonably possible or the amount of the loss cannot be reasonably estimated, no liability is recorded in the consolidated financial statements, but disclosures, as necessary, are provided. For the three months ended December 31, 2024 there have been no material changes with respect to provisions relating to legal proceedings for the Company. X - References No definition available. + Details Name: us-gaap CommitmentsAndContingenciesDisclosureAbstract Namespace Prefix: us-gaap Data Type: xbrli:stringItem Type: Balance Type: na Period Type: duration X - Definition The entire disclosure for commitments and contingencies. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 405 -SubTopic 30 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/405-30/tableOfContentReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 440 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 450 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/450/tableOfContentReference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 954 -SubTopic 440 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478522/954-440-50-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 440 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 440 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/440/tableOfContent + Details Name: us-gaap CommitmentsAndContingenciesDisclosureTextBlock Namespace Prefix: us-gaap Data Type: dtr-types:textBlockItem Type: Balance Type: na Period Type: duration XML 45 R38.htm IDEA: XBRL DOCUMENT v3.25.0.1 Segment Information 9 Months Ended Dec. 31, 2024 Segment Reporting [Abstract] A Segment Information 29. SEGMENT INFORMATION Reportable segments The Company reports its financial results for the following four reportable segments: “Canada cannabis” includes the production, distribution and sale of a diverse range of cannabis, hemp and cannabis-related products in Canada pursuant to the Cannabis Act and cannabis-related areas such as merchandise and clinics; “International markets cannabis” includes the production, distribution and sale of a diverse range of cannabis and hemp products internationally pursuant to applicable international legislation, regulations and permits. Priority markets include medical cannabis in Australia and Europe where the Company offers branded high-quality flower, oil and extract products under the Company’s recognized Spectrum Therapeutics, Canopy Medical and Tweed brands, as well as the Company’s Storz & Bickel line of medically approved vaporizers in Australia; “Storz & Bickel” includes the production, distribution and sale of vaporizers and accessories; and “This Works” includes the production, distribution and sale of beauty, skincare, wellness and sleep products, some of which have been blended with hemp-derived CBD isolate. On December 18, 2023, the Company completed the sale of This Works and as of such date, the results of This Works are no longer included in the Company’s financial results. These segments reflect how the Company’s operations are managed, how the Company’s Chief Executive Officer, who is the Chief Operating Decision Maker (“CODM”), allocates resources and evaluates performance, and how the Company’s internal management financial reporting is structured. The Company’s CODM evaluates the performance of these segments, with a focus on (i) segment net revenue, and (ii) segment gross margin as the measure of segment profit or loss. The remainder of the Company’s operations include revenue derived from, and cost of sales associated with, the Company’s non-cannabis extraction activities and other ancillary activities; these are included within “other.” A Three months ended A Nine months ended A A December 31, A A December 31, A A December 31, A A December 31, A A 2024 A A 2023 A A 2024 A A 2023 A Segmented net revenue A A A A A A A A A A Canada cannabis A \$ 40,728 A A \$ 40,384 A A \$ 115,483 A A \$ 120,543 A International markets cannabis A \$ 12,024 A A \$ 10,527 A A \$ 32,166 A A \$ 29,666 A Storz & Bickel A \$ 22,009 A A \$ 18,453 A A \$ 56,315 A A \$ 48,517 A This Works A - A \$ 8,165 A A \$ 21,256 A Other A - A \$ 976 A A - A \$ 4,376 A A \$ 74,761 A A \$ 78,505 A A \$ 203,964 A A \$ 224,358 A Segmented gross margin: A A A A A A A A A A A A A A A A \$ 11,306 A A \$ 34,225 A A \$ 25,340 A International markets cannabis A \$ 4,932 A A \$ 4,192 A A \$ 13,297 A A \$ 10,364 A Storz & Bickel A \$ 8,985 A A \$ 9,449 A A \$ 21,445 A A \$ 21,074 A This Works A - A \$ 4,253 A A - A \$ 10,534 A Other A - A \$ (974) A A - A \$ (1,898) A A \$ 24,098 A A \$ 28,226 A A \$ 68,967 A A \$ 65,414 A Selling, general and administrative expenses A \$ 41,476 A A \$ 54,436 A A \$ 131,174 A A \$ 174,810 A Share-based compensation A \$ 5,159 A A \$ 3,693 A A \$ 14,531 A A \$ 10,127 A Loss on asset impairment and restructuring A \$ 1,285 A A \$ 30,413 A A \$ 22,135 A A \$ 2,452 A Operating loss from continuing operations A \$ (23,822) A A \$ (60,316) A A \$ (98,873) A A \$ (121,975) A Other income (expense), net A \$ (97,758) A A \$ (171,037) A A \$ (276,952) A A \$ (253,270) Loss from continuing operations before income taxes A \$ (121,580) A A \$ (231,353) A A \$ (375,825) A A \$ (375,245) Asset information by segment is not provided to, or reviewed by, the Company’s CODM as it is not used to make strategic decisions, allocate resources, or assess performance. Entity-wide disclosures Disaggregation of net revenue by geographic area: A Three months ended A Nine months ended A A December 31, A A December 31, A A December 31, A A December 31, A A 2024 A A 2023 A A 2024 A A 2023 A Canada A \$ 40,728 A A \$ 41,024 A A \$ 115,483 A A \$ 123,724 A Germany A \$ 17,735 A A \$ 13,460 A A \$ 47,455 A A \$ 35,287 A United States A \$ 11,560 A A \$ 10,334 A A \$ 27,515 A A \$ 28,102 A Other A \$ 4,738 A A \$ 13,687 A A \$ 13,511 A A \$ 37,245 A A \$ 74,761 A A \$ 78,505 A A \$ 203,964 A A \$ 224,358 A Disaggregation of property, plant and equipment by geographic area: A A December 31, A A March 31, A A 2024 A A 2024 A Canada A \$ 247,414 A A \$ 266,086 A Germany A \$ 51,030 A A \$ 50,527 A Other A \$ 1,160 A A \$ 3,490 A A \$ 299,604 A A \$ 320,103 A For the three months ended December 31, 2024, one customer represented more than 10% of the Company’s net revenue (three months ended December 31, 2023 “æ” one). For the nine months ended December 31, 2024, one customer represented more than 10% of the Company’s net revenue (nine months ended December 31, 2023 “æ” one). X - References No definition available. + Details Name: us-gaap SegmentReportingAbstract Namespace Prefix: us-gaap Data Type: xbrli:stringItem Type: Balance Type: na Period Type: duration X - Definition The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it’s reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments. + References Reference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 54 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54Reference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 47 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47Reference 8: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 54 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54Reference 9: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 47 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47Reference 10: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 54 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54Reference 11: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 47 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 34 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-34Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 26C -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26CReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 26B -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26BReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-15Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/280/tableOfContentReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 26 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 21 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 21 -Subparagraph (b) -Publisher FASB -URI

https://asc.fasb.org/1943274/2147482810/280-10-50-21Reference 25:

gain on deconsolidation of \$12,417 and loss on deconsolidation of \$9,820, respectively). The assets and liabilities related to the BioSteel Entities business units are classified as discontinued operations and the major categories are as follows: A A December 31, A A March 31, A A 2024 A A 2024 A Receivable from BioSteel Entities A \$ - A A \$ 8,038 A Total assets of discontinued operations A \$ - A A \$ 8,038 A A A A A A Total liabilities of discontinued operations A \$ - A A \$ - A Canopy USA A Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] A Summary of Derecognized Assets and Liabilities Transferred The deconsolidation of Canopy USA from the financial results of Canopy Growth resulted in the derecognition of the following assets and liabilities: Cash A \$ 6,968 A Other financial assets A A 386,045 A Other assets A A 1,315 A Other liabilities A A (20,067) Cumulative translation adjustment A A 10,398 A Net assets disposed A \$ 384,659 A A A A Derecognition of non-controlling interest in Canopy USA A A 139 A A A A Equity method investment A \$ 227,119 A Elevate loan receivable A A 174,864 A Total retained non-controlling interest in the former subsidiaries A \$ 401,983 A A A A Issuance of common shares A \$ (12,452) A A A Consideration received in cash A \$ - A Total consideration A \$ - A A A A Gain on disposal of consolidated entity A \$ 5,011 A X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems Namespace Prefix: us-gaap_Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of information related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef-NameAccountingStandardsCodification-Section50-Paragraph3-SubTopic10-Topic360-PublisherFASB-URI> <https://asc.fasb.org/1943274/2147482099/360-10-50-3>Reference 2: <http://fasb.org/us-gaap/role/ref/legacyRef-Topic205-SubTopic20-NameAccountingStandardsCodification-Section45-Paragraph11-PublisherFASB-URI> <https://asc.fasb.org/1943274/2147483475/205-20-45-11>Reference 3: <http://fasb.org/us-gaap/role/ref/legacyRef-Topic205-SubTopic20-NameAccountingStandardsCodification-Section50-Paragraph3A-PublisherFASB-URI> <https://asc.fasb.org/1943274/2147483499/205-20-50-3A>Reference 4: <http://fasb.org/us-gaap/role/ref/legacyRef-Topic205-SubTopic20-NameAccountingStandardsCodification-Section50-Paragraph4A-PublisherFASB-URI> <https://asc.fasb.org/1943274/2147483499/205-20-50-4A>Reference 5: <http://fasb.org/us-gaap/role/ref/legacyRef-Topic205-SubTopic20-NameAccountingStandardsCodification-Section50-Paragraph4B-PublisherFASB-URI> <https://asc.fasb.org/1943274/2147483499/205-20-50-4B>Reference 6: <http://fasb.org/us-gaap/role/ref/legacyRef-Topic205-SubTopic20-NameAccountingStandardsCodification-Section50-Paragraph5A-PublisherFASB-URI> <https://asc.fasb.org/1943274/2147483499/205-20-50-5A>Reference 7: <http://fasb.org/us-gaap/role/ref/legacyRef-Topic205-SubTopic20-NameAccountingStandardsCodification-Section50-Paragraph5B-PublisherFASB-URI> <https://asc.fasb.org/1943274/2147483499/205-20-50-5B>Reference 8: <http://fasb.org/us-gaap/role/ref/legacyRef-Topic205-SubTopic20-NameAccountingStandardsCodification-Section50-Paragraph5C-PublisherFASB-URI> <https://asc.fasb.org/1943274/2147483499/205-20-50-5C>Reference 9: <http://fasb.org/us-gaap/role/ref/legacyRef-Topic205-SubTopic20-NameAccountingStandardsCodification-Section50-Paragraph5D-PublisherFASB-URI> <https://asc.fasb.org/1943274/2147483499/205-20-50-5D>Reference 10: <http://fasb.org/us-gaap/role/ref/legacyRef-Topic205-SubTopic20-NameAccountingStandardsCodification-Section50-Paragraph7-PublisherFASB-URI> <https://asc.fasb.org/1943274/2147483499/205-20-50-7>Reference 11: <http://fasb.org/us-gaap/role/ref/legacyRef-Topic360-SubTopic10-NameAccountingStandardsCodification-Section50-Paragraph3A-PublisherFASB-URI> <https://asc.fasb.org/1943274/2147482099/360-10-50-3A>Reference 12: <http://fasb.org/us-gaap/role/ref/legacyRef-NameAccountingStandardsCodification-Section50-Paragraph1-SubTopic20-Topic205-PublisherFASB-URI> <https://asc.fasb.org/1943274/2147483499/205-20-50-1>Reference 13: <http://fasb.org/us-gaap/role/ref/legacyRef-NameAccountingStandardsCodification-Topic205-SubTopic20-Section50-Paragraph3-PublisherFASB-URI> <https://asc.fasb.org/1943274/2147483499/205-20-50-3> + Details Name: us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock Namespace Prefix: us-gaap_Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=cgc_CanopyUsaMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 49 R42.htm IDEA: XBRL DOCUMENT v3.25.0.1 Biosteel (Tables) 9 Months Ended Dec. 31, 2024 Discontinued Operations and Disposal Groups [Abstract] A Summary of Discontinued Operations A A Three months ended A A Nine months ended A A December 31, A A December 31, A A December 31, A A December 31, A A December 31, A A 2024 A A 2023 A A Net revenue A \$ - A A \$ 172 A A \$ - A A \$ 56,610 A Cost of goods sold A A - A A 1,900 A A - A A 145,625 A Operating expenses A A - A A (726) A A - A A 97,851 A Operating loss A A - A A (1,002) A A - A A (186,866) Other income (expense), net1 A A - A A 14,481 A A - A A 5,310 A A (8,521) Income tax (expense) recovery A A - A A - A A - A A 936 A Net income (loss) on discontinued operations, net of tax A \$ - A A \$ 13,479 A A \$ 5,310 A A (194,451) 1 Included in Other income (expense), net for the three and nine months ended December 31, 2024 is a gain/loss on deconsolidation of \$nil and \$nil, respectively (three and nine months ended December 31, 2023 - gain on deconsolidation of \$12,417 and loss on deconsolidation of \$9,820, respectively). The assets and liabilities related to the BioSteel Entities business units are classified as discontinued operations and the major categories are as follows: A A December 31, A A March 31, A A 2024 A A 2024 A Receivable from BioSteel Entities A \$ - A A \$ 8,038 A Total assets of discontinued operations A \$ - A A \$ 8,038 A A A A A Total liabilities of discontinued operations A \$ - A A \$ - A X - ReferencesNo definition available. + Details Name: us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract Namespace Prefix: us-gaap_Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of information related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef-NameAccountingStandardsCodification-Section50-Paragraph3-SubTopic10-Topic360-PublisherFASB-URI> <https://asc.fasb.org/1943274/2147482099/360-10-50-3>Reference 2: <http://fasb.org/us-gaap/role/ref/legacyRef-Topic205-SubTopic20-NameAccountingStandardsCodification-Section45-Paragraph11-PublisherFASB-URI> <https://asc.fasb.org/1943274/2147483475/205-20-45-11>Reference 3: <http://fasb.org/us-gaap/role/ref/legacyRef-Topic205-SubTopic20-NameAccountingStandardsCodification-Section50-Paragraph3A-PublisherFASB-URI> <https://asc.fasb.org/1943274/2147483499/205-20-50-3A>Reference 4: <http://fasb.org/us-gaap/role/ref/legacyRef-Topic205-SubTopic20-NameAccountingStandardsCodification-Section50-Paragraph4A-PublisherFASB-URI> <https://asc.fasb.org/1943274/2147483499/205-20-50-4A>Reference 5: <http://fasb.org/us-gaap/role/ref/legacyRef-Topic205-SubTopic20-NameAccountingStandardsCodification-Section50-Paragraph4B-PublisherFASB-URI> <https://asc.fasb.org/1943274/2147483499/205-20-50-4B>Reference 6: <http://fasb.org/us-gaap/role/ref/legacyRef-Topic205-SubTopic20-NameAccountingStandardsCodification-Section50-Paragraph5A-PublisherFASB-URI> <https://asc.fasb.org/1943274/2147483499/205-20-50-5A>Reference 7: <http://fasb.org/us-gaap/role/ref/legacyRef-Topic205-SubTopic20-NameAccountingStandardsCodification-Section50-Paragraph5B-PublisherFASB-URI> <https://asc.fasb.org/1943274/2147483499/205-20-50-5B>Reference 8: <http://fasb.org/us-gaap/role/ref/legacyRef-Topic205-SubTopic20-NameAccountingStandardsCodification-Section50-Paragraph5C-PublisherFASB-URI> <https://asc.fasb.org/1943274/2147483499/205-20-50-5C>Reference 9: <http://fasb.org/us-gaap/role/ref/legacyRef-Topic205-SubTopic20-NameAccountingStandardsCodification-Section50-Paragraph5D-PublisherFASB-URI> <https://asc.fasb.org/1943274/2147483499/205-20-50-5D>Reference 10: <http://fasb.org/us-gaap/role/ref/legacyRef-Topic205-SubTopic20-NameAccountingStandardsCodification-Section50-Paragraph7-PublisherFASB-URI> <https://asc.fasb.org/1943274/2147483499/205-20-50-7>Reference 11: <http://fasb.org/us-gaap/role/ref/legacyRef-Topic360-SubTopic10-NameAccountingStandardsCodification-Section50-Paragraph3A-PublisherFASB-URI> <https://asc.fasb.org/1943274/2147482099/360-10-50-3A>Reference 12: <http://fasb.org/us-gaap/role/ref/legacyRef-NameAccountingStandardsCodification-Section50-Paragraph1-SubTopic20-Topic205-PublisherFASB-URI> <https://asc.fasb.org/1943274/2147483499/205-20-50-1>Reference 13: <http://fasb.org/us-gaap/role/ref/legacyRef-NameAccountingStandardsCodification-Topic205-SubTopic20-Section50-Paragraph3-PublisherFASB-URI> <https://asc.fasb.org/1943274/2147483499/205-20-50-3> + Details Name: us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock Namespace Prefix: us-gaap_Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 50 R43.htm IDEA: XBRL DOCUMENT v3.25.0.1 Cash and Cash Equivalents (Tables) 9 Months Ended Dec. 31, 2024 Cash and Cash Equivalents [Abstract] A Components of Cash and Cash Equivalents The components of cash and cash equivalents are as follows: A A December 31, A A March 31, A A 2024 A A 2024 A Cash A \$ 145,599 A A \$ 115,427 A Cash equivalents A A 16,310 A A 54,873 A A \$ 161,909 A A \$ 170,300 A X - ReferencesNo definition available. + Details Name: us-gaap_CashAndCashEquivalentsAbstract Namespace Prefix: us-gaap_Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of the components of cash and cash equivalents. + ReferencesNo definition available. + Details Name: us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock Namespace Prefix: us-gaap_Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 51 R44.htm IDEA: XBRL DOCUMENT v3.25.0.1 Short-term Investments (Tables) 9 Months Ended Dec. 31, 2024 Short-Term Investments [Abstract] A Components of Short-term Investments The components of short-term investments are as follows: A A December 31, A A March 31, A A 2024 A A 2024 A Term deposits A \$ 16,435 A A \$ 33,161 A A \$ 16,435 A A \$ 33,161 A X - DefinitionSchedule of short term investments. + ReferencesNo definition available. + Details Name: cgc_ScheduleOfShortTermInvestmentsTableTextBlock Namespace Prefix: cgc_Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_ShortTermInvestmentsAbstract Namespace Prefix: us-gaap_Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 52 R45.htm IDEA: XBRL DOCUMENT v3.25.0.1 Amounts Receivable, Net (Tables) 9 Months Ended Dec. 31, 2024 Receivables [Abstract] A Components of Amounts Receivable, Net The components of amounts receivable, net are as follows: A A December 31, A A March 31, A A 2024 A A 2024 A Accounts receivable, net A \$ 44,393 A A \$ 44,943 A Indirect taxes receivable A A 3,655 A A 2,517 A Interest receivable A A 1,004 A A 876 A Other receivables A A 6 A A 3,511 A A \$ 49,058 A A \$ 51,847 A X - ReferencesNo definition available. + Details Name: us-gaap_ReceivablesAbstract Namespace Prefix: us-gaap_Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of the various types of trade accounts and notes receivable and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic210-SubTopic10-NameAccountingStandardsCodification-SectionS99-Paragraph1-Subparagraph\(SX210.5-02\(4\)\)-PublisherFASB-URI](http://fasb.org/us-gaap/role/ref/legacyRef-Topic210-SubTopic10-NameAccountingStandardsCodification-SectionS99-Paragraph1-Subparagraph(SX210.5-02(4))-PublisherFASB-URI) <https://asc.fasb.org/1943274/2147480566/210-10-S99-1>Reference 2: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic210-SubTopic10-NameAccountingStandardsCodification-SectionS99-Paragraph1-Subparagraph\(SX210.5-02\(3\)\)-PublisherFASB-URI](http://fasb.org/us-gaap/role/ref/legacyRef-Topic210-SubTopic10-NameAccountingStandardsCodification-SectionS99-Paragraph1-Subparagraph(SX210.5-02(3))-PublisherFASB-URI) <https://asc.fasb.org/1943274/2147480566/210-10-S99-1> + Details Name: us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock Namespace Prefix: us-gaap_Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 53 R46.htm IDEA: XBRL DOCUMENT v3.25.0.1 Inventory (Tables) 9 Months Ended Dec. 31, 2024 Inventory Disclosure [Abstract] A Components of Inventory The components of inventory are as follows: A A December 31, A A March 31, A A 2024 A A 2024 A Raw materials, packaging supplies and consumables A \$ 15,980 A A \$ 18,872 A Work in progress A A 42,733 A A 31,367 A Finished goods A A 32,040 A A 27,053 A A 90,753 A A \$ 77,292 A X - ReferencesNo definition available. + Details Name: us-gaap_InventoryDisclosureAbstract Namespace Prefix: us-gaap_Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic210-SubTopic10-NameAccountingStandardsCodification-SectionS99-Paragraph1-Subparagraph\(SX210.5-02\(6\)\(a\)\)-PublisherFASB-URI](http://fasb.org/us-gaap/role/ref/legacyRef-Topic210-SubTopic10-NameAccountingStandardsCodification-SectionS99-Paragraph1-Subparagraph(SX210.5-02(6)(a))-PublisherFASB-URI) <https://asc.fasb.org/1943274/2147480566/210-10-S99-1>Reference 2: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic210-SubTopic10-NameAccountingStandardsCodification-SectionS99-Paragraph1-Subparagraph\(SX210.5-02\(6\)\(b\)\)-PublisherFASB-URI](http://fasb.org/us-gaap/role/ref/legacyRef-Topic210-SubTopic10-NameAccountingStandardsCodification-SectionS99-Paragraph1-Subparagraph(SX210.5-02(6)(b))-PublisherFASB-URI) <https://asc.fasb.org/1943274/2147480566/210-10-S99-1>Reference 3: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic210-SubTopic10-NameAccountingStandardsCodification-SectionS99-Paragraph1-Subparagraph\(SX210.5-02\(6\)\(c\)\)-PublisherFASB-URI](http://fasb.org/us-gaap/role/ref/legacyRef-Topic210-SubTopic10-NameAccountingStandardsCodification-SectionS99-Paragraph1-Subparagraph(SX210.5-02(6)(c))-PublisherFASB-URI) <https://asc.fasb.org/1943274/2147480566/210-10-S99-1>Reference 4: <http://fasb.org/us-gaap/role/ref/legacyRef-Topic210-SubTopic10-Section50-Paragraph1-PublisherFASB-URI> <https://asc.fasb.org/1943274/2147483489/210-10-50-1> + Details Name: us-gaap_ScheduleOfInventoryCurrentTabularTextBlock Namespace Prefix: us-gaap_Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 54 R47.htm IDEA: XBRL DOCUMENT v3.25.0.1 Prepaid Expenses and Other Assets (Tables) 9 Months Ended Dec. 31, 2024 Prepaid Expense and Other Assets, Current [Abstract] A Components of Prepaid Expenses and Other Assets The components of prepaid expenses and other assets are as follows: A A December 31, A A March 31, A A 2024 A A 2024 A Prepaid expenses A \$ 5,609 A A \$ 6,621 A Deposits A A 5,254 A A 2,365 A Other assets A A 4,959 A A 14,246 A A \$ 15,822 A A \$ 23,232 A X - DefinitionSchedule of prepaid expense and other assets. + ReferencesNo definition available. + Details Name: cgc_ScheduleOfPrepaidExpenseAndOtherAssetsTableTextBlock Namespace Prefix: cgc_Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract Namespace Prefix: us-gaap_Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 55 R48.htm IDEA: XBRL DOCUMENT v3.25.0.1 Equity Method Investments (Tables) 9 Months Ended Dec. 31, 2024 Equity Method Investments and Joint Ventures [Abstract] A Schedule of Equity Method Investments The components of equity method investments are as follows: A A December 31, A A March 31, A A 2024 A A 2024 A Canopy USA A \$ 49,834 A A \$ - A A \$ 49,834 A A \$ - A X - ReferencesNo definition available. + Details Name: us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract Namespace Prefix: us-gaap_Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of equity method investments including, but not limited to, name of each investee or group of investments, percentage ownership, difference between recorded amount of an investment and the value of the underlying equity in the net assets, and summarized financial information. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef-Topic323-SubTopic10-NameAccountingStandardsCodification-Section50-Paragraph3-PublisherFASB-URI> <https://asc.fasb.org/1943274/2147481687/323-10-50-3> + Details Name: us-gaap_EquityMethodInvestmentsTextBlock Namespace Prefix: us-gaap_Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 56 R49.htm IDEA: XBRL DOCUMENT v3.25.0.1 Other Financial Assets (Tables) 9 Months Ended Dec. 31, 2024 Schedule of Investments [Abstract] A Summary of Changes in Other Financial Assets The following table outlines changes in other financial assets. Additional details on how the fair value of significant investments is calculated are included in Note 23. A A A A A A A A A A Foreign A A A A A A A A Balance at A A A A A A currency A A A A A A Balance at A A A A A A March 31, A A A A Fair value A A translation A A A A A A December 31, A A Entity A Instrument A 2024 A Additions A A changes A A adjustments A A Other A A 2024 A Acreege1 A Fixed Shares option and Floating Shares agreement A \$ 10,000 A A \$ - A A \$ (31,808) A A \$ (35) A A \$ 21,843 A A \$ - A TerrAscend Exchangeable Shares A Exchangeable shares A A 120,000 A A A - A A A 17,291 A A 2,109 A A A (139,400) A A - A TerrAscend - December 2022 A Warrants A A 32,500 A A - A A 7,929 A A A 571 A A (41,000) A A - A TerrAscend A Option A 2,000 A A - A A 265 A A A 35 A A (2,300) A A - A Wana A Option A 149,766 A A - A A - A A 1,537 A A A (151,303) A A - A Jetty A Options A 59,915 A A - A A - A 615 A A A (60,530) A A - A Acreege Hempco A Debenture A A 11,780 A A - A A - A 121 A A A (11,901) A A - A Acreege Debt Option Premium A Option A 37,574 A A - A A 3,147 A A 386 A A (41,107) A A - A Acreege Tax Receivable Agreement A Other A A 1,287 A A - A A - A A 13 A A (1,300) A A - A Acreege Debt A Loan receivable A A - A A 133,595 A A (1,239) A A 6,512 A A - A A 138,868 A Elevate loan receivable2 A Loan receivable A A - A A 174,864 A A 24,804 A A 4,137 A A (24,622) A A 179,183 A Other A Various A A 12,807 A A - A A (2,915) A A 24 A A (6,599) A A 3,317 A A A \$ 437,629 A A \$ 308,459 A A 17,474 A A \$ 16,025 A A \$ (458,219) A A 321,368 A 1 See Note 27 for information regarding the Acreege Amended Arrangement.2 Upon deconsolidation of the financial results of Canopy USA within the Company's financial statements, the Elevate loan receivable, which was previously recorded at amortized cost, is now recorded at fair value. The remeasurement of this retained non-controlling interest from the deconsolidation of Canopy USA is part of the gain on disposal of consolidated entity described in Note 3. X - DefinitionSchedule of other financial assets. + ReferencesNo definition available. + Details Name: cgc_ScheduleOfOtherFinancialAssetsTableTextBlock Namespace Prefix: cgc_Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_ScheduleOfInvestmentsAbstract Namespace Prefix: us-gaap_

Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration XML 57 R50.htm IDEA: XBRL DOCUMENT v3.25.0.1 Property, Plant and Equipment (Tables) 9 Months Ended Dec. 31, 2024 Property, Plant and Equipment [Abstract] A Summary of Expected Useful Life of Property, Plant and Equipment The components of property, plant and equipment are as follows: A A December 31, A A March 31, A A A 2024 A A 2024 A Buildings and greenhouses A A 304,356 A A 305,606 A Production and warehouse equipment A A 60,685 A A 62,026 A Leasehold improvements A A 3,160 A A 7,787 A Office and lab equipment A A 10,389 A A 11,041 A Computer equipment A A 7,119 A A 7,784 A Land A A 4,923 A A 5,323 A Right-of-use-assets A A A A Buildings and greenhouses A A 11,822 A A 17,697 A Assets in process A A 4,910 A A 1,019 A A A 407,364 A A A 418,283 A Less: Accumulated depreciation A A (107,760) A A (98,180) A A \$ 299,604 A A \$ 320,103 A X - ReferencesNo definition available. + Details Name: us-gaap_PropertyPlantAndEquipmentAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration X - DefinitionTabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated depreciation. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 360 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482099/360-10-50-1> + Details Name: us-gaap_PropertyPlantAndEquipmentTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItem Type Balance Type: na Period Type: duration XML 58 R51.htm IDEA: XBRL DOCUMENT v3.25.0.1 Intangible Assets (Tables) 9 Months Ended Dec. 31, 2024 Intangible Assets, Net (Excluding Goodwill) [Abstract] A Summary of Components of Intangible Assets The components of intangible assets are as follows: A A December 31, 2024 A A March 31, 2024 A A A Gross A A Net A A Gross A A Net A A Carrying A A Carrying A A Carrying A A Carrying A A Amount A A Amount A A Amount A A Finite lived intangible assets A A A A A A A A Intellectual property A A \$ 83,977 A A \$ 32,974 A A \$ 82,423 A A \$ 38,571 A Distribution channel A A 46,112 A A A 2,317 A A \$ 45,981 A A \$ 3,029 A Operating licenses A A 24,400 A A 13,674 A A 24,400 A A 15,964 A Software and domain names A A 33,002 A A A 3,124 A A 32,262 A A A 7,010 A Brands A A 14,498 A A 8,307 A A 14,493 A A 10,850 A Amortizable intangibles in process A A 256 A A 256 A A 29 A A 29 A Total A A \$ 202,245 A A \$ 60,652 A A \$ 199,588 A A \$ 75,453 A A A A A A A A Indefinite lived intangible assets A A A A A A A A Acquired brands A A A A \$ 29,139 A A A \$ 28,600 A Total intangible assets A A A \$ 89,791 A A A \$ 104,053 A X - ReferencesNo definition available. + Details Name: us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration X - DefinitionTabular disclosure of goodwill and intangible assets, which may be broken down by segment or major class. + ReferencesReference 1: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Publisher FASB -URI <https://asc.fasb.org/350-30/tableOfContentReference> 2: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Publisher FASB -URI <https://asc.fasb.org/350-20/tableOfContent> + Details Name: us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItem Type Balance Type: na Period Type: duration XML 59 R52.htm IDEA: XBRL DOCUMENT v3.25.0.1 Goodwill (Tables) 9 Months Ended Dec. 31, 2024 Goodwill and Intangible Assets Disclosure [Abstract] A Changes in Carrying Amount of Goodwill The changes in the carrying amount of goodwill are as follows: Balance, March 31, 2023 A \$ 85,563 A Impairment losses A A (42,081) Foreign currency translation adjustments A A (243) Balance, March 31, 2024 A \$ 43,239 A Foreign currency translation adjustments A A 854 A Balance, December 31, 2024 A \$ 44,093 A X - ReferencesNo definition available. + Details Name: us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration X - DefinitionTabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule. + ReferencesReference 1: <http://www.xbrl.org/2003/role/exampleRef> -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 24 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482548/350-20-55-24Reference> 2: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482573/350-20-50-1Reference> 3: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (h) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482573/350-20-50-1Reference> 4: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482573/350-20-50-1Reference> 5: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482573/350-20-50-1Reference> 6: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482573/350-20-50-1Reference> 7: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482573/350-20-50-1Reference> 8: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (e) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482573/350-20-50-1Reference> 9: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482573/350-20-50-1Reference> 10: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482573/350-20-50-1Reference> 11: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482573/350-20-50-1Reference> 12: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482573/350-20-50-2> + Details Name: us-gaap_ScheduleOfGoodwillTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItem Type Balance Type: na Period Type: duration XML 60 R53.htm IDEA: XBRL DOCUMENT v3.25.0.1 Other Accrued Expenses and Liabilities (Tables) 9 Months Ended Dec. 31, 2024 Accounts Payable and Accrued Liabilities, Current [Abstract] A Components of Other Accrued Expenses and Liabilities The components of other accrued expenses and liabilities are as follows: A A December 31, A A March 31, A A A 2024 A A 2024 A Employee compensation A A \$ 10,822 A A \$ 21,468 A Taxes and government fees A A 11,337 A A 10,519 A Professional fees A A 3,120 A A 5,849 A Other A A 11,912 A A 16,203 A A A 37,191 A A \$ 54,039 A X - ReferencesNo definition available. + Details Name: us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration X - DefinitionTabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses. + ReferencesNo definition available. + Details Name: us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItem Type Balance Type: na Period Type: duration XML 61 R54.htm IDEA: XBRL DOCUMENT v3.25.0.1 Debt (Tables) 9 Months Ended Dec. 31, 2024 Debt Disclosure [Abstract] A Summary of Components of Debt The components of debt are as follows: A A A December 31, A A A March 31, A A A Maturity Date A 2024 A A 2024 A Credit facility A December 18, 2026 A A A A Principal amount A A A 360,481 A A 486,935 A Accrued interest A A A 284 A A A 831 A Deferred financing costs A A A (10,410) A A (17,948) A A A A 350,355 A A 469,818 A Supreme convertible debentures A September 10, 2025 A A 2,267 A A 30,654 A Accretion debentures A September 10, 2025 A A 417 A A 6,390 A May 2024 Convertible Debenture A May 14, 2029 A A 88,067 A A A - Promissory note A December 31, 2024 A A - A A 89,224 A Other revolving debt facility, loan, and financings A A A 465 A A A 1,143 A A A A 441,571 A A 597,229 A Less: current portion A A A (3,167) A A (103,935) Long-term portion A A A \$ 438,404 A A \$ 493,294 A X - ReferencesNo definition available. + Details Name: us-gaap_DebtDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration X - DefinitionTabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation. + ReferencesNo definition available. + Details Name: us-gaap_ScheduleOfDebtTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItem Type Balance Type: na Period Type: duration XML 62 R55.htm IDEA: XBRL DOCUMENT v3.25.0.1 Other Liabilities (Tables) 9 Months Ended Dec. 31, 2024 Other Liabilities Disclosure [Abstract] A Components of Other Liabilities The components of other liabilities are as follows: A A As at December 31, 2024 A A As at March 31, 2024 A A A Current A A Long-term A A Total A A Current A A Long-term A A Total A Lease liabilities A \$ 18,579 A A \$ 29,524 A A \$ 48,103 A A \$ 15,173 A A \$ 55,597 A A \$ 70,770 A Acquisition consideration A A and other investment A A related liabilities A A - A A 4,265 A A A 4,265 A A 12,809 A A A 10,558 A A A 23,367 A Refund liability A A 2,727 A A A - A A 2,727 A A A 4,169 A A A - A A 4,169 A Settlement liabilities and A A other A A 6,434 A A 3,535 A A 9,969 A A A 15,917 A A A 5,659 A A A 21,576 A A A \$ 27,740 A A \$ 37,324 A A \$ 65,064 A A \$ 48,068 A A \$ 71,814 A A \$ 119,882 A X - ReferencesNo definition available. + Details Name: us-gaap_OtherLiabilitiesDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration X - DefinitionTabular disclosure of other liabilities. + ReferencesNo definition available. + Details Name: us-gaap_OtherLiabilitiesTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItem Type Balance Type: na Period Type: duration XML 63 R56.htm IDEA: XBRL DOCUMENT v3.25.0.1 Share Capital (Tables) 9 Months Ended Dec. 31, 2024 Equity [Abstract] A Summary of Issuances of Stock Other During the nine months ended December 31, 2024, the Company had the following other issuances and share capital transactions: A A Number of common shares A A Sharecapital A A Share and warrantreserve A Settlement of Acreage Acquisition A 12,559,230 A A \$ 63,915 A A \$ 11,939 A Other issuances and share issue costs A A - A A (6,567) A A - A Total A 12,559,230 A A \$ 57,348 A A \$ 11,939 A During the nine months ended December 31, 2023, the Company had the following other issuances and share capital transactions: A A Number of common shares A A Sharecapital A A Sharebasedreserve A Settlement of convertible debentures A 8,445,894 A A \$ 108,055 A A \$ - A Settlement of Canopy Notes A 11,477,366 A A 57,084 A A A - A Settlement of debentures A 7,341,818 A A 87,754 A A A - A Other issuances and share issue costs A 6,165 A A (317) A A (80) Total A 27,271,243 A A \$ 252,576 A A \$ (80) Summary of Warrants A A Number of wholewarrants A A Averageexerciseprice A A Warrantvalue A Balance outstanding at March 31, 2024 A 10,451,457 A A \$ 9.12 A A \$ 2,610,519 A Issuance of warrants A 4,548,088 A A 13.31 A A 13,525 A Issuance of replacement warrants resulting from the Acreage Acquisition A 1,845,843 A A 10.72 A A 7,111 A Exercise of warrants A (1,279,660) A A 6.60 A A (3,018) Balance outstanding at December 31, 2024 A 15,565,728 A A \$ 11.09 A A \$ 2,628,137 A A A Number of wholewarrants A A Averageexerciseprice A A Warrantvalue A Balance outstanding at March 31, 2023 A 12,819,305 A A \$ 580.40 A A \$ 2,581,788 A Issuance of warrants from private placement A 2,292,947 A A 18.33 A A 8,977 A Expiry of Warrants A (12,692,731) A A 583.62 A A - A Balance outstanding at December 31, 2023 A 2,419,521 A A \$ 30.34 A A \$ 2,590,765 A 1 This balance excludes warrants previously issued by the Company to CBG (as defined below) which were exercisable to acquire 1,281,815 common shares at an exercise price equal to the 5-day volume-weighted average price of the Company common shares immediately prior to exercise (the "Tranche C Warrants"). The Tranche C Warrants represent a derivative liability and have nominal value. As of November 1, 2023, the Tranche C Warrants are considered expired in accordance with their terms. X - ReferencesNo definition available. + Details Name: us-gaap_EquityAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration X - DefinitionTabular disclosure of the equity interest issued or issuable in a business acquisition (or series of individually immaterial business acquisitions) planned, initiated, or completed during the period. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 805 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(4) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479581/805-30-50-1> + Details Name: us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionEquityInterestIssuedOrIssuableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItem Type Balance Type: na Period Type: duration X - DefinitionTabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480429/718-10-50-1> + Details Name: us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItem Type Balance Type: na Period Type: duration XML 64 R57.htm IDEA: XBRL DOCUMENT v3.25.0.1 Share-Based Compensation (Tables) 9 Months Ended Dec. 31, 2024 Share-Based Payment Arrangement [Abstract] A Summary of Changes in Options Outstanding The following is a summary of the changes in the Options outstanding during the nine months ended December 31, 2024: A A Optionissued A A Weightedaverageexercise price A Balance outstanding at March 31, 2024 A 2,883,922 A A \$ 70.01 A Options granted A 765,107 A A 10.37 A Replacement options issued resulting from the Acreage Acquisition A 93,383 A A 85.67 A Options exercised A (18,621) A A 6.05 A Options expired/forfeited A (243,483) A A 226.05 A Balance outstanding at December 31, 2024 A 3,480,308 A A \$ 37.84 A Summary of Options Outstanding The following is a summary of the Options outstanding as at December 31, 2024: A A Options Outstanding A A Options Exercisable A A A A Weighted Average A A A A Weighted Average A A A A Remaining A A A A Remaining A A A A Outstanding A A Contractual Life A A Exercisable at A A Contractual Life A Range of Exercise Prices A December 31, 2024 A A (years) A A December 31, 2024 A A (years) A \$0.60A - \$7.50 A 2,030,678 A A 4.50 A A 668,981 A A 4.50 A \$7.51A - \$56.10 A 1,040,200 A A 4.96 A A 183,390 A A 3.64 A \$56.11A - \$85.10 A 409,430 A A 1.08 A A 301,556 A A 1.16 A A 3,480,308 A A 4.32 A A 1,153,927 A A 3.69 A 1 Prior period Options and exercise price amounts have been retrospectively adjusted to reflect the Share Consolidation, which became effective on December 15, 2023. See Note 2 for details. Summary of Assumptions Applied to Establish Fair Value of Options Granted Using Black-Scholes Option Pricing Model The Company uses the Black-Scholes option pricing model to establish the fair value of Options granted during the three months ended December 31, 2024 and 2023, on their measurement date by applying the following assumptions: A A December 31, A December 31, A 2024 A 2023 Risk-free interest rate A A 3.95% Expected life of options (years) A A 3A - 5 Expected volatility A A 101% Expected forfeiture rate A A 21% Expected dividend yield A A nil Black-Scholes value of each Option A A \$5.33 Summary of Changes in RSUs and PSUs The following is a summary of the changes in the Company's RSUs and PSUs during the nine months ended December 31, 2024: A A Number of RSUsand PSUs A Balance outstanding at March 31, 2024 A A 1,272,299 A RSUs and PSUs granted A 720,873 A Replacement RSUs issued resulting from the Acreage Acquisition A 6,627 A RSUs and PSUs released A (433,268) RSUs and PSUs cancelled and forfeited A (130,257) Balance outstanding at December 31, 2024 A 1,436,274 A X - ReferencesNo definition available. + Details Name: us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration X - DefinitionTabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480429/718-10-50-2> + Details Name: us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItem Type Balance Type: na Period Type: duration X - DefinitionTabular disclosure of option exercise prices, by grouped ranges, including the upper and lower limits of the price range, the number of shares under option, weighted average exercise price and remaining contractual option terms. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480429/718-10-50-2> + Details Name: us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItem Type

Balance Sheet Type: na Period Type: duration X - DefinitionTabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end year, grants, exercises, forfeitures, and weighted-average grant date fair value. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d) -SubTopic 10 -Topic 718 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e) -SubTopic 10 -Topic 718 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock Namespace Prefix: us-gaap Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 718 -SubTopic 10 -Subparagraph (f)(2) -Name Accounting Standards Codification -Paragraph 2 -Section 50 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock Namespace Prefix: us-gaap Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 65 R58.htm IDEA: XBRL DOCUMENT v3.25.0.1 Accumulated Other Comprehensive Income (Loss) (Tables) 9 Months Ended Dec. 31, 2024 Equity [Abstract] Accumulated Other Comprehensive Income Accumulated other comprehensive income includes the following components: A Foreign currency translation adjustments A Changes of own credit risk of financial liabilities A Accumulated other comprehensive income (loss) A As at March 31, 2024 A \$ (31,178) A \$ 15,127 A \$ (16,051) Disposal and liquidation of consolidated entities A \$ 18,593 A A A \$ 18,593 A Extinguishment of promissory note and issuance of exchangeable shares A A A \$ (15,127) A \$ (15,127) Other comprehensive income A \$ 3,586 A A A A \$ 3,586 A As at December 31, 2024 A \$ (8,999) A A A \$ (8,999) A A Foreign currency translation adjustments A Changes of own credit risk of financial liabilities A A Accumulated other comprehensive income (loss) A As at March 31, 2023 A \$ (30,261) A A \$ 16,401 A A \$ (13,860) Settlement of unsecured senior notes, net of deferred income tax A A A A \$ 11,060 A A \$ 11,060 Other comprehensive income (loss) A \$ 575 A A \$ (13,824) A A \$ (13,249) As at December 31, 2023 A \$ (29,686) A A \$ 13,637 A A \$ (16,049) X - ReferencesNo definition available. + Details Name: us-gaap EquityAbstract Namespace Prefix: us-gaap Data Type: xbrli:stringItemText Block Namespace Prefix: us-gaap Data Type: duration X - DefinitionTabular disclosure of the components of accumulated other comprehensive income (loss). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 14A -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481674/830-30-50-1Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 20 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20 + Details Name: us-gaap ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock Namespace Prefix: us-gaap Data Type: dtr-types:textBlockItemText Block Namespace Prefix: us-gaap Data Type: duration XML 66 R59.htm IDEA: XBRL DOCUMENT v3.25.0.1 Noncontrolling Interests (Tables) 9 Months Ended Dec. 31, 2024 Noncontrolling Interest [Abstract] Summary of Net Change in Noncontrolling Interests The net change in the noncontrolling interests is as follows: A Other A Total A As at March 31, 2024 A \$ 139 A \$ 139 A Comprehensive income (loss) A A A A A A Canopy USA Transaction A A (139) A A (139) As at December 31, 2024 A \$ - A \$ - A BioSteel A A Other A Total A As at March 31, 2023 A \$ 1,447 A A \$ 140 A A \$ 1,587 A Comprehensive loss A A (18,526) A A (18,526) Net loss attributable to redeemable noncontrolling interest A A 18,526 A A A 18,526 A Share-based compensation A A 148 A A A 148 A Ownership changes A A (1,595) A A (1,595) A As at December 31, 2023 A \$ - A \$ 139 A A \$ 139 X - DefinitionThe tabular disclosure of the effects of any changes in a parent's ownership interest in a subsidiary on the equity attributable to the parent if the ownership interests in a subsidiary changes during the period. The changes represented by this element did not result in the deconsolidation of the subsidiary. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 55 -Paragraph 4M -Publisher FASB -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4MReference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (d) -SubTopic 10 -Topic 810 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A + Details Name: us-gaap ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTextBlock Namespace Prefix: us-gaap Data Type: dtr-types:textBlockItemText Block Namespace Prefix: us-gaap Data Type: duration X - ReferencesNo definition available. + Details Name: us-gaap NoncontrollingInterestAbstract Namespace Prefix: us-gaap Data Type: xbrli:stringItemText Block Namespace Prefix: us-gaap Data Type: duration XML 67 R60.htm IDEA: XBRL DOCUMENT v3.25.0.1 Fair Value of Financial Instruments (Tables) 9 Months Ended Dec. 31, 2024 Summary of Financial Assets and Liabilities Measured at Estimated Fair Value on a Recurring Basis The following table represents the Company's financial assets and liabilities measured at estimated fair value on a recurring basis: A Fair value measurement using A A A A Quoted A A Significant A A A A A prices in A A other A A Significant A A A A active A A observable A A unobservable A A A A markets A A inputs A A inputs A A A A (Level 1) A A (Level 2) A A (Level 3) A A Total A December 31, 2024 A A A A A A A Assets: A A A A A A Short-term investments A \$ 16,435 A A \$ - A A \$ 16,435 Restricted short-term investments A A 7,108 A A 7,108 A Equity method investments A A A A A 49,834 A A 49,834 A Other financial assets A A 46 A A A 318,051 A A 318,097 A A A A A A A March 31, 2024 A A A A A A Assets: A A A A A A Short-term investments A \$ 33,161 A A \$ - A A \$ 33,161 A Restricted short-term investments A A 7,310 A A A 7,310 A Other financial assets A A 2,957 A A A 426,306 A A 429,263 A Liabilities: A A A A A A Long-term debt A A A A 89,224 A A 89,224 A Other liabilities A A A A A 18,983 A A 18,983 A Level 3 A Summary of Valuation Techniques and Significant Unobservable Inputs in the Fair Value Measurement of Significant Level 2 and Level 3 Financial Instruments The following table summarizes the valuation techniques and significant unobservable inputs in the fair value measurement of significant level 3 financial instruments: A Financial asset / financial liability A Valuation techniques A Significant unobservable inputs A Relationship of unobservable inputs to fair value A Canopy USA Equity Method Investment A Asset based approach A Probability and timing of US legalization A Increase or decrease in probability of US legalization will result in an increase or decrease in fair value A A Discount rate A Increase or decrease in discount rate will result in a decrease or increase in fair value A A Expected future cash flows A Increase or decrease in expected future cash flows will result in an increase or decrease in fair value A A Volatility of Wana and Jetty equity A Increase or decrease in volatility will result in an increase or decrease in fair value A Elevate Loan Receivable A Lesser of discounted cash flow and debtor net assets A Equity value of Canopy USA A Increase or decrease in equity value will result in an increase or decrease in fair value A Acreege Debt A Discounted cash flow A Discount rate A Increase or decrease in discount rate will result in a decrease or increase in fair value X - DefinitionTabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 103 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-103Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock Namespace Prefix: us-gaap Data Type: dtr-types:textBlockItemText Block Namespace Prefix: us-gaap Data Type: duration X - DefinitionTabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3). + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock Namespace Prefix: us-gaap Data Type: dtr-types:textBlockItemText Block Namespace Prefix: us-gaap Data Type: duration X - Details Name: us-gaap FairValueByFairValueHierarchyLevelAxis-us-gaap FairValueInputsLevel3Member Namespace Prefix: Data Type: na Balance Type: Period Type: XML 68 R61.htm IDEA: XBRL DOCUMENT v3.25.0.1 Revenue (Tables) 9 Months Ended Dec. 31, 2024 Revenue from Contract with Customer [Abstract] Summary of Disaggregation of Revenue Revenue is disaggregated as follows: A Three months ended A Nine months ended A A December 31, A A December 31, A A December 31, A A December 31, A A 2024 A A 2023 A A 2024 A A 2023 A Canada cannabis A A A A A A Canadian adult-use cannabis A \$ 21,153 A A \$ 23,490 A A \$ 58,424 A A \$ 71,848 A Canadian medical cannabis A \$ 19,575 A A \$ 16,894 A A \$ 57,059 A A \$ 48,695 A A \$ 40,728 A A \$ 40,384 A A \$ 115,483 A A \$ 120,543 A A A A International markets cannabis A \$ 12,024 A A \$ 10,527 A A \$ 32,166 A A \$ 29,666 A Storz & Bickel A \$ 22,009 A A \$ 18,453 A A \$ 56,315 A A \$ 48,517 A This Works A \$ - A A \$ 8,165 A A A \$ 21,256 A Other A A A 976 A A A A 4,376 A A A A A A Net revenue A \$ 74,761 A A \$ 78,505 A A \$ 203,964 A A \$ 22

[illegible]

Type: xbrli:sharesItem Type Balance Type: na Period Type: duration X - DefinitionAggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1>Reference 2: <http://www.xbrl.org/2003/role/exampleRef> -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481372/852-10-55-10>Reference 3: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(22)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147478777/944-210-S99-1> + Details Name: us-gaap_CommonStockValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItem Type Balance Type: credit Period Type: instant X - DefinitionFace (par) amount of debt instrument at time of issuance. + ReferencesReference 1: <http://www.xbrl.org/2003/role/exampleRef> -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 8 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482949/835-30-55-8>Reference 2: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481139/470-20-50-1B>Reference 3: <http://www.xbrl.org/2003/role/exampleRef> -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69B -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481568/470-20-55-69B>Reference 4: <http://www.xbrl.org/2003/role/exampleRef> -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69C -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481568/470-20-55-69C>Reference 5: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482900/835-30-50-1>Reference 6: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482925/835-30-45-2> + Details Name: us-gaap_DebtInstrumentFaceAmount Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItem Type Balance Type: credit Period Type: instant X - Details Name: us-gaap_FinancialInstrumentAxis=cgc_AcreegeDebtOptionAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_InvestmentIssuerAffiliationAxis=cgc_OtherLenderMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_BusinessAcquisitionAxis=cgc_AcreegeHoldingsIncMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_BusinessAcquisitionAxis=cgc_HSCPHoldersPursuantToAmendedTRAMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FreshStartAdjustmentsTypeOfFreshStartAdjustmentAxis=cgc_FloatingSharesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FreshStartAdjustmentsTypeOfFreshStartAdjustmentAxis=cgc_FixedSharesMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 74 R67.htm IDEA: XBRL DOCUMENT v3.25.0.1 Canopy USA - Summary of Derecognized Assets and Liabilities Transferred (Details) - CAD (\$) in Thousands 3 Months Ended Apr. 30, 2024 Jun. 30, 2024 Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] Á Á Issuance of common shares Á Á (\$ 22,711) Canopy USA Á Á Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] Á Á Cash \$ 6,968 Á Other financial assets 386,045 Á Other assets 1,315 Á Other liabilities (20,067) Á Cumulative translation adjustment 10,398 Á Net assets disposed 384,659 Á Derecognition of non-controlling interest in Canopy USA 139 Á Equity method investment 227,119 Á Elevate loan receivable 174,864 Á Total retained non-controlling interest in the former subsidiaries 401,983 Á Issuance of common shares (12,452) Á Gain on disposal of consolidated entity \$ (5,011) Á X - DefinitionDisposal group, including discontinued operation, cumulative translation adjustment. + ReferencesNo definition available. + Details Name: cgc_DisposalGroupIncludingDiscontinuedOperationCumulativeTranslationAdjustment Namespace Prefix: cgc_ Data Type: xbrli:monetaryItem Type Balance Type: debit Period Type: instant X - DefinitionDisposal group including discontinued operation deconsolidation of noncontrolling interest. + ReferencesNo definition available. + Details Name: cgc_DisposalGroupIncludingDiscontinuedOperationDeconsolidationOfNoncontrollingInterest Namespace Prefix: cgc_ Data Type: xbrli:monetaryItem Type Balance Type: debit Period Type: instant X - DefinitionDisposal group including discontinued operation elevate loan receivable. + ReferencesNo definition available. + Details Name: cgc_DisposalGroupIncludingDiscontinuedOperationElevateLoanReceivable Namespace Prefix: cgc_ Data Type: xbrli:monetaryItem Type Balance Type: debit Period Type: instant X - DefinitionDisposal group including discontinued operation equity method investments. + ReferencesNo definition available. + Details Name: cgc_DisposalGroupIncludingDiscontinuedOperationEquityMethodInvestments Namespace Prefix: cgc_ Data Type: xbrli:monetaryItem Type Balance Type: debit Period Type: instant X - DefinitionDisposal group including discontinued operation issuance of common shares. + ReferencesNo definition available. + Details Name: cgc_DisposalGroupIncludingDiscontinuedOperationIssuanceOfCommonShares Namespace Prefix: cgc_ Data Type: xbrli:monetaryItem Type Balance Type: credit Period Type: duration X - DefinitionDisposal group including discontinued operation other financial assets. + ReferencesNo definition available. + Details Name: cgc_DisposalGroupIncludingDiscontinuedOperationOtherFinancialAssets Namespace Prefix: cgc_ Data Type: xbrli:monetaryItem Type Balance Type: debit Period Type: instant X - DefinitionRetained non-controlling investment interest in subsidiaries. + ReferencesNo definition available. + Details Name: cgc_RetainedNonControllingInvestmentInterestInSubsidiaries Namespace Prefix: cgc_ Data Type: xbrli:monetaryItem Type Balance Type: debit Period Type: instant X - DefinitionAmount classified as assets attributable to disposal group held for sale or disposed of. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Section 45 -Paragraph 10 -SubTopic 20 -Topic 205 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483475/205-20-45-10>Reference 2: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483499/205-20-50-7>Reference 3: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Subparagraph (e) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483499/205-20-50-5B>Reference 5: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (e) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482099/360-10-50-3>Reference 6: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483475/205-20-45-11> + Details Name: us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItem Type Balance Type: debit Period Type: instant X - DefinitionAmount classified as cash and cash equivalents attributable to disposal group held for sale or disposed of. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Section 45 -Paragraph 10 -SubTopic 20 -Topic 205 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483475/205-20-45-10>Reference 2: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Subparagraph (e) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483499/205-20-50-5B>Reference 3: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (e) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482099/360-10-50-3>Reference 4: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483475/205-20-45-11> + Details Name: us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItem Type Balance Type: debit Period Type: instant X - DefinitionAmount classified as other assets attributable to disposal group held for sale or disposed of. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Section 45 -Paragraph 10 -SubTopic 20 -Topic 205 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483475/205-20-45-10>Reference 2: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Subparagraph (e) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483499/205-20-50-5B>Reference 3: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (e) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482099/360-10-50-3>Reference 4: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483475/205-20-45-11> + Details Name: us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItem Type Balance Type: debit Period Type: instant X - DefinitionAmount classified as other liabilities attributable to disposal group held for sale or disposed of. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Section 45 -Paragraph 10 -SubTopic 20 -Topic 205 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483475/205-20-45-10>Reference 2: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Subparagraph (e) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483499/205-20-50-5B>Reference 3: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (e) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482099/360-10-50-3>Reference 4: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483475/205-20-45-11> + Details Name: us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherLiabilities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItem Type Balance Type: credit Period Type: instant X - DefinitionAmount of gain (loss) from sale and disposal of integrated set of activities and assets capable of being conducted and managed for purpose of providing return in form of dividend, lower cost, or other economic benefit to investor, owner, member and participant. + ReferencesReference 1: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482740/230-10-45-28>Reference 2: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481203/810-10-50-1B> + Details Name: us-gaap_GainLossOnSaleOfBusiness Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItem Type Balance Type: credit Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration X - Details Name: us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=cgc_CanopyUSA Member Namespace Prefix: Data Type: na Balance Type: Period Type: XML 75 R68.htm IDEA: XBRL DOCUMENT v3.25.0.1 Biosteel - Additional Information (Details) - CAD (\$) in Thousands 9 Months Ended Dec. 31, 2024 Sep. 14, 2023 BioSteel Á Á Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] Á Á Fair value of equity investments \$ 0 Á Receivable from BioSteel 0 \$ 29,000 Disposal group including discontinued operation receivable \$ 0 \$ 29,000 BioSteel US and BioSteel Manufacturing Á Á Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] Á Á Discontinued operations, description On November 16, 2023, BioSteel Sports Nutrition USA LLC (á€œBioSteel USá€) and BioSteel Manufacturing LLC (á€œBioSteel Manufacturingá€ and collectively with BioSteel Canada and BioSteel US, the á€œBioSteel Entitiesá€) were added as additional applicants in the CCAA Proceedings. As a result, the most relevant activity of both entities became the liquidation and sale of assets and distribution of cash and proceeds to their respective stakeholders and management concluded that Canopy Growth ceased to have the power to direct the relevant activities of BioSteel US and BioSteel Manufacturing because those activities required approval from the CCAA Court. As a result of the conclusion of the sale of assets and distribution of the cash and proceeds of the BioSteel Entities, on July 31, 2024, the CCAA Court granted an order which provided, among other things, for the termination of the CCAA Proceedings upon service of a certificate (the á€œCCAA Termination Certificateá€) and authorization for the BioSteel Entities to file assignments in bankruptcy pursuant to the Bankruptcy and Insolvency Act. The BioSteel Entities were assigned into bankruptcy as of October 2, 2024. The bankruptcy of the BioSteel Entities will deal with any remaining nominal assets of the BioSteel Entities. The CCAA Termination Certificate was served on October 22, 2024.As a result of the foregoing, Canopy Growth no longer has a controlling interest in BioSteel US and BioSteel Manufacturing and has deconsolidated both entities effective November 16, 2023. The deconsolidation of BioSteel US and BioSteel Manufacturing and related impairment charges were classified under losses from discontinued operations. Á BioSteel Canada Á Á Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] Á Á Discontinued operations, description As a result of the CCAA Proceedings, the most relevant activity of BioSteel Canada became the liquidation and sale of assets. Management concluded that Canopy Growth ceased to have the power to direct the relevant activity of BioSteel Canada because the liquidation and sale transactions required approval from the CCAA Court. Thus, Canopy Growth no longer had a controlling interest in BioSteel Canada and had deconsolidated the entity effective September 14, 2023. The deconsolidation of BioSteel Canada and related impairment charges were classified under losses from discontinued operations. Á BioSteel US Á Á Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] Á Á Ownership percentage 100.00% Á BioSteel Manufacturing Á Á Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] Á Á Ownership percentage 100.00% Á X - DefinitionDisposal group including discontinued operation receivable. + ReferencesNo definition available. + Details Name: cgc_DisposalGroupIncludingDiscontinuedOperationReceivable Namespace Prefix: cgc_ Data Type: xbrli:monetaryItem Type Balance Type: debit Period Type: instant X - DefinitionDescription of the facts and circumstances leading to the completed or expected disposal, and the manner and timing of that disposal. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a)(1) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483499/205-20-50-1>Reference 2: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a)(2) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483499/205-20-50-1>Reference 3: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482099/360-10-50-3>Reference 4: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482099/360-10-50-3>Reference 5: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 5.2.5.Q2) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480781/205-20-S99-2> + Details Name: us-gaap_DisposalGroupIncludingDiscontinuedOperationDescriptionAndTimingOfDisposal Namespace Prefix: us-gaap_ Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration X - DefinitionThe percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a)(1) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481687/323-10-50-3> + Details Name: us-gaap_EquityMethodInvestmentOwnershipPercentage Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItem Type Balance Type: na Period Type: instant X - DefinitionFair value portion of investments accounted under the equity method. + ReferencesReference 1: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2E -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482106/820-10-50-2E>Reference 2: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482106/820-10-50-2>Reference 3: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482106/820-10-50-2>Reference 4: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(12)) -Publisher

FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_EquityMethodInvestmentsFairValueDisclosure Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=cgc_BioSteelMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=cgc_BioSteelUSAndBioSteelManufacturingMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=cgc_BioSteelCanadaMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=cgc_BioSteelUSMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=cgc_BioSteelManufacturingMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 76 R69.htm IDEA: XBRL DOCUMENT v3.25.0.1 Biosteel - Summary of Deconsolidation and Costs to Exit Classified as Discontinued Operations (Details) - CAD (\$) \$ in Thousands 3 Months Ended 9 months Ended Dec. 31, 2024 Dec. 31, 2023 Dec. 31, 2024 Dec. 31, 2023 Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] Á Á Á Discontinued Operation, Gain (Loss) on Disposal, Statement of Income or Comprehensive Income [Extensible Enumeration] Comprehensive income (loss), net of tax, from discontinued operations including portion attributable to noncontrolling interest Comprehensive income (loss), net of tax, from discontinued operations including portion attributable to noncontrolling interest Comprehensive income (loss), net of tax, from discontinued operations including portion attributable to noncontrolling interest Comprehensive income (loss), net of tax, from discontinued operations including portion attributable to noncontrolling interest Comprehensive income (loss), net of tax, from discontinued operations including portion attributable to noncontrolling interest BioSteel Á Á Á Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] Á Á Á Net revenue Á \$ 172 Á \$ 56,610 Cost of goods sold Á 1,900 Á 145,625 Operating expenses Á (726) Á 97,851 Operating loss Á (1,002) Á (186,866) Other income (expense), net [1] \$ 0 14,481 \$ 5,310 (8,521) Income tax (expense) recovery Á 0 Á 936 Net income (loss) on discontinued operations, net of tax \$ 0 \$ 13,479 \$ 5,310 \$ (194,451) [1] Included in Other income (expense), net for the three and nine months ended December 31, 2024 is a gain/loss on deconsolidation of \$nil and \$nil, respectively (three and nine months ended December 31, 2023 - gain on deconsolidation of \$12,417 and loss on deconsolidation of \$9,820, respectively). X - DefinitionDisposal group, including discontinued operation, other income (expense). + ReferencesNo definition available. + Details Name: cgc_DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpense Namespace Prefix: cgc_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount after tax of gain (loss) not previously recognized resulting from the disposal of a discontinued operation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5C -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5CReference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 3B -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-3BReference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-3 + Details Name: us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionIndicates line item in statement of income or comprehensive income that includes gain (loss) from disposal of discontinued operation. + ReferencesReference 1: http://www.xbrli.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-1 + Details Name: us-gaap_DiscontinuedOperationGainLossOnDisposalStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration Namespace Prefix: us-gaap_ Data Type: enum2:enumerationSetItemType Balance Type: na Period Type: duration X - DefinitionAmount of tax expense (benefit) related to a discontinued operation. Includes, but is not limited to, tax expense (benefit) related to income (loss) from operations during the phase-out period, tax expense (benefit) related to gain (loss) on disposal, tax expense (benefit) related to gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and tax expense (benefit) related to adjustments of a prior period gain (loss) on disposal. + ReferencesReference 1: http://www.xbrli.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 6.1.7) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1Reference 2: http://www.xbrli.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10Reference 3: http://www.xbrli.org/2003/role/disclosureRef -Topic 740 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 3A -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-3AReference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5BReference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5C -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5CReference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 3B -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-3BReference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-4Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-1 + Details Name: us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of costs of goods sold attributable to disposal group, including, but not limited to, discontinued operation. + ReferencesReference 1: http://www.xbrli.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5B + Details Name: us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of operating expense attributable to disposal group, including, but not limited to, discontinued operation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5B + Details Name: us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of operating income (loss) attributable to disposal group, including, but not limited to, discontinued operation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5B + Details Name: us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of revenue attributable to disposal group, including, but not limited to, discontinued operation. + ReferencesReference 1: http://www.xbrli.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5B + Details Name: us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=cgc_BioSteelMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 77 R70.htm IDEA: XBRL DOCUMENT v3.25.0.1 Biosteel - Summary of Deconsolidation and Costs to Exit Classified as Discontinued Operations (Parenthetical) (Details) - CAD (\$) \$ in Thousands 3 Months Ended 9 Months Ended Dec. 31, 2024 Dec. 31, 2023 Dec. 31, 2024 Dec. 31, 2023 BioSteel Á Á Á Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] Á Á Á Gain (loss) on deconsolidation \$ 0 \$ 12,417 \$ 0 \$ (9,820) X - DefinitionAmount of gain (loss) from deconsolidation of subsidiary and derecognition of group of assets constituting transfer of business or nonprofit activity, excluding conveyance of oil and gas mineral rights and transfer of good or service in contract with customer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 50 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1B + Details Name: us-gaap_DeconsolidationGainOrLossAmount Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=cgc_BioSteelMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 78 R71.htm IDEA: XBRL DOCUMENT v3.25.0.1 Biosteel - Summary of Assets and Liabilities Classified as Discontinued Operations and Major Categories (Details) - BioSteel \$ in Thousands Mar. 31, 2024 CAD (\$) (Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] Á Receivable from BioSteel Entities \$ 8,038 Total assets of discontinued operations \$ 8,038 X - DefinitionDisposal group including discontinued operation receivable. + ReferencesNo definition available. + Details Name: cgc_DisposalGroupIncludingDiscontinuedOperationReceivable Namespace Prefix: cgc_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount classified as assets attributable to disposal group held for sale or disposed of. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 10 -SubTopic 20 -Topic 205 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-10Reference 2: http://www.xbrli.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 3: http://www.xbrli.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5C -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5CReference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5BReference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-3Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-11 + Details Name: us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=cgc_BioSteelMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 79 R72.htm IDEA: XBRL DOCUMENT v3.25.0.1 Loss on Asset Impairment and Restructuring - Additional Information (Details) - CAD (\$) \$ in Thousands 3 Months Ended 9 Months Ended Dec. 31, 2024 Dec. 31, 2023 Dec. 31, 2024 Dec. 31, 2023 Restructuring Cost And Reserve [Line Items] Á Á Á Loss on asset impairment and restructuring \$ 1,285 \$ 30,413 \$ 22,135 \$ 2,452 X - DefinitionAmount of gain (loss) from the difference between the sale price or salvage price and the book value of an asset that was sold or retired, and gain (loss) from the write down of assets from their carrying value to fair value. + ReferencesReference 1: http://www.xbrli.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrli.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 5.P.4.d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2Reference 2: http://www.xbrli.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 5.P.4.b.1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2Reference 3: http://www.xbrli.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 5.P.4.b.2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2Reference 4: http://www.xbrli.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1Reference 5: http://www.xbrli.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1Reference 6: http://www.xbrli.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1Reference 7: http://www.xbrli.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1 + Details Name: us-gaap_RestructuringCostAndReserveLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 80 R73.htm IDEA: XBRL DOCUMENT v3.25.0.1 Cash and Cash Equivalents - Components of Cash and Cash Equivalents (Details) - CAD (\$) \$ in Thousands Dec. 31, 2024 Mar. 31, 2024 Cash and Cash Equivalents [Abstract] Á Á Cash \$ 145,599 \$ 115,427 Cash equivalents 16,310 54,873 Cash and cash equivalents \$ 161,909 \$ 170,300 X - DefinitionAmount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation. + ReferencesReference 1: http://www.xbrli.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 2: http://www.xbrli.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 3: http://www.xbrli.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name

Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(2)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147478777/944-210-S99-1>Reference 4: [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.6-04\(4\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1)Reference 5: <http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 45 -Paragraph 21 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477796/946-210-45-2>Reference 6: [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(1\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1)Reference 7: [http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(1\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 45 -Paragraph 20 -SubTopic 210 -Topic 946 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477796/946-210-45-20 + Details Name: us-gaap_CashAndCashEquivalentsAbstract Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_CashAndCashEquivalentsAbstract Namespace Prefix: us-gaap_Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1)Reference 2: [http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1](http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1)Reference 3: [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.7-03\(a\)\(2\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4 + Details Name: us-gaap_CashAndCashEquivalentsAtCarryingValue Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1)Reference 2: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.9-03\(4\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_CashEquivalentsAtCarryingValue Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant XML 81 R74.htm IDEA: XBRL DOCUMENT v3.25.0.1 Short-term Investments - Components of Short-term Investments (Details) - CAD ($) $ in Thousands Dec. 31, 2024 Mar. 31, 2024 Marketable Securities [Line Items] A A Short-term investments $ 16,435 $ 33,161 Term Deposits A A Marketable Securities [Line Items] A A Short-term investments $ 16,435 $ 33,161 X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: us-gaap_MarketableSecuritiesLineItems Namespace Prefix: us-gaap_Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1)Reference 2: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.9-03\(5\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1)Reference 3: [http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.7-03\(a\)\(1\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_ShortTermInvestments Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - Details Name: us-gaap_FinancialInstrumentAxis=us-gaap_DepositsMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 82 R75.htm IDEA: XBRL DOCUMENT v3.25.0.1 Short-term Investments - Additional Information (Details) - CAD ($) $ in Thousands Dec. 31, 2024 Mar. 31, 2024 Short-Term Investments [Abstract] A A Amortized cost of short-term investments $ 16,435 $ 33,161 X - DefinitionAmortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1)Reference 2: [http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2)Reference 3: [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 310 -SubTopic 20 -Name Accounting Standards Codification -Section 40 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481628/310-20-40-7](http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1 + Details Name: us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_ShortTermInvestmentsAbstract Namespace Prefix: us-gaap_Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 83 R76.htm IDEA: XBRL DOCUMENT v3.25.0.1 Amounts Receivable, Net - Components of Amounts Receivable, Net (Details) - CAD ($) $ in Thousands Dec. 31, 2024 Mar. 31, 2024 Receivables [Abstract] A A Accounts receivable, net $ 44,393 $ 44,943 Indirect taxes receivable 3,655 2,517 Interest receivable 1,004 876 Other receivables 6,351 Amounts receivable, net $ 49,058 $ 51,847 X - DefinitionAmount, after allowance for credit loss, of accounts and financing receivables, classified as current. Includes, but is not limited to, notes and loan receivable. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481990/310-10-45-2 + Details Name: us-gaap_AccountsNotesAndLoansReceivableNetCurrent Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481990/310-10-45-2 + Details Name: us-gaap_AccountsReceivableNetCurrent Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionCarrying amount as of the balance sheet date of current interest earned but not received. Also called accrued interest or accrued interest receivable. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(3)(a)(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_InterestReceivableCurrent Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount, after allowance, of receivables classified as other, due within one year or the operating cycle, if longer. + ReferencesNo definition available. + Details Name: us-gaap_OtherReceivablesNetCurrent Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_ReceivablesAbstract Namespace Prefix: us-gaap_Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionCarrying amount as of the balance sheet date of value added taxes due either from customers arising from sales on credit terms, or as previously overpaid to tax authorities. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(3)(a)(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_ValueAddedTaxReceivable Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant XML 84 R77.htm IDEA: XBRL DOCUMENT v3.25.0.1 Amounts Receivable, Net - Additional Information (Details) - CAD ($) $ in Thousands Dec. 31, 2024 Mar. 31, 2024 Accounts, Notes, Loans and Financing Receivable [Line Items] A A Allowance for doubtful accounts $ 8,161 $ 9,903 X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 310 -SubTopic 20 -Name Accounting Standards Codification -Section 40 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481628/310-20-40-7)Reference 2: [http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(4\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481990/310-10-45-2 + Details Name: us-gaap_AccountsNotesAndLoansReceivableLineItems Namespace Prefix: us-gaap_Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of allowance for credit loss on accounts receivable, classified as current. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1)Reference 2: <http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479344/326-20-45-1>Reference 3: [http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10](http://www.xbrl.org/2003/role/disclosureRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481962/310-10-50-4 + Details Name: us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant XML 85 R78.htm IDEA: XBRL DOCUMENT v3.25.0.1 Inventory - Components of Inventory (Details) - CAD ($) $ in Thousands Dec. 31, 2024 Mar. 31, 2024 Inventory Disclosure [Abstract] A A Raw materials, packaging supplies and consumables $ 15,980 $ 18,872 Work in progress 42,733 31,367 Finished goods 32,040 27,053 Inventory $ 90,753 $ 77,992 X - ReferencesNo definition available. + Details Name: us-gaap_InventoryDisclosureAbstract Namespace Prefix: us-gaap_Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(6)(a)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_InventoryFinishedGoods Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10)Reference 2: [http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1](http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1)Reference 3: [http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10](http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_InventoryNet Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionGross amount of unprocessed materials to be used in manufacturing or production process and supplies that will be consumed. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_InventoryRawMaterialsAndSupplies Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(6)(a)(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_InventoryWorkInProcess Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant XML 86 R79.htm IDEA: XBRL DOCUMENT v3.25.0.1 Inventory - Additional Information (Details) - CAD ($) $ in Thousands 3 Months Ended 9 Months Ended Dec. 31, 2024 Dec. 31, 2023 Dec. 31, 2024 Dec. 31, 2023 Inventory Disclosure [Abstract] A A Inventory write-downs $ 1,225 $ 859 $ 3,130 $ 8,362 X - ReferencesNo definition available. + Details Name: us-gaap_InventoryDisclosureAbstract Namespace Prefix: us-gaap_Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 330 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483080/330-10-50-2 + Details Name: us-gaap_InventoryWriteDown Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration XML 87 R80.htm IDEA: XBRL DOCUMENT v3.25.0.1 Prepaid Expenses and Other Assets - Components of Prepaid Expenses and Other Assets (Details) - CAD ($) $ in Thousands Dec. 31, 2024 Mar. 31, 2024 Prepaid Expense and Other Assets, Current [Abstract] A A Prepaid expenses $ 5,609 $ 6,621 Deposits 5,254 2,365 Other assets 4,959 14,246 Prepaid and other assets $ 15,822 $ 23,232 X - DefinitionPrepaid deposits current. + ReferencesNo definition available. + Details Name: cgc_PrepaidDepositsCurrent Namespace Prefix: cgc_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of current assets classified as other. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10)Reference 2: [http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph \(g\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_OtherAssetsCurrent Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_PrepaidExpenseAndOtherAssetsCurrent Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract Namespace Prefix: us-gaap_Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1)Reference 2: <http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482955/340-10-05-5>Reference 4: [http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph \(i\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 340 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483032/340-10-45-1 + Details Name: us-gaap_PrepaidExpenseCurrent Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant XML 88 R81.htm IDEA: XBRL DOCUMENT v3.25.0.1 Equity Method Investments - Components of Equity Method Investments (Details) $ in Thousands Dec. 31, 2024 CAD ($) Schedule of Equity Method Investments [Line Items] A Equity method investments $ 49,834 X - DefinitionThis item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1)Reference 2:

[http://www.xbrl.org/2003/role/disclosureRef-Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph \(ee\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 3](http://www.xbrl.org/2003/role/disclosureRef-Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 3): <http://www.xbrl.org/2003/role/disclosureRef-Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481664/323-10-45-1Reference 4>: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph \(a\)\(3\)-Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-32Reference 5](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a)(3)-Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-32Reference 5):

S99-6Reference 48:

[illegible]

http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 10 -Name Accounting Standards Codification -Section 545 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480265/350-10-545-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 928 -SubTopic 340 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478859/928-340-50-1 + Details Name: us-gaap_FiniteLivedIntangibleAssetsGross Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 926 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483154/926-20-50-5 + Details Name: us-gaap_FiniteLivedIntangibleAssetsNet Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 10 -Name Accounting Standards Codification -Section 545 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480265/350-10-545-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2 + Details Name: us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionSum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482686/350-30-45-1 + Details Name: us-gaap_IntangibleAssetsNetExcludingGoodwill Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - Details Name: us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_IntellectualPropertyMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=cgc_DistributionChannelMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=cgc_OperatingLicensesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=cgc_SoftwareAndDomainNamesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=cgc_BrandsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=cgc_AmortizableIntangiblesInProcessMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=cgc_AcquiredBrandsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: XML 94 R87.htm IDEA: XBRL DOCUMENT v3.25.0.1 Intangible Assets - Additional Information (Details) - CAD (\$) in Thousands 3 Months Ended 9 Months Ended Dec. 31, 2024 Dec. 31, 2023 Dec. 31, 2024 Dec. 31, 2023 Finite Lived Intangible Assets [Line Items] Á Á Á Amortization of intangible assets Á Á \$ 16,081 \$ 19,396 Costs Recorded in Cost of Goods Sold Á Á Á Finite Lived Intangible Assets [Line Items] Á Á Á Á Amortization of intangible assets \$ 5 \$ 13 29 41 Selling, General and Administrative Expenses Á Á Á Á Finite Lived Intangible Assets [Line Items] Á Á Á Á Amortization of intangible assets \$ 5,367 \$ 6,310 \$ 16,052 \$ 19,355 X - DefinitionThe aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482686/350-30-45-2 + Details Name: us-gaap_AmortizationOfIntangibleAssets Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482686/350-30-45-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-3Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 985 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 926 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483154/926-20-50-5 + Details Name: us-gaap_FiniteLivedIntangibleAssetsLineItems Namespace Prefix: us-gaap_Data Type: xbrli:stringItemBalance Type: na Period Type: duration X - Details Name: us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: XML 95 R88.htm IDEA: XBRL DOCUMENT v3.25.0.1 Goodwill - Changes in Carrying Amount of Goodwill (Details) - CAD (\$) in Thousands 9 Months Ended 12 Months Ended Dec. 31, 2024 Mar. 31, 2024 Goodwill [Line Items] Á Á Beginning Balance \$ 43,239 \$ 85,563 Impairment losses Á (42,081) Foreign currency translation adjustments 854 (243) Ending Balance \$ 44,093 \$ 43,239 X - DefinitionAmount, after accumulated impairment loss, of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 49 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482548/350-20-55-24Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 100 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-50-99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482598/350-20-45-1Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Sub

Page 24 - Publisher FASB -URI https://asc.fasb.org/1943274/2147482548/350-20-55-24Reference 2: [http://www.xbrl.org/2003/role/disclosureRef-Topic 350-SubTopic 20-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \(b\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482573/350-20-50-2Reference 3](http://www.xbrl.org/2003/role/disclosureRef-Topic 350-SubTopic 20-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (b)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482573/350-20-50-2Reference 3): <http://www.xbrl.org/2003/role/disclosureRef-Topic 350-SubTopic 20-Name Accounting Standards Codification-Section 50-Paragraph 1-Publisher FASB-URI https://asc.fasb.org/1943274/2147482573/350-20-50-1Reference 4>: [http://www.xbrl.org/2003/role/disclosureRef-Topic 350-SubTopic 20-Name Accounting Standards Codification-Section 50-Paragraph 1-Subparagraph \(a\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482573/350-20-50-1Reference 5](http://www.xbrl.org/2003/role/disclosureRef-Topic 350-SubTopic 20-Name Accounting Standards Codification-Section 50-Paragraph 1-Subparagraph (a)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482573/350-20-50-1Reference 5): [http://www.xbrl.org/2003/role/disclosureRef-Topic 350-SubTopic 20-Name Accounting Standards Codification-Section 50-Paragraph 1-Subparagraph \(b\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482573/350-20-50-1Reference 6](http://www.xbrl.org/2003/role/disclosureRef-Topic 350-SubTopic 20-Name Accounting Standards Codification-Section 50-Paragraph 1-Subparagraph (b)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482573/350-20-50-1Reference 6): [http://www.xbrl.org/2003/role/disclosureRef-Topic 350-SubTopic 20-Name Accounting Standards Codification-Section 50-Paragraph 1-Subparagraph \(c\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482573/350-20-50-1Reference 7](http://www.xbrl.org/2003/role/disclosureRef-Topic 350-SubTopic 20-Name Accounting Standards Codification-Section 50-Paragraph 1-Subparagraph (c)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482573/350-20-50-1Reference 7): [http://www.xbrl.org/2003/role/disclosureRef-Topic 350-SubTopic 20-Name Accounting Standards Codification-Section 50-Paragraph 1-Subparagraph \(d\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482573/350-20-50-1Reference 8](http://www.xbrl.org/2003/role/disclosureRef-Topic 350-SubTopic 20-Name Accounting Standards Codification-Section 50-Paragraph 1-Subparagraph (d)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482573/350-20-50-1Reference 8): [http://www.xbrl.org/2003/role/disclosureRef-Topic 350-SubTopic 20-Name Accounting Standards Codification-Section 50-Paragraph 1-Subparagraph \(e\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482573/350-20-50-1Reference 9](http://www.xbrl.org/2003/role/disclosureRef-Topic 350-SubTopic 20-Name Accounting Standards Codification-Section 50-Paragraph 1-Subparagraph (e)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482573/350-20-50-1Reference 9): [http://www.xbrl.org/2003/role/disclosureRef-Topic 350-SubTopic 20-Name Accounting Standards Codification-Section 50-Paragraph 1-Subparagraph \(f\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482573/350-20-50-1Reference 10](http://www.xbrl.org/2003/role/disclosureRef-Topic 350-SubTopic 20-Name Accounting Standards Codification-Section 50-Paragraph 1-Subparagraph (f)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482573/350-20-50-1Reference 10): [http://www.xbrl.org/2003/role/disclosureRef-Topic 350-SubTopic 20-Name Accounting Standards Codification-Section 50-Paragraph 1-Subparagraph \(g\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482573/350-20-50-1Reference 11](http://www.xbrl.org/2003/role/disclosureRef-Topic 350-SubTopic 20-Name Accounting Standards Codification-Section 50-Paragraph 1-Subparagraph (g)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482573/350-20-50-1Reference 11): [http://www.xbrl.org/2003/role/disclosureRef-Topic 350-SubTopic 20-Name Accounting Standards Codification-Section 50-Paragraph 1-Subparagraph \(h\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482573/350-20-50-1Reference 12](http://www.xbrl.org/2003/role/disclosureRef-Topic 350-SubTopic 20-Name Accounting Standards Codification-Section 50-Paragraph 1-Subparagraph (h)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482573/350-20-50-1Reference 12): [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.5-02\(20\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480566/210-10-50-1Reference 2](http://www.xbrl.org/2003/role/disclosureRef-Topic 350-SubTopic 20-Name Accounting Standards Codification-Section 50-Paragraph 1A-Publisher FASB-URI https://asc.fasb.org/1943274/2147482573/350-20-50-1A+Details Name: us-gaap_GoodwillLineItems Namespace Prefix: us-gaap_Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X-Details Name: us-gaap_StatementBusinessSegmentsAxis=cgc_StorzBickelReportingUnitMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 97 R90.htm IDEA: XBRL DOCUMENT v3.25.0.1 Other Accrued Expenses and Liabilities - Components of Other Accrued Expenses and Liabilities (Details) - CAD ($) in Thousands Dec. 31, 2024 Mar. 31, 2024 Accounts Payable and Accrued Liabilities, Current [Abstract] A Employee compensation $ 10,822 $ 21,468 Taxes and government fees 11,337 10,519 Professional fees 3,120 5,849 Other 11,912 16,203 Other accrued expenses and liabilities $ 37,191 $ 54,039 X-DefinitionTaxes and government fees payable&c; current. + ReferencesNo definition available. + Details Name: cgc_TaxesAndGovernmentFeesPayableCurrent Namespace Prefix: cgc_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X-ReferencesNo definition available. + Details Name: us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract Namespace Prefix: us-gaap_Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X-DefinitionAmount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other. + ReferencesNo definition available. + Details Name: us-gaap_AccruedLiabilitiesAndOtherLiabilities Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X-DefinitionCarrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesReference 1: <a href=): [http://www.xbrl.org/2003/role/disclosureRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.5-02\(20\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480566/210-10-50-1Reference 3](http://www.xbrl.org/2003/role/disclosureRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.5-02(20))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480566/210-10-50-1Reference 3): [http://www.xbrl.org/2003/role/disclosureRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.5-02\(20\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480566/210-10-50-1Reference 4](http://www.xbrl.org/2003/role/disclosureRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.5-02(20))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480566/210-10-50-1Reference 4): [http://www.xbrl.org/2003/role/disclosureRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.5-02\(20\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480566/210-10-50-1Reference 5](http://www.xbrl.org/2003/role/disclosureRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.5-02(20))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480566/210-10-50-1Reference 5): [http://www.xbrl.org/2003/role/disclosureRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.5-02\(20\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480566/210-10-50-1Reference 6](http://www.xbrl.org/2003/role/disclosureRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.5-02(20))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480566/210-10-50-1Reference 6): [http://www.xbrl.org/2003/role/disclosureRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.5-02\(20\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480566/210-10-50-1Reference 7](http://www.xbrl.org/2003/role/disclosureRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.5-02(20))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480566/210-10-50-1Reference 7):

[illegible]

borrowing rate 1.00% Aggregate principal amount of debentures \$ 96,358 Accretion Rate + ReferencesNo definition available. + Details Name: cgc_AccretionRate Namespace Prefix: cgc_Data Type: dtr-types:percentItem Type: na Period Type: duration X - DefinitionAdditional incremental debt. + ReferencesNo definition available. + Details Name: cgc_AdditionalIncrementalSeniorSecuredDebt Namespace Prefix: cgc_Data Type: xbrli:monetaryItem Type: Balance Type: credit Period Type: duration X - DefinitionAdditional incremental term loan facility. + ReferencesNo definition available. + Details Name: cgc_AdditionalIncrementalTermLoanFacility Namespace Prefix: cgc_Data Type: xbrli:monetaryItem Type: Balance Type: credit Period Type: instant X - DefinitionAggregate principal amount of debentures. + ReferencesNo definition available. + Details Name: cgc_AggregatePrincipalAmountOfDebentures Namespace Prefix: cgc_Data Type: xbrli:monetaryItem Type: Balance Type: debit Period Type: duration X - DefinitionAverage closing trading price of common shares. + ReferencesNo definition available. + Details Name: cgc_AverageClosingTradingPriceOfCommonShares Namespace Prefix: cgc_Data Type: dtr-types:perShareItem Type: Balance Type: na Period Type: duration X - DefinitionCancellation of Debt. + ReferencesNo definition available. + Details Name: cgc_CancellationOfDebt Namespace Prefix: cgc_Data Type: xbrli:monetaryItem Type: Balance Type: debit Period Type: duration X - DefinitionConversion OF Outstanding Debentures Description + ReferencesNo definition available. + Details Name: cgc_ConversionOfOutstandingDebenturesDescription Namespace Prefix: cgc_Data Type: xbrli:stringItem Type: Balance Type: na Period Type: duration X - DefinitionDebt instrument acquired. + ReferencesNo definition available. + Details Name: cgc_DebtInstrumentAcquired Namespace Prefix: cgc_Data Type: xbrli:monetaryItem Type: Balance Type: debit Period Type: duration X - DefinitionDebt instrument cancelled. + ReferencesNo definition available. + Details Name: cgc_DebtInstrumentCancelled Namespace Prefix: cgc_Data Type: xbrli:monetaryItem Type: Balance Type: debit Period Type: duration X - DefinitionDebt instrument discounted price. + ReferencesNo definition available. + Details Name: cgc_DebtInstrumentDiscountedPrice Namespace Prefix: cgc_Data Type: xbrli:monetaryItem Type: Balance Type: credit Period Type: instant X - DefinitionDebt instrument discounted price per us dollar. + ReferencesNo definition available. + Details Name: cgc_DebtInstrumentDiscountedPricePerUsDollar Namespace Prefix: cgc_Data Type: dtr-types:perShareItem Type: Balance Type: na Period Type: instant X - DefinitionDebt instrument final closing trading days. + ReferencesNo definition available. + Details Name: cgc_DebtInstrumentFinalClosingTradingDays Namespace Prefix: cgc_Data Type: xbrli:durationItem Type: Balance Type: na Period Type: duration X - DefinitionDebt Instrument Monthly Interest Rate Percentage. + ReferencesNo definition available. + Details Name: cgc_DebtInstrumentMonthlyInterestRatePercentage Namespace Prefix: cgc_Data Type: dtr-types:percentItem Type: Balance Type: na Period Type: instant X - DefinitionDebt instrument principal reduction. + ReferencesNo definition available. + Details Name: cgc_DebtInstrumentPrincipalReduction Namespace Prefix: cgc_Data Type: xbrli:monetaryItem Type: Balance Type: credit Period Type: duration X - DefinitionDebt instrument shares acquired percentage. + ReferencesNo definition available. + Details Name: cgc_DebtInstrumentSharesAcquiredPercentage Namespace Prefix: cgc_Data Type: dtr-types:percentItem Type: Balance Type: na Period Type: duration X - DefinitionGross proceeds from exchange and subscription agreement of debt. + ReferencesNo definition available. + Details Name: cgc_GrossProceedsFromExchangeAndSubscriptionAgreementOfDebt Namespace Prefix: cgc_Data Type: xbrli:monetaryItem Type: Balance Type: debit Period Type: duration X - DefinitionLiquidity requirement. + ReferencesNo definition available. + Details Name: cgc_LiquidityRequirement Namespace Prefix: cgc_Data Type: xbrli:monetaryItem Type: Balance Type: debit Period Type: instant X - DefinitionNumber of canopy shares exchanged. + ReferencesNo definition available. + Details Name: cgc_NumberOfCanopySharesExchanged Namespace Prefix: cgc_Data Type: xbrli:sharesItem Type: Balance Type: na Period Type: duration X - DefinitionPrincipal amount of accretion debentures. + ReferencesNo definition available. + Details Name: cgc_PrincipalAmountOfAccretionDebentures Namespace Prefix: cgc_Data Type: xbrli:monetaryItem Type: Balance Type: credit Period Type: instant X - DefinitionPrincipal payments of accretion debentures. + ReferencesNo definition available. + Details Name: cgc_PrincipalPaymentsOfAccretionDebentures Namespace Prefix: cgc_Data Type: xbrli:monetaryItem Type: Balance Type: credit Period Type: duration X - DefinitionProceeds from the Credit Facility. + ReferencesNo definition available. + Details Name: cgc_ProceedsFromCreditFacility Namespace Prefix: cgc_Data Type: xbrli:monetaryItem Type: Balance Type: debit Period Type: duration X - DefinitionSubscription percentage for proposed financing. + ReferencesNo definition available. + Details Name: cgc_SubscriptionPercentageForProposedFinancing Namespace Prefix: cgc_Data Type: dtr-types:percentItem Type: Balance Type: na Period Type: duration X - DefinitionWarrant issued. + ReferencesNo definition available. + Details Name: cgc_WarrantIssued Namespace Prefix: cgc_Data Type: xbrli:sharesItem Type: Balance Type: na Period Type: duration X - DefinitionExercise price per share or per unit of warrants or rights outstanding. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef-Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3 + Details Name: us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 Namespace Prefix: us-gaap_Data Type: dtr-types:perShareItem Type: Balance Type: na Period Type: instant X - DefinitionAmount of annual principal payment for debt instrument. + ReferencesReference 1:

[if longer.](#) + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph \(SX 210.6-03\(i\)\(1\)\)](http://www.xbrl.org/2003/role/disclosureRef-Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(1))) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479886/946-10-S99-3>Reference 2: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 15 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15](http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 14 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14 + Details Name: us-gaap ProceedsFromIssuanceOfLongTermDebt Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef-Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 15 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15)Reference 2: [http://www.xbrl.org/2003/role/disclosureRef-Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph \(SX 210.6-03\(i\)\(2\)\)](http://www.xbrl.org/2003/role/disclosureRef-Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(2))) -Publisher FASB -URI [http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2](https://asc.fasb.org/1943274/2147479886/946-10-S99-3 + Details Name: us-gaap RepaymentsOfLongTermDebt Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionPeriod type of a single share of a number of saleable stocks of a company. + ReferencesNo definition available. + Details Name: us-gaap SharePrice Namespace Prefix: us-gaap_Data Type: dt-types:perShareItem Type Balance Type: na Period Type: instant X - DefinitionNumber of shares issued during the period as a result of the conversion of convertible securities. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2)Reference 2: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(29\)\)](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29))) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1>Reference 3: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(30\)\)](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30))) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1>Reference 4: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph \(c\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1)Reference 5: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.3-04\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1)Reference 6:

10-S99-3Reference 16: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(1)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference> 17: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(2)(i)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference> 18: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(2)(ii)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479886/946-10-S99-3> + Details Name: us-gaap_ClassOfStockLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTotal number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1> + Details Name: us-gaap_CommonStockSharesIssued Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionThe cash inflow from the additional capital contribution to the entity. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482740/230-10-45-14> + Details Name: us-gaap_ProceedsFromIssuanceOfCommonStock Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe cash inflow from the issuance of an equity stock that has been previously reacquired by the entity. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482740/230-10-45-14> + Details Name: us-gaap_ProceedsFromSaleOfTreasuryStock Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe number of shares issued or sold by the subsidiary or equity method investee per stock transaction. + ReferencesNo definition available. + Details Name: us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481112/505-10-50-2> + Details Name: us-gaap_SharesIssued Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionNumber of shares issued during the period as a result of the conversion of convertible securities. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference> 2: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference> 3: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference> 4: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (c) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference> 5: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480008/505-10-S99-1Reference> 6: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 3 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481112/505-10-50-3> + Details Name: us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of new stock issued during the period. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference> 2: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference> 3: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference> 4: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147478448/946-505-50-2Reference> 5: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference> 6: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(1)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference> 7: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480008/505-10-S99-1> + Details Name: us-gaap_StockIssuedDuringPeriodSharesNewIssues Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionEquity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference> 2: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference> 3: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference> 4: <http://www.xbrl.org/2003/role/exampleRef> -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 11 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479168/946-830-55-11Reference> 5: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 946 -SubTopic 205 -Name Accounting Standards Codification -Section 45 -Paragraph 4 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147478009/946-205-45-4Reference> 6: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147478448/946-505-50-2Reference> 7: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference> 8: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480008/505-10-S99-1> + Details Name: us-gaap_StockIssuedDuringPeriodValueNewIssues Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - Details Name: us-gaap_SubsidarySaleOfStockAxis=cgc_ChiExchangeMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_TypeOfArrangementAxis=cgc_ChiExchangeAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_TypeOfArrangementAxis=cgc_SubscriptionAgreementWithInstitutionalInvestorsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_SubsidarySaleOfStockAxis=us-gaap_PrivatePlacementMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 103 R96.htm IDEA: XBRL DOCUMENT v3.25.0.1 Share Capital - Summary of Issuances of Stock Other (Details) - CAD (\$) \$ in Thousands 9 Months Ended Dec. 31, 2024 Dec. 31, 2023 Settlement of Acreage Acquisition [Member] Å Equity Class Of Treasury Stock [Line Items] Å Number of common shares 12,559,230 Å Share capital \$ 63,915 Å Share and warrant reserve 11,939 Å Settlement of Convertible Debentures [Member] Å Equity Class Of Treasury Stock [Line Items] Å Number of common shares 8,445,894 Å Share capital \$ 108,055 Å Settlement of Canopy Notes [Member] Å Equity Class Of Treasury Stock [Line Items] Å Number of common shares 11,477,366 Å Share capital \$ 57,084 Å Settlement of Debentures [Member] Å Equity Class Of Treasury Stock [Line Items] Å Number of common shares 7,341,818 Å Share capital \$ 87,754 Å Other Issuances and Share Issue Costs [Member] Å Equity Class Of Treasury Stock [Line Items] Å Number of common shares 6,165 Å Share capital \$ (6,567) Å (317) Å Share and warrant reserve 4 Å (80) Å Total [Member] Å Equity Class Of Treasury Stock [Line Items] Å Number of common shares 12,559,230 27,271,243 Å Share capital \$ 57,348 Å 252,576 Å Share and warrant reserve \$ 11,939 Å (80) X - DefinitionBusiness acquisition share based compensation reserve. + ReferencesNo definition available. + Details Name: cgc_BusinessAcquisitionShareBasedCompensationReserve Namespace Prefix: cgc_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionOther issuances of common shares net of share issuance cost. + ReferencesNo definition available. + Details Name: cgc_OtherIssuancesOfCommonSharesNetOfShareIssuanceCost Namespace Prefix: cgc_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionNumber of shares of equity interests issued or issuable to acquire entity. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 805 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(4) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479581/805-30-50-1> + Details Name: us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: us-gaap_EquityClassOfTreasuryStockLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_BusinessAcquisitionAxis=cgc_SettlementOfAcreageAcquisitionMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_BusinessAcquisitionAxis=cgc_SettlementOfConvertibleDebenturesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_BusinessAcquisitionAxis=cgc_SettlementOfCanopyNotesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_BusinessAcquisitionAxis=cgc_SettlementOfDebenturesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_BusinessAcquisitionAxis=cgc_OtherIssuancesAndShareIssueCostsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_BusinessAcquisitionAxis=cgc_TotalMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 104 R97.htm IDEA: XBRL DOCUMENT v3.25.0.1 Share Capital - Summary of Warrants (Details) - CAD (\$) \$ / shares in Units, \$ in Thousands 3 Months Ended Sep. 30, 2024 Jun. 30, 2024 Dec. 31, 2023 Warrants and Rights Note Disclosure [Abstract] Å Å Number of whole warrants, Beginning balance 10,451,457 10,451,457 12,819,305 [1] Number of whole warrants, Issuance of warrants Å 4,548,088 Å Number of whole warrants, Issuance of replacement warrants resulting from the Acreage Acquisition Å 1,845,843 Å Number of whole warrants, Exercise of warrants Å 1,279,660 Å Number of whole warrants, Expiry of warrants Å Å (12,692,731) Number of whole warrants, Issuance of warrants from private placement Å Å 2,292,947 Number of whole warrants, Ending balance Å 15,565,728 2,419,521 [1] Average exercise price, Beginning balance Å 9.12 9.12 580.4 [1] Average exercise price, Issuance of warrants Å 13.31 Å Average exercise price, Issuance of replacement warrants resulting from the Acreage Acquisition Å 10.72 Å Average exercise price, Exercise of warrants Å 6.6 Å Average exercise price, Expiry of warrants Å Å 583.62 Å Average exercise price, Issuance of warrants from private placement Å Å 18.33 Å Average exercise price, Ending balance Å Å \$ 11.09 \$ 30.34 [1] Warrant value, Beginning balance Å 2,610,519 2,610,519 2,581,788 [1] Warrant value, Issuance of warrants 2,635 8,697 13,525 Å Warrant value, Issuance of replacement warrants resulting from Acreage Acquisition Å 7,111 Å Warrant value, Exercise of warrants Å (3,018) Å Warrant value, Issuance of warrants from private placement Å Å 8,977 Å Warrant value, Ending balance Å Å 2,628,137 2,590,765 [1] [1] This balance excludes warrants previously issued by the Company to CBG (as defined below) which were exercisable to acquire 1,281,815 common shares at an exercise price equal to the 5-day volume-weighted average price of the Company common shares immediately prior to exercise (the "Tranche C Warrants"). The Tranche C Warrants represent a derivative liability and have nominal value. As of November 1, 2023, the Tranche C Warrants are considered expired in accordance with their terms. X - DefinitionAverage exercise price on issuance of replacement warrants resulting from acreage acquisition. + ReferencesNo definition available. + Details Name: cgc_AverageExercisePriceOnIssuanceOfReplacementWarrantsResultingFromAcreageAcquisition Namespace Prefix: cgc_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionAverage exercise price on issuance of warrants. + ReferencesNo definition available. + Details Name: cgc_AverageExercisePriceOnIssuanceOfWarrants Namespace Prefix: cgc_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionAverage exercise price on issuance of warrants from private placement. + ReferencesNo definition available. + Details Name: cgc_AverageExercisePriceOnIssuanceOfWarrantsFromPrivatePlacement Namespace Prefix: cgc_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionAverage exercise price on warrants exercised. + ReferencesNo definition available. + Details Name: cgc_AverageExercisePriceOnWarrantExercised Namespace Prefix: cgc_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionAverage Exercise Price On Warrant Expiry. + ReferencesNo definition available. + Details Name: cgc_AverageExercisePriceOnWarrantExpiry Namespace Prefix: cgc_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionIssuance of replacement warrants resulting from acreage acquisition, warrants value. + ReferencesNo definition available. + Details Name: cgc_IssuanceOfReplacementWarrantsResultingFromAcreageAcquisitionWarrantsValue Namespace Prefix: cgc_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionNumber of whole warrants on exercise of warrants. + ReferencesNo definition available. + Details Name: cgc_NumberOfWholeWarrantsOnExerciseOfWarrants Namespace Prefix: cgc_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of whole warrants on expiry of warrants. + ReferencesNo definition available. + Details Name: cgc_NumberOfWholeWarrantsOnExpiryOfWarrants Namespace Prefix: cgc_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of whole warrants on issuance of replacement warrants resulting from acreage acquisition. + ReferencesNo definition available. + Details Name: cgc_NumberOfWholeWarrantsOnIssuanceOfReplacementWarrantsResultingFromAcreageAcquisition Namespace Prefix: cgc_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of whole warrants on issuance of warrants. + ReferencesNo definition available. + Details Name: cgc_NumberOfWholeWarrantsOnIssuanceOfWarrants Namespace Prefix: cgc_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionWarrant value. + ReferencesNo definition available. + Details Name: cgc_WarrantValue Namespace Prefix: cgc_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionWarrant value exercise of warrants. + ReferencesNo definition available. + Details Name: cgc_WarrantValueExerciseOfWarrants Namespace Prefix: cgc_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionWarrant value issuance of warrants. + ReferencesNo definition available. + Details Name: cgc_WarrantValueIssuanceOfWarrants Namespace Prefix: cgc_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionWarrant value issuance of warrants from private placement. + ReferencesNo definition available. + Details Name: cgc_WarrantValueIssuanceOfWarrantsFromPrivatePlacement Namespace Prefix: cgc_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionWarrant average exercise price. + ReferencesNo definition available. + Details Name: cgc_WarrantsAverageExercisePrice Namespace Prefix: cgc_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionNumber of warrants or rights outstanding. + ReferencesNo definition available. + Details Name: us-gaap_ClassOfWarrantOrRightOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_WarrantsAndRightsNoteDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 105 R98.htm IDEA: XBRL DOCUMENT v3.25.0.1 Share Capital - Summary of Warrants (Parenthetical) (Details) Mar. 31, 2024 shares Warrants and Rights Note Disclosure [Abstract] Å Warrants exercisable 1,281,815 X

- DefinitionNumber of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3> + Details Name: us-gaap ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights Namespace Prefix: us-gaap Data Type: xbrli:sharesItem Type Balance Type: na Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap WarrantsAndRightsNoteDisclosureAbstract Namespace Prefix: us-gaap Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration XML 106 R99.htm IDEA: XBRL DOCUMENT v3.25.0.1 Share-Based Compensation - Additional Information (Details) - CAD (\$) \$ / shares in Units, \$ in Thousands 3 Months Ended 9 Months Ended Sep. 25, 2023 Dec. 31, 2024 Dec. 31, 2023 Dec. 31, 2024 Dec. 31, 2023 Mar. 31, 2024 Share Based Compensation Arrangement By Share Based Payment Award [Line Items] Å Å Å Å Å Options extended period 10 years Å Å Å Å Å Number of common shares reserved for issuance upon exercise or vesting of Awards Å 0 Å 0 Å Weighted average exercise price of options outstanding Å \$ 37.84 Å \$ 37.84 Å \$ 70.01 Weighted average exercise price of options exercisable Å \$ 75.56 Å \$ 75.56 Å \$ 312.68 Stock options outstanding Å 3,480,308 Å 3,480,308 Å 2,883,922 Share-based compensation Å \$ 5,159 Å \$ 3,693 Å 14,531 Å 10,127 Å Employee Stock Option Å Å Å Å Å Share Based Compensation Arrangement By Share Based Payment Award [Line Items] Å Å Å Å Å Share-based compensation expense Å 3,262 Å 2,671 Å 9,484 Å 7,637 Å Stock Option Subject To Performance Conditions Å Å Å Å Å Share Based Compensation Arrangement By Share Based Payment Award [Line Items] Å Å Å Å Å Share-based compensation expense, options subject to performance conditions Å Å Å 107,874 107,874 Å RSUs Å Å Å Å Å Share Based Compensation Arrangement By Share Based Payment Award [Line Items] Å Å Å Å Å Share-based compensation expense Å \$ 1,897 Å \$ 1,022 Å \$ 5,047 Å 2,490 Å Omnibus Equity Incentive Plan Å Å Å Å Å Share Based Compensation Arrangement By Share Based Payment Award [Line Items] Å Å Å Å Å Number of common shares reserved for issuance upon exercise or vesting of Awards Å 12,915,301 Å 12,915,301 Å Å Maximum | Omnibus Equity Incentive Plan Å Å Å Å Å Share Based Compensation Arrangement By Share Based Payment Award [Line Items] Å Å Å Å Å Options expiration period 10 years Å Å Å Å Å Minimum | Omnibus Equity Incentive Plan Å Å Å Å Å Share Based Compensation Arrangement By Share Based Payment Award [Line Items] Å Å Å Å Å Percentage of number of shares issuable from treasury pursuant to awards 10.00% Å Å Å Å Å X - DefinitionMaximum period of option from grant date. + ReferencesNo definition available. + Details Name: cgc ExtendedPeriodOfOptionFromGrantDate Namespace Prefix: cgc Data Type: xbrli:durationItem Type Balance Type: na Period Type: duration X - DefinitionPercentage of options exercisable on each anniversaries from date of grant. + ReferencesNo definition available. + Details Name: cgc PercentageOfOptionsExercisableOnEachAnniversariesFromDateOfGrant Namespace Prefix: cgc Data Type: dtr-types:percentItem Type Balance Type: na Period Type: duration X - DefinitionAmount of expense for award under share-based payment arrangement. Excludes amount capitalized. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SAB Topic 14.F\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 14.F) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1)Reference 2: [http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(h\)\(1\)\(i\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2) + Details Name: us-gaap AllocatedShareBasedCompensationExpense Namespace Prefix: us-gaap Data Type: xbrli:monetaryItem Type Balance Type: debit Period Type: duration X - DefinitionAmount of noncash expense for share-based payment arrangement. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph \(a\) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28](http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28) + Details Name: us-gaap ShareBasedCompensation Namespace Prefix: us-gaap Data Type: xbrli:monetaryItem Type Balance Type: debit Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 1D -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D>Reference 2: <http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3>Reference 3: [http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(a\)\(1\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 4: [http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(a\)\(2\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 5: [http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(a\)\(3\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 6: [http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(1\)\(i\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 7: [http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(1\)\(ii\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 8: [http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(1\)\(iii\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 9: [http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(1\)\(iv\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 10: [http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(1\)\(iv\)\(01\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 11: [http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(1\)\(iv\)\(02\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 12: [http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(1\)\(iv\)\(03\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 13: [http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(1\)\(iv\)\(04\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 14: [http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(2\)\(i\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 15: [http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(2\)\(ii\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 16: [http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(2\)\(iii\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 17: [http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(2\)\(iii\)\(01\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 18: [http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(2\)\(iii\)\(02\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 19: [http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(2\)\(iii\)\(03\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 20: [http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(d\)\(1\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 21: [http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(d\)\(2\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 22: [http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(e\)\(1\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 23: [http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(e\)\(2\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 24: [http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(f\)\(2\)\(i\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 25: [http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(f\)\(2\)\(ii\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 26: [http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(f\)\(2\)\(iii\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 27: [http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(f\)\(2\)\(iv\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 28: [http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(f\)\(2\)\(v\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(v) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2) + Details Name: us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems Namespace Prefix: us-gaap Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration X - DefinitionThe difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2> + Details Name: us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant Namespace Prefix: us-gaap Data Type: xbrli:sharesItem Type Balance Type: na Period Type: instant X - DefinitionThe weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(1\)\(iii\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2) + Details Name: us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice Namespace Prefix: us-gaap Data Type: dtr-types:perShareItem Type Balance Type: na Period Type: instant X - DefinitionNumber of options outstanding, including both vested and non-vested options. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(1\)\(i\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 2: [http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(1\)\(ii\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2) + Details Name: us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice Namespace Prefix: us-gaap Data Type: dtr-types:perShareItem Type Balance Type: na Period Type: instant X - DefinitionPeriod from grant date that an equity-based award expires, in "PnYnMndTnHnMns" format, for example, "P1Y5M13D" represents the reported fact of one year, five months, and thirteen days. + ReferencesReference 1: [http://www.xbrl.org/2003/role/exampleRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(a\)\(2\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/exampleRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2) + Details Name: us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationPeriod Namespace Prefix: us-gaap Data Type: xbrli:durationItem Type Balance Type: na Period Type: duration X - DefinitionNumber, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP). + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2>Reference 2: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(28\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1)Reference 3: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(29\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1)Reference 4: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.3-04\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1) + Details Name: us-gaap StockIssuedDuringPeriodSharesShareBasedCompensation Namespace Prefix: us-gaap Data Type: xbrli:sharesItem Type Balance Type: na Period Type: duration X - Details Name: us-gaap AwardTypeAxis=us-gaap EmployeeStockOptionMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap AwardTypeAxis=cgc StockOptionSubjectToPerformanceConditionsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap AwardTypeAxis=us-gaap RestrictedStockUnitsRSUMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap PlanNameAxis=cgc OmnibusEquityIncentivePlanMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt RangeAxis=srt MaximumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt RangeAxis=srt MinimumMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 107 R100.htm IDEA: XBRL DOCUMENT v3.25.0.1 Share-Based Compensation - Summary of the Changes in Options Outstanding (Details) 9 Months Ended Dec. 31, 2024 \$ / shares shares Share-Based Payment Arrangement [Abstract] Å Options outstanding, beginning balance | shares 2,883,922 Options granted | shares 765,107 Replacement options issued resulting from the Acreage Acquisition | shares 93,383 Options exercised | shares (18,621) Options expired/forfeited | shares (243,483) Options outstanding, ending balance | shares 3,480,308 Weighted average exercise price outstanding, beginning balance | \$ / shares 70.01 Weighted average exercise price, Options granted | \$ / shares 10.37 Weighted average exercise price, Replacement options issued resulting from the Acreage Acquisition | \$ / shares 85.67 Weighted average exercise price, Options exercised | \$ / shares 6.05 Weighted average exercise price, Options expired/forfeited | \$ / shares 226.05 Weighted average exercise price outstanding, ending balance | \$ / shares \$ 37.84 X - DefinitionShare based compensation arrangement by share based payment award replacement options issued resulting from the acreage acquisition. + ReferencesNo definition available. + Details Name: cgc ShareBasedCompensationArrangementByShareBasedPaymentAwardReplacementOptionsIssuedResultingFromTheAcreageAcquisition Namespace Prefix: cgc Data Type: xbrli:sharesItem Type Balance Type: na Period Type: duration X - DefinitionShare based compensation arrangement by share based payment award replacement options issued resulting from the acreage acquisition weighted average exercise price. + ReferencesNo definition available. + Details Name: cgc ShareBasedCompensationArrangementByShareBasedPaymentAwardReplacementOptionsIssuedResultingFromTheAcreageAcquisitionWeightedAverageExercisePrice Namespace Prefix: cgc Data Type: dtr-types:perShareItem Type Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract Namespace Prefix: us-gaap Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration X - DefinitionFor presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired. + ReferencesReference 1: [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(1\)\(iv\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2) + Details Name: us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod Namespace Prefix: us-gaap Data Type: xbrli:sharesItem Type Balance Type: na Period Type: duration X - DefinitionWeighted average price of options that were either forfeited or expired. + ReferencesReference 1: [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(1\)\(iv\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)

https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice Namespace Prefix: us-gaap_Data Type: dtr-types:perShareItem Type Balance Type: na Period Type: duration X - DefinitionGross number of share options (or share units) granted during the period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross Namespace Prefix: us-gaap_Data Type: xbrli:sharesItem Type Balance Type: na Period Type: duration X - DefinitionNumber of options outstanding, including both vested and non-vested options. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber Namespace Prefix: us-gaap_Data Type: xbrli:sharesItem Type Balance Type: na Period Type: instant X - DefinitionWeighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice Namespace Prefix: us-gaap_Data Type: dtr-types:perShareItem Type Balance Type: na Period Type: instant X - DefinitionWeighted average price at which option holders acquired shares when converting their stock options into shares. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice Namespace Prefix: us-gaap_Data Type: dtr-types:perShareItem Type Balance Type: na Period Type: duration X - DefinitionWeighted average per share amount at which grantees can acquire shares of common stock by exercise of options. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice Namespace Prefix: us-gaap_Data Type: dtr-types:perShareItem Type Balance Type: na Period Type: duration X - DefinitionNumber of share options (or share units) exercised during the current period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised Namespace Prefix: us-gaap_Data Type: xbrli:sharesItem Type Balance Type: na Period Type: duration XML 108 R101.htm IDEA: XBRL DOCUMENT v3.25.0.1 Share-Based Compensation - Summary of Options Outstanding (Details) - \$ / shares 9 Months Ended Dec. 31, 2024 Mar. 31, 2024 Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range [Line Items] Á Á Options Outstanding 3,480,308 2,883,922 Options Outstanding, Weighted Average Remaining Contractual Life 4 years 3 months 25 days Á Options Exercisable 1,153,927 Á Options Exercisable, Weighted Average Remaining Contractual Life 3 years 8 months 8 days Á Range One Á Á Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range [Line Items] Á Á Range of Exercise Prices, Lower Range \$ 0.6 Á Range of Exercise Prices, Upper Range \$ 7.5 Á Options Outstanding 2,030,678 Á Options Outstanding, Weighted Average Remaining Contractual Life 4 years 6 months Á Options Exercisable 668,981 Á Options Exercisable, Weighted Average Remaining Contractual Life 4 years 6 months Á Range Two Á Á Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range [Line Items] Á Á Range of Exercise Prices, Lower Range \$ 7.51 Á Range of Exercise Prices, Upper Range \$ 56.1 Á Options Outstanding 1,040,200 Á Options Outstanding, Weighted Average Remaining Contractual Life 4 years 11 months 15 days Á Options Exercisable 183,390 Á Options Exercisable, Weighted Average Remaining Contractual Life 3 years 7 months 20 days Á Range Three Á Á Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range [Line Items] Á Á Range of Exercise Prices, Lower Range \$ 56.11 Á Range of Exercise Prices, Upper Range \$ 585.1 Á Options Outstanding 409,430 Á Options Outstanding, Weighted Average Remaining Contractual Life 1 year 29 days Á Options Exercisable 301,556 Á Options Exercisable, Weighted Average Remaining Contractual Life 1 year 1 month 28 days Á X - DefinitionThe number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber Namespace Prefix: us-gaap_Data Type: xbrli:sharesItem Type Balance Type: na Period Type: instant X - DefinitionNumber of options outstanding, including both vested and non-vested options. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber Namespace Prefix: us-gaap_Data Type: xbrli:sharesItem Type Balance Type: na Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems Namespace Prefix: us-gaap_Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration X - DefinitionThe floor of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit Namespace Prefix: us-gaap_Data Type: dtr-types:perShareItem Type Balance Type: na Period Type: duration X - DefinitionThe ceiling of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit Namespace Prefix: us-gaap_Data Type: dtr-types:perShareItem Type Balance Type: na Period Type: duration X - DefinitionWeighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMndTnHnMns' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_SharebasedCompensationStandardsArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 Namespace Prefix: us-gaap_Data Type: xbrli:durationItem Type Balance Type: na Period Type: duration X - DefinitionWeighted average remaining contractual term for option awards outstanding, in 'PnYnMndTnHnMns' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 718 -SubTopic 10 -Subparagraph (e)(1) -Name Accounting Standards Codification -Paragraph 2 -Section 50 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 Namespace Prefix: us-gaap_Data Type: xbrli:durationItem Type Balance Type: na Period Type: duration X - Details Name: us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=cgc_RangeOneMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=cgc_RangeTwoMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=cgc_RangeThreeMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 109 R102.htm IDEA: XBRL DOCUMENT v3.25.0.1 Share-Based Compensation - Summary of Assumptions Applied to Establish Fair Value of Options Granted Using Black-Scholes Option Pricing Model (Details) - \$ / shares 9 Months Ended Dec. 31, 2023 Share Based Compensation Arrangement By Share Based Payment Award [Line Items] Á Á Risk-free interest rate 0.00% 3.95% Expected volatility 0.00% 101.00% Expected forfeiture rate 0.00% 21.00% Expected dividend yield Black-Scholes value of each option \$ 0 \$ 5.33 Minimum Á Á Share Based Compensation Arrangement By Share Based Payment Award [Line Items] Á Á Expected life of options (years) Á Á Expected life of options (years) Á 3 years Maximum Á Á Share Based Compensation Arrangement By Share Based Payment Award [Line Items] Á Á Expected life of options (years) Á 5 years X - DefinitionShare-based compensation arrangement by share-based payment award fair value assumptions expected forfeiture rate. + ReferencesNo definition available. + Details Name: cgc_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate Namespace Prefix: cgc_Data Type: dtr-types:percentItem Type Balance Type: na Period Type: duration X - DefinitionThe estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2) (iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate Namespace Prefix: us-gaap_Data Type: dtr-types:percentItem Type Balance Type: na Period Type: duration X - DefinitionThe estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate Namespace Prefix: us-gaap_Data Type: dtr-types:percentItem Type Balance Type: na Period Type: duration X - DefinitionThe risk-free interest rate assumption that is used in valuing an option on its own shares. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate Namespace Prefix: us-gaap_Data Type: dtr-types:percentItem Type Balance Type: na Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 1D -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1DReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iv)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(03) -

Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(v) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems Namespace Prefix: us-gaap Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue Namespace Prefix: us-gaap Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionExpected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 Namespace Prefix: us-gaap Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - Details Name: srt_RangeAxis=srt_MinimumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MaximumMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 110 R103.htm IDEA: XBRL DOCUMENT v3.25.0.1 Share-Based Compensation - Summary of the Changes in RSUs and PSUs (Details) - RSUs 9 Months Ended Dec. 31, 2024 shares Share Based Compensation Arrangement By Share Based Payment Award [Line Items] A Beginning balance 1,272,299 RSUs and PSUs granted 720,873 Replacement RSUs issued resulting from the Acreage Acquisition 6,627 RSUs and PSUs released (433,268) RSUs and PSUs cancelled and forfeited (130,257) Ending balance 1,436,274 X - DefinitionShare based compensation arrangement by share based payment award equity instruments other than options replacement RSUs issued resulting from the acreage acquisition. + ReferencesNo definition available. + Details Name: cgc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReplacementRSUsIssuedResultingFromTheAcreageAcquisition Namespace Prefix: cgc Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionThe number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod Namespace Prefix: us-gaap Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionThe number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod Namespace Prefix: us-gaap Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionThe number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber Namespace Prefix: us-gaap Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionThe number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod Namespace Prefix: us-gaap Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 1D -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1DReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(v) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems Namespace Prefix: us-gaap Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 111 R104.htm IDEA: XBRL DOCUMENT v3.25.0.1 Accumulated Other Comprehensive Income (Loss) - Accumulated Other Comprehensive Income (Details) - CAD (\$) \$ in Thousands 3 Months Ended 9 Months Ended Dec. 31, 2024 Dec. 31, 2023 Accumulated Other Comprehensive Income Loss [Line Items] A A Beginning balance \$ 509,668 \$ 500,507 \$ 760,022 Disposal and liquidation of consolidated entities 8,195 A A Ending balance 591,475 591,475 544,663 Foreign Currency Translation Adjustments A A Accumulated Other Comprehensive Income Loss [Line Items] A A Beginning balance A A (31,178) (30,261) Disposal and liquidation of consolidated entities A 18,593 A Other comprehensive income (loss) A 3,586 575 Ending balance (8,999) (8,999) (29,686) Changes of Own Credit Risk of Financial Liabilities A A Accumulated Other Comprehensive Income Loss [Line Items] A A Beginning balance A 15,127 16,401 Settlement of unsecured senior notes, net of deferred income tax A A 11,060 Extinguishment of promissory note and issuance of exchangeable shares A (15,127) A Other comprehensive income (loss) A A (13,824) Ending balance A A 13,637 Accumulated Other Comprehensive Income (Loss) A A Accumulated Other Comprehensive Income Loss [Line Items] A A Beginning balance (16,032) (16,051) (13,860) Disposal and liquidation of consolidated entities 8,195 18,593 A Settlement of unsecured senior notes, net of deferred income tax A A 11,060 Extinguishment of promissory note and issuance of exchangeable shares A (15,127) A Other comprehensive income (loss) A 3,586 (13,249) Ending balance \$ (8,999) \$ (8,999) \$ (16,049) X - DefinitionDisposal and liquidation of consolidated entities. + ReferencesNo definition available. + Details Name: cgc_DisposalAndLiquidationOfConsolidatedEntities Namespace Prefix: cgc Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionExtinguishment of promissory note and issuance of exchangeable shares. + ReferencesNo definition available. + Details Name: cgc_ExtinguishmentOfPromissoryNoteAndIssuanceOfExchangeableShares Namespace Prefix: cgc Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionStock issued during period, value, settlement of unsecured senior notes, net of deferred income tax. + ReferencesNo definition available. + Details Name: cgc_StockIssuedDuringPeriodValueSettlementOfUnsecuredSeniorNotesNetOfDeferredIncomeTax Namespace Prefix: cgc Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-4Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-5Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481674/830-30-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 17 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481694/830-30-45-17Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 20 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 20 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 20 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 20 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20 + Details Name: us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems Namespace Prefix: us-gaap Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount before tax, after reclassification adjustments of other comprehensive income (loss). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481674/830-30-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 17 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481694/830-30-45-17Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-4Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -

Accounting Standards Codification -Section 45 -Paragraph 20 -Publisher FASB -URI https://asc.fasb.org/1943274/214748321/250-10-45-23Reference 11:

SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 8 -Subparagraph (c)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479832/842-10-65-8Reference 10:

us-gaap FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems Namespace Prefix: us-gaap Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Definition Describes the methodologies and assumptions on which the valuation allowance is based for deferred tax assets for which it is more likely than not that all or a portion of the deferred tax asset will not be realized. + ReferencesReference 1: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic 740-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \(c\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482685/740-10-50-2](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 740-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (c)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482685/740-10-50-2) + Details Name: us-gaap ValuationAllowanceMethodologiesAndAssumptions Namespace Prefix: us-gaap Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap FairValueByFairValueHierarchyLevelAxis=us-gaap FairValueInputsLevel3Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap FairValueByLiabilityClassAxis=cgc CanopyUsaEquityMethodInvestmentProbabilityOfEachAcreeageScenarioMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap FairValueByLiabilityClassAxis=cgc CanopyUsaEquityMethodInvestmentDiscountRateMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap FairValueByLiabilityClassAxis=cgc CanopyUsaEquityMethodInvestmentExpectedFutureCashFlowsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap FairValueByLiabilityClassAxis=cgc CanopyUsaEquityMethodInvestmentVolatilityOfWanaAndJetyEquityMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap FairValueByLiabilityClassAxis=cgc ElevateLoanReceivableMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap FairValueByLiabilityClassAxis=cgc AcreeageDebtMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 115 R108.htm IDEA: XBRL DOCUMENT v3.25.0.1 Revenue - Summary of Disaggregation of Revenue (Details) - CAD (\$) \$ in Thousands 3 Months Ended 9 Months Ended Dec. 31, 2024 Dec. 31, 2023 Dec. 31, 2024 Dec. 31, 2023 Dec. 31, 2024 Dec. 31, 2023 Disaggregation Of Revenue [Line Items] Á Á Á Gross revenue \$ 86,244 \$ 90,061 \$ 235,985 \$ 260,781 Net revenue 74,761 78,505 203,964 224,358 Canadian Cannabis Net Revenue Á Á Á Disaggregation Of Revenue [Line Items] Á Á Á Gross revenue 40,728 40,384 115,483 120,543 Canadian Adult-use Cannabis | Canadian Medical Cannabis Net Revenue Á Á Á Disaggregation Of Revenue [Line Items] Á Á Á Gross revenue [1] 21,153 23,490 58,424 71,848 Canadian Medical Cannabis | Canadian Medical Cannabis Net Revenue Á Á Á Disaggregation Of Revenue [Line Items] Á Á Á Gross revenue [2] 19,575 16,894 57,059 48,695 Other Á Á Á Disaggregation Of Revenue [Line Items] Á Á Á Gross revenue Á 976 Á 4,376 International Markets Cannabis Á Á Á Disaggregation Of Revenue [Line Items] Á Á Á Gross revenue 12,024 10,527 32,166 29,666 Storz & Bickel Á Á Á Disaggregation Of Revenue [Line Items] Á Á Á Gross revenue \$ 22,009 18,453 \$ 56,315 48,517 This Work Á Á Á Disaggregation Of Revenue [Line Items] Á Á Á Gross revenue Á \$ 8,165 Á \$ 21,256 [1] Canadian adult-use net revenue during the three and nine months ended December 31, 2024 reflects excise taxes of \$9,335 and \$25,755, respectively (three and nine months ended December 31, 2023 á€" \$9,741 and \$31,596, respectively). [2] Canadian medical cannabis net revenue for the three and nine months ended December 31, 2024 reflects excise taxes of \$2,148 and \$6,266, respectively (three and nine months ended December 31, 2023 á€" \$1,815 and \$4,827, respectively). X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef-Topic 606-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 5-Publisher FASB-URI https://asc.fasb.org/1943274/2147479806/606-10-50-5>Reference 2: [http://www.xbrl.org/2003/role/exampleRef-Topic 606-SubTopic 10-Name Accounting Standards Codification-Section 55-Paragraph 91-Subparagraph \(a\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147479777/606-10-55-91](http://www.xbrl.org/2003/role/exampleRef-Topic 606-SubTopic 10-Name Accounting Standards Codification-Section 55-Paragraph 91-Subparagraph (a)-Publisher FASB-URI https://asc.fasb.org/1943274/2147479777/606-10-55-91)Reference 3: [http://www.xbrl.org/2003/role/exampleRef-Topic 606-SubTopic 10-Name Accounting Standards Codification-Section 55-Paragraph 91-Subparagraph \(b\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147479777/606-10-55-91](http://www.xbrl.org/2003/role/exampleRef-Topic 606-SubTopic 10-Name Accounting Standards Codification-Section 55-Paragraph 91-Subparagraph (b)-Publisher FASB-URI https://asc.fasb.org/1943274/2147479777/606-10-55-91)Reference 4: [http://www.xbrl.org/2003/role/exampleRef-Topic 606-SubTopic 10-Name Accounting Standards Codification-Section 55-Paragraph 91-Subparagraph \(c\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147479777/606-10-55-91](http://www.xbrl.org/2003/role/exampleRef-Topic 606-SubTopic 10-Name Accounting Standards Codification-Section 55-Paragraph 91-Subparagraph (c)-Publisher FASB-URI https://asc.fasb.org/1943274/2147479777/606-10-55-91)Reference 5: [http://www.xbrl.org/2003/role/exampleRef-Topic 606-SubTopic 10-Name Accounting Standards Codification-Section 55-Paragraph 91-Subparagraph \(d\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147479777/606-10-55-91](http://www.xbrl.org/2003/role/exampleRef-Topic 606-SubTopic 10-Name Accounting Standards Codification-Section 55-Paragraph 91-Subparagraph (d)-Publisher FASB-URI https://asc.fasb.org/1943274/2147479777/606-10-55-91)Reference 6: [http://www.xbrl.org/2003/role/exampleRef-Topic 606-SubTopic 10-Name Accounting Standards Codification-Section 55-Paragraph 91-Subparagraph \(e\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147479777/606-10-55-91](http://www.xbrl.org/2003/role/exampleRef-Topic 606-SubTopic 10-Name Accounting Standards Codification-Section 55-Paragraph 91-Subparagraph (e)-Publisher FASB-URI https://asc.fasb.org/1943274/2147479777/606-10-55-91)Reference 7: [http://www.xbrl.org/2003/role/exampleRef-Topic 606-SubTopic 10-Name Accounting Standards Codification-Section 55-Paragraph 91-Subparagraph \(f\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147479777/606-10-55-91](http://www.xbrl.org/2003/role/exampleRef-Topic 606-SubTopic 10-Name Accounting Standards Codification-Section 55-Paragraph 91-Subparagraph (f)-Publisher FASB-URI https://asc.fasb.org/1943274/2147479777/606-10-55-91)Reference 8: [http://www.xbrl.org/2003/role/exampleRef-Topic 606-SubTopic 10-Name Accounting Standards Codification-Section 55-Paragraph 91-Subparagraph \(g\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147479777/606-10-55-91](http://www.xbrl.org/2003/role/exampleRef-Topic 606-SubTopic 10-Name Accounting Standards Codification-Section 55-Paragraph 91-Subparagraph (g)-Publisher FASB-URI https://asc.fasb.org/1943274/2147479777/606-10-55-91) + Details Name: us-gaap DisaggregationOfRevenueLineItems Namespace Prefix: us-gaap Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic 280-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 41-Subparagraph \(a\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482810/280-10-50-41](http://www.xbrl.org/2003/role/disclosureRef-Topic 280-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 41-Subparagraph (a)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482810/280-10-50-41)Reference 2: [http://www.xbrl.org/2003/role/disclosureRef-Topic 280-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 41-Subparagraph \(b\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482810/280-10-50-41](http://www.xbrl.org/2003/role/disclosureRef-Topic 280-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 41-Subparagraph (b)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482810/280-10-50-41)Reference 3: [http://www.xbrl.org/2003/role/disclosureRef-Topic 280-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 41-Subparagraph \(c\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482810/280-10-50-41](http://www.xbrl.org/2003/role/disclosureRef-Topic 280-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 41-Subparagraph (c)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482810/280-10-50-41)Reference 4: [http://www.xbrl.org/2003/role/disclosureRef-Topic 280-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 41-Subparagraph \(d\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482810/280-10-50-41](http://www.xbrl.org/2003/role/disclosureRef-Topic 280-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 41-Subparagraph (d)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482810/280-10-50-41)Reference 5: [http://www.xbrl.org/2003/role/disclosureRef-Topic 280-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 41-Subparagraph \(e\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482810/280-10-50-41](http://www.xbrl.org/2003/role/disclosureRef-Topic 280-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 41-Subparagraph (e)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482810/280-10-50-41)

https://asc.fasb.org/1943274/2147479806/606-10-50-4 + Details Name: us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - Details Name: srt_StatementGeographicalAxis=cg Country CA Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ProductOrServiceAxis=cg CanadianMedicalCannabisMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ProductOrServiceAxis=cg CanadianMedicalCannabisMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 117 R110.htm IDEA: XBRL DOCUMENT v3.25.0.1 Revenue - Additional Information (Details) - CAD (\$) \$ in Thousands 3 Months Ended 9 Months Ended Dec. 31, 2024 Dec. 31, 2023 Dec. 31, 2024 Dec. 31, 2023 Mar. 31, 2024 Revenue from Contract with Customer [Abstract] Å Å Å Allowance for estimated returns and price adjustments \$ 986 \$ 1,430 \$ 3,486 \$ 2,937 Å Liability for estimated returns and price adjustments \$ 2,727 Å \$ 2,727 Å \$ 4,169 X - DefinitionAllowance for estimated returns and price adjustments. + ReferencesNo definition available. + Details Name: cgc_AllowanceForEstimatedReturnsAndPriceAdjustments Namespace Prefix: cgc_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionLiability for estimated sales returns and price adjustments. + ReferencesNo definition available. + Details Name: cgc_LiabilityForEstimatedSalesReturnsAndPriceAdjustments Namespace Prefix: cgc_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_RevenueFromContractWithCustomerAbstract Namespace Prefix: us-gaap_Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 118 R111.htm IDEA: XBRL DOCUMENT v3.25.0.1 Other Income (Expense), Net - Schedule of Other Income (Expense), Net (Details) - CAD (\$) \$ in Thousands 3 Months Ended 9 Months Ended Dec. 31, 2024 Dec. 31, 2023 Dec. 31, 2024 Dec. 31, 2023 Mar. 31, 2023 Other Income and Expenses [Abstract] Å Å Å Fair value changes on Canopy USA related assets \$ (76,251) \$ (148,734) \$ (209,643) \$ (164,985) Fair value changes on other financial assets (50) 2,062 (2,915) 1,125 Fair value changes on debt Å (5,400) Å (30,614) Fair value changes on acquisition related contingent consideration and other 0 8,629 (33,472) 19,146 Gain (charges) related to settlement of debt 0 (571) 22,439 (13,124) Interest income 1,941 2,548 6,415 13,833 Interest expense (16,766) (24,623) (59,187) (84,223) Foreign currency gain (loss) 723 (4,069) 1,430 529 Other income (expense), net (7,355) (879) (2,019) 5,043 Other income (expense), net (97,758) \$ (171,037) \$ (276,952) \$ (253,270) X - DefinitionDebt fair value adjustment. + ReferencesNo definition available. + Details Name: cgc_DebtFairValueAdjustment Namespace Prefix: cgc_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionFair value changes on related assets. + ReferencesNo definition available. + Details Name: cgc_FairValueChangesOnRelatedAssets Namespace Prefix: cgc_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionGain (loss) and charges related to settlement of debt. + ReferencesNo definition available. + Details Name: cgc_GainLossAndChargesRelatedToSettlementOfDebt Namespace Prefix: cgc_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionInterest income. + ReferencesNo definition available. + Details Name: cgc_InterestIncome Namespace Prefix: cgc_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of expense (income) related to adjustment to fair value of other financial assets. + ReferencesNo definition available. + Details Name: cgc_OtherFinancialAssetsFairValueAdjustment Namespace Prefix: cgc_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionOther miscellaneous non operating income (expense) net. + ReferencesNo definition available. + Details Name: cgc_OtherMiscellaneousNonOperatingIncomeExpenseNet Namespace Prefix: cgc_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement. + ReferencesReference 1: [http://www.xbrli.org/2009/role/commonPracticeRef-Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28](http://www.xbrli.org/2009/role/commonPracticeRef-Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28)Reference 2: [http://www.xbrli.org/2003/role/disclosureRef-Topic 805 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph \(a\)\(1\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479581/805-30-50-4](http://www.xbrli.org/2003/role/disclosureRef-Topic 805 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479581/805-30-50-4) + Details Name: us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1 Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount, before tax, of realized gain (loss) from foreign currency transaction. + ReferencesReference 1: <http://www.xbrli.org/2003/role/exampleRef-Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10>Reference 2: [http://www.xbrli.org/2003/role/disclosureRef-Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 6 -Subparagraph \(a\)\(2\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-6](http://www.xbrli.org/2003/role/disclosureRef-Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 6 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-6)Reference 3: [http://www.xbrli.org/2009/role/commonPracticeRef-Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-077\)\(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1](http://www.xbrli.org/2009/role/commonPracticeRef-Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-077)(a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1)Reference 4: <http://www.xbrli.org/2009/role/commonPracticeRef-Topic 830 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481956/830-20-45-1>Reference 5: <http://www.xbrli.org/2009/role/commonPracticeRef-Topic 830 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481926/830-20-50-1> + Details Name: us-gaap_ForeignCurrencyTransactionGainLossRealized Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of interest expense classified as operating and nonoperating. Includes, but is not limited to, cost of borrowing accounted for as interest expense. + ReferencesReference 1: [http://www.xbrli.org/2003/role/disclosureRef-Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph \(d\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22](http://www.xbrli.org/2003/role/disclosureRef-Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22)Reference 2: <http://www.xbrli.org/2003/role/exampleRef-Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48>Reference 3: <http://www.xbrli.org/2003/role/exampleRef-Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 49 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49>Reference 4: [http://www.xbrli.org/2003/role/disclosureRef-Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph \(i\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1](http://www.xbrli.org/2003/role/disclosureRef-Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1)Reference 5: [http://www.xbrli.org/2003/role/disclosureRef-Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph \(ee\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32](http://www.xbrli.org/2003/role/disclosureRef-Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32)Reference 6: <http://www.xbrli.org/2003/role/disclosureRef-Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-24>Reference 7: <http://www.xbrli.org/2003/role/disclosureRef-Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22>Reference 8: [http://www.xbrli.org/2003/role/disclosureRef-Topic 835 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483013/835-20-50-1](http://www.xbrli.org/2003/role/disclosureRef-Topic 835 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483013/835-20-50-1) + Details Name: us-gaap_InterestExpense Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_OtherIncomeAndExpensesAbstract Namespace Prefix: us-gaap_Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of income (expense) related to nonoperating activities, classified as other. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph \(SX 210.5-03\(9\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2) + Details Name: us-gaap_OtherNonoperatingIncomeExpense Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration XML 119 R112.htm IDEA: XBRL DOCUMENT v3.25.0.1 Other Income (Expense), Net - Schedule of Other Income (Expense), Net (Parenthetical) (Details) - CAD (\$) \$ in Thousands 3 Months Ended 9 Months Ended Dec. 31, 2024 Dec. 31, 2023 Dec. 31, 2024 Dec. 31, 2023 Mar. 31, 2024 Other Income and Expenses [Line Items] Å Å Å Å Other financial assets \$ 321,368 Å \$ 321,368 Å \$ 437,629 Fair value changes on other financial assets 50 \$ (2,062) 2,915 \$ (1,125) Å Canopy USA Assets Å Å Å Å Other Income and Expenses [Line Items] Å Å Å Å Fair value changes on other financial assets 64,143 (148,734) 20,389 (164,985) Å Fair value changes on equity method investments \$ (140,394) \$ 0 \$ (230,032) \$ 0 Å X - DefinitionFair value changes on equity method investments. + ReferencesNo definition available. + Details Name: cgc_EquityMethodInvestmentsFairValueAdjustment Namespace Prefix: cgc_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionOther financial assets. + ReferencesNo definition available. + Details Name: cgc_OtherFinancialAssets Namespace Prefix: cgc_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of expense (income) related to adjustment to fair value of other financial assets. + ReferencesNo definition available. + Details Name: cgc_OtherFinancialAssetsFairValueAdjustment Namespace Prefix: cgc_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionOther income and expenses line items. + ReferencesNo definition available. + Details Name: cgc_OtherIncomeAndExpensesLineItems Namespace Prefix: cgc_Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: srt_ConsolidatedEntitiesAxis=cg CanopyUSASSETSMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 120 R113.htm IDEA: XBRL DOCUMENT v3.25.0.1 Acreage Arrangement - Additional Information (Details) - shares Dec. 09, 2024 Oct. 24, 2022 Dec. 31, 2024 Mar. 31, 2024 Business Acquisition [Line Items] Å Å Å Å Percentage ownership of wholly owned subsidiaries Å 100.00% Å Å Common stock, shares issued Å 129,153,014 91,115,501 Acreage Å Å Å Å Business Acquisition [Line Items] Å Å Å Å Percentage ownership of wholly owned subsidiaries 100.00% Å Å Å Common stock, shares issued 5,888,291 Å Å X - DefinitionPercentage ownership of wholly owned subsidiaries. + ReferencesNo definition available. + Details Name: cgc_PercentageOwnershipOfWhollyOwnedSubsidiaries Namespace Prefix: cgc_Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: [http://www.xbrli.org/2003/role/disclosureRef-Topic 805 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479907/805-20-50-5](http://www.xbrli.org/2003/role/disclosureRef-Topic 805 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479907/805-20-50-5) + Details Name: us-gaap_BusinessAcquisitionLineItems Namespace Prefix: us-gaap_Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTotal number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(29\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1) + Details Name: us-gaap_CommonStockSharesIssued Namespace Prefix: us-gaap_Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - Details Name: us-gaap_BusinessAcquisitionAxis=cg AcreageHoldingsIncMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 121 R114.htm IDEA: XBRL DOCUMENT v3.25.0.1 Segment Information - Additional Information (Details) 3 Months Ended 9 Months Ended Dec. 31, 2024 Customer Dec. 31, 2023 Customer Dec. 31, 2024 Segment Customer Dec. 31, 2023 Customer Segment Reporting Information [Line Items] Å Å Å Å Number of operating segments | Segment Å Å Å Å Customer Concentration Risk | Revenue from Contract with Customer Benchmark Å Å Å Å Segment Reporting Information [Line Items] Å Å Å Å Concentration risk customer number of customers | Customer 1 1 1 X - DefinitionConcentration risk customer number of customers. + ReferencesNo definition available. + Details Name: cgc_ConcentrationRiskCustomerNumberOfCustomers Namespace Prefix: cgc_Data Type: xbrli:integerItemType Balance Type: na Period Type: duration X - DefinitionNumber of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues. + ReferencesReference 1: <http://www.xbrli.org/2003/role/exampleRef-Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 49 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49>Reference 2: <http://www.xbrli.org/2009/role/commonPracticeRef-Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-18> + Details Name: us-gaap_NumberOfOperatingSegments Namespace Prefix: us-gaap_Data Type: xbrli:integerItemType Balance Type: na Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: us-gaap_SegmentReportingInformationLineItems Namespace Prefix: us-gaap_Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 122 R115.htm IDEA: XBRL DOCUMENT v3.25.0.1 Segment Information - Summary of Reconciliation of Operating Profit (Loss) from Segments to Consolidated (Details) - CAD (\$) \$ in Thousands 3 Months Ended 9 Months Ended Dec. 31, 2024 Dec. 31, 2023 Dec. 31, 2024 Dec. 31, 2023 Mar. 31, 2023 Segment Reporting Information [Line Items] Å Å Å Å Net revenue \$ 74,761 \$ 78,505 \$ 203,964 \$ 224,358 Gross margin 24,098 28,226 68,967 65,414 Selling, general and administrative expenses 41,476 54,436 131,174 174,810 Share-based compensation 5,159 3,693 14,531 10,127 Loss on asset impairment and restructuring 1,285 30,413 22,135 2,452 Operating loss from continuing operations (23,822) (60,316) (98,873) (121,975) Other income (expense), net (97,758) (171,037) (276,952) (253,270) Loss from continuing operations before income taxes (121,580) (231,353) (375,825) (375,245) Canada Cannabis Å Å Å Å Segment Reporting Information [Line Items] Å Å Å Å Net revenue 40,728 40,384 115,483 120,543 Gross margin 10,181 11,306 34,225 25,340 International Markets Cannabis Å Å Å Å Segment Reporting Information [Line Items] Å Å Å Å Net revenue 12,024 10,527 32,166 29,666 Gross margin 4,932 4,192 13,297 10,364 Storz & Bickel Å Å Å Å Segment Reporting Information [Line Items] Å Å Å Å Net revenue 22,009 18,453 56,315 48,517 Gross margin \$ 8,985 9,449 \$ 21,445 21,074 This Works Å Å Å Å Segment Reporting Information [Line Items] Å Å Å Å Net revenue 4,253 Å 10,534 Other Å Å Å Å Segment Reporting Information [Line Items] Å Å Å Å Net revenue Å 976 Å 4,376 Gross margin Å (\$ 974) Å (\$ 1,898) X - DefinitionAmount of gain (loss) from the difference between the sale price or salvage price and the book value of an asset that was sold or retired, and gain (loss) from the write down of assets from their carrying value to fair value. + ReferencesReference 1: [http://www.xbrli.org/2009/role/commonPracticeRef-Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28](http://www.xbrli.org/2009/role/commonPracticeRef-Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28) + Details Name: us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity. + ReferencesReference 1: <http://www.xbrli.org/2009/role/commonPracticeRef-Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22>Reference 2: <http://www.xbrli.org/2003/role/exampleRef-Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48>Reference 3: [http://www.xbrli.org/2009/role/commonPracticeRef-Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph \(f\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32](http://www.xbrli.org/2009/role/commonPracticeRef-Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32)Reference 4: [http://www.xbrli.org/2009/role/commonPracticeRef-Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30](http://www.xbrli.org/2009/role/commonPracticeRef-Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30)Reference 5: [http://www.xbrli.org/2009/role/commonPracticeRef-Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph \(ee\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32](http://www.xbrli.org/2009/role/commonPracticeRef-Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32)Reference 6: [http://www.xbrli.org/2009/role/commonPracticeRef-Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph \(c\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32](http://www.xbrli.org/2009/role/commonPracticeRef-Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32)Reference 7: [http://www.xbrli.org/2009/role/commonPracticeRef-Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph \(d\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32](http://www.xbrli.org/2009/role/commonPracticeRef-Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32)Reference 8: [http://www.xbrli.org/2009/role/commonPracticeRef-Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph \(e\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32](http://www.xbrli.org/2009/role/commonPracticeRef-Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32)Reference 9: [http://www.xbrli.org/2009/role/commonPracticeRef-Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph \(f\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32](http://www.xbrli.org/2009/role/commonPracticeRef-Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32)Reference 10: [http://www.xbrli.org/2009/role/commonPracticeRef-Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph \(g\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32](http://www.xbrli.org/2009/role/commonPracticeRef-Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32)Reference 11: [http://www.xbrli.org/2009/role/commonPracticeRef-Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph \(h\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32](http://www.xbrli.org/2009/role/commonPracticeRef-Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32)Reference 12: [http://www.xbrli.org/2009/role/commonPracticeRef-Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph \(i\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32](http://www.xbrli.org/2009/role/commonPracticeRef-Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32)Reference 13: [http://www.xbrli.org/2009/role/commonPracticeRef-Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph \(j\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32](http://www.xbrli.org/2009/role/commonPracticeRef-Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (j) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32)Reference 14: [http://www.xbrli.org/2009/role/commonPracticeRef-Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph \(k\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32](http://www.xbrli.org/2009/role/commonPracticeRef-Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (k) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32)Reference 15: [http://www.xbrli.org/2009/role/commonPracticeRef-Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph \(l\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32](http://www.xbrli.org/2009/role/commonPracticeRef-Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (l) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32)Reference 16: [http://www.xbrli.org/2009/role/commonPracticeRef-Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph \(m\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32](http://www.xbrli.org/2009/role/commonPracticeRef-Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (m) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32)Reference 17: [http://www.xbrli.org/2009/role/commonPracticeRef-Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph \(n\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32](http://www.xbrli.org/2009/role/commonPracticeRef-Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (n) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32)Reference 18: [http://www.xbrli.org/2009/role/commonPracticeRef-Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph \(o\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32](http://www.xbrli.org/2009/role/commonPracticeRef-Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (o) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32)Reference 19: [http://www.xbrli.org/2009/role/commonPracticeRef-Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph \(p\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32](http://www.xbrli.org/2009/role/commonPracticeRef-Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (p) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32)Reference 20: [http://www.xbrli.org/2009/role/commonPracticeRef-Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph \(q\) -Publisher FASB -URI https://asc.fasb.org/1943274](http://www.xbrli.org/2009/role/commonPracticeRef-Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (q) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32)

[Line Items] A -> Property, plant and equipment 247,414,266,086 Germany A -> Revenues From External Customers And Long Lived Assets [Line Items] A -> Property, plant and equipment 51,030,50,527 Other A -> Revenues From External Customers And Long Lived Assets [Line Items] A -> Property, plant and equipment 1,160 \$,3,490 X - DefinitionAmount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.

+ ReferencesReference 1: http://fasb.org/us-gaap/ref/legacyRef-Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 360 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1-Reference 2:
http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7A -Subparagraph (a) -Publisher FASB -URI
https://asc.fasb.org/1943274/2147478964/842-20-50-7ARefence 3: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -
Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name
Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 5:
http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 360 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI
https://asc.fasb.org/1943274/2147478451/942-360-50-1 + Details Name: us-gaap_PropertyPlantAndEquipmentNet Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance
Type: debit Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain
members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineltms Namespace
Prefix: us-gaap_Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: srt_StatementGeographicalAxis=country_CA Namespace Prefix: Data Type: na
Balance Type: Period Type: X - Details Name: srt_StatementGeographicalAxis=country_DE Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name:
srt_StatementGeographicalAxis=cgc_OtherGeographicalAreaMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 125 R118.htm IDEA: XBRL DOCUMENT v3.25.0.1
Subsequent Events - Additional Information (Details) - CAD (\$) in Thousands 9 Months Ended Dec. 31, 2024 Mar. 31, 2024 Subsequent Event [Line Items] A -> Additional common stock
issued 129,153,014 91,115,501 ATM Program A -> Subsequent Event [Line Items] A -> Additional common stock issued 17,896,019 A Gross proceeds from common shares \$ 58,902 A X -
DefinitionTotal number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These
shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and
shares held in the treasury. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1
Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_CommonStockSharesIssued Namespace Prefix: us-
gaap_Data Type: xbrli:sharesItemNamespace Balance Type: na Period Type: instant X - DefinitionThe cash inflow from the additional capital contribution to the entity. + ReferencesReference 1:
http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 14 -SubParagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI
https://asc.fasb.org/1943274/2147482740/230-10-45-14 + Details Name: us-gaap_ProceedsFromissuanceOfCommonStock Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType
Balance Type: debit Period Type: duration X - DefinitionDetail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the
primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event. + ReferencesReference 1:
http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI
https://asc.fasb.org/1943274/2147481764/830-30-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 855 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -
Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483399/855-10-50-2 + Details Name: us-gaap_SubsequentEventLineltms Namespace Prefix: us-gaap_Data Type:
xbrli:stringItemNamespace Balance Type: na Period Type: duration X - Details Name: us-gaap_SubsidiarySaleOfStockAxis=cgc_AtMarketEquityProgramMember Namespace Prefix: Data Type: na
Balance Type: Period Type: EXCEL 126 Financial Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4\$!#I0 (*PU1UH'04UB@+0 \$ 0 9&J'C4')O<,087!P+GAM
M;\$V\LO),!!S @QO)=IP4BJ0-I2L+U-></D>LOED+1LD>!OCGI/CXV%>;QA&WPIG M*N*I*Bv&5 C(I/(H?K7R?>=>)N=)HI6-Y *OGDK7A.YNJQ<+GPZDA4IW J=OUIRUEA 6#MI7E!+ P04 M " "L-
4=-:5V%'>% V &'0 QAOBU'RWIS+W-V-O&ULS9+V M3L,P#=?>-?>.NTVO?'>?>(GD)'8!(.6)>16XBQC'F%J.VK1,"1 8??Y? MGRVA@.@H=X&KZDD&K1Q753HNJGHG>.:8BB ,CZ@[SEFC
MV/B/G-A">UO]&D81[6.29A&1CM %&STQALXJ-G=B>BTR M.O24HHK8*<[OKSJ]V .5,(DIOM)?30<=:K~BWJT(J)/MLYU7VS=V2VFWM+!> /3Z SNHV7M PF937.F4'S*M
IXI=[JM-KAV&R9JK7]'7A7J,EM58KD2 JC=A=W=GVPVB=M & ULS!'5<|HXNY%>[MKJ]5 9,>(*D?)80VC=(T'BWT-JMNTFR83M M3A^='EBDD81 OTV23JJ/ OLZ70.14?GZAY'>XN8NB&B)3R M>
+JOEN[I3+ MUES@6HQHO][RM-L0=5H11,'*\$81V1 ?>5XL'\$05%;Y%,UM,M.4?, @5RU92.J1. MS&UI[KFM(Y,Y,Z,VNMX'^< LATR@6XP&UY@/@YVOI'.16HCFA5,+SP&IG/U9K
MOJ'?2"-RW74)]J.'3?>60[RJ-M3LGZGS=C,SQVQ,VYC,K,-#IM&N';CVt@XMLO2 MBW A(M>5> 5 TR ME6IVULS ZY9+'?IUIEUK9,@=0SSPX.XYBI'QL4QUFGCA2&98TI G'=D 4.#?\$ MT4QO?
*)IMHK(P1+27)#6SRFU4(HFLB)!4="(<7K,XH) MSZ%82=JS'!=&N*K<<~9STS6![ZS&T?9SO-RCEU@5 9<8WS2J-2S%UGB5P/MC MGCP=SQ+E
'LW70)'82J3'E ~34@3 BNEUVQKR2.FJW'M2'/F9 I-MAIRMI1!MG&IA&?!LL>1>[\$2M!]':6:PUDSY@R-D.S77.U\$.9)\$->T('8LZ+ MD!& H'8X2IKMHG%8/V>7L-P>B'RV;J'N'Z&U3-L+
(WI072NO/JJ< Z3(T MI.Z-.60fJA&9RGZJ'>ZH'C*(?Y&JC=E@G-Y,I&O'%N@GL] :'-)*K'+@ M.TAN?<=@([GT/?MSAD6R4)RU3393?<* \$M'IY'VMJ4 5*=E?
EKIDNHNQ,Q.Y.FOH70^+, Y/Y GM,T,L T.WFY) \$M-M-2D& #>#>G>+1KB.=RB7V'8SVWG-V-'?!"?:4[CISR6'<>([J(AJ&F, #
MOX>=Y>U 89Y7&4#04(6RL)'Q&MMNV XU %LY.ID8'HV@X.I.O40+RAES05.&O RN0 MHQG,C7H<~>77 CT9+CVZ9NEM6ZO*?>9,2.)<-[FI-GJK>9;/'51W/55OR
ML+YJ/>053L '>G>U(GPV3AB+S'DACE!)>F2+&S&5..YRMYQ4OXOTASMA*7&S+C ML=Y=Q3E.XSG:>V-FRN)LXY7JE,6-FMMM#@ DL6XA9SN'L>?W5YYNTB42[P#[4A
M+M+W-CI<~3'6>U HL[G6V5&S?]DU1?'XCGI(3-ROAJ4)? NVBB+A=A=OB5,VJ&KXF MCSO=Q+=F+2? VUl4(/07,LA:SHYG@< K MYA.LOZ1*'P7*HB JV?'>26<-[1[N8\$>F2 SE6VZ3VV>.<?-
ZKG6JD'QS_M2P=~Y(V(&XQ);#1'PCQIBKK:=QQ<==.;OOY@CS%#%F.-'19H,J6+K#F.'FJI MU4#/E/J04#6CV30.9FFV/JD3/HBF/W/O#=#>QOI[A8N_51+PO4 M "L4-=:[MGG])\$% #6@ &
&'AL+W=ON4=. =K.MYQ4>?EY'D:'ODB:#HY0 2'#MDX3)VWOV/Q?:ZXW3V%QZC9?FA12L6K\$EGEW-U"!PIE5J011PM,\$LB\$FVI]= MF3A7HDGMUO/(\$Q?"
9J'.B4-9' &L3-Z'ZZXM2AI(CBLMP> IGPS? QUHRQO%) M'=JIWDJ70 OU:A4JVML,FAT2ETJ?GXCH+.93Y4+'9' M.).D'A)-'16N?> H.'H1GDMK#2N'X?7QE>EL],35(KLF/C2F)=JEQ7>)|EJ@<
M!:I,Y,M+>PJ}>L182W5=CZSBMD-0X?4J) 30 '*RS,OI@UC'TV M'2,D,GH'H(+>+[JWQIF5EI]MVQCF@TLZ,&'BP6TY7QD'YRC.M9Z2 CJRF(F MTB69%?),M?> XA>C ?
#PJ]+IBK+PHXSJG|MPPBVQ' R [1BJ2]\$>3 JZ ">'8S,OLAsFB1EVQ MU(Q)'7J?>1Z.%Q?>78ER JR[U(OIWLTXZIN9N70=9KY3N& G-H'.AK'PG'> M%PNJ!#1#+-B<0?FT%/886><1W@ M %>:
(U@:(XGREGS_RYL4)>KDC=[V@- '#j9!8,49SE!A;>@#J1083K2V? MP(Q)'7VK/>?7?>J.ZUNZ"N =>GM@+N0O [T6+r6'>6)\$,XY'VW;6+/R/O/P0 MK1TO<4E'?>.RRSD,W4K8ZI(A#/%XA"M']S'
MRAX57(S' PK)+&F?>?.E9NSNDWBDB8','10J2ULO]]J40:IH],(4F M2GUSGC3' =>8T(X).5XHJ)7J4421 'P08+JARC';712N'XP(2PD;&O)A5JB
MM5FBIRQ,3BHYTE;#'189[XJV? M42RVLVD(M:F0AB7&+18H-J0=>#> OUAJII) UC MJ;@&AOMHAD;B718RTZ>95%S&NWNER(B).REIMK-X6\$OSVAGYN'&IJTD@<
M2!H[L11ERI.L<?>QT

[illegible]

[illegible]

[illegible]

!+<8S"/P?2C.M#95<YKSAC7J.6H/>/V>=ZDWBFL703::Z<78V.MO.WVENHC.A1F#.M43IX&UY4.9H&Nl:"\$10JJ"H(4>W.Z<&XBB)"G."ZEI"Q-Q15&7?>)@2<1D*+E
F18(\$UD66T ME)=5(VJ)?0.Y.QC.K3TF.HB<=>\$48(GZ81RUCIEF4E*G-3.-)HF+IV M(8V>W#O<36ER9IP/EZX&SW-WK3 99|@<ZIEFYCKXh39?FJL9OGL05 ML?
%<(U92L>6=>"JVL>2">2 KIKL2U=>2< HF<-(FM JH-IRUE F=F8-G MN\$H&F=US-\$822=V1 -9IOZ3DBY-D?>=/PCBH/F>DL5MHNO=P&A=H=O MDSE&N=5=KNIEJ9E?
FE=GVGMEOPJ.U55U=GDUBRM?>2STORMWOVINE(O)>M>SF7+5Z+Y4 Y7VYX4XY+T L L#45L#H10 ("PUUIUO-> <\$ 4 1 B +>PO-VIR-W.H965T@>F-CFW>&OF518
MX-EFRF40IO< /IN5#0ZIF?79G2DP2%>(DO#).GGW/Q.O.K#<32(5=<.3<-<1 M?1P6Q6XZ+2X%VOIDE#LH*K9BI# H#>K2V25Y+/-H(5M7# *9*U
M+=U28<C/GDS&A)""S W<=2I\$E Z.W."/C.J39BJWT?>N9CQUAFW.#FEK *.*MU&7 T5\$5 AKCAI7430?>53SO"2 .1TOJ.1%DA(.0.5UJ+4T8.4HS.(F&N"8-HH/
X\$/<L N6.NYO07YN552#Q M1H9XI49 P^8>+<=QQODZN?B975..89H/H.MXXIH0K72S9I=60)3HO MO#A(F KP#J&K.M.L.:1)JX+KLBT)#27=N1 N.Y
IXIU/P+ZTB0AO/VGAL(SV2MO#G>1955 M..X<5Y(KL<@>ZCND3.P.WMQW+LH2OE4A?>D.3AIOP0102X?+9<?>2.V729 MMH8"POBNHJ"TWCHZ>TSI23\$+(H
9V1&7?>3<=UTIE>F.TUGDE?H&KCY MOG.G6MHHL(T8R)Q=2%>(C1-LPB-P. "Q@5510?YCH(<48%DS4AD?>A(MT&NT(MBWYK-KY&VUF.F9N>K2N.A5GVAl3E2.
%>HIRE6"ROK.WMI>JP># ME.C5.D730?FF. D&MF(QEDOXIQ2VO)C%EAV)=<IO(SGV7IK"W<EUX A D MRMN3"RX97?>29 DEEN.8%CE2>A"BH\$N
>3".MG&SK50>KOKX74>2E5OG(Q.ML?P=C&E=Z@ZDNA.@6L"(4K8E15>8N#U.CI"TW3PRBDH5.>?>H=>2.ML+/PI-O~3\$M\$*>E.DK&5FIW%#MU.
%>FT0EK>/7@HLL<#.G1446-& GA.\$1 M#7+L(B)M?1(E0IZPAVI<+<L.C5MC2D VAW4?+TW-CCS.R5LFV2T?>AV07FV MP?<E1#LSH>VIT .MK76+1 MK?
ELP5TOW&K=DKOJ=UYHC4X?+>L 4APLZNU==MEG"E<SQ0NBAMIK&Q%-Z>B6QGFFP2P?>W.8UH=8A#JF MUUV51LH)ZYU4QF&17A
/T=IY6RN4.EFX095<1/VR/FPSHX?>JPN .MHIPTZP7<=9 5XHTB7OI&EJHJO. MC4FSI2A-VBAMD DTICWX<=I5U+3?P&A.OKEGV IN-TL 4 V&Q TIB.92.23
MSFPWS<G7L\$<CV(E+H&IS2X&.)>3PGUI<XLBH&OVGB(X-KZL M.?>01"YH.CR3IG.3IW/@<1-KH.1?>5Z.SEM)2FY/E4LO .%ZYI.%M4PIE M2U X2JHNT8.PSOE#B&&.>
W29PV2MPA**>H IL.\$fEQ.F=D<+5&PKP29 M2<+L \$9P<7&X&Y3B.G.L.BIB#@7.T4OW.E0&1HKH.K2PEEG/GH/L.3..2W2>90SV4C30<+B?>J.3IEIN.QH(M2J5JOE MT<+<?0C
<LFI?>ENN7M#+Y+YTCO>..M25R?6 G T+5".ISEDEL/M?Y MP.M1BXBP?>AGT8"IMLH<@V.F.L.3=+4JIS+YH&<.>77K M@Q@D&NDH=VHZO MH.OM3<~<\$?
38+K18Z8HRIAQ<=>."SA"1-F1\$P10P\$R%\$.%KEVF2BGNH MXJLFI?BVH? W=HJF\$6B"VP=PL+V?>P?>AGC+2O CRRRS9ZNT4.G1\$7RL
MD.M+DIJD8<2RRRYVR4=L=HJB8=UY4 .5Vc+4L6XSID<=8PEIXKRBKA?I K.M.MXS<+L H.\$H\$>=L\$R#QX\$SQE>D>Q2RTW. "+L48+XF7PK&K&S\$L<3VC<.
M.\$L1S<+UO">A?>GVH.IU.TKK.R?>XIB ?3MRQJ>+>0X%RBL?>K M&74SI PJ5.M\$>1IA3?>S...CGZPJ.10W.NU199 %HA"12TL"AJO643+B+A
ML.U0Y3&4/RBA01BUH9IH72J@>J=A/V&KA.P/O?P=C(UF)E=Y>39G.TE MF3K.O IV86/I+.V.E+V.W*95.0X1-M+QFOA"JV=NH.Y.--7A2?G3.
JN5..I7LM#KIZ\$ W\$Q14HME31/CBI? M.+2=K^K/AHFC=29FHE2ZMT8R3+5^H(WP
ML.A1D.J0NB8U21#>937LBA\$(S.XW.D.<E72QOYX JV=IQV<365UXK7.DNK.O/UHW:8#>D>6-KO>HVPX*5*MMF?=3A-MT-N0>7^Q(>@V!
IN51&SHVHQ<69T6ME.#6DT<+YZG;.%524.YJ@<~>+L M.D Q#517I8H)E GXQ?Z?4XIXZK>602UQ. "OK615+MA +JY-YLB) OYR MMY46'99&?>7B?*V+IR\$P4KS'
<7KWLP\$> T49&6UNCKTG WHA?4H?P82 V.ML.G6F6V.S-M52G?>VLD LO99CACME6W5NUG#\$K(C)/F<1KX57S:4"S U
MD<~<9.JYR5=3OT86H.SC6GX4V.IHG&P%K">W47V.NLSKPT(SN.Z?M(E MP?>P.FN9=0VN.V.5 N7V=ON<F6IG1A W.@N<.) Y7WKMU#H?>KST#BN<I
MCT552IYW@>=I.O@JY4+00K6<+&HVW.JOI'DAT.LHU:/I/YZU;G.M.PN 7S948(423LQ?>Q?IL/52&MD WR6E&J/RL#K@>IMWFV9%&6Y\$)0MCH11S?U
M&SXZHTGR 5IB03. ">#&G-TH\$>+I OJIN=9I.\$ISOJEV1\$\$.50>1.2# (<M#9?>YH"Q@B-K8Y726LOQ?>5..3+>Q9W2WG= RTU 4MR?>IDS-X"JH KN0"JAJU62+E+ORS3'
I=MO50H&5XE) @2X;DJWK1 K&8.52&5E 75&Z.LIK(L=N2HOO(U10JG?>744ESDY?>D)4JIS&RMJ3GHP M+SVZZHJLBUA04V47XJ9J8A7F#<+<1 MWM1 Y9365'W
BDMY(PG6F15+.WCDO#<S"IN-SU5.O>J=>4K&G9K.EN9 M&. IMOIZ48R(P4C%WCOIKV58T?>J@>OD-R=IAQ0DD6(I BU.B0K412F1<I MUWKK<+Y@OC(NHXHKB\$U#H/ZN&S+
Q%BSA&B-GHWZG(I=AS7T M2I2=>H.L MO8>J9FASI=>WAA)M&ULBFM.CBP<+<4&G MLDI=SH56M/KFWM=>M3 M.3E%P%>J+71YOY.3C0?>T15M6X)YK&+L(H)
I.EKW<#O(CH)LFND M?>XW/H..(XCM<@WMBP)? U9P..J0#V7<+B.C#F#?>UO M#5X>#WYDD7(?>?C@9IX#&@=>M@D8>2I?P8?>IMZH(CX) SPWY15\$Y.E)9IA&AY#
(^2+V8I TB2262/IGN1 ?>H/A<=(BD?3UC(DTGC CF<@I2/W2L12325+?>2H&4/M?>5X..MX&C&+S1GJP/H.L4/@>F@O(COR)<@>PMUOJ68.FNP10I#>P.J M.YICEB"?
N&DXOG>=7&K#>I#>O.Q%W5(3?>HP E3Y1\$?>(VS=DN)(2LM&P=IPB=Q?>POX4J9=20WISH+L&XL.M&8A1D9O/NM2.LGH0IC/N4QC M+1+WGH?
(GBY<+>B%9WIWKTIE&SINH&B&H8EPH2X1QZVTE+EE>EI MUR<+>WDV(AKKMBJ9JISJ81.S&L.PCN2W76J7.SNBC6<+>I #C7HK?>9/L M6I+AT<@T4I>Z L6"OP&C<+
7W>.(OIG6BBI+&2YOMW23C?>DI1Q5IOO0=MZ<WS98BT?>JG2=X<(UUXBMPP?>T2)QZ(4.8R14O2R=>J8B0FK7C4&W.980 M5830F(L8ZIBWPNZI3-A1F)2K4?F+?
I190(GP?"IX"N+>@>I%#9E6(KA+E MYT95+GI.O.ZV8W Y6P.L&@>4T?>@DY DG O2I@>O1"HM=MAB<@>+>I T M)+>L.'O'A&OB.D>R%
IUIY(ZRR?)<2V8+.0Q?>T.W.DNRW53PT?> BOMKD.B M?>+>G&V&9./>V.D OD-AZSBOG J+>X&TM7R;C/VK3R'L+>FETB>@GR MIGW?>C4+>I 4K4TW9=U^XMK.C07K?>
Q7+VYZ+>LH6EOGT(YGC<@>XR&S1MO.XJ?7EOD=0W7W7 I4YQM#OYUK7FP=2LUU<O&S4&LH0 (*PU M1UIZS>2A8P?>#8%>9+>PO=VIR.W:
H965TVZ8H9I.B6CA17H9D?>LT9A8BK43+35S5.MDH+9E4Q>A M#J36RWV&lt

MRJ<?H<^>W0&0<AL+W=OY&SKH M"B QY<^C7-D;Z5T 6B;>Zs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lt

01 02 03 04 05 06 07 08 09 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100 101 102 103 104 105 106 107 108 109 110 111 112 113 114 115 116 117 118 119 120 121 122 123 124 125 126 127 128 129 130 131 132 133 134 135 136 137 138 139 140 141 142 143 144 145 146 147 148 149 150 151 152 153 154 155 156 157 158 159 160 161 162 163 164 165 166 167 168 169 170 171 172 173 174 175 176 177 178 179 180 181 182 183 184 185 186 187 188 189 190 191 192 193 194 195 196 197 198 199 200 201 202 203 204 205 206 207 208 209 210 211 212 213 214 215 216 217 218 219 220 221 222 223 224 225 226 227 228 229 230 231 232 233 234 235 236 237 238 239 240 241 242 243 244 245 246 247 248 249 250 251 252 253 254 255 256 257 258 259 260 261 262 263 264 265 266 267 268 269 270 271 272 273 274 275 276 277 278 279 280 281 282 283 284 285 286 287 288 289 290 291 292 293 294 295 296 297 298 299 300 301 302 303 304 305 306 307 308 309 310 311 312 313 314 315 316 317 318 319 320 321 322 323 324 325 326 327 328 329 330 331 332 333 334 335 336 337 338 339 340 341 342 343 344 345 346 347 348 349 350 351 352 353 354 355 356 357 358 359 360 361 362 363 364 365 366 367 368 369 370 371 372 373 374 375 376 377 378 379 380 381 382 383 384 385 386 387 388 389 390 391 392 393 394 395 396 397 398 399 400 401 402 403 404 405 406 407 408 409 410 411 412 413 414 415 416 417 418 419 420 421 422 423 424 425 426 427 428 429 430 431 432 433 434 435 436 437 438 439 440 441 442 443 444 445 446 447 448 449 450 451 452 453 454 455 456 457 458 459 460 461 462 463 464 465 466 467 468 469 470 471 472 473 474 475 476 477 478 479 480 481 482 483 484 485 486 487 488 489 490 491 492 493 494 495 496 497 498 499 500 501 502 503 504 505 506 507 508 509 510 511 512 513 514 515 516 517 518 519 520 521 522 523 524 525 526 527 528 529 530 531 532 533 534 535 536 537 538 539 540 541 542 543 544 545 546 547 548 549 550 551 552 553 554 555 556 557 558 559 560 561 562 563 564 565 566 567 568 569 570 571 572 573 574 575 576 577 578 579 580 581 582 583 584 585 586 587 588 589 590 591 592 593 594 595 596 597 598 599 600 601 602 603 604 605 606 607 608 609 610 611 612 613 614 615 616 617 618 619 620 621 622 623 624 625 626 627 628 629 630 631 632 633 634 635 636 637 638 639 640 641 642 643 644 645 646 647 648 649 650 651 652 653 654 655 656 657 658 659 660 661 662 663 664 665 666 667 668 669 670 671 672 673 674 675 676 677 678 679 680 681 682 683 684 685 686 687 688 689 690 691 692 693 694 695 696 697 698 699 700 701 702 703 704 705 706 707 708 709 710 711 712 713 714 715 716 717 718 719 720 721 722 723 724 725 726 727 728 729 730 731 732 733 734 735 736 737 738 739 740 741 742 743 744 745 746 747 748 749 750 751 752 753 754 755 756 757 758 759 760 761 762 763 764 765 766 767 768 769 770 771 772 773 774 775 776 777 778 779 780 781 782 783 784 785 786 787 788 789 790 791 792 793 794 795 796 797 798 799 800 801 802 803 804 805 806 807 808 809 810 811 812 813 814 815 816 817 818 819 820 821 822 823 824 825 826 827 828 829 830 831 832 833 834 835 836 837 838 839 840 841 842 843 844 845 846 847 848 849 850 851 852 853 854 855 856 857 858 859 860 861 862 863 864 865 866 867 868 869 870 871 872 873 874 875 876 877 878 879 880 881 882 883 884 885 886 887 888 889 890 891 892 893 894 895 896 897 898 899 900 901 902 903 904 905 906 907 908 909 910 911 912 913 914 915 916 917 918 919 920 921 922 923 924 925 926 927 928 929 930 931 932 933 934 935 936 937 938 939 940 941 942 943 944 945 946 947 948 949 950 951 952 953 954 955 956 957 958 959 960 961 962 963 964 965 966 967 968 969 970 971 972 973 974 975 976 977 978 979 980 981 982 983 984 985 986 987 988 989 990 991 992 993 994 995 996 997 998 999 1000

[illegible]

"LEWQOW>N12H;I::D9.7A1)B1\$SW3?^M16P+J02BIFSD;*LKGKBP#%1:G;M405D07F&IAGSMBBT?7BEJG0\$SXO= M^A/J).S=163*=O)DE^XXDCLJ@KS;PLHV7IF<^
#Q#59Z2>?>1WJ AI N12 MYRNN1FY<+>@%5H\$825S)GPIYGO04C13?>103AXIMJ56<^Z%#Z.7A02GH M(9<=<@=77?2RA+?#5)K>=K W5.FUKQV?L L\$XKYRQ0?6KR%?(S<1X<5*
M1HY5>2H^H\$HFKR<2VM;K1H JHW@>1 MJG?C<?>31+5%Z.KF@M.S.UN2T\$S04 = 2%#X%UJ40<1B>B^UGM1Y 1^A34K05 M(LMYMBZ 3U3C^M =M<6.SAA<?P2M<?>JNC?#<^?2
STH>74BH0JHJ. AHWZMKH#G8HMSF&FJ MQ.G@=<=DKU.YL?>+>^XV8E.6G8UJLGOJ.W0<=<B^S"Q0J?>E>U^Y4J>Q31F V M2<K+R&RRI7FQ?4MK6K0<@>B2N+E&29 14Q3L>
(4)S\$K50GDE\$R6@PDDLF.MU).^AIOQ54ET6= S.J8?&2L\$N\$F\$E7WUW.#%?)?&DR.L-0F++>ZZ0F.E.3 1XR M%-O.D\$U8:A.668)U.C1N.S2V7X.&CXYOU#WTHR<?2M@526N1Z
D1R5E5B416C1FTH?P5Y1.1J1D&T\$31-0^ZL KVKX2 N5L1V51 MYVYGVO9L&K+H F?H?I?>93W9?K&N1ONIG+S?S\$R10?2MERCL=JVKZQ.Y.MBDV.3W-09.1)H52&1<^
^Y@W18D1P1M?..#HJR+J+U+ P04 1^L= M&1819.0^#YJP &0^A1+W=OF?718F5FH< ME94 G.E025W2R?WQ(OY26SG.D021Y6BA.&0?)5EE@1S8BR.39+>N)J6X2
MRDR2355A?Y>U.NA1Z+4W&3F2<(<8%1?>= Y?YEZ6^P\$N1W/CY)IS.MX.XRB.9P01A5091JS U^2@V1E9&IX73.50K@IO.6 8/KUWK<8PES3K<3
M31439-R#@)9X1<4MWWR@OJ.01-6<2ON+>DVMZT7D140&564H6 1^?@1@U.M.W3#2.1^@L\$&TIL TU@>L5KQ9=<6 BN8Y2 186B4@B+&23D1?80GRV1L+312A1?QC<L%
M.CUY@TX.Z\$0150\$S3..NTLL.OYLVF.U^O^@<B@MTS9D)K/L@ZV/<^#O M(7U2IJ^<^N^S/Q>Q@6DYR@80\$6^YX==@OKAUU@<@<^)=IM^BQ?1(V?BL M51^5@E+^f.IS31-
VYA(CN)033F?B2&1@<EB#DIQ^8B1U>?>O9GN.P=1SV ML2K9.P1C+1?%WQVCBL&^<^4=161>D.MOJ& MO?JNR@H3H?>(<N641A1BZP1A<ACKJF>U.M(8^E3T@IS^3%=
^A^SYAS56?GDBD1ZL61ZA7L 17S@8 MHL.#\$7H?P3.M\$51OZ<6Y>ZD.PBBMY.1^?EQCHIV&FV7IO..? EM>7?HHX% M?>HEHK#44.IJL&HNPHE^BA>V-R^YTHGOWTL?<
T.PA3H127G.CLP1-VAO<^0^M4\$ML#10<^@PU1UK^4^WCO@O 9<^>P=O.V1R.W.H96572.2A1^JJE\$S=@X/^N35U14J@<SNRRI5YX.35J^@M1#>2MTSVU>E(<DX0&^&Y=>X'
MMXR0R13<^X%#K21J631<=IYMG&14Q<^0%50@>KYQ9F0?DQTFH&R=>BHC.MW&T.N^S&M.M%EC<G<0%U^U+ET49+O^ICEH1HG8KPK31@>KJ.1ZT.
(+>#KFW^+JCU1M1V^<B@ TM11&16HWIW#CCS-Z^X^O")*%PU/>?>Q5L-7M0G M2-U1O+1GWH(K78+9JY-BD^8 #V^Y%PI=&PO=VJR.W-H965Tl@&WN.3JW<TIVC#^>#(B;8Y+<
<3BRJ0L.Y0?>G6D6R9@<K@U64QOU> M^1^1.3307?P?<2 M=8X71"61<Z%#1&MY5WB8>?>ZIG<?PC?>H5FE7Y0@>9+R@8#W&+<1RX1^*M<^4?>CE9.E3 1J2H>+>?>C?<
39 1&U@BL.6.K0^<JL^T.W>+>IUGOGIA> M&..WQOGBV.103L&0 EFG4>6L1&RFXDDBOZ.<SCHV.G@>QU-Y7#11.MHFS14J1)CTSH.31RQ@.NE.E^L^S(I2D
7K<1J8^NS1-WQ 1ZL>R1X<=K&K21-0 61?Z>^AO?MT1OY>R3 3&H^01%51) HP*>P&SLM5EK.LH6W/TKA08+.91&5(O6PE.D&6@=<51 MD.S08=>119JCH1+HD:3=>N1DJ1^1=>
SH(O)>?>PW-(?>Y<G.KJG 1M8\$R+1.MR1G8N1L=O1Y#124D1<ZB0.YL<^+>C%2514ZD3Y1L M5GB.RVP>V.TJJO.<2UDNRK1@75.D/2K91L4>5R^C^U?109Z(3H1.2>@<
M.(\$)=@<1^\$OPZP2^<5LQ^63=8XOF4LSW@.EJAZO.EW)392DU&I3<2JHN9BI/MSF.(DP27X+<1.JF0?1>4>G<6^JH^P^TDA?C?)Y^"OHNO.NQO.G9..HXA^\$IX@S
M D&G^F.F21-83JC^ADU>L?>YEP5Y1(ENXPQ?JO0\$1^..99G1N1Y 53^M^Z^6&^PRBF7JOHR+70T2EH/HK6.W#ZPZNZ2.HJBCG7C12<=<U\$ M55B@<^<S0?1A^
^D@<HJ6@)WYH9ADU>1J2T.21R7AB8UA)P@/P2XK"B(2SO M41^8&4&A.KPX7Z3QPLPD^>P@.GR.F5JAS^W.DL)JN#<=<C1HEQ6.^PFL M\$QSA1?6Y1JGF=H<.
G^N&L^<DUBDUY6=1UX0W61^<1@6Q 1^BH^>VS41^6^M.5W3^TM UPBH1A+<^XW\$561^>P@.PA1=I^M@ M^Z+<1T1U06>V.Y^XW8ZUY>.&H.G1K70VOC^G126EH
MV<^AW01TUWO1Z.H41<(<#7P^+H.WXO^R8 MBX VEW.Z2^TYS^2C2J1KRK^MT1<0?1O8@PHM^LH\$OY>19XJM<W6CYM1LW^WVR6\$ FOP 85+6&31T6-?
MJZIS7FW+>H:DO(DRMXF131GGQ21Q5\$1.FT0L<1)16)U-3BWA(BH=8B&M% M.E711T&0L^14Y/&C_0\$MTC4^AADAW\$X77V>..MT@IPVD5H00JR>Y51 MSHL..9?RC?<
HT0KPMDW4AH?>VMY&T3<2MNU..L=<#XEL.A.O^1/1@1AB MCV1?>1T@.N10<4>MLD>US\$XW19VO..P<^CI^5V@>7RNV14>10<^XP1AZH M#E9^7CO.JV 5Z1^<DN>1
141QB>F1Z1#<^N^5X2K@/4 153ZU>Z>Z>656N1 M^7I02P.\$%>@ K^56M=>96+C2 1&T& ID 1X."HW.W&K&ULW=<U^K<^>XJFQKZ^H=W8B.CY1.133.AGIDB81 2&N>..M>4^RDQV^<
^KJN.Z<8<D>).0YHW6U17295E2N DG>2T1 7 W<^<+ YK M33U)5L8^ O1FR1<1GVU>OKM1^<EW?2D<+<1?>2N0 1G6<^>1RLUO^Z>?>Y M^1<10024PG27APE@<^SY.%C<^
MECS_ SK<1>=<C1031J7VU^U/MIT<3^TFL0^O<^FL1RYWMSDY61Z1Y<=<G^MY1ML.E^2PW^O 1+>2DH2D M.K51NO<^R.DP1J&QV1Q271YAN1Z
^#0>?>?>Y^<^M^X.EDF1?G#8J^ M^O177Z1>.>Z3KY/GAU4T 1.L=<^EBXUW-W1800RO>?>V8TN.<?>R171<70C M12.XG.Y>..W.RS<U/Q<=<^5VW.E#9WJR?<
(=>VY0W>Z@>NX1U+8WJW+>X^W.MX61@XMS.WY0<^ET0JHJW@<GN#JZ.E&OOW:1Z>X^K<9?1>D1-G -V?K?>N^21?>25ZGLW3W1M?>G?<
?>FMGO.R1?>21.M.LGOGS1W+>P?>2GLY1Z>+1+9S JE=>V57SG1 MV.LGOW+55 K.U 19S JE=>V57SG1ZVR> 8KQ1<^>S291N51Y 1RN19KQP M^<^?>215XZ?<?<
=<OLGOV^<^<Y7<LUIY<1FOH1ZMG?>G7W1M?>P.O.KNV M>O.S7WV1S2H1?>Z..K9S 1J=V57SW1V NGOW1V<^=>?251U^JHN191Z M1K^?W3W1U>G J.W7861H91HVK-?
YSW1M1.2<KNV<1U/N27?>EWSG6?FE PMMOYGLB.W/K5V1R-2 1W^ZXA1TJEF HM7R 5.G.YOMH1UDRUKX1W=>1/M.
10Y.%P9ZISW68Z^MIFLL.Y 90S%<^PLOT6R=<8SHS>+1. OK<#Z1 MN?M1 KKK1 EYKX^WYT?>?>PU\$57>>41EPY/5M^7AC613^YVW#1. MOGTU1 8RLX&.#.#S^J?<
W>>X1O1E FLESPNS1^1N601154J1F1V3<1^U<^M1@0JVO1F4ULF1F.W/P.G.5.K7>+<^N12< C%+EZ#<=<1K1^<9 M1=5MHWE1N.8ORC^BD=<M
MF1?>=<X7A?>FWR8D1.M6<1^OG^B>=<Z2EG1<NX7A7B>NX09^741.O2ASD1V0237Y1#W^GSWR^JAM=EK.JGZ1NGR5WUU<?>UC1PR>?>Y?>4<
MR1E=<SBU%>92616B=DDYH81<=<1FN2F3=<B+1^S2.O@&A1236&L1(O3<2 MZY8C13Z)8&L2&G1C4AL3&2(H1%>QIUH547FG6A71<=<1P%E1YVH671Z&G>A
M1=1>=<2%1QIX485131^UMQVEF16 1C&3 0YSUAW>S91G1?>=>1L13?>TRF M621/2&3K30?P21TG.J&C&B.DDBU80QC11.36)O&E711@>7.71WQ^U.M.M3^MZ 2?<
QON^*1=D@L(K&8Q+HDBU.O1ID-2&O(8B.2&Y.8LHM=>=<1-3370GLM.M-A^BRTTF4^+33.0JLM-M^NRTTW\$+<K05J1^*G12+MPWE(G->B9^GR8>7 MW63^U:A?<
KRNG51).HNA^OF(FB5D91.80V1<6^>KJ&E7HFU2.PGL31)206 MDEG1Q^2BTF12V1SN3V?<=<AB0V(K&O&B2D1Y(47%U1#HZYMUO 9+15MG1>2.C1X76KDNFZ^>10TLK
15^6RLTMD1KJ2W0GLK^1A) MBRL1N.E.XOMD1G.W^3#1^E3Z3(1513D729)K\$=B M21G.D-B0Q&8D-B8Q92>Z1Z.FBMA>9>..<^<EMH184F6VBSA49+<6%9EMH
MMX6&6VBV142M9)H=>=6D^NWU>02ZF1N7G4YXRPQPNV&=1Y+4>G1=<78D1O1PW1J1.6191>=<Q=2.TG.(G&:Q1P2.3^82V)>=<O<F
MKX5B5H1P1R@<L9&\$.B0606< 7VU=>147>21=<NN116) 1\$B0V1+1\$B8U13-G) M1KR8H1Z1&1\$ALH<46FFRAS18>..5%1MH1=6&FZAY1H^E^M31FTHY=>1
MCK(YX^MG2.EO+O)Z>@1F7^U3#?N<(<KFRFZ^>B6H6JMFHYJ1. 15<5&NB MFH=1+5354.V.<@JA5OMRXYZ^+<C181NND+2 M101<9^E1/UE/O1C6:R\$1H78C(OMN-
B0BRVYV21>..G8F1M(NM=N=BGJ1?>SWFS&FJ1NT7RIDV8Y1U?M60&A1<74C 154U14<5&N@<FHMJ M33534^Y%>CZ1MMS5M0+40U3H1?>G01O1WB5R10X16A=<QNC6A75>1J6114
M1@U18118U133K1+1RXH0Y<..K&MEQL5.767&5.Q29<..#%>EULT14V654 MO59=6.3NMO<M/ERYD&0M YMOK<1.X>QOC=U<81Y154 154U14<5&N@<
MFHMJ135354^Y%>CZ1M55M0+51PJOV 7^#Y<^<RLSX14H1C&1=5.NA6A 51J@V M1+11JH1U133GY14&KZ9L1&L1Q1+<6%>MMHL\$566VFO1F1...<A&EMJL.D6V1JQ M159<(<G>G
9^& /H2L5.3^G<=<5Y.O+<QB 7A1F31.13Q1=<1.MYU68R+1N7E1Z1Y1T1=VHEHS1H.E 12UZY7A781.EH1+1Z2MP
M1YD<^#<F#1KY4.D^FW1ZDOW1BLV1S9TBKQ>3%>7VEX?8^MXIKZRW7C^<KO M.E^\$B.Y^?>1O3&=K>.<O/CZ.MO^C_UX6Q?Y2>EC?<
<11^S.V WK3XSOY1J151^Y1Y>N^N@<6 V1%E.M9AMU1 G7OZFWU1>(<FY<^>O>B1SXO>6&KS2W?>1V^W9 671^W1XN=2
MO1AB5.NB6@.5^J@V0+4AJHU0.8QJIRAG1BN^T^2.VC1+<3&6<13NP)W:CM\$S0&B1WCQ.YQ81@U.M.KP>=<95Q1G1M1A.FPU.
H1<D>..MU5#>1S4(U14<5&N@<FHMJ135354^Y%>CZ1MMS5M0+40U3H1?>G01O1WB5R10X16A=<QNC6A75>1J6114
1J21EBA51T=>9^1EULT14V75C4ATU>Z7GR35Y1M\$<G>9K1VR1J1+05D>T^1/15^1%25421E11.B MYT&XG1HK02NCGF&MLB RYVTS
(3+>18B.MMO&B.RYV1T)>#1+4PE\$=WE6N.M1HM^JGA 60V27Q^+<F(D\$>PUE11#4+U604V.M7^1>1^#>?1>6G^X.Z2Q^5_GEQWR-9>..% M1E1H1
<4F7VSSQ49?>17%9E11L67&VSYQ:9261M3ZT1E11.N5#<61+T%>1M1+P7&E1E1V1275 12000IRK G=1.Z^N<K19TGVRZ3Z1.B6H6JMFHYJ1 15<M5&NBFH=1+5354.V.
=<@JA:66V6H2Y7K%26<HBB13Y5.NB6@.5^J@V0+4AJHU0.8QJIRFEX166Y1E=B.BPVY1Z+<3.G8EH1N=B.B.PVY1Z+<#>K8H1M.NMBF
M^XN2>1D1H1>95%<6>..W1J1P1BWEH157%<E11^<=<QOM<L1=47FWY1A1401719E1KTHK1Z>3 MUE11#4+U604WEV1^>VEEK1F1P1U>9E7K66&U\$O41U#11C4^U1JHY1>814
M5&NAFH11614^1U\$M1JG61141J@U1.81H M8U133N1+1SLH0>9>..% M1E1L+4F7VSSQ492?>17%9E11L67&VSYQ:9261O31 M1+P7&E1E1V1275
>4>091=5.5+0548U141..B6A15%1KH91FU4^U.M.M1+4.JD6H1J1=<15Z1-9^M0&J#5%MA&1C5)8C1V1V1R+1W8X1(LMOMCDBVY<^MV.B+K
181(OMOMCPBRV V1O+1W1ZG.C.KSN91X?>AHOH&1Z1D^DPH SYW>@ MHT>751 1^U641W1F1+DU4U1MA6H^JK51+4^U M=4Z1^A6HQ1753KH5H1U>H-D2U\$1
44TVZ2Z1R1V<^<1S.YH1O.O1BR1V1Y^1+1S181LLO M.O-W1Y1>=<1FV1X>1T>+>11^1=5.51-0548U141..B6A15%1KH91FU4^U.M.M1+4.JD6H1J1=<15Z1
19^M0&J#5%MA&1C5)8C1V1V1R+1W8X1(LMOMCDB1MBVY<^V.B+K181(OMOMCPBRV V1O+1W1JW.F6V1M=<N8QH6=<D1Y3^%UQ4.U\$ M-005^1S1B>..721M C1Z^1V150?
51FC1H51H+U?Q4.Z>=<@HAJG50+1^U&6Z M19^9^M3Z1#51MB&1H5&1NCG1+77A183D1V01+<1G.E1ELN^781HN-OMC1BV1^MV.Z1# 81HM-O1V1Y>?>1G1YR1P1?>1W0=<KDRT
B+1+1UO=A.<O1R<7&2^<= M1G1H1FAFH91^LY6NSA89&1Y2)>1f19XDR1OUD6U1H1Y19^1 15V1@6H1% M1A14B1M1K1ANJ050K81H
1U1HMH1U<^H1HRO1H1D1XMN=B1B1VY1Y1C+83FV M^6^C+1LZ8K.OMOMBPRV<^V<+<3Z1Z1V1FLM1@<Y1W^YB1XOG1#D?>RTT2Q7 MFK18616&O1U1C1H1E1AFH91
1Y6NS18.ZX W921OKRUE14Z1AVH511 M1K8U1 1^J191M0C58E3KHEH1UJH-D1U1C14V1L1Z1O&=<N78C(OMN-B0 MBRYV19C1FR1^F^K1S181KLO
OQBRRV<+<1G1Y1ON1O1HS1O1O>5D00B>@<W1H1L7V7SP1O1921+>1^E1L M1.567VSYQ792.C1%>CE1E1H1H6U1W6U1913NW1H1XQ8.M1PZP1E1AFH91<=<@Z1 M
5#<141FG1H1U171J1<16HAJ^52+1^U&6M2JH15^MCVH151NBV@C5Q1@F M1L1O1&1Y1M1L<^<E76WR0R121+1^U1M1L=D7VWQX11>2^K1M1@11LS151W
M1@1%O17^F2SN1O1S>?>1Y9FW^U2ASLEA.1JME H51Y.FE=50S48V>B=JC60147U1JHY1?>1515&NC6H1H1C14^U^M1C5N1C6014^M1@U0.8A1(U01HY1RBEY14\$YMN
B0RZ1Y=<CBBT1V M1+1C18ZHO1OMCNBPV MV^1+3^>P1J=>7FLO121Y1=<M.ULE+W=E3-9^<XO1ZO1E.N1A1F54.U1VFKE MTL^Z4O1H1AHX17E<1>V50K81J+1JHU4?1+
%QML1=47FWYQ MW1<3^K1E1M1N^8U1KR1?>4E1^<S1GWN1^YF=V1V1PSYBE93.VTWSOC1+<C MY7^531Y1+G.D>3UE11#4KY2=OFK3O.WTRES1P1G8 1AMC.G1M1O0QGSQ
MZV8K71U/G1G31Z1Z>1J6S1<368 12MU91TRF1 L1SU1PZ1MS.Q 7 M1+11JH1W1+QW^1+1M81V1M1Y1H1O14051N1U1 61O1P1PW1PQ7TSS1+ MPW.Z>2EH1?<
15<5&NBFH=1+5354.V1+<@JA:66A14U1614Z2)>1#71Z#9 MM2&1C51M&C&K^F8 1^U1HOXY18F<@YQO1Q1=1E&31L1Y81.OMO1BLR<^V1Y1+ M1+18M.0K.W1L1ZOPAFGHWZ^D1D2?
Z52%<G1_4H?K<=<M1U>+R?WF1<1G1T? MG4>=>XU1-1/5KOR?QG+1O91C11.W=<#H1(1J+1JHU4?>=<QOM<L1=47FWY1A1401719E1KTHK1Z>3 MUE11#4+U604WEV1^>VEEK1F1P1U>9E7K66&U\$O41U#11C4^U1JHY1>814
1>9AV5R11L1S16V1WQ881E1B1B165N1M7\$Y=N1Y1MZ1JLS1L01L15<5&NBFH=1+5354.V1+<@JA:66A14U1614Z2)>1#71Z#9 MM2&1C51M&C&K^F81O&1Y1H1O14051N1U1 61O1P1PW1PQ7TSS1+ MPW.Z>2EH1?<
9C1DV1+1C18ZHO1OMCNBPV V1Y+ M3^>P1J=6EEK166199Y1U1EN7S.Y1%N1L74>7E311RWA@AVRNZ1H^B6K65DN1 M1+M4 7XC101V50K81J+1JHU4?1+
%QML1=47FWYQ MW1<3^K1E1M1N^8U1KR1?>4E1^<S1GWN1^YF=V1V1PSYBE93.VTWSOC1+<C MY7^531Y1+G.D>3UE11#4KY2=OFK3O.WTRES1P1G8 1AMC.G1M1O0QGSQ
(M1F1&191O1Q3L137L MD 62DKR1U1U15F1=7&S4U1K1J1C1B&K57\$G1C0.RN701@G1BPRY^KW1=71&S1M&KPK&JFH1UD01451S1:66A05
E014.Y#<A1Q1C614>1J051181J0U0.H=H8 MU9121>+1^?>F M3Z1Q MU7T.DWD&Z6W1X+V5C^?GQ7J1621^=<D71M&719.1543U1RM<C^X1S15BU^M M6C16.6.h0 =1?>U1K5054>U
1H1J1B1B1=25E2+4.V+CU4ZZ1 M=6&1J9^M3&1P27Q>5&E.C1+>2LE9.9C1DV16^+5.Z81JO1OMB1NRV1+<1M1S1PM1PWE1J^WYEEKFOO1K1C1Q7MY151U52AC=<31?<
31Z?>+90=<1A M151^12541J1=5.51+V.MVN\$1F27^GRZNGB11<140&1JKFH1UD0151S1:66A05 E014.Y#<A1Q1C614>1J051181J0U0.H=H8U913>+>1K#1JQ1<1C MZ1M1.C.D
1%U51-1S4(U1H14<5&N@<FHMJ135354^Y%>CZ1MMS5M0+40U3H1?>G01O1WB5R10X16A=<QNC6A75>1J6114
4&V.H.H0U4.H.D8U1ZD1 M1+1B1U1S17^REF MV31V&XW1Y1S0VQ1Y1H1&7G1W5Y32&S4.U&O125&1CFHEH31U304.Z&: MCV1M5 M0+42U1H1J1C6A2
5>1J61141J@U1.81H18U133N1+1SLH0>9>..% M1E1L+4F7VSSQ492?>17%9E11L67&VSYQ:9261O3R1?MEY1Z1>X1SD32 M1J91&1FAFH1U1JHU4^U.M.M21>?>C60C4?<
U=1H1J1B1B1=5C1M0+4.V+1JKU4^V1M1@<4&Z+>..7&J1O1M1L.D7VWNO1P1=>1+>1JML=<76VWQV121>A^U.M1L>D7UO14NG19>EWM+C111W1K^C6 M0C4?U=JH1FRUBO?<
M1<^<GZ1P1SH1H1&A&HJG51K8=1P50.H.H0U4.H.D8U MY>21V1U1R1E M1.M 722>=<3G1<1O1Z01+9>81+<S1E1K3U1Z>201O1J1C^<3N^<G^#>7CY&81
M1GDI1S43Z1Q241U1O1&1JKFH1UD0151S1:66A05@1UVN1ABPVY1Z+<3.K81H1N.NMB1BV1Z1L^1V17>1^K1Q2.S1+<1H7S1+Z16Z521QX176M31^?<
SY^>EF<?>PRX<+>?>Z91&1FAFH1U1JHU4^U.M.M21>?>C60C4?U=JH1FRUG1E12U1O1=U M0K48U1H1UD1U1JH1&4V1M.B1&4&Z1?<
*M1...E8F.M8N9B3.H.7V1K<^9PY1Z2U1Y6D=U4Q4U1M11C4^U1JHY1>814M5&NAFH15014^U1SM0Z1J1<6HUH7U7JH1UD1U1H146V1F44T1@BVAX^?F
M17SOO0921?>1E1L15&7V1SU069?>12%AE1L<6F7UC1TQO.Y711M1N6004R1/M1-VCFHE1P1KJ91<@6@=<57U1KH1J1BU4U1M&C6H1JH6H1UD1U1M1S1NB6@5
M1J@>V0+4AJHU0.QO1SLN1Z1>1&1%QML1<47FWRS1<1>2.5%YML1=F7WZQ.MY1>1?>F M3Z1L1M1>1S1EXF4W&V19W1TODGOC1KW1+1H1D171R @<S^M
M1H1D1A1J1V1CFH1H1U150Q4.Z1AVH1M51K8U1U1O1Q1&1CZ12R61L1<1C1T4U1 M1.5B5.NB6@.5^J@V0+4AJHU0.8QJIRFEX166Y1E=B.BPVY1Z+<3.G8EH1N=B.B.PVY1Z+<#>K8H1M.NMBF
M1B1V1Z121.S8R1NMO^R17WRO@.CF7G.H1V1L1R1U1J1O1&1G&C31J91&1FAFH1U1JHU4^U.M.M21>?>C60C4?U=JH1FRUPO?>7V1W141>1=51M0+4.U1JKU4^V1M1@<4&Z+>..7&J1
<=<A=27E1.#.G8DH1M.N=B6B1X1Y1V1+>S.G8GHL.NMBB1B1V1Z1MV18K8^FL>GEX7E.O&O>#21Z#=<1E1PW1 71YMU&E1B1D1GOC1&121FXN1^3A1F754.M1U1OC41U1Q4.Z1>BY1-
51-0K851JHU42U1M1#51J@>6H51J@>E4UZZ1?>14& M1#9&M1&1C1J5<=<4000@<?)M1L?F7&WROQ1>?>1+>1%QML1=47FWQV1<1>2^<A^U.M1L>D7UO14NG19>EWM+C111W1K^C6 M0C4?U=JH1FRUBO?<
KOW1J1S1M21)1#H91&1FAFH1U1JHU4^U.M.M21>?>C60C4?U=JH1FRU MWX=1J67F1?52+4^U&M2Z1151MCVH151NBV@C5Q1BFG1@7WE18C1LVX1Z1^M1.G8DH1M
N=B6B1X1Y1V1+>S.G8GHL.NMB1B1V1Z1MV18K8^FL>GEX7E.O&O>#21Z#=<1E1PW1 71YMU&E1B1D1GOC1&121FXN1^3A1F754.M1U1OC41U1Q4.Z1>BY1-
FU41#557YV1E91<1^<YB7C1Z@>6H11U14^U1Y1G141Z&=<5& M1#9&M1&1C1J5<=<4000@<?)M1L?F7&WROQ1>?>1+>1%QML1=47FWQV1<1>2^<A^U.M1L>D7UO14NG19>EWM+C111W1K^C6 M0C4?U=JH1FRUBO?<
1MOWO1M1D1V1Z7R7W2M321EZLEQ?>K?K1Z1+1J1L7WEO1C^P6EG^R2G 1%IMRL3&7 M6W1Q11<1%1%1%QML1D7VW1A44 0^A1?7275Q1O=<19^UN1^F&S1A.O+2SD
<1S11Q1M1447FW1K1Z1EZLEQ?>K?K1Z1+1J1L7WEO1C^P6EG^R2G 1%IMRL3&7 M6W1Q11<1%1%1%QML1D7VW1A44 0^A1?7275Q1O=<19^UN1^F&S1A.O+2SD
MR9Q1U5#>W6KEF1^21AW50?>XN1H1JCFH1#51S4.V1.AZ1M5#>114V1@6H M1V1D14B51M1Q1H153KH1H1U8.H.D^U1.H1H1H1EQ248T.ND78X(LMOMCDB1MBVY<^V.B+K
181(OMOMCPBRV V1O+1W1Z2G1UE1O1&1WEXD1 S1+>MR8 1^91S0H1622+R12>1GCEV

FLA;ZT P17R>/RI+I#2LU91S43U2Q4LU-04&JKFHU0U M15J:L:C6A05 E0+4V#;A&IQ:C614>J051L8J10U0:H=H8U2268VLO-O=B M>RV<+*+S;Y8LO-OIBJRIV<Y#
L+S;8LLO-OW"VII">=ZWZTIF<9FWX=L MF6&6<1EY&<=>U4Q4LU-1C4U1HHJ7J1415&NAFHJL50+MEKJ70.O-Y \$ M2/RN-2I=E M0K48U;JHJUD.U/HJL-4&Y&B-4&Z...2
2>3SF07D-B"=VUE-M1#4+U604U22DVSQO==7E7+UW7+M#U\$K\$Y<XN M-M2J>=5/Y&KKBV/GZ<^/XK U4DZ4A<A&H0G51K8=J550.H-H0U4.H-D8U MU>2T<#I/G3/U/H17
MH=IXKSP&H/GNN2C19=.#1#4+U604U22DVSQO==7E7+UW7+M#U\$K\$Y<XN M-M2J>=5/Y&KKBV/GZ<^/XK U4DZ4A<A&H0G51K8=J550.H-H0U4.H-D8U MU>2T<#I/G3/U/H17
M0+42U#HJ#J:C6A75>JC61H4J|@U1.81J8U236(ZMO=CMVIMM>=S+P7I>=Z7I=N9N MJS;7CB7WFO@IDZ>H=-%EY2.U\$-005;%1S4^V1:BZJ-5^0I46JOFHUD.U-ZM
-5/N:6HJ1.U4-Y:G4Z&Z#P-5&K#9&=440 C<@W/LJL7V7FSPQ19?I/M>+>#EJL1567V5VQ079?/BU"=Z K3EX<Q41=6I?P0R4LO.17 UCJ<4+1 MXWEIU^P8H+XU-67XS/QO+
U9/U83NXYF>=6>1A-1/5+>254BPPV<#P-3>18VHN-OMCJBIV-Y-Z+>#IY4+3024EH>+1.TD9S1M=IRL4-4+>#ES^/NH9J?>A6HVJGCHUD.U#H6J.A6<0574KJHJ.B&J M=5
M0K48U;JHJUD.U/HJL-4&Y&B-4&Z-9S/R.WL/KX<@M13P/Q/VYKGBJ2B3N<U+Z^VGR-KW8-YLE@EBY.#7F49W53%254.U\$-075 M&SJCFFHEH3U304.Z&:CVMIM5
M0+42U#HJ#J:C6A75>JC61H4J|@U1.81J8U13 M30>+1.S0H0^9>.#EJL1<4E7VZSQ0492?7^9&EIL7G10R^WHG3R2C3T.MKK&PHI-Z1.U6DWD2VHGWH3N3N.GLWNB|
|C...=U&KJ=1Y%I23%9^3)G754.U-M0C4.U1O4.Z^BVI-5/-0K85J/JHU42U-M1#5.J@6H5J;EU4ZZ%14&J#9\$ MM1&JC5%-?TOOMV@)MHLT7&WROQI>+?+?
%QMH=L>FQW9QW1<#?K&E^YM-M8>U+I#7P7H13+I&W4R<+Z&ZAFHJ?>C.J.C604747U9HJ?>#J53&NC M6HJG1U4^U^M1C5JF60I4^@U0.8AUFU.O.HYK\$9>...%JEH|
<4F M7V5SO422>7%9&EILH6&Z75Q9.926/O3212.MWV>SS.G02F8M2KJ5^CMV.C6Y^YMO<6>9AXI|M.M1T^M&BPFJF.FAH9I>@ZJ5^J1.4JFGJHCHUD.U?17JL>6HAJ52+4^U\$
MM2JH5^MCMVH51&NBV<@C5JQBFG.87WELN^CY%Y+>FLG9U0^FPI=I&K7&S0Q>5-M.0^OEOL5<7F7>2J7Y7J0-O^RYV9#6.68FM M=B>R TLV.E-L525^#4JCSQ
MHGNI<+FBP&MLOW^2PNFI.AFH9I>@ZJ5^1.4JFGJHCHUD.U?17JL>6HAJ52+4^U\$M2JH5^MCMVH51&NBV<@C5JQBFG^P77U0CJLVY-Z1+>18XHM-OMCSQ MBXV-Y1+>S
I8IHL-OJCRBTY-L^GJY^*OJY|>N3>LW.#7D2:1W53%2S4.U& M-075&JCFHEH3U304.Z&:CVMIM5 M0+42U#HJ#J:C6A75>JC61H4J|@U1.81J M8U236(ZMO=CMVIMM>=S-
SWW-3+92>1A-1/5+>254U-H-46V3.N.MEM41JN7+Q085IDU5^EQOL5Y7&S(C99-W-MC+&)MMHML9%61/32>WRIG1BCV83+1+18B.LMLB|B.RRLP<D^%YK<+&2>NG6B
M&3#V.FQ^EJ@M13P^M^U5#154(U&K14<5&N@FHMJ353S4^>#E.CZJM5SM0+40 MUJHJ3P^Y.C&S1=5.NA6A.5J|@VY1+41JHU133G1|JZTHR>+>#QML<47FWRQ
MS1<2.5^WYH M+T7&WZQY1>?F M3R1.E-1WZ/6 3NRU.3QH754.U^O4C^M1O44.Z^BVI-5^0K85J/JHU42U-M1#5.J@6H5J;EU4ZZ%14&J#9\$ MM1&JC5%-?TOOMV@)MHLT7&WROQI>+?+?
I.W8H.OMOABDR<V^C<4HJ.Z8K.GOMQBPR<V-6+1+ZSIZ77G.M-K.N9J?>29K8<@S0NNHJ?>A6HVJGCHUD.U#J6HJ.A6<0574KJHJ.B&J M=5 M0K48U;JHJUD.U/HJL-
4&Y&B-4&Z-9S/R.WL/KX<@M13P/Q/VYKGBJ2B3N<U+Z^VGR-KW8-YLE@EBY.#7F49W53%254.U\$-075 M&SJCFFHEH3U304.Z&:CVMIM5 M0+42U#HJ#J:C6A75>JC61H4J|@U1.81J M8U236(ZMO=CMVIMM>=S-
SWW-3+92>1A-1/5+>254U-H-46V3.N.MEM41JN7+Q085IDU5^EQOL5Y7&S(C99-W-MC+&)MMHML9%61/32>WRIG1BCV83+1+18B.LMLB|B.RRLP<D^%YK<+&2>NG6B
M&3#V.FQ^EJ@M13P^M^U5#154(U&K14<5&N@FHMJ353S4^>#E.CZJM5SM0+40 MUJHJ3P^Y.C&S1=5.NA6A.5J|@VY1+41JHU133G1|JZTHR>+>#QML<47FWRQ
MS1<2.5^WYH M+T7&WZQY1>?F M3R1.E-1WZ/6 3NRU.3QH754.U^O4C^M1O44.Z^BVI-5^0K85J/JHU42U-M1#5.J@6H5J;EU4ZZ%14&J#9\$ MM1&JC5%-?TOOMV@)MHLT7&WROQI>+?+?
I.W8H.OMOABDR<V^C<4HJ.Z8K.GOMQBPR<V-6+1+ZSIZ77G.M-K.N9J?>29K8<@S0NNHJ?>A6HVJGCHUD.U#J6HJ.A6<0574KJHJ.B&J M=5 M0K48U;JHJUD.U/HJL-
4&Y&B-4&Z-9S/R.WL/KX<@M13P/Q/VYKGBJ2B3N<U+Z^VGR-KW8-YLE@EBY.#7F49W53%254.U\$-075 M&SJCFFHEH3U304.Z&:CVMIM5 M0+42U#HJ#J:C6A75>JC61H4J|@U1.81J M8U236(ZMO=CMVIMM>=S-
SWW-3+92>1A-1/5+>254U-H-46V3.N.MEM41JN7+Q085IDU5^EQOL5Y7&S(C99-W-MC+&)MMHML9%61/32>WRIG1BCV83+1+18B.LMLB|B.RRLP<D^%YK<+&2>NG6B
M&3#V.FQ^EJ@M13P^M^U5#154(U&K14<5&N@FHMJ353S4^>#E.CZJM5SM0+40 MUJHJ3P^Y.C&S1=5.NA6A.5J|@VY1+41JHU133G1|JZTHR>+>#QML<47FWRQ
MS1<2.5^WYH M+T7&WZQY1>?F M3R1.E-1WZ/6 3NRU.3QH754.U^O4C^M1O44.Z^BVI-5^0K85J/JHU42U-M1#5.J@6H5J;EU4ZZ%14&J#9\$ MM1&JC5%-?TOOMV@)MHLT7&WROQI>+?+?
I.W8H.OMOABDR<V^C<4HJ.Z8K.GOMQBPR<V-6+1+ZSIZ77G.M-K.N9J?>29K8<@S0NNHJ?>A6HVJGCHUD.U#J6HJ.A6<0574KJHJ.B&J M=5 M0K48U;JHJUD.U/HJL-
4&Y&B-4&Z-9S/R.WL/KX<@M13P/Q/VYKGBJ2B3N<U+Z^VGR-KW8-YLE@EBY.#7F49W53%254.U\$-075 M&SJCFFHEH3U304.Z&:CVMIM5 M0+42U#HJ#J:C6A75>JC61H4J|@U1.81J M8U236(ZMO=CMVIMM>=S-
SWW-3+92>1A-1/5+>254U-H-46V3.N.MEM41JN7+Q085IDU5^EQOL5Y7&S(C99-W-MC+&)MMHML9%61/32>WRIG1BCV83+1+18B.LMLB|B.RRLP<D^%YK<+&2>NG6B
M&3#V.FQ^EJ@M13P^M^U5#154(U&K14<5&N@FHMJ353S4^>#E.CZJM5SM0+40 MUJHJ3P^Y.C&S1=5.NA6A.5J|@VY1+41JHU133G1|JZTHR>+>#QML<47FWRQ
MS1<2.5^WYH M+T7&WZQY1>?F M3R1.E-1WZ/6 3NRU.3QH754.U^O4C^M1O44.Z^BVI-5^0K85J/JHU42U-M1#5.J@6H5J;EU4ZZ%14&J#9\$ MM1&JC5%-?TOOMV@)MHLT7&WROQI>+?+?
I.W8H.OMOABDR<V^C<4HJ.Z8K.GOMQBPR<V-6+1+ZSIZ77G.M-K.N9J?>29K8<@S0NNHJ?>A6HVJGCHUD.U#J6HJ.A6<0574KJHJ.B&J M=5 M0K48U;JHJUD.U/HJL-
4&Y&B-4&Z-9S/R.WL/KX<@M13P/Q/VYKGBJ2B3N<U+Z^VGR-KW8-YLE@EBY.#7F49W53%254.U\$-075 M&SJCFFHEH3U304.Z&:CVMIM5 M0+42U#HJ#J:C6A75>JC61H4J|@U1.81J M8U236(ZMO=CMVIMM>=S-
SWW-3+92>1A-1/5+>254U-H-46V3.N.MEM41JN7+Q085IDU5^EQOL5Y7&S(C99-W-MC+&)MMHML9%61/32>WRIG1BCV83+1+18B.LMLB|B.RRLP<D^%YK<+&2>NG6B
M&3#V.FQ^EJ@M13P^M^U5#154(U&K14<5&N@FHMJ353S4^>#E.CZJM5SM0+40 MUJHJ3P^Y.C&S1=5.NA6A.5J|@VY1+41JHU133G1|JZTHR>+>#QML<47FWRQ
MS1<2.5^WYH M+T7&WZQY1>?F M3R1.E-1WZ/6 3NRU.3QH754.U^O4C^M1O44.Z^BVI-5^0K85J/JHU42U-M1#5.J@6H5J;EU4ZZ%14&J#9\$ MM1&JC5%-?TOOMV@)MHLT7&WROQI>+?+?
I.W8H.OMOABDR<V^C<4HJ.Z8K.GOMQBPR<V-6+1+ZSIZ77G.M-K.N9J?>29K8<@S0NNHJ?>A6HVJGCHUD.U#J6HJ.A6<0574KJHJ.B&J M=5 M0K48U;JHJUD.U/HJL-
4&Y&B-4&Z-9S/R.WL/KX<@M13P/Q/VYKGBJ2B3N<U+Z^VGR-KW8-YLE@EBY.#7F49W53%254.U\$-075 M&SJCFFHEH3U304.Z&:CVMIM5 M0+42U#HJ#J:C6A75>JC61H4J|@U1.81J M8U236(ZMO=CMVIMM>=S-
SWW-3+92>1A-1/5+>254U-H-46V3.N.MEM41JN7+Q085IDU5^EQOL5Y7&S(C99-W-MC+&)MMHML9%61/32>WRIG1BCV83+1+18B.LMLB|B.RRLP<D^%YK<+&2>NG6B
M&3#V.FQ^EJ@M13P^M^U5#154(U&K14<5&N@FHMJ353S4^>#E.CZJM5SM0+40 MUJHJ3P^Y.C&S1=5.NA6A.5J|@VY1+41JHU133G1|JZTHR>+>#QML<47FWRQ
MS1<2.5^WYH M+T7&WZQY1>?F M3R1.E-1WZ/6 3NRU.3QH754.U^O4C^M1O44.Z^BVI-5^0K85J/JHU42U-M1#5.J@6H5J;EU4ZZ%14&J#9\$ MM1&JC5%-?TOOMV@)MHLT7&WROQI>+?+?
I.W8H.OMOABDR<V^C<4HJ.Z8K.GOMQBPR<V-6+1+ZSIZ77G.M-K.N9J?>29K8<@S0NNHJ?>A6HVJGCHUD.U#J6HJ.A6<0574KJHJ.B&J M=5 M0K48U;JHJUD.U/HJL-
4&Y&B-4&Z-9S/R.WL/KX<@M13P/Q/VYKGBJ2B3N<U+Z^VGR-KW8-YLE@EBY.#7F49W53%254.U\$-075 M&SJCFFHEH3U304.Z&:CVMIM5 M0+42U#HJ#J:C6A75>JC61H4J|@U1.81J M8U236(ZMO=CMVIMM>=S-
SWW-3+92>1A-1/5+>254U-H-46V3.N.MEM41JN7+Q085IDU5^EQOL5Y7&S(C99-W-MC+&)MMHML9%61/32>WRIG1BCV83+1+18B.LMLB|B.RRLP<D^%YK<+&2>NG6B
M&3#V.FQ^EJ@M13P^M^U5#154(U&K14<5&N@FHMJ353S4^>#E.CZJM5SM0+40 MUJHJ3P^Y.C&S1=5.NA6A.5J|@VY1+41JHU133G1|JZTHR>+>#QML<47FWRQ
MS1<2.5^WYH M+T7&WZQY1>?F M3R1.E-1WZ/6 3NRU.3QH754.U^O4C^M1O44.Z^BVI-5^0K85J/JHU42U-M1#5.J@6H5J;EU4ZZ%14&J#9\$ MM1&JC5%-?TOOMV@)MHLT7&WROQI>+?+?
I.W8H.OMOABDR<V^C<4HJ.Z8K.GOMQBPR<V-6+1+ZSIZ77G.M-K.N9J?>29K8<@S0NNHJ?>A6HVJGCHUD.U#J6HJ.A6<0574KJHJ.B&J M=5 M0K48U;JHJUD.U/HJL-
4&Y&B-4&Z-9S/R.WL/KX<@M13P/Q/VYKGBJ2B3N<U+Z^VGR-KW8-YLE@EBY.#7F49W53%254.U\$-075 M&SJCFFHEH3U304.Z&:CVMIM5 M0+42U#HJ#J:C6A75>JC61H4J|@U1.81J M8U236(ZMO=CMVIMM>=S-
SWW-3+92>1A-1/5+>254U-H-46V3.N.MEM41JN7+Q085IDU5^EQOL5Y7&S(C99-W-MC+&)MMHML9%61/32>WRIG1BCV83+1+18B.LMLB|B.RRLP<D^%YK<+&2>NG6B
M&3#V.FQ^EJ@M13P^M^U5#154(U&K14<5&N@FHMJ353S4^>#E.CZJM5SM0+40 MUJHJ3P^Y.C&S1=5.NA6A.5J|@VY1+41JHU133G1|JZTHR>+>#QML<47FWRQ
MS1<2.5^WYH M+T7&WZQY1>?F M3R1.E-1WZ/6 3NRU.3QH754.U^O4C^M1O44.Z^BVI-5^0K85J/JHU42U-M1#5.J@6H5J;EU4ZZ%14&J#9\$ MM1&JC5%-?TOOMV@)MHLT7&WROQI>+?+?
I.W8H.OMOABDR<V^C<4HJ.Z8K.GOMQBPR<V-6+1+ZSIZ77G.M-K.N9J?>29K8<@S0NNHJ?>A6HVJGCHUD.U#J6HJ.A6<0574KJHJ.B&J M=5 M0K48U;JHJUD.U/HJL-
4&Y&B-4&Z-9S/R.WL/KX<@M13P/Q/VYKGBJ2B3N<U+Z^VGR-KW8-YLE@EBY.#7F49W53%254.U\$-075 M&SJCFFHEH3U304.Z&:CVMIM5 M0+42U#HJ#J:C6A75>JC61H4J|@U1.81J M8U236(ZMO=CMVIMM>=S-
SWW-3+92>1A-1/5+>254U-H-46V3.N.MEM41JN7+Q085IDU5^EQOL5Y7&S(C99-W-MC+&)MMHML9%61/32>WRIG1BCV83+1+18B.LMLB|B.RRLP<D^%YK<+&2>NG6B
M&3#V.FQ^EJ@M13P^M^U5#154(U&K14<5&N@FHMJ353S4^>#E.CZJM5SM0+40 MUJHJ3P^Y.C&S1=5.NA6A.5J|@VY1+41JHU133G1|JZTHR>+>#QML<47FWRQ
MS1<2.5^WYH M+T7&WZQY1>?F M3R1.E-1WZ/6 3NRU.3QH754.U^O4C^M1O44.Z^BVI-5^0K85J/JHU42U-M1#5.J@6H5J;EU4ZZ%14&J#9\$ MM1&JC5%-?TOOMV@)MHLT7&WROQI>+?+?
I.W8H.OMOABDR<V^C<4HJ.Z8K.GOMQBPR<V-6+1+ZSIZ77G.M-K.N9J?>29K8<@S0NNHJ?>A6HVJGCHUD.U#J6HJ.A6<0574KJHJ.B&J M=5 M0K48U;JHJUD.U/HJL-
4&Y&B-4&Z-9S/R.WL/KX<@M13P/Q/VYKGBJ2B3N<U+Z^VGR-KW8-YLE@EBY.#7F49W53%254.U\$-075 M&SJCFFHEH3U304.Z&:CVMIM5 M0+42U#HJ#J:C6A75>JC61H4J|@U1.81J M8U236(ZMO=CMVIMM>=S-
SWW-3+92>1A-1/5+>254U-H-46V3.N.MEM41JN7+Q085IDU5^EQOL5Y7&S(C99-W-MC+&)MMHML9%61/32>WRIG1BCV83+1+18B.LMLB|B.RRLP<D^%YK<+&2>NG6B
M&3#V.FQ^EJ@M13P^M^U5#154(U&K14<5&N@FHMJ353S4^>#E.CZJM5SM0+40 MUJHJ3P^Y.C&S1=5.NA6A.5J|@VY1+41JHU133G1|JZTHR>+>#QML<47FWRQ
MS1<2.5^WYH M+T7&WZQY1>?F M3R1.E-1WZ/6 3NRU.3QH754.U^O4C^M1O44.Z^BVI-5^0K85J/JHU42U-M1#5.J@6H5J;EU4ZZ%14&J#9\$ MM1&JC5%-?TOOMV@)MHLT7&WROQI>+?+?
I.W8H.OMOABDR<V^C<4HJ.Z8K.GOMQBPR<V-6+1+ZSIZ77G.M-K.N9J?>29K8<@S0NNHJ?>A6HVJGCHUD.U#J6HJ.A6<0574KJHJ.B&J M=5 M0K48U;JHJUD.U/HJL-
4&Y&B-4&Z-9S/R.WL/KX<@M13P/Q/VYKGBJ2B3N<U+Z^VGR-KW8-YLE@EBY.#7F49W53%254.U\$-075 M&SJCFFHEH3U304.Z&:CVMIM5 M0+42U#HJ#J:C6A75>JC61H4J|@U1.81J M8U236(ZMO=CMVIMM>=S-
SWW-3+92>1A-1/5+>254U-H-46V3.N.MEM41JN7+Q085IDU5^EQOL5Y7&S(C99-W-MC+&)MMHML9%61/32>WRIG1BCV83+1+18B.LMLB|B.RRLP<D^%YK<+&2>NG6B
M&3#V.FQ^EJ@M13P^M^U5#154(U&K14<5&N@FHMJ353S4^>#E.CZJM5SM0+40 MUJHJ3P^Y.C&S1=5.NA6A.5J|@VY1+41JHU133G1|JZTHR>+>#QML<47FWRQ
MS1<2.5^WYH M+T7&WZQY1>?F M3R1.E-1WZ/6 3NRU.3QH754.U^O4C^M1O44.Z^BVI-5^0K85J/JHU42U-M1#5.J@6H5J;EU4ZZ%14&J#9\$ MM1&JC5%-?TOOMV@)MHLT7&WROQI>+?+?
I.W8H.OMOABDR<V^C<4HJ.Z8K.GOMQBPR<V-6+1+ZSIZ77G.M-K.N9J?>29K8<@S0NNHJ?>A6HVJGCHUD.U#J6HJ.A6<0574KJHJ.B&J M=5 M0K48U;JHJUD.U/HJL-
4&Y&B-4&Z-9S/R.WL/KX<@M13P/Q/VYKGBJ2B3N<U+Z^VGR-KW8-YLE@EBY.#7F49W53%254.U\$-075 M&SJCFFHEH3U304.Z&:CVMIM5 M0+42U#HJ#J:C6A75>JC61H4J|@U1.81J M8U236(ZMO=CMVIMM>=S-
SWW-3+92>1A-1/5+>254U-H-46V3.N.MEM41JN7+Q085IDU5^EQOL5Y7&S(C99-W-MC+&)MMHML9%61/32>WRIG1BCV83+1+18B.LMLB|B.RRLP<D^%YK<+&2>NG6B
M&3#V.FQ^EJ@M13P^M^U5#154(U&K14<5&N@FHMJ353S4^>#E.CZJM5SM0+40 MUJHJ3P^Y.C&S1=5.NA6A.5J|@VY1+41JHU133G1|JZTHR>+>#QML<47FWRQ
MS1<2.5^WYH M+T7&WZQY1>?F M3R1.E-1WZ/6 3NRU.3QH754.U^O4C^M1O44.Z^BVI-5^0K85J/JHU42U-M1#5.J@6H5J;EU4ZZ%14&J#9\$ MM1&JC5%-?TOOMV@)MHLT7&WROQI>+?+?
I.W8H.OMOABDR<V^C<4HJ.Z8K.GOMQBPR<V-6+1+ZSIZ77G.M-K.N9J?>29K8<@S0NNHJ?>A6HVJGCHUD.U#J6HJ.A6<0574KJHJ.B&J M=5 M0K48U;JHJUD.U/HJL-
4&Y&B-4&Z-9S/R.WL/KX<@M13P/Q/VYKGBJ2B3N<U+Z^VGR-KW8-YLE@EBY.#7F49W53%254.U\$-075 M&SJCFFHEH3U304.Z&:CVMIM5 M0+42U#HJ#J:C6A75>JC61H4J|@U1.81J M8U236(ZMO=CMVIMM>=S-
SWW-3+92>1A-1/5+>254U-H-46V3.N.MEM41JN7+Q085IDU5^EQOL5Y7&S(C99-W-MC+&)MMHML9%61/32>WRIG1BCV83+1+18B.LMLB|B.RRLP<D^%YK<+&2>NG6B
M&3#V.FQ^EJ@M13P^M^U5#154(U&K14<5&N@FHMJ353S4^>#E.CZJM5SM0+40 MUJHJ3P^Y.C&S1=5.NA6A.5J|@VY1+41JHU133G1|JZTHR>+>#QML<47FWRQ
MS1<2.5^WYH M+T7&WZQY1>?F M3R1.E-1WZ/6 3NRU.3QH754.U^O4C^M1O44.Z^BVI-5^0K85J/JHU42U-M1#5.J@6H5J;EU4ZZ%14&J#9\$ MM1&JC5%-?TOOMV@)MHLT7&WROQI>+?+?
I.W8H.OMOABDR<V^C<4HJ.Z8K.GOMQBPR<V-6+1+ZSIZ77G.M-K.N9J?>29K8<@S0NNHJ?>A6HVJGCHUD.U#J6HJ.A6<0574KJHJ.B&J M=5 M0K48U;JHJUD.U/HJL-
4&Y&B-4&Z-9S/R.WL/KX<@M13P/Q/VYKGBJ2B3N<U+Z^VGR-KW8-YLE@EBY.#7F49W53%254.U\$-075 M&SJCFFHEH3U304.Z&:CVMIM5 M0+42U#HJ#J:C6A75>JC61H4J|@U1.81J M8U236(ZMO=CMVIMM>=S-
SWW-3+92>1A-1/5+>254U-H-46V3.N.MEM41JN7+Q085IDU5^EQOL5Y7&S(C99-W-MC+&)MMHML9%61/32>WRIG1BCV83+1+18B.LMLB|B.RRLP<D^%YK<+&2>NG6B
M&3#V.FQ^EJ@M13P^M^U5#154(U&K14<5&N@FHMJ353S4^>#E.CZJM5SM0+40 MUJHJ3P^Y.C&S1=5.NA6A.5J|@VY1+41JHU133G1|JZTHR>+>#QML<47FWRQ
MS1<2.5^WYH M+T7&WZQY1>?F M3R1.E-1WZ/6 3NRU.3QH754.U^O4C^M1O44.Z^BVI-5^0K85J/JHU42U-M1#5.J@6H5J;EU4ZZ%14&J#9\$ MM1&JC5%-?TOOMV@)MHLT7&WROQI>+?+?
I.W8H.OMOABDR<V^C<4HJ.Z8K.GOMQBPR<V-6+1+ZSIZ77G.M-K.N9J?>29K8<@S0NNHJ?>A6HVJGCHUD.U#J6HJ.A6<0574KJHJ.B&J M=5 M0K48U;JHJUD.U/HJL-
4&Y&B-4&Z-9S/R.WL/KX<@M13P/Q/VYKGBJ2B3N<U+Z^VGR-KW8-YLE@EBY.#7F49W53%254.U\$-075 M&SJCFFHEH3U304.Z&:CVMIM5 M0+42U#HJ#J:C6A75>JC61H4J|@U1.81J M8U236(ZMO=CMVIMM>=S-
SWW-3+92>1A-1/5+>254U-H-46V3.N.MEM41JN7+Q085IDU5^EQOL5Y7&S(C99-W-MC+&)MMHML9%61/32>WRIG1BCV83+1+18B.LMLB|B.RRLP<D^%YK<+&2>NG6B
M&3#V.FQ^EJ@M13P^M^U5#154(U&K14<5&N@FHMJ353S4^>#E.CZJM5SM0+40 MUJHJ3P^Y.C&S1=5.NA6A.5J|@VY1+41JHU133G1|JZTHR>+>#QML<47FWRQ
MS1<2.5^WYH M+T7&WZQY1>?F M3R1.E-1WZ/6 3NRU.3QH754.U^O4C^M1O44.Z^BVI-5^0K85J/JHU42U-M1#5.J@6H5J;EU4ZZ%14&J#9\$ MM1&JC5%-?TOOMV@)MHLT7&WROQI>+?+?
I.W8H.OMOABDR<V^C<4HJ.Z8K.GOMQBPR<V-6+1+ZSIZ77G.M-K.N9J?>29K8<@S0NNHJ?>A6HVJGCHUD.U#J6HJ.A6<0574KJHJ.B&J M=5 M0K48U;JHJUD.U/HJL-
4&Y&B-4&Z-9S/R.WL/KX<@M13P/Q/VYKGBJ2B3N<U+Z^VGR-KW8-YLE@EBY.#7F49W53%254.U\$-075 M&SJCFFHEH3U304.Z&:CVMIM5 M0+42U#HJ#J:C6A75>JC61H4J|@U1.81J M8U236(ZMO=CMVIMM>=S-
SWW-3+92>1A-1/5+>254U-H-46V3.N.MEM41JN7+Q085IDU5^EQOL5Y7&S(C99-W-MC+&)MMHML9%61/32>WRIG1BCV83+1+18B.LMLB|B.RRLP<D^%YK<+&2>NG6B
M&3#V.FQ^EJ@M13P^M^U5#154(U&K14<5&N@FHMJ353S4^>#E.CZJM5SM0+40 MUJHJ3P^Y.C&S1=5.NA6A.5J|@VY1+41JHU133G1|JZTHR>+>#QML<47FWRQ
MS1<2.5^WYH M+T7&WZQY1>?F M3R1.E-1WZ/6 3NRU.3QH754.U^O4C^M1O44.Z^BVI-5^0K85J/JHU42U-M1#5.J@6H5J;EU4ZZ%14&J#9\$ MM1&JC5%-?TOOMV@)MHLT7&WROQI>+?+?
I.W8H.OMOABDR<V^C<4HJ.Z8K.GOMQBPR<V-6+1+ZSIZ77G.M-K.N9J?>29K8<@S0NNHJ?>A6HVJGCHUD.U#J6HJ.A6<0574KJHJ.B&J M=5 M0K48U;JHJUD.U/HJL-
4&Y&B-4&Z-9S/R.WL/KX<@M13P/Q/VYKGBJ2B3N<U+Z^VGR-KW8-YLE@EBY.#7F49W53%254.U\$-075 M&SJCFFHEH3U304.Z&:CVMIM5 M0+42U#HJ#J:C6A75>JC61H4J|@U1.81J M8U236(ZMO=CMVIMM>=S-
SWW-3+92>1A-1/5+>254U-H-46V3.N.MEM41JN7+Q085IDU5^EQOL5Y7&S(C99-W-MC+&)MMHML9%61/32>WRIG1BCV83+1+18B.LMLB|B.RRLP<D^%YK<+&2>NG6B
M&3#V.FQ^EJ@M13P^M^U5#154(U&K14<5&N@FHMJ353S4^>#E.CZJM5SM0+40 MUJHJ3P^Y.C&S1=5.NA6A.5J|@VY1+41JHU133G1|JZTHR>+>#QML<47FWRQ
MS1<2.5^WYH M+T7&WZQY1>?F M3R1.E-1WZ/6 3NRU.3QH754.U^O4C^M1O44.Z^BVI-5^0K85J/JHU42U-M1#5.J@6H5J;EU4ZZ%14&J#9\$ MM1&JC5%-?TOOMV@)MHLT7&WROQI>+?+?
I.W8H.OMOABDR<V^C<4HJ.Z8K.GOMQBPR<V-6+1+ZSIZ77G.M-K.N9J?>29K8<@S0NNHJ?>A6HVJGCHUD.U#J6HJ.A6<0574KJHJ.B&J M=5 M0K48U;JHJUD.U/HJL-
4&Y&B-4&Z-9S/R.WL/KX<@M13P/Q/VYKGBJ2B3N&lt

EV(4.6I@KJ8D)T1-GC(UK03E)T3BNT2Y1J480C<S'A1053>1T051X M NTZ3<1&KXN14_OHS.OV%>AG6NA@G.F=877<1U2@1S_X@.KU4C) KMYA10J1_UY17D:OS_VF MUAA)M<1A4C:899HJW1ZK71LQNI0HC=HTRQ5_P_P02P2% @<K#5* M6I(HLHDJ(UK5JUT1F3U3QSE0_6=MYVGWU2U1_M3)1_J)U>+&K MOH15(KBC#6777SFI

*H1&_QL11H=6Z_W%>21>7990 MG1E%F\$A=1G_Y%>M&1PUBDD(3699KICBC)NM1:EQ211%>3G210%_0_T0=1P1P0L96<G01_4EA76*MI MB=>8.G5TEENR=8FM99H@CAIXX<

@1P@1<3D88D92701S\$>K4QKNXCM1_Z7P_M664#GX%>1@=>BVPX#K102L@IRLBUC2^1@>0Q2K^G175KXK&0_G7(51C.DU1) M=>K7G1+>2H01656SEISM5^2

*F1OISZIN1AB9.9_G1.KU>J0G:2PLVS+JY0U_MNUU*UR1LX<1Y=>M9-GD6K8S2J_6C^B&SQQOMAY1,UN3YFJBA6SK\$11B2.BF<1EIK6R1+>A0%RRIFN&N=5S27>1=J

M%&H+U1<@>EG642WIW*Q0161NM^91E^<0%ZL1Q-QCX1LE/NQ1DL^ID4^1_MLC_U41.KK:6DL132+00+>0^Q.RH8MR3%502IS^2S4^PCJ10=N9WL_H

MH1A1B#A1J6L5S201+>1YX_9+107A07B5ON&JRM0*RIPIF12UD60=P_M1&:PBDD^MO+K^Y8^213(42_U^R%>R"G8QC^DFJ12Y^Q00?

Q01>7@.B5W1^1TQ26314W1B2PZ_MKV6^FSYV6=RSREIN3Y^4WRP#P_ZL5:ZRKWZ<1_P1Y=&N3Y=Z^Y4Z^ZDUUYV=M_+D>1^R^T^#XR_P1P^F%V+>KB?

63M^W719KM@4=1Y_1SF#Y:4S2505K.K:4V_MZYM25_5A1=0_OZ17_H0:4Q=Q9A(16Z+HET1SY=QR):CIVANO2%>FJKUE<MGVB>WV^Y^&350C^7IE90(0_1O7H:\$2

05:JD^2716%&ZN218DEYR@P31_U1L M_1Y^>73K^45L#10(1_PU1UK_KNN0_1^>+>PQ=VIR:M_W-H965T13BR30Q&^XR_OZ0_1.6

M8@>R022:17K.21^RVR^AD99_Q2^<ES9_11_N^TP150I@C00150E@E.MA409HR11(0_0199)H7P_1QY3M%2J7H+G&T^<2YLRKS1ZNEA&1^>QJABRPD^PR+1^#%>R1005^&5?_

OM#>BA5VSIEH^2K1A7@/M-DMB<^<0N2L374+94M_>2^H1(27616%_MUX_ZKD^R4)<1>+>RIP6_1Q3=5N4UW32+2K5CTIO&^>PKEIK%>X2@>1.D.GVO^4169G1AV00E17(IJH

MG:FK49B1+>16^43PCBCBDNI>5%>E1X^NEK<0=>=>KWR#UXM_1^T@N23X^M1^S^O1E%01L\$K_K%>1GWI(AW1FDMH@H%LGBA1R26157NS5249F21M^MOH1

30KC@>U_>N2G_1K1U_1Y@Y>1_5R^T1XW1P@1#1W1_1L5NVN1<+>R1G_MGPO>8YF7E^201^>1%&D<+&WA<+>2^P^RE.K%>NY1RSWY7Y=43E&41MA@>M_>C

<=>XX^KK1P1Y<1>N1P2YD19^4R1#28(XWV1X0DD2R^RUY=>8_1^S1H_MPQ>2S^91H%>ZEB9M32C_PBQ2.YF^JR13A00Q^>1^>NP6.6P^C_0^0_MF1H2P36<+>W0

7FQCA5Y^P1^9P(R125>05@N^N^4X^RW148^<XG=>XC=>MHPY@AF:B_M16W180V_WML^G%>0Y@N9\$H1P.03M_QW_51+>P04^1^>4=>81_M1L^>170(&@

<1A1W=O&U051K1CML^M^T5^U6K^0VB=>IN>1-OM95^M61NP<K261H_K1(041E7H@N.OXX0P^M<8212Y+C>P<

1P.OO.M%U1E1H@=>T7.Y4@4VIS_1S^>1%>E1_YAC#19.5%_M@96<+>NAW_B^T1JR(QF^2Y921CP+1BBP^>Y_B186.2TH(P23D#>1PN1^P(PD83XU19_M_57)5NY=>O^#>=>?SO_MH?

5_K&9ZD^>N>T^U3E1T1(0_0D4AN<6_1>1@>41C@YPP27^>8%>1@>0_ME%>+>QH6;+>2>HV_WCNJY@>0_8W=>M0_ZUR&L^<@A1S)A_M^18V85L1C^M1A1=SP=>&N

9BXJ.BMO^Y1EIM^>Z&6^4NYVG^E=1A49ECA51>50&860_C_M^=>=>T0_6Y^P^H^GHB1A<1_C^Y1312F>6R0(KH1VL1:G%>YAGSGAIYACMSTIFU<+>P^>M^>P00<2H_1^

<1YUG^M1OGOH9^91LD18X86&PEF(1_WFEG1%_100YK1A=M_332-132:57<+>3LGE0_1^>C1FH8^K1^S^<K^OZL1L^3687C4^>QRH2^>NR9H1M^M6%:92HR^>GWT1^XBJ+1O5(1^

P5Z1SFF1+>S.MEFW58SW_MFC:1L1^E1_YV1_U13V^>R1Z&1LAF^9D^T&S<+>6.4121%_MHJ28^>1%>G%>H5801^PL2R5^21Z+>1^>P(S1Z^>VZ_RK13Z176A_H:W1D?OFH1

ML2>P#J13AM^131NZ4V1_>P2+>8%U&XU4_>GW6=>\$^V1FOW-O56:QSO5-HKUHNX&T0A8Z5=>QBF6&V)M%_1P1:05@>1DE(0^E^YU121H4S^1_71_M>57Q^M6M

HFG031L.MH1761F5V=>1ML1: MNMP80^2JEN5P^>AOL1^E1^H^V^4M^Y71^A6R91^>DKKEQ&A_U5+>DE2N2D1&4^>M1^X(0E1^2G)>5%>91G:050K.2Y^RR^T5^T6)XK_A#^+>!

(1M3H=NH1H_MG+>1^>H0R9N<1^>RWA1H^>3B1>5B101F76E7E_H1G1>G^>R872P^715135_10P9P^K<G.D.BPU>C0^51_41AXE>+>2^>(KWF+>DW1V+>66111+H%

(K80RPP&^>M&^<U^>Z>GED^41A^>9^>X^>M9M5M^>P01K+C=F16+>GD481^2B01_9B2&^>M4ZOCT0.Z_D510L^1_8W1F^>9O:5%>0U1X^1FZ<+>R+61^>ZESI

MABO^B^>HR(5@EPACH9RNNYU1MR1H10518_102P.5%>@>K#56M+5Z1_M10>0>BH_H1<1L1W.W_K104WHU^171.WEB77(4NH2.MW+>7O^1_M4^400=>2^1^>HDC=>8@O.MFE

1\$BWE<1X-8/E>05^>@>DITE^Q<=>O/M^>MW<=>90=1X&U^E=VP^O=>W1(54Y1W^X2^>LBK^>D18^>B.>(1&+>1F.WSBW1L1P@>M^1^>Q

IRZ7^70GGG^>MVA.BYG1G918K56&H^K7^>UNR_Y1^CG^>+>CRF=F^>M>1SZE^Y1^>KP.YE1^>MN3QGI^>A7>CZ0A.MY#>=Q^>HC^>S^RH<+>FLO.M_A^>MXK8015^>5%>7/

%>MEH3Y^>G_K76^>HC2^>1^>E1L1N^>M^>1S0_1U0^>M^>NMNMWN@O54PP2120.MB1B@>C_HK&L^>1^>H1K1U5P12_8GFMV&92W1Z_M91^>9KZ7^>W-N:770Y>NK77Y@>%

<1>QRC=>H7+>1%>YS381^>816=>M^>TLGH181LW8_S8^>1^>P4B_3PCV_1XGN7EYV.N+>1L_GWA0I&S^>239Y5S_MOCV1=U^>1^>2^>59_26^>H1C^>40DWVW5+>GAN

R1^>F_EG19W4B0>+>Y%>S9_M_B^>H1<1N<1Z4:SA2_P1P@>OK%>4MR1^>Z1O^>M^>V2M^>1H1_E58Y1N61<=>^>H22(11=>MY&74V3^>G1ZM^>C^>M=>W6KN1UA012-IN@=>=MA52PFVRIV

U3_0

[DisclosureSheethhttp://xbrl.sec.gov/ecd/role/PvpDisclosurePay vs Performance-DisclosureNotes8 falsefalseR9.htm995445](http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureCashAndCashEquivalentsCash-and-Cash-EquivalentsNotes15) - Disclosure - Insider Trading ArrangementsSheethhttp://xbrl.sec.gov/ecd/role/InsiderTradingArrangementsInsider Trading ArrangementsNotes9 falsefalseR10.htm995455 - Disclosure - Description of BusinessSheethhttp://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureDescriptionOfBusinessDescription of BusinessNotes10 falsefalseR11.htm995465 - Disclosure - Basis of PresentationSheethhttp://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureBasisOfPresentationBasis of PresentationNotes11 falsefalseR12.htm995475 - Disclosure - Canopy USASheethttp://www.canopygrowth.com/20241231/taxonomy/role/DisclosureCanopyUsaCanopy_USANotes12 falsefalseR13.htm995485 - Disclosure - BiosteelSheethttp://www.canopygrowth.com/20241231/taxonomy/role/DisclosureBiosteelBiosteelNotes13 falsefalseR14.htm995495 - Disclosure - Loss on Asset Impairment and RestructuringSheethhttp://www.canopygrowth.com/20241231/taxonomy/role/DisclosureLossOnAssetHmpairmentAndRestructuringLoss on Asset Impairment and RestructuringNotes14 falsefalseR15.htm995505 - Disclosure - Cash and Cash EquivalentsSheethhttp://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureCashAndCashEquivalentsCash-and-Cash-EquivalentsNotes15 falsefalseR16.htm995515 - Disclosure - Short-term InvestmentsSheethhttp://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureShortTermInvestmentsShort-term InvestmentsNotes16 falsefalseR17.htm995525 - Disclosure - Amounts Receivable, NetSheethhttp://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureAmountsReceivableNetAmounts Receivable, NetNotes17 falsefalseR18.htm995535 - Disclosure - InventorySheethhttp://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureInventoryInventoryNotes18 falsefalseR19.htm995545 - Disclosure - Prepaid Expenses and Other AssetsSheethhttp://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherAssetsPrepaid Expenses and Other AssetsNotes19 falsefalseR20.htm995555 - Disclosure - Equity Method InvestmentsSheethhttp://www.canopygrowth.com/20241231/taxonomy/role/DisclosureEquityMethodInvestmentsEquity Method InvestmentsNotes20 falsefalseR21.htm995565 - Disclosure - Other Financial AssetsSheethhttp://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureOtherFinancialAssetsOther Financial AssetsNotes21 falsefalseR22.htm995575 - Disclosure - Property, Plant and EquipmentSheethhttp://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosurePropertyPlantAndEquipmentProperty, Plant and EquipmentNotes22 falsefalseR23.htm995585 - Disclosure - Intangible AssetsSheethhttp://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureIntangibleAssetsIntangible AssetsNotes23 falsefalseR24.htm995595 - Disclosure - GoodwillSheethhttp://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureGoodwillGoodwillNotes24 falsefalseR25.htm995605 - Disclosure - Other Accrued Expenses and LiabilitiesSheethhttp://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureOtherAccruedExpensesAndLiabilitiesOther Accrued Expenses and LiabilitiesNotes25 falsefalseR26.htm995615 - Disclosure - DebtSheethhttp://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureDebtDebtNotes26 falsefalseR27.htm995625 - Disclosure - Other LiabilitiesSheethhttp://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureOtherLiabilitiesOther LiabilitiesNotes27 falsefalseR28.htm995645 - Disclosure - Share CapitalSheethhttp://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureShareCapitalShare CapitalNotes28 falsefalseR29.htm995655 - Disclosure - Share-Based CompensationSheethhttp://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureShareBasedCompensationShare-Based CompensationNotes29 falsefalseR30.htm995665 - Disclosure - Accumulated Other Comprehensive Income (Loss)Sheethhttp://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureAccumulatedOtherComprehensiveIncomeLossAccumulated Other Comprehensive Income (Loss)Notes30 falsefalseR31.htm995675 - Disclosure - Noncontrolling InterestsSheethhttp://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureNoncontrollingInterestsNoncontrolling InterestsNotes31 falsefalseR32.htm995685 - Disclosure - Fair Value of Financial InstrumentsSheethhttp://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsFair Value of Financial InstrumentsNotes32 falsefalseR33.htm995695 - Disclosure - RevenueSheethhttp://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureRevenueRevenueNotes33 falsefalseR34.htm995705 - Disclosure - Other Income (Expense), NetSheethhttp://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureOtherIncomeExpenseNetOther Income (Expense), NetNotes34 falsefalseR35.htm995715 - Disclosure - Income TaxesSheethhttp://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesIncome TaxesNotes35 falsefalseR36.htm995745 - Disclosure - Acreage ArrangementSheethhttp://www.canopygrowth.com/20241231/taxonomy/role/DisclosureAcreageArrangementAcreage ArrangementNotes36 falsefalseR37.htm995755 - Disclosure - Commitments and ContingenciesSheethhttp://www.canopygrowth.com/20241231/taxonomy/role/DisclosureCommitmentsAndContingenciesCommitments and ContingenciesNotes37 falsefalseR38.htm995765 - Disclosure - Segment InformationSheethhttp://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureSegmentInformationSegment InformationNotes38 falsefalseR39.htm995775 - Disclosure - Subsequent EventsSheethhttp://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureSubsequentEventsSubsequent EventsNotes39 falsefalseR40.htm995785 - Disclosure - Summary of Significant Accounting Policies (Policies)Sheethhttp://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPoliciesSummary of Significant Accounting Policies (Policies)Policies40 falsefalseR41.htm995795 - Disclosure - Canopy USA (Tables)Sheethhttp://www.canopygrowth.com/20241231/taxonomy/role/DisclosureCanopyUsaTablesCanopy_USA (Tables)Tables41 falsefalseR42.htm995805 - Disclosure - Biosteel (Tables)Sheethhttp://www.canopygrowth.com/20241231/taxonomy/role/DisclosureBiosteelTablesBiosteel (Tables)Tables42 falsefalseR43.htm995815 - Disclosure - Cash and Cash Equivalents (Tables)Sheethhttp://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureCashAndCashEquivalentsTablesCash-and-Cash-Equivalents (Tables)Tables43 falsefalseR44.htm995825 - Disclosure - Short-term Investments (Tables)Sheethhttp://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureShortTermInvestmentsTablesShort-term Investments (Tables)Tables44 falsefalseR45.htm995835 - Disclosure - Amounts Receivable, Net (Tables)Sheethhttp://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureAmountsReceivableNetTablesAmounts Receivable, Net (Tables)Tables45 falsefalseR46.htm995845 - Disclosure - Inventory (Tables)Sheethhttp://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureInventoryTablesInventory (Tables)Tables46 falsefalseR47.htm995855 - Disclosure - Prepaid Expenses and Other Assets (Tables)Sheethhttp://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherAssetsTablesPrepaid Expenses and Other Assets (Tables)Tables47 falsefalseR48.htm995865 - Disclosure - Equity Method Investments (Tables)Sheethhttp://www.canopygrowth.com/20241231/taxonomy/role/DisclosureEquityMethodInvestmentsTablesEquity Method Investments (Tables)Tables48 falsefalseR49.htm995875 - Disclosure - Other Financial Assets (Tables)Sheethhttp://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureOtherFinancialAssetsTablesOther Financial Assets (Tables)Tables49 falsefalseR50.htm995885 - Disclosure - Property, Plant and Equipment (Tables)Sheethhttp://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosurePropertyPlantAndEquipmentTablesProperty, Plant and Equipment (Tables)Tables50 falsefalseR51.htm995895 - Disclosure - Intangible Assets (Tables)Sheethhttp://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureIntangibleAssetsTablesIntangible Assets (Tables)Tables51 falsefalseR52.htm995905 - Disclosure - Goodwill (Tables)Sheethhttp://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureGoodwillTablesGoodwill (Tables)Tables52 falsefalseR53.htm995915 - Disclosure - Other Accrued Expenses and Liabilities (Tables)Sheethhttp://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureOtherAccruedExpensesAndLiabilitiesTablesOther Accrued Expenses and Liabilities (Tables)Tables53 falsefalseR54.htm995925 - Disclosure - Debt (Tables)Sheethhttp://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureDebtTablesDebt (Tables)Tables54 falsefalseR55.htm995935 - Disclosure - Other Liabilities (Tables)Sheethhttp://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureOtherLiabilitiesTablesOther Liabilities (Tables)Tables55 falsefalseR56.htm995955 - Disclosure - Share Capital (Tables)Sheethhttp://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureShareCapitalTablesShare Capital (Tables)Tables56 falsefalseR57.htm995965 - Disclosure - Share-Based Compensation (Tables)Sheethhttp://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureShareBasedCompensationTablesShare-Based Compensation (Tables)Tables57 falsefalseR58.htm995975 - Disclosure - Accumulated Other Comprehensive Income (Loss) (Tables)Sheethhttp://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureAccumulatedOtherComprehensiveIncomeLossTablesAccumulated Other Comprehensive Income (Loss) (Tables)Tables58 falsefalseR59.htm995985 - Disclosure - Noncontrolling Interests (Tables)Sheethhttp://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureNoncontrollingInterestsTablesNoncontrolling Interests (Tables)Tables59 falsefalseR60.htm995995 - Disclosure - Fair Value of Financial Instruments (Tables)Sheethhttp://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsTablesFair Value of Financial Instruments (Tables)Tables60 falsefalseR61.htm996005 - Disclosure - Revenue (Tables)Sheethhttp://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureRevenueTablesRevenue (Tables)Tables61 falsefalseR62.htm996015 - Disclosure - Other Income (Expense), Net (Tables)Sheethhttp://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureOtherIncomeExpenseNetTablesOther Income (Expense), Net (Tables)Tables62 falsefalseR63.htm996045 - Disclosure - Segment Information (Tables)Sheethhttp://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureSegmentInformationTablesSegment Information (Tables)Tables63 falsefalseR64.htm996055 - Disclosure - Basis of Presentation - Additional Information (Details)Sheethhttp://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureBasisOfPresentationAdditionalInformationDetailsBasis of Presentation - Additional Information (Details)Details64 falsefalseR65.htm996065 - Disclosure - Canopy USA - Additional Information (Details)Sheethhttp://www.canopygrowth.com/20241231/taxonomy/role/DisclosureCanopyUsaAdditionalInformationDetailsCanopy_USA - Additional Information (Details)Details65 falsefalseR66.htm996075 - Disclosure - Canopy USA - Acreage Agreements - Additional Information (Details)Sheethhttp://www.canopygrowth.com/20241231/taxonomy/role/DisclosureCanopyUsaAcreageAgreementsAdditionalInformationDetailsCanopy_USA - Acreage Agreements - Additional Information (Details)Details66 falsefalseR67.htm996085 - Disclosure - Canopy USA - Summary of Derecognized Assets and Liabilities Transferred (Details)Sheethhttp://www.canopygrowth.com/20241231/taxonomy/role/DisclosureCanopyUsaSummaryOfDerecognizedAssetsAndLiabilitiesTransferredDetailsCanopy_USA - Summary of Derecognized Assets and Liabilities Transferred (Details)Details67 falsefalseR68.htm996095 - Disclosure - Biosteel - Additional Information (Details)Sheethhttp://www.canopygrowth.com/20241231/taxonomy/role/DisclosureBiosteelAdditionalInformationDetailsBiosteel - Additional Information (Details)Details68 falsefalseR69.htm996105 - Disclosure - Biosteel - Summary of Deconsolidation and Costs to Exit Classified as Discontinued Operations (Details)Sheethhttp://www.canopygrowth.com/20241231/taxonomy/role/DisclosureBiosteelSummaryOfDeconsolidationAndCostsToExitClassifiedAsDiscontinuedOperationsDetails - Summary of Deconsolidation and Costs to Exit Classified as Discontinued Operations (Details)Details69 falsefalseR70.htm996115 - Disclosure - Biosteel - Summary of Deconsolidation and Costs to Exit Classified as Discontinued Operations (Parenthetical) (Details)Sheethhttp://www.canopygrowth.com/20241231/taxonomy/role/DisclosureBiosteelSummaryOfDeconsolidationAndCostsToExitClassifiedAsDiscontinuedOperationsParent - Summary of Deconsolidation and Costs to Exit Classified as Discontinued Operations (Parenthetical) (Details)Details70 falsefalseR71.htm996125 - Disclosure - Biosteel - Summary of Assets and Liabilities Classified as Discontinued Operations and Major Categories (Details)Sheethhttp://www.canopygrowth.com/20241231/taxonomy/role/DisclosureBiosteelSummaryOfAssetsAndLiabilitiesClassifiedAsDiscontinuedOperationsAndMajorCategories - Summary of Assets and Liabilities Classified as Discontinued Operations and Major Categories (Details)Details71 falsefalseR72.htm996135 - Disclosure - Loss on Asset Impairment and Restructuring - Additional Information (Details)Sheethhttp://www.canopygrowth.com/20241231/taxonomy/role/DisclosureLossOnAssetHmpairmentAndRestructuringAdditionalInformationDetailsLoss on Asset

Impact and Restructuring - Additional Information (Details)Details72 falsefalseR73.htm996145 - Disclosure - Cash and Cash Equivalents - Components of Cash and Cash Equivalents

(Details)Sheethttp://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureCashAndCashEquivalentsComponentsOfCashAndCashEquivalentsDetailsCashAndCashEquivalents

Equivalents (Details)Details73 falsefalseR74.htm996153 - Disclosure - Short-term Investments - Components of Short-term Investments (Details)Sheethttp://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureShortTermInvestmentsComponentsOfShortTermInvestmentsDetailsShort-term Investments - Components of Short-term Investments (Details)Details74 falsefalseR75.htm996165 - Disclosure - Short-term Investments - Additional Information

(Details)Sheethttp://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureShortTermInvestmentsAdditionalInformationDetailsShort-term Investments - Additional Information (Details)Details75 falsefalseR76.htm996175 - Disclosure - Amounts Receivable, Net - Components of Amounts Receivable, Net

(Details)Sheethttp://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureAmountsReceivableNetComponentsOfAmountsReceivableNetDetailsAmounts Receivable, Net - Components of Amounts Receivable, Net (Details)Details76 falsefalseR77.htm996185 - Disclosure - Amounts Receivable, Net - Additional Information

(Details)Sheethttp://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureAmountsReceivableNetAdditionalInformationDetailsAmounts Receivable, Net - Additional Information (Details)Details77 falsefalseR78.htm996195 - Disclosure - Inventory - Components of Inventory

(Details)Sheethttp://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureInventoryComponentsOfInventoryDetailsInventory - Components of Inventory

(Details)Details78 falsefalseR79.htm996205 - Disclosure - Inventory - Additional Information

(Details)Sheethttp://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureInventoryAdditionalInformationDetailsInventory - Additional Information

(Details)Details79 falsefalseR80.htm996215 - Disclosure - Prepaid Expenses and Other Assets - Components of Prepaid Expenses and Other Assets

(Details)Sheethttp://www.canopygrowth.com/20241231/taxonomy/role/DisclosurePrepaidExpensesAndOtherAssetsComponentsOfPrepaidExpensesAndOtherAssetsDetailsPrepaid Expenses and Other Assets - Components of Prepaid Expenses and Other Assets (Details)Details80 falsefalseR81.htm996225 - Disclosure - Equity Method Investments - Components of Equity Method Investments

(Details)Sheethttp://www.canopygrowth.com/20241231/taxonomy/role/DisclosureEquityMethodInvestmentsComponentsOfEquityMethodInvestmentsDetailsEquity Method Investments - Components of Equity Method Investments (Details)Details81 falsefalseR82.htm996235 - Disclosure - Other Financial Assets - Summary of Changes in Other Financial Assets

(Details)Sheethttp://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureOtherFinancialAssetsSummaryOfChangesInOtherFinancialAssetsDetailsOther Financial Assets - Summary of Changes in Other Financial Assets (Details)Details82 falsefalseR83.htm996245 - Disclosure - Other Financial Assets - Additional Information

(Details)Sheethttp://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureOtherFinancialAssetsAdditionalInformationDetailsOther Financial Assets - Additional Information (Details)Details83 falsefalseR84.htm996255 - Disclosure - Property, Plant and Equipment - Schedule of Components of Property, Plant and Equipment

(Details)Sheethttp://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosurePropertyPlantAndEquipmentScheduleOfComponentsOfPropertyPlantAndEquipmentDetail Plant and Equipment - Schedule of Components of Property, Plant and Equipment (Details)Details84 falsefalseR85.htm996265 - Disclosure - Property, Plant and Equipment - Additional Information

(Details)Sheethttp://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosurePropertyPlantAndEquipmentAdditionalInformationDetailsProperty, Plant and Equipment - Additional Information (Details)Details85 falsefalseR86.htm996275 - Disclosure - Intangible Assets - Summary of Components of Intangible Assets

(Details)Sheethttp://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureIntangibleAssetsSummaryOfComponentsOfIntangibleAssetsDetailsIntangible Assets - Summary of Components of Intangible Assets (Details)Details86 falsefalseR87.htm996285 - Disclosure - Intangible Assets - Additional Information

(Details)Sheethttp://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureIntangibleAssetsAdditionalInformationDetailsIntangible Assets - Additional Information

(Details)Details87 falsefalseR88.htm996295 - Disclosure - Goodwill - Changes in Carrying Amount of Goodwill

(Details)Sheethttp://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureGoodwillChangesInCarryingAmountOfGoodwillDetailsGoodwill - Changes in Carrying Amount of Goodwill (Details)Details88 falsefalseR89.htm996305 - Disclosure - Goodwill - Additional Information

(Details)Sheethttp://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureGoodwillAdditionalInformationDetailsGoodwill - Additional Information

(Details)Details89 falsefalseR90.htm996315 - Disclosure - Other Accrued Expenses and Liabilities - Components of Other Accrued Expenses and Liabilities

(Details)Sheethttp://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureOtherAccruedExpensesAndLiabilitiesComponentsOfOtherAccruedExpensesAndLiabilitiesE Other Accrued Expenses and Liabilities - Components of Other Accrued Expenses and Liabilities (Details)Details90 falsefalseR91.htm996325 - Disclosure - Debt - Summary of Components of Debt (Details)Sheethttp://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureDebtSummaryOfComponentsOfDebtDetailsDebt - Summary of Components of Debt (Details)Details91 falsefalseR92.htm996335 - Disclosure - Debt - Additional Information

(Details)Sheethttp://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetailsDebt - Additional Information (Details)Details92 falsefalseR93.htm996345 - Disclosure - Other Liabilities - Components of Other Liabilities

(Details)Sheethttp://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureOtherLiabilitiesComponentsOfOtherLiabilitiesDetailsOther Liabilities - Components of Other Liabilities (Details)Details93 falsefalseR94.htm996355 - Disclosure - Redeemable Noncontrolling Interest - Summary of Net Changes in Redeemable Noncontrolling Interests

(Details)Sheethttp://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureRedeemableNoncontrollingInterestSummaryOfNetChangesInRedeemableNoncontrolling Noncontrolling Interest - Summary of Net Changes in Redeemable Noncontrolling Interests (Details)Details94 falsefalseR95.htm996375 - Disclosure - Share Capital - Additional Information (Details)Sheethttp://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureShareCapitalAdditionalInformationDetailsShare Capital - Additional Information (Details)Details95 falsefalseR96.htm996385 - Disclosure - Share Capital - Summary of Issuances of Stock Other

(Details)Sheethttp://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureShareCapitalSummaryOfIssuancesOfStockOtherDetailsShare Capital - Summary of Issuances of Stock Other (Details)Details96 falsefalseR97.htm996395 - Disclosure - Share Capital - Summary of Warrants

(Details)Sheethttp://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureShareCapitalSummaryOfWarrantsDetailsShare Capital - Summary of Warrants

(Details)Details97 falsefalseR98.htm996405 - Disclosure - Share Capital - Summary of Warrants (Parenthetical)

(Details)Sheethttp://www.canopygrowth.com/20241231/taxonomy/role/DisclosureShareCapitalSummaryOfWarrantsParentheticalDetailsShare Capital - Summary of Warrants (Parenthetical) (Details)Details98 falsefalseR99.htm996415 - Disclosure - Share-Based Compensation - Additional Information

(Details)Sheethttp://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureShareBasedCompensationAdditionalInformationDetailsShare-Based Compensation - Additional Information (Details)Details99 falsefalseR100.htm996425 - Disclosure - Share-Based Compensation - Summary of the Changes in Options Outstanding

(Details)Sheethttp://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureShareBasedCompensationSummaryOfChangesInOptionsOutstandingDetailsShare-Based Compensation - Summary of the Changes in Options Outstanding (Details)Details100 falsefalseR101.htm996435 - Disclosure - Share-Based Compensation - Summary of Options Outstanding

(Details)Sheethttp://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureShareBasedCompensationSummaryOfOptionsOutstandingDetailsShare-Based Compensation - Summary of Options Outstanding (Details)Details101 falsefalseR102.htm996445 - Disclosure - Share-Based Compensation - Summary of Assumptions Applied to Establish Fair Value of Options Granted Using Black-Scholes Option Pricing Model

(Details)Sheethttp://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureShareBasedCompensationSummaryOfAssumptionsAppliedToEstablishFairValueOfOptions Based Compensation - Summary of Assumptions Applied to Establish Fair Value of Options Granted Using Black-Scholes Option Pricing Model (Details)Details102 falsefalseR103.htm996455 - Disclosure - Share-Based Compensation - Summary of the Changes in RSUs and PSUs

(Details)Sheethttp://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureShareBasedCompensationSummaryOfChangesInRsusAndPsusDetailsShare-Based Compensation - Summary of the Changes in RSUs and PSUs (Details)Details103 falsefalseR104.htm996465 - Disclosure - Accumulated Other Comprehensive Income (Loss) - Accumulated Other Comprehensive Income

(Details)Sheethttp://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureAccumulatedOtherComprehensiveIncomeLossAccumulatedOtherComprehensiveIncomeDe Other Comprehensive Income (Loss) - Accumulated Other Comprehensive Income

(Details)Detailshhttp://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureAccumulatedOtherComprehensiveIncomeLossTables104 falsefalseR105.htm996475 - Disclosure - Noncontrolling Interests - Summary of Net Change in Noncontrolling Interests

(Details)Sheethttp://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureNoncontrollingInterestsSummaryOfNetChangeInNoncontrollingInterestsDetailsNoncontr Interests - Summary of Net Change in Noncontrolling Interests (Details)Details105 falsefalseR106.htm996485 - Disclosure - Fair Value of Financial Instruments - Summary of Financial Assets and Liabilities Measured at Estimated Fair Value on a Recurring Basis

(Details)Sheethttp://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureFairValueOffinancialInstrumentsSummaryOffinancialAssetsAndLiabilitiesMeasuredAtEst Value of Financial Instruments - Summary of Financial Assets and Liabilities Measured at Estimated Fair Value on a Recurring Basis (Details)Details106 falsefalseR107.htm996505 - Disclosure - Fair Value of Financial Instruments - Summary of Valuation Techniques and Significant Unobservable Inputs in the Fair Value Measurement of Significant Level 3 Financial Instruments

(Details)Sheethttp://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureFairValueOffinancialInstrumentsSummaryOfValuationTechniquesAndSignificantUnobser Value of Financial Instruments - Summary of Valuation Techniques and Significant Unobservable Inputs in the Fair Value Measurement of Significant Level 3 Financial Instruments (Details)Details107 falsefalseR108.htm996515 - Disclosure - Revenue - Summary of Disaggregation of Revenue

(Details)Sheethttp://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureRevenueSummaryOfDisaggregationOfRevenueDetailsRevenue - Summary of Disaggregation of Revenue (Details)Details108 falsefalseR109.htm996525 - Disclosure - Revenue - Summary of Disaggregation of Revenue (Parenthetical)

(Details)Sheethttp://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureRevenueSummaryOfDisaggregationOfRevenueParentheticalDetailsRevenue - Summary of Disaggregation of Revenue (Parenthetical) (Details)Details109 falsefalseR110.htm996535 - Disclosure - Revenue - Additional Information

(Details)Sheethttp://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureRevenueAdditionalInformationDetailsRevenue - Additional Information

(Details)Details110 falsefalseR111.htm996545 - Disclosure - Other Income (Expense), Net - Schedule of Other Income (Expense), Net

(Details)Sheethttp://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureOtherIncomeExpenseNetScheduleOfOtherIncomeExpenseNetDetailsOther Income (Expense), Net - Schedule of Other Income (Expense), Net

(Details)Detailshhttp://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureOtherIncomeExpenseNetTables111 falsefalseR112.htm996555 - Disclosure - Other Income (Expense), Net - Schedule of Other Income (Expense), Net (Parenthetical)

(Details)Sheethttp://www.canopygrowth.com/20241231/taxonomy/role/DisclosureOtherIncomeExpenseNetScheduleOfOtherIncomeExpenseNetParentheticalDetailsOther Income (Expense), Net - Schedule of Other Income (Expense), Net (Parenthetical)

(Details)Detailshhttp://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureOtherIncomeExpenseNetTables112 falsefalseR113.htm996585 - Disclosure - Acreage Arrangement - Additional Information

(Details)Sheethttp://www.canopygrowth.com/20241231/taxonomy/role/DisclosureAcreageArrangementAdditionalInformationDetailsAcreage Arrangement - Additional Information (Details)Details113 falsefalseR114.htm996605 - Disclosure - Segment Information - Additional Information

(Details)Sheethttp://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureSegmentInformationAdditionalInformationDetailsSegment Information - Additional Information (Details)Details114 falsefalseR115.htm996615 - Disclosure - Segment Information - Summary of Reconciliation of Operating Profit (Loss) from Segments to Consolidated

(Details)Sheethttp://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureSegmentInformationSummaryOfReconciliationOfOperatingProfitLossFromSegmentsToCo Information - Summary of Reconciliation of Operating Profit (Loss) from Segments to Consolidated (Details)Details115 falsefalseR116.htm996625 - Disclosure - Segment Information - Summary of Disaggregation of Net Revenue by Geographic Area

(Details)Sheethttp://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureSegmentInformationSummaryOfDisaggregationOfNetRevenueByGeographicAreaDetailsSe Information - Summary of Disaggregation of Net Revenue by Geographic Area (Details)Details116 falsefalseR117.htm996635 - Disclosure - Segment Information - Summary of Disaggregation of


```

Events - Additional Information (Details)Details2118 falsefalseAll ReportsBookAll Reports cgc-20241231.htmcgc-20241231.xsd http://fasb.org/us-gaap/2024http://xbrl.sec.gov/dei/2024http://xbrl.sec.gov/ecd/2024falsefalse JSON 133 MetaLinks.json IDEA: XBRL DOCUMENT f "version": "2.2", "instance": { "cgc-20241231.htm": { "nsPrefix": "cgc", "nsURI": "http://www.canopygrowth.com/20241231", "dts": { "inline": { "local": { "cgc-20241231.htm" } } }, "schema": { "local": { "cgc-20241231.xsd" } }, "remote": { "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd": "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xt-2003-12-31.xsd": "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd": "http://www.xbrl.org/2006/rel-2006-02-27.xsd", "http://www.xbrl.org/lrr/arcrrole/esma-arcrrole-2018-11-21.xsd": "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd": "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/2023/calculation-1.1.xsd": "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd": "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd": "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd": "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd": "https://xbrl.sec.gov/country/2024/country-2024.xsd", "https://xbrl.sec.gov/dei/2024/dei-2024.xsd": "https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd", "https://xbrl.sec.gov/ecd/2024/ecd-sub-2024.xsd": "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd" } } }, "keyStandard": 298, "keyCustom": 147, "axisStandard": 31, "axisCustom": 0, "memberStandard": 7, "memberCustom": 104, "hidden": { "total": 15, "http://xbrl.sec.gov/dei/2024": 6, "http://fasb.org/us-gaap/2024": 9 }, "contextCount": 451, "entityCount": 1, "segmentCount": 151, "elementCount": 1118, "unitCount": 8, "baseTaxonomies": { "http://fasb.org/us-gaap/2024": 984, "http://xbrl.sec.gov/dei/2024": 29, "http://xbrl.sec.gov/ecd/2024": 4 }, "report": { "R1": { "role": "http://www.canopygrowth.com/20241231/taxonomy/role/Role_StatementDocumentAndEntityInformation", "longName": "100000 - Document - Document and Entity Information", "shortName": "Document and Entity Information", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "C b53bc95e-9d0f-46e3-9804-86cce50a4afc", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "span": "p", "body": "html" } }, "reportCount": 1, "baseRef": "cgc-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C b53bc95e-9d0f-46e3-9804-86cce50a4afc", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "span": "p", "body": "html" } }, "reportCount": 1, "baseRef": "cgc-20241231.htm", "first": true, "unique": true } }, "R2": { "role": "http://www.canopygrowth.com/20241231/taxonomy/role/Role_StatementCondensedInterimConsolidatedBalanceSheetsUnaudited", "longName": "100010 - Statement - Condensed Interim Consolidated Balance Sheets (Unaudited)", "shortName": "Condensed Interim Consolidated Balance Sheets (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "2", "firstAnchor": { "contextRef": "C 7e7811a8-7a20-4b99-bf40-0dfbf727e666", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "U_CAD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": { "span": "p", "td": "tr", "table": "body", "html": "table", "reportCount": 1, "baseRef": "cgc-20241231.htm", "first": true }, "uniqueAnchor": { "contextRef": "C 7e7811a8-7a20-4b99-bf40-0dfbf727e666", "name": "us-gaap:RestrictedInvestmentsCurrent", "unitRef": "U_CAD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": { "span": "p", "td": "tr", "table": "body", "html": "table", "reportCount": 1, "baseRef": "cgc-20241231.htm", "first": true }, "uniqueAnchor": { "contextRef": "C 7e7811a8-7a20-4b99-bf40-0dfbf727e666", "name": "us-gaap:RestrictedInvestmentsCurrent", "unitRef": "U_CAD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": { "span": "p", "td": "tr", "table": "body", "html": "table", "reportCount": 1, "baseRef": "cgc-20241231.htm", "first": true }, "uniqueAnchor": { "contextRef": "C 7e7811a8-7a20-4b99-bf40-0dfbf727e666", "name": "us-gaap:RestrictedInvestmentsCurrent", "unitRef": "U_CAD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": { "span": "p", "td": "tr", "table": "body", "html": "table", "reportCount": 1, "baseRef": "cgc-20241231.htm", "first": true }, "uniqueAnchor": { "contextRef": "C 7e7811a8-7a20-4b99-bf40-0dfbf727e666", "name": "us-gaap:RestrictedInvestmentsCurrent", "unitRef": "U_CAD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": { "span": "p", "td": "tr", "table": "body", "html": "table", "reportCount": 1, "baseRef": "cgc-20241231.htm", "first": true }, "uniqueAnchor": { "contextRef": "C 7e7811a8-7a20-4b99-bf40-0dfbf727e666", "name": "us-gaap:RestrictedInvestmentsCurrent", "unitRef": "U_CAD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": { "span": "p", "td": "tr", "table": "body", "html": "table", "reportCount": 1, "baseRef": "cgc-20241231.htm", "first": true }, "uniqueAnchor": { "contextRef": "C 7e7811a8-7a20-4b99-bf40-0dfbf727e666", "name": "us-gaap:RestrictedInvestmentsCurrent", "unitRef": "U_CAD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": { "span": "p", "td": "tr", "table": "body", "html": "table", "reportCount": 1, "baseRef": "cgc-20241231.htm", "first": true }, "uniqueAnchor": { "contextRef": "C 7e7811a8-7a20-4b99-bf40-0dfbf727e666", "name": "us-gaap:RestrictedInvestmentsCurrent", "unitRef": "U_CAD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": { "span": "p", "td": "tr", "table": "body", "html": "table", "reportCount": 1, "baseRef": "cgc-20241231.htm", "first": true }, "uniqueAnchor": { "contextRef": "C 7e7811a8-7a20-4b99-bf40-0dfbf727e666", "name": "us-gaap:RestrictedInvestmentsCurrent", "unitRef": "U_CAD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": { "span": "p", "td": "tr", "table": "body", "html": "table", "reportCount": 1, "baseRef": "cgc-20241231.htm", "first": true }, "uniqueAnchor": { "contextRef": "C 7e7811a8-7a20-4b99-bf40-0dfbf727e666", "name": "us-gaap:RestrictedInvestmentsCurrent", "unitRef": "U_CAD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": { "span": "p", "td": "tr", "table": "body", "html": "table", "reportCount": 1, "baseRef": "cgc-20241231.htm", "first": true }, "uniqueAnchor": { "contextRef": "C 7e7811a8-7a20-4b99-bf40-0dfbf727e666", "name": "us-gaap:RestrictedInvestmentsCurrent", "unitRef": "U_CAD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": { "span": "p", "td": "tr", "table": "body", "html": "table", "reportCount": 1, "baseRef": "cgc-20241231.htm", "first": true }, "uniqueAnchor": { "contextRef": "C 7e7811a8-7a20-4b99-bf40-0dfbf727e666", "name": "us-gaap:RestrictedInvestmentsCurrent", "unitRef": "U_CAD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": { "span": "p", "td": "tr", "table": "body", "html": "table", "reportCount": 1, "baseRef": "cgc-20241231.htm", "first": true }, "uniqueAnchor": { "contextRef": "C 7e7811a8-7a20-4b99-bf40-0dfbf727e666", "name": "us-gaap:RestrictedInvestmentsCurrent", "unitRef": "U_CAD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": { "span": "p", "td": "tr", "table": "body", "html": "table", "reportCount": 1, "baseRef": "cgc-20241231.htm", "first": true }, "uniqueAnchor": { "contextRef": "C 7e7811a8-7a20-4b99-bf40-0dfbf727e666", "name": "us-gaap:RestrictedInvestmentsCurrent", "unitRef": "U_CAD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": { "span": "p", "td": "tr", "table": "body", "html": "table", "reportCount": 1, "baseRef": "cgc-20241231.htm", "first": true }, "uniqueAnchor": { "contextRef": "C 7e7811a8-7a20-4b99-bf40-0dfbf727e666", "name": "us-gaap:RestrictedInvestmentsCurrent", "unitRef": "U_CAD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": { "span": "p", "td": "tr", "table": "body", "html": "table", "reportCount": 1, "baseRef": "cgc-20241231.htm", "first": true }, "uniqueAnchor": { "contextRef": "C 7e7811a8-7a20-4b99-bf40-0dfbf727e666", "name": "us-gaap:RestrictedInvestmentsCurrent", "unitRef": "U_CAD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": { "span": "p", "td": "tr", "table": "body", "html": "table", "reportCount": 1, "baseRef": "cgc-20241231.htm", "first": true }, "uniqueAnchor": { "contextRef": "C 7e7811a8-7a20-4b99-bf40-0dfbf727e666", "name": "us-gaap:RestrictedInvestmentsCurrent", "unitRef": "U_CAD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": { "span": "p",
```

`"html": "I", "reportCount": 1, "baseRef": "cgc-20241231.htm", "first": true, "unique": true } }, "R17": { "role":
"http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureAmountsReceivableNet", "longName": "995525 - Disclosure - Amounts Receivable Net", "shortName": "Amounts
Receivable Net", "isDefault": false, "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": 17, "firstAnchor": { "contextRef": "C b53bc95e-
9d0f-46e3-9804-86cce50a4afc", "name": "us-gAAP:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock", "unitRef": null, "xsiNil": false, "lang": "en-US", "decimals":
null, "ancestors": { "div": "body", "html": "I", "reportCount": 1, "baseRef": "cgc-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C b53bc95e-9d0f-
46e3-9804-86cce50a4afc", "name": "us-gAAP:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock", "unitRef": null, "xsiNil": false, "lang": "en-US", "decimals": null,
"ancestors": { "div": "body", "html": "I", "reportCount": 1, "baseRef": "cgc-20241231.htm", "first": true, "unique": true }, "R18": { "role":
"http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureInventory", "longName": "995535 - Disclosure - Inventory", "shortName": "Inventory", "isDefault":
false, "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": 18, "firstAnchor": { "contextRef": "C b53bc95e-9d0f-46e3-9804-86cce50a4afc", "name": "
us-gAAP:InventoryDisclosureTextBlock", "unitRef": null, "xsiNil": false, "lang": "en-US", "decimals": null, "ancestors": { "div": "body", "html": "I", "reportCount": 1, "baseRef": "
cgc-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C b53bc95e-9d0f-46e3-9804-86cce50a4afc", "name": "us-
gaap:InventoryDisclosureTextBlock", "unitRef": null, "xsiNil": false, "lang": "en-US", "decimals": null, "ancestors": { "div": "body", "html": "I", "reportCount": 1, "baseRef": "cgc-
20241231.htm", "first": true, "unique": true }, "R19": { "role": "http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherAssets",
"longName": "995545 - Disclosure - Prepaid Expenses and Other Assets", "shortName": "Prepaid Expenses and Other Assets", "isDefault": false, "groupType": "disclosure",
"subGroupType": "", "menuCat": "Notes", "order": 19, "firstAnchor": { "contextRef": "C b53bc95e-9d0f-46e3-9804-86cce50a4afc", "name": "
cgc:PrepaidExpenseAndOtherAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": false, "lang": "en-US", "decimals": null, "ancestors": { "div": "body", "html": "I",
"reportCount": 1, "baseRef": "cgc-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C b53bc95e-9d0f-46e3-9804-86cce50a4afc", "name": "
cgc:PrepaidExpenseAndOtherAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": false, "lang": "en-US", "decimals": null, "ancestors": { "div": "body", "html": "I",
"reportCount": 1, "baseRef": "cgc-20241231.htm", "first": true, "unique": true }, "R20": { "role":
"http://www.canopygrowth.com/20241231/taxonomy/role/DisclosureEquityMethodInvestments", "longName": "995555 - Disclosure - Equity Method Investments", "shortName": "
Equity Method Investments", "isDefault": false, "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": 20, "firstAnchor": { "contextRef": "
C b53bc95e-9d0f-46e3-9804-86cce50a4afc", "name": "us-gAAP:EquityMethodInvestmentsDisclosureTextBlock", "unitRef": null, "xsiNil": false, "lang": "en-US", "decimals":
null, "ancestors": { "div": "body", "html": "I", "reportCount": 1, "baseRef": "cgc-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C b53bc95e-9d0f-
46e3-9804-86cce50a4afc", "name": "us-gAAP:EquityMethodInvestmentsDisclosureTextBlock", "unitRef": null, "xsiNil": false, "lang": "en-US", "decimals": null, "ancestors": { "div":
"body", "html": "I", "reportCount": 1, "baseRef": "cgc-20241231.htm", "first": true, "unique": true }, "R21": { "role":
"http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureOtherFinancialAssets", "longName": "995565 - Disclosure - Other Financial Assets", "shortName": "
Other Financial Assets", "isDefault": false, "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": 21, "firstAnchor": { "contextRef": "C b53bc95e-
9d0f-46e3-9804-86cce50a4afc", "name": "cgc:OtherFinancialAssetsTextBlock", "unitRef": null, "xsiNil": false, "lang": "en-US", "decimals": null, "ancestors": { "span": "p", "body": "html"
I", "reportCount": 1, "baseRef": "cgc-20241231.htm", "first": true, "unique": true }, "R22": { "role":
"http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosurePropertyPlantAndEquipment", "longName": "995575 - Disclosure - Property Plant and Equipment",
"shortName": "Property Plant and Equipment", "isDefault": false, "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": 22, "firstAnchor": {
"contextRef": "C b53bc95e-9d0f-46e3-9804-86cce50a4afc", "name": "us-gAAP:PropertyPlantAndEquipmentDisclosureTextBlock", "unitRef": null, "xsiNil": false, "lang": "en-
US", "decimals": null, "ancestors": { "div": "body", "html": "I", "reportCount": 1, "baseRef": "cgc-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "
C b53bc95e-9d0f-46e3-9804-86cce50a4afc", "name": "us-gAAP:PropertyPlantAndEquipmentDisclosureTextBlock", "unitRef": null, "xsiNil": false, "lang": "en-US",
"decimals": null, "ancestors": { "div": "body", "html": "I", "reportCount": 1, "baseRef": "cgc-20241231.htm", "first": true, "unique": true }, "R23": { "role":
"http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureIntangibleAssets", "longName": "995585 - Disclosure - Intangible Assets", "shortName": "Intangible
Assets", "isDefault": false, "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": 23, "firstAnchor": { "contextRef": "C b53bc95e-9d0f-46e3-9804-
86cce50a4afc", "name": "us-gAAP:IntangibleAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": false, "lang": "en-US", "decimals": null, "ancestors": { "div": "body", "html": "
I", "reportCount": 1, "baseRef": "cgc-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C b53bc95e-9d0f-46e3-9804-86cce50a4afc", "name": "us-
gAAP:IntangibleAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": false, "lang": "en-US", "decimals": null, "ancestors": { "div": "body", "html": "I", "reportCount": 1,
"baseRef": "cgc-20241231.htm", "first": true, "unique": true }, "R24": { "role": "http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureGoodwill",
"longName": "995595 - Disclosure - Goodwill", "shortName": "Goodwill", "isDefault": false, "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": 24,
"firstAnchor": { "contextRef": "C b53bc95e-9d0f-46e3-9804-86cce50a4afc", "name": "us-gAAP:GoodwillDisclosureTextBlock", "unitRef": null, "xsiNil": false, "lang": "en-US",
"decimals": null, "ancestors": { "div": "body", "html": "I", "reportCount": 1, "baseRef": "cgc-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "
C b53bc95e-9d0f-46e3-9804-86cce50a4afc", "name": "us-gAAP:GoodwillDisclosureTextBlock", "unitRef": null, "xsiNil": false, "lang": "en-US", "decimals": null, "ancestors": {
"div": "body", "html": "I", "reportCount": 1, "baseRef": "cgc-20241231.htm", "first": true, "unique": true }, "R25": { "role":
"http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureOtherAccruedExpensesAndLiabilities", "longName": "995605 - Disclosure - Other Accrued Expenses
and Liabilities", "shortName": "Other Accrued Expenses and Liabilities", "isDefault": false, "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": 25,
"firstAnchor": { "contextRef": "C b53bc95e-9d0f-46e3-9804-86cce50a4afc", "name": "us-
gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "unitRef": null, "xsiNil": false, "lang": "en-US", "decimals": null, "ancestors": {
"div": "body", "html": "I", "reportCount": 1, "baseRef": "cgc-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C b53bc95e-9d0f-46e3-9804-
86cce50a4afc", "name": "us-gAAP:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "unitRef": null, "xsiNil": false, "lang": "en-US",
"decimals": null, "ancestors": { "div": "body", "html": "I", "reportCount": 1, "baseRef": "cgc-20241231.htm", "first": true, "unique": true }, "R26": { "role":
"http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureDebt", "longName": "995615 - Disclosure - Debt", "shortName": "Debt", "isDefault": false,
"groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": 26, "firstAnchor": { "contextRef": "C b53bc95e-9d0f-46e3-9804-86cce50a4afc", "name": "us-
gaap:DebtDisclosureTextBlock", "unitRef": null, "xsiNil": false, "lang": "en-US", "decimals": null, "ancestors": { "div": "body", "html": "I", "reportCount": 1, "baseRef": "cgc-
20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C b53bc95e-9d0f-46e3-9804-86cce50a4afc", "name": "us-gAAP:DebtDisclosureTextBlock",
"unitRef": null, "xsiNil": false, "lang": "en-US", "decimals": null, "ancestors": { "div": "body", "html": "I", "reportCount": 1, "baseRef": "cgc-20241231.htm", "first": true,
"unique": true }, "R27": { "role": "http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureOtherLiabilities", "longName": "995625 - Disclosure - Other
Liabilities", "shortName": "Other Liabilities", "isDefault": false, "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": 27, "firstAnchor": {
"contextRef": "C b53bc95e-9d0f-46e3-9804-86cce50a4afc", "name": "us-gAAP:OtherLiabilitiesDisclosureTextBlock", "unitRef": null, "xsiNil": false, "lang": "en-US",
"decimals": null, "ancestors": { "div": "body", "html": "I", "reportCount": 1, "base`

[illegible]

```

"Tables", "order": "53", "firstAnchor": f "contextRef": "C_b53bc95e-9d0f-46e3-9804-86cce50a4afc", "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": f "div": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "div": "body", "html": l "reportCount": 1, "baseRef": "cgc-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": f "contextRef": "C_b53bc95e-9d0f-46e3-9804-86cce50a4afc", "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": f "div": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "div": "body", "html": l "reportCount": 1, "baseRef": "cgc-20241231.htm", "first": true, "unique": true }, "R54": f "role": "http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureDebtTables", "longName": "995925 - Disclosure - Debt (Tables)", "shortName": "Debt (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "54", "firstAnchor": f "contextRef": "C_b53bc95e-9d0f-46e3-9804-86cce50a4afc", "name": "us-gaap:ScheduleOfDebtTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": f "div": "us-gaap:DebtDisclosureTableTextBlock", "div": "body", "html": l "reportCount": 1, "baseRef": "cgc-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": f "contextRef": "C_b53bc95e-9d0f-46e3-9804-86cce50a4afc", "name": "us-gaap:ScheduleOfDebtTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": f "div": "us-gaap:DebtDisclosureTableTextBlock", "div": "body", "html": l "reportCount": 1, "baseRef": "cgc-20241231.htm", "first": true, "unique": true }, "R55": f "role": "http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureOtherLiabilitiesTables", "longName": "995935 - Disclosure - Other Liabilities (Tables)", "shortName": "Other Liabilities (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "55", "firstAnchor": f "contextRef": "C_b53bc95e-9d0f-46e3-9804-86cce50a4afc", "name": "us-gaap:OtherLiabilitiesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": f "div": "us-gaap:OtherLiabilitiesDisclosureTextBlock", "div": "body", "html": l "reportCount": 1, "baseRef": "cgc-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": f "contextRef": "C_b53bc95e-9d0f-46e3-9804-86cce50a4afc", "name": "us-gaap:OtherLiabilitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": f "div": "us-gaap:OtherLiabilitiesDisclosureTextBlock", "div": "body", "html": l "reportCount": 1, "baseRef": "cgc-20241231.htm", "first": true, "unique": true }, "R56": f "role": "http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureShareCapitalTables", "longName": "995955 - Disclosure - Share Capital (Tables)", "shortName": "Share Capital (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "56", "firstAnchor": f "contextRef": "C_b53bc95e-9d0f-46e3-9804-86cce50a4afc", "name": "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionEquityInterestIssuedOrIssuableTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": f "div": "ix:continuation", "div": "body", "html": l "reportCount": 1, "baseRef": "cgc-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": f "contextRef": "C_b53bc95e-9d0f-46e3-9804-86cce50a4afc", "name": "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionEquityInterestIssuedOrIssuableTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": f "div": "ix:continuation", "div": "body", "html": l "reportCount": 1, "baseRef": "cgc-20241231.htm", "first": true, "unique": true }, "R57": f "role": "http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureShareBasedCompensationTables", "longName": "995965 - Disclosure - Share Based Compensation (Tables)", "shortName": "Share Based Compensation (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "57", "firstAnchor": f "contextRef": "C_b53bc95e-9d0f-46e3-9804-86cce50a4afc", "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": f "div": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTableTextBlock", "div": "body", "html": l "reportCount": 1, "baseRef": "cgc-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": f "contextRef": "C_b53bc95e-9d0f-46e3-9804-86cce50a4afc", "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": f "div": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTableTextBlock", "div": "body", "html": l "reportCount": 1, "baseRef": "cgc-20241231.htm", "first": true, "unique": true }, "R58": f "role": "http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureAccumulatedOtherComprehensiveIncomeLossTables", "longName": "995975 - Disclosure - Accumulated Other Comprehensive Income (Loss) (Tables)", "shortName": "Accumulated Other Comprehensive Income (Loss) (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "58", "firstAnchor": f "contextRef": "C_b53bc95e-9d0f-46e3-9804-86cce50a4afc", "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": f "div": "us-gaap:ComprehensiveIncomeNoteTextBlock", "div": "body", "html": l "reportCount": 1, "baseRef": "cgc-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": f "contextRef": "C_b53bc95e-9d0f-46e3-9804-86cce50a4afc", "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": f "div": "us-gaap:ComprehensiveIncomeNoteTextBlock", "div": "body", "html": l "reportCount": 1, "baseRef": "cgc-20241231.htm", "first": true, "unique": true }, "R59": f "role": "http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureNoncontrollingInterestsTables", "longName": "995985 - Disclosure - Noncontrolling Interests (Tables)", "shortName": "Noncontrolling Interests (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "59", "firstAnchor": f "contextRef": "C_b53bc95e-9d0f-46e3-9804-86cce50a4afc", "name": "us-gaap:ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": f "div": "us-gaap:MinorityInterestDisclosureTextBlock", "div": "body", "html": l "reportCount": 1, "baseRef": "cgc-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": f "contextRef": "C_b53bc95e-9d0f-46e3-9804-86cce50a4afc", "name": "us-gaap:ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": f "div": "us-gaap:MinorityInterestDisclosureTextBlock", "div": "body", "html": l "reportCount": 1, "baseRef": "cgc-20241231.htm", "first": true, "unique": true }, "R60": f "role": "http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureFairValueOffinancialInstrumentsTables", "longName": "995995 - Disclosure - Fair Value of Financial Instruments (Tables)", "shortName": "Fair Value of Financial Instruments (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "60", "firstAnchor": f "contextRef": "C_b53bc95e-9d0f-46e3-9804-86cce50a4afc", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": f "div": "us-gaap:FairValueDisclosuresTextBlock", "div": "body", "html": l "reportCount": 1, "baseRef": "cgc-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": f "contextRef": "C_b53bc95e-9d0f-46e3-9804-86cce50a4afc", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": f "div": "us-gaap:FairValueDisclosuresTextBlock", "div": "body", "html": l "reportCount": 1, "baseRef": "cgc-20241231.htm", "first": true, "unique": true }, "R61": f "role": "http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureRevenueTables", "longName": "996005 - Disclosure - Revenue (Tables)", "shortName": "Revenue (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "61", "firstAnchor": f "contextRef": "C_b53bc95e-9d0f-46e3-9804-86cce50a4afc", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": f "div": "us-gaap:RevenueFromContractWithCustomerTableTextBlock", "div": "body", "html": l "reportCount": 1, "baseRef": "cgc-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": f "contextRef": "C_b53bc95e-9d0f-46e3-9804-86cce50a4afc", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": f "div": "us-gaap:RevenueFromContractWithCustomerTableTextBlock", "div": "body", "html": l "reportCount": 1, "baseRef": "cgc-20241231.htm", "first": true, "unique": true }, "R62": f "role": "http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureOtherIncomeExpenseNetTables", "longName": "996015 - Disclosure - Other Income (Expense), Net (Tables)", "shortName": "Other Income (Expense), Net (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "62", "firstAnchor": f "contextRef": "C_b53bc95e-9d0f-46e3-9804-86cce50a4afc", "name": "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": f "div": "us-gaap:OtherIncomeAndOtherExpenseDisclosureTableTextBlock", "div": "body", "html": l "reportCount": 1, "baseRef": "cgc-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": f "contextRef": "C_b
```

"key": "html", "l": "reportCount": 1, "baseRef": "/cgc-20241231.htm", "first": true, "unique": true }, {"key": "uniqueAnchor": { "contextRef": "/C fd64c4d7-7c43-46f6-bcef-5f3aeecbd85a7", "name": "-us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue", "unitRef": "U_CAD", "xsiNil": false, "lang": null, "decimals": -3, "ancestors": ["span", "p", "td", "tr", "table"], "ix.continuation": "div", "ix.continuation": "div", "body": "html", "l": "reportCount": 1, "baseRef": "/cgc-20241231.htm", "first": true, "unique": true } }, "R70": { "role": "http://www.canopygrowth.com/20241231/taxonomy/role/DisclosureBiosteelSummaryOfDeconsolidationAndCostsToExitClassifiedAsDiscontinuedOperationsParenteticalDetails", "longName": "996115-Disclosure-Biosteel-Summary of Deconsolidation and Costs to Exit Classified as Discontinued Operations (Parenthetical) (Details)", "shortName": "Biosteel-Summary of Deconsolidation and Costs to Exit Classified as Discontinued Operations (Parenthetical) (Details)", "isDefault": false, "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": 70, "firstAnchor": { "contextRef": "/C lccc53c6-ad0f-4734-814e-12221f4d09e1", "name": "-us-gaap:DeconsolidationGainOrLossAmount", "unitRef": "U_CAD", "xsiNil": false, "lang": null, "decimals": -3, "ancestors": ["span", "link:footnote", "p", "us-gaap:ScheduleOffDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock"], "ix.continuation": "div", "body": "html", "l": "reportCount": 1, "baseRef": "/cgc-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "/C lccc53c6-ad0f-4734-814e-12221f4d09e1", "name": "-us-gaap:DeconsolidationGainOrLossAmount", "unitRef": "U_CAD", "xsiNil": false, "lang": null, "decimals": -3, "ancestors": ["span", "link:footnote", "p", "us-gaap:ScheduleOffDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock"], "ix.continuation": "div", "body": "html", "l": "reportCount": 1, "baseRef": "/cgc-20241231.htm", "first": true, "unique": true } }, "R71": { "role": "http://www.canopygrowth.com/20241231/taxonomy/role/DisclosureBiosteelSummaryOfAssetsAndLiabilitiesClassifiedAsDiscontinuedOperationsAndMajorCategoriesDetails", "longName": "996125-Disclosure-Biosteel-Summary of Assets and Liabilities Classified as Discontinued Operations and Major Categories (Details)", "shortName": "Biosteel-Summary of Assets and Liabilities Classified as Discontinued Operations and Major Categories (Details)", "isDefault": false, "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": 71, "firstAnchor": { "contextRef": "/C 9196a355-a12b-4ce7-8ceb-883868166e09", "name": "-cgcc:DisposalGroupIncludingDiscontinuedOperationReceivable", "unitRef": "U_CAD", "xsiNil": false, "lang": null, "decimals": -3, "ancestors": ["span", "p", "td", "tr", "table"], "ix.continuation": "div", "ix.continuation": "div", "body": "html", "l": "reportCount": 1, "baseRef": "/cgc-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "/C 9196a355-a12b-4ce7-8ceb-883868166e09", "name": "-cgcc:DisposalGroupIncludingDiscontinuedOperationReceivable", "unitRef": "U_CAD", "xsiNil": false, "lang": null, "decimals": -3, "ancestors": ["span", "p", "td", "tr", "table"], "ix.continuation": "div", "ix.continuation": "div", "body": "html", "l": "reportCount": 1, "baseRef": "/cgc-20241231.htm", "first": true, "unique": true } }, "R72": { "role": "http://www.canopygrowth.com/20241231/taxonomy/role/DisclosureLossOnAssetImpairmentAndRestructuringAdditionalInformationDetails", "longName": "996135-Disclosure-Loss on Asset Impairment and Restructuring- Additional Information (Details)", "shortName": "Loss on Asset Impairment and Restructuring- Additional Information (Details)", "isDefault": false, "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": 72, "firstAnchor": { "contextRef": "/C 0036d9b1-14a3-4feb-b55a-e83c71d22bf5", "name": "-us-gaap:GainLossOnSalesOfAssetsAndAssetImpairmentCharges", "unitRef": "U_CAD", "xsiNil": false, "lang": null, "decimals": -3, "ancestors": ["span", "p", "td", "tr", "table"], "ix.continuation": "div", "ix.continuation": "div", "body": "html", "l": "reportCount": 1, "baseRef": "/cgc-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "/C 0036d9b1-14a3-4feb-b55a-e83c71d22bf5", "name": "-us-gaap:GainLossOnSalesOfAssetsAndAssetImpairmentCharges", "unitRef": "U_CAD", "xsiNil": false, "lang": null, "decimals": -3, "ancestors": ["span", "p", "td", "tr", "table"], "ix.continuation": "div", "ix.continuation": "div", "body": "html", "l": "reportCount": 1, "baseRef": "/cgc-20241231.htm", "first": true, "unique": true } }, "R73": { "role": "http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureCashAndCashEquivalentsComponentsOfCashAndCashEquivalentsDetails", "longName": "996145-Disclosure-Cash and Cash Equivalents- Components of Cash and Cash Equivalents (Details)", "shortName": "Cash and Cash Equivalents- Components of Cash and Cash Equivalents (Details)", "isDefault": false, "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": 73, "firstAnchor": { "contextRef": "/C 7e7811a8-7a20-4b99-bf40-0dfbf727e6e6", "name": "-us-gaap:Cash", "unitRef": "U_CAD", "xsiNil": false, "lang": null, "decimals": -3, "ancestors": ["span", "p", "td", "tr", "table"], "ix.continuation": "div", "ix.continuation": "div", "body": "html", "l": "reportCount": 1, "baseRef": "/cgc-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "/C 7e7811a8-7a20-4b99-bf40-0dfbf727e6e6", "name": "-us-gaap:Cash", "unitRef": "U_CAD", "xsiNil": false, "lang": null, "decimals": -3, "ancestors": ["span", "p", "td", "tr", "table"], "ix.continuation": "div", "ix.continuation": "div", "body": "html", "l": "reportCount": 1, "baseRef": "/cgc-20241231.htm", "first": true, "unique": true } }, "R74": { "role": "http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureShortTermInvestmentsComponentsOfShortTermInvestmentsDetails", "longName": "996155-Disclosure- Short-term Investments- Components of Short-term Investments (Details)", "shortName": "Short-term Investments- Components of Short-term Investments (Details)", "isDefault": false, "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": 74, "firstAnchor": { "contextRef": "/C 7e7811a8-7a20-4b99-bf40-0dfbf727e6e6", "name": "-us-gaap:ShortTermInvestments", "unitRef": "U_CAD", "xsiNil": false, "lang": null, "decimals": -3, "ancestors": ["span", "p", "td", "tr", "table"], "ix.continuation": "div", "ix.continuation": "div", "body": "html", "l": "reportCount": 1, "baseRef": "/cgc-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "/C f7602147-ba68-4a43-9b90-6ba3164f7fc1", "name": "-us-gaap:ShortTermInvestments", "unitRef": "U_CAD", "xsiNil": false, "lang": null, "decimals": -3, "ancestors": ["span", "p", "td", "tr", "table"], "ix.continuation": "div", "ix.continuation": "div", "body": "html", "l": "reportCount": 1, "baseRef": "/cgc-20241231.htm", "first": true, "unique": true } }, "R75": { "role": "http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureShortTermInvestmentsAdditionalInformationDetails", "longName": "996165-Disclosure- Short-term Investments- Additional Information (Details)", "shortName": "Short-term Investments- Additional Information (Details)", "isDefault": false, "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": 75, "firstAnchor": { "contextRef": "/C 7e7811a8-7a20-4b99-bf40-0dfbf727e6e6", "name": "-us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis", "unitRef": "U_CAD", "xsiNil": false, "lang": null, "decimals": -3, "ancestors": ["span", "p", "td", "tr", "table"], "ix.continuation": "div", "ix.continuation": "div", "body": "html", "l": "reportCount": 1, "baseRef": "/cgc-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "/C 7e7811a8-7a20-4b99-bf40-0dfbf727e6e6", "name": "-us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis", "unitRef": "U_CAD", "xsiNil": false, "lang": null, "decimals": -3, "ancestors": ["span", "p", "td", "tr", "table"], "ix.continuation": "div", "ix.continuation": "div", "body": "html", "l": "reportCount": 1, "baseRef": "/cgc-20241231.htm", "first": true, "unique": true } }, "R76": { "role": "http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureAccountsReceivableNetComponentsOfAccountsReceivableNetDetails", "longName": "996175-Disclosure-Accounts Receivable, Net- Components of Accounts Receivable, Net (Details)", "shortName": "Accounts Receivable, Net- Components of Accounts Receivable, Net (Details)", "isDefault": false, "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": 76, "firstAnchor": { "contextRef": "/C 7e7811a8-7a20-4b99-bf40-0dfbf727e6e6", "name": "-us-gaap:AccountsReceivableNetCurrent", "unitRef": "U_CAD", "xsiNil": false, "lang": null, "decimals": -3, "ancestors": ["span", "p", "td", "tr", "table"], "ix.continuation": "div", "ix.continuation": "div", "body": "html", "l": "reportCount": 1, "baseRef": "/cgc-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "/C 7e7811a8-7a20-4b99-bf40-0dfbf727e6e6", "name": "-us-gaap:AccountsReceivableNetCurrent", "unitRef": "U_CAD", "xsiNil": false, "lang": null, "decimals": -3, "ancestors": ["span", "p", "td", "tr", "table"], "ix.continuation": "div", "ix.continuation": "div", "body": "html", "l": "reportCount": 1, "baseRef": "/cgc-20241231.htm", "first": true, "unique": true } }, "R77": { "role": "http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureLoansNotesTradeAndOtherReceivablesDisclosureTextBlock", "longName": "996185-Disclosure-Amounts Receivable, Net- Additional Information (Details)", "shortName": "Accounts Receivable, Net- Additional Information (Details)", "isDefault": false, "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": 77, "firstAnchor": { "contextRef": "/C 7e7811a8-7a20-4b99-bf40-0dfbf727e6e6", "name": "-us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent", "unitRef": "U_CAD", "xsiNil": false, "lang": null, "decimals": -3, "ancestors": ["span", "p", "td", "tr", "table"], "ix.continuation": "div", "ix.continuation": "div", "body": "html", "l": "reportCount": 1, "baseRef": "/cgc-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "/C 7e7811a8-7a20-4b99-bf40-0dfbf727e6e6", "name": "-us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent", "unitRef": "U_CAD", "xsiNil": false, "lang": null, "decimals": -3


```

http://www.canopygrowth.com/20241231/taxonomy/role/Role-DisclosurePropertyPlantAndEquipmentScheduleOfComponentsOfPropertyPlantAndEquipmentDetails,
"longName": "996255 - Disclosure - Property, Plant and Equipment - Schedule of Components of Property, Plant and Equipment (Details)", "shortName": "Property, Plant and Equipment - Schedule of Components of Property, Plant and Equipment (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "84", "firstAnchor": { "contextRef": "C 7e7811a8-7a20-4b99-bf40-0dfbf727e66", "name": "us-gaap:PropertyPlantAndEquipmentGross", "unitRef": "U_CAD", "xsiNil": "false", "lang": "null", "decimals": "-3", "ancestors": { "span": "p", "td": "tr", "table": "us-gaap:PropertyPlantAndEquipmentTextBlock", "div": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div": "body", "html": "reportCount": 1, "baseRef": "cgc-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C 7e7811a8-7a20-4b99-bf40-0dfbf727e66", "name": "us-gaap:PropertyPlantAndEquipmentGross", "unitRef": "U_CAD", "xsiNil": "false", "lang": "null", "decimals": "-3", "ancestors": { "span": "p", "td": "tr", "table": "us-gaap:PropertyPlantAndEquipmentTextBlock", "div": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div": "body", "html": "reportCount": 1, "baseRef": "cgc-20241231.htm", "first": true, "unique": true } }, "R85": { "role": "http://www.canopygrowth.com/20241231/taxonomy/role/Role-DisclosurePropertyPlantAndEquipmentAdditionalInformationDetails", "longName": "996265 - Disclosure - Property, Plant and Equipment - Additional Information (Details)", "shortName": "Property, Plant and Equipment - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "85", "firstAnchor": { "contextRef": "C b53bc95e-9d0f-46e3-9804-86cce50a4afe", "name": "us-gaap:Depreciation", "unitRef": "U_CAD", "xsiNil": "false", "lang": "null", "decimals": "-3", "ancestors": { "span": "p", "td": "tr", "table": "body", "html": "reportCount": 1, "baseRef": "cgc-20241231.htm", "first": true }, "uniqueAnchor": { "contextRef": "C d5861c85-a241-463e-811a-9ccc2eaa017d", "name": "us-gaap:Depreciation", "unitRef": "U_CAD", "xsiNil": "false", "lang": "null", "decimals": "-3", "ancestors": { "span": "p", "td": "tr", "table": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div": "body", "html": "reportCount": 1, "baseRef": "cgc-20241231.htm", "unique": true } }, "R86": { "role": "http://www.canopygrowth.com/20241231/taxonomy/role/Role-DisclosureIntangibleAssetsSummaryOfComponentsOfIntangibleAssetsDetails", "longName": "996275 - Disclosure - Intangible Assets - Summary of Components of Intangible Assets (Details)", "shortName": "Intangible Assets - Summary of Components of Intangible Assets (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "86", "firstAnchor": { "contextRef": "C 7e7811a8-7a20-4b99-bf40-0dfbf727e66", "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "unitRef": "U_CAD", "xsiNil": "false", "lang": "null", "decimals": "-3", "ancestors": { "span": "p", "td": "tr", "table": "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock", "div": "us-gaap:IntangibleAssetsDisclosureTextBlock", "div": "body", "html": "reportCount": 1, "baseRef": "cgc-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C 7e7811a8-7a20-4b99-bf40-0dfbf727e66", "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "unitRef": "U_CAD", "xsiNil": "false", "lang": "null", "decimals": "-3", "ancestors": { "span": "p", "td": "tr", "table": "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock", "div": "us-gaap:IntangibleAssetsDisclosureTextBlock", "div": "body", "html": "reportCount": 1, "baseRef": "cgc-20241231.htm", "first": true, "unique": true } }, "R87": { "role": "http://www.canopygrowth.com/20241231/taxonomy/role/Role-DisclosureIntangibleAssetsAdditionalInformationDetails", "longName": "996285 - Disclosure - Intangible Assets - Additional Information (Details)", "shortName": "Intangible Assets - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "87", "firstAnchor": { "contextRef": "C b53bc95e-9d0f-46e3-9804-86cce50a4afe", "name": "us-gaap:AmortizationOfIntangibleAssets", "unitRef": "U_CAD", "xsiNil": "false", "lang": "null", "decimals": "-3", "ancestors": { "span": "p", "td": "tr", "table": "body", "html": "reportCount": 1, "baseRef": "cgc-20241231.htm", "first": true }, "uniqueAnchor": { "contextRef": "C d5861c85-a241-463e-811a-9ccc2eaa017d", "name": "us-gaap:AmortizationOfIntangibleAssets", "unitRef": "U_CAD", "xsiNil": "false", "lang": "null", "decimals": "-3", "ancestors": { "span": "p", "td": "tr", "table": "us-gaap:IntangibleAssetsDisclosureTextBlock", "div": "body", "html": "reportCount": 1, "baseRef": "cgc-20241231.htm", "unique": true } }, "R88": { "role": "http://www.canopygrowth.com/20241231/taxonomy/role/Role-DisclosureGoodwillChangesInCarryingAmountOfGoodwillDetails", "longName": "996295 - Disclosure - Goodwill - Changes in Carrying Amount of Goodwill (Details)", "shortName": "Goodwill - Changes in Carrying Amount of Goodwill (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "88", "firstAnchor": { "contextRef": "C 8dcce511c-8ab6-4daf-aaa3-0bc74da2d6c2", "name": "us-gaap:Goodwill", "unitRef": "U_CAD", "xsiNil": "false", "lang": "null", "decimals": "-3", "ancestors": { "span": "p", "td": "tr", "table": "body", "html": "reportCount": 1, "baseRef": "cgc-20241231.htm", "first": true }, "uniqueAnchor": { "contextRef": "C 2cccd9f10-26c1-4986-8438-7fb7fe5a7ce8", "name": "us-gaap:GoodwillImpairmentLoss", "unitRef": "U_CAD", "xsiNil": "false", "lang": "null", "decimals": "-3", "ancestors": { "span": "p", "td": "tr", "table": "us-gaap:ScheduleOfGoodwillTextBlock", "div": "us-gaap:GoodwillDisclosureTextBlock", "div": "body", "html": "reportCount": 1, "baseRef": "cgc-20241231.htm", "unique": true } }, "R89": { "role": "http://www.canopygrowth.com/20241231/taxonomy/role/Role-DisclosureGoodwillAdditionalInformationDetails", "longName": "996305 - Disclosure - Goodwill - Additional Information (Details)", "shortName": "Goodwill - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "89", "firstAnchor": { "contextRef": "C 7e7811a8-7a20-4b99-bf40-0dfbf727e66", "name": "us-gaap:Goodwill", "unitRef": "U_CAD", "xsiNil": "false", "lang": "null", "decimals": "-3", "ancestors": { "span": "p", "td": "tr", "table": "body", "html": "reportCount": 1, "baseRef": "cgc-20241231.htm", "first": true }, "uniqueAnchor": { "contextRef": "C dbfd653c-79fe-434f-afa3-e0e06ba144b", "name": "us-gaap:Goodwill", "unitRef": "U_CAD", "xsiNil": "false", "lang": "null", "decimals": "-3", "ancestors": { "span": "p", "td": "tr", "table": "us-gaap:GoodwillDisclosureTextBlock", "div": "body", "html": "reportCount": 1, "baseRef": "cgc-20241231.htm", "unique": true } }, "R90": { "role": "http://www.canopygrowth.com/20241231/taxonomy/role/Role-DisclosureOtherAccruedExpensesAndLiabilitiesComponentsOfOtherAccruedExpensesAndLiabilitiesDetails", "longName": "996315 - Disclosure - Other Accrued Expenses and Liabilities - Components of Other Accrued Expenses and Liabilities (Details)", "shortName": "Other Accrued Expenses and Liabilities - Components of Other Accrued Expenses and Liabilities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "90", "firstAnchor": { "contextRef": "C 7e7811a8-7a20-4b99-bf40-0dfbf727e66", "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent", "unitRef": "U_CAD", "xsiNil": "false", "lang": "null", "decimals": "-3", "ancestors": { "span": "p", "td": "tr", "table": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "div": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "div": "body", "html": "reportCount": 1, "baseRef": "cgc-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C 7e7811a8-7a20-4b99-bf40-0dfbf727e66", "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent", "unitRef": "U_CAD", "xsiNil": "false", "lang": "null", "decimals": "-3", "ancestors": { "span": "p", "td": "tr", "table": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "div": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "div": "body", "html": "reportCount": 1, "baseRef": "cgc-20241231.htm", "first": true, "unique": true } }, "R91": { "role": "http://www.canopygrowth.com/20241231/taxonomy/role/Role-DisclosureDebtSummaryOfComponentsOfDebtDetails", "longName": "996325 - Disclosure - Debt - Summary of Components of Debt (Details)", "shortName": "Debt - Summary of Components of Debt (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "91", "firstAnchor": { "contextRef": "C 7e7811a8-7a20-4b99-bf40-0dfbf727e66", "name": "us-gaap:OtherLongTermDebt", "unitRef": "U_CAD", "xsiNil": "false", "lang": "null", "decimals": "-3", "ancestors": { "span": "p", "td": "tr", "table": "us-gaap:ScheduleOfDebtTableTextBlock", "div": "us-gaap:DebtDisclosureTextBlock", "div": "body", "html": "reportCount": 1, "baseRef": "cgc-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C 7e7811a8-7a20-4b99-bf40-0dfbf727e66", "name": "us-gaap:OtherLongTermDebt", "unitRef": "U_CAD", "xsiNil": "false", "lang": "null", "decimals": "-3", "ancestors": { "span": "p", "td": "tr", "table": "us-gaap:ScheduleOfDebtTableTextBlock", "div": "us-gaap:DebtDisclosureTextBlock", "div": "body", "html": "reportCount": 1, "baseRef": "cgc-20241231.htm", "first": true, "unique": true } }, "R92": { "role": "http://www.canopygrowth.com/20241231/taxonomy/role/Role-DisclosureDebtAdditionalInformationDetails", "longName": "996335 - Disclosure - Debt - Additional Information (Details)", "shortName": "Debt - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "92", "firstAnchor": { "contextRef": "C 0f398b7f-ce8e-4d29-b1c6-87b5e5bad8d2", "name": "cgc:DebtInstrumentDiscountedPrice", "unitRef": "U_USD", "xsiNil": "false", "lang": "null", "decimals": "-3", "ancestors": { "span": "p", "td": "tr", "table": "us-gaap:DebtDisclosureTextBlock", "div": "body", "html": "reportCount": 1
```


gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights","unitRef":"","U_shares","xsiNil":"false","lang":null,"decimals":"","INF","ancestors":{"span":"","link:footnote":"","p":"","us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock","div","ix:continuation","div","body","html"},"reportCount":1,"baseRef":"cgc-20241231.htm","first":true,"unique":true},"R99":{"role":"http://www.canopygrowth.com/20241231/taxonomy/role/Role-DisclosureShareBasedCompensationAdditionalInformationDetails","longName":"996415-Disclosure-Share-Based Compensation - Additional Information (Details)","shortName":"Share-Based Compensation - Additional Information (Details)","isDefault":"false","groupType":"disclosure","subGroupType":"details","menuCat":"Details","order":"99","firstAnchor":{"contextRef":"C 9238a3b7-d6a0-493a-8b0a-38dfc3aa495d","name":"cgc:ExtendedPeriodOfOptionFromGrantDate","unitRef":null,"xsiNil":"false","lang":"en-US","decimals":null,"ancestors":{"span":"","p":"","us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock","div","body","html"},"reportCount":1,"baseRef":"cgc-20241231.htm","first":true,"unique":true},"uniqueAnchor":{"contextRef":"C 9238a3b7-d6a0-493a-8b0a-38dfc3aa495d","name":"cgc:ExtendedPeriodOfOptionFromGrantDate","unitRef":null,"xsiNil":"false","lang":"en-US","decimals":null,"ancestors":{"span":"","p":"","us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock","div","body","html"},"reportCount":1,"baseRef":"cgc-20241231.htm","first":true,"unique":true},"R100":{"role":"http://www.canopygrowth.com/20241231/taxonomy/role/Role-DisclosureShareBasedCompensationSummaryOfChangesInOptionsOutstandingDetails","longName":"996425-Disclosure-Share-Based Compensation - Summary of the Changes in Options Outstanding (Details)","shortName":"Share-Based Compensation - Summary of the Changes in Options Outstanding (Details)","isDefault":"false","groupType":"disclosure","subGroupType":"details","menuCat":"Details","order":"100","firstAnchor":{"contextRef":"C 8dc511c-8ab6-4daf-aaa3-0bc74da2d6e2","name":"us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber","unitRef":"","U_shares","xsiNil":"false","lang":null,"decimals":"","INF","ancestors":{"span":"","p":"","td":"","tr","table","us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock","div","us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock","div","body","html"},"reportCount":1,"baseRef":"cgc-20241231.htm","first":true},"R101":{"role":"http://www.canopygrowth.com/20241231/taxonomy/role/Role-DisclosureShareBasedCompensationSummaryOfOptionsOutstandingDetails","longName":"996435-Disclosure-Share-Based Compensation - Summary of Options Outstanding (Details)","shortName":"Share-Based Compensation - Summary of Options Outstanding (Details)","isDefault":"false","groupType":"disclosure","subGroupType":"details","menuCat":"Details","order":"101","firstAnchor":{"contextRef":"C 7e7811a8-7a20-4b99-b40-0dfbf727c66c","name":"us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber","unitRef":"","U_shares","xsiNil":"false","lang":null,"decimals":"","INF","ancestors":{"span":"","p":"","td":"","tr","table","us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock","div","us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock","div","body","html"},"reportCount":1,"baseRef":"cgc-20241231.htm","first":true},"uniqueAnchor":{"contextRef":"C b53bc95e-9d0f-46e3-9804-86cce50a4afc","name":"us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2","unitRef":null,"xsiNil":"false","lang":"en-US","decimals":null,"ancestors":{"span":"","p":"","td":"","tr","table","us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock","div","us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock","div","body","html"},"reportCount":1,"baseRef":"cgc-20241231.htm","first":true},"R102":{"role":"http://www.canopygrowth.com/20241231/taxonomy/role/Role-DisclosureShareBasedCompensationSummaryOfAssumptionsAppliedToEstablishFairValueOfOptionsGrantedUsing Pricing Model (Details)","shortName":"Share-Based Compensation - Summary of Assumptions Applied to Establish Fair Value of Options Granted Using Black-Scholes Option Pricing Model (Details)","isDefault":"false","groupType":"disclosure","subGroupType":"details","menuCat":"Details","order":"102","firstAnchor":{"contextRef":"C b53bc95e-9d0f-46e3-9804-86cce50a4afc","name":"us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate","unitRef":"","U_pure","xsiNil":"false","lang":null,"decimals":"","2","ancestors":{"span":"","p":"","td":"","tr","table","us-gaap:ScheduleOfShareBasedCompensationStockOptionsValuationAssumptionsTableTextBlock","div","ix:continuation","div","body","html"},"reportCount":1,"baseRef":"cgc-20241231.htm","first":true,"unique":true},"uniqueAnchor":{"contextRef":"C b53bc95e-9d0f-46e3-9804-86cce50a4afc","name":"us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate","unitRef":"","U_pure","xsiNil":"false","lang":null,"decimals":"","2","ancestors":{"span":"","p":"","td":"","tr","table","us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock","div","ix:continuation","div","body","html"},"reportCount":1,"baseRef":"cgc-20241231.htm","first":true,"unique":true},"R103":{"role":"http://www.canopygrowth.com/20241231/taxonomy/role/Role-DisclosureShareBasedCompensationSummaryOfChangesInRSUsAndPSUsDetails","longName":"996455-Disclosure-Share-Based Compensation - Summary of the Changes in RSUs and PSUs (Details)","isDefault":"false","groupType":"disclosure","subGroupType":"details","menuCat":"Details","order":"103","firstAnchor":{"contextRef":"C 52931ab7-007e-463c-aa0f-3bc843eea14f","name":"us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber","unitRef":"","U_shares","xsiNil":"false","lang":null,"decimals":"","INF","ancestors":{"span":"","p":"","td":"","tr","table","us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock","div","ix:continuation","div","body","html"},"reportCount":1,"baseRef":"cgc-20241231.htm","first":true,"unique":true},"R104":{"role":"http://www.canopygrowth.com/20241231/taxonomy/role/Role-DisclosureAccumulatedOtherComprehensiveIncomeLossAccumulatedOtherComprehensiveIncomeDetails","longName":"996465-Disclosure-Accumulated Other Comprehensive Income (Loss) - Accumulated Other Comprehensive Income (Details)","shortName":"Accumulated Other Comprehensive Income (Loss) - Accumulated Other Comprehensive Income (Details)","isDefault":"false","groupType":"disclosure","subGroupType":"details","menuCat":"Details","order":"104","firstAnchor":{"contextRef":"C c129d323-be1b-427d-8f16-637da0fb585e","name":"us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest","unitRef":"","U_CAD","xsiNil":"false","lang":null,"decimals":"","3","ancestors":{"span":"","p":"","td":"","tr","table","body","html"},"reportCount":1,"baseRef":"cgc-20241231.htm","first":true},"uniqueAnchor":{"contextRef":"C 7d3cd6c-2c9e-4fed-af0e-5070369c4bd6","name":"us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest","unitRef":"","U_CAD","xsiNil":"false","lang":null,"decimals":"","3","ancestors":{"span":"","p":"","td":"","tr","table","us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock","div","R105":{"role":"http://www.canopygrowth.com/20241231/taxonomy/role/Role-DisclosureNoncontrollingInterestsSummaryOfNetChangeInNoncontrollingInterestsDetails","longName":"996475-Disclosure-Noncontrolling Interests - Summary of Net Change in Noncontrolling Interests (Details)","shortName":"Noncontrolling Interests - Summary of Net Change in Noncontrolling Interests (Details)","isDefault":"false","groupType":"disclosure","subGroupType":"details","menuCat":"Details","order":"105","firstAnchor":{"contextRef":"C c129d323-be1b-427d-8f16-637da0fb585e","name":"us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest","unitRef":"","U_CAD","xsiNil":"false","lang":null,"decimals":"","3","ancestors":{"span":"","p":"","td":"","tr","table","body","html"},"reportCount":1,"baseRef":"cgc-20241231.htm","first":true},"uniqueAnchor":{"contextRef":"C 2c35d0c5-3ebf-453b-93f7-a4f154c79e9c","name":"us-gaap:NetIncomeLossAttributableToNoncontrollingInterest","unitRef":"","U_CAD","xsiNil":"false","lang":null,"decimals":"","3","ancestors":{"span":"","p":"","td":"","tr","table","us-gaap:ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTextBlock","div","us-gaap:MinorityInterestDisclosureTextBlock","div","body","html"},"reportCount":1,"baseRef":"cgc-20241231.htm","first":true},"R106":{"role":"http://www.canopygrowth.com/20241231/taxonomy/role/Role-DisclosureFairValueOfFinancialInstrumentsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtEstimatedFairVa","longName":"996485-Disclosure-Fair Value of Financial Instruments - Summary of Financial Assets and Liabilities Measured at Estimated Fair Value on a Recurring Basis (Details)","shortName":"Fair Value of Financial Instruments - Summary of Financial Assets and Liabilities Measured at Estimated Fair Value on a Recurring Basis (Details)","isDefault":"false","groupType":"disclosure","subGroupType":"details","menuCat":"Details","order":"106","firstAnchor":{"contextRef":"C a0daa18f-22df-459e-89f5-fd7a25c74482","name":"cgc:ShortTermInvestmentsFairValueDisclosure","unitRef":"","U_CAD","xsiNil":"false","lang":null,"decimals":"","3","ancestors":{"span":"","p":"","td":"","tr","table","us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock","div","us-gaap:FairValueDisclosuresTextBlock","div","body","html"},"reportCount":1,"baseRef":"cgc-20241231.htm","first":true,"unique":true},"uniqueAnchor":{"contextRef":"C a0daa18f-22df-459e-89f5-fd7a25c74482","name":"cgc:ShortTermInvestmentsFairValueDisclosure","unitRef":"","U_CAD","xsiNil":"false","lang":null,"decimals":"","3","ancestors":{"span":"","p":"","td":"","tr","table","us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock","div","us-gaap:FairValueDisclosuresTextBlock","div","body","html"},"reportCount":1,"baseRef":"cgc-20241231.htm","first":true,"unique":true},"R107":{"role":"http://www.canopygrowth.com/20241231/taxonomy/role/Role-DisclosureRevenueSummaryOfDisaggregationOfRevenueDetails","longName":"996515-Disclosure-Revenue - Summary of Disaggregation of Revenue (Details)","shortName":"Revenue - Summary of Disaggregation of Revenue (Details)","isDefault":"false","groupType":"disclosure","subGroupType":"details","menuCat":"Details","order":"107","firstAnchor":{"contextRef":"C 528c4306-adc1-4361-af7e-f3806efef0c9","name":"us-gaap:ValuationAllowanceMethodologiesAndAssumptions","unitRef":null,"xsiNil":"false","lang":"en-US","decimals":null,"ancestors":{"span":"","p":"","td":"","tr","table","us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock","div","ix:continuation","div","body","html"},"reportCount":1,"baseRef":"cgc-20241231.htm","first":true,"unique":true},"uniqueAnchor":{"contextRef":"C 528c4306-adc1-4361-af7e-f3806efef0c9","name":"us-gaap:ValuationAllowanceMethodologiesAndAssumptions","unitRef":null,"xsiNil":"false","lang":"en-US","decimals":null,"ancestors":{"span":"","p":"","td":"","tr","table","us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock","div","ix:continuation","div","body","html"},"reportCount":1,"baseRef":"cgc-20241231.htm","first":true,"unique":true},"R108":{"role":"http://www.canopygrowth.com/20241231/taxonomy/role/Role-DisclosureRevenueSummaryOfDisaggregationOfRevenueParenteticalDetails","longName":"996525-Disclosure-Revenue - Summary of Disaggregation of Revenue (Parentetical) (Details)","shortName":"Revenue - Summary of Disaggregation of Revenue (Parentetical) (Details)","isDefault":"false","groupType":"disclosure","subGroupType":"parentetical","menuCat":"Details","order":"108","firstAnchor":{"contextRef":"C 0036d9b1-14a3-4feb-b55a-e83c71d22bf5","name":"us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax","unitRef":"","U_CAD","xsiNil":"false","lang":null,"decimals":"","3","ancestors":{"span":"","p":"","td":"","tr","table","body","html"},"reportCount":1,"baseRef":"cgc-20241231.htm","first":true},"uniqueAnchor":{"contextRef":"C 58ad3fd9-60fd-496e-8801-053292c9f27e","name":"us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax","unitRef":"","U_CAD","xsiNil":"false","lang":null,"decimals":"","3","ancestors":{"span":"","p":"","td":"","tr","table","us-gaap:DisaggregationOfRevenueTableTextBlock","div","us-gaap:RevenueFromContractWithCustomerTextBlock","div","body","html"},"reportCount":1,"baseRef":"cgc-20241231.htm","first":true,"unique":true},"

```

"reportCount": 1, "baseRef": "cgc-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C-0036d9b1-14a3-4feb-b55a-e83c71d22bf5", "name": "cgc:AllowanceForEstimatedReturnsAndPriceAdjustments", "unitRef": "U-CAD", "xsiNil": "false", "lang": null, "decimals": "3", "ancestors": { "span": "p", "us-gaap:RevenueFromContractWithCustomerTextBlock", "div", "body", "html" }, "reportCount": 1, "baseRef": "cgc-20241231.htm", "first": true, "unique": true } } "R111": { "role": "http://www.canopygrowth.com/20241231/taxonomy/role/Role-DisclosureOtherIncomeExpenseNetScheduleOfOtherIncomeExpenseNetDetails", "longName": "996545-Disclosure-Other Income (Expense), Net-Schedule of Other Income (Expense), Net (Details)", "shortName": "Other Income (Expense), Net-Schedule of Other Income (Expense), Net (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "111", "firstAnchor": { "contextRef": "C-0036d9b1-14a3-4feb-b55a-e83c71d22bf5", "name": "cgc:FairValueChangesOnRelatedAssets", "unitRef": "U-CAD", "xsiNil": "false", "lang": null, "decimals": "3", "ancestors": { "span": "p", "us-gaap:RevenueFromContractWithCustomerTextBlock", "div", "body", "html" }, "reportCount": 1, "baseRef": "cgc-20241231.htm", "first": true, "unique": true } } "R112": { "role": "http://www.canopygrowth.com/20241231/taxonomy/role/DisclosureOtherIncomeExpenseNetScheduleOfOtherIncomeExpenseNetParenteticalDetails", "longName": "996555-Disclosure-Other Income (Expense), Net-Schedule of Other Income (Expense), Net (Parenthetical) (Details)", "shortName": "Other Income (Expense), Net-Schedule of Other Income (Expense), Net (Parenthetical) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "112", "firstAnchor": { "contextRef": "C-7e7811a8-7a20-4b99-bf40-0dffb727e6e6", "name": "cgc:OtherFinancialAssets", "unitRef": "U-CAD", "xsiNil": "false", "lang": null, "decimals": "3", "ancestors": { "span": "p", "us-gaap:RevenueFromContractWithCustomerTextBlock", "div", "body", "html" }, "reportCount": 1, "baseRef": "cgc-20241231.htm", "first": true, "uniqueAnchor": { "contextRef": "C-c212e6dc-423a-4252-986f-c333aad542db", "name": "cgc:OtherFinancialAssetsFairValueAdjustment", "unitRef": "U-CAD", "xsiNil": "false", "lang": null, "decimals": "3", "ancestors": { "span": "p", "us-gaap:RevenueFromContractWithCustomerTextBlock", "div", "body", "html" }, "reportCount": 1, "baseRef": "cgc-20241231.htm", "first": true, "unique": true } } "R113": { "role": "http://www.canopygrowth.com/20241231/taxonomy/role/DisclosureAcreageArrangementAdditionalInformationDetails", "longName": "996585-Disclosure-Acreage Arrangement-Additional Information (Details)", "shortName": "Acreage Arrangement-Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "113", "firstAnchor": { "contextRef": "C-859c6587-aeec-4b62-af4f-74705e8bd5be", "name": "cgc:PercentageOwnershipOfWhollyOwnedSubsidiaries", "unitRef": "U-pure", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": { "span": "p", "ix:continuation", "div", "body", "html" }, "reportCount": 1, "baseRef": "cgc-20241231.htm", "first": true, "uniqueAnchor": null }, "R114": { "role": "http://www.canopygrowth.com/20241231/taxonomy/role/Role-DisclosureSegmentInformationAdditionalInformationDetails", "longName": "996605-Disclosure-Segment Information-Additional Information (Details)", "shortName": "Segment Information-Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "114", "firstAnchor": { "contextRef": "C-b53bc95e-9d0f-46e3-9804-86cee50a4afe", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "div", "body", "html" }, "reportCount": 1, "baseRef": "cgc-20241231.htm", "first": true, "unique": true } } "R115": { "role": "http://www.canopygrowth.com/20241231/taxonomy/role/Role-DisclosureSegmentInformationSummaryOfReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedDebt", "longName": "996615-Disclosure-Segment Information-Summary of Reconciliation of Operating Profit (Loss) from Segments to Consolidated (Details)", "shortName": "Segment Information-Summary of Reconciliation of Operating Profit (Loss) from Segments to Consolidated (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "115", "firstAnchor": { "contextRef": "C-0036d9b1-14a3-4feb-b55a-e83c71d22bf5", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "U-CAD", "xsiNil": "false", "lang": null, "decimals": "3", "ancestors": { "span": "p", "td", "tr", "table", "body", "html" }, "reportCount": 1, "baseRef": "cgc-20241231.htm", "first": true, "uniqueAnchor": { "contextRef": "C-89173cde-92f5-417f-87a5-3b20b540095c", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "U-CAD", "xsiNil": "false", "lang": null, "decimals": "3", "ancestors": { "span": "p", "td", "tr", "table", "body", "html" }, "reportCount": 1, "baseRef": "cgc-20241231.htm", "first": true, "unique": true } } "R116": { "role": "http://www.canopygrowth.com/20241231/taxonomy/role/Role-DisclosureSegmentInformationSummaryOfDisaggregationOfNetRevenueByGeographicAreaDetails", "longName": "996625-Disclosure-Segment Information-Summary of Disaggregation of Net Revenue by Geographic Area (Details)", "shortName": "Segment Information-Summary of Disaggregation of Net Revenue by Geographic Area (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "116", "firstAnchor": { "contextRef": "C-0036d9b1-14a3-4feb-b55a-e83c71d22bf5", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "U-CAD", "xsiNil": "false", "lang": null, "decimals": "3", "ancestors": { "span": "p", "td", "tr", "table", "body", "html" }, "reportCount": 1, "baseRef": "cgc-20241231.htm", "first": true, "uniqueAnchor": { "contextRef": "C-66e0bb8d-b7a3-4c74-93a5-0db266dd8056", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "U-CAD", "xsiNil": "false", "lang": null, "decimals": "3", "ancestors": { "span": "p", "td", "tr", "table", "body", "html" }, "reportCount": 1, "baseRef": "cgc-20241231.htm", "first": true, "unique": true } } "R117": { "role": "http://www.canopygrowth.com/20241231/taxonomy/role/DisclosureSegmentInformationSummaryOfDisaggregationOfPropertyPlantAndEquipmentByGeographicAreaDetails", "longName": "996635-Disclosure-Segment Information-Summary of Disaggregation of Property, Plant and Equipment by Geographic Area (Details)", "shortName": "Segment Information-Summary of Disaggregation of Property, Plant and Equipment by Geographic Area (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "117", "firstAnchor": { "contextRef": "C-7e7811a8-7a20-4b99-bf40-0dffb727e6e6", "name": "us-gaap:PropertyPlantAndEquipmentNet", "unitRef": "U-CAD", "xsiNil": "false", "lang": null, "decimals": "3", "ancestors": { "span": "p", "td", "tr", "table", "body", "html" }, "reportCount": 1, "baseRef": "cgc-20241231.htm", "first": true, "uniqueAnchor": { "contextRef": "C-7f41c781-72b2-4d0b-b48c-1b7b4bb5f58d", "name": "us-gaap:PropertyPlantAndEquipmentNet", "unitRef": "U-CAD", "xsiNil": "false", "lang": null, "decimals": "3", "ancestors": { "span": "p", "td", "tr", "table", "body", "html" }, "reportCount": 1, "baseRef": "cgc-20241231.htm", "first": true, "unique": true } } "R118": { "role": "http://www.canopygrowth.com/20241231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails", "longName": "996645-Disclosure-Subsequent Events-Additional Information (Details)", "shortName": "Subsequent Events-Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "118", "firstAnchor": { "contextRef": "C-7e7811a8-7a20-4b99-bf40-0dffb727e6e6", "name": "us-gaap:CommonStockSharesIssued", "unitRef": "U-shares", "xsiNil": "false", "lang": null, "decimals": "3", "ancestors": { "span": "p", "td", "tr", "table", "body", "html" }, "reportCount": 1, "baseRef": "cgc-20241231.htm", "first": true, "uniqueAnchor": null } } "tag": { "cgc:AccelerationOfShareBasedCompensationExpenseRelatedToAcquisitionMilestonesMember": { "xbrli:type": "domainItemType", "nsuri": "http://www.canopygrowth.com/20241231/taxonomy/role/Role-DisclosureOtherFinancialAssetsSummaryOfChangesInOtherFinancialAssetsDetails", "lang": { "en-us": { "role": { "terseLabel": "Exchangeable Shares", "label": "Acceleration of Share Based Compensation Expense Related To Acquisition Milestones [Member]", "documentation": "Acceleration of share-based compensation expense related to acquisition milestones." } } }, "auth ref": { "us-gaap:AccountingPoliciesAbstract": { "xbrli:type": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountingPoliciesAbstract" } } }, "auth ref": { "us-gaap:AccountingStandardsUpdateExtensibleList": { "xbrli:type": "enumerationSetItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountingStandardsUpdateExtensibleList", "presentation": { "http://www.canopygrowth.com/20241231/taxonomy/role/Role-DisclosureBasisOfPresentationAdditionalInformationDetails": { "http://www.canopygrowth.com/20241231/taxonomy/role/Role-StatementCondensedInterimConsolidatedStatementsOfShareholderSEquityUnaudited", "lang": { "en-us": { "role": { "terseLabel": "Accounting Standards Update [Extensible Enumeration]", "label": "Accounting Standards Update [Extensible Enumeration]", "documentation": "Indicates amendment to accounting standards." } } }, "auth ref": { "r238", "r239", "r240", "r241", "r242", "r243", "r303", "r304", "r305", "r368", "r369", "r411", "r412", "r413", "r414", "r415", "r416", "r417", "r418", "r419", "r420", "r421", "r422", "r423", "r424", "r425", "r426", "r427", "r428", "r429", "r430", "r431", "r432", "r433", "r434", "r435", "r436", "r437", "r438", "r439", "r440", "r441", "r442", "r443", "r444", "r445", "r446", "r447", "r448", "r449", "r450", "r451", "r452", "r453", "r454", "r455", "r456", "r457", "r458", "r459", "r460", "r461", "r462", "r463", "r464", "r465", "r466", "r467", "r468", "r469", "r470", "r471", "r472", "r473", "r474", "r475", "r476", "r477", "r478", "r479", "r480", "r481", "r482", "r483", "r484", "r485", "r486", "r487", "r488", "r489", "r490", "r491", "r492", "r493",
```

```

percentItemType": "nsuri": "http://www.canopygrowth.com/20241231", "localname": "AccretionRate", "presentation": "http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails", "lang": "en-us", "role": "terseLabel", "Accretion Rate", "label": "Accretion Rate", "documentation": "Accretion Rate", "auth_ref": "us-gaap_AccruedLiabilitiesAndOtherLiabilities", "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccruedLiabilitiesAndOtherLiabilities", "crdr": "credit", "presentation": "http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureOtherAccruedExpensesAndLiabilitiesComponentsOfOtherAccruedExpensesAndLiabilitiesDetails", "http://www.canopygrowth.com/20241231/taxonomy/role/Role_StatementCondensedInterimConsolidatedBalanceSheetsUnaudited", "lang": "en-us", "role": "totalLabel", "Other accrued expenses and liabilities", "terseLabel": "Other accrued expenses and liabilities", "label": "Accrued Liabilities and Other Liabilities", "documentation": "Amount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other", "auth_ref": "us-gaap_AccruedProfessionalFeesCurrent", "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccruedProfessionalFeesCurrent", "crdr": "credit", "presentation": "http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureOtherAccruedExpensesAndLiabilitiesComponentsOfOtherAccruedExpensesAndLiabilitiesDetails", "lang": "en-us", "role": "terseLabel": "Professional fees", "label": "Accrued Professional Fees, Current", "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)", "auth_ref": "r125", "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "crdr": "credit", "presentation": "http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosurePropertyPlantAndEquipmentScheduleOfComponentsOfPropertyPlantAndEquipmentDetails", "lang": "en-us", "role": "periodEndLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Ending Balance", "periodStartLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Beginning Balance", "totalLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Total", "negatedLabel": "Less: Accumulated depreciation", "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment", "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services", "auth_ref": "r53", "r254", "r337", "us-gaap_AccumulatedGainLossFinancialLiabilityFairValueOptionAttributableToParentMember", "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedGainLossFinancialLiabilityFairValueOptionAttributableToParentMember", "presentation": "http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureAccumulatedOtherComprehensiveIncomeLossAccumulatedOtherComprehensiveIncomeDetails", "lang": "en-us", "role": "terseLabel": "Changes of Own Credit Risk of Financial Liabilities", "label": "Accumulated Gain (Loss), Financial Liability, Fair Value Option, Attributable to Parent [Member]", "documentation": "Accumulated other comprehensive income (loss) from increase (decrease) in instrument-specific credit risk of financial liability measured under fair value option, attributable to parent", "auth_ref": "r273", "r274", "r281", "r282", "r660", "r1288", "cgc_AccumulatedOtherComprehensiveIncomeIntoIncomeTaxExpenseTax", "xbrltype": "monetaryItemType", "nsuri": "http://www.canopygrowth.com/20241231", "localname": "AccumulatedOtherComprehensiveIncomeIntoIncomeTaxExpenseTax", "crdr": "debit", "presentation": "http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails", "lang": "en-us", "role": "terseLabel": "Tax impact on aggregated principal amount", "label": "Accumulated other comprehensive income into income tax expense, Tax", "documentation": "Accumulated other comprehensive income into income tax expense, Tax", "auth_ref": "us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems", "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedOtherComprehensiveIncomeLossLineItems", "presentation": "http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureAccumulatedOtherComprehensiveIncomeLossAccumulatedOtherComprehensiveIncomeDetails", "lang": "en-us", "role": "terseLabel": "Accumulated Other Comprehensive Income Loss [Line Items]", "label": "Accumulated Other Comprehensive Income (Loss) [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table", "auth_ref": "r280", "r281", "r715", "r717", "r718", "r719", "r720", "r721", "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax", "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "crdr": "credit", "presentation": "http://www.canopygrowth.com/20241231/taxonomy/role/Role_StatementCondensedInterimConsolidatedBalanceSheetsUnaudited", "lang": "en-us", "role": "totalLabel": "Accumulated Other Comprehensive Income (Loss), Net of Tax, Total", "terseLabel": "Accumulated other comprehensive loss", "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source", "auth_ref": "r32", "r33", "r149", "r264", "r832", "r880", "r884", "us-gaap_AccumulatedOtherComprehensiveIncomeLossTable", "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedOtherComprehensiveIncomeLossTable", "presentation": "http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureAccumulatedOtherComprehensiveIncomeLossAccumulatedOtherComprehensiveIncomeDetails", "lang": "en-us", "role": "terseLabel": "Accumulated Other Comprehensive Income Loss [Table]", "label": "Accumulated Other Comprehensive Income (Loss) [Table]", "documentation": "Disclosure of information about components of accumulated other comprehensive income (loss)", "auth_ref": "r280", "r281", "r715", "r717", "r718", "r719", "r720", "r721", "us-gaap_AccumulatedOtherComprehensiveIncomeMember", "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedOtherComprehensiveIncomeMember", "presentation": "http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureAccumulatedOtherComprehensiveIncomeLossAccumulatedOtherComprehensiveIncomeDetails", "http://www.canopygrowth.com/20241231/taxonomy/role/Role_StatementCondensedInterimConsolidatedStatementsOfShareholdersEquityUnaudited", "lang": "en-us", "role": "terseLabel": "Accumulated Other Comprehensive Income (Loss)", "label": "AOCI Attributable to Parent [Member]", "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss) and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners", "auth_ref": "r5", "r17", "r33", "r668", "r674", "r735", "r875", "r876", "r1288", "r1289", "r1290", "r1305", "r1306", "r1307", "r1310", "us-gaap_AccumulatedTranslationAdjustmentMember", "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedTranslationAdjustmentMember", "presentation": "http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureAccumulatedOtherComprehensiveIncomeLossAccumulatedOtherComprehensiveIncomeDetails", "lang": "en-us", "role": "terseLabel": "Foreign Currency Translation Adjustments", "label": "Accumulated Foreign Currency Adjustment Attributable to Parent [Member]", "documentation": "Accumulated other comprehensive income (loss) resulting from foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term investment nature, attributable to the parent", "auth_ref": "r6", "r17", "r33", "r147", "r148", "r281", "r282", "r717", "r718", "r719", "r720", "r721", "r1288", "cgc_AcquiredBrandsMember", "xbrltype": "domainItemType", "nsuri": "http://www.canopygrowth.com/20241231", "localname": "AcquiredBrandsMember", "presentation": "http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureIntangibleAssetsSummaryOfComponentsOfIntangibleAssetsDetails", "lang": "en-us", "role": "terseLabel": "Acquired Brands", "label": "Acquired Brands [Member]", "documentation": "Acquired brands", "auth_ref": "cgc_AcquisitionConsiderationRelatedLiabilities", "xbrltype": "monetaryItemType", "nsuri": "http://www.canopygrowth.com/20241231", "localname": "AcquisitionConsiderationRelatedLiabilities", "crdr": "credit", "presentation": "http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureOtherLiabilitiesComponentsOfOtherLiabilitiesDetails", "lang": "en-us", "role": "terseLabel": "Acquisition consideration and other investment related liabilities", "label": "Acquisition Consideration Related Liabilities", "documentation": "Acquisition consideration related liabilities", "auth_ref": "cgc_AcquisitionConsiderationRelatedLiabilitiesCurrent", "xbrltype": "monetaryItemType", "nsuri": "http://www.canopygrowth.com/20241231", "localname": "AcquisitionConsiderationRelatedLiabilitiesCurrent", "crdr": "credit", "presentation": "http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureOtherLiabilitiesComponentsOfOtherLiabilitiesDetails", "lang": "en-us", "role": "terseLabel": "Acquisition consideration and other investment related liabilities, current", "label": "Acquisition Consideration Related Liabilities Current", "documentation": "Acquisition consideration related liabilities current", "auth_ref": "cgc_AcquisitionConsiderationRelatedLiabilitiesNoncurrent", "xbrltype": "monetaryItemType", "nsuri": "http://www.canopygrowth.com/20241231", "localname": "AcquisitionConsiderationRelatedLiabilitiesNoncurrent", "crdr": "credit", "presentation": "http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureOtherLiabilitiesComponentsOfOtherLiabilitiesDetails", "lang": "en-us", "role": "terseLabel": "Acquisition consideration and other investment related liabilities, long term", "label": "Acquisition Consideration Related Liabilities Noncurrent", "documentation": "Acquisition consideration related liabilities noncurrent", "auth_ref": "cgc_AcreageAcquisitionMember", "xbrltype": "domainItemType", "nsuri": "http://www.canopygrowth.com/20241231", "localname": "AcreageAcquisitionMember", "presentation": "http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureCanopyUsaAdditionalInformationDetails", "lang": "en-us", "role": "documentation": "Acreage acquisition", "label": "Acreage Acquisition [Member]", "terseLabel": "Acreage Acquisition", "auth_ref": "cgc_AcreageDebtMember", "xbrltype": "domainItemType", "nsuri": "http://www.canopygrowth.com/20241231", "localname": "AcreageDebtMember", "presentation": "http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureFairValueOffFinancialInstrumentsSummaryOfValuationTechniquesAndSignificantUnobservableInputsIn", "http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureOtherFinancialAssetsSummaryOfChangesInOtherFinancialAssetsDetails", "lang": "en-us", "role": "documentation": "Acreage debt", "label": "Acreage Debt [Member]", "terseLabel": "Acreage Debt", "auth_ref": "cgc_AcreageDebtOptionAgreementMember", "xbrltype": "domainItemType", "nsuri": "http://www.canopygrowth.com/20241231", "localname": "AcreageDebtOptionAgreementMember", "presentation": "http://www.canopygrowth.com/20241231/taxonomy/role/DisclosureCanopyUsaAcreageAgreementsAdditionalInformationDetails", "http://www.canopygrowth.com/20241231/taxonomy/role/DisclosureCanopyUsaAdditionalInformationDetails", "http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureOtherFinancialAssetsAdditionalInformationDetails", "lang": "en-us", "role": "documentation": "Acreage debt option agreement", "label": "Acreage Debt Option Agreement [Member]", "terseLabel": "Acreage Debt Option Agreement", "auth_ref": "cgc_AcreageDebtOptionPremiumMember", "xbrltype": "domainItemType", "nsuri": "http://www.canopygrowth.com/20241231", "localname": "AcreageDebtOptionPremiumMember", "presentation": "http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureFairValueOffFinancialInstrumentsSummaryOfValuationTechniquesAndSignificantUnobservableInputsIn", "http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureOtherFinancialAssetsSummaryOfChangesInOtherFinancialAssetsDetails", "lang": "en-us", "role": "documentation": "Acreage Debt Option Premium", "label": "Acreage Debt Option Premium [Member]", "terseLabel": "Acreage Debt Option Premium", "auth_ref": "cgc_AcreageDisclosureTextBlock", "xbrltype": "textBlockItemType", "nsuri": "http://www.canopygrowth.com/20241231", "localname": "AcreageDisclosureTextBlock", "presentation": "http://www.canopygrowth.com/20241231/taxonomy/role/DisclosureAcreageArrangement1", "lang": "en-us",
```

"http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureFairValueOffinancialInstrumentsSummaryOfValuationTechniquesAndSignificantUnobservableInputsIn
l,"lang":f"en-us":f"role":f"terseLabel": "Acreage Financial Instrument Market Access Premium", "label": "Acreage Financial Instrument Market Access Premium
[Member]", "documentation": "Acreage financial instrument market access premium." } } }, "auth_ref": f"1", "cgc_AcreageFinancialInstrumentMember": f"xbrltype":
"domainItemtype", "nsuri": "http://www.canopygrowth.com/20241231", "localname": "AcreageFinancialInstrumentMember", "presentation": f"
"http://www.canopygrowth.com/20241231/taxonomy/role/DisclosureAcreageArrangementAdditionalInformationDetails" l,"lang":f"en-us":f"role":f"terseLabel": "Acreage
Financial Instrument", "label": "Acreage Financial Instrument [Member]", "documentation": "Acreage financial instrument." } } }, "auth_ref": f"1",
"cgc_AcreageFinancialInstrumentProbabilityAndTimingOfUSLegalizationMember": f"xbrltype": "domainItemtype", "nsuri": "http://www.canopygrowth.com/20241231",
"localname": "AcreageFinancialInstrumentProbabilityAndTimingOfUSLegalizationMember", "presentation": f"
"http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureFairValueOffinancialInstrumentsSummaryOfValuationTechniquesAndSignificantUnobservableInputsIn
l,"lang":f"en-us":f"role":f"terseLabel": "Acreage Financial Instrument Probability and Timing of US Legalization", "label": "Acreage Financial Instrument Probability And
Timing Of U S Legalization [Member]", "documentation": "Acreage financial instrument probability and timing of us legalization." } } }, "auth_ref": f"1",
"cgc_AcreageFinancialInstrumentProbabilityOfEachScenarioMember": f"xbrltype": "domainItemtype", "nsuri": "http://www.canopygrowth.com/20241231", "localname":
"AcreageFinancialInstrumentProbabilityOfEachScenarioMember", "presentation": f"
"http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureFairValueOffinancialInstrumentsSummaryOfValuationTechniquesAndSignificantUnobservableInputsIn
l,"lang":f"en-us":f"role":f"terseLabel": "Acreage Financial Instrument Probability of Each Scenario", "label": "Acreage Financial Instrument Probability Of Each Scenario
[Member]", "documentation": "Acreage financial instrument probability of each scenario." } } }, "auth_ref": f"1",
"cgc_AcreageFinancialInstrumentValueAndNumberOfCanopySharesIssuedMember": f"xbrltype": "domainItemtype", "nsuri": "http://www.canopygrowth.com/20241231",
"localname": "AcreageFinancialInstrumentValueAndNumberOfCanopySharesIssuedMember", "presentation": f"
"http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureFairValueOffinancialInstrumentsSummaryOfValuationTechniquesAndSignificantUnobservableInputsIn
l,"lang":f"en-us":f"role":f"terseLabel": "Acreage Financial Instrument Value and Number of Canopy Shares Issued", "label": "Acreage Financial Instrument Value And
Number Of Canopy Shares Issued [Member]", "documentation": "Acreage financial instrument value and number of canopy shares issued." } } }, "auth_ref": f"1",
"cgc_AcreageHempco1Member": f"xbrltype": "domainItemtype", "nsuri": "http://www.canopygrowth.com/20241231", "localname": "AcreageHempco1Member",
"presentation": f" http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureOtherFinancialAssetsSummaryOfChangesInOtherFinancialAssetsDetails" l,"lang":f"en-us":f"role":f"terseLabel": "Acreage Hempco1", "label": "Acreage Hempco1 [Member]", "documentation": "Acreage Hempco1." } } }, "auth_ref": f"1",
"cgc_AcreageHoldingsIncMember": f"xbrltype": "domainItemtype", "nsuri": "http://www.canopygrowth.com/20241231", "localname": "AcreageHoldingsIncMember",
"presentation": f" http://www.canopygrowth.com/20241231/taxonomy/role/DisclosureAcreageArrangementAdditionalInformationDetails",
"http://www.canopygrowth.com/20241231/taxonomy/role/DisclosureCanopyUsaAcreageAgreementsAdditionalInformationDetails",
"http://www.canopygrowth.com/20241231/taxonomy/role/DisclosureCanopyUsaAdditionalInformationDetails",
"http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureFairValueOffinancialInstrumentsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtEstimatedFairVa
"http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureOtherFinancialAssetsAdditionalInformationDetails" l,"lang":f"en-us":f"role":f"terseLabel":
"Acreage", "label": "Acreage Holdings Inc [Member]", "documentation": "Acreage Holdings Inc." } } }, "auth_ref": f"1", "cgc_AcreageOneMember": f"xbrltype":
"domainItemtype", "nsuri": "http://www.canopygrowth.com/20241231", "localname": "AcreageOneMember", "presentation": f"
"http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureOtherFinancialAssetsSummaryOfChangesInOtherFinancialAssetsDetails" l,"lang":f"en-us":f"role":
f"terseLabel": "Acreage1", "label": "Acreage One [Member]", "documentation": "Acreage1 member." } } }, "auth_ref": f"1",
"cgc_AcreageTaxReceivableAgreementDiscountedCashFlowMember": f"xbrltype": "domainItemtype", "nsuri": "http://www.canopygrowth.com/20241231", "localname":
"AcreageTaxReceivableAgreementDiscountedCashFlowMember", "presentation": f"
"http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureFairValueOffinancialInstrumentsSummaryOfValuationTechniquesAndSignificantUnobservableInputsIn
l,"lang":f"en-us":f"role":f"terseLabel": "Acreage Tax Receivable Agreement Discounted Cash Flow", "label": "Acreage Tax Receivable Agreement Discounted Cash Flow
[Member]", "documentation": "Acreage tax receivable agreement discounted cash flow." } } }, "auth_ref": f"1", "cgc_AcreageTaxReceivableAgreementMember": f"xbrltype":
"domainItemtype", "nsuri": "http://www.canopygrowth.com/20241231", "localname": "AcreageTaxReceivableAgreementMember", "presentation": f"
"http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureOtherFinancialAssetsSummaryOfChangesInOtherFinancialAssetsDetails" l,"lang":f"en-us":f"role":
f"documentation": "Acreage Tax Receivable Agreement.", "label": "Acreage Tax Receivable Agreement [Member]", "terseLabel": "Acreage Tax Receivable Agreement" } } },
"auth_ref": f"1", "cgc_AcreageTaxReceivableAgreementProbabilityAndTimingOfUSLegalizationMember": f"xbrltype": "domainItemtype", "nsuri":
"http://www.canopygrowth.com/20241231", "localname": "AcreageTaxReceivableAgreementProbabilityAndTimingOfUSLegalizationMember", "presentation": f"
"http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureFairValueOffinancialInstrumentsSummaryOfValuationTechniquesAndSignificantUnobservableInputsIn
l,"lang":f"en-us":f"role":f"terseLabel": "Acreage Tax Receivable Agreement Probability and Timing of US Legalization", "label": "Acreage tax receivable agreement
probability and timing of U S legalization [Member]", "documentation": "Acreage tax receivable agreement probability and timing of US legalization." } } }, "auth_ref": f"1",
"cgc_AcreageTaxReceivableAgreementProbabilityWeightedExpectedReturnModelMember": f"xbrltype": "domainItemtype", "nsuri":
"http://www.canopygrowth.com/20241231", "localname": "AcreageTaxReceivableAgreementProbabilityWeightedExpectedReturnModelMember", "presentation": f"
"http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureFairValueOffinancialInstrumentsSummaryOfValuationTechniquesAndSignificantUnobservableInputsIn
l,"lang":f"en-us":f"role":f"terseLabel": "Acreage Tax Receivable Agreement Probability-weighted Expected Return Model", "label": "Acreage Tax Receivable Agreement
Probability Weighted Expected Return Model [Member]", "documentation": "Acreage tax receivable agreement probability weighted expected return model." } } }, "auth_ref":
f"1", "ecd_Additional402vDisclosureTextBlock": f"xbrltype": "textBlockItemtype", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Additional402vDisclosureTextBlock",
"presentation": f" http://xbrl.sec.gov/ecd/role/PvpDisclosure" l,"lang":f"en-us":f"role":f"label": "Additional 402(v) Disclosure [Text Block]", "terseLabel": "Additional
402(v) Disclosure" } } }, "auth_ref": f"r1211" } }, "cgc_AdditionalConvertibleDebenturesAmountPurchasedInTheEventOfCertainConditionsAreSatisfiedOrWaived": f"xbrltype":
"monetaryItemtype", "nsuri": "http://www.canopygrowth.com/20241231", "localname":
"AdditionalConvertibleDebenturesAmountPurchasedInTheEventOfCertainConditionsAreSatisfiedOrWaived", "crdr": "credit", "presentation": f"
"http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails" l,"lang":f"en-us":f"role":f"terseLabel": "Additional
convertible debentures amount purchased in the event of certain conditions are satisfied or waived", "label": "Additional convertible debentures amount purchased in the event
of certain conditions are satisfied or waived", "documentation": "Additional convertible debentures amount purchased in the event of certain conditions are satisfied or waived."
} } }, "auth_ref": f"1", "cgc_AdditionalIncrementalSeniorSecuredDebt": f"xbrltype": "monetaryItemtype", "nsuri": "http://www.canopygrowth.com/20241231", "localname":
"AdditionalIncrementalSeniorSecuredDebt", "crdr": "credit", "presentation": f"
"http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails" l,"lang":f"en-us":f"role":f"terseLabel": "Senior credit
facility", "label": "Additional Incremental Senior Secured Debt", "documentation": "Additional incremental debt." } } }, "auth_ref": f"1",
"cgc_AdditionalIncrementalTermLoanFacility": f"xbrltype": "monetaryItemtype", "nsuri": "http://www.canopygrowth.com/20241231", "localname":
"AdditionalIncrementalTermLoanFacility", "crdr": "credit", "presentation": f"
"http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails" l,"lang":f"en-us":f"role":f"terseLabel": "Additional
incremental term loan facility", "label": "Additional Incremental Term Loan Facility", "documentation": "Additional incremental term loan facility." } } }, "auth_ref": f"1", "us-
gaap_AdditionalPaidInCapital": f"xbrltype": "monetaryItemtype", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdditionalPaidInCapital", "crdr": "credit",
"presentation": f" http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureBasisOfPresentationAdditionalInformationDetails" l,"lang":f"en-us":f"role":f"
"totalLabel": "Additional Paid in Capital, Total", "terseLabel": "Additional paid in capital", "label": "Additional Paid in Capital", "documentation": "Amount of excess of issue
price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common
and preferred stock." } } }, "auth_ref": f"r136", "r1147", "r1477" } }, "us-gaap_AdditionalPaidInCapitalCommonStock": f"xbrltype": "monetaryItemtype", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "AdditionalPaidInCapitalCommonStock", "crdr": "credit", "presentation": f"
"http://www.canopygrowth.com/20241231/taxonomy/role/Role_StatementCondensedInterimConsolidatedBalanceSheetsUnaudited" l,"lang":f"en-us":f"role":f"terseLabel":
"Additional paid-in capital", "label": "Additional Paid in Capital, Common Stock", "documentation": "Value received from shareholders in common stock-related transactions
that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock
transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital." } } }, "auth_ref": f"r136" } }, "us-
gaap_AdditionalPaidInCapitalMember": f"xbrltype": "domainItemtype", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdditionalPaidInCapitalMember",
"presentation": f" http://www.canopygrowth.com/20241231/taxonomy/role/Role_StatementCondensedInterimConsolidatedStatementsOfShareholderSEquityUnaudited" l,
"lang":f"en-us":f"role":f"terseLabel": "Additional Paid in capital", "label": "Additional Paid-in Capital [Member]", "documentation": "Excess of issue price over par or
stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders." } } }, "auth_ref": f"r999", "r1305",
"r1306", "r1307", "r1310", "r1410", "r1479" } }, "ecd_AdjToCompAmt": f"xbrltype": "monetaryItemtype", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"AdjToCompAmt", "presentation": f" http://xbrl.sec.gov/ecd/role/PvpDisclosure" l,"lang":f"en-us":f"role":f"label": "Adjustment to Compensation Amount", "terseLabel":
"Adjustment to Compensation, Amount" } } }, "auth_ref": f"r1224" } }, "ecd_AdjToCompAxis": f"xbrltype": "stringItemtype", "nsuri": "http://xbrl.sec.gov/ecd/2024",
"localname": "AdjToCompAxis", "presentation": f" http://xbrl.sec.gov/ecd/role/PvpDisclosure" l,"lang":f"en-us":f"role":f"label": "Adjustment to Compensation [Axis]",
"terseLabel": "Adjustment to Compensation", "documentation": "Adjustment to Compensation." } } }, "auth_ref": f"r1224" } }, "ecd_AdjToNonPeeoCompFnTextBlock": f"xbrltype": "textBlockItemtype", "nsuri":
"http://xbrl.sec.gov/ecd/2024", "localname": "AdjToNonPeeoCompFnTextBlock", "presentation": f" http://xbrl.sec.gov/ecd/role/PvpDisclosure" l,"lang":f"en-us":f"role":f"
"label": "Adjustment to Non-PEO-NEO Compensation Footnote [Text Block]", "terseLabel": "Adjustment to Non-PEO-NEO Compensation Footnote" } } }, "auth_ref": f"r1224" l,
"ecd_AdjToPeeoCompFnTextBlock": f"xbrltype": "textBlockItemtype", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToPeeoCompFnTextBlock", "presentation": f"
"http://xbrl.sec.gov/ecd/role/PvpDisclosure" l,"lang":f"en-us":f"role":f"label": "Adjustment To PEO Compensation, Footnote [Text Block]", "terseLabel": "Adjustment To
PEO Compensation, Footnote" } } }, "auth_ref": f"r1224" } }, "us-gaap_AdjustmentForAmortization": f"xbrltype": "monetaryItemtype", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "AdjustmentForAmortization", "crdr": "debit", "presentation": f"
"http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails" l,"lang":f"en-us":f"role":f"totalLabel": "Amortization, Total",
"terseLabel": "Loan amortization payment", "label": "Amortization", "documentation": "The aggregate amount of recurring noncash expense charged against earnings in the
period to allocate the cost of assets over their estimated remaining economic lives." } } }, "auth_ref": f"r11" } },
"cgc_AdjustmentsToAdditionalPaidInCapitalExtinguishmentOfPromissoryNoteAndIssuanceOfExchangeableShares": f"xbrltype": "monetaryItemtype", "nsuri":
"http://www.canopygrowth.com/20241231", "localname": "AdjustmentsToAdditionalPaidInCapitalExtinguishmentOfPromissoryNoteAndIssuanceOfExchangeableShares",
"crdr": "credit", "presentation": f"
"http://www.canopygrowth.com/20241231/taxonomy/role/Role_StatementCondensedInterimConsolidatedStatementsOfShareholderSEquityUnaudited" l,"lang":f"en-us":f"
"role":f"documentation": "Adjustments to additional paid in capital extinguishment of promissory note and issuance of exchangeable shares.", "label": "Adjustments To
Additional Paid In Capital Extinguishment Of Promissory Note And Issuance Of Exchangeable Shares", "terseLabel": "Extinguishment of promissory note and issuance of
exchangeable shares" } } }, "auth_ref": f"1", "cgc_AdjustmentsToAdditionalPaidInCapitalOtherIssuancesOfCommonSharesAndShareIssueCosts": f"xbrltype":
"monetaryItemtype", "nsuri": "http://www.canopygrowth.com/20241231", "localname":
"AdjustmentsToAdditionalPaidInCapitalOtherIssuancesOfCommonSharesAndShareIssueCosts", "crdr": "credit", "presentation": f"
"http://www.canopygrowth.com/20241231/taxonomy/role/Role_StatementCondensedInterimConsolidatedStatementsOfShareholderSEquityUnaudited" l,"lang":f"en-us":f"
"role":f"documentation": "Adjustments to additional paid in capital other issuances of common shares and share issue costs.", "label": "Adjustments To Additional Paid In
Capital Other Issuances Of Common Shares And Share Issue Costs", "terseLabel": "Other issuances of common shares warrants and share issue costs" } } }, "auth_ref": f"1",
"cgc_AdjustmentsToAdditionalPaidInCapitalOtherIssuancesOfCommonSharesAndWarrantsValue": f"xbrltype": "monetaryItemtype", "nsuri":
"http://www.canopygrowth.com/20241231", "localname": "AdjustmentsToAdditionalPaidInCapitalOtherIssuancesOfCommonSharesAndWarrantsValue", "crdr": "credit",
"presentation": f" http://www.canopygrowth.com/20241231/taxonomy/role/Role_StatementCondensedInterimConsolidatedStatementsOfShareholderSEquityUnaudited" l,
"lang":f"en-us":f"role":f"terseLabel": "Other issuances of common shares and warrants", "label": "Adjustments To Additional Paid In Capital Other Issuances Of Common
Shares And Warrants Value", "documentation": "Adjustments to additional paid in capital other issuances of common shares and warrants value." } } }, "auth_ref": f"1",
"cgc_AdjustmentsToAdditionalPaidInCapitalPrivatePlacement": f"xbrltype": "monetaryItemtype", "nsuri": "http://www.canopygrowth.com/20241231", "localname":
"AdjustmentsToAdditionalPaidInCapitalPrivatePlacement", "crdr": "debit", "presentation": f"

"AdjustmentsToAdditionalPaidInCapitalPrivatePlacement", "crdr": "credit", "presentation": "http://www.canopygrowth.com/20241231/taxonomy/role/Role-StatementCondensedInterimConsolidatedStatementsOfShareholderSEquityUnaudited", "lang": "en-us", "role": "documentation", "Adjustments to additional paid in capital private placement", "label": "Adjustments to additional paid in capital private placement", "terseLabel": "Private Placement", "auth_ref": "http://www.canopygrowth.com/20241231/taxonomy/role/Role-StatementCondensedInterimConsolidatedStatementsOfShareholderSEquityUnaudited", "xbrltype": "monetaryItemType", "nsuri": "http://www.canopygrowth.com/20241231", "localname": "AdjustmentsToAdditionalPaidInCapitalPrivatePlacementNetOfIssuanceCosts", "crdr": "credit", "presentation": "http://www.canopygrowth.com/20241231/taxonomy/role/Role-StatementCondensedInterimConsolidatedStatementsOfShareholderSEquityUnaudited", "lang": "en-us", "role": "documentation", "Adjustments to additional paid in capital private placement net of issuance costs", "label": "Adjustments To Additional Paid In Capital Private Placement Net Of Issuance Costs", "verboseLabel": "Private Placement, net of issuance costs", "auth_ref": "http://www.us-gaap.org/us-gaap/2024", "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "crdr": "credit", "presentation": "http://www.canopygrowth.com/20241231/taxonomy/role/Role-StatementCondensedInterimConsolidatedStatementsOfShareholderSEquityUnaudited", "lang": "en-us", "role": "totalLabel", "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition, Total", "terseLabel": "Share-based compensation", "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition", "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement", "auth_ref": "r573", "r74", "r574", "us-gaap-AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": "http://www.canopygrowth.com/20241231/taxonomy/role/Role-StatementCondensedInterimConsolidatedStatementsOfCashFlowsUnaudited", "lang": "en-us", "role": "terseLabel", "Adjustments to reconcile net loss to net cash used in operating activities", "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]", "auth_ref": "http://www.canopygrowth.com/20241231/taxonomy/role/Role-StatementCondensedInterimConsolidatedStatementsOfCashFlowsUnaudited", "xbrltype": "perShareItemType", "nsuri": "http://www.canopygrowth.com/20241231", "localname": "AggregateExercisePriceOfCommonShares", "presentation": "http://www.canopygrowth.com/20241231/taxonomy/role/DisclosureCanopyUsaAdditionalInformationDetails", "lang": "en-us", "role": "terseLabel", "Aggregate exercise price of common shares", "label": "Aggregate Exercise Price of Common Shares", "documentation": "Aggregate exercise price of common shares", "auth_ref": "http://www.canopygrowth.com/20241231/taxonomy/role/DisclosureCanopyUsaAdditionalInformationDetails", "localname": "AggregateInvestmentAmount", "xbrltype": "monetaryItemType", "nsuri": "http://www.canopygrowth.com/20241231/taxonomy/role/DisclosureCanopyUsaAdditionalInformationDetails", "lang": "en-us", "role": "terseLabel", "Aggregate investment amount", "label": "Aggregate Investment Amount", "documentation": "Aggregate investment amount", "auth_ref": "http://www.canopygrowth.com/20241231/taxonomy/role/DisclosureCanopyUsaAdditionalInformationDetails", "localname": "AggregatePrincipalAmountOfDebentures", "crdr": "debit", "presentation": "http://www.canopygrowth.com/20241231/taxonomy/role/DisclosureDebtAdditionalInformationDetails", "lang": "en-us", "role": "terseLabel", "Aggregate principal amount of debentures", "label": "Aggregate principal amount of debentures", "documentation": "Aggregate principal amount of debentures", "auth_ref": "http://www.canopygrowth.com/20241231/taxonomy/role/DisclosureDebtAdditionalInformationDetails", "localname": "AggregateValueOfSharesIssuedInTwoTranches", "xbrltype": "monetaryItemType", "nsuri": "http://www.canopygrowth.com/20241231/taxonomy/role/DisclosureValueOfSharesIssuedInTwoTranches", "crdr": "credit", "presentation": "http://www.canopygrowth.com/20241231/taxonomy/role/DisclosureCanopyUsaAdditionalInformationDetails", "lang": "en-us", "role": "terseLabel", "Aggregate value of shares issued in two tranches", "label": "Aggregate Value Of Shares Issued In Two Tranches", "documentation": "Aggregate value of shares issued in two tranches", "auth_ref": "http://www.canopygrowth.com/20241231/taxonomy/role/DisclosureCanopyUsaAdditionalInformationDetails", "localname": "AggtChngPnsnValInSummryCompstnTblForApblYrMember", "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtChngPnsnValInSummryCompstnTblForApblYrMember", "presentation": "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "lang": "en-us", "role": "label", "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]", "terseLabel": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table", "auth_ref": "r1257", "ecd-AggtErrCompAmt", "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtErrCompAmt", "presentation": "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "lang": "en-us", "role": "label", "Aggregate Erroneous Compensation Amount", "terseLabel": "Aggregate Erroneous Compensation Amount", "auth_ref": "r1183", "r1193", "r1203", "r1235", "ecd-AggtErrCompNotYetDeterminedTextBlock", "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtErrCompNotYetDeterminedTextBlock", "presentation": "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "lang": "en-us", "role": "label", "Aggregate Erroneous Compensation Not Yet Determined [Text Block]", "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined", "auth_ref": "r1186", "r1196", "r1206", "r1238", "ecd-AggtPnsnAdjSvcCstMember", "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtPnsnAdjSvcCstMember", "presentation": "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "lang": "en-us", "role": "label", "Aggregate Pension Adjustments Service Cost [Member]", "terseLabel": "Aggregate Pension Adjustments Service Cost", "auth_ref": "r1258", "ecd-AllAdjToCompMember", "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllAdjToCompMember", "presentation": "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "lang": "en-us", "role": "label", "All Adjustments to Compensation [Member]", "terseLabel": "All Adjustments to Compensation", "auth_ref": "r1224", "ecd-AllExecutiveCategoriesMember", "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllExecutiveCategoriesMember", "presentation": "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "lang": "en-us", "role": "label", "All Executive Categories [Member]", "terseLabel": "All Executive Categories", "auth_ref": "r1231", "ecd-AllIndividualsMember", "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllIndividualsMember", "presentation": "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "lang": "en-us", "role": "label", "All Individuals [Member]", "terseLabel": "All Individuals", "auth_ref": "r1187", "r1197", "r1207", "r1231", "r1239", "r1243", "r1251", "us-gaap-AllOtherSegmentsMember", "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AllOtherSegmentsMember", "presentation": "http://www.canopygrowth.com/20241231/taxonomy/role/Role-DisclosureSegmentInformationSummaryOfReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedDel", "lang": "en-us", "role": "terseLabel", "Other", "label": "Other Operating Segment [Member]", "documentation": "Operating segments classified as other. Excludes intersegment elimination and reconciling items", "auth_ref": "r334", "r354", "r355", "r356", "r357", "r358", "r361", "r1100", "r1101", "ecd-AllTradingArrangementsMember", "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllTradingArrangementsMember", "presentation": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "lang": "en-us", "role": "label", "All Trading Arrangements [Member]", "terseLabel": "All Trading Arrangements", "auth_ref": "r1249", "us-gaap-AllocatedShareBasedCompensationExpense", "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AllocatedShareBasedCompensationExpense", "crdr": "debit", "presentation": "http://www.canopygrowth.com/20241231/taxonomy/role/Role-DisclosureShareBasedCompensationAdditionalInformationDetails", "lang": "en-us", "role": "terseLabel", "Share-based compensation expense", "label": "Share-Based Payment Arrangement, Expense", "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized", "auth_ref": "r603", "r607", "us-gaap-AllowanceForDoubtfulAccountsReceivableCurrent", "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AllowanceForDoubtfulAccountsReceivableCurrent", "crdr": "credit", "presentation": "http://www.canopygrowth.com/20241231/taxonomy/role/Role-DisclosureAmountsReceivableNetAdditionalInformationDetails", "lang": "en-us", "role": "terseLabel", "Allowance for doubtful accounts", "label": "Accounts Receivable, Allowance for Credit Loss, Current", "documentation": "Amount of allowance for credit loss on accounts receivable, classified as current", "auth_ref": "r265", "r372", "r421", "ecg-AllowanceForEstimatedReturnsAndPriceAdjustments", "xbrltype": "monetaryItemType", "nsuri": "http://www.canopygrowth.com/20241231", "localname": "AllowanceForEstimatedReturnsAndPriceAdjustments", "crdr": "credit", "presentation": "http://www.canopygrowth.com/20241231/taxonomy/role/Role-DisclosureRevenueAdditionalInformationDetails", "lang": "en-us", "role": "terseLabel", "Allowance for estimated returns and price adjustments", "label": "Allowance For Estimated Returns And Price Adjustments", "documentation": "Allowance for estimated returns and price adjustments", "auth_ref": "http://www.canopygrowth.com/20241231/taxonomy/role/Role-DisclosureDocumentAndEntityInformation", "lang": "en-us", "role": "terseLabel", "Amendment", "verboseLabel": "Amendment Flag", "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission", "auth_ref": "http://www.canopygrowth.com/20241231", "localname": "AmortizableIntangiblesInProcessMember", "xbrltype": "domainItemType", "nsuri": "http://www.canopygrowth.com/20241231", "localname": "AmortizableIntangiblesInProcessMember", "presentation": "http://www.canopygrowth.com/20241231/taxonomy/role/Role-DisclosureIntangibleAssetsSummaryOfComponentsOfIntangibleAssetsDetails", "lang": "en-us", "role": "terseLabel", "Amortizable intangibles in process", "label": "Amortizable Intangibles In Process [Member]", "documentation": "Amortizable intangibles in process", "auth_ref": "http://www.us-gaap.org/us-gaap/2024", "localname": "AmortizationOfIntangibleAssets", "crdr": "debit", "presentation": "http://www.canopygrowth.com/20241231/taxonomy/role/Role-StatementCondensedInterimConsolidatedStatementsOfCashFlowsUnaudited", "lang": "en-us", "role": "terseLabel", "Amortization of intangible assets", "label": "Amortization of Intangible Assets", "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method", "auth_ref": "r11", "r454", "r461", "r1108", "ecg-AmountOffloatingSharesIssuedForSecondPayment", "xbrltype": "monetaryItemType", "nsuri": "http://www.canopygrowth.com/20241231", "localname": "AmountOffloatingSharesIssuedForSecondPayment", "crdr": "credit", "presentation": "http://www.canopygrowth.com/20241231/taxonomy/role/DisclosureCanopyUsaAcreegeAgreementsAdditionalInformationDetails", "lang": "en-us", "role": "terseLabel", "Amount of floating shares issued for second payment", "label": "Amount Of Floating Shares Issued For Second Payment", "documentation": "Amount of floating shares issued for second payment", "auth_ref": "http://www.canopygrowth.com/20241231", "localname": "AmountOffloatingSharesIssuedInFirstInstallment", "xbrltype": "monetaryItemType", "nsuri": "http://www.canopygrowth.com/20241231", "localname": "AmountOffloatingSharesIssuedInFirstInstallment", "crdr": "credit", "presentation": "http://www.canopygrowth.com/20241231/taxonomy/role/DisclosureCanopyUsaAcreegeAgreementsAdditionalInformationDetails", "lang": "en-us", "role": "terseLabel", "Amount of floating shares issued in first installment", "label": "Amount Of Floating Shares Issued In First Installment", "documentation": "Amount of floating shares issued in first installment", "auth_ref": "http://www.us-gaap.org/us-gaap/2024", "localname": "April2024ExchangeAgreementMember", "xbrltype": "domainItemType", "nsuri": "http://www.canopygrowth.com/20241231", "localname": "April2024ExchangeAgreementMember", "presentation": "http://www.canopygrowth.com/20241231/taxonomy/role/Role-DisclosureDebtAdditionalInformationDetails", "lang": "en-us", "role": "documentation", "April 2024 exchange agreement", "label": "April 2024 Exchange Agreement [Member]", "terseLabel": "April 2024 Exchange Agreement", "auth_ref": "http://www.canopygrowth.com/20241231/taxonomy/role/Role-DisclosureAriseBioscienceTermLoanMember", "xbrltype": "domainItemType", "nsuri": "http://www.canopygrowth.com/20241231", "localname": "AriseBioscienceTermLoanMember", "presentation": "http://www.canopygrowth.com/20241231/taxonomy/role/Role-DisclosureFairValueOffinancialInstrumentsSummaryOfValuationTechniquesAndSignificantUnobservableInputsIn", "lang": "en-us", "role": "terseLabel", "Arise Bioscience term loan", "label": "Arise Bioscience Term Loan [Member]", "documentation": "Arise bioscience term loan member", "auth_ref": "http://www.us-gaap.org/us-gaap/2024", "localname": "ArrangementsAndNonarrangementTransactionsMember", "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ArrangementsAndNonarrangementTransactionsMember", "presentation": "http://www.canopygrowth.com/20241231/taxonomy/role/DisclosureShareCapitalAdditionalInformationDetails", "http://www.canopygrowth.com/20241231/taxonomy/role/DisclosureCanopyUsaAdditionalInformationDetails", "http://www.canopygrowth.com/20241231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails", "http://www.canopygrowth.com/20241231/taxonomy/role/Role-DisclosureBasisOfPresentationAdditionalInformationDetails", "http://www.canopygrowth.com/20241231/taxonomy/role/Role-DisclosureDebtAdditionalInformationDetails", "http://www.canopygrowth.com/20241231/taxonomy/role/Role-DisclosureShareCapitalAdditionalInformationDetails", "lang": "en-us", "role": "terseLabel", "Collaborative Arrangement and Arrangement Other than Collaborative", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]", "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations", "auth_ref": "r654", "us-gaap-AssetBackedSecuritiesMember", "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetBackedSecuritiesMember", "presentation": "http://www.canopygrowth.com/20241231/taxonomy/role/Role-DisclosureShortTermInvestmentsComponentsOfShortTermInvestmentsDetails", "lang": "en-us", "role": "terseLabel", "Asset-backed securities", "label": "Asset-Backed Securities [Member]", "documentation": "Securities that are primarily serviced by the cash flows of a discrete

pool of receivables or other financial assets for example, but not limited to: credit card receivables, car loans, recreational vehicle loans, and mobile home loans." } } }
"auth_ref": f"r123" f"r148" f"r1322" f"r1323" f"r1324" } } }
"us-gaap_AssetUnderConstructionMember": f"xrbltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetUnderConstructionMember", "presentation": f
"http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosurePropertyPlantAndEquipmentScheduleOfComponentsOfPropertyPlantAndEquipmentDetails" } } }
"en-us": f"role": f"terseLabel": "Assets in Process", "label": "Asset under Construction {Member}", "documentation": "Asset in process of being built." } } }
"auth_ref": f
"us-gaap_Assets": f"xrbltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Assets", "crdr": "debit", "presentation": f
"http://www.canopygrowth.com/20241231/taxonomy/role/Role_StatementCondensedInterimConsolidatedBalanceSheetsUnaudited" } } }
"en-us": f"role": f"totalLabel":
"Total assets", "label": "Assets", "documentation": "Amount of asset recognized for present right to economic benefit." } } }
"auth_ref": f"r205" f"r224" f"r257" f"r296"
"r329" f"r337" f"r356" f"r360" f"r409" f"r496" f"r497" f"r498" f"r499" f"r500" f"r501" f"r502" f"r503" f"r504" f"r656" f"r662" f"r713" f"r825" f"r944" f"r1100" f"r1101" f"r1147"
"r1174" f"r1366" f"r1367" f"r1429" } } }
"us-gaap_AssetsAbstract": f"xrbltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsAbstract"
"presentation": f"http://www.canopygrowth.com/20241231/taxonomy/role/Role_StatementCondensedInterimConsolidatedBalanceSheetsUnaudited" } } }
"en-us": f
"role": f"terseLabel": "ASSETS", "label": "Assets {Abstract}" } } }
"auth_ref": f
"us-gaap_AssetsCurrent": f"xrbltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsCurrent", "crdr": "debit", "presentation": f
"http://www.canopygrowth.com/20241231/taxonomy/role/Role_StatementCondensedInterimConsolidatedBalanceSheetsUnaudited" } } }
"en-us": f"role": f"totalLabel":
"Total current assets", "label": "Assets, Current", "documentation": "Amount of asset recognized for present right to economic benefit, classified as current." } } }
"auth_ref": f"r250" f"r269" f"r296" f"r409" f"r496" f"r497" f"r498" f"r499" f"r500" f"r501" f"r502" f"r503" f"r504" f"r656" f"r662" f"r713" f"r1147" f"r1366" f"r1367" f"r1429" } } }
"us-gaap_AssetsCurrentAbstract": f"xrbltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsCurrentAbstract", "presentation": f
"http://www.canopygrowth.com/20241231/taxonomy/role/Role_StatementCondensedInterimConsolidatedBalanceSheetsUnaudited" } } }
"en-us": f"role": f"terseLabel":
"Current assets", "label": "Assets, Current {Abstract}" } } }
"auth_ref": f
"us-gaap_AssetsFairValueDisclosureAbstract": f"xrbltype": "stringItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "AssetsFairValueDisclosureAbstract", "presentation": f
"http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtEstimatedFairVa
l." } } }
"en-us": f"role": f"terseLabel": "Assets, Fair Value Disclosure {Abstract}" } } }
"auth_ref": f
"us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation": f"xrbltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"AssetsOfDisposalGroupIncludingDiscontinuedOperation", "crdr": "debit", "presentation": f
"http://www.canopygrowth.com/20241231/taxonomy/role/DisclosureBiosteelSummaryOfAssetsAndLiabilitiesClassifiedAsDiscontinuedOperationsAndMajorCategoriesDetails"
"http://www.canopygrowth.com/20241231/taxonomy/role/DisclosureCanopyUsaSummaryOfDerecognizedAssetsAndLiabilitiesTransferredDetails" } } }
"en-us": f"role": f"totalLabel":
"Total assets of discontinued operations", "label": "Disposal Group, Including Discontinued Operation, Assets", "terseLabel": "Net assets disposed",
"documentation": "Amount classified as assets attributable to disposal group held for sale or disposed of." } } }
"auth_ref": f"r4" f"r103" f"r117" f"r180" f"r248" f"r249" } } }
"us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent": f"xrbltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent", "crdr": "debit", "presentation": f
"http://www.canopygrowth.com/20241231/taxonomy/role/Role_StatementCondensedInterimConsolidatedBalanceSheetsUnaudited" } } }
"en-us": f"role": f"totalLabel":
"Disposal Group, Including Discontinued Operation, Assets, Current, Total", "label": "Disposal Group, Including Discontinued Operation, Assets, Current", "terseLabel":
"Current assets", "verboseLabel": "Assets of discontinued operations", "documentation": "Amount classified as assets attributable to disposal group held for sale or disposed
of, expected to be disposed of within one year or the normal operating cycle, if longer." } } }
"auth_ref": f"r4" f"r103" f"r117" f"r176" f"r180" f"r248" f"r249" } } }
"cgc_AtTheMarketEquityProgramMember": f"xrbltype": "domainItemType", "nsuri": "http://www.canopygrowth.com/20241231", "localname":
"AtTheMarketEquityProgramMember", "presentation": f"http://www.canopygrowth.com/20241231/taxonomy/role/DisclosureCanopyUsaAdditionalInformationDetails",
"http://www.canopygrowth.com/20241231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails",
"http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureBasisOfPresentationAdditionalInformationDetails",
"http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureShareCapitalAdditionalInformationDetails",
"http://www.canopygrowth.com/20241231/taxonomy/role/Role_StatementCondensedInterimConsolidatedStatementsOfShareholderSEquityUnaudited" } } }
"en-us": f"role": f"documentation": "At the market equity program.", "label": "At The Market Equity Program {Member}", "terseLabel": "ATM Program" } } }
"auth_ref": f
"cgc_AugustTwentyTwentyFourSupremeConvertibleDebtExchangeMember": f"xrbltype": "domainItemType", "nsuri": "http://www.canopygrowth.com/20241231", "localname":
"AugustTwentyTwentyFourSupremeConvertibleDebtExchangeMember", "presentation": f
"http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails" } } }
"en-us": f"role": f"terseLabel": "August 2024
Supreme Convertible Debt Exchange", "label": "August Twenty Twenty Four Supreme Convertible Debt Exchange {Member}", "documentation": "August 2024 Supreme
Convertible Debt Exchange." } } }
"auth_ref": f
"us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": f"xrbltype": "monetaryItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis", "crdr": "debit", "presentation": f
"http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureShortTermInvestmentsAdditionalInformationDetails" } } }
"en-us": f"role": f"totalLabel":
"Debt Securities, Available for Sale, Amortized Cost, Total", "terseLabel": "Amortized cost of short-term investments", "label": "Debt Securities, Available for Sale, Amortized
Cost", "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available
for sale)." } } }
"auth_ref": f"r374" f"r427" f"r824" } } }
"cgc_AverageClosingTradingPriceOfCommonShares": f"xrbltype": "perShareItemType", "nsuri":
"http://www.canopygrowth.com/20241231", "localname": "AverageClosingTradingPriceOfCommonShares", "presentation": f
"http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails" } } }
"en-us": f"role": f"documentation": "Average closing
trading price of common shares.", "label": "Average Closing Trading Price of Common Shares", "terseLabel": "Average closing trading price of common shares" } } }
"auth_ref": f
"cgc_AverageExercisePriceOnIssuanceOfReplacementWarrantsResultingFromAcreageAcquisition": f"xrbltype": "perShareItemType", "nsuri":
"http://www.canopygrowth.com/20241231", "localname": "AverageExercisePriceOnIssuanceOfReplacementWarrantsResultingFromAcreageAcquisition", "presentation": f
"http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureShareCapitalSummaryOfWarrantsDetails" } } }
"en-us": f"role": f"label": "Average Exercise
Price on Issuance of Replacement Warrants Resulting from Acreage Acquisition", "terseLabel": "Average exercise price, Issuance of replacement warrants resulting from the
Acreage Acquisition", "documentation": "Average exercise price on issuance of replacement warrants resulting from acreage acquisition." } } }
"auth_ref": f
"cgc_AverageExercisePriceOnIssuanceOfReplacementWarrantsResultingFromAcreageTransaction": f"xrbltype": "perShareItemType", "nsuri":
"http://www.canopygrowth.com/20241231", "localname": "AverageExercisePriceOnIssuanceOfReplacementWarrantsResultingFromAcreageTransaction", "presentation": f
"http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureShareCapitalSummaryOfWarrantsDetails" } } }
"en-us": f"role": f"label": "Average Exercise
Price On Issuance of Replacement Warrants Resulting from Acreage Transaction", "documentation": "Average exercise price on issuance of replacement warrants resulting
from acreage transaction.", "terseLabel": "Average exercise price, Issuance of replacement warrants resulting from the Acreage Transaction" } } }
"auth_ref": f
"cgc_AverageExercisePriceOnIssuanceOfWarrants": f"xrbltype": "perShareItemType", "nsuri": "http://www.canopygrowth.com/20241231", "localname":
"AverageExercisePriceOnIssuanceOfWarrants", "presentation": f
"http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureShareCapitalSummaryOfWarrantsDetails" } } }
"en-us": f"role": f"terseLabel": "Average
exercise price, Issuance of warrants", "label": "Average Exercise Price On Issuance Of Warrants", "documentation": "Average exercise price on issuance of warrants." } } }
"auth_ref": f
"cgc_AverageExercisePriceOnIssuanceOfWarrantsFromPrivatePlacement": f"xrbltype": "perShareItemType", "nsuri":
"http://www.canopygrowth.com/20241231", "localname": "AverageExercisePriceOnIssuanceOfWarrantsFromPrivatePlacement", "presentation": f
"http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureShareCapitalSummaryOfWarrantsDetails" } } }
"en-us": f"role": f"terseLabel": "Average
exercise price, Issuance of warrants from private placement", "label": "Average Exercise Price On Issuance Of Warrants From Private Placement", "documentation": "Average
exercise price on issuance of warrants from private placement." } } }
"auth_ref": f
"cgc_AverageExercisePriceOnWarrantExercised": f"xrbltype": "perShareItemType", "nsuri": "http://www.canopygrowth.com/20241231", "localname":
"AverageExercisePriceOnWarrantExercised", "presentation": f
"http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureShareCapitalSummaryOfWarrantsDetails" } } }
"en-us": f"role": f"terseLabel": "Average
exercise price, Exercise of warrants", "label": "Average Exercise Price On Warrant Exercised", "documentation": "Average exercise price on warrants exercised." } } }
"auth_ref": f
"cgc_AverageExercisePriceOnWarrantExpiry": f"xrbltype": "perShareItemType", "nsuri": "http://www.canopygrowth.com/20241231", "localname":
"AverageExercisePriceOnWarrantExpiry", "presentation": f"http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureShareCapitalSummaryOfWarrantsDetails"
l." } } }
"en-us": f"role": f"terseLabel": "Average exercise price, Expiry of warrants", "label": "Average Exercise Price On Warrant Expiry", "documentation": "Average
Exercise Price On Warrant Expiry." } } }
"auth_ref": f
"ecd_AwardExrcPrice": f"xrbltype": "perShareItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"AwardExrcPrice", "presentation": f"http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" } } }
"en-us": f"role": f"label": "Award Exercise Price", "terseLabel": "Exercise
Price" } } }
"auth_ref": f"r1246" } } }
"ecd_AwardGrantDateFairValue": f"xrbltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"AwardGrantDateFairValue", "presentation": f"http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" } } }
"en-us": f"role": f"label": "Award Grant Date Fair Value",
"terseLabel": "Fair Value as of Grant Date" } } }
"auth_ref": f"r1247" } } }
"ecd_AwardTmgDiscLineItems": f"xrbltype": "stringItemType", "nsuri":
"http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgDiscLineItems", "lang": f"en-us": f"role": f"label": "Award Timing Disclosures {Line Items}", "terseLabel": "Award
Timing Disclosures" } } }
"auth_ref": f"r1242" } } }
"ecd_AwardTmgHowMnpiCnsdrdTextBlock": f"xrbltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024",
"localname": "AwardTmgHowMnpiCnsdrdTextBlock", "presentation": f"http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" } } }
"en-us": f"role": f"label": "Award
Timing, How MNPI Considered {Text Block}", "terseLabel": "Award Timing, How MNPI Considered" } } }
"auth_ref": f"r1242" } } }
"ecd_AwardTmgMethodTextBlock": f"xrbltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMethodTextBlock", "presentation": f
"http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" } } }
"en-us": f"role": f"label": "Award Timing Method {Text Block}", "terseLabel": "Award Timing Method" } } }
"auth_ref": f"r1242" } } }
"ecd_AwardTmgMnpiCnsdrdFlag": f"xrbltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMnpiCnsdrdFlag",
"presentation": f"http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" } } }
"en-us": f"role": f"label": "Award Timing MNPI Considered {Flag}", "terseLabel": "Award
Timing MNPI Considered" } } }
"auth_ref": f"r1242" } } }
"ecd_AwardTmgMnpiDiscTextBlock": f"xrbltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024",
"localname": "AwardTmgMnpiDiscTextBlock", "presentation": f"http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" } } }
"en-us": f"role": f"label": "Award Timing
MNPI Disclosure {Text Block}", "terseLabel": "Award Timing MNPI Disclosure" } } }
"auth_ref": f"r1242" } } }
"ecd_AwardTmgPredtrmndFlag": f"xrbltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgPredtrmndFlag", "presentation": f"http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
l." } } }
"en-us": f"role": f"label": "Award Timing Predetermined {Flag}", "terseLabel": "Award Timing Predetermined" } } }
"auth_ref": f"r1242" } } }
"us-gaap_AwardTypeAxis": f"xrbltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AwardTypeAxis", "presentation": f
"http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureShareBasedCompensationAdditionalInformationDetails",
"http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureShareBasedCompensationSummaryOfChangesInRsusAndPsusDetails",
"http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" } } }
"en-us": f"role": f"label": "Award Type {Axis}", "terseLabel": "Award Type", "documentation": "Information by
type of award under share-based payment arrangement." } } }
"auth_ref": f"r577" f"r578" f"r579" f"r580" f"r581" f"r582" f"r583" f"r584" f"r585" f"r586" f"r587" f"r588"
"r589" f"r590" f"r591" f"r592" f"r593" f"r594" f"r595" f"r596" f"r597" f"r598" f"r599" f"r600" f"r601" f"r602" } } }
"ecd_AwardUndrlygSecuritiesAmt": f"xrbltype":
"decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardUndrlygSecuritiesAmt", "presentation": f"http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
l." } } }
"en-us": f"role": f"label": "Award Underlying Securities Amount", "terseLabel": "Underlying Securities" } } }
"auth_ref": f"r1245" } } }
"ecd_AwardsCloseToMnpiDiscIndName": f"xrbltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscIndName",
"presentation": f"http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" } } }
"en-us": f"role": f"label": "Awards Close in Time to MNPI Disclosures, Individual Name",
"terseLabel": "Name" } } }
"auth_ref": f"r1244" } } }
"ecd_AwardsCloseToMnpiDiscTable": f"xrbltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"AwardsCloseToMnpiDiscTable", "presentation": f"http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" } } }
"en-us": f"role": f"label": "Awards Close in Time to MNPI
Disclosures {Table}", "terseLabel": "Awards Close in Time to MNPI Disclosures" } } }
"auth_ref": f"r1243" } } }
"ecd_AwardsCloseToMnpiDiscTableTextBlock": f"xrbltype":
"textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscTableTextBlock", "presentation": f
"http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" } } }
"en-us": f"role": f"label": "Awards Close in Time to MNPI Disclosures {Table Text Block}", "terseLabel":
"Awards Close in Time to MNPI Disclosures, Table" } } }
"auth_ref": f"r1243" } } }
"us-gaap_BalanceSheetLocationAxis": f"xrbltype": "stringItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "BalanceSheetLocationAxis", "presentation": f


```

http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosurePropertyPlantAndEquipmentScheduleOfComponentsOfPropertyPlantAndEquipmentDetails"},"lang":
{"en-us":{"role":{"terseLabel":"Balance Sheet Location","label":"Statement of Financial Position Location, Balance [Axis]","documentation":"Information by location in
statement of financial position where disaggregated cumulative balance has been reported."}}},"auth_ref":{"r477","r443","r444"}},"us-
gaap_BalanceSheetLocationDomain":{"xbrltype":"domainItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":"BalanceSheetLocationDomain","presentation":{"
http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosurePropertyPlantAndEquipmentScheduleOfComponentsOfPropertyPlantAndEquipmentDetails"},"lang":
{"en-us":{"role":{"terseLabel":"Balance Sheet Location","label":"Statement of Financial Position Location, Balance [Domain]","documentation":"Location in statement
of financial position where disaggregated cumulative balance has been reported."}}},"auth_ref":{"r92","r93","r477","r443","r444"}},"
cgc_BasisOfPresentationLineItems":{"xbrltype":"stringItemType","nsuri":"http://www.canopygrowth.com/20241231","localname":"BasisOfPresentationLineItems","
presentation":{"http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureBasisOfPresentationAdditionalInformationDetails"},"lang":{"en-us":{"role":{"
terseLabel":"Basis Of Presentation [Line Items]","label":"Basis Of Presentation [Line Items]","documentation":"Basis of presentation."}}},"auth_ref":{"
cgc_BasisOfPresentationTable":{"xbrltype":"stringItemType","nsuri":"http://www.canopygrowth.com/20241231","localname":"BasisOfPresentationTable","presentation":{"
http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureBasisOfPresentationAdditionalInformationDetails"},"lang":{"en-us":{"role":{"terseLabel":
"Basis Of Presentation [Table]","label":"Basis Of Presentation [Table]","documentation":"Basis of presentation."}}},"auth_ref":{"cgc_BioSteelCanadaMember":{"
xbrltype":"domainItemType","nsuri":"http://www.canopygrowth.com/20241231","localname":"BioSteelCanadaMember","presentation":{"
http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureBioSteelAdditionalInformationDetails"},"lang":{"en-us":{"role":{"terseLabel":"BioSteel Canada",
"label":"Bio Steel Canada [Member]","documentation":"BioSteel Canada."}}},"auth_ref":{"cgc_BioSteelManufacturingMember":{"xbrltype":"domainItemType",
"nsuri":"http://www.canopygrowth.com/20241231","localname":"BioSteelManufacturingMember","presentation":{"
http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureBioSteelAdditionalInformationDetails"},"lang":{"en-us":{"role":{"terseLabel":"BioSteel
Manufacturing","label":"Bio Steel Manufacturing [Member]","documentation":"BioSteel Manufacturing."}}},"auth_ref":{"cgc_BioSteelMember":{"xbrltype":
"domainItemType","nsuri":"http://www.canopygrowth.com/20241231","localname":"BioSteelMember","presentation":{"
http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureBioSteelAdditionalInformationDetails"},"
http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureBioSteelSummaryOfAssetsAndLiabilitiesClassifiedAsDiscontinuedOperationsAndMajorCategoriesDetails",
http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureBioSteelSummaryOfDeconsolidationAndCostsToExitClassifiedAsDiscontinuedOperationsDetails",
http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureBioSteelSummaryOfDeconsolidationAndCostsToExitClassifiedAsDiscontinuedOperationsParentheticalDetails",
http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureBasisOfPresentationAdditionalInformationDetails",
http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureNoncontrollingInterestsSummaryOfNetChangeInNoncontrollingInterestsDetails",
http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureRedeemableNoncontrollingInterestSummaryOfNetChangesInRedeemableNoncontrollingInterestsDetail",
http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureRevenueSummaryOfDisaggregationOfRevenueDetails"},"lang":{"en-us":{"role":{"terseLabel":
"BioSteel","label":"Bio Steel [Member]","documentation":"BioSteel."}}},"auth_ref":{"cgc_BioSteelRedeemableNoncontrollingInterestDiscountRateMember":{"
xbrltype":"domainItemType","nsuri":"http://www.canopygrowth.com/20241231","localname":"BioSteelRedeemableNoncontrollingInterestDiscountRateMember",
"presentation":{"
http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsSummaryOfValuationTechniquesAndSignificantUnobservableInputsIn
"},"lang":{"en-us":{"role":{"terseLabel":"BioSteel Redeemable Noncontrolling Interest Discount Rate","label":"Bio Steel Redeemable Noncontrolling Interest Discount
Rate [Member]","documentation":"Bio Steel redeemable noncontrolling interest discount rate."}}},"auth_ref":{"
cgc_BioSteelRedeemableNoncontrollingInterestFutureWholesalePriceAndProductionLevelsMember":{"xbrltype":"domainItemType","nsuri":
"http://www.canopygrowth.com/20241231","localname":"BioSteelRedeemableNoncontrollingInterestFutureWholesalePriceAndProductionLevelsMember","presentation":{"
http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsSummaryOfValuationTechniquesAndSignificantUnobservableInputsIn
"},"lang":{"en-us":{"role":{"terseLabel":"BioSteel Redeemable Noncontrolling Interest Future Wholesale Price and Production Levels","label":"Bio Steel Redeemable
Noncontrolling Interest Future Wholesale Price And Production Levels [Member]","documentation":"Bio Steel redeemable noncontrolling interest future wholesale price and
production levels."}}},"auth_ref":{"cgc_BioSteelUSAndBioSteelManufacturingMember":{"xbrltype":"domainItemType","nsuri":
"http://www.canopygrowth.com/20241231","localname":"BioSteelUSAndBioSteelManufacturingMember","presentation":{"
http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureBioSteelAdditionalInformationDetails"},"lang":{"en-us":{"role":{"terseLabel":"BioSteel US and
BioSteel Manufacturing","label":"Bio Steel U S and Bio Steel Manufacturing [Member]","documentation":"BioSteel US and BioSteel Manufacturing."}}},"auth_ref":{"
cgc_BioSteelUSMember":{"xbrltype":"domainItemType","nsuri":"http://www.canopygrowth.com/20241231","localname":"BioSteelUSMember","presentation":{"
http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureBioSteelAdditionalInformationDetails"},"lang":{"en-us":{"role":{"terseLabel":"BioSteel US","label":
"Bio Steel U S [Member]","documentation":"BioSteel US."}}},"auth_ref":{"cgc_BioSteelSportsNutritionInc1Member":{"xbrltype":"domainItemType","nsuri":
"http://www.canopygrowth.com/20241231","localname":"BioSteelSportsNutritionInc1Member","presentation":{"
http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureSportsNutritionInc1Member"},"lang":{"en-us":{"role":{"terseLabel":
"Bio Steel Sports Nutrition Inc","label":"BioSteel Sports Nutrition Inc1 [Member]","documentation":"BioSteel sports nutrition inc1 Member."}}},"auth_ref":{"
cgc_BrandsMember":{"xbrltype":"domainItemType","nsuri":"http://www.canopygrowth.com/20241231","localname":"BrandsMember","presentation":{"
http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureIntangibleAssetsSummaryOfComponentsOfIntangibleAssetsDetails"},"lang":{"en-us":{"role":{"
terseLabel":"Brands","label":"Brands [Member]","documentation":"Brands."}}},"auth_ref":{"cgc_BuildingsAndGreenhousesMember":{"xbrltype":
"domainItemType","nsuri":"http://www.canopygrowth.com/20241231","localname":"BuildingsAndGreenhousesMember","presentation":{"
http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosurePropertyPlantAndEquipmentScheduleOfComponentsOfPropertyPlantAndEquipmentDetails"},"lang":
{"en-us":{"role":{"terseLabel":"Buildings and Greenhouses","label":"Buildings And Greenhouses [Member]","documentation":"Buildings and greenhouses."}}},"
auth_ref":{"us-gaap_BusinessAcquisitionAcquireeDomain":{"xbrltype":"domainItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":
"BusinessAcquisitionAcquireeDomain","presentation":{"http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureAcquisitionAdditionalInformationDetails",
http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureAcquireeArrangementAdditionalInformationDetails",
http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureAcquisitionSummaryOfConsolidatedBalanceSheetImpactAtAcquisitionOfCompanysBusinessCombinationDetail",
http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureCanopyUsaAcquireeAgreementsAdditionalInformationDetails",
http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureCanopyUsaAdditionalInformationDetails",
http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureRedeemableNoncontrollingInterestAdditionalInformationDetails",
http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtEstimatedFairVa",
http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureOtherFinancialAssetsAdditionalInformationDetails",
http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureShareBasedCompensationAdditionalInformationDetails",
http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureShareCapitalSummaryOfIssuancesOfStockOtherDetails"},"lang":{"en-us":{"role":{"terseLabel":
"Business Acquisition, Acquiree","label":"Business Acquisition, Acquiree [Domain]","documentation":"Identification of the acquiree in a material business combination (or
series of individually immaterial business combinations) which may include the name or other type of identification of the acquiree."}}},"auth_ref":{"r455","r456",
"r457","r458","r459","r642","r1126","r1127"},"us-gaap_BusinessAcquisitionAxis":{"xbrltype":"stringItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":
"BusinessAcquisitionAxis","presentation":{"http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureAcquisitionAdditionalInformationDetails",
http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureAcquireeArrangementAdditionalInformationDetails",
http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureAcquisitionSummaryOfConsolidatedBalanceSheetImpactAtAcquisitionOfCompanysBusinessCombinationDetail",
http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureCanopyUsaAcquireeAgreementsAdditionalInformationDetails",
http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureCanopyUsaAdditionalInformationDetails",
http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureRedeemableNoncontrollingInterestAdditionalInformationDetails",
http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtEstimatedFairVa",
http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureOtherFinancialAssetsAdditionalInformationDetails",
http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureShareBasedCompensationAdditionalInformationDetails",
http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureShareCapitalSummaryOfIssuancesOfStockOtherDetails"},"lang":{"en-us":{"role":{"terseLabel":
"Business Acquisition","label":"Business Acquisition [Axis]","documentation":"Information by business combination or series of individually immaterial business
combinations."}}},"auth_ref":{"r75","r77","r455","r456","r457","r458","r459","r642","r1126","r1127"},"us-gaap_BusinessAcquisitionEffectiveDateOfAcquisition1":
{"xbrltype":"dateItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":"BusinessAcquisitionEffectiveDateOfAcquisition1","presentation":{"
http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureOtherFinancialAssetsAdditionalInformationDetails"},"lang":{"en-us":{"role":{"terseLabel":
"Acquisition date","label":"Business Acquisition, Effective Date of Acquisition","documentation":"Date when the acquirer obtains control of the acquiree, in YYYY-MM-DD
format."}}},"auth_ref":{"r1","r2","r20"},"cgc_BusinessAcquisitionEquityInterestsAdditionalNumberOfSharesIssuable":{"xbrltype":"sharesItemType","nsuri":
"http://www.canopygrowth.com/20241231","localname":"BusinessAcquisitionEquityInterestsAdditionalNumberOfSharesIssuable","presentation":{"
http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureCanopyUsaAdditionalInformationDetails"},"lang":{"en-us":{"role":{"terseLabel":"Business acquisition
additional number of shares issuable","label":"Business Acquisition Equity Interests Additional Number Of Shares Issuable","documentation":"Business acquisition equity
interests additional number of shares issuable."}}},"auth_ref":{"us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued":{"xbrltype":
"sharesItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":"BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued","presentation":{"
http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureCanopyUsaAcquireeAgreementsAdditionalInformationDetails",
http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureRedeemableNoncontrollingInterestAdditionalInformationDetails",
http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureShareCapitalSummaryOfIssuancesOfStockOtherDetails"},"lang":{"en-us":{"role":{"
verboseLabel":"Number of common shares issued","terseLabel":"Number of common shares","label":"Business Acquisition, Equity Interest Issued or Issuable, Number of
Shares","documentation":"Number of shares of equity interests issued or issuable to acquire entity."}}},"auth_ref":{"r197"},"us-gaap_BusinessAcquisitionLineItems":{"
xbrltype":"stringItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":"BusinessAcquisitionLineItems","presentation":{"
http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureAcquisitionAdditionalInformationDetails",
http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureAcquireeArrangementAdditionalInformationDetails",
http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureAcquisitionSummaryOfConsolidatedBalanceSheetImpactAtAcquisitionOfCompanysBusinessCombinationDetail",
"lang":{"en-us":{"role":{"terseLabel":"Business Acquisition [Line Items]","label":"Business Acquisition [Line Items]","documentation":"Line items represent financial
concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one
```

```

"Indemnity Holdbacks", "terseLabel": "Consideration transferred in remediation and indemnity holdbacks" } } }, "auth_ref": "us-gaap_BusinessCombinationConsiderationTransferredIncludingEquityInterestInAcquireeHeldPriorToCombination1", "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationConsiderationTransferredIncludingEquityInterestInAcquireeHeldPriorToCombination1", "crdr": "credit", "presentation": "http://www.canopygrowth.com/20241231/taxonomy/role/DisclosureAcquisitionAdditionalInformationDetails", "lang": "en-us", "role": "label", "terseLabel": "Consideration", "label": "Business Combination, Consideration Transferred, Including Equity Interest in Acquiree Held before Combination", "totalLabel": "Total consideration", "verboseLabel": "Total consideration", "documentation": "Fair value at acquisition date of the assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interests issued by the acquirer, including but not limited to: instruments or interests issued or issuable in consideration for the business combination" } } }, "auth_ref": "r14", "r23" } }, "us-gaap_BusinessCombinationConsiderationTransferredOther1", "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationConsiderationTransferredOther1", "crdr": "credit", "presentation": "http://www.canopygrowth.com/20241231/taxonomy/role/DisclosureAcquisitionSummaryOfConsolidatedBalanceSheetImpactAtAcquisitionOfCompanysBusinessCombinationDetails", "lang": "en-us", "role": "label", "Business Combination, Consideration Transferred, Other", "terseLabel": "Other consideration", "documentation": "Amount of tangible or intangible assets, including a business or subsidiary of the acquirer transferred by the entity to the former owners of the acquiree. Excludes cash" } } }, "auth_ref": "r15" } }, "cgc_BusinessCombinationConsiderationTransferredRelatedToRepaymentOfDebtAndRetirementOfCertainLeaseObligations", "xbrltype": "monetaryItemType", "nsuri": "http://www.canopygrowth.com/20241231", "localname": "BusinessCombinationConsiderationTransferredRelatedToRepaymentOfDebtAndRetirementOfCertainLeaseObligations", "crdr": "credit", "presentation": "http://www.canopygrowth.com/20241231/taxonomy/role/DisclosureAcquisitionAdditionalInformationDetails", "lang": "en-us", "role": "documentation", "Business combination consideration transferred related to repayment of debt and retirement of certain lease obligations", "label": "Business Combination Consideration Transferred Related To Repayment Of Debt And Retirement Of Certain Lease Obligations", "terseLabel": "Consideration transferred related to repayment of debt and retirement of certain lease obligations" } } }, "auth_ref": "us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1", "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1", "crdr": "debit", "presentation": "http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureOtherIncomeExpenseNetScheduleOfOtherIncomeExpenseNetDetails", "lang": "en-us", "role": "negatedLabel", "Fair value changes on acquisition related contingent consideration and other", "label": "Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability", "documentation": "Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement" } } }, "auth_ref": "r648", "r1298" } }, "us-gaap_BusinessCombinationDisclosureTextBlock", "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationDisclosureTextBlock", "presentation": "http://www.canopygrowth.com/20241231/taxonomy/role/DisclosureAcquisition1", "lang": "en-us", "role": "label", "Business Combination Disclosure [Text Block]", "terseLabel": "Acquisition", "documentation": "The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable)" } } }, "auth_ref": "r196", "r643" } }, "cgc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDebtAndOtherLiabilities", "xbrltype": "monetaryItemType", "nsuri": "http://www.canopygrowth.com/20241231", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDebtAndOtherLiabilities", "crdr": "credit", "presentation": "http://www.canopygrowth.com/20241231/taxonomy/role/DisclosureAcquisitionSummaryOfConsolidatedBalanceSheetImpactAtAcquisitionOfCompanysBusinessCombinationDetails", "lang": "en-us", "role": "negatedLabel", "Debt and other liabilities", "label": "Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Debt And Other Liabilities", "documentation": "Business combination recognized identifiable assets acquired and liabilities assumed debt and other liabilities" } } }, "auth_ref": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment", "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment", "crdr": "debit", "presentation": "http://www.canopygrowth.com/20241231/taxonomy/role/DisclosureAcquisitionSummaryOfConsolidatedBalanceSheetImpactAtAcquisitionOfCompanysBusinessCombinationDetails", "lang": "en-us", "role": "totalLabel", "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment, Total", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment", "terseLabel": "Property, plant and equipment", "documentation": "The amount of property, plant, and equipment recognized as of the acquisition date" } } }, "auth_ref": "r78", "r79" } }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedLessNoncontrollingInterest", "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedLessNoncontrollingInterest", "crdr": "debit", "presentation": "http://www.canopygrowth.com/20241231/taxonomy/role/DisclosureAcquisitionSummaryOfConsolidatedBalanceSheetImpactAtAcquisitionOfCompanysBusinessCombinationDetails", "lang": "en-us", "role": "label", "Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Less Noncontrolling Interest", "terseLabel": "Net assets acquired", "totalLabel": "Net assets acquired", "documentation": "Amount recognized as of the acquisition date for the assets, including goodwill, in excess of (less than) the aggregate liabilities assumed, less the noncontrolling interest in the acquiree" } } }, "auth_ref": "r79" } }, "us-gaap_BusinessCombinationsAbstract", "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationsAbstract", "lang": "en-us", "role": "label", "Business Combinations [Abstract]", "auth_ref": "us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock", "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessDescriptionAndBasisOfPresentationTextBlock", "presentation": "http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureBasisOfPresentation", "lang": "en-us", "role": "terseLabel", "Basis of Presentation", "label": "Business Description and Basis of Presentation [Text Block]", "documentation": "The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)" } } }, "auth_ref": "r101", "r169", "r170" } }, "cgc_BusinessToBusinessMember", "xbrltype": "domainItemType", "nsuri": "http://www.canopygrowth.com/20241231", "localname": "BusinessToBusinessMember", "presentation": "http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureRevenueSummaryOfDisaggregationOfRevenueDetails", "lang": "en-us", "role": "terseLabel", "Business to Business", "label": "Business To Business [Member]", "documentation": "Business to business" } } }, "auth_ref": "cgc_BusinessToConsumerMember", "xbrltype": "domainItemType", "nsuri": "http://www.canopygrowth.com/20241231", "localname": "BusinessToConsumerMember", "presentation": "http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureRevenueSummaryOfDisaggregationOfRevenueDetails", "lang": "en-us", "role": "terseLabel", "Business to Consumer", "label": "Business To Consumer [Member]", "documentation": "Business to consumer" } } }, "auth_ref": "country_CA", "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/country/2024", "localname": "CA", "presentation": "http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureSegmentInformationSummaryOfDisaggregationOfPropertyPlantAndEquipmentByGeographicAreaDetails", "lang": "en-us", "role": "terseLabel", "CANADA", "label": "CANADA", "auth_ref": "cgc_CThreeMember", "xbrltype": "domainItemType", "nsuri": "http://www.canopygrowth.com/20241231", "localname": "CThreeMember", "presentation": "http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureRevenueSummaryOfDisaggregationOfRevenueDetails", "lang": "en-us", "role": "terseLabel", "C3", "label": "C Three [Member]", "documentation": "C three" } } }, "auth_ref": "cgc_CallRightOverRollingLendersRemainingInterestInAcreeagesDebt", "xbrltype": "monetaryItemType", "nsuri": "http://www.canopygrowth.com/20241231", "localname": "CallRightOverRollingLendersRemainingInterestInAcreeagesDebt", "crdr": "credit", "presentation": "http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureOtherFinancialAssetsAdditionalInformationDetails", "lang": "en-us", "role": "documentation", "Right to call over rolling lender's remaining interest in acreage's debt", "label": "Call Right Over Rolling Lenders Remaining Interest In Acreages Debt", "terseLabel": "Remaining acreage debt of rolling lender's" } } }, "auth_ref": "cgc_CanadaCannabisMember", "xbrltype": "domainItemType", "nsuri": "http://www.canopygrowth.com/20241231", "localname": "CanadaCannabisMember", "presentation": "http://www.canopygrowth.com/20241231/taxonomy/role/DisclosureLossOnAssetImpairmentAndRestructuringAdditionalInformationDetails", "lang": "en-us", "role": "terseLabel", "Canada Cannabis", "label": "Canada cannabis [Member]", "documentation": "Canada cannabis" } } }, "auth_ref": "cgc_CanadianAdultUseCannabisMember", "xbrltype": "domainItemType", "nsuri": "http://www.canopygrowth.com/20241231", "localname": "CanadianAdultUseCannabisMember", "presentation": "http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureRevenueSummaryOfDisaggregationOfRevenueDetails", "lang": "en-us", "role": "terseLabel", "Canadian Cannabis Net Revenue", "label": "Canadian Cannabis Net Revenue [Member]", "documentation": "Canadian cannabis net revenue" } } }, "auth_ref": "cgc_CanadianMedicalCannabisMember", "xbrltype": "domainItemType", "nsuri": "http://www.canopygrowth.com/20241231", "localname": "CanadianMedicalCannabisMember", "presentation": "http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureRevenueSummaryOfDisaggregationOfRevenueDetails", "lang": "en-us", "role": "terseLabel", "Canadian Medical Cannabis Net Revenue", "label": "Canadian Medical Cannabis Net Revenue [Member]", "documentation": "Canadian medical cannabis net revenue" } } }, "auth_ref": "cgc_CanadianMedicalCannabisNetRevenueMember", "xbrltype": "domainItemType", "nsuri": "http://www.canopygrowth.com/20241231", "localname": "CanadianMedicalCannabisNetRevenueMember", "presentation": "http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureRevenueSummaryOfDisaggregationOfRevenueDetails", "lang": "en-us", "role": "terseLabel", "Canadian Recreational Cannabis Net Revenue", "label": "Canadian Recreational Cannabis Net Revenue [Member]", "documentation": "Canadian recreational cannabis net revenue member" } } }, "auth_ref": "cgc_CancellationOfDebt", "xbrltype": "monetaryItemType", "nsuri": "http://www.canopygrowth.com/20241231", "localname": "CancellationOfDebt", "crdr": "debit", "presentation": "http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails", "lang": "en-us", "role": "terseLabel", "Cancellation of Debt", "label": "Cancellation Of Debt", "documentation": "Cancellation of Debt" } } }, "auth_ref": "cgc_CannabisOperationsReportingUnitMember", "xbrltype": "domainItemType", "nsuri": "http://www.canopygrowth.com/20241231", "localname": "CannabisOperationsReportingUnitMember", "presentation": "http://www.canopygrowth.com/20241231/taxonomy/role/DisclosureLossOnAssetImpairmentAndRestructuringAdditionalInformationDetails", "lang": "en-us", "role": "documentation", "Cannabis operations reporting unit member", "label": "Cannabis Operations Reporting Unit [Member]", "terseLabel": "Cannabis Operations Reporting Unit" } } }, "auth_ref": "cgc_CanopyRiversMember", "xbrltype": "domainItemType", "nsuri": "http://www.canopygrowth.com/20241231", "localname": "CanopyRiversMember", "presentation": "http://www.canopygrowth.com/20241231/taxonomy/role/DisclosureCanopyUsaAdditionalInformationDetails", "lang": "en-us", "role": "terseLabel", "Canopy Rivers", "label": "Canopy Rivers [Member]", "documentation": "Canopy Rivers" } } }, "auth_ref": "cgc_CanopyUSAssetsMember", "xbrltype": "domainItemType", "nsuri": "http://www.canopygrowth.com/20241231", "localname": "CanopyUSAssetsMember", "presentation": "http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureRevenueSummaryOfDisaggregationOfRevenueDetails", "lang": "en-us", "role": "label", "Canadian Recreational Cannabis Net Revenue", "label": "Canadian Recreational Cannabis Net Revenue [Member]", "documentation": "Canadian recreational cannabis net revenue member" } } }, "auth_ref": "cgc_CancellationOfDebt", "xbrltype
```

```
"http://www.canopygrowth.com/20241231", "localname": "CanopyUSAAssetsMember", "presentation": "http://www.canopygrowth.com/20241231/taxonomy/role/DisclosureOtherIncomeExpenseNetScheduleOfOtherIncomeExpenseNetParenteticalDetails"}], "lang": {"en-us": {"role": {"label": "Canopy USA Assets [Member]", "documentation": "Canopy USA assets member.", "terseLabel": "Canopy USA Assets"} }}, "auth_ref": [] }, {"cgc_CanopyUsaEquityMethodInvestmentControlPremiumMember": {"xbrltype": "domainItemType", "nsuri": "http://www.canopygrowth.com/20241231", "localname": "CanopyUsaEquityMethodInvestmentControlPremiumMember", "presentation": "http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureFairValueOffinancialInstrumentsSummaryOfValuationTechniquesAndSignificantUnobservableInputsIn", "lang": {"en-us": {"role": {"documentation": "Canopy USA equity method investment control premium.", "label": "Canopy USA Equity Method Investment Control Premium [Member]", "terseLabel": "Canopy USA Equity Method Investment Control Premium"} }}, "auth_ref": [], "cgc_CanopyUsaEquityMethodInvestmentDiscountRateMember": {"xbrltype": "domainItemType", "nsuri": "http://www.canopygrowth.com/20241231", "localname": "CanopyUsaEquityMethodInvestmentDiscountRateMember", "presentation": "http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureFairValueOffinancialInstrumentsSummaryOfValuationTechniquesAndSignificantUnobservableInputsIn", "lang": {"en-us": {"role": {"documentation": "Canopy USA equity method investment discount rate.", "label": "Canopy USA Equity Method Investment Discount Rate [Member]", "terseLabel": "Canopy USA Equity Method Investment Discount Rate"} }}, "auth_ref": [], "cgc_CanopyUsaEquityMethodInvestmentExpectedFutureCashFlowsMember": {"xbrltype": "domainItemType", "nsuri": "http://www.canopygrowth.com/20241231", "localname": "CanopyUsaEquityMethodInvestmentExpectedFutureCashFlowsMember", "presentation": "http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureFairValueOffinancialInstrumentsSummaryOfValuationTechniquesAndSignificantUnobservableInputsIn", "lang": {"en-us": {"role": {"documentation": "Canopy USA equity method investment expected future cash flows.", "label": "Canopy USA Equity Method Investment Expected Future Cash Flows [Member]", "terseLabel": "Canopy USA Equity Method Investment Expected Future Cash Flows"} }}, "auth_ref": [], "cgc_CanopyUsaEquityMethodInvestmentIntrinsicValueOfAcreageMember": {"xbrltype": "domainItemType", "nsuri": "http://www.canopygrowth.com/20241231", "localname": "CanopyUsaEquityMethodInvestmentIntrinsicValueOfAcreageMember", "presentation": "http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureFairValueOffinancialInstrumentsSummaryOfValuationTechniquesAndSignificantUnobservableInputsIn", "lang": {"en-us": {"role": {"documentation": "Canopy USA equity method investment intrinsic value of acreage.", "label": "Canopy USA Equity Method Investment Intrinsic Value of Acreage [Member]", "terseLabel": "Canopy USA Equity Method Investment Intrinsic Value of Acreage"} }}, "auth_ref": [], "cgc_CanopyUsaEquityMethodInvestmentMarketAccessPremiumMember": {"xbrltype": "domainItemType", "nsuri": "http://www.canopygrowth.com/20241231", "localname": "CanopyUsaEquityMethodInvestmentMarketAccessPremiumMember", "presentation": "http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureFairValueOffinancialInstrumentsSummaryOfValuationTechniquesAndSignificantUnobservableInputsIn", "lang": {"en-us": {"role": {"documentation": "Canopy USA equity method investment market access premium.", "label": "Canopy USA Equity Method Investment Market Access Premium [Member]", "terseLabel": "Canopy USA Equity Method Investment Market Access Premium"} }}, "auth_ref": [], "cgc_CanopyUsaEquityMethodInvestmentNumberOfAcreageCommonSharesToBeIssuedMember": {"xbrltype": "domainItemType", "nsuri": "http://www.canopygrowth.com/20241231", "localname": "CanopyUsaEquityMethodInvestmentNumberOfAcreageCommonSharesToBeIssuedMember", "presentation": "http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureFairValueOffinancialInstrumentsSummaryOfValuationTechniquesAndSignificantUnobservableInputsIn", "lang": {"en-us": {"role": {"documentation": "Canopy USA equity method investment number of acreage common shares to be issued.", "label": "Canopy USA Equity Method Investment Number of Acreage Common Shares To Be Issued [Member]", "terseLabel": "Canopy USA Equity Method Investment Number of Acreage Common Shares To Be Issued"} }}, "auth_ref": [], "cgc_CanopyUsaEquityMethodInvestmentProbabilityAndTimingOfUSLegalizationMember": {"xbrltype": "domainItemType", "nsuri": "http://www.canopygrowth.com/20241231", "localname": "CanopyUsaEquityMethodInvestmentProbabilityAndTimingOfUSLegalizationMember", "presentation": "http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureFairValueOffinancialInstrumentsSummaryOfValuationTechniquesAndSignificantUnobservableInputsIn", "lang": {"en-us": {"role": {"documentation": "Canopy USA equity method investment probability and timing of US legalization.", "label": "Canopy USA Equity Method Investment Probability and Timing of US Legalization [Member]", "terseLabel": "Canopy USA Equity Method Investment Probability and Timing of US Legalization"} }}, "auth_ref": [], "cgc_CanopyUsaEquityMethodInvestmentProbabilityOfEachAcreageScenarioMember": {"xbrltype": "domainItemType", "nsuri": "http://www.canopygrowth.com/20241231", "localname": "CanopyUsaEquityMethodInvestmentProbabilityOfEachAcreageScenarioMember", "presentation": "http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureFairValueOffinancialInstrumentsSummaryOfValuationTechniquesAndSignificantUnobservableInputsIn", "lang": {"en-us": {"role": {"documentation": "Canopy USA equity method investment probability of each acreage scenario.", "label": "Canopy USA Equity Method Investment Probability of Each Acreage Scenario [Member]", "terseLabel": "Canopy USA Equity Method Investment Probability of Each Acreage Scenario"} }}, "auth_ref": [], "cgc_CanopyUsaEquityMethodInvestmentVolatilityOfWanaAndJettyEquityMember": {"xbrltype": "domainItemType", "nsuri": "http://www.canopygrowth.com/20241231", "localname": "CanopyUsaEquityMethodInvestmentVolatilityOfWanaAndJettyEquityMember", "presentation": "http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureFairValueOffinancialInstrumentsSummaryOfValuationTechniquesAndSignificantUnobservableInputsIn", "lang": {"en-us": {"role": {"documentation": "Canopy USA equity method investment volatility of wana and jetty equity.", "label": "Canopy USA Equity Method Investment Volatility of Wana and Jetty Equity [Member]", "terseLabel": "Canopy USA Equity Method Investment Volatility of Wana and Jetty Equity"} }}, "auth_ref": [], "cgc_CanopyUsaMember": {"xbrltype": "domainItemType", "nsuri": "http://www.canopygrowth.com/20241231", "localname": "CanopyUsaMember", "presentation": "http://www.canopygrowth.com/20241231/taxonomy/role/DisclosureCanopyUsaAdditionalInformationDetails"}, {"http://www.canopygrowth.com/20241231/taxonomy/role/DisclosureCanopyUsaSummaryOfDerecognizedAssetsAndLiabilitiesTransferredDetails"}, {"http://www.canopygrowth.com/20241231/taxonomy/role/DisclosureCanopyUsaTables"}, {"http://www.canopygrowth.com/20241231/taxonomy/role/DisclosureEquityMethodInvestmentsComponentsOfEquityMethodInvestmentsDetails"}], "lang": {"en-us": {"role": {"documentation": "Canopy USA.", "label": "Canopy USA [Member]", "terseLabel": "Canopy USA"} }}, "auth_ref": [], "us-gaap_Cash": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Cash", "crdr": "debit", "presentation": "http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureCashAndCashEquivalentsComponentsOfCashAndCashEquivalentsDetails"}], "lang": {"en-us": {"role": {"terseLabel": "Cash", "label": "Cash", "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation." } }}, "auth_ref": [{"r226", "r830", "r910", "r939", "r1147", "r1174", "r1279"}], "us-gaap_CashAcquiredFromAcquisition": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAcquiredFromAcquisition", "crdr": "debit", "presentation": "http://www.canopygrowth.com/20241231/taxonomy/role/DisclosureAcquisitionSummaryOfConsolidatedBalanceSheetImpactAtAcquisitionOfCompaniesBusinessCombinationDetail", "lang": {"en-us": {"role": {"label": "Cash Acquired from Acquisition", "negatedLabel": "Less: Cash and cash equivalents acquired", "documentation": "The cash inflow associated with the acquisition of business during the period (for example, cash that was held by the acquired business)."} }}, "auth_ref": [{"r36"}], "cgc_CashAcquiredFromLenders": {"xbrltype": "monetaryItemType", "nsuri": "http://www.canopygrowth.com/20241231", "localname": "CashAcquiredFromLenders", "crdr": "debit", "presentation": "http://www.canopygrowth.com/20241231/taxonomy/role/DisclosureCanopyUsaAcreageAgreementsAdditionalInformationDetails"}, {"http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureOtherFinancialAssetsAdditionalInformationDetails"}], "lang": {"en-us": {"role": {"documentation": "Cash acquired from lenders.", "label": "Cash Acquired From Lenders", "terseLabel": "Cash acquired from lenders"} }}, "auth_ref": [], "us-gaap_CashAndCashEquivalentsAbstract": {"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsAbstract", "lang": {"en-us": {"role": {"label": "Cash and Cash Equivalents [Abstract]"} }}, "auth_ref": [], "us-gaap_CashAndCashEquivalentsAtCarryingValue": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsAtCarryingValue", "crdr": "debit", "presentation": "http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureCashAndCashEquivalentsComponentsOfCashAndCashEquivalentsDetails"}, {"http://www.canopygrowth.com/20241231/taxonomy/role/Role_StatementCondensedInterimConsolidatedBalanceSheetsUnaudited"}], "lang": {"en-us": {"role": {"totalLabel": "Cash and cash equivalents", "terseLabel": "Cash and cash equivalents", "label": "Cash and Cash Equivalents at Carrying Value", "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation." } }}, "auth_ref": [{"r39", "r252", "r1088"}], "us-gaap_CashAndCashEquivalentsDisclosureTextBlock": {"xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsDisclosureTextBlock", "presentation": "http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureCashAndCashEquivalents"}], "lang": {"en-us": {"role": {"terseLabel": "Cash and Cash Equivalents", "label": "Cash and Cash Equivalents Disclosure [Text Block]", "documentation": "The entire disclosure for cash and cash equivalent footnotes, which may include the types of deposits and money market instruments, applicable carrying amounts, restricted amounts and compensating balance arrangements. Cash and equivalents include: (1) currency on hand (2) demand deposits with banks or financial institutions (3) other kinds of accounts that have the general characteristics of demand deposits (4) short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Generally, only investments maturing within three months from the date of acquisition qualify." } }}, "auth_ref": [{"r252", "r830"}], "us-gaap_CashCashEquivalentsAndShortTermInvestments": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsAndShortTermInvestments", "crdr": "debit", "presentation": "http://www.canopygrowth.com/20241231/taxonomy/role/DisclosureCanopyUsaAdditionalInformationDetails"}, {"http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureBasisOfPresentationAdditionalInformationDetails"}], "lang": {"en-us": {"role": {"terseLabel": "Cash and cash equivalents and short-term investments", "label": "Cash, Cash Equivalents, and Short-Term Investments", "totalLabel": "Cash, Cash Equivalents, and Short-Term Investments, Total", "documentation": "Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable." } }}, "auth_ref": [{"r1287}], "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations", "crdr": "debit", "presentation": "http://www.canopygrowth.com/20241231/taxonomy/role/StatementCondensedInterimConsolidatedStatementsOfCashFlowsUnaudited"}], "lang": {"en-us": {"role": {"totalLabel": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Disposal Group, Including Discontinued Operations", "terseLabel": "Cash and cash equivalents, including discontinued operations", "
```

of changes in value because of changes in interest rates." } } } , "auth_ref": "r39", "r165", "r293" } } , "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "crdr": "debit", "presentation": { "http://www.canopygrowth.com/20241231/taxonomy/role/Role_StatementCondensedInterimConsolidatedStatementsOfCashFlowsUnaudited": { "lang": { "en-us": { "role": { "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "totalLabel": "Net decrease in cash and cash equivalents", "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage, including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } } , "auth_ref": "r3", "r165" } } , "us-gaap_CashEquivalentsAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashEquivalentsAtCarryingValue", "crdr": "debit", "presentation": { "http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureCashAndCashEquivalentsComponentsOfCashAndCashEquivalentsDetails": { "lang": { "en-us": { "role": { "totalLabel": "Cash Equivalents, at Carrying Value, Total", "terseLabel": "Cash equivalents", "label": "Cash Equivalents, at Carrying Value", "documentation": "Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation." } } } , "auth_ref": "r1279", "r1440" } } , "cgc_CashPaidDuringTheYearAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.canopygrowth.com/20241231", "localname": "CashPaidDuringTheYearAbstract", "presentation": { "http://www.canopygrowth.com/20241231/taxonomy/role/Role_StatementCondensedInterimConsolidatedStatementsOfCashFlowsUnaudited": { "lang": { "en-us": { "role": { "terseLabel": "Cash paid during the period", "label": "Cash Paid During The Year [Abstract]", "documentation": "Cash paid during the year." } } } , "auth_ref": { "cgc_CashPaymentOrAnyOtherPropertyPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://www.canopygrowth.com/20241231", "localname": "CashPaymentOrAnyOtherPropertyPayable", "crdr": "credit", "presentation": { "http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails": { "lang": { "en-us": { "role": { "terseLabel": "Cash payment or any other property payable", "label": "Cash Payment Or Any Other Property Payable", "documentation": "Cash payment or any other property payable." } } } , "auth_ref": { "us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations", "crdr": "debit", "presentation": { "http://www.canopygrowth.com/20241231/taxonomy/role/Role_StatementCondensedInterimConsolidatedStatementsOfCashFlowsUnaudited": { "lang": { "en-us": { "role": { "terseLabel": "Net cash provided by (used in) investing activities - discontinued operations", "label": "Cash Provided by (Used in) Investing Activities, Discontinued Operations", "documentation": "Amount of cash inflow (outflow) of investing activities of discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets." } } } , "auth_ref": "r116", "r165" } } , "us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations", "crdr": "debit", "presentation": { "http://www.canopygrowth.com/20241231/taxonomy/role/Role_StatementCondensedInterimConsolidatedStatementsOfCashFlowsUnaudited": { "lang": { "en-us": { "role": { "label": "Cash Provided by (Used in) Operating Activities, Discontinued Operations", "terseLabel": "Net cash used in operating activities - discontinued operations", "documentation": "Amount of cash inflow (outflow) of operating activities of discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities." } } } , "auth_ref": "r116", "r165" } } , "cgc_CashReceivedDuringYearAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.canopygrowth.com/20241231", "localname": "CashReceivedDuringYearAbstract", "presentation": { "http://www.canopygrowth.com/20241231/taxonomy/role/Role_StatementCondensedInterimConsolidatedStatementsOfCashFlowsUnaudited": { "lang": { "en-us": { "role": { "terseLabel": "Cash received during the period", "label": "Cash Received During Year [Abstract]", "documentation": "Cash received during the year abstract." } } } , "auth_ref": { "cgc_CbiExchangeAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.canopygrowth.com/20241231", "localname": "CbiExchangeAgreementMember", "presentation": { "http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails": { "lang": { "en-us": { "role": { "documentation": "CBI Exchange Agreement member", "label": "CBI Exchange Agreement [Member]", "terseLabel": "CBI Exchange Agreement" } } } , "auth_ref": { "cgc_CbiExchangeMember": { "xbrltype": "domainItemType", "nsuri": "http://www.canopygrowth.com/20241231", "localname": "CbiExchangeMember", "presentation": { "http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureShareCapitalAdditionalInformationDetails": { "lang": { "en-us": { "role": { "documentation": "CBI Exchange member", "label": "CBI Exchange [Member]", "terseLabel": "CBI Exchange" } } } , "auth_ref": { "cgc_CbiPromissoryNoteMember": { "xbrltype": "domainItemType", "nsuri": "http://www.canopygrowth.com/20241231", "localname": "CbiPromissoryNoteMember", "presentation": { "http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsSummaryOfValuationTechniquesAndSignificantUnobservableInputsIn": { "lang": { "en-us": { "role": { "terseLabel": "CBI Promissory Note", "label": "CBI Promissory Note [Member]", "documentation": "CBI promissory note." } } } , "auth_ref": { "cgc_ChangeInNoncontrollingInterestsDueToAcquisitionAndOwnership": { "xbrltype": "monetaryItemType", "nsuri": "http://www.canopygrowth.com/20241231", "localname": "ChangeInNoncontrollingInterestsDueToAcquisitionAndOwnership", "crdr": "credit", "presentation": { "http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureNoncontrollingInterestsSummaryOfNetChangeInNoncontrollingInterestsDetails": { "lang": { "en-us": { "role": { "documentation": "Change in noncontrolling interests due to acquisition and ownership", "label": "Change In Noncontrolling Interests Due To Acquisition And Ownership", "terseLabel": "Ownership changes" } } } , "auth_ref": { "cgc_ChangeInNoncontrollingInterestsDueToIssuanceOfWarrants": { "xbrltype": "monetaryItemType", "nsuri": "http://www.canopygrowth.com/20241231", "localname": "ChangeInNoncontrollingInterestsDueToIssuanceOfWarrants", "crdr": "credit", "presentation": { "http://www.canopygrowth.com/20241231/taxonomy/role/Role_StatementCondensedInterimConsolidatedStatementsOfShareholderSEquityUnaudited": { "lang": { "en-us": { "role": { "documentation": "Change in noncontrolling interests due to issuance of warrants", "label": "Change In Noncontrolling Interests Due To Issuance Of Warrants", "terseLabel": "Warrants" } } } , "auth_ref": { "cgc_ChangeInNoncontrollingInterestsOfOwner": { "xbrltype": "monetaryItemType", "nsuri": "http://www.canopygrowth.com/20241231", "localname": "ChangeInNoncontrollingInterestsOfOwner", "crdr": "credit", "presentation": { "http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureNoncontrollingInterestsSummaryOfNetChangeInNoncontrollingInterestsDetails": { "lang": { "en-us": { "role": { "documentation": "Change in the noncontrolling interests of owner", "label": "Change In Noncontrolling Interests Of Owner", "terseLabel": "Canopy USA Transaction" } } } , "auth_ref": { "ecd_ChangedPeerGroupFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ChangedPeerGroupFnTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure": { "lang": { "en-us": { "role": { "label": "Changed Peer Group, Footnote [Text Block]", "terseLabel": "Changed Peer Group, Footnote" } } } , "auth_ref": { "cgc_ChangesInOtherFinancialAssetFairValueThroughProfitOrLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://www.canopygrowth.com/20241231", "localname": "ChangesInOtherFinancialAssetFairValueThroughProfitOrLoss", "crdr": "credit", "presentation": { "http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureOtherFinancialAssetsSummaryOfChangesInOtherFinancialAssetsDetails": { "lang": { "en-us": { "role": { "terseLabel": "Fair value changes", "label": "Changes In Other Financial Asset Fair Value Through Profit Or Loss", "documentation": "Changes in other financial asset fair value through profit or loss." } } } , "auth_ref": { "ecd_ChngInFrValAsOfVstngDtOfPrYrEqtyAwrdVsYstdInCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ChngInFrValAsOfVstngDtOfPrYrEqtyAwrdVsYstdInCvrdYrMember", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure": { "lang": { "en-us": { "role": { "label": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]", "terseLabel": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year" } } } , "auth_ref": { "ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdVsGrntdInPrYrsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ChngInFrValOfOutsdngAndUnvstdEqtyAwrdVsGrntdInPrYrsMember", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure": { "lang": { "en-us": { "role": { "label": "Year-over Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]", "terseLabel": "Year-over Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested" } } } , "auth_ref": { "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CityAreaCode", "presentation": { "http://www.canopygrowth.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation": { "lang": { "en-us": { "role": { "terseLabel": "City Area Code", "label": "City Area Code", "documentation": "Area code of city" } } } , "auth_ref": { "cgc_ClassDSubordinatedVotingSharesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.canopygrowth.com/20241231", "localname": "ClassDSubordinatedVotingSharesMember", "presentation": { "http://www.canopygrowth.com/20241231/taxonomy/role/DisclosureAcreegArrangementAdditionalInformationDetails": { "lang": { "en-us": { "role": { "terseLabel": "Class D Subordinated Voting Shares", "label": "Class D Subordinated Voting Shares [Member]", "documentation": "Class D subordinated voting shares." } } } , "auth_ref": { "cgc_ClassESubordinatedVotingSharesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.canopygrowth.com/20241231", "localname": "ClassESubordinatedVotingSharesMember", "presentation": { "http://www.canopygrowth.com/20241231/taxonomy/role/DisclosureAcreegArrangementAdditionalInformationDetails": { "lang": { "en-us": { "role": { "terseLabel": "Class E Subordinated Voting Shares", "label": "Class E Subordinated Voting Shares [Member]", "documentation": "Class E subordinated voting shares." } } } , "auth_ref": { "us-gaap_ClassOfStockDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfStockDomain", "presentation": { "http://www.canopygrowth.com/20241231/taxonomy/role/DisclosureAcreegArrangementAdditionalInformationDetails": { "lang": { "en-us": { "role": { "documentation": "Class of Stock [Line Items]", "label": "Line items represent financial conceptual concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } } , "auth_ref": { "r261", "r262", "r263", "r264", "r265", "r266", "r267", "r268", "r269", "r270", "r271", "r272", "r273", "r274", "r275", "r276", "r277", "r278", "r279", "r280", "r281", "r282", "r283", "r284", "r285", "r286", "r287", "r288", "r289", "r290", "r291", "r292", "r293", "r294", "r295", "r296", "r297", "r298", "r299", "r300", "r301", "r302", "r303", "r304", "r305", "r306", "r307", "r308", "r309", "r310", "r311", "r312", "r313", "r314", "r315", "r316", "r317", "r318", "r319", "r320", "r321", "r322", "r323", "r324", "r325", "r326", "r327", "r328", "r329", "r330", "r331", "r332", "r333", "r334", "r335", "r336", "r337", "r338", "r339", "r340", "r341", "r342", "r343", "r344", "r345", "r346", "r347", "r348", "r349", "r350", "r351", "r352", "r353", "r354", "r355", "r356", "r357", "r358", "r359", "r360", "r361", "r362", "r363", "r364", "r365", "r366", "r367", "r368", "r369", "r370", "r371", "r372", "r373", "r374", "r375", "r376", "r377", "r378", "r379", "r380", "r381", "r382", "r383", "r384", "r385", "r386", "r387", "r388", "r389", "r390", "r391", "r392", "r393", "r394", "r395", "r396", "r397", "r398", "r399", "r400", "r401", "r402", "r403", "r404", "r405", "r406", "r407", "r408", "r409", "r410", "r411", "r412", "r413", "r414", "r415", "r416", "r417", "r418", "r419", "r420", "r421", "r422", "r423", "r424", "r425", "r426", "r427", "r428", "r429", "r430", "r431", "r432", "r433", "r434", "r435", "r436", "r437", "r438", "r439", "r440", "r441", "r442", "r443", "r444", "r445", "r446", "r447", "r448", "r449", "r450", "r451", "r452", "r453", "r454", "r455", "r456", "r457", "r458", "r459", "r460", "r461", "r462", "r463", "r464", "r465", "r466", "r467", "r468", "r469", "r470", "r471", "r472", "r473", "r474", "r475", "r476", "r477", "r478", "r479", "r480", "r481", "r482", "r483", "r484", "r485", "r486", "r487", "r488", "r489", "r490", "r491", "r492", "r493", "r494", "r495", "r496", "r497", "r498", "r499", "r500", "r501", "r502", "r503", "r504", "r505", "r506", "r507", "r508", "r509", "r510", "r511", "r512", "r513", "r514", "r515", "r516", "r517", "r518", "r519", "r520", "r521", "r522", "r523", "r524", "r525", "r526", "r527", "r528", "r529", "r530", "r531", "r532", "r533", "r534", "r535", "r536", "r537", "r538", "r539", "r540", "r541", "r542", "r543", "r544", "r545", "r546", "r547", "r548", "r549", "r550", "r551", "r552", "r553", "r554", "r555", "r556", "r557", "r558", "r559", "r560", "r561", "r562", "r563", "r564", "r565", "r566", "r567", "r568", "r569", "r570", "r571", "r572", "r573", "r574", "r575", "r576", "r577", "r578", "r579", "r580", "r581", "r582", "r583", "r584", "r585", "r586", "r587", "r588", "r589", "r590", "r591", "r592", "r593", "r594", "r595", "r596", "r597", "r598", "r599", "r600", "r601", "r602", "r603", "r604", "r605", "r606", "r607", "r608", "r609", "r610", "r611", "r612", "r613", "r614", "r615", "r616", "r617", "r618", "r619", "r620", "r621", "r622", "r623", "r624", "r625", "r626", "r627", "r628", "r629", "r630", "r631", "r632", "r633", "r634", "r635", "r636", "r637", "r638", "r639", "r640", "r641", "r642", "r643", "r644", "r645", "r646", "r647", "r648", "r649", "r650", "r651", "r652", "r653", "r654", "r655", "r656", "r657", "r658", "r659", "r660", "r661", "r662", "r663", "r664", "r665", "r666", "r667", "r668", "r669", "r670", "r671", "r672", "r673", "r674", "r675", "r676", "r677", "r678", "r679", "r680", "r681", "r682", "r683", "r684", "r685", "r686", "r687", "r688", "r689", "r690", "r691", "r692", "r693", "r694", "r695", "r696", "r697", "r698", "r699", "r700", "r701", "r702", "r703", "r704", "r705", "r706", "r707", "r708", "r709", "r710", "r711", "r712", "r713", "r714", "r715", "r716", "r717", "r718", "r719", "r720", "r721", "r722", "r723", "r724", "r725", "r726", "r727", "r728", "r729", "r730", "r731", "r732", "r733", "r734", "r735", "r736", "r737", "r738", "r739", "r740", "r741", "r742", "r743", "r744", "r745", "r746", "r747", "r748", "r749", "r750", "r751", "r752", "r753", "r754", "r755", "r756", "r757", "r758", "r759", "r760", "r761", "r762", "r763", "r764", "r765", "r766", "r767", "r768", "r769", "r770", "r771", "r772", "r773", "r774", "r775", "r776", "r777", "r778", "r779", "r780", "r781", "r782", "r783", "r784", "r785", "r786", "r787", "r788", "r789", "r790", "r791", "r792", "r793", "r794", "r795", "r796", "r797", "r798", "r799", "r800", "r801", "r802", "r803", "r804", "r805", "r806", "r807", "r808", "r809", "r810", "r811", "r812", "r813", "r814", "r815", "r816", "r817", "r818", "r819", "r820", "r821", "r822", "r823", "r824", "r825", "r826", "r827", "r828", "r829", "r830", "r831", "r832", "r833", "r834", "r835", "r836", "r837", "r838", "r839", "r840", "r841", "r842", "r843", "r844", "r845", "r846", "r847", "r848", "r849", "r850", "r851", "r852", "r853", "r854", "r855", "r856", "r857", "r858", "r859", "r860", "r861", "r862", "r863", "r864", "r865", "r866", "r867", "r868", "r869", "r870", "r871", "r872", "r873", "r874", "r875", "r876", "r877", "r878", "r879", "r880", "r881", "r882", "r883", "r884", "r885", "r886", "r887", "r888", "r889", "r890", "r891", "r892", "r893", "r894", "r895", "r896", "r897", "r898", "r899", "r900", "r901", "r902", "r903", "r904", "r905", "r906", "r907", "r908", "r909", "r910", "r911", "r912", "r913", "r914", "r915", "r916", "r917", "r918", "r919", "r920", "r921", "r922", "r923", "r924", "r925", "r926", "r927", "r928", "r929", "r930", "r931", "r932", "r933", "r934", "r935", "r936", "r937", "r938", "r939", "r940", "r941", "r942", "r943", "r944", "r945", "r946", "r947", "r948", "r949", "r950", "r951", "r952", "r953", "r954", "r955", "r956", "r957", "r958", "r959", "r960", "r961", "r962", "r963", "r964", "r965", "r966", "r967", "r968", "r969", "r970", "r971", "r972", "r973", "r974", "r975", "r976", "r977", "r978", "r979", "r980", "r981", "r982", "r983", "r984", "r985", "r986", "r987", "r988", "r989", "r990", "r991", "r992", "r993", "r994", "r995", "r996", "r997", "r998", "r999", "r1000", "r1001", "r1002", "r1003", "r1004", "r1005", "r1006", "r1007", "r1008", "r1009", "r1010", "r1011", "r1012", "r1013", "r1014", "r1015", "r1016", "r1017", "r1018", "r1019", "r1020", "r1021", "r1022", "r1023", "r1024", "r1025", "r1026", "r1027", "r1028", "r1029", "r1030", "r1031", "r1032", "r1033", "r1034", "r1035", "r1036", "r1037", "r1038", "r1039", "r1040", "r1041", "r1042", "r1043", "r1044", "r1045", "r1046", "r1047", "r1048", "r1049", "r1050", "r1051", "r1052", "r1053", "r1054", "r1055", "r1056", "r1057", "r1058", "r1059", "r1060", "r1061", "r1062", "r1063", "r1064", "r1065", "r1066", "r1067", "r1068", "r1069", "r1070", "r1071", "r1072", "r1073", "r1074", "r1075", "r1076", "r1077", "r1078", "r1079", "r1080", "r1081", "r1082", "r1083", "r1084", "r1085", "r1086", "r1087", "r1088", "r1089", "r1090", "r1091", "r1092", "r1093", "r1094", "r1095", "r1096", "r1097", "r1098", "r1099", "r1100", "r1101", "r1102", "r1103", "r1104", "r1105", "r1106", "r1107", "r1108", "r1109", "r1110", "r1111", "r1112", "r1113", "r1114", "r1115", "r1116", "r1117", "r1118", "r1119", "r1120", "r1121", "r1122", "r1123", "r1124", "r1125", "r1126", "r1127", "r1128", "r1129", "r1130", "r1131", "r1132", "r1133", "r1134", "r1135", "r1136", "r1137", "r1138", "r1139", "r1140", "r1141", "r1142", "r1143", "r1144", "r1145", "r1146", "r1147", "r1148", "r1149", "r1150", "r1151", "r1152", "r1153", "r1154", "r1155", "r1156", "r1157", "r1158", "r1159", "r1160", "r1161", "r1162", "r1163", "r1164", "r1165", "r1166", "r1167", "r1168", "r1169", "r1170", "r1171", "r1172", "r1173", "r1174", "r1175", "r1176", "r1177", "r1178", "r1179", "r1180", "r1181", "r1182", "r1183", "r1184", "r1185", "r1186", "r1187", "r1188", "r1189", "r1190", "r1191", "r1192", "r1193", "r1194", "r1195", "r1196", "r1197", "r1198", "r1199", "r1200", "r1201", "r1202", "r1203", "r1204", "r1205", "r1206", "r1207", "r1208", "r1209", "r1210", "r1211", "r1212", "r1213", "r1214", "r1215", "r1216", "r1217", "r1218", "r1219", "r1220", "r1221", "r1222", "r1223", "r1224", "r1225", "r1226", "r1227", "r1228", "r1229", "r1230", "r1231", "r1232", "r1233", "r1234", "r1235", "r1236", "r1237", "r1238", "r1239", "r1240", "r1241", "r1242", "r1243", "r1244", "r1245", "r1246", "r1247", "r1248", "r1249", "r1250", "r1251", "r1252", "r1253", "r1254", "r1255", "r1256", "r1257", "r1258", "r1259", "r1260", "r1261", "r1262", "r1263", "r1264", "r1265", "r1266", "r1267", "r1268", "r1269", "r1270", "r1271", "r1272", "r1273", "r1274", "r1275", "r1276", "r1277", "r1278", "r1279", "r1280", "r1281", "r1282", "r1283", "r1284", "r1285", "r1286", "r1287", "r1288", "r1289", "r1290", "r1291", "r1292", "r1293", "r1294", "r1295", "r1296", "r1297", "r1298", "r1299", "r1300", "r1301", "r1302", "r1303", "r1304", "r1305", "r1306", "r1307", "r1308", "r1309", "r1310", "r1311", "r1312", "r1313", "r1314", "r1315", "r1316", "r1317", "r1318", "r1319", "r1320", "r1321", "r1322", "r1323", "r1324", "r1325", "r1326", "r1327", "r1328", "r1329", "r1330", "r1331", "r1332", "r1333", "r1334", "r1335", "r1336", "r1337", "r1338", "r1339", "r1340", "r1341", "r1342", "r1343", "r1344", "r1345", "r1346", "r1347", "r1348", "r1349", "r1350", "r1351", "r1352", "r1353", "r1354", "r1355", "r1356", "r1357", "r1358", "r1359", "r1360", "r1361", "r1362", "r1363", "r1364", "r1365", "r1366", "r1367", "r1368", "r1369", "r1370", "r1371", "r1372", "r1373", "r1374", "r1375", "r1376", "r1377", "r1378", "r1379", "r1380", "r1381", "r1382", "r1383", "r1384", "r1385", "r1386", "r1387", "r1388", "r1389", "r1390", "r1391", "r1392", "r1393", "r1394", "r1395", "r1396", "r1397", "r1398", "r1399", "r1400", "r1401", "r1402", "r1403", "r1404", "r1405", "r1406", "r1407", "r1408", "r1409", "r1410", "r1411", "r1412", "r1413", "r1414", "r1415", "r1416", "r1417", "r1418", "r1419", "r1420", "r1421", "r1422", "r1423", "r1424", "r1425", "r1426", "r1427", "r1428", "r1429", "r1430", "r1431", "r1432", "r1433", "r1434", "r1435", "r1436", "r1437", "r1438", "r1439", "r1440", "r1441", "r1442", "r1443", "r1444", "r1445", "r1446", "r1447", "r1448", "r1449", "r1450", "r1451", "r1452", "r1453", "r1454", "r1455", "r1456", "r1457", "r1458", "r1459", "r1460", "r1461", "r1462", "r1463", "r1464", "r1465", "r1466", "r1467", "r1468", "r1469", "r1470", "r1471", "r1472", "r1473", "r1474", "r1475", "r1476", "r1477", "r1478", "r1479", "r1480", "r1481", "r1482", "r1483", "r1484", "r1485", "r1486", "r1487", "r1488", "r1489", "r1490", "r1491", "r1492", "r1493", "r1494", "r1495", "r1496", "r1497", "r1498", "r1499", "r1500", "r1501", "r1502", "r1503", "r1504", "r1505", "r1506", "r1507", "r1508", "r1509", "r1510", "r1511", "r1512", "r1513", "r1514", "r1515", "r1516", "r1517", "r1518", "r1519", "r1520", "r1521", "r1522", "r1523", "r1524", "r1525", "r1526", "r1527", "r1528", "r1529", "r1530", "r1531", "r1532", "r1533", "r1534", "r1535", "r1536", "r1537", "r1538", "r1539", "r1540", "r1541", "r1542", "r1543", "r1544", "r1545", "r1546", "r1547", "r1548", "r1549", "r1550", "r1551", "r1552", "r1553", "r1554", "r1555", "r1556", "r1557", "r1558", "r1559", "r1560", "r1561", "r1562", "r1563", "r1564", "r1565", "r1566", "r1567", "r1568", "r1569", "r1570", "r1571", "r1572", "r1573", "r157

```

"exercisePriceOfWarrantsOrRights": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "presentation": "http://www.canopygrowth.com/20241231/taxonomy/role/DisclosureCanopyUsaAdditionalInformationDetails", "lang": "en-us", "role": "terseLabel", "label": "Exercise price of warrants", "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights", "verboseLabel": "Weighted average exercise price of warrants", "documentation": "Exercise price per share or per unit of warrants or rights outstanding.", "auth_ref": "r549", "us-gaap": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "presentation": "http://www.canopygrowth.com/20241231/taxonomy/role/DisclosureShareCapitalSummaryOfWarrantsParentheticalDetails", "lang": "en-us", "role": "label", "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights", "terseLabel": "Warrants exercisable", "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.", "auth_ref": "r549", "us-gaap": "ClassOfWarrantOrRightOutstanding", "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightOutstanding", "presentation": "http://www.canopygrowth.com/20241231/taxonomy/role/End_DisclosureShareCapitalSummaryOfWarrantsDetails", "lang": "en-us", "role": "periodStartLabel", "label": "Number of whole warrants, Beginning balance", "periodEndLabel": "Number of whole warrants, Ending balance", "label": "Class of Warrant or Right, Outstanding", "documentation": "Number of warrants or rights outstanding.", "auth_ref": "r549", "us-gaap": "ClassOfWarrantOrRightUnissued", "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightUnissued", "presentation": "http://www.canopygrowth.com/20241231/taxonomy/role/DisclosureCanopyUsaAdditionalInformationDetails", "lang": "en-us", "role": "terseLabel", "label": "Warrants to acquire shares", "label": "Class of Warrant or Right, Unissued", "documentation": "The number of warrants or rights which entitle the entity to receive future services in exchange for the unvested, forfeitable warrants or rights.", "auth_ref": "r549", "us-gaap": "CommonStockAdditionalSharesIssued", "xbrltype": "sharesItemType", "nsuri": "http://www.canopygrowth.com/20241231", "localname": "CommonStockAdditionalSharesIssued", "presentation": "http://www.canopygrowth.com/20241231/taxonomy/role/DisclosureCanopyUsaAdditionalInformationDetails", "lang": "en-us", "role": "label", "label": "Common Stock Additional Shares Issued", "documentation": "Common stock additional shares issued.", "terseLabel": "Additional shares issued", "auth_ref": "r549", "us-gaap": "CommonStockAdditionalSharesIssued", "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/eod/2024", "localname": "CommonStockAdditionalSharesIssued", "presentation": "http://xbrl.sec.gov/eod/role/PvpDisclosure", "lang": "en-us", "role": "label", "label": "Company Selected Measure Amount", "terseLabel": "Company Selected Measure Amount", "auth_ref": "r1223", "us-gaap": "CommonStockAdditionalSharesIssued", "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/eod/2024", "localname": "CommonStockAdditionalSharesIssued", "presentation": "http://xbrl.sec.gov/eod/role/PvpDisclosure", "lang": "en-us", "role": "label", "label": "Company Selected Measure Name", "terseLabel": "Company Selected Measure Name", "auth_ref": "r1223", "us-gaap": "CommonStockAdditionalSharesIssued", "xbrltype": "domainItemType", "nsuri": "http://www.canopygrowth.com/20241231", "localname": "CommonStockAdditionalSharesIssued", "presentation": "http://www.canopygrowth.com/20241231/taxonomy/role/DisclosureCanopyUsaAdditionalInformationDetails", "lang": "en-us", "role": "terseLabel", "label": "Commitments and contingencies", "label": "Commitments and contingencies", "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.", "auth_ref": "r131", "us-gaap": "CommitmentsAndContingenciesDisclosureAbstract", "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingenciesDisclosureAbstract", "lang": "en-us", "role": "label", "label": "Commitments and Contingencies Disclosure [Abstract]", "auth_ref": "r131", "us-gaap": "CommitmentsAndContingenciesDisclosureTextBlock", "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "presentation": "http://www.canopygrowth.com/20241231/taxonomy/role/DisclosureCommitmentsAndContingencies", "lang": "en-us", "role": "terseLabel", "label": "Commitments and Contingencies", "label": "Commitments and Contingencies Disclosure [Text Block]", "documentation": "The entire disclosure for commitments and contingencies.", "auth_ref": "r182", "us-gaap": "CommonClassBMember", "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonClassBMember", "presentation": "http://www.canopygrowth.com/20241231/taxonomy/role/DisclosureCanopyUsaAdditionalInformationDetails", "lang": "en-us", "role": "terseLabel", "label": "Class B Shares", "label": "Common Class B [Member]", "documentation": "Classification of common stock that has different rights than Common Class A, representing ownership interest in a corporation.", "auth_ref": "r1479", "us-gaap": "CommonStockMember", "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockMember", "presentation": "http://www.canopygrowth.com/20241231/taxonomy/role/DisclosureCanopyUsaAdditionalInformationDetails", "lang": "en-us", "role": "terseLabel", "label": "Common Stock", "label": "Common Stock [Member]", "documentation": "Stock that is subordinate to all other stock of the issuer.", "auth_ref": "r1164", "us-gaap": "CommonStockParOrStatedValuePerShare", "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockParOrStatedValuePerShare", "presentation": "http://www.canopygrowth.com/20241231/taxonomy/role/DisclosureCanopyUsaAdditionalInformationDetails", "lang": "en-us", "role": "terseLabel", "label": "Common stock, par value", "label": "Common Stock, Par or Stated Value Per Share", "documentation": "Face amount or stated value per share of common stock.", "auth_ref": "r134", "us-gaap": "CommonStockSharesConversionRatio", "xbrltype": "pureItemType", "nsuri": "http://www.canopygrowth.com/20241231", "localname": "CommonStockSharesConversionRatio", "presentation": "http://www.canopygrowth.com/20241231/taxonomy/role/DisclosureCanopyUsaAdditionalInformationDetails", "lang": "en-us", "role": "terseLabel", "label": "Common stock shares conversion ratio", "label": "Common Stock Shares Conversion Ratio", "documentation": "Common stock shares conversion ratio.", "auth_ref": "r134", "us-gaap": "CommonStockSharesIssued", "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesIssued", "presentation": "http://www.canopygrowth.com/20241231/taxonomy/role/DisclosureCanopyUsaAdditionalInformationDetails", "lang": "en-us", "role": "terseLabel", "label": "Common stock, shares issued", "label": "Common Stock, Shares, Issued", "verboseLabel": "Additional common stock issued", "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "auth_ref": "r134", "us-gaap": "CommonStockSharesIssuedToMinorityInterests", "xbrltype": "sharesItemType", "nsuri": "http://www.canopygrowth.com/20241231", "localname": "CommonStockSharesIssuedToMinorityInterests", "presentation": "http://www.canopygrowth.com/20241231/taxonomy/role/DisclosureCanopyUsaAdditionalInformationDetails", "lang": "en-us", "role": "label", "label": "Common Stock Shares Issued to Minority Interests", "documentation": "Common stock shares issued to minority interests.", "terseLabel": "Common shares issued to minority interests", "auth_ref": "r134", "us-gaap": "CommonStockSharesOnHold", "xbrltype": "sharesItemType", "nsuri": "http://www.canopygrowth.com/20241231", "localname": "CommonStockSharesOnHold", "presentation": "http://www.canopygrowth.com/20241231/taxonomy/role/DisclosureCanopyUsaAdditionalInformationDetails", "lang": "en-us", "role": "label", "label": "Common Stock Shares On Hold", "documentation": "Common stock shares on hold.", "terseLabel": "Common stock shares on hold", "auth_ref": "r134", "us-gaap": "CommonStockSharesOutstanding", "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesOutstanding", "presentation": "http://www.canopygrowth.com/20241231/taxonomy/role/DisclosureCanopyUsaAdditionalInformationDetails", "lang": "en-us", "role": "terseLabel", "label": "Common stock, shares outstanding", "label": "Common Stock, Shares, Outstanding", "periodEndLabel": "Common Stock, Shares, Outstanding, Ending Balance", "periodStartLabel": "Common Stock, Shares, Outstanding, Beginning Balance", "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "auth_ref": "r134", "us-gaap": "CommonStockValue", "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockValue", "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "auth_ref": "r134", "us-gaap": "CommonStockValue", "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/eod/2024", "localname": "CommonStockValue", "presentation": "http://xbrl.sec.gov/eod/role/PvpDisclosure", "lang": "en-us", "role": "label", "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]", "terseLabel": "Compensation Actually Paid vs. Company Selected Measure", "auth_ref": "r1228", "us-gaap": "CompensationActuallyPaidVsNetIncomeTextBlock", "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/eod/2024", "localname": "CompensationActuallyPaidVsNetIncomeTextBlock", "presentation": "http://xbrl.sec.gov/eod/role/PvpDisclosure", "lang": "en-us", "role": "label", "label": "Compensation Actually Paid vs. Net Income [Text Block]", "terseLabel": "Compensation Actually Paid vs. Net Income", "auth_ref": "r1227", "us-gaap": "CompensationActuallyPaidVsOtherMeasureTextBlock", "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/eod/2024", "localname": "CompensationActuallyPaidVsOtherMeasureTextBlock", "presentation": "http://xbrl.sec.gov/eod/role/PvpDisclosure", "lang": "en-us", "role": "label", "label": "Compensation Actually Paid vs. Other Measure [Text Block]", "terseLabel": "Compensation Actually Paid vs. Other Measure", "auth_ref": "r1229", "us-gaap": "CompensationActuallyPaidVsTotalShareholderRtnTextBlock", "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/eod/2024", "localname": "CompensationActuallyPaidVsTotalShareholderRtnTextBlock", "presentation": "http://xbrl.sec.gov/eod/role/PvpDisclosure", "lang": "en-us", "role": "label", "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]", "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return", "auth_ref": "r1226", "us-gaap": "ComprehensiveIncomeLossNetOfTaxFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest", "xbrltype": "monetaryItemType", "nsuri": "http://www.canopygrowth.com/20241231", "localname": "ComprehensiveIncomeLossNetOfTaxFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest", "documentation": "Comprehensive income (loss), net of tax, from continuing operations including portion attributable to noncontrolling interest.", "label": "Comprehensive income (loss), net of tax, from continuing operations including portion attributable to noncontrolling interest", "terseLabel": "Comprehensive income loss from continuing operations", "totalLabel": "Comprehensive income (loss), net of tax, from continuing operations including portion attributable to noncontrolling interest, Total", "auth_ref": "r134", "us-gaap": "ComprehensiveIncomeLossNetOfTaxFromDiscontinuedOperationsAttributableToNoncontrollingInterestsAndRedeemableNoncontrollingInterest", "xbrltype": "monetaryItemType", "nsuri": "http://www.canopygrowth.com/20241231", "localname": "ComprehensiveIncomeLossNetOfTaxFromDiscontinuedOperationsAttributableToNoncontrollingInterestsAndRedeemableNoncontrollingInterest", "documentation": "Comprehensive income (loss), net of tax, from discontinued operations including portion attributable to noncontrolling interest and redeemable noncontrolling interest.", "label": "Comprehensive income loss from discontinued operations including portion attributable to noncontrolling interest and redeemable noncontrolling interest", "terseLabel": "Comprehensive income loss from discontinued operations including portion attributable to noncontrolling interest and redeemable noncontrolling interest, Total", "auth_ref": "r134", "us-gaap": "ComprehensiveIncomeLossNetOfTaxFromDiscontinuedOperationsAttributableToNoncontrollingInterestsAndRedeemableNoncontrollingInterest", "xbrltype
```

us": { "role": { "documentation": "Comprehensive Income (Loss), Net of Tax, from discontinued operations attributable to noncontrolling interests and redeemable noncontrolling interest.", "label": "Comprehensive Income (Loss), Net of Tax, from discontinued operations attributable to noncontrolling interests and redeemable noncontrolling interest", "terseLabel": "Comprehensive loss from discontinued operations attributable to noncontrolling interests and redeemable noncontrolling interest" } }, "auth_ref": { } }, "cgc_ComprehensiveIncomeLossNetOfTaxFromDiscontinuedOperationsIncludingPortionAttributableToNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://www.canopygrowth.com/20241231", "localname": "ComprehensiveIncomeLossNetOfTaxFromDiscontinuedOperationsIncludingPortionAttributableToNoncontrollingInterest", "crdr": "credit", "presentation": { "http://www.canopygrowth.com/20241231/taxonomy/role/StatementCondensedInterimConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited" }, "lang": { "en-us": { "role": { "terseLabel": "Comprehensive income (loss) from discontinued operations", "documentation": "Comprehensive income (loss), net of tax, from discontinued operations including portion attributable to noncontrolling interest.", "label": "Comprehensive income (loss), net of tax, from discontinued operations including portion attributable to noncontrolling interest" } } }, "auth_ref": { } }, "cgc_ComprehensiveIncomeLossNetOfTaxIncludingPortionAttributableToNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://www.canopygrowth.com/20241231", "localname": "ComprehensiveIncomeLossNetOfTaxIncludingPortionAttributableToNoncontrollingInterest", "crdr": "credit", "presentation": { "http://www.canopygrowth.com/20241231/taxonomy/role/Role-StatementCondensedInterimConsolidatedStatementsOfShareholderEquityUnaudited" }, "lang": { "en-us": { "role": { "terseLabel": "Comprehensive income (loss)", "label": "Comprehensive Income Loss Net Of Tax Including Portion Attributable To Noncontrolling Interest", "documentation": "Comprehensive income (loss), net of tax, including portion attributable to noncontrolling interest." } } }, "auth_ref": { } }, "us-gaap_ComprehensiveIncomeNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ComprehensiveIncomeNetOfTax", "crdr": "credit", "presentation": { "http://www.canopygrowth.com/20241231/taxonomy/role/StatementCondensedInterimConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited" }, "lang": { "en-us": { "role": { "totalLabel": "Comprehensive loss attributable to Canopy Growth Corporation", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners." } } }, "auth_ref": { "r34", "r277", "r279", "r286", "r819", "r847", "r948" } }, "us-gaap_ComprehensiveIncomeNetOfTaxAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ComprehensiveIncomeNetOfTaxAbstract", "presentation": { "http://www.canopygrowth.com/20241231/taxonomy/role/StatementCondensedInterimConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited" }, "lang": { "en-us": { "role": { "terseLabel": "Comprehensive income (loss)", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract]", "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners." } } }, "auth_ref": { } }, "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest", "crdr": "credit", "presentation": { "http://www.canopygrowth.com/20241231/taxonomy/role/StatementCondensedInterimConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited" }, "lang": { "en-us": { "role": { "totalLabel": "Comprehensive loss", "label": "Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest", "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners." } } }, "auth_ref": { "r90", "r199", "r277", "r279", "r285", "r818", "r847" } }, "us-gaap_ComprehensiveIncomeNoteTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ComprehensiveIncomeNoteTextBlock", "presentation": { "http://www.canopygrowth.com/20241231/taxonomy/role/Role-DisclosureAccumulatedOtherComprehensiveIncomeLoss", "lang": { "en-us": { "role": { "terseLabel": "Accumulated Other Comprehensive Income (Loss)", "label": "Comprehensive Income (Loss) Note [Text Block]", "documentation": "The entire disclosure for comprehensive income, which includes, but is not limited to, 1) the amount of income tax expense or benefit allocated to each component of other comprehensive income, including reclassification adjustments, 2) the reclassification adjustments for each classification of other comprehensive income and 3) the ending accumulated balances for each component of comprehensive income." } } }, "auth_ref": { "r146", "r284", "r817", "r845" } }, "us-gaap_ComputerEquipmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ComputerEquipmentMember", "presentation": { "http://www.canopygrowth.com/20241231/taxonomy/role/Role-DisclosurePropertyPlantAndEquipmentScheduleOfComponentsOfPropertyPlantAndEquipmentDetails", "lang": { "en-us": { "role": { "terseLabel": "Computer Equipment", "label": "Computer Equipment [Member]", "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems." } } }, "auth_ref": { } }, "us-gaap_ConcentrationRiskBenchmarkDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskBenchmarkDomain", "presentation": { "http://www.canopygrowth.com/20241231/taxonomy/role/Role-DisclosureSegmentInformationAdditionalInformationDetails", "lang": { "en-us": { "role": { "terseLabel": "Concentration Risk Benchmark", "label": "Concentration Risk Benchmark [Domain]", "documentation": "The denominator in a calculation of a disclosed concentration risk percentage." } } }, "auth_ref": { "r41", "r42", "r96", "r97", "r367", "r1070" } }, "us-gaap_ConcentrationRiskByBenchmarkAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskByBenchmarkAxis", "presentation": { "http://www.canopygrowth.com/20241231/taxonomy/role/Role-DisclosureSegmentInformationAdditionalInformationDetails", "lang": { "en-us": { "role": { "terseLabel": "Concentration Risk Benchmark", "label": "Concentration Risk Benchmark [Axis]", "documentation": "Information by benchmark of concentration risk." } } }, "auth_ref": { "r41", "r42", "r96", "r97", "r367", "r886", "r1070" } }, "us-gaap_ConcentrationRiskByTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskByTypeAxis", "presentation": { "http://www.canopygrowth.com/20241231/taxonomy/role/Role-DisclosureSegmentInformationAdditionalInformationDetails", "lang": { "en-us": { "role": { "terseLabel": "Concentration Risk Type", "label": "Concentration Risk Type [Axis]", "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender." } } }, "auth_ref": { "r41", "r42", "r96", "r97", "r367", "r1070", "r1270" } }, "cgc_ConcentrationRiskCustomerNumberOfCustomers": { "xbrltype": "integerItemType", "nsuri": "http://www.canopygrowth.com/20241231", "localname": "ConcentrationRiskCustomerNumberOfCustomers", "presentation": { "http://www.canopygrowth.com/20241231/taxonomy/role/Role-DisclosureSegmentInformationAdditionalInformationDetails", "lang": { "en-us": { "role": { "terseLabel": "Concentration risk customer number of customers", "label": "Concentration Risk Customer Number Of Customers", "documentation": "Concentration risk customer number of customers." } } }, "auth_ref": { } }, "us-gaap_ConcentrationRiskTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskTypeDomain", "presentation": { "http://www.canopygrowth.com/20241231/taxonomy/role/Role-DisclosureSegmentInformationAdditionalInformationDetails", "lang": { "en-us": { "role": { "terseLabel": "Concentration Risk Type", "label": "Concentration Risk Type [Domain]", "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration." } } }, "auth_ref": { "r41", "r42", "r96", "r97", "r367", "r1070" } }, "srt_ConsolidatedEntitiesAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ConsolidatedEntitiesAxis", "presentation": { "http://www.canopygrowth.com/20241231/taxonomy/role/DisclosureCanopyUsaAdditionalInformationDetails", "lang": { "en-us": { "role": { "terseLabel": "Consolidated Entities", "label": "Consolidated Entities [Axis]", "documentation": "Summary of net changes in redeemable noncontrolling interests details." } } }, "auth_ref": { "r298", "r656", "r657", "r662", "r663", "r739", "r1076", "r1365", "r1368", "r1369" } }, "srt_ConsolidatedEntitiesDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ConsolidatedEntitiesDomain", "presentation": { "http://www.canopygrowth.com/20241231/taxonomy/role/DisclosureCanopyUsaAdditionalInformationDetails", "lang": { "en-us": { "role": { "terseLabel": "Consolidated Entities", "label": "Consolidated Entities [Member]", "documentation": "Entities which have been consolidated for financial statement presentation purposes." } } }, "auth_ref": { } }, "us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTextBlock", "presentation": { "http://www.canopygrowth.com/20241231/taxonomy/role/Role-DisclosureNoncontrollingInterestsTables", "lang": { "en-us": { "role": { "terseLabel": "Summary of Net Change in Noncontrolling Interests", "label": "Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Table Text Block]", "documentation": "The tabular disclosure of the effects of any changes in a parent's ownership interest in a subsidiary on the equity attributable to the parent if the ownership interests in a subsidiary changes during the period. The changes represented by this element did not result in the deconsolidation of the subsidiary." } } }, "auth_ref": { "r18", "r91" } }, "us-gaap_ConsolidationPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConsolidationPolicyTextBlock", "presentation": { "http://www.canopygrowth.com/20241231/taxonomy/role/Role-DisclosureSummaryOfSignificantAccountingPolicies", "lang": { "en-us": { "role": { "terseLabel": "Principles of consolidation", "label": "Consolidation, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary." } } }, "auth_ref": { "r83", "r1092" } }, "us-gaap_ConsolidationVariableInterestEntityPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConsolidationVariableInterestEntityPolicy", "presentation": { "http://www.canopygrowth.com/20241231/taxonomy/role/Role-DisclosureSummaryOfSignificantAccountingPolicies", "lang": { "en-us": { "role": { "label": "Consolidation, Variable Interest Entity, Policy [Policy Text Block]", "terseLabel": "Variable interest entities", "documentation": "Disclosure of accounting policy for consolidation to describe the significant judgments and assumptions made in determining whether a variable interest held by the entity requires the variable interest entity to be consolidated and (or) disclose information about its involvement with the variable interest entity; the methodology used by the entity for determining whether or not it is the primary beneficiary of the variable interest entity; and the significant factors considered and judgments made in determining that the power to direct the activities that significantly impact the economic performance of the variable interest entity are shared (as defined)."} } }, "auth_ref": { "r80", "r86", "r87" } }, "cgc_ConsumerProductsAndOtherMember": { "xbrltype": "domainItemType", "nsuri": "http://www.canopygrowth.com/20241231", "localname": "ConsumerProductsAndOtherMember", "presentation": { "http://www.canopygrowth.com/20241231/taxonomy/role/Role-DisclosureRevenueSummaryOfDisaggregationOfRevenueDetails", "lang": { "en-us": { "role": { "terseLabel": "Consumer Products and Other", "label": "Consumer Products And Other [Member]", "documentation": "Consumer products and other member." } } }, "auth_ref": { } }, "cgc_ConversionOfOutstandingDebenturesDescription": { "xbrltype": "stringItemType", "nsuri": "http://www.canopygrowth.com/20241231", "localname": "ConversionOfOutstandingDebenturesDescription", "presentation": { "http://www.canopygrowth.com/20241231/taxonomy/role/Role-DisclosureDebtAdditionalInformationDetails", "lang": { "en-us": { "role": { "terseLabel": "Conversion Of Outstanding Debentures Description", "label": "Conversion Of Outstanding Debentures Description", "documentation": "Conversion Of Outstanding Debentures Description"} } }, "auth_ref": { } }, "cgc_ConvertibleDebtAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.canopygrowth.com/20241231", "localname": "ConvertibleDebtAgreementMember", "presentation": { "http://www.canopygrowth.com/20241231/taxonomy/role/Role-DisclosureDebtAdditionalInformationDetails", "lang": { "en-us": { "role": { "label": "Convertible Debt Agreement [Member]", "documentation": "Convertible debt agreement." } } }, "auth_ref": { } }, "cgc_ConvertibleDebentures": { "xbrltype": "monetaryItemType", "nsuri": "http://www.canopygrowth.com/20241231", "localname": "ConvertibleDebentures", "crdr": "credit", "presentation": { "http://www.canopygrowth.com/20241231/taxonomy/role/Role-DisclosureDebtSummaryOfComponentsOfDebtDetails", "lang": { "en-us": { "role": {

"verboseLabel": "Supreme convertible debentures", "terseLabel": "Convertible debentures", "label": "Convertible Debentures", "documentation": "Convertible debentures." } } }
"auth_ref": { } }, "cgc_ConvertibleDebenturesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.canopygrowth.com/20241231", "localname":
"ConvertibleDebenturesMember", "presentation": { "http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails" }, "lang": {
"en-us": { "role": { "documentation": "Convertible Debentures [Member]", "label": "Convertible Debentures [Member]", "terseLabel": "Convertible Debentures" } } },
"auth_ref": { } }, "us-gaap_CostOfGoodsAndServicesSold": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"CostOfGoodsAndServicesSold", "crdr": "debit", "presentation": { }
"http://www.canopygrowth.com/20241231/taxonomy/role/StatementCondensedInterimConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited" }, "lang": { "en-
us": { "role": { "totalLabel": "Cost of Goods and Services Sold, Total", "terseLabel": "Cost of goods sold", "label": "Cost of Goods and Services Sold", "documentation": "The
aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period
related to financial services rendered and other revenue generating activities." } } }, "auth_ref": { "r155", "r156", "r782" } }, "us-gaap_CostOfSalesMember": { "xbrltype":
"domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CostOfSalesMember", "presentation": { }
"http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureIntangibleAssetsAdditionalInformationDetails",
"http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosurePropertyPlantAndEquipmentAdditionalInformationDetails" }, "lang": { "en-us": { "role": {
"verboseLabel": "Costs Recorded in Cost of Goods Sold", "label": "Cost of Sales [Member]", "documentation": "Primary financial statement caption encompassing cost of
sales." } } }, "auth_ref": { } }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CoverAbstract", "lang": { "en-us": {
"role": { "terseLabel": "Cover", "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": { } }, "cgc_CreditFacility": { "xbrltype": "monetaryItemType",
"nsuri": "http://www.canopygrowth.com/20241231", "localname": "CreditFacility", "crdr": "credit", "presentation": { }
"http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureDebtSummaryOfComponentsOfDebtDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Credit
facility", "label": "Credit Facility", "documentation": "Credit facility" } } }, "auth_ref": { } }, "cgc_CreditFacilityMember": { "xbrltype": "domainItemType", "nsuri":
"http://www.canopygrowth.com/20241231", "localname": "CreditFacilityMember", "presentation": { }
"http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Credit Facility
[Member]", "label": "Credit Facility [Member]", "documentation": "Credit facility." } } }, "auth_ref": { } }, "srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember": { "xbrltype":
"domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "CumulativeEffectPeriodOfAdoptionAdjustmentMember", "presentation": { }
"http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureBasisOfPresentationAdditionalInformationDetails" }, "lang": { "en-us": { "role": { "terseLabel":
"Cumulative effect from adoption of ASU 2020-06", "label": "Cumulative Effect, Period of Adoption, Adjustment [Member]" } } }, "auth_ref": { "r240", "r302", "r308", "r315",
"r414", "r420", "r469", "r620", "r621", "r636", "r638", "r667", "r668", "r669", "r671", "r672", "r673", "r679", "r682", "r684", "r685", "r733" } },
"srt_CumulativeEffectPeriodOfAdoptionAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "CumulativeEffectPeriodOfAdoptionAxis",
"presentation": { "http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureBasisOfPresentationAdditionalInformationDetails" }, "lang": { "en-us": { "role": {
"terseLabel": "Cumulative Effect, Period of Adoption", "label": "Cumulative Effect, Period of Adoption [Axis]" } } }, "auth_ref": { "r240", "r302", "r308", "r315", "r414", "r420",
"r469", "r620", "r621", "r636", "r638", "r667", "r668", "r669", "r671", "r672", "r673", "r679", "r682", "r684", "r685", "r733" } },
"srt_CumulativeEffectPeriodOfAdoptionDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname":
"CumulativeEffectPeriodOfAdoptionDomain", "presentation": { }
"http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureBasisOfPresentationAdditionalInformationDetails" }, "lang": { "en-us": { "role": { "terseLabel":
"Cumulative Effect, Period of Adoption", "label": "Cumulative Effect, Period of Adoption [Domain]" } } }, "auth_ref": { "r240", "r302", "r308", "r315", "r414", "r420", "r469",
"r620", "r621", "r636", "r638", "r667", "r668", "r669", "r671", "r672", "r673", "r679", "r682", "r684", "r685", "r733" } }, "dei_CurrentFiscalYearEndDate": { "xbrltype":
"gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CurrentFiscalYearEndDate", "presentation": { }
"http://www.canopygrowth.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" }, "lang": { "en-us": { "role": { "terseLabel": "Current Fiscal Year End
Date", "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format-MM-DD." } } }, "auth_ref": { } }, "us-
gaap_CustomerConcentrationRiskMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CustomerConcentrationRiskMember",
"presentation": { "http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureSegmentInformationAdditionalInformationDetails" }, "lang": { "en-us": { "role": {
"terseLabel": "Customer Concentration Risk", "label": "Customer Concentration Risk [Member]", "documentation": "Reflects the percentage that revenues in the period from
one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially
adverse effects of loss of a significant customer." } } }, "auth_ref": { "r171", "r367" } }, "country_DE": { "xbrltype": "domainItemType", "nsuri":
"http://xbrl.sec.gov/country/2024", "localname": "DE", "presentation": { }
"http://www.canopygrowth.com/20241231/taxonomy/role/DisclosureSegmentInformationSummaryOfDisaggregationOfPropertyPlantAndEquipmentByGeographicAreaDetails",
"http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureSegmentInformationSummaryOfDisaggregationOfNetRevenueByGeographicAreaDetails" }, "lang": {
"en-us": { "role": { "terseLabel": "Germany", "label": "GERMANY" } } }, "auth_ref": { } }, "cgc_DebentureMember": { "xbrltype": "domainItemType", "nsuri":
"http://www.canopygrowth.com/20241231", "localname": "DebentureMember", "presentation": { }
"http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureAcreageArrangementAdditionalInformationDetails",
"http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureOtherFinancialAssetsSummaryOfChangesInOtherFinancialAssetsDetails" }, "lang": { "en-us": { "role": {
"terseLabel": "Debenture", "label": "Debenture [Member]", "documentation": "Debenture" } } }, "auth_ref": { } }, "cgc_DebenturesBearInterestRatePerAnnum": { "xbrltype":
"percentItemType", "nsuri": "http://www.canopygrowth.com/20241231", "localname": "DebenturesBearInterestRatePerAnnum", "presentation": { }
"http://www.canopygrowth.com/20241231/taxonomy/role/DisclosureAcreageArrangementAdditionalInformationDetails" }, "lang": { "en-us": { "role": { "terseLabel":
"Debentures bear interest rate per annum", "label": "Debentures Bear Interest Rate Per Annum", "documentation": "Debentures bear interest rate per annum." } } },
"auth_ref": { } }, "us-gaap_DebtConversionDescription": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtConversionDescription",
"presentation": { "http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails" }, "lang": { "en-us": { "role": { "terseLabel":
"Debt Conversion, Description", "label": "Debt Conversion, Description", "documentation": "Description of conversion of original debt instrument in noncash or part noncash
transaction." } } }, "auth_ref": { } }, "us-gaap_DebtDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"DebtDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Debt Disclosure [Abstract]" } } }, "auth_ref": { } }, "us-gaap_DebtDisclosureTextBlock": { "xbrltype":
"textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtDisclosureTextBlock", "presentation": { }
"http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureDebt", "lang": { "en-us": { "role": { "terseLabel": "Debt", "label": "Debt Disclosure [Text Block]",
"documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit,
note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the
underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities,
whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance
with debt covenants." } } }, "auth_ref": { "r183", "r294", "r472", "r473", "r474", "r475", "r476", "r494", "r495", "r505", "r511", "r512", "r513", "r514", "r515", "r516", "r521",
"r528", "r529", "r531", "r724" } }, "cgc_DebtFairValueAdjustment": { "xbrltype": "monetaryItemType", "nsuri": "http://www.canopygrowth.com/20241231", "localname":
"DebtFairValueAdjustment", "crdr": "credit", "presentation": { }
"http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureOtherIncomeExpenseNetScheduleOfOtherIncomeExpenseNetDetails" }, "lang": { "en-us": { "role": {
"terseLabel": "Fair value changes on debt", "label": "Debt Fair Value Adjustment", "documentation": "Debt fair value adjustment." } } }, "auth_ref": { } },
"cgc_DebtInstrumentAcquired": { "xbrltype": "monetaryItemType", "nsuri": "http://www.canopygrowth.com/20241231", "localname": "DebtInstrumentAcquired", "crdr":
"debit", "presentation": { "http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails" }, "lang": { "en-us": { "role": {
"verboseLabel": "Debt instrument acquired", "label": "Debt Instrument Acquired", "documentation": "Debt instrument acquired." } } }, "auth_ref": { } },
"cgc_DebtInstrumentAggregatePurchasePrice": { "xbrltype": "monetaryItemType", "nsuri": "http://www.canopygrowth.com/20241231", "localname":
"DebtInstrumentAggregatePurchasePrice", "crdr": "debit", "presentation": { }
"http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Aggregate purchase
price", "label": "Debt Instrument Aggregate Purchase Price", "documentation": "Debt instrument aggregate purchase price." } } }, "auth_ref": { } },
"cgc_DebtInstrumentAggregateRedemptionAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://www.canopygrowth.com/20241231", "localname":
"DebtInstrumentAggregateRedemptionAmount", "crdr": "credit", "presentation": { }
"http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Aggregate
redemption amount", "label": "Debt Instrument Aggregate Redemption Amount", "documentation": "Debt instrument aggregate redemption amount." } } }, "auth_ref": { } },
"us-gaap_DebtInstrumentAnnualPrincipalPayment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"DebtInstrumentAnnualPrincipalPayment", "crdr": "debit", "presentation": { }
"http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails" }, "lang": { "en-us": { "role": { "label": "Debt Instrument, Annual
Principal Payment", "terseLabel": "Aggregate principal payment amount", "documentation": "Amount of annual principal payment for debt instrument." } } }, "auth_ref": {
"r29" } }, "us-gaap_DebtInstrumentAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentAxis", "presentation": { }
"http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureBasisOfPresentationAdditionalInformationDetails",
"http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails",
"http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureDebtSummaryOfComponentsOfDebtDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Debt
Instrument", "label": "Debt Instrument [Axis]", "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities." } } },
"auth_ref": { "r29", "r124", "r125", "r206", "r209", "r298", "r506", "r507", "r508", "r509", "r510", "r512", "r517", "r518", "r519", "r520", "r522", "r523", "r524", "r525", "r526",
"r527", "r1110", "r1111", "r1112", "r1113", "r1114", "r1146", "r1303", "r1355", "r1356", "r1357", "r1426", "r1427" } }, "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1":
{ "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentBasisSpreadOnVariableRate1", "presentation": { }
"http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails" }, "lang": { "en-us": { "role": { "label": "Debt Instrument, Basis
Spread on Variable Rate", "terseLabel": "Credit agreement borrowing rate", "documentation": "Percentage points added to the reference rate to compute the variable rate on
the debt instrument." } } }, "auth_ref": { } }, "us-gaap_DebtInstrumentCallDateEarliest": { "xbrltype": "dateItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"DebtInstrumentCallDateEarliest", "presentation": { }
"http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureOtherFinancialAssetsAdditionalInformationDetails" }, "lang": { "en-us": { "role": { "label": "Debt
Instrument, Call Date, Earliest", "terseLabel": "Earliest date to call", "documentation": "Earliest date before maturity when the issuer can call the outstanding debt instrument
for repayment or conversion to equity, in YYYY-MM-DD format." } } }, "auth_ref": { "r29", "r60", "r220" } }, "us-gaap_DebtInstrumentCallDateLatest": { "xbrltype":
"dateItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentCallDateLatest", "presentation": { }
"http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureOtherFinancialAssetsAdditionalInformationDetails" }, "lang": { "en-us": { "role": { "label": "Debt
Instrument, Call Date, Latest", "terseLabel": "Latest date to call", "documentation": "Latest date before maturity which the issuer can call the outstanding debt instrument for
repayment or conversion to equity, in YYYY-MM-DD format." } } }, "auth_ref": { "r29", "r60", "r220" } }, "us-gaap_DebtInstrumentCallFeature": { "xbrltype": "stringItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentCallFeature", "presentation": { }
"http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureOtherFinancialAssetsAdditionalInformationDetails" }, "lang": { "en-us": { "role": { "label": "Debt
Instrument, Call Feature", "terseLabel": "Description of call feature", "documentation": "Description of a feature that permits the issuer of the debt to repay or convert it
before the stated maturity date (early retirement date). The description may include such items as the call price, the period that the issuer can call the debt, including the
earliest call date, and other significant terms of the call feature, which may include the debt holders' ability to convert the debt to equity if the call option is exercised and
contingent events that trigger the issuer's ability to call the debt." } } }, "auth_ref": { "r128", "r220" } }, "cgc_DebtInstrumentCancelled": { "xbrltype": "monetaryItemType",
"nsuri": "http://www.canopygrowth.com/20241231", "localname": "DebtInstrumentCancelled", "crdr": "debit", "presentation": { }
"http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails" }, "lang": { "en-us": { "role": { "verboseLabel": "Debt instrument
cancelled", "label": "Debt Instrument Cancelled", "documentation": "Debt instrument cancelled." } } }, "auth_ref": { } }, "us-
gaap_DebtInstrumentConvertibleConversionPrice1": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":

```

"DebtInstrumentConvertibleConversionPrice": {"presentation": "http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails", "lang": "en-us", "role": "terseLabel", "label": "Conversion price", "documentation": "The price per share of the conversion feature embedded in the debt instrument." }, {"auth_ref": "r184", "cgc_DebtInstrumentConvertibleConversionPriceMeasurementPeriod": {"xbrltype": "perShareItemType", "nsuri": "http://www.canopygrowth.com/20241231", "localname": "DebtInstrumentConvertibleConversionPriceMeasurementPeriod", "presentation": "http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails", "lang": "en-us", "role": "terseLabel", "label": "Convertible conversion price", "documentation": "Debt instrument convertible conversion price measurement period." }, {"auth_ref": "cgc_DebtInstrumentConvertibleConversionPricePercentage": {"xbrltype": "percentItemType", "nsuri": "http://www.canopygrowth.com/20241231", "localname": "DebtInstrumentConvertibleConversionPricePercentage", "presentation": "http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails", "lang": "en-us", "role": "terseLabel", "label": "Debt Instrument Convertible Conversion Price percentage", "documentation": "Debt instrument convertible conversion price percentage." }, {"auth_ref": "cgc_DebtInstrumentConvertibleMeasurementThresholdConsecutiveTradingPeriod": {"xbrltype": "durationItemType", "nsuri": "http://www.canopygrowth.com/20241231", "localname": "DebtInstrumentConvertibleMeasurementThresholdConsecutiveTradingPeriod", "presentation": "http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails", "lang": "en-us", "role": "terseLabel", "label": "Convertible measurement period threshold consecutive trading days", "documentation": "Debt instrument convertible measurement threshold consecutive trading period." }, {"auth_ref": "cgc_DebtInstrumentConvertibleMeasurementThresholdTradingPeriod": {"xbrltype": "durationItemType", "nsuri": "http://www.canopygrowth.com/20241231", "localname": "DebtInstrumentConvertibleMeasurementThresholdTradingPeriod", "presentation": "http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails", "lang": "en-us", "role": "terseLabel", "label": "Convertible measurement period threshold trading period", "documentation": "Debt instrument convertible measurement threshold trading period." }, {"auth_ref": "us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays": {"xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentConvertibleThresholdConsecutiveTradingDays", "presentation": "http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails", "lang": "en-us", "role": "terseLabel", "label": "Threshold consecutive trading days", "documentation": "Threshold period of specified consecutive trading days within which common stock price to conversion price of convertible debt instrument must exceed threshold percentage for specified number of trading days to trigger conversion feature." }, {"auth_ref": "us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger": {"xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger", "presentation": "http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails", "lang": "en-us", "role": "terseLabel", "label": "Conversion price percentage", "documentation": "Minimum percentage of common stock price to conversion price of convertible debt instruments to determine eligibility of conversion." }, {"auth_ref": "cgc_DebtInstrumentDiscountedPrice": {"xbrltype": "monetaryItemType", "nsuri": "http://www.canopygrowth.com/20241231", "localname": "DebtInstrumentDiscountedPrice", "credit": "presentation": "http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails", "lang": "en-us", "role": "terseLabel", "label": "Debt instrument discounted price", "documentation": "Debt instrument discounted price." }, {"auth_ref": "cgc_DebtInstrumentDiscountedPricePerUsDollar": {"xbrltype": "perShareItemType", "nsuri": "http://www.canopygrowth.com/20241231", "localname": "DebtInstrumentDiscountedPricePerUsDollar", "presentation": "http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails", "lang": "en-us", "role": "terseLabel", "label": "Debt instrument discounted price per us dollar", "documentation": "Debt instrument discounted price per us dollar." }, {"auth_ref": "us-gaap_DebtInstrumentFaceAmount": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentFaceAmount", "credit": "presentation": "http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails", "lang": "en-us", "role": "terseLabel", "label": "Debt instrument face amount", "documentation": "Debt instrument face amount." }, {"auth_ref": "cgc_DebtInstrumentFairValueOfCommonShares": {"xbrltype": "monetaryItemType", "nsuri": "http://www.canopygrowth.com/20241231", "localname": "DebtInstrumentFairValueOfCommonShares", "credit": "presentation": "http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails", "lang": "en-us", "role": "terseLabel", "label": "Debt instrument fair value of common shares", "documentation": "Debt instrument fair value of common shares." }, {"auth_ref": "cgc_DebtInstrumentFairValueRedeemed": {"xbrltype": "monetaryItemType", "nsuri": "http://www.canopygrowth.com/20241231", "localname": "DebtInstrumentFairValueRedeemed", "credit": "presentation": "http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails", "lang": "en-us", "role": "terseLabel", "label": "Debt instrument fair value redeemed", "documentation": "Debt instrument fair value redeemed." }, {"auth_ref": "cgc_DebtInstrumentFinalClosingTradingDays": {"xbrltype": "durationItemType", "nsuri": "http://www.canopygrowth.com/20241231", "localname": "DebtInstrumentFinalClosingTradingDays", "presentation": "http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails", "lang": "en-us", "role": "terseLabel", "label": "Debt instrument final closing trading days", "documentation": "Debt instrument final closing trading days." }, {"auth_ref": "us-gaap_DebtInstrumentFrequencyOfPeriodicPayment": {"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentFrequencyOfPeriodicPayment", "presentation": "http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails", "lang": "en-us", "role": "terseLabel", "label": "Frequency of periodic payment team", "documentation": "Description of the frequency of periodic payments (monthly, quarterly, annual)."}, {"auth_ref": "r29", "r100": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentIncreaseAccruedInterest", "credit": "presentation": "http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails", "lang": "en-us", "role": "terseLabel", "label": "Debt instrument increase accrued interest", "documentation": "Increase for accrued, but unpaid interest on the debt instrument for the period." }, {"auth_ref": "r1303": {"xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentInterestRateStatedPercentage", "presentation": "http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails", "lang": "en-us", "role": "terseLabel", "label": "Debt instrument interest rate stated percentage", "documentation": "Contractual interest rate for funds borrowed under the debt agreement." }, {"auth_ref": "r127", "r507": {"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentLineItems", "presentation": "http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails", "lang": "en-us", "role": "terseLabel", "label": "Debt instrument line items", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." }, {"auth_ref": "r298", "r506", "r507", "r508", "r509", "r510", "r512", "r517", "r518", "r519", "r520", "r522", "r523", "r524", "r525", "r526", "r527", "r530", "r1110", "r1112", "r1113", "r1114", "r1146", "r1303", "r1426", "r1427": {"xbrltype": "dateItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentMaturityDate", "presentation": "http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails", "lang": "en-us", "role": "terseLabel", "label": "Debt instrument maturity date", "documentation": "Date when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format." }, {"auth_ref": "r259", "r1110", "r1415", "r1416": {"xbrltype": "percentItemType", "nsuri": "http://www.canopygrowth.com/20241231", "localname": "DebtInstrumentMonthlyInterestRatePercentage", "presentation": "http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails", "lang": "en-us", "role": "terseLabel", "label": "Debt instrument monthly interest rate percentage", "documentation": "Debt instrument monthly interest rate percentage." }, {"auth_ref": "us-gaap_DebtInstrumentNameDomain": {"xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentNameDomain", "presentation": "http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails", "lang": "en-us", "role": "terseLabel", "label": "Debt instrument name domain", "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities." }, {"auth_ref": "r29", "r298", "r506", "r507", "r508", "r509", "r510", "r512", "r517", "r518", "r519", "r520", "r522", "r523", "r524", "r525", "r526", "r527", "r1110", "r1112", "r1113", "r1114", "r1446", "r1303", "r1355", "r1356", "r1357", "r1426", "r1427": {"xbrltype": "monetaryItemType", "nsuri": "http://www.canopygrowth.com/20241231", "localname": "DebtInstrumentPrincipalRedemption", "credit": "presentation": "http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails", "lang": "en-us", "role": "terseLabel", "label": "Debt instrument principal redemption", "documentation": "Debt instrument principal redemption." }, {"auth_ref": "cgc_DebtInstrumentPrincipalReduction": {"xbrltype": "monetaryItemType", "nsuri": "http://www.canopygrowth.com/20241231", "localname": "DebtInstrumentPrincipalReduction", "credit": "presentation": "http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails", "lang": "en-us", "role": "terseLabel", "label": "Debt instrument principal reduction", "documentation": "Debt instrument principal reduction." }, {"auth_ref": "cgc_DebtInstrumentPutDateEarliest": {"xbrltype": "dateItemType", "nsuri": "http://www.canopygrowth.com/20241231", "localname": "DebtInstrumentPutDateEarliest", "presentation": "http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails", "lang": "en-us", "role": "terseLabel", "label": "Debt instrument put date earliest", "documentation": "Earliest date when the issuer can put the outstanding debt instrument for repayment or conversion to equity." }, {"auth_ref": "us-gaap_DebtInstrumentRedemptionDescription": {"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentRedemptionDescription", "presentation": "http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails", "lang": "en-us", "role": "terseLabel", "label": "Debt instrument redemption description", "documentation": "Description of debt redemption features under terms of the debt agreement." }, {"auth_ref": "r220": {"xbrltype": "dateItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentRedemptionPeriodStartDate", "presentation": "http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails", "lang": "en-us", "role": "terseLabel", "label": "Debt instrument redemption period start date", "documentation": "Start date of debt instrument redemption period, in YYYY-MM-DD format." }, {"auth_ref": "r220": {"xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentRedemptionPricePercentage", "presentation": "http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails", "lang": "en-us", "role": "terseLabel", "label": "Debt instrument redemption price percentage", "documentation": "Percentage price of original principal amount of debt at which debt can be redeemed by the issuer." }, {"auth_ref": "cgc_DebtInstrumentRedemptionThresholdConsecutiveTradingPeriod": {"xbrltype": "durationItemType", "nsuri": "http://www.canopygrowth.com/20241231", "localname": "DebtInstrumentRedemptionThresholdConsecutiveTradingPeriod", "presentation": "http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails", "lang": "en-us", "role": "terseLabel", "label": "Debt instrument redemption threshold consecutive trading days", "documentation": "De
```

redemption threshold trading days." "label": "Debt Instrument Redemption Threshold Trading Period", "documentation": "Debt instrument redemption threshold trading period." } } }, "auth_ref": "f" } }, "cgc_DebtInstrumentSharesAcquiredPercentage": { "xbrltype": "percentageItemType", "nsuri": "http://www.canopygrowth.com/20241231", "localname": "DebtInstrumentSharesAcquiredPercentage", "presentation": { "http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Percentage of shares acquired", "label": "Debt Instrument Shares Acquired Percentage", "documentation": "Debt instrument shares acquired percentage." } } }, "auth_ref": "f" }, "us-gaap_DebtInstrumentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentTable", "presentation": { "http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument Table", "label": "Schedule of Long-Term Debt Instruments Table", "documentation": "Disclosure of information about long-term debt instrument or arrangement." } } }, "auth_ref": "f" } }, "r29", "r60", "r63", "r99", "r189", "r190", "r298", "r506", "r507", "r508", "r509", "r510", "r512", "r517", "r518", "r519", "r520", "r522", "r523", "r524", "r525", "r526", "r527", "r530", "r1110", "r1111", "r1112", "r1113", "r1114", "r1146", "r1303", "r1426", "r1427" } } }, "us-gaap_DebtInstrumentsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentsAbstract", "lang": { "en-us": { "role": { "label": "Debt Instruments Abstract" } } }, "auth_ref": "f" }, "us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestWriteoff": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtSecuritiesAvailableForSaleAccruedInterestWriteoff", "crdr": "debit", "presentation": { "http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Accrued and unpaid interest", "label": "Debt Securities, Available-for-Sale, Accrued Interest Writeoff", "documentation": "Amount of writeoff of accrued interest on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), recognized by reversing interest income." } } }, "auth_ref": "f" } }, "r429" } } }, "cgc_DebtToBeExchanged": { "xbrltype": "monetaryItemType", "nsuri": "http://www.canopygrowth.com/20241231", "localname": "DebtToBeExchanged", "crdr": "credit", "presentation": { "http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureBasisOfPresentationAdditionalInformationDetails" }, "lang": { "en-us": { "role": { "documentation": "Debt to be exchanged", "label": "Debt to be Exchanged", "terseLabel": "Debt to be exchanged" } } }, "auth_ref": "f" }, "us-gaap_DeconsolidationGainOrLossAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeconsolidationGainOrLossAmount", "crdr": "credit", "presentation": { "http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureBiosteelSummaryOfDeconsolidationAndCostsToExitClassifiedAsDiscontinuedOperationsParentheticalDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Gain (loss) on deconsolidation", "label": "Deconsolidation, Gain (Loss), Amount", "documentation": "Amount of gain (loss) from deconsolidation of subsidiary and derecognition of group of assets constituting transfer of business or nonprofit activity, excluding conveyance of oil and gas mineral rights and transfer of good or service in contract with customer." } } }, "auth_ref": "f" } }, "r85" } } }, "us-gaap_DeferredFinanceCostsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredFinanceCostsNet", "crdr": "debit", "presentation": { "http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureDebtSummaryOfComponentsOfDebtDetails" }, "lang": { "en-us": { "role": { "totalLabel": "Debt Issuance Costs, Net, Total", "label": "Debt Issuance Costs, Net", "negatedLabel": "Deferred financing costs", "documentation": "Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs." } } }, "auth_ref": "f" } }, "r1371", "r1425", "r1426", "r1427" } } }, "us-gaap_DeferredIncomeTaxLiabilitiesNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredIncomeTaxLiabilitiesNet", "crdr": "credit", "presentation": { "http://www.canopygrowth.com/20241231/taxonomy/role/Role_StatementCondensedInterimConsolidatedBalanceSheetsUnaudited" }, "lang": { "en-us": { "role": { "label": "Deferred Income Tax Liabilities, Net", "terseLabel": "Deferred income tax liabilities", "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting." } } }, "auth_ref": "f" } }, "r611", "r612", "r826" } } }, "us-gaap_DepositsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DepositsMember", "presentation": { "http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureShortTermInvestmentsComponentsOfShortTermInvestmentsDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Term Deposits", "label": "Deposits Member", "documentation": "Amounts held on account by the entity representing a liability to the depositor. Deposits may take various forms (for example, demand deposits, saving deposits, Negotiable Order of Withdrawal (NOW) and time deposits) and may be categorized in multiple ways (such as, foreign and domestic, interest and noninterest bearing)." } } }, "auth_ref": "f" } }, "r219" } } }, "us-gaap_Depreciation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Depreciation", "crdr": "debit", "presentation": { "http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosurePropertyPlantAndEquipmentAdditionalInformationDetails" }, "lang": { "en-us": { "role": { "totalLabel": "Depreciation, Total", "terseLabel": "Depreciation of property, plant and equipment", "label": "Depreciation", "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation." } } }, "auth_ref": "f" } }, "r11", "r52" } } }, "us-gaap_DerivativeFairValueOfDerivativeLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeFairValueOfDerivativeLiability", "crdr": "credit", "presentation": { "http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtEstimatedFairValue", "lang": { "en-us": { "role": { "terseLabel": "Derivative Liability", "label": "Derivative Liability", "documentation": "Fair value, before effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities elected not to be offset. Excludes liabilities not subject to a master netting arrangement." } } }, "auth_ref": "f" } }, "r26", "r145", "r202", "r203", "r270", "r1091" } } }, "us-gaap_DerivativeLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeLiabilities", "crdr": "credit", "presentation": { "http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails" }, "lang": { "en-us": { "role": { "totalLabel": "Derivative Liability, Total", "terseLabel": "Derivative Liability", "label": "Derivative Liability", "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset." } } }, "auth_ref": "f" } }, "r271", "r272", "r688", "r689", "r702", "r712", "r912", "r913", "r914", "r915", "r918", "r919", "r920", "r921", "r922", "r945", "r947", "r948", "r1028", "r1029", "r1030", "r1031", "r1032", "r1033", "r1034", "r1091", "r1414", "r1415", "r1416", "r1475" } } }, "cgc_DerivativeLiabilityRelatedToSettlementOfConvertibleSeniorNotes": { "xbrltype": "monetaryItemType", "nsuri": "http://www.canopygrowth.com/20241231", "localname": "DerivativeLiabilityRelatedToSettlementOfConvertibleSeniorNotes", "crdr": "credit", "presentation": { "http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureOtherLiabilitiesComponentsOfOtherLiabilitiesDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Derivative liability related to settlement of convertible senior notes", "label": "Derivative Liability Related To Settlement Of Convertible Senior Notes", "documentation": "Derivative liability related to settlement of convertible senior notes." } } }, "auth_ref": "f" }, "cgc_DerivativeLiabilityRelatedToSettlementOfConvertibleSeniorNotesLongTerm": { "xbrltype": "monetaryItemType", "nsuri": "http://www.canopygrowth.com/20241231", "localname": "DerivativeLiabilityRelatedToSettlementOfConvertibleSeniorNotesLongTerm", "crdr": "credit", "presentation": { "http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureOtherLiabilitiesComponentsOfOtherLiabilitiesDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Derivative liability related to settlement of convertible senior notes, long term", "label": "Derivative Liability Related To Settlement Of Convertible Senior Notes Long Term", "documentation": "Derivative liability related to settlement of convertible senior notes long term." } } }, "auth_ref": "f" }, "us-gaap_DisaggregationOfRevenueLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisaggregationOfRevenueLineItems", "presentation": { "http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureRevenueSummaryOfDisaggregationOfRevenueDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Disaggregation of Revenue [Line Items]", "label": "Disaggregation of Revenue [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": "f" } }, "r560", "r1116", "r1117", "r1118", "r1119", "r1120", "r1121", "r1122" } } }, "us-gaap_DisaggregationOfRevenueTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisaggregationOfRevenueTable", "presentation": { "http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureRevenueSummaryOfDisaggregationOfRevenueDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Disaggregation of Revenue Table", "label": "Disaggregation of Revenue Table", "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor." } } }, "auth_ref": "f" } }, "r560", "r1116", "r1117", "r1118", "r1119", "r1120", "r1121", "r1122" } } }, "us-gaap_DisaggregationOfRevenueTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisaggregationOfRevenueTableTextBlock", "presentation": { "http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureRevenueTables", "lang": { "en-us": { "role": { "terseLabel": "Summary of Disaggregation of Revenue", "label": "Disaggregation of Revenue Table Text Block", "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor." } } }, "auth_ref": "f" } }, "r1373" } } }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "presentation": { "http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureShareBasedCompensation", "lang": { "en-us": { "role": { "terseLabel": "Share-Based Compensation", "label": "Share-Based Payment Arrangement [Text Block]", "documentation": "The entire disclosure for share-based payment arrangement." } } }, "auth_ref": "f" } }, "r572", "r576", "r604", "r605", "r606", "r1129" } } }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsAbstract", "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement Abstract" } } }, "auth_ref": "f" }, "us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax", "crdr": "credit", "presentation": { "http://www.canopygrowth.com/20241231/taxonomy/role/DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax", "lang": { "en-us": { "role": { "totalLabel": "Net income (loss) on discontinued operations, net of tax", "label": "Discontinued Operation, Gain (Loss) on Disposal of Discontinued Operation, Net of Tax", "documentation": "Amount after tax of gain (loss) not previously recognized resulting from the disposal of a discontinued operation." } } }, "auth_ref": "f" } }, "r104", "r106", "r108", "r119" } } }, "us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration": { "xbrltype": "enumerationSetItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration", "presentation": { "http://www.canopygrowth.com/20241231/taxonomy/role/DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration", "lang": { "en-us": { "role": { "label": "Discontinued Operation, Gain (Loss) on Disposal, Statement of Income or Comprehensive Income [Extensible Enumeration]", "documentation": "Indicates line item in statement of income or comprehensive income that includes gain (loss) from disposal of discontinued operation." } } }, "auth_ref": "f" }, "us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare", "presentation": { "http://www.canopygrowth.com/20241231/taxonomy/role/StatementCondensedInterimConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited", "lang": { "en-us": { "role": { "label": "Discontinued Operation, Income (Loss) from Discontinued Operation, Net of Tax, Per Basic Share", "terseLabel": "Basic loss per share discontinued operations", "documentation": "Per basic share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation." } } }, "auth_ref": "f" }, "us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare", "presentation": { "http://www.canopygrowth.com/20241231/taxonomy/role/StatementCondensedInterimConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited", "lang": { "en-us": { "role": { "label": "Discontinued Operation, Income (Loss) from Discontinued Operation, Net of Tax, Per Diluted Share", "terseLabel": "Diluted loss per share discontinued operations", "documentation": "Per diluted share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation." } } }, "auth_ref": "f" }, "us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DiscontinuedOperationTaxEffectOfDiscontinuedOperation", "crdr": "debit", "presentation": { "http://www.canopygrowth.com/20241231/taxonomy/role/DiscontinuedOperationTaxEffectOfDiscontinuedOperation", "lang": {

```
"en-us": {"role": "terseLabel", "Income tax (expense) recovery", "label": "Discontinued Operations, Tax Effect of Discontinued Operation", "documentation": "Amount of tax expense (benefit) related to a discontinued operation. Includes, but is not limited to, tax expense (benefit) related to income (loss) from operations during the phase-out period, tax expense (benefit) related to gain (loss) on disposal, tax expense (benefit) related to gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and tax expense (benefit) related to adjustments of a prior period gain (loss) on disposal."}, {"r105": "r106", "r107": "r108", "r114": "r119", "r613": "r626", "r628"}], "us-gaap": {"DiscontinuedOperationsAndDisposalGroupsAbstract": {"xbrlType": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DiscontinuedOperationsAndDisposalGroupsAbstract"}, {"lang": {"en-us": {"role": "label", "Discontinued Operations and Disposal Groups [Abstract]"}}, {"auth_ref": {}}, {"cgc_DisposalAndLiquidationOfConsolidatedEntities": {"xbrlType": "monetaryItemType", "nsuri": "http://www.canopygrowth.com/20241231", "localname": "DisposalAndLiquidationOfConsolidatedEntities"}, {"crdr": "credit", "presentation": {}}, {"http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureAccumulatedOtherComprehensiveIncomeLossAccumulatedOtherComprehensiveIncomeDetails": {"lang": {"en-us": {"role": "label", "Disposal and liquidation of consolidated entities", "documentation": "Disposal and liquidation of consolidated entities", "terseLabel": "Disposal and liquidation of consolidated entities"}}, {"auth_ref": {}}, {"us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet": {"xbrlType": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet"}, {"crdr": "debit", "presentation": {}}, {"http://www.canopygrowth.com/20241231/taxonomy/role/DisclosureBiosteelSummaryOfAssetsAndLiabilitiesClassifiedAsDiscontinuedOperationsAndMajorCategoriesDetails": {"lang": {"en-us": {"role": "label", "Disposal Group, Including Discontinued Operation, Accounts, Notes and Loans Receivable, Net", "terseLabel": "Amounts receivable, net", "documentation": "Amount classified as accounts, notes and loans receivable attributable to disposal group held for sale or disposed of."}}, {"auth_ref": {"r4": "r103", "r117", "r180"}}, {"us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableAndAccruedLiabilitiesCurrent": {"xbrlType": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisposalGroupIncludingDiscontinuedOperationAccountsPayableAndAccruedLiabilitiesCurrent"}, {"crdr": "credit", "presentation": {}}, {"http://www.canopygrowth.com/20241231/taxonomy/role/DisclosureBiosteelSummaryOfAssetsAndLiabilitiesClassifiedAsDiscontinuedOperationsAndMajorCategoriesDetails": {"lang": {"en-us": {"role": "totalLabel", "Disposal Group, Including Discontinued Operation, Accounts Payable and Accrued Liabilities, Current, Total", "label": "Disposal Group, Including Discontinued Operation, Accounts Payable and Accrued Liabilities, Current", "terseLabel": "Other accrued expenses and liabilities", "documentation": "Amount classified as accounts payable and accrued liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer."}}, {"auth_ref": {"r4": "r103", "r117", "r176", "r180"}}, {"us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent": {"xbrlType": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent"}, {"crdr": "credit", "presentation": {}}, {"http://www.canopygrowth.com/20241231/taxonomy/role/DisclosureBiosteelSummaryOfAssetsAndLiabilitiesClassifiedAsDiscontinuedOperationsAndMajorCategoriesDetails": {"lang": {"en-us": {"role": "label", "Disposal Group, Including Discontinued Operation, Accounts Payable, Current", "terseLabel": "Accounts payable", "documentation": "Amount classified as accounts payable attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer."}}, {"auth_ref": {"r4": "r103", "r117", "r176", "r180"}}, {"us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent": {"xbrlType": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent"}, {"crdr": "debit", "presentation": {}}, {"http://www.canopygrowth.com/20241231/taxonomy/role/Role_StatementCondensedInterimConsolidatedBalanceSheetsUnaudited": {"lang": {"en-us": {"role": "negatedLabel", "Less: valuation allowance", "totalLabel": "Disposal Group, Including Discontinued Operation, Assets, Noncurrent, Total", "label": "Disposal Group, Including Discontinued Operation, Assets, Noncurrent", "verboseLabel": "Noncurrent assets of discontinued operations", "documentation": "Amount classified as assets attributable to disposal group held for sale or disposed of, expected to be disposed of after one year or the normal operating cycle, if longer."}}, {"auth_ref": {"r4": "r7", "r103", "r117", "r180", "r248", "r249"}}, {"us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents": {"xbrlType": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents"}, {"crdr": "debit", "presentation": {}}, {"http://www.canopygrowth.com/20241231/taxonomy/role/DisclosureBiosteelSummaryOfAssetsAndLiabilitiesClassifiedAsDiscontinuedOperationsAndMajorCategoriesDetails": {"lang": {"en-us": {"role": "label", "Disposal Group, Including Discontinued Operation, Cash and Cash Equivalents", "terseLabel": "Cash", "documentation": "Amount classified as cash and cash equivalents attributable to disposal group held for sale or disposed of."}}, {"auth_ref": {"r4": "r103", "r117", "r180"}}, {"us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration": {"xbrlType": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisposalGroupIncludingDiscontinuedOperationConsideration"}, {"crdr": "debit", "presentation": {}}, {"http://www.canopygrowth.com/20241231/taxonomy/role/DisclosureCanopyUsaSummaryOfDerecognizedAssetsAndLiabilitiesTransferredDetails": {"lang": {"en-us": {"role": "verboseLabel", "Value of transaction including cash", "label": "Disposal Group, Including Discontinued Operation, Consideration", "totalLabel": "Total consideration", "terseLabel": "Total consideration", "documentation": "Amount of consideration received or receivable for the disposal of assets and liabilities, including discontinued operation."}}, {"auth_ref": {}}, {"us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold": {"xbrlType": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold"}, {"crdr": "debit", "presentation": {}}, {"http://www.canopygrowth.com/20241231/taxonomy/role/DisclosureBiosteelSummaryOfDeconsolidationAndCostsToExitClassifiedAsDiscontinuedOperationsDetails": {"lang": {"en-us": {"role": "label", "Disposal Group, Including Discontinued Operation, Costs of Goods Sold", "terseLabel": "Cost of goods sold", "documentation": "Amount of costs of goods sold attributable to disposal group, including, but not limited to, discontinued operation."}}, {"auth_ref": {"r115", "r249"}}, {"cgc_DisposalGroupIncludingDiscontinuedOperationCumulativeTranslationAdjustment": {"xbrlType": "monetaryItemType", "nsuri": "http://www.canopygrowth.com/20241231", "localname": "DisposalGroupIncludingDiscontinuedOperationCumulativeTranslationAdjustment"}, {"crdr": "debit", "presentation": {}}, {"http://www.canopygrowth.com/20241231/taxonomy/role/DisclosureCanopyUsaSummaryOfDerecognizedAssetsAndLiabilitiesTransferredDetails": {"lang": {"en-us": {"role": "documentation": "Disposal group, including discontinued operation, cumulative translation adjustment", "label": "Disposal Group Including Discontinued Operation Cumulative Translation Adjustment", "terseLabel": "Cumulative translation adjustment"}}, {"auth_ref": {}}, {"cgc_DisposalGroupIncludingDiscontinuedOperationDeconsolidationOfNoncontrollingInterest": {"xbrlType": "monetaryItemType", "nsuri": "http://www.canopygrowth.com/20241231", "localname": "DisposalGroupIncludingDiscontinuedOperationDeconsolidationOfNoncontrollingInterest"}, {"crdr": "debit", "presentation": {}}, {"http://www.canopygrowth.com/20241231/taxonomy/role/DisclosureCanopyUsaSummaryOfDerecognizedAssetsAndLiabilitiesTransferredDetails": {"lang": {"en-us": {"role": "documentation": "Disposal group including discontinued operation deconsolidation of noncontrolling interest", "label": "Disposal Group Including Discontinued Operation Deconsolidation Of Noncontrolling Interest", "terseLabel": "Derecognition of non-controlling interest in Canopy USA"}}, {"auth_ref": {}}, {"us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxLiabilities": {"xbrlType": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisposalGroupIncludingDiscontinuedOperationDeferredTaxLiabilities"}, {"crdr": "credit", "presentation": {}}, {"http://www.canopygrowth.com/20241231/taxonomy/role/DisclosureBiosteelSummaryOfAssetsAndLiabilitiesClassifiedAsDiscontinuedOperationsAndMajorCategoriesDetails": {"lang": {"en-us": {"role": "label", "Disposal Group, Including Discontinued Operation, Deferred Tax Liabilities", "terseLabel": "Deferred income tax liabilities", "documentation": "Amount classified as deferred tax liabilities attributable to disposal group held for sale or disposed of."}}, {"auth_ref": {"r4": "r103", "r117", "r180"}}, {"us-gaap_DisposalGroupIncludingDiscontinuedOperationDescriptionAndTimingOfDisposal": {"xbrlType": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisposalGroupIncludingDiscontinuedOperationDescriptionAndTimingOfDisposal"}, {"presentation": {}}, {"http://www.canopygrowth.com/20241231/taxonomy/role/DisclosureBiosteelAdditionalInformationDetails": {"lang": {"en-us": {"role": "label", "Disposal Group, Including Discontinued Operation, Description and Timing of Disposal", "terseLabel": "Discontinued operations, description", "documentation": "Description of the facts and circumstances leading to the completed or expected disposal, and the manner and timing of that disposal."}}, {"auth_ref": {"r122", "r179", "r179", "r244", "r245"}}, {"cgc_DisposalGroupIncludingDiscontinuedOperationElevateLoanReceivable": {"xbrlType": "monetaryItemType", "nsuri": "http://www.canopygrowth.com/20241231", "localname": "DisposalGroupIncludingDiscontinuedOperationElevateLoanReceivable"}, {"crdr": "debit", "presentation": {}}, {"http://www.canopygrowth.com/20241231/taxonomy/role/DisclosureCanopyUsaSummaryOfDerecognizedAssetsAndLiabilitiesTransferredDetails": {"lang": {"en-us": {"role": "documentation": "Disposal group including discontinued operation elevate loan receivable", "label": "Disposal Group Including Discontinued Operation Elevate Loan Receivable", "terseLabel": "Elevate loan receivable"}}, {"auth_ref": {}}, {"cgc_DisposalGroupIncludingDiscontinuedOperationEquityMethodInvestments": {"xbrlType": "monetaryItemType", "nsuri": "http://www.canopygrowth.com/20241231", "localname": "DisposalGroupIncludingDiscontinuedOperationEquityMethodInvestments"}, {"crdr": "debit", "presentation": {}}, {"http://www.canopygrowth.com/20241231/taxonomy/role/DisclosureCanopyUsaSummaryOfDerecognizedAssetsAndLiabilitiesTransferredDetails": {"lang": {"en-us": {"role": "label", "Disposal Group, Including Discontinued Operation, Equity Method Investments", "terseLabel": "Equity method investment"}}, {"auth_ref": {}}, {"us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill": {"xbrlType": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisposalGroupIncludingDiscontinuedOperationGoodwill"}, {"crdr": "debit", "presentation": {}}, {"http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureGoodwillChangesInCarryingAmountOfGoodwillDetails": {"lang": {"en-us": {"role": "negatedLabel", "Disposal of consolidated entities", "terseLabel": "Disposal of consolidated entities", "label": "Disposal Group, Including Discontinued Operation, Goodwill", "verboseLabel": "Goodwill", "documentation": "Amount classified as goodwill attributable to disposal group held for sale or disposed of."}}, {"auth_ref": {"r4": "r103", "r117", "r180"}}, {"us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets": {"xbrlType": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisposalGroupIncludingDiscontinuedOperationIntangibleAssets"}, {"crdr": "debit", "presentation": {}}, {"http://www.canopygrowth.com/20241231/taxonomy/role/DisclosureBiosteelSummaryOfAssetsAndLiabilitiesClassifiedAsDiscontinuedOperationsAndMajorCategoriesDetails": {"lang": {"en-us": {"role": "label", "Disposal Group, Including Discontinued Operation, Intangible Assets", "terseLabel": "Intangible assets", "documentation": "Amount classified as intangible assets, excluding goodwill, attributable to disposal group held for sale or disposed of."}}, {"auth_ref": {"r4": "r103", "r117", "r180"}}, {"us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory": {"xbrlType": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisposalGroupIncludingDiscontinuedOperationInventory"}, {"crdr": "debit", "presentation": {}}, {"http://www.canopygrowth.com/20241231/taxonomy/role/DisclosureBiosteelSummaryOfAssetsAndLiabilitiesClassifiedAsDiscontinuedOperationsAndMajorCategoriesDetails": {"lang": {"en-us": {"role": "label", "Disposal Group, Including Discontinued Operation, Inventory", "terseLabel": "Inventory", "documentation": "Amount classified as inventory attributable to disposal group held for sale or disposed of."}}, {"auth_ref": {"r4": "r103", "r117", "r180"}}, {"cgc_DisposalGroupIncludingDiscontinuedOperationIssuanceOfCommonShares": {"xbrlType": "monetaryItemType", "nsuri": "http://www.canopygrowth.com/20241231", "localname": "DisposalGroupIncludingDiscontinuedOperationIssuanceOfCommonShares"}, {"crdr": "credit", "presentation": {}}, {"http://www.canopygrowth.com/20241231/taxonomy/role/DisclosureCanopyUsaSummaryOfDerecognizedAssetsAndLiabilitiesTransferredDetails": {"lang": {"en-us": {"role": "documentation": "Disposal group including discontinued operation issuance of common shares", "label": "Disposal Group Including Discontinued Operation Issuance Of Common Shares", "negatedLabel": "Issuance of common shares", "terseLabel": "Canopy USA Transaction"}}, {"
```

"label": "Disposal Group, Including Discontinued Operation, Other Assets", "terseLabel": "Other assets", "documentation": "Amount classified as other assets attributable to disposal group held for sale or disposed of." } } }, "auth_ref": { "r4": "r103", "r117", "r180" } } }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities", "crdr": "credit", "presentation": { "http://www.canopygrowth.com/20241231/taxonomy/role/DisclosureBiosteelSummaryOfAssetsAndLiabilitiesClassifiedAsDiscontinuedOperationsAndMajorCategoriesDetails": { "lang": { "en-us": { "role": { "label": "Disposal Group, Including Discontinued Operation, Other Liabilities, Current", "terseLabel": "Other current liabilities", "documentation": "Amount classified as other liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer." } } }, "auth_ref": { "r4": "r103", "r117", "r176", "r180" } } }, "cgc_DisposalGroupIncludingDiscontinuedOperationOtherFinancialAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://www.canopygrowth.com/20241231", "localname": "DisposalGroupIncludingDiscontinuedOperationOtherFinancialAssets", "crdr": "debit", "presentation": { "http://www.canopygrowth.com/20241231/taxonomy/role/DisclosureCanopyUsaSummaryOfDerecognizedAssetsAndLiabilitiesTransferredDetails": { "lang": { "en-us": { "role": { "documentation": "Disposal group including discontinued operation other financial assets.", "label": "Disposal Group Including Discontinued Operation Other Financial Assets", "terseLabel": "Other financial assets" } } }, "auth_ref": { "r4": "r103", "r117", "r180" } } }, "cgc_DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://www.canopygrowth.com/20241231", "localname": "DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpense", "crdr": "credit", "presentation": { "http://www.canopygrowth.com/20241231/taxonomy/role/DisclosureBiosteelSummaryOfDeconsolidationAndCostsToExitClassifiedAsDiscontinuedOperationsDetails": { "lang": { "en-us": { "role": { "negatedLabel": "Other income (expense), net", "terseLabel": "Other income (expense), net", "label": "Disposal Group, Including Discontinued Operation, Other Income (Expense)", "documentation": "Disposal group, including discontinued operation, other income (expense).", "auth_ref": { "r4": "r103", "r117", "r180" } } } }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisposalGroupIncludingDiscontinuedOperationOtherLiabilities", "crdr": "credit", "presentation": { "http://www.canopygrowth.com/20241231/taxonomy/role/DisclosureCanopyUsaSummaryOfDerecognizedAssetsAndLiabilitiesTransferredDetails": { "lang": { "en-us": { "role": { "label": "Disposal Group, Including Discontinued Operation, Other Liabilities, Noncurrent", "terseLabel": "Other liabilities", "documentation": "Amount classified as other liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of beyond one year or the normal operating cycle, if longer." } } }, "auth_ref": { "r4": "r7", "r103", "r117", "r180" } } }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssets", "crdr": "debit", "presentation": { "http://www.canopygrowth.com/20241231/taxonomy/role/DisclosureBiosteelSummaryOfAssetsAndLiabilitiesClassifiedAsDiscontinuedOperationsAndMajorCategoriesDetails": { "lang": { "en-us": { "role": { "label": "Disposal Group, Including Discontinued Operation, Prepaid and Other Assets", "terseLabel": "Prepaid expenses and other assets", "documentation": "Amount classified as prepaid and other assets attributable to disposal group held for sale or disposed of." } } }, "auth_ref": { "r4": "r103", "r117", "r180" } } } }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment", "crdr": "debit", "presentation": { "http://www.canopygrowth.com/20241231/taxonomy/role/DisclosureBiosteelSummaryOfAssetsAndLiabilitiesClassifiedAsDiscontinuedOperationsAndMajorCategoriesDetails": { "lang": { "en-us": { "role": { "label": "Disposal Group, Including Discontinued Operation, Property, Plant and Equipment", "terseLabel": "Property, plant and equipment", "documentation": "Amount classified as property, plant and equipment attributable to disposal group held for sale or disposed of." } } }, "auth_ref": { "r4": "r103", "r117", "r180" } } }, "cgc_DisposalGroupIncludingDiscontinuedOperationReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://www.canopygrowth.com/20241231", "localname": "DisposalGroupIncludingDiscontinuedOperationReceivable", "crdr": "debit", "presentation": { "http://www.canopygrowth.com/20241231/taxonomy/role/DisclosureBiosteelAdditionalInformationDetails": { "http://www.canopygrowth.com/20241231/taxonomy/role/DisclosureBiosteelSummaryOfAssetsAndLiabilitiesClassifiedAsDiscontinuedOperationsAndMajorCategoriesDetails": { "lang": { "en-us": { "role": { "verboseLabel": "Receivable from BioSteel Entities", "terseLabel": "Receivable from BioSteel", "documentation": "Disposal group including discontinued operation receivable.", "label": "Disposal group including discontinued operation receivable" } } }, "auth_ref": { "r4": "r115", "r249" } } }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisposalGroupIncludingDiscontinuedOperationRevenue", "crdr": "credit", "presentation": { "http://www.canopygrowth.com/20241231/taxonomy/role/DisclosureBiosteelSummaryOfDeconsolidationAndCostsToExitClassifiedAsDiscontinuedOperationsDetails": { "lang": { "en-us": { "role": { "label": "Disposal Group, Including Discontinued Operation, Revenue", "terseLabel": "Net revenue", "documentation": "Amount of revenue attributable to disposal group, including, but not limited to, discontinued operation." } } }, "auth_ref": { "r4": "r115", "r249" } } }, "cgc_DisposalGroupIncludingDiscontinuedOperationShortTermInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://www.canopygrowth.com/20241231", "localname": "DisposalGroupIncludingDiscontinuedOperationShortTermInvestments", "crdr": "debit", "presentation": { "http://www.canopygrowth.com/20241231/taxonomy/role/DisclosureBiosteelSummaryOfAssetsAndLiabilitiesClassifiedAsDiscontinuedOperationsAndMajorCategoriesDetails": { "lang": { "en-us": { "role": { "documentation": "Disposal group including discontinued operation short term investments.", "label": "Disposal group including discontinued operation short term investments", "terseLabel": "Short-term investments" } } }, "auth_ref": { "r4": "r115", "r249" } } }, "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock", "presentation": { "http://www.canopygrowth.com/20241231/taxonomy/role/DisclosureBiosteel": { "lang": { "en-us": { "role": { "terseLabel": "This Works Divestiture", "label": "Disposal Groups, Including Discontinued Operations, Disclosure [Text Block]", "verboseLabel": "Biosteel", "documentation": "The entire disclosure related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component." } } }, "auth_ref": { "r102", "r175" } } }, "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisposalGroupsIncludingDiscontinuedOperationsNameDomain", "presentation": { "http://www.canopygrowth.com/20241231/taxonomy/role/DisclosureBiosteelAdditionalInformationDetails": { "http://www.canopygrowth.com/20241231/taxonomy/role/DisclosureBiosteelSummaryOfAssetsAndLiabilitiesClassifiedAsDiscontinuedOperationsAndMajorCategoriesDetails": { "http://www.canopygrowth.com/20241231/taxonomy/role/DisclosureBiosteelSummaryOfDeconsolidationAndCostsToExitClassifiedAsDiscontinuedOperationsDetails": { "http://www.canopygrowth.com/20241231/taxonomy/role/DisclosureBiosteelSummaryOfDeconsolidationAndCostsToExitClassifiedAsDiscontinuedOperationsParenteticalDetails": { "http://www.canopygrowth.com/20241231/taxonomy/role/DisclosureCanopyUsaAdditionalInformationDetails": { "http://www.canopygrowth.com/20241231/taxonomy/role/DisclosureCanopyUsaSummaryOfDerecognizedAssetsAndLiabilitiesTransferredDetails": { "http://www.canopygrowth.com/20241231/taxonomy/role/DisclosureCanopyUsaTables": { "http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureAmountsReceivableNetAdditionalInformationDetails": { "lang": { "en-us": { "role": { "label": "Disposal Group Name [Domain]", "documentation": "Name of disposal group." } } }, "auth_ref": { "r1126", "r1127" } } }, "cgc_DisposalOfConsolidatedEntities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.canopygrowth.com/20241231", "localname": "DisposalOfConsolidatedEntities", "crdr": "credit", "presentation": { "http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureAccumulatedOtherComprehensiveIncomeLossAccumulatedOtherComprehensiveIncomeDetails": { "lang": { "en-us": { "role": { "terseLabel": "Disposal of consolidated entities", "label": "Disposal Of Consolidated Entities", "documentation": "Disposal of consolidated entities." } } }, "auth_ref": { "r4": "r102", "r175" } } }, "cgc_DistributionChannelMember": { "xbrltype": "domainItemType", "nsuri": "http://www.canopygrowth.com/20241231", "localname": "DistributionChannelMember", "presentation": { "http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureIntangibleAssetsSummaryOfComponentsOfIntangibleAssetsDetails": { "lang": { "en-us": { "role": { "terseLabel": "Distribution Channel", "label": "Distribution Channel [Member]", "documentation": "Relationships with distribution channels obtained through acquisitions." } } }, "auth_ref": { "r4": "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalPeriodFocus", "presentation": { "http://www.canopygrowth.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation": { "lang": { "en-us": { "role": { "terseLabel": "Document Fiscal Period Focus", "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY: Q1, Q2, and Q3; 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively; with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": { "r4": "dei_DocumentFiscalYearFocus": { "xbrltype": "yearItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalYearFocus", "presentation": { "http://www.canopygrowth.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation": { "lang": { "en-us": { "role": { "terseLabel": "Document Fiscal Year Focus", "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report for a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": { "r4": "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentPeriodEndDate", "presentation": { "http://www.canopygrowth.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation": { "lang": { "en-us": { "role": { "terseLabel": "Document Period End Date", "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": { "r4": "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentQuarterlyReport", "presentation": { "http://www.canopygrowth.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation": { "lang": { "en-us": { "role": { "terseLabel": "Document Quarterly Report", "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": { "r4": "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentTransitionReport", "presentation": { "http://www.canopygrowth.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation": { "lang": { "en-us": { "role": { "terseLabel": "Document Transition Report", "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": { "r4": "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentType", "presentation": { "http://www.canopygrowth.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation": { "lang": { "en-us": { "role": { "terseLabel": "Document Type", "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": { "r4": "ecd_DvdsOrOthrErngsPdOnEqtyAwrdsNtOthrRflctdInTtlCompForCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "DvdsOrOthrErngsPdOnEqtyAwrdsNtOthrRflctdInTtlCompForCvrdYrMember", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure": { "lang": { "en-us": { "role": { "label": "Dividends or Other Earnings Paid on Equity Awards Not Otherwise Reflected in Total Compensation for Covered Year [Member]", "terseLabel": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year" } } }, "auth_ref": { "r4": "us-gaap_EarningsPerShareAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareAbstract", "presentation": { "http://www.canopygrowth.com/20241231/taxonomy/role/StatementCondensedInterimConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited": { "lang": { "en-us": { "role": { "label": "Earnings Per Share [Abstract]", "terseLabel": "Basic and diluted loss per share" } } }, "auth_ref": { "r4": "us-gaap_EarningsPerShareBasic": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareBasic", "presentation": { "http://www.canopygrowth.com/20241231/taxonomy/role/StatementCondensedInterimConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited": { "lang": { "en-us": { "role": { "terseLabel": "Basic loss per share", "totalLabel": "Earnings Per Share, Basic, Total", "verboseLabel": "Basic (loss) earnings per share", "label": "Earnings Per Share, Basic", "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period." } } }, "auth_ref": { "r4": "us-gaap_EarningsPerShareDiluted": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareDiluted", "presentation": { "http://www.canopygrowth.com/20241231/taxonomy/role/StatementCondensedInterimConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited": { "lang": { "en-us": { "role": { "terseLabel": "Diluted loss per share", "totalLabel": "Earnings Per Share, Diluted, Total", "verboseLabel": "Diluted (loss) earnings per share", "label": "Earnings

Per Share, Diluted", "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period." } } }, "auth_ref": { "r287": "r306", "r307": "r308", "r309": "r310", "r311": "r319", "r322": "r323", "r324": "r328", "r340": "r653", "r685", "r686", "r820", "r849", "r1093" } }, "us-gaap_EarningsPerShareTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareTextBlock", "presentation": { "http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureEarningsLossPerShare": { "lang": { "en-us": { "role": { "terseLabel": "Earnings (Loss) Per Share", "label": "Earnings Per Share [Text Block]", "documentation": "The entire disclosure for earnings per share." } } }, "auth_ref": { "r316": "r325", "r326": "r327" } } }, "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "crdr": "debit", "presentation": { "http://www.canopygrowth.com/20241231/taxonomy/role/Role_StatementCondensedInterimConsolidatedStatementsOfCashFlowsUnaudited": { "lang": { "en-us": { "role": { "terseLabel": "Effect of exchange rate changes on cash and cash equivalents", "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations", "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": { "r714" } } }, "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "crdr": "debit", "presentation": { "http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureOtherFinancialAssetsSummaryOfChangesInOtherFinancialAssetsDetails": { "lang": { "en-us": { "role": { "totalLabel": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations, Total", "terseLabel": "Foreign currency translation adjustments", "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations", "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": { "r1422" } } }, "cgc_ElevateLoanReceivableEquityValueOfWanaAndCanopyUsaMember": { "xbrltype": "domainItemType", "nsuri": "http://www.canopygrowth.com/20241231", "localname": "ElevateLoanReceivableEquityValueOfWanaAndCanopyUsaMember", "presentation": { "http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureFairValueOffFinancialInstrumentsSummaryOfValuationTechniquesAndSignificantUnobservableInputsIn": { "lang": { "en-us": { "role": { "documentation": "Elevate loan receivable equity value of wana and canopy USA.", "label": "Elevate Loan Receivable Equity value of Wana and Canopy USA [Member]", "terseLabel": "Elevate Loan Receivable Equity Value of Wana And Canopy USA", "auth_ref": { "cgc_ElevateLoanReceivableMember": { "xbrltype": "domainItemType", "nsuri": "http://www.canopygrowth.com/20241231", "localname": "ElevateLoanReceivableMember", "presentation": { "http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureFairValueOffFinancialInstrumentsSummaryOfValuationTechniquesAndSignificantUnobservableInputsIn": { "http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureOtherFinancialAssetsSummaryOfChangesInOtherFinancialAssetsDetails": { "lang": { "en-us": { "role": { "documentation": "Elevate loan receivable.", "label": "Elevate Loan Receivable [Member]", "terseLabel": "Elevate Loan Receivable" } } }, "auth_ref": { "us-gaap_EmployeeRelatedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeRelatedLiabilitiesCurrent", "crdr": "credit", "presentation": { "http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureOtherAccruedExpensesAndLiabilitiesComponentsOfOtherAccruedExpensesAndLiabilitiesDetails": { "lang": { "en-us": { "role": { "totalLabel": "Employee-related Liabilities, Current, Total", "terseLabel": "Employee compensation", "label": "Employee-related Liabilities, Current", "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": { "r125" } } }, "us-gaap_EmployeeStockOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeStockOptionMember", "presentation": { "http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureShareBasedCompensationAdditionalInformationDetails": { "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure": { "lang": { "en-us": { "role": { "label": "Employee Stock Option [Member]", "terseLabel": "Employee Stock Option", "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time." } } }, "auth_ref": { "cgc_EmployeeStockOptionPlanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.canopygrowth.com/20241231", "localname": "EmployeeStockOptionPlanMember", "presentation": { "http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureShareBasedCompensationAdditionalInformationDetails": { "lang": { "en-us": { "role": { "terseLabel": "Employee Stock Purchase Plan", "label": "Employee Stock Option Plan [Member]", "documentation": "Employee stock option plan." } } }, "auth_ref": { "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine1", "presentation": { "http://www.canopygrowth.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation": { "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Address Line One", "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": { "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressCityOrTown", "presentation": { "http://www.canopygrowth.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation": { "lang": { "en-us": { "role": { "terseLabel": "Entity Address, City or Town", "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": { "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressPostalZipCode", "presentation": { "http://www.canopygrowth.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation": { "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Postal Zip Code", "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": { "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItem", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressStateOrProvince", "presentation": { "http://www.canopygrowth.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation": { "lang": { "en-us": { "role": { "terseLabel": "Entity Address, State or Province", "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": { "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCentralIndexKey", "presentation": { "http://www.canopygrowth.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation": { "lang": { "en-us": { "role": { "terseLabel": "Entity Central Index Key", "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": { "r1176" } } }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCommonStockSharesOutstanding", "presentation": { "http://www.canopygrowth.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation": { "lang": { "en-us": { "role": { "terseLabel": "Entity Common Stock, Shares Outstanding", "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": { "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItem", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCurrentReportingStatus", "presentation": { "http://www.canopygrowth.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation": { "lang": { "en-us": { "role": { "verboselabel": "Entity Current Reporting Status", "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports); and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": { "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityEmergingGrowthCompany", "presentation": { "http://www.canopygrowth.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation": { "lang": { "en-us": { "role": { "terseLabel": "Entity Emerging Growth Company", "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": { "r1176" } } }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFileNumber", "presentation": { "http://www.canopygrowth.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation": { "lang": { "en-us": { "role": { "terseLabel": "Entity File Number", "label": "Securities Act File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": { "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFilerCategory", "presentation": { "http://www.canopygrowth.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation": { "lang": { "en-us": { "role": { "terseLabel": "Entity Filer Category", "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": { "r1176" } } }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItem", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityIncorporationStateCountryCode", "presentation": { "http://www.canopygrowth.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation": { "lang": { "en-us": { "role": { "terseLabel": "Entity Incorporation, State or Country Code", "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": { "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItem", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityInteractiveDataCurrent", "presentation": { "http://www.canopygrowth.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation": { "lang": { "en-us": { "role": { "terseLabel": "Entity Interactive Data Current", "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": { "r1260" } } }, "cgc_EntityOtherMember": { "xbrltype": "domainItemType", "nsuri": "http://www.canopygrowth.com/20241231", "localname": "EntityOtherMember", "presentation": { "http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureOtherFinancialAssetsSummaryOfChangesInOtherFinancialAssetsDetails": { "lang": { "en-us": { "role": { "label": "Entity Other [Member]", "documentation": "Entity other member.", "terseLabel": "Other" } } }, "auth_ref": { "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityRegistrantName", "presentation": { "http://www.canopygrowth.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation": { "lang": { "en-us": { "role": { "terseLabel": "Entity Registrant Name", "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": { "r1176" } } }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityShellCompany", "presentation": { "http://www.canopygrowth.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation": { "lang": { "en-us": { "role": { "terseLabel": "Entity Shell Company", "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": { "r1176" } } }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntitySmallBusiness", "presentation": { "http://www.canopygrowth.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation": { "lang": { "en-us": { "role": { "terseLabel": "Entity Small Business", "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": { "r1176" } } }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItem", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityTaxIdentificationNumber", "presentation": { "http://www.canopygrowth.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation": { "lang": { "en-us": { "role": { "terseLabel": "Entity Tax Identification Number", "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": { "r1176" } } }, "ecd_EqtyAwrdsAdjFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/role/PyPDisclosure": { "lang": { "en-us": { "role": { "label":

"Equity Awards Adjustments, Footnote [Text Block]", "terseLabel": "Equity Awards Adjustments, Footnote" } } }, "auth_ref": "r1215" } } },
"ecd_EqtyAwrdsAdjsExclgValRprtdInSummaryCompstnTblMember", { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"EqtyAwrdsAdjsExclgValRprtdInSummaryCompstnTblMember", "presentation": "http://xbrl.sec.gov/ecd/role/PvpDisclosure" }, { "lang": "en-us", "role": "label", "Equity
Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]", "terseLabel": "Equity Awards Adjustments, Excluding Value Reported in Compensation
Table" } } }, "auth_ref": "r1256" } } }, "ecd_EqtyAwrdsAdjsMember", { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"EqtyAwrdsAdjsMember", "presentation": "http://xbrl.sec.gov/ecd/role/PvpDisclosure" }, { "lang": "en-us", "role": "label", "Equity Awards Adjustments [Member]",
"terseLabel": "Equity Awards Adjustments" } } }, "auth_ref": "r1256" } } }, "ecd_EqtyAwrdsInSummaryCompstnTblForApblbYrMember", { "xbrltype": "domainItemType", "nsuri":
"http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsInSummaryCompstnTblForApblbYrMember", "presentation": "http://xbrl.sec.gov/ecd/role/PvpDisclosure" }, { "lang": {
"en-us": { "role": "label", "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]", "terseLabel": "Aggregate Grant
Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table" } } }, "auth_ref": "r1256" } } }, "us-gaap_EquityAbstract", { "xbrltype": "stringItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityAbstract", "lang": "en-us", "role": "label", "Equity [Abstract]" } } }, "auth_ref": { "us-
gaap_EquityClassOfTreasuryStockLineItems", { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityClassOfTreasuryStockLineItems",
"presentation": "http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureShareCapitalSummaryOfIssuancesOfStockOtherDetails" }, { "lang": "en-us", "role":
"terseLabel", "Equity Class Of Treasury Stock [Line Items]", "label": "Equity: Class of Treasury Stock [Line Items]", "documentation": "Line items represent financial
concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } },
"auth_ref": { "us-gaap_EquityComponentDomain", { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityComponentDomain",
"presentation": {
"http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureAccumulatedOtherComprehensiveIncomeLossAccumulatedOtherComprehensiveIncomeDetails",
"http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureNoncontrollingInterestsSummaryOfNetChangeInNoncontrollingInterestsDetails",
"http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureOtherFinancialAssetsSummaryOfChangesInOtherFinancialAssetsDetails",
"http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureShareCapitalSummaryOfIssuancesOfStockOtherDetails",
"http://www.canopygrowth.com/20241231/taxonomy/role/Role_StatementCondensedInterimConsolidatedStatementsOfShareholderEquityUnaudited" }, { "lang": "en-us", {
"role": "terseLabel", "Equity Component", "label": "Equity Component [Domain]", "documentation": "Components of equity are the parts of the total Equity balance including
that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "auth_ref": "r19", "r240", "r280", "r281", "r282", "r299", "r300", "r301", "r304",
"r310", "r312", "r314", "r330", "r414", "r420", "r469", "r550", "r620", "r621", "r636", "r637", "r638", "r641", "r652", "r653", "r667", "r668", "r669", "r670", "r671", "r673",
"r684", "r715", "r717", "r718", "r719", "r720", "r721", "r726", "r728", "r735", "r845", "r875", "r876", "r877", "r899", "r974" }, { "srt_EquityMethodInvesteeNameDomain", {
"xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "EquityMethodInvesteeNameDomain", "presentation": {
"http://www.canopygrowth.com/20241231/taxonomy/role/DisclosureBiosteelAdditionalInformationDetails",
"http://www.canopygrowth.com/20241231/taxonomy/role/DisclosureCanopyUsaAdditionalInformationDetails" }, { "lang": "en-us", { "role": "terseLabel", "Investment, Name",
"label": "Investment, Name [Domain]" } } }, "auth_ref": "r405", "r406", "r408", "r632", "r1263", "r1264", "r1265", "r1405", "r1406", "r1407", "r1408" } } }, "us-
gaap_EquityMethodInvestmentOwnershipPercentage", { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"EquityMethodInvestmentOwnershipPercentage", "presentation": "http://www.canopygrowth.com/20241231/taxonomy/role/DisclosureBiosteelAdditionalInformationDetails",
"http://www.canopygrowth.com/20241231/taxonomy/role/DisclosureCanopyUsaAdditionalInformationDetails",
"http://www.canopygrowth.com/20241231/taxonomy/role/DisclosureEquityMethodInvestmentsComponentsOfEquityMethodInvestmentsDetails" }, { "lang": "en-us", { "role": {
"terseLabel", "Ownership percentage", "label": "Equity Method Investment, Ownership Percentage", "documentation": "The percentage of ownership of common stock or
equity participation in the investee accounted for under the equity method of accounting." } } }, "auth_ref": "r405" } } }, "us-gaap_EquityMethodInvestments", { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityMethodInvestments", "crdr": "debit", "presentation": {
"http://www.canopygrowth.com/20241231/taxonomy/role/DisclosureEquityMethodInvestmentsComponentsOfEquityMethodInvestmentsDetails",
"http://www.canopygrowth.com/20241231/taxonomy/role/Role_StatementCondensedInterimConsolidatedBalanceSheetsUnaudited" }, { "lang": "en-us", { "role": { "label":
"Equity Method Investments", "terseLabel": "Equity method investments", "documentation": "This item represents the carrying amount on the entity's balance sheet of its
investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share
of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized." } } }, "auth_ref": "r329",
"r348", "r360", "r403", "r1280", "r1329" } } }, "us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract", { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "EquityMethodInvestmentsAndJointVenturesAbstract", "lang": "en-us", "role": "label", "Equity Method Investments and Joint Ventures
[Abstract]" } } }, "auth_ref": { "us-gaap_EquityMethodInvestmentsDisclosureTextBlock", { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "EquityMethodInvestmentsDisclosureTextBlock", "presentation": "http://www.canopygrowth.com/20241231/taxonomy/role/DisclosureEquityMethodInvestments"
}, { "lang": "en-us", { "role": "label", "Equity Method Investments and Joint Ventures Disclosure [Text Block]", "terseLabel": "Equity Method Investments", "documentation":
The entire disclosure for equity method investments and joint ventures. Equity method investments are investments that give the investor the ability to exercise significant
influence over the operating and financial policies of an investee. Joint ventures are entities owned and operated by a small group of businesses as a separate and specific
business or project for the mutual benefit of the members of the group." } } }, "auth_ref": "r235", "r407", "r410", "r1265" } } },
"cgc_EquityMethodInvestmentsFairValueAdjustment", { "xbrltype": "monetaryItemType", "nsuri": "http://www.canopygrowth.com/20241231", "localname":
"EquityMethodInvestmentsFairValueAdjustment", "crdr": "credit", "presentation": {
"http://www.canopygrowth.com/20241231/taxonomy/role/DisclosureOtherIncomeExpenseNetScheduleOfOtherIncomeExpenseNetParentheticalDetails" }, { "lang": "en-us", {
"role": "documentation", "Fair value changes on equity method investments.", "label": "Equity Method Investments Fair Value Adjustment", "negatedLabel": "Fair value
changes on equity method investments", "terseLabel": "Fair value changes on equity method investments" } } }, "auth_ref": { "us-
gaap_EquityMethodInvestmentsFairValueDisclosure", { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"EquityMethodInvestmentsFairValueDisclosure", "crdr": "debit", "presentation": {
"http://www.canopygrowth.com/20241231/taxonomy/role/DisclosureBiosteelAdditionalInformationDetails",
"http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtEstimatedFairVa
l", "lang": "en-us", { "role": "label", "Equity Method Investments, Fair Value Disclosure", "terseLabel": "Fair value of equity investments", "verboseLabel": "Equity method
investments", "documentation": "Fair value portion of investments accounted under the equity method." } } }, "auth_ref": "r1261", "r1412", "r1413", "r1417" } } }, "us-
gaap_EquityMethodInvestmentsPolicy", { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityMethodInvestmentsPolicy",
"presentation": "http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" }, { "lang": "en-us", { "role": {
"label": "Equity Method Investments [Policy Text Block]", "terseLabel": "Equity method investments", "documentation": "Disclosure of accounting policy for equity method
of accounting for investments and other interests. Investment includes, but is not limited to, unconsolidated subsidiary, corporate joint venture, noncontrolling interest in real
estate venture, limited partnership, and limited liability company. Information includes, but is not limited to, ownership percentage, reason equity method is or is not
considered appropriate, and accounting policy election for distribution received." } } }, "auth_ref": "r49", "r98", "r406" } } }, "us-gaap_EquityMethodInvestmentsTextBlock", {
"xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityMethodInvestmentsTextBlock", "presentation": {
"http://www.canopygrowth.com/20241231/taxonomy/role/DisclosureEquityMethodInvestmentsTables" }, { "lang": "en-us", { "role": "label", "Equity Method Investments
[Table Text Block]", "terseLabel": "Schedule of Equity Method Investments", "documentation": "Tabular disclosure of equity method investments including, but not limited to,
name of each investee or group of investments, percentage ownership, difference between recorded amount of an investment and the value of the underlying equity in the net
assets, and summarized financial information." } } }, "auth_ref": "r404" } } }, "cgc_EquitySettledConvertibleDebenturesMember", { "xbrltype": "domainItemType", "nsuri":
"http://www.canopygrowth.com/20241231", "localname": "EquitySettledConvertibleDebenturesMember", "presentation": {
"http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureDebtSummaryOfComponentsOfDebtDetails" }, { "lang": "en-us", { "role": "terseLabel", "Equity
Settled Convertible Debentures", "label": "Equity settled convertible debentures [Member]", "documentation": "Equity settled convertible debentures." } } }, "auth_ref": {
"ecd_EquityValuationAssumptionDifferenceFnTextBlock", { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"EquityValuationAssumptionDifferenceFnTextBlock", "presentation": "http://xbrl.sec.gov/ecd/role/PvpDisclosure" }, { "lang": "en-us", { "role": "label", "Equity Valuation
Assumption Difference, Footnote [Text Block]", "terseLabel": "Equity Valuation Assumption Difference, Footnote" } } }, "auth_ref": "r1225" } } },
"ecd_ErrCompAnalysisTextBlock", { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ErrCompAnalysisTextBlock", "presentation": {
"http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" }, { "lang": "en-us", { "role": "label", "Erroneous Compensation Analysis [Text Block]", "terseLabel": "Erroneous
Compensation Analysis" } } }, "auth_ref": "r1183", "r1193", "r1203", "r1235" } } }, "ecd_ErrCompRecoveryTable", { "xbrltype": "stringItemType", "nsuri":
"http://xbrl.sec.gov/ecd/2024", "localname": "ErrCompRecoveryTable", "presentation": "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" }, { "lang": "en-us", { "role": "label":
"Erroneously Awarded Compensation Recovery [Table]", "terseLabel": "Erroneously Awarded Compensation Recovery" } } }, "auth_ref": "r1180", "r1190", "r1200", "r1232" }
}, "cgc_EstimatedFairValueOfNotesUsingDiscountedCashFlow", { "xbrltype": "monetaryItemType", "nsuri": "http://www.canopygrowth.com/20241231", "localname":
"EstimatedFairValueOfNotesUsingDiscountedCashFlow", "crdr": "debit", "presentation": {
"http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails" }, { "lang": "en-us", { "role": "terseLabel", "Estimated fair value
of notes using discounted cash flow", "label": "Estimated fair value of notes using discounted cash flow", "documentation": "Estimated fair value of notes using discounted
cash flow." } } }, "auth_ref": { "cgc_ExchangeAndSubscriptionAgreementTerms", { "xbrltype": "stringItemType", "nsuri": "http://www.canopygrowth.com/20241231",
"localname": "ExchangeAndSubscriptionAgreementTerms", "presentation": {
"http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails" }, { "lang": "en-us", { "role": "documentation", "Exchange and
subscription agreement terms.", "label": "Exchange and Subscription Agreement Terms", "documentation": "Exchange and subscription agreement terms." } } }, "auth_ref": {
"cgc_ExchangeableSharesMember", { "xbrltype": "domainItemType", "nsuri": "http://www.canopygrowth.com/20241231", "localname": "ExchangeableSharesMember",
"presentation": "http://www.canopygrowth.com/20241231/taxonomy/role/Role_StatementCondensedInterimConsolidatedBalanceSheetsParentheticalUnaudited" }, { "lang": {
"en-us": { "role": "documentation", "Exchangeable Shares", "label": "Exchangeable Shares [Member]", "terseLabel": "Exchangeable shares" } } }, "auth_ref": { "us-
gaap_ExciseAndSalesTaxes", { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ExciseAndSalesTaxes", "crdr": "debit", "presentation": {
"http://www.canopygrowth.com/20241231/taxonomy/role/StatementCondensedInterimConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited" }, { "lang": "en-
us", { "role": "terseLabel", "Excise taxes", "label": "Excise and Sales Taxes", "documentation": "The amount of excise and sales taxes included in sales and revenues, which
are then deducted as a cost of sales. Includes excise taxes, which are applied to specific types of transactions or items (such as gasoline or alcohol) and sales, use and value
added taxes, which are applied to a broad class of revenue-producing transactions involving a wide range of goods and services." } } }, "auth_ref": "r283" } } },
"ecd_ExecutiveCategoryAxis", { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ExecutiveCategoryAxis", "presentation": {
"http://xbrl.sec.gov/ecd/role/PvpDisclosure" }, { "lang": "en-us", { "role": "label", "Executive Category [Axis]", "terseLabel": "Executive Category" } } }, "auth_ref": "r1231"
}, "cgc_ExerciseOfWarrants", { "xbrltype": "monetaryItemType", "nsuri": "http://www.canopygrowth.com/20241231", "localname": "ExerciseOfWarrants", "crdr": "credit",
"presentation": "http://www.canopygrowth.com/20241231/taxonomy/role/Role_StatementCondensedInterimConsolidatedStatementsOfShareholderEquityUnaudited" }, {
"lang": "en-us", { "role": "documentation", "Exercise of warrants", "label": "Exercise Of Warrants", "terseLabel": "Exercise of warrants" } } }, "auth_ref": {
"cgc_ExpectedCreditLossesOnFinancialAssetsAndRelatedCharges", { "xbrltype": "monetaryItemType", "nsuri": "http://www.canopygrowth.com/20241231", "localname":
"ExpectedCreditLossesOnFinancialAssetsAndRelatedCharges", "crdr": "debit", "presentation": {
"http://www.canopygrowth.com/20241231/taxonomy/role/Role_StatementCondensedInterimConsolidatedStatementsOfCashFlowsUnaudited" }, { "lang": "en-us", { "role": {
"documentation", "Expected credit losses on financial assets and related charges.", "label": "Expected Credit Losses On Financial Assets And Related Charges", "terseLabel":
"Expected credit losses on financial assets and related charges" } } }, "auth_ref": { "cgc_ExtendedPeriodOfOptionFromGrantDate", { "xbrltype": "durationItemType",
"nsuri": "http://www.canopygrowth.com/20241231", "localname": "ExtendedPeriodOfOptionFromGrantDate", "presentation": {
"http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureShareBasedCompensationAdditionalInformationDetails" }, { "lang": "en-us", { "role": "terseLabel",
"Options extended period", "label": "Extended Period Of Option From Grant Date", "documentation": "Maximum period of option from grant date." } } }, "auth_ref": {
"cgc_ExtinguishmentOfPromissoryNoteAndIssuanceOfExchangeableShares", { "xbrltype": "monetaryItemType", "nsuri": "http://www.canopygrowth.com/20241231",
"localname": "ExtinguishmentOfPromissoryNoteAndIssuanceOfExchangeableShares", "crdr": "credit", "presentation": {

```
"http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureAccumulatedOtherComprehensiveIncomeLossAccumulatedOtherComprehensiveIncomeDetails"}
{"lang": "en-us", "role": "role", "documentation": "Extinguishment of promissory note and issuance of exchangeable shares.", "label": "Extinguishment Of Promissory Note And Issuance Of Exchangeable Shares", "negatedLabel": "Extinguishment of promissory note and issuance of exchangeable shares"} } } } {"auth_ref": "f1"}, {"cgc_FacilitySaleMember": {"xbrlType": "domainItemType", "nsuri": "http://www.canopygrowth.com/20241231", "localname": "FacilitySaleMember", "presentation": {"http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureAmountsReceivableNetAdditionalInformationDetails"}, {"lang": "en-us", "role": "role", "terseLabel": "Facility Sale", "label": "Facility Sale [Member]", "documentation": "Facility sale."} } } {"auth_ref": "f1"}, {"us_gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {"xbrlType": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Line Items", "presentation": {"http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureFairValueOffFinancialInstrumentsSummaryOfValuationTechniquesAndSignificantUnobservableInputsIn"}, {"lang": "en-us", "role": "role", "terseLabel": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Line Items", "label": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Line Items", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."} } } {"auth_ref": "r688", "r689", "r702", "r1135"} }, {"us_gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {"xbrlType": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Table", "presentation": {"http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureFairValueOffFinancialInstrumentsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtEstimatedFairVa"}, {"lang": "en-us", "role": "role", "terseLabel": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Table", "label": "Fair Value, Recurring and Nonrecurring Table", "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis."} } } {"auth_ref": "r688", "r689", "r702", "r1135"} }, {"us_gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable": {"xbrlType": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques Table", "presentation": {"http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureFairValueOffFinancialInstrumentsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtEstimatedFairVa"}, {"lang": "en-us", "role": "role", "terseLabel": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Table", "label": "Fair Value, Recurring and Nonrecurring Table", "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis."} } } {"auth_ref": "r688", "r689", "r702", "r1135"} }, {"us_gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock": {"xbrlType": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques Table Text Block", "presentation": {"http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureFairValueOffFinancialInstrumentsTables"}, {"lang": "en-us", "role": "role", "terseLabel": "Summary of Valuation Techniques and Significant Unobservable Inputs in the Fair Value Measurement of Significant Level 2 and Level 3 Financial Instruments", "label": "Fair Value Measurement Inputs and Valuation Techniques Table Text Block", "documentation": "Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis."} } } {"auth_ref": "r690", "r691", "r1139"} }, {"us_gaap_FairValueByFairValueHierarchyLevelAxis": {"xbrlType": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Fair Value By Fair Value Hierarchy Level Axis", "presentation": {"http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureFairValueOffFinancialInstrumentsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtEstimatedFairVa"}, {"lang": "en-us", "role": "role", "terseLabel": "Fair Value Hierarchy and NAV", "label": "Fair Value Hierarchy and NAV [Axis]", "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient."} } } {"auth_ref": "r510", "r563", "r564", "r565", "r566", "r567", "r568", "r687", "r689", "r690", "r691", "r692", "r701", "r702", "r704", "r753", "r754", "r755", "r1111", "r1112", "r1123", "r1124", "r1125", "r1135", "r1139"} }, {"us_gaap_FairValueByLiabilityClassAxis": {"xbrlType": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Fair Value By Liability Class Axis", "presentation": {"http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureFairValueOffFinancialInstrumentsSummaryOfValuationTechniquesAndSignificantUnobservableInputsIn"}, {"lang": "en-us", "role": "role", "terseLabel": "Liability Class", "label": "Liability Class [Axis]", "documentation": "Information by class of liability."} } } {"auth_ref": "r693", "r694", "r695", "r696", "r697", "r698", "r703"} }, {"us_gaap_FairValueByMeasurementFrequencyAxis": {"xbrlType": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Fair Value By Measurement Frequency Axis", "presentation": {"http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureFairValueOffFinancialInstrumentsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtEstimatedFairVa"}, {"lang": "en-us", "role": "role", "terseLabel": "Measurement Frequency", "label": "Measurement Frequency [Axis]", "documentation": "Information by measurement frequency."} } } {"auth_ref": "r688", "r689", "r690", "r692", "r1135", "r1415", "r1418"} }, {"cgc_FairValueChangesOnRelatedAssets": {"xbrlType": "monetaryItemType", "nsuri": "http://www.canopygrowth.com/20241231", "localname": "Fair Value Changes On Related Assets", "crdr": "credit", "presentation": {"http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureOtherIncomeExpenseNetScheduleOfOtherIncomeExpenseNetDetails"}, {"lang": "en-us", "role": "role", "terseLabel": "Fair Value Changes On Related Assets", "label": "Fair Value Changes On Related Assets", "documentation": "Fair value changes on related assets."} } } {"auth_ref": "f1"}, {"us_gaap_FairValueDisclosuresAbstract": {"xbrlType": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Fair Value Disclosures Abstract", "presentation": {"http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureFairValueOffFinancialInstrumentsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtEstimatedFairVa"}, {"lang": "en-us", "role": "role", "terseLabel": "Fair Value Disclosures Abstract", "label": "Fair Value Disclosures Abstract", "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of similar groups of items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information."} } } {"auth_ref": "r697", "r699", "r700", "r701", "r704", "r705", "r706", "r707", "r708", "r815", "r1135", "r1140"} }, {"us_gaap_FairValueInputsLevel1Member": {"xbrlType": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Fair Value Inputs Level 1 Member", "presentation": {"http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureFairValueOffFinancialInstrumentsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtEstimatedFairVa"}, {"lang": "en-us", "role": "role", "terseLabel": "Level 1", "label": "Fair Value, Inputs, Level 1 [Member]", "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date."} } } {"auth_ref": "r510", "r563", "r568", "r689", "r702", "r753", "r1123", "r1124", "r1125", "r1135"} }, {"us_gaap_FairValueInputsLevel2Member": {"xbrlType": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Fair Value Inputs Level 2 Member", "presentation": {"http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureFairValueOffFinancialInstrumentsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtEstimatedFairVa"}, {"lang": "en-us", "role": "role", "terseLabel": "Level 2", "label": "Fair Value, Inputs, Level 2 [Member]", "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets."} } } {"auth_ref": "r510", "r563", "r568", "r689", "r690", "r702", "r754", "r1111", "r1112", "r1123", "r1124", "r1125", "r1135"} }, {"us_gaap_FairValueInputsLevel3Member": {"xbrlType": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Fair Value Inputs Level 3 Member", "presentation": {"http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureFairValueOffFinancialInstrumentsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtEstimatedFairVa"}, {"lang": "en-us", "role": "role", "terseLabel": "Level 3", "label": "Fair Value, Inputs, Level 3 [Member]", "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."} } } {"auth_ref": "r510", "r563", "r564", "r565", "r566", "r567", "r568", "r689", "r690", "r691", "r692", "r702", "r755", "r1111", "r1112", "r1123", "r1124", "r1125", "r1135", "r1139"} }, {"us_gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain": {"xbrlType": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation By Liability Class Domain", "presentation": {"http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureFairValueOffFinancialInstrumentsSummaryOfValuationTechniquesAndSignificantUnobservableInputsIn"}, {"lang": "en-us", "role": "role", "terseLabel": "Level 1", "label": "Fair Value, Inputs, Level 1 [Member]", "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date."} } } {"auth_ref": "r510", "r563", "r568", "r689", "r702", "r753", "r1123", "r1124", "r1125", "r1135"} }, {"us_gaap_FairValueMeasurementsFairValueHierarchyDomain": {"xbrlType": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Fair Value Measurements Fair Value Hierarchy Domain", "presentation": {"http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureFairValueOffFinancialInstrumentsSummaryOfValuationTechniquesAndSignificantUnobservableInputsIn"}, {"lang": "en-us", "role": "role", "terseLabel": "Level 1", "label": "Fair Value, Inputs, Level 1 [Member]", "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date."} } } {"auth_ref": "r510", "r563", "r568", "r689", "r702", "r753", "r1123
```

```

measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value." } } }, "auth_ref": "r1135",
"r1412", "r1413", "r1414", "r1415", "r1416", "r1418" } }, "cgic_FairValueMeasurementsSignificantUnobservableInputDescription": { "xbrltype": "stringItemType", "nsuri":
"http://www.canopygrowth.com/20241231/taxonomy/role", "localname": "Fair Value Measurements Significant Unobservable Input Description", "presentation": {
"http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureFairValueOffFinancialInstrumentsSummaryOfValuationTechniquesAndSignificantUnobservableInputsIn
"http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureFairValueOffFinancialInstrumentsSummaryOfValuationTechniquesAndSignificantUnobservableInputsIn
"lang": { "en-us": { "role": { "terseLabel": "Significant unobservable inputs", "terseLabel": "Key Inputs", "label": "Fair Value Measurements Significant Unobservable Input
Description", "documentation": "Fair value measurements significant unobservable input description." } } }, "auth_ref": { "r375", "r376", "r377", "r378", "r379", "r380", "r381", "r382", "r383", "r384", "r385", "r386", "r387", "r388", "r389", "r390", "r391", "r392", "r393", "r394", "r395", "r396",
"r397", "r398", "r399", "r400", "r401", "r402", "r422", "r423", "r424", "r425", "r426", "r429", "r430", "r431", "r432", "r433", "r434", "r435", "r436", "r437", "r438", "r439", "r440", "r441", "r442", "r443", "r444", "r445", "r446", "r447", "r448", "r449", "r450", "r451", "r452", "r453", "r454", "r455", "r456", "r457", "r458", "r459", "r460", "r461", "r462", "r463", "r464", "r465", "r466", "r467", "r468", "r469", "r470", "r471", "r472", "r473", "r474", "r475", "r476",
"r477", "r478", "r479", "r480", "r481", "r482", "r483", "r484", "r485", "r486", "r487", "r488", "r489", "r490", "r491", "r492", "r493", "r494", "r495", "r496", "r497", "r498", "r499", "r500", "r501", "r502", "r503", "r504", "r505", "r506", "r507", "r508", "r509", "r510", "r511", "r512", "r513", "r514", "r515", "r516", "r517", "r518", "r519", "r520", "r521", "r522", "r523", "r524", "r525", "r526", "r527", "r528", "r529", "r530", "r531", "r532", "r533", "r534", "r535", "r536", "r537", "r538", "r539", "r540", "r541", "r542", "r543", "r544", "r545", "r546", "r547", "r548", "r549", "r550", "r551", "r552", "r553", "r554", "r555", "r556", "r557", "r558", "r559", "r560", "r561", "r562", "r563", "r564", "r565", "r566", "r567", "r568", "r569", "r570", "r571", "r572", "r573", "r574", "r575", "r576",
"r577", "r578", "r579", "r580", "r581", "r582", "r583", "r584", "r585", "r586", "r587", "r588", "r589", "r590", "r591", "r592", "r593", "r594", "r595", "r596", "r597", "r598", "r599", "r600", "r601", "r602", "r603", "r604", "r605", "r606", "r607", "r608", "r609", "r610", "r611", "r612", "r613", "r614", "r615", "r616", "r617", "r618", "r619", "r620", "r621", "r622", "r623", "r624", "r625", "r626", "r627", "r628", "r629", "r630", "r631", "r632", "r633", "r634", "r635", "r636", "r637", "r638", "r639", "r640", "r641", "r642", "r643", "r644", "r645", "r646", "r647", "r648", "r649", "r650", "r651", "r652", "r653", "r654", "r655", "r656", "r657", "r658", "r659", "r660", "r661", "r662", "r663", "r664", "r665", "r666", "r667", "r668", "r669", "r670", "r671", "r672", "r673", "r674", "r675", "r676", "r677", "r678", "r679", "r680", "r681", "r682", "r683", "r684", "r685", "r686", "r687", "r688", "r689", "r690", "r691", "r692", "r693", "r694", "r695", "r696", "r697", "r698", "r699", "r700", "r701", "r702", "r703", "r704", "r705", "r706", "r707", "r708", "r709", "r710", "r711", "r712", "r713", "r714", "r715", "r716", "r717", "r718", "r719", "r720", "r721", "r722", "r723", "r724", "r725", "r726", "r727", "r728", "r729", "r730", "r731", "r732", "r733", "r734", "r735", "r736", "r737", "r738", "r739", "r740", "r741", "r742", "r743", "r744", "r745", "r746", "r747", "r748", "r749", "r750", "r751", "r752", "r753", "r754", "r755", "r756", "r757", "r758", "r759", "r760", "r761", "r762", "r763", "r764", "r765", "r766", "r767", "r768", "r769", "r770", "r771", "r772", "r773", "r774", "r775", "r776",
"r777", "r778", "r779", "r780", "r781", "r782", "r783", "r784", "r785", "r786", "r787", "r788", "r789", "r790", "r791", "r792", "r793", "r794", "r795", "r796", "r797", "r798", "r799", "r800", "r801", "r802", "r803", "r804", "r805", "r806", "r807", "r808", "r809", "r810", "r811", "r812", "r813", "r814", "r815", "r816", "r817", "r818", "r819", "r820", "r821", "r822", "r823", "r824", "r825", "r826", "r827", "r828", "r829", "r830", "r831", "r832", "r833", "r834", "r835", "r836", "r837", "r838", "r839", "r840", "r841", "r842", "r843", "r844", "r845", "r846", "r847", "r848", "r849", "r850", "r851", "r852", "r853", "r854", "r855", "r856", "r857", "r858", "r859", "r860", "r861", "r862", "r863", "r864", "r865", "r866", "r867", "r868", "r869", "r870", "r871", "r872", "r873", "r874", "r875", "r876", "r877", "r878", "r879", "r880", "r881", "r882", "r883", "r884", "r885", "r886", "r887", "r888", "r889", "r890", "r891", "r892", "r893", "r894", "r895", "r896", "r897", "r898", "r899", "r900", "r901", "r902", "r903", "r904", "r905", "r906", "r907", "r908", "r909", "r910", "r911", "r912", "r913", "r914", "r915", "r916", "r917", "r918", "r919", "r920", "r921", "r922", "r923", "r924", "r925", "r926", "r927", "r928", "r929", "r930", "r931", "r932", "r933", "r934", "r935", "r936", "r937", "r938", "r939", "r940", "r941", "r942", "r943", "r944", "r945", "r946", "r947", "r948", "r949", "r950", "r951", "r952", "r953", "r954", "r955", "r956", "r957", "r958", "r959", "r960", "r961", "r962", "r963", "r964", "r965", "r966", "r967", "r968", "r969", "r970", "r971", "r972", "r973", "r974", "r975", "r976", "r977", "r978", "r979", "r980", "r981", "r982", "r983", "r984", "r985", "r986", "r987", "r988", "r989", "r990", "r991", "r992", "r993", "r994", "r995", "r996", "r997", "r998", "r999", "r1000", "r1001", "r1002", "r1003", "r1004", "r1005", "r1006", "r1007", "r1008", "r1009", "r1010", "r1011", "r1012", "r1013", "r1014", "r1015", "r1016", "r1017", "r1018", "r1019", "r102
```

"http://www.canopygrowth.com/20241231", "localname": "GainLossOnAssetImpairmentAndRestructuringTextBlock", "presentation": f

"http://www.canopygrowth.com/20241231/taxonomy/role/DisclosureLossOnAssetImpairmentAndRestructuring", "lang": f "en-us": f "role": f "terseLabel": "Loss on Asset Impairment and Restructuring", "documentation": "(Gain)/loss on asset impairment and restructuring.", "label": "(Gain) loss on asset impairment and restructuring fText Blockl", "auth_ref": f f, "us-gaap_GainLossOnSaleOfBusiness": f "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GainLossOnSaleOfBusiness", "crdr": "credit", "presentation": f

"http://www.canopygrowth.com/20241231/taxonomy/role/DisclosureCanopyUsaSummaryOfDerecognizedAssetsAndLiabilitiesTransferredDetails", "lang": f "en-us": f "role": f "label": "Gain (Loss) on Disposition of Business", "terseLabel": "Gain on disposal of consolidated entity", "verboseLabel": "Loss on disposal of consolidated entity", "negatedLabel": "Gain on disposal of consolidated entity", "documentation": "Amount of gain (loss) from sale and disposal of integrated set of activities and assets capable of being conducted and managed for purpose of providing return in form of dividend, lower cost, or other economic benefit to investor, owner, member and participant.", "auth_ref": f "r661", "r1299", "us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges": f "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GainLossOnSalesOfAssetsAndAssetImpairmentCharges", "crdr": "credit", "presentation": f

"http://www.canopygrowth.com/20241231/taxonomy/role/DisclosureLossOnAssetImpairmentAndRestructuringAdditionalInformationDetails",

"http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureSegmentInformationSummaryOfReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedDel

"http://www.canopygrowth.com/20241231/taxonomy/role/StatementCondensedInterimConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited", "lang": f "en-us": f "role": f "label": "Gain (Loss) on Sale of Assets and Asset Impairment Charges", "terseLabel": "(Gain)/loss on asset impairment and restructuring", "negatedLabel": "Loss on asset impairment and restructuring", "negatedTerseLabel": "Loss on asset impairment and restructuring", "documentation": "Amount of gain (loss) from the difference between the sale price or salvage price and the book value of an asset that was sold or retired, and gain (loss) from the write down of assets from their carrying value to fair value.", "auth_ref": f "r1299", "ecgc_GlobalCannabisNetRevenueMember": f "xbrltype": "domainItemType", "nsuri": "http://www.canopygrowth.com/20241231", "localname": "GlobalCannabisNetRevenueMember", "presentation": f

"http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureRevenueSummaryOfDisaggregationOfRevenueDetails", "lang": f "en-us": f "role": f "terseLabel": "Global Cannabis Net Revenue", "label": "Global Cannabis Net Revenue fMember", "documentation": "Global cannabis net revenue.", "auth_ref": f f

"ecgc_GoingConcernPolicyTextBlock": f "xbrltype": "textBlockItemType", "nsuri": "http://www.canopygrowth.com/20241231", "localname": "GoingConcernPolicyTextBlock", "presentation": f "http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies", "lang": f "en-us": f "role": f "terseLabel": "Going Concern", "label": "Going Concern fPolicy Text Blockl", "documentation": "Disclosure of accounting policy for going concern.", "auth_ref": f f, "us-gaap_Goodwill": f "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Goodwill", "crdr": "debit", "presentation": f

"http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureGoodwillAdditionalInformationDetails",

"http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureGoodwillChangesInCarryingAmountOfGoodwillDetails",

"http://www.canopygrowth.com/20241231/taxonomy/role/Role_StatementCondensedInterimConsolidatedBalanceSheetsUnaudited", "lang": f "en-us": f "role": f "totalLabel": "Goodwill, Total", "terseLabel": "Goodwill", "periodStartLabel": "Beginning Balance", "periodEndLabel": "Ending Balance", "label": "Goodwill", "documentation": "Amount, after accumulated impairment loss, of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized.", "auth_ref": f "r255", "r438", "r816", "r1101", "r1107", "r1136", "r1147", "r1333", "r1340", "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": f "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract", "lang": f "en-us": f "role": f "label": "Goodwill and Intangible Assets Disclosure fAbstractl", "auth_ref": f f, "us-gaap_GoodwillDisclosureTextBlock": f "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GoodwillDisclosureTextBlock", "presentation": f

"http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureGoodwill", "lang": f "en-us": f "role": f "terseLabel": "Goodwill", "label": "Goodwill Disclosure fText Blockl", "documentation": "The entire disclosure for goodwill.", "auth_ref": f "r437", "r440", "r450", "r1107", "us-gaap_GoodwillForeignCurrencyTranslationGainLoss": f "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GoodwillForeignCurrencyTranslationGainLoss", "crdr": "credit", "presentation": f

"http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureGoodwillChangesInCarryingAmountOfGoodwillDetails", "lang": f "en-us": f "role": f "terseLabel": "Foreign currency translation adjustments", "label": "Goodwill, Foreign Currency Translation Gain (Loss)", "documentation": "Amount of foreign currency translation gain (loss) which increases (decreases) asset representing future economic benefit from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized.", "auth_ref": f "r446", "us-gaap_GoodwillImpairmentLoss": f "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GoodwillImpairmentLoss", "crdr": "debit", "presentation": f

"http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureGoodwillChangesInCarryingAmountOfGoodwillDetails", "lang": f "en-us": f "role": f "negatedLabel": "Impairment losses", "terseLabel": "Goodwill impairment loss", "label": "Goodwill, Impairment Loss", "documentation": "Amount of impairment loss from asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized.", "auth_ref": f "r11", "r439", "r445", "r451", "r1107", "r1136", "us-gaap_GoodwillLineItems": f "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GoodwillLineItems", "presentation": f

"http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureGoodwillAdditionalInformationDetails",

"http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureGoodwillChangesInCarryingAmountOfGoodwillDetails", "lang": f "en-us": f "role": f "terseLabel": "Goodwill fLine Itemsl", "label": "Goodwill fLine Itemsl", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "auth_ref": f "r440", "r441", "r442", "r443", "r444", "r445", "r446", "r447", "r448", "r449", "r451", "r1107", "us-gaap_GoodwillPurchaseAccountingAdjustments": f "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GoodwillPurchaseAccountingAdjustments", "crdr": "debit", "presentation": f

"http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureGoodwillChangesInCarryingAmountOfGoodwillDetails", "lang": f "en-us": f "role": f "terseLabel": "Purchase accounting allocations", "label": "Goodwill, Measurement Period Adjustment", "documentation": "Amount of increase (decrease) from measurement period adjustment of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized.", "auth_ref": f "r0", "r1339", "ecgc_GovernmentDebtSecuritiesMember": f "xbrltype": "domainItemType", "nsuri": "http://www.canopygrowth.com/20241231", "localname": "GovernmentDebtSecuritiesMember", "presentation": f

"http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureShortTermInvestmentsComponentsOfShortTermInvestmentsDetails", "lang": f "en-us": f "role": f "documentation": "Government debt securities.", "label": "Government Debt Securities fMember", "terseLabel": "Government securities", "auth_ref": f f

"ecgc_GrossProceedsFromExchangeAndSubscriptionAgreementOfDebt": f "xbrltype": "monetaryItemType", "nsuri": "http://www.canopygrowth.com/20241231", "localname": "GrossProceedsFromExchangeAndSubscriptionAgreementOfDebt", "crdr": "debit", "presentation": f

"http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureBasisOfPresentationAdditionalInformationDetails",

"http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails", "lang": f "en-us": f "role": f "documentation": "Gross proceeds from exchange and subscription agreement of debt", "auth_ref": f f, "us-gaap_GrossProfit": f "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GrossProfit", "crdr": "credit", "presentation": f

"http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureSegmentInformationSummaryOfReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedDel

"http://www.canopygrowth.com/20241231/taxonomy/role/StatementCondensedInterimConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited", "lang": f "en-us": f "role": f "totalLabel": "Gross margin", "terseLabel": "Gross margin", "label": "Gross Profit", "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.", "auth_ref": f "r150", "r157", "r223", "r296", "r409", "r496", "r497", "r498", "r499", "r500", "r501", "r502", "r503", "r504", "r713", "r1095", "r1100", "r1313", "r1315", "r1316", "r1317", "r1318", "r1366", "ecgc_HSCPHoldersPursuantToAmendedTRAMember": f "xbrltype": "domainItemType", "nsuri": "http://www.canopygrowth.com/20241231", "localname": "HSCP HSCPHoldersPursuantToAmendedTRAMember", "presentation": f

"http://www.canopygrowth.com/20241231/taxonomy/role/DisclosureCanopyUsaAcreageAgreementsAdditionalInformationDetails",

"http://www.canopygrowth.com/20241231/taxonomy/role/DisclosureCanopyUsaAdditionalInformationDetails", "lang": f "en-us": f "role": f "label": "H S C P Holders Pursuant To Amended T R A Member", "documentation": "HSCP Holders pursuant to Amended TRA", "terseLabel": "HSCP", "auth_ref": f f, "ecgc_HempcoDebtMember": f "xbrltype": "domainItemType", "nsuri": "http://www.canopygrowth.com/20241231", "localname": "HempcoDebtMember", "presentation": f

"http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsSummaryOfValuationTechniquesAndSignificantUnobservableInputsIn", "lang": f "en-us": f "role": f "documentation": "Hempco debenture.", "label": "Hempco Debenture fMember", "terseLabel": "Hempco Debenture", "auth_ref": f f, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": f "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "crdr": "credit", "presentation": f

"http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureSegmentInformationSummaryOfReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedDel

"http://www.canopygrowth.com/20241231/taxonomy/role/StatementCondensedInterimConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited", "lang": f "en-us": f "role": f "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest", "totalLabel": "Loss from continuing operations before income taxes", "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.", "auth_ref": f "r151", "r216", "r223", "r821", "r840", "r1095", "r1100", "r1313", "r1315", "r1316", "r1317", "r1318", "us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest": f "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest", "crdr": "credit", "presentation": f

"http://www.canopygrowth.com/20241231/taxonomy/role/Role_StatementCondensedInterimConsolidatedStatementsOfCashFlowsUnaudited",

"http://www.canopygrowth.com/20241231/taxonomy/role/StatementCondensedInterimConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited", "lang": f "en-us": f "role": f "label": "Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest", "totalLabel": "Net loss from continuing operations", "terseLabel": "Net loss", "verboseLabel": "Net loss from continuing operations", "documentation": "Amount after tax of income (loss) from continuing operations including portion attributable to the noncontrolling interest.", "auth_ref": f "r199", "r223", "r296", "r303", "r310", "r409", "r496", "r497", "r498", "r499", "r500", "r501", "r502", "r503", "r504", "r640", "r653", "r686", "r713", "r840", "r1095", "r1313", "r1315", "r1316", "r1317", "r1318", "r1366", "us-gaap_IncomeLossFromContinuingOperationsPerBasicShare": f "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeLossFromContinuingOperationsPerBasicShare", "presentation": f

"http://www.canopygrowth.com/20241231/taxonomy/role/StatementCondensedInterimConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited", "lang": f "en-us": f "role": f "label": "Income (Loss) from Continuing Operations, Per Basic Share", "terseLabel": "Basic loss per share continuing operations", "documentation": "The amount of net income (loss) from continuing operations per each share of common stock or unit outstanding during the reporting period.", "auth_ref": f "r153", "r217", "r287", "r303", "r306", "r307", "r308", "r309", "r310", "r319", "r322", "r323", "r640", "r653", "r686", "r820", "r1441", "us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare": f "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeLossFromContinuingOperationsPerDilutedShare", "presentation": f

"http://www.canopygrowth.com/20241231/taxonomy/role/StatementCondensedInterimConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited", "lang": f "en-us": f "role": f "label": "Income (Loss) from Continuing Operations, Per Diluted Share", "terseLabel": "Diluted loss per share continuing operations", "documentation": "The amount of net income (loss) derived from continuing operations during the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "auth_ref": f "r153", "r287", "r303", "r306", "r307", "r308", "r309", "r310", "r319", "r322", "r323", "r324", "r653", "r686", "r820", "r1441", "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax": f "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeLossFromDiscontinuedOperationsNetOfTax", "crdr": "credit", "presentation": f

"http://www.canopygrowth.com/20241231/taxonomy/role/Role_StatementCondensedInterimConsolidatedStatementsOfCashFlowsUnaudited",

"http://www.canopygrowth.com/20241231/taxonomy/role/StatementCondensedInterimConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited", "lang": f "en-us": f "role": f "terseLabel": "Discontinued operations, net of income tax", "totalLabel": "Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest", "label": "Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest", "verboseLabel": "Gain (loss) from discontinued operations, net of income tax", "documentation": "Amount after tax of income (loss) from a discontinued operation including

```

the portion attributable to noncontrolling interest. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal." } } }, "auth_ref": "r104", "r105", "r106", "r107", "r108", "r109", "r110", "r111", "r112", "r113", "r114", "r115", "r116", "r117", "r118", "r119", "r120", "r121", "r122", "r123", "r124", "r125", "r126", "r127", "r128", "r129", "r130", "r131", "r132", "r133", "r134", "r135", "r136", "r137", "r138", "r139", "r140", "r141", "r142", "r143", "r144", "r145", "r146", "r147", "r148", "r149", "r150", "r151", "r152", "r153", "r154", "r155", "r156", "r157", "r158", "r159", "r160", "r161", "r162", "r163", "r164", "r165", "r166", "r167", "r168", "r169", "r170", "r171", "r172", "r173", "r174", "r175", "r176", "r177", "r178", "r179", "r180", "r181", "r182", "r183", "r184", "r185", "r186", "r187", "r188", "r189", "r190", "r191", "r192", "r193", "r194", "r195", "r196", "r197", "r198", "r199", "r200", "r201", "r202", "r203", "r204", "r205", "r206", "r207", "r208", "r209", "r210", "r211", "r212", "r213", "r214", "r215", "r216", "r217", "r218", "r219", "r220", "r221", "r222", "r223", "r224", "r225", "r226", "r227", "r228", "r229", "r230", "r231", "r232", "r233", "r234", "r235", "r236", "r237", "r238", "r239", "r240", "r241", "r242", "r243", "r244", "r245", "r246", "r247", "r248", "r249", "r250", "r251", "r252", "r253", "r254", "r255", "r256", "r257", "r258", "r259", "r260", "r261", "r262", "r263", "r264", "r265", "r266", "r267", "r268", "r269", "r270", "r271", "r272", "r273", "r274", "r275", "r276", "r277", "r278", "r279", "r280", "r281", "r282", "r283", "r284", "r285", "r286", "r287", "r288", "r289", "r290", "r291", "r292", "r293", "r294", "r295", "r296", "r297", "r298", "r299", "r300", "r301", "r302", "r303", "r304", "r305", "r306", "r307", "r308", "r309", "r310", "r311", "r312", "r313", "r314", "r315", "r316", "r317", "r318", "r319", "r320", "r321", "r322", "r323", "r324", "r325", "r326", "r327", "r328", "r329", "r330", "r331", "r332", "r333", "r334", "r335", "r336", "r337", "r338", "r339", "r340", "r341", "r342", "r343", "r344", "r345", "r346", "r347", "r348", "r349", "r350", "r351", "r352", "r353", "r354", "r355", "r356", "r357", "r358", "r359", "r360", "r361", "r362", "r363", "r364", "r365", "r366", "r367", "r368", "r369", "r370", "r371", "r372", "r373", "r374", "r375", "r376", "r377", "r378", "r379", "r380", "r381", "r382", "r383", "r384", "r385", "r386", "r387", "r388", "r389", "r390", "r391", "r392", "r393", "r394", "r395", "r396", "r397", "r398", "r399", "r400", "r401", "r402", "r403", "r404", "r405", "r406", "r407", "r408", "r409", "r410", "r411", "r412", "r413", "r414", "r415", "r416", "r417", "r418", "r419", "r420", "r421", "r422", "r423", "r424", "r425", "r426", "r427", "r428", "r429", "r430", "r431", "r432", "r433", "r434", "r435", "r436", "r437", "r438", "r439", "r440", "r441", "r442", "r443", "r444", "r445", "r446", "r447", "r448", "r449", "r450", "r451", "r452", "r453", "r454", "r455", "r456", "r457", "r458", "r459", "r460", "r461", "r462", "r463", "r464", "r465", "r466", "r467", "r468", "r469", "r470", "r471", "r472", "r473", "r474", "r475", "r476", "r477", "r478", "r479", "r480", "r481", "r482", "r483", "r484", "r485", "r486", "r487", "r488", "r489", "r490", "r491", "r492", "r493", "r494", "r495", "r496", "r497", "r498", "r499", "r500", "r501", "r502", "r503", "r504", "r505", "r506", "r507", "r508", "r509", "r510", "r511", "r512", "r513", "r514", "r515", "r516", "r517", "r518", "r519", "r520", "r521", "r522", "r523", "r524", "r525", "r526", "r527", "r528", "r529", "r530", "r531", "r532", "r533", "r534", "r535", "r536", "r537", "r538", "r539", "r540", "r541", "r542", "r543", "r544", "r545", "r546", "r547", "r548", "r549", "r550", "r551", "r552", "r553", "r554", "r555", "r556", "r557", "r558", "r559", "r560", "r561", "r562", "r563", "r564", "r565", "r566", "r567", "r568", "r569", "r570", "r571", "r572", "r573", "r574", "r575", "r576", "r577", "r578", "r579", "r580", "r581", "r582", "r583", "r584", "r585", "r586", "r587", "r588", "r589", "r590", "r591", "r592", "r593", "r594", "r595", "r596", "r597", "r598", "r599", "r600", "r601", "r602", "r603", "r604", "r605", "r606", "r607", "r608", "r609", "r610", "r611", "r612", "r613", "r614", "r615", "r616", "r617", "r618", "r619", "r620", "r621", "r622", "r623", "r624", "r625", "r626", "r627", "r628", "r629", "r630", "r631", "r632", "r633", "r634", "r635", "r636", "r637", "r638", "r639", "r640", "r641", "r642", "r643", "r644", "r645", "r646", "r647", "r648", "r649", "r650", "r651", "r652", "r653", "r654", "r655", "r656", "r657", "r658", "r659", "r660", "r661", "r662", "r663", "r664", "r665", "r666", "r667", "r668", "r669", "r670", "r671", "r672", "r673", "r674", "r675", "r676", "r677", "r678", "r679", "r680", "r681", "r682", "r683", "r684", "r685", "r686", "r687", "r688", "r689", "r690", "r691", "r692", "r693", "r694", "r695", "r696", "r697", "r698", "r699", "r700", "r701", "r702", "r703", "r704", "r705", "r706", "r707", "r708", "r709", "r710", "r711", "r712", "r713", "r714", "r715", "r716", "r717", "r718", "r719", "r720", "r721", "r722", "r723", "r724", "r725", "r726", "r727", "r728", "r729", "r730", "r731", "r732", "r733", "r734", "r735", "r736", "r737", "r738", "r739", "r740", "r741", "r742", "r743", "r744", "r745", "r746", "r747", "r748", "r749", "r750", "r751", "r752", "r753", "r754", "r755", "r756", "r757", "r758", "r759", "r760", "r761", "r762", "r763", "r764", "r765", "r766", "r767", "r768", "r769", "r770", "r771", "r772",
```

```
"periodEndLabel": "Indefinite-Lived Intangible Assets (Excluding Goodwill). Ending Balance.", "periodStartLabel": "Indefinite-Lived Intangible Assets (Excluding Goodwill). Beginning Balance.", "totalLabel": "Indefinite-Lived Intangible Assets (Excluding Goodwill), Total", "terseLabel": "Indefinite lived intangible assets", "label": "Indefinite-Lived Intangible Assets (Excluding Goodwill)", "documentation": "Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit." } }, "auth_ref": { "r436", "r462", "r108", "r462_IndividualAxis", "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "IndividualAxis", "presentation": "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErtCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "lang": { "en-us": { "role": { "label": "Individual [Axis]", "terseLabel": "Individual", "auth_ref": { "r187", "r197", "r207", "r1231", "r1239", "r1243", "r1251", "cgc_InitialPrincipalAmount", "xbrltype": "monetaryItemType", "nsuri": "http://www.canopygrowth.com/20241231", "localname": "InitialPrincipalAmount", "crdr": "debit", "presentation": "http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails", "lang": { "en-us": { "role": { "terseLabel": "Initial principal amount", "label": "Initial Principal Amount", "documentation": "Initial Principal Amount" } }, "auth_ref": { "r129", "r1255", "ecd_InsiderTradingArrLineItems", "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTradingArrLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Arrangements [Line Items]", "terseLabel": "Insider Trading Arrangements", "auth_ref": { "r1249", "ecd_InsiderTradingPoliciesProcLineItems", "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTradingPoliciesProcLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures [Line Items]", "terseLabel": "Insider Trading Policies and Procedures", "auth_ref": { "r1179", "r1255", "ecd_InsiderTrdPoliciesProcAdoptedFlag", "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTrdPoliciesProcAdoptedFlag", "presentation": "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc", "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures Adopted [Flag]", "terseLabel": "Insider Trading Policies and Procedures Adopted", "auth_ref": { "r1179", "r1255", "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock", "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock", "presentation": "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc", "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]", "terseLabel": "Insider Trading Policies and Procedures Not Adopted", "auth_ref": { "r1179", "r1255", "us-gaap_IntangibleAssetsDisclosureTextBlock", "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IntangibleAssetsDisclosureTextBlock", "presentation": "http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureIntangibleAssets", "lang": { "en-us": { "role": { "terseLabel": "Intangible Assets", "label": "Intangible Assets Disclosure [Text Block]", "documentation": "The entire disclosure for all or part of the information related to intangible assets." } }, "auth_ref": { "r452", "r465", "r467", "r1084", "r1085", "us-gaap_IntangibleAssetsNetExcludingGoodwill", "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IntangibleAssetsNetExcludingGoodwill", "crdr": "debit", "presentation": "http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureIntangibleAssetsSummaryOfComponentsOffIntangibleAssetsDetails", "http://www.canopygrowth.com/20241231/taxonomy/role/Role_StatementCondensedInterimConsolidatedBalanceSheetsUnaudited", "lang": { "en-us": { "role": { "totalLabel": "Intangible Assets, Net (Excluding Goodwill), Total", "verboseLabel": "Total intangible assets", "terseLabel": "Intangible assets", "label": "Intangible Assets, Net (Excluding Goodwill)", "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges." } }, "auth_ref": { "r453", "r1349", "r1350", "us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract", "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IntangibleAssetsNetExcludingGoodwillAbstract", "lang": { "en-us": { "role": { "label": "Intangible Assets, Net (Excluding Goodwill) [Abstract]", "auth_ref": { "r124", "cgc_IntangibleAssetsNetExcludingGoodwillLineItems", "xbrltype": "stringItemType", "nsuri": "http://www.canopygrowth.com/20241231", "localname": "IntangibleAssetsNetExcludingGoodwillLineItems", "presentation": "http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureIntangibleAssetsSummaryOfComponentsOffIntangibleAssetsDetails", "lang": { "en-us": { "role": { "terseLabel": "Intangible Assets Net Excluding Goodwill [Line Items]", "label": "Intangible Assets Net Excluding Goodwill [Line Items]", "documentation": "Intangible assets net excluding goodwill line items." } }, "auth_ref": { "r124", "us-gaap_IntellectualPropertyMember", "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IntellectualPropertyMember", "presentation": "http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureIntangibleAssetsSummaryOfComponentsOffIntangibleAssetsDetails", "lang": { "en-us": { "role": { "terseLabel": "Intellectual Property", "label": "Intellectual Property [Member]", "documentation": "Intangible asset arising from original creative thought. Include, but is not limited to, trademarks, patents, and copyrights." } }, "auth_ref": { "r28", "r1344", "r1345", "r1346", "r1347", "r1348", "r1349", "r1351", "r1352", "us-gaap_InterestExpense", "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestExpense", "crdr": "debit", "presentation": "http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureOtherIncomeExpenseNetScheduleOfOtherIncomeExpenseNetDetails", "lang": { "en-us": { "role": { "totalLabel": "Interest Expense, Total", "negatedLabel": "Interest expense", "label": "Interest Expense, Operating and Nonoperating", "documentation": "Amount of interest expense classified as operating and nonoperating. Includes, but is not limited to, cost of borrowing accounted for as interest expense." } }, "auth_ref": { "r329", "r337", "r341", "r347", "r360", "r723", "r100", "r101", "cgc_InterestIncome", "xbrltype": "monetaryItemType", "nsuri": "http://www.canopygrowth.com/20241231", "localname": "InterestIncome", "crdr": "credit", "presentation": "http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureOtherIncomeExpenseNetScheduleOfOtherIncomeExpenseNetDetails", "lang": { "en-us": { "role": { "terseLabel": "Interest income", "label": "Interest Income", "documentation": "Interest income." } }, "auth_ref": { "r124", "us-gaap_InterestPaidNet", "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestPaidNet", "crdr": "debit", "presentation": "http://www.canopygrowth.com/20241231/taxonomy/role/Role_StatementCondensedInterimConsolidatedStatementsOfCashFlowsUnaudited", "lang": { "en-us": { "role": { "terseLabel": "Interest", "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities", "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount." } }, "auth_ref": { "r288", "r291", "r292", "us-gaap_InterestPayableCurrentAndNoncurrent", "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestPayableCurrentAndNoncurrent", "crdr": "credit", "presentation": "http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureDebtSummaryOfComponentsOfDebtDetails", "lang": { "en-us": { "role": { "terseLabel": "Accrued interest", "label": "Interest Payable", "documentation": "Amount of interest payable on debt, including, but not limited to, trade payables." } }, "auth_ref": { "r207", "r1437", "us-gaap_InterestReceivableCurrent", "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestReceivableCurrent", "crdr": "debit", "presentation": "http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureAmountsReceivableNetComponentsOfAmountsReceivableNetDetails", "lang": { "en-us": { "role": { "terseLabel": "Interest receivable", "label": "Interest Receivable, Current", "documentation": "Carrying amount as of the balance sheet date of current interest earned but not received. Also called accrued interest or accrued interest receivable. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer." } }, "auth_ref": { "r1282", "cgc_InternationalAndOtherRevenueMember", "xbrltype": "domainItemType", "nsuri": "http://www.canopygrowth.com/20241231", "localname": "InternationalAndOtherRevenueMember", "presentation": "http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureRevenueSummaryOfDisaggregationOfRevenueDetails", "lang": { "en-us": { "role": { "terseLabel": "International and Other Revenue", "label": "International And Other Revenue [Member]", "documentation": "International and other revenue member." } }, "auth_ref": { "r124", "cgc_InternationalMarketsCannabisMember", "xbrltype": "domainItemType", "nsuri": "http://www.canopygrowth.com/20241231", "localname": "InternationalMarketsCannabisMember", "presentation": "http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureRevenueSummaryOfDisaggregationOfRevenueDetails", "http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureSegmentInformationSummaryOfReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedDel", "lang": { "en-us": { "role": { "documentation": "International markets cannabis", "label": "International Markets Cannabis [Member]", "terseLabel": "International Markets Cannabis", "auth_ref": { "r124", "us-gaap_InventoryDisclosureAbstract", "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Inventory Disclosure [Abstract]", "auth_ref": { "r124", "us-gaap_InventoryDisclosureTextBlock", "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryDisclosureTextBlock", "presentation": "http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureInventory", "lang": { "en-us": { "role": { "terseLabel": "Inventory", "label": "Inventory Disclosure [Text Block]", "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory." } }, "auth_ref": { "r432", "us-gaap_InventoryFinishedGoods", "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryFinishedGoods", "crdr": "debit", "presentation": "http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureInventoryComponentsOfInventoryDetails", "lang": { "en-us": { "role": { "terseLabel": "Finished goods", "label": "Inventory, Finished Goods, Gross", "documentation": "Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer." } }, "auth_ref": { "r1283", "us-gaap_InVENTORYNet", "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryNet", "crdr": "debit", "presentation": "http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureInventoryComponentsOfInventoryDetails", "http://www.canopygrowth.com/20241231/taxonomy/role/Role_StatementCondensedInterimConsolidatedBalanceSheetsUnaudited", "lang": { "en-us": { "role": { "totalLabel": "Inventory", "terseLabel": "Inventory", "label": "Inventory, Net", "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer." } }, "auth_ref": { "r266", "r1089", "r1147", "us-gaap_InVENTORYRawMaterialsAndSupplies", "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryRawMaterialsAndSupplies", "crdr": "debit", "presentation": "http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureInventoryComponentsOfInventoryDetails", "lang": { "en-us": { "role": {
```


"http://www.canopygrowth.com/20241231/taxonomy/role/Role_StatementCondensedInterimConsolidatedBalanceSheetsParentheticalUnaudited", "lang": "en-us", "role": "label", "label": "Investment Issuer Affiliation", "documentation": "Affiliation of issuer of investment.", "auth_ref": "r889", "r896", "r916", "r923", "r934", "r935", "r955", "r956", "r957", "r958", "r960", "r961", "r966", "r967", "r989", "r990", "r996", "r1020", "r1024", "r1025", "r1048", "r1049", "r1050", "r1051", "r1052", "r1053", "r1054", "r1055", "r1056", "cgc_IssuanceAndVestingOfRestricted", "xbrltype": "monetaryItemType", "nsuri": "http://www.canopygrowth.com/20241231", "localname": "IssuanceAndVestingOfRestricted", "crdr": "credit", "presentation": "http://www.canopygrowth.com/20241231/taxonomy/role/Role_StatementCondensedInterimConsolidatedStatementsOfShareholderEquityUnaudited", "lang": "en-us", "role": "label", "label": "Issuance And Vesting Of Restricted", "documentation": "Issuance and vesting of restricted share units.", "terseLabel": "Issuance and vesting of restricted share units and performance share units", "auth_ref": "cgc_IssuanceAndVestingOfRestrictedAndPerformance", "xbrltype": "monetaryItemType", "nsuri": "http://www.canopygrowth.com/20241231", "localname": "IssuanceAndVestingOfRestrictedAndPerformance", "crdr": "credit", "presentation": "http://www.canopygrowth.com/20241231/taxonomy/role/Role_StatementCondensedInterimConsolidatedStatementsOfShareholderEquityUnaudited", "lang": "en-us", "role": "label", "label": "Issuance and vesting of restricted and performance share units.", "label": "Issuance And Vesting Of Restricted And Performance", "terseLabel": "Issuance and vesting of restricted share units and performance share units", "auth_ref": "cgc_IssuanceOfDebtDebtSharesInExcessPercentageOfIssuedCommonShares", "xbrltype": "percentItemType", "nsuri": "http://www.canopygrowth.com/20241231", "localname": "IssuanceOfDebtDebtSharesInExcessPercentageOfIssuedCommonShares", "presentation": "http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails", "lang": "en-us", "role": "label", "label": "Issuance Of DebtDebt Shares In Excess Percentage Of Issued Common Shares", "documentation": "Issuance of debtDebt shares in excess percentage of issued common shares.", "auth_ref": "cgc_IssuanceOfDebtDebtSharesInExcessPercentageOfOutstandingCommonShares", "xbrltype": "percentItemType", "nsuri": "http://www.canopygrowth.com/20241231", "localname": "IssuanceOfDebtDebtSharesInExcessPercentageOfOutstandingCommonShares", "presentation": "http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails", "lang": "en-us", "role": "label", "label": "Issuance of debtDebt shares in excess percentage of outstanding common shares.", "label": "Issuance Of DebtDebt Shares In Excess Percentage Of Outstanding Common Shares", "documentation": "Issuance of debtDebt shares in excess percentage of outstanding common shares.", "auth_ref": "cgc_IssuanceOfReplacementWarrantsResultingFromAcquireAcquisitionWarrantsValue", "xbrltype": "monetaryItemType", "nsuri": "http://www.canopygrowth.com/20241231", "localname": "IssuanceOfReplacementWarrantsResultingFromAcquireAcquisitionWarrantsValue", "crdr": "debit", "presentation": "http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureShareCapitalSummaryOfWarrantsDetails", "lang": "en-us", "role": "label", "label": "Warrant value. Issuance of replacement warrants resulting from Acquire Acquisition", "label": "Issuance of Replacement Warrants Resulting from Acquire Acquisition. Warrants Value", "documentation": "Issuance of replacement warrants resulting from acquire acquisition. warrants value.", "auth_ref": "cgc_JettyFinancialInstrumentCallOptionsDiscountRateMember", "xbrltype": "domainItemType", "nsuri": "http://www.canopygrowth.com/20241231", "localname": "JettyFinancialInstrumentCallOptionsDiscountRateMember", "presentation": "http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsSummaryOfValuationTechniquesAndSignificantUnobservableInputsIn", "lang": "en-us", "role": "label", "label": "Jetty Financial Instrument - Call Options. Discount Rate", "label": "Jetty Financial Instrument Call Options Discount Rate", "documentation": "Jetty financial instrument call options discount rate.", "auth_ref": "cgc_JettyFinancialInstrumentCallOptionsMember", "xbrltype": "domainItemType", "nsuri": "http://www.canopygrowth.com/20241231", "localname": "JettyFinancialInstrumentCallOptionsMember", "presentation": "http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsSummaryOfValuationTechniquesAndSignificantUnobservableInputsIn", "lang": "en-us", "role": "label", "label": "Jetty Financial Instrument - Call Options", "label": "Jetty Financial Instrument Call Options", "documentation": "Jetty financial instrument call options.", "auth_ref": "cgc_JettyFinancialInstrumentDeferredPaymentsMember", "xbrltype": "domainItemType", "nsuri": "http://www.canopygrowth.com/20241231", "localname": "JettyFinancialInstrumentDeferredPaymentsMember", "presentation": "http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsSummaryOfValuationTechniquesAndSignificantUnobservableInputsIn", "lang": "en-us", "role": "label", "label": "Jetty Financial Instrument - Deferred Payments", "label": "Jetty Financial Instrument Deferred Payments", "documentation": "Jetty financial instrument deferred payments.", "auth_ref": "cgc_JettyFinancialInstrumentVolatilityOfJettyEquityAndRevenueMember", "xbrltype": "domainItemType", "nsuri": "http://www.canopygrowth.com/20241231", "localname": "JettyFinancialInstrumentVolatilityOfJettyEquityAndRevenueMember", "presentation": "http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsSummaryOfValuationTechniquesAndSignificantUnobservableInputsIn", "lang": "en-us", "role": "label", "label": "Jetty Financial Instrument Volatility of Jetty Equity and Revenue", "label": "Jetty Financial Instrument Volatility of Jetty Equity And Revenue", "documentation": "Jetty financial instrument volatility of jetty equity and revenue.", "auth_ref": "cgc_JettyMember", "xbrltype": "domainItemType", "nsuri": "http://www.canopygrowth.com/20241231", "localname": "JettyMember", "presentation": "http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureCanopyUsaAdditionalInformationDetails", "lang": "en-us", "role": "label", "label": "July Two Thousand And Twenty Three Pay Down Member", "presentation": "http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureOtherFinancialAssetsSummaryOfChangesInOtherFinancialAssetsDetails", "lang": "en-us", "role": "label", "label": "July Two Thousand And Twenty Three Pay Down Member", "presentation": "http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails", "lang": "en-us", "role": "label", "label": "July 2023 Paydown", "label": "July Two Thousand And Twenty Three Pay Down", "documentation": "July two thousand and twenty three pay down.", "auth_ref": "cgc_LIBORFloorMember", "xbrltype": "domainItemType", "nsuri": "http://www.canopygrowth.com/20241231", "localname": "LIBORFloorMember", "presentation": "http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails", "lang": "en-us", "role": "label", "label": "LIBOR Floor", "label": "LIBOR Floor", "documentation": "LIBOR Floor", "auth_ref": "cgc_LIBORPlusMember", "xbrltype": "domainItemType", "nsuri": "http://www.canopygrowth.com/20241231", "localname": "LIBORPlusMember", "presentation": "http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails", "lang": "en-us", "role": "label", "label": "LIBOR Plus", "label": "LIBOR Plus", "documentation": "LIBOR Plus", "auth_ref": "us-gaap_LandMember", "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LandMember", "presentation": "http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosurePropertyPlantAndEquipmentScheduleOfComponentsOfPropertyPlantAndEquipmentDetails", "lang": "en-us", "role": "label", "label": "Land", "label": "Land", "documentation": "Part of earth's surface not covered by water.", "auth_ref": "r1374", "us-gaap_LeaseholdImprovementsMember", "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LeaseholdImprovementsMember", "presentation": "http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosurePropertyPlantAndEquipmentScheduleOfComponentsOfPropertyPlantAndEquipmentDetails", "lang": "en-us", "role": "label", "label": "Leasehold Improvements", "label": "Leasehold Improvements", "documentation": "Additions or improvements to assets held under a lease arrangement.", "auth_ref": "r177", "r729", "us-gaap_Liabilities", "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Liabilities", "crdr": "credit", "presentation": "http://www.canopygrowth.com/20241231/taxonomy/role/Role_StatementCondensedInterimConsolidatedBalanceSheetsUnaudited", "lang": "en-us", "role": "label", "label": "Total Liabilities", "label": "Liabilities", "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others.", "auth_ref": "r29", "r124", "r125", "r126", "r129", "r130", "r131", "r132", "r296", "r409", "r496", "r497", "r498", "r499", "r500", "r501", "r502", "r503", "r504", "r657", "r662", "r663", "r713", "r929", "r1094", "r1174", "r1366", "r1429", "r1430", "us-gaap_LiabilitiesAndStockholdersEquity", "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesAndStockholdersEquity", "crdr": "credit", "presentation": "http://www.canopygrowth.com/20241231/taxonomy/role/Role_StatementCondensedInterimConsolidatedBalanceSheetsUnaudited", "lang": "en-us", "role": "label", "label": "Total Liabilities and Shareholders' Equity", "label": "Liabilities and Equity", "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "auth_ref": "r140", "r212", "r835", "r1147", "r1304", "r1330", "r1419", "us-gaap_LiabilitiesAndStockholdersEquityAbstract", "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesAndStockholdersEquityAbstract", "presentation": "http://www.canopygrowth.com/20241231/taxonomy/role/Role_StatementCondensedInterimConsolidatedBalanceSheetsUnaudited", "lang": "en-us", "role": "label", "label": "LIABILITIES AND SHAREHOLDERS' EQUITY", "label": "Liabilities and Equity", "documentation": "LIABILITIES AND SHAREHOLDERS' EQUITY", "auth_ref": "us-gaap_LiabilitiesCurrent", "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesCurrent", "crdr": "credit", "presentation": "http://www.canopygrowth.com/20241231/taxonomy/role/Role_StatementCondensedInterimConsolidatedBalanceSheetsUnaudited", "lang": "en-us", "role": "label", "label": "Total current liabilities", "label": "Liabilities, Current", "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "auth_ref": "r126", "r251", "r296", "r409", "r496", "r497", "r498", "r499", "r500", "r501", "r502", "r503", "r504", "r657", "r662", "r663", "r713", "r1147", "r1366", "r1429", "r1430", "us-gaap_LiabilitiesCurrentAbstract", "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesCurrentAbstract", "presentation": "http://www.canopygrowth.com/20241231/taxonomy/role/Role_StatementCondensedInterimConsolidatedBalanceSheetsUnaudited", "lang": "en-us", "role": "label", "label": "Current liabilities", "label": "Liabilities, Current", "documentation": "Current liabilities", "auth_ref": "us-gaap_LiabilitiesFairValueAdjustment", "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesFairValueAdjustment", "crdr": "credit", "presentation": "http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails", "lang": "en-us", "role": "label", "label": "Debt instrument change in fair value of notes", "label": "Liabilities, Fair Value Adjustment", "documentation": "Amount of addition (reduction) to the amount at which a liability could be incurred (settled) in a current transaction between willing parties.", "auth_ref": "us-gaap_LiabilitiesFairValueDisclosureAbstract", "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesFairValueDisclosureAbstract", "presentation": "http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtEstimatedFairVa", "lang": "en-us", "role": "label", "label": "Liabilities", "label": "Liabilities, Fair Value Disclosure", "documentation": "Liabilities, Fair Value Disclosure", "auth_ref": "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation", "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation", "crdr": "credit", "presentation": "http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureBiosteelSummaryOfAssetsAndLiabilitiesClassifiedAsDiscontinuedOperationsAndMajorCategoriesDetails", "lang": "en-us", "role": "label", "label": "Disposal Group, Including Discontinued Operation, Liabilities", "label": "Total Liabilities of discontinued operations", "documentation": "Amount classified as liabilities attributable to disposal group held for sale or disposed of.", "auth_ref": "r4", "r103", "r117", "r180", "r248", "r249", "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent", "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent", "crdr": "credit", "presentation": "http://www.canopygrowth.com/20241231/taxonomy/role/Role_StatementCondensedInterimConsolidatedBalanceSheetsUnaudited", "lang": "en-us", "role": "label", "label": "Disposal Group, Including Discontinued Operation, Liabilities, Current", "label": "Total Liabilities of discontinued operations, Current", "documentation": "Amount classified as liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.", "auth_ref": "r147", "r176", "r180", "r248", "r249", "cgc_LiabilityForEstimatedSalesReturnsAndPriceAdjustments", "xbrltype": "monetaryItemType", "nsuri": "http://www.canopygrowth.com/20241231", "localname": "LiabilityForEstimatedSalesReturnsAndPriceAdjustments", "crdr": "credit", "presentation": "http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureRevenueAdditionalInformationDetails", "lang": "en-us", "role": "label", "label": "Liability for estimated returns and price adjustments", "label": "Liability For Estimated Sales Returns And Price Adjustments", "documentation": "Liability for estimated sales returns and price adjustments.", "auth_ref": "us-gaap_LineOfCredit", "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LineOfCredit", "crdr": "credit", "presentation": "http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureDebtSummaryOfComponentsOfDebtDetails", "lang": "en-us", "role": "label", "label": "Long-Term Line of Credit, Total", "label": "Long-Term Line of Credit", "label": "Principal amount", "documentation": "The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit

arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long-term obligation to refinance the short-term obligation on a long-term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long-term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement." } } } , "auth_ref": { "r29", "r209", "r1438" } } , "cgc_LiquidityRequirement": { "xbrltype": "monetaryItemType", "nsuri": "http://www.canopygrowth.com/20241231", "localname": "LiquidityRequirement", "crdr": "debit", "presentation": { "http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails" } , "lang": { "en-us": { "role": { "verboseLabel": "Minimum liquidity covenant", "terseLabel": "Minimum liquidity, each fiscal quarter", "label": "Liquidity Requirement", "documentation": "Liquidity requirement." } } } , "auth_ref": { } } , "cgc_LoanReceivableMember": { "xbrltype": "domainItemType", "nsuri": "http://www.canopygrowth.com/20241231", "localname": "LoanReceivableMember", "presentation": { "http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureOtherFinancialAssetsSummaryOfChangesInOtherFinancialAssetsDetails" } , "lang": { "en-us": { "role": { "terseLabel": "Loan Receivable", "label": "Loan Receivable {Member}", "documentation": "Loan receivable." } } } , "auth_ref": { } } , "us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LoansNotesTradeAndOtherReceivablesDisclosureTextBlock", "presentation": { "http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureAmountsReceivableNet" } , "lang": { "en-us": { "role": { "terseLabel": "Amounts Receivable, Net", "label": "Loans, Notes, Trade and Other Receivables Disclosure {Text Block}", "documentation": "The entire disclosure for claims held for amounts due to entity, excluding financing receivables. Examples include, but are not limited to, trade accounts receivables, notes receivables, loans receivables. Includes disclosure for allowance for credit losses." } } } , "auth_ref": { "r724", "r1319" } } , "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "LocalPhoneNumber", "presentation": { "http://www.canopygrowth.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" } , "lang": { "en-us": { "role": { "terseLabel": "Local Phone Number", "label": "Local Phone Number", "documentation": "Local phone number for entity." } } } , "auth_ref": { } } , "us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongLivedAssetsByGeographicAreasTableTextBlock", "presentation": { "http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureSegmentInformationTables" } , "lang": { "en-us": { "role": { "terseLabel": "Summary of Disaggregation of Property, Plant and Equipment by Geographic Area", "label": "Long-Lived Assets by Geographic Areas {Table Text Block}", "documentation": "Tabular disclosure of long-lived assets, excluding financial instruments, long-term customer relationships of a financial institution, mortgage rights, deferred policy acquisition costs, and deferred tax assets, by geographic areas located in the entity's country of domicile and foreign countries in which the entity holds assets." } } } , "auth_ref": { "r173" } } , "us-gaap_LongTermDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebt", "crdr": "credit", "presentation": { "http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureBasisOfPresentationAdditionalInformationDetails" } , "lang": { "en-us": { "role": { "verboseLabel": "Long-term debt", "totalLabel": "Total debt", "label": "Long-Term Debt", "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation." } } } , "auth_ref": { "r29", "r209", "r518", "r532", "r1111", "r1112", "r1146", "r1438" } } , "us-gaap_LongTermDebtCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtCurrent", "crdr": "credit", "presentation": { "http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureDebtSummaryOfComponentsOfDebtDetails" } , "http://www.canopygrowth.com/20241231/taxonomy/role/Role_StatementCondensedInterimConsolidatedBalanceSheetsUnaudited" } , "lang": { "en-us": { "role": { "totalLabel": "Long-Term Debt, Current Maturities, Total", "negatedLabel": "Less: current portion", "label": "Long-Term Debt, Current Maturities", "terseLabel": "Current portion of long-term debt", "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as current. Excludes lease obligation." } } } , "auth_ref": { "r258" } } , "us-gaap_LongTermDebtFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtFairValue", "crdr": "credit", "presentation": { "http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureFairValueOffFinancialInstrumentsSummaryOffFinancialAssetsAndLiabilitiesMeasuredAtEstimatedFairVa" } , "lang": { "en-us": { "role": { "terseLabel": "Long-term debt/Unsecured senior notes", "label": "Long-Term Debt, Fair Value", "verboseLabel": "Long-term debt", "documentation": "The fair value amount of long-term debt whether such amount is presented as a separate caption or as a parenthetical disclosure. Additionally, this element may be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements. The element may be used in both the balance sheet and disclosure in the same submission." } } } , "auth_ref": { "r1412", "r1414", "r1415", "r1416" } } , "us-gaap_LongTermDebtMaturityDate": { "xbrltype": "dateItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtMaturityDate", "presentation": { "http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails" } , "http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureDebtSummaryOfComponentsOfDebtDetails" } , "lang": { "en-us": { "role": { "verboseLabel": "Supreme Convertible Debentures", "label": "Long-Term Debt, Maturity Date", "terseLabel": "Maturity date", "documentation": "Maturity date of long-term debt, in YYYY-MM-DD format." } } } , "auth_ref": { "r1414", "r1415", "r1416" } } , "us-gaap_LongTermDebtMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtMember", "presentation": { "http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureFairValueOffFinancialInstrumentsSummaryOfValuationTechniquesAndSignificantUnobservableInputsIn" } , "lang": { "en-us": { "role": { "verboseLabel": "Unsecured Senior Notes {Member}", "terseLabel": "Unsecured Senior Notes", "label": "Long-Term Debt {Member}", "documentation": "Debt arrangement having an initial term longer than one year or beyond the normal operating cycle, if longer." } } } , "auth_ref": { } } , "us-gaap_LongTermDebtNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtNoncurrent", "crdr": "credit", "presentation": { "http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureDebtSummaryOfComponentsOfDebtDetails" } , "http://www.canopygrowth.com/20241231/taxonomy/role/Role_StatementCondensedInterimConsolidatedBalanceSheetsUnaudited" } , "lang": { "en-us": { "role": { "totalLabel": "Long-Term Debt, Excluding Current Maturities, Total", "verboseLabel": "Long-term portion", "terseLabel": "Long-term debt", "label": "Long-Term Debt, Excluding Current Maturities", "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation." } } } , "auth_ref": { "r260" } } , "us-gaap_LongTermDebtTerm": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtTerm", "presentation": { "http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails" } , "lang": { "en-us": { "role": { "terseLabel": "Senior secured debt, Term", "label": "Long-Term Debt, Term", "documentation": "Period between issuance and maturity of long-term debt, in PnYnMdNtInMnS format, for example, P1Y5M13D, represents reported fact of one year, five months, and thirteen days." } } } , "auth_ref": { "r1414", "r1415", "r1416" } } , "us-gaap_LongtermDebtTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongtermDebtTypeAxis", "presentation": { "http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails" } , "lang": { "en-us": { "role": { "terseLabel": "Long-Term Debt, Type", "label": "Long-Term Debt, Type {Axis}", "documentation": "Information by type of long-term debt." } } } , "auth_ref": { "r29", "r354", "r1355", "r1356", "r1357" } } , "us-gaap_LongtermDebtTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongtermDebtTypeDomain", "presentation": { "http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails" } , "lang": { "en-us": { "role": { "terseLabel": "Long-Term Debt, Type", "label": "Long-Term Debt, Type {Domain}", "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer." } } } , "auth_ref": { "r29", "r354", "r1355", "r1356", "r1357" } } , "us-gaap_LossContingenciesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LossContingenciesLineItems", "presentation": { "http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" } , "lang": { "en-us": { "role": { "label": "Loss Contingencies {Line Items}", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } } , "auth_ref": { "r488", "r489", "r490", "r493", "r608", "r1109", "r1361", "r1362" } } , "us-gaap_LossContingenciesTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LossContingenciesTable", "presentation": { "http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" } , "lang": { "en-us": { "role": { "label": "Loss Contingencies {Table}", "documentation": "Disclosure of information about loss contingency. Excludes environmental contingency, warranty, and unconditional purchase obligation." } } } , "auth_ref": { "r488", "r489", "r490", "r493", "r608", "r1109", "r1361", "r1362" } } , "us-gaap_LossContingencyDamagesAwardedValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LossContingencyDamagesAwardedValue", "crdr": "debit", "presentation": { "http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" } , "lang": { "en-us": { "role": { "terseLabel": "Damages", "label": "Loss Contingency, Damages Awarded, Value", "documentation": "Amount of damages awarded to the plaintiff in the legal matter." } } } , "auth_ref": { "r1360", "r1361", "r1362" } } , "us-gaap_MarketableSecuritiesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MarketableSecuritiesLineItems", "presentation": { "http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureShortTermInvestmentsComponentsOfShortTermInvestmentsDetails" } , "lang": { "en-us": { "role": { "terseLabel": "Marketable Securities {Line Items}", "label": "Marketable Securities {Line Items}", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } } , "auth_ref": { } } , "us-gaap_MarketableSecuritiesTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MarketableSecuritiesTable", "presentation": { "http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureShortTermInvestmentsComponentsOfShortTermInvestmentsDetails" } , "lang": { "en-us": { "role": { "terseLabel": "Marketable Securities {Table}", "label": "Marketable Securities {Table}", "documentation": "Disclosure of information about investment in marketable security." } } } , "auth_ref": { } } , "cgc_MaximumDiscountToLastReportedSalesPrice": { "xbrltype": "percentItemType", "nsuri": "http://www.canopygrowth.com/20241231", "localname": "MaximumDiscountToLastReportedSalesPrice", "presentation": { "http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails" } , "lang": { "en-us": { "role": { "terseLabel": "Maximum discount to last reported sales price", "label": "Maximum Discount To Last Reported Sales Price", "documentation": "Maximum discount to last reported sales price." } } } , "auth_ref": { } } , "srt_MaximumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "MaximumMember", "presentation": { "http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureShareBasedCompensationAdditionalInformationDetails" } , "http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureCanopyUsaAdditionalInformationDetails" } , "http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureBasisOfPresentationAdditionalInformationDetails" } , "http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails" } , "http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureShareBasedCompensationAdditionalInformationDetails" } , "http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureShareBasedCompensationSummaryOfAssumptionsAppliedToEstablishFairValueOfOptionsGrantedUsing" } , "lang": { "en-us": { "role": { "terseLabel": "Maximum", "label": "Maximum {Member}" } } } , "auth_ref": { "r489", "r490", "r491", "r492", "r570", "r608", "r692", "r781", "r869", "r871", "r885", "r921", "r922", "r983", "r1002", "r1007", "r1008", "r1044", "r1082", "r1083", "r1105", "r1115", "r1128", "r1139", "r1140", "r1144", "r1145", "r1158", "r1370", "r1431", "r1432", "r1433", "r1434", "r1435", "r1436" } } , "cgc_MaximumPeriodOfOptionFromGrantDate": { "xbrltype": "durationItemType", "nsuri": "http://www.canopygrowth.com/20241231", "localname": "MaximumPeriodOfOptionFromGrantDate", "presentation": { "http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureShareBasedCompensationAdditionalInformationDetails" } , "lang": { "en-us": { "role": { "terseLabel": "Maximum period of option from grant date", "label": "Maximum Period Of Option From Grant Date", "documentation": "Maximum period of option from grant date." } } } , "auth_ref": { } } , "cgc_MayTwoThousandAndTwentyFourConvertibleDebtMember": { "xbrltype": "domainItemType", "nsuri": "http://www.canopygrowth.com/20241231", "localname": "MayTwoThousandAndTwentyFourConvertibleDebtMember", "presentation": { "http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureDebtSummaryOfComponentsOfDebtDetails" } , "lang": { "en-us": { "role": { "documentation": "May 2024 Convertible Debenture", "label": "May Two Thousand and Twenty Four Convertible Debenture {Member}", "terseLabel": "May 2024 Convertible Debenture" } } } , "auth_ref": { } } , "cgc_MayTwoThousandAndTwentyFourConvertibleDebtMember": { "xbrltype": "domainItemType", "nsuri": "http://www.canopygrowth.com/20241231", "localname": "MayTwoThousandAndTwentyFourConvertibleDebtMember", "presentation": { "http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails" } , "lang": { "en-us": { "role": { "documentation": "May 2024 Convertible Debenture", "label": "May Two Thousand and Twenty Four Convertible Debenture {Member}", "terseLabel": "May 2024 Convertible Debenture" } } } , "auth_ref": { } } , "ecd_MeasureAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MeasureAxis", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure" } , "lang": { "en-us": { "role": { "label": "Measure {Axis}", "terseLabel": "Measure", "documentation": "Measure Name", "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MeasureName", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure" } , "lang": { "en-us": { "role": { "label": "Measure Name", "terseLabel": "Name" } } } , "auth_ref": { "r1223" } } } }

"*ecg_MedicalCannabisRevenueMember*": { "xbrltype": "domainItemType", "nsuri": "http://www.canopygrowth.com/20241231", "localname": "MedicalCannabisRevenueMember", "presentation": ["http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureRevenueSummaryOfDisaggregationOfRevenueParenteticalDetails"], "lang": { "en-us": { "role": { "terseLabel": "Medical Cannabis Revenue", "label": "Medical Cannabis Revenue [Member]", "documentation": "Medical cannabis revenue." } } }, "auth_ref": [] }, "ecg_MinimumCallPricePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://www.canopygrowth.com/20241231", "localname": "MinimumCallPricePerShare", "presentation": ["http://www.canopygrowth.com/20241231/taxonomy/role/DisclosureAcreageArrangementAdditionalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Minimum call price", "label": "Minimum Call Price Per Share", "documentation": "Minimum call price per share." } } }, "auth_ref": [] }, "srt_MinimumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "MinimumMember", "presentation": ["http://www.canopygrowth.com/20241231/taxonomy/role/DisclosureAcreageArrangementAdditionalInformationDetails", "http://www.canopygrowth.com/20241231/taxonomy/role/DisclosureCanopyUsaAdditionalInformationDetails", "http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails", "http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureShareBasedCompensationAdditionalInformationDetails", "http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureShareBasedCompensationSummaryOfAssumptionsAppliedToEstablishFairValueOfOptionsGrantedUsing", "lang": { "en-us": { "role": { "label": "Minimum [Member]", "terseLabel": "Minimum", "auth_ref": ["r489", "r490", "r491", "r492", "r570", "r608", "r692", "r781", "r869", "r871", "r885", "r921", "r922", "r983", "r1002", "r1007", "r1008", "r1044", "r1082", "r1083", "r1103", "r1115", "r1128", "r1139", "r1140", "r1144", "r1158", "r1370", "r1431", "r1432", "r1433", "r1434", "r1435", "r1436"] }, "us-gaap_MinorityInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MinorityInterest", "crdr": "credit", "presentation": ["http://www.canopygrowth.com/20241231/taxonomy/role/Role_StatementCondensedInterimConsolidatedBalanceSheetsUnaudited"], "lang": { "en-us": { "role": { "periodEndLabel": "Stockholders' Equity Attributable to Noncontrolling Interest, Ending Balance", "periodStartLabel": "Stockholders' Equity Attributable to Noncontrolling Interest, Beginning Balance", "totalLabel": "Stockholders' Equity Attributable to Noncontrolling Interest, Total", "terseLabel": "Noncontrolling interests", "label": "Equity, Attributable to Noncontrolling Interest", "documentation": "Amount of equity (deficit) attributable to noncontrolling interest. Excludes temporary equity." } } }, "auth_ref": ["r139", "r211", "r296", "r409", "r496", "r498", "r499", "r500", "r503", "r504", "r713", "r834", "r933"] }, "us-gaap_MinorityInterestDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MinorityInterestDisclosureTextBlock", "presentation": ["http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureNoncontrollingInterests"], "lang": { "en-us": { "role": { "terseLabel": "Noncontrolling Interests", "label": "Noncontrolling Interest Disclosure [Text Block]", "documentation": "The entire disclosure for noncontrolling interest in consolidated subsidiaries, which could include the name of the subsidiary, the ownership percentage held by the parent, the ownership percentage held by the noncontrolling owners, the amount of the noncontrolling interest, the location of this amount on the balance sheet (when not reported separately), an explanation of the increase or decrease in the amount of the noncontrolling interest, the noncontrolling interest share of the net income or loss of the subsidiary, the location of this amount on the income statement (when not reported separately), the nature of the noncontrolling interest such as background information and terms, the amount of the noncontrolling interest represented by preferred stock, a description of the preferred stock, and the dividend requirements of the preferred stock." } } }, "auth_ref": ["r198"] }, "us-gaap_MinorityInterestLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MinorityInterestLineItems", "presentation": ["http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureNoncontrollingInterestsSummaryOfNetChangeInNoncontrollingInterestsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Minority Interest [Line Items]", "label": "Noncontrolling Interest [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_MinorityInterestPeriodIncreaseDecrease": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MinorityInterestPeriodIncreaseDecrease", "presentation": ["http://www.canopygrowth.com/20241231/taxonomy/role/Role_StatementCondensedInterimConsolidatedStatementsOfShareholderSEquityUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "Noncontrolling Interest, Period Increase (Decrease)", "label": "Changes in redeemable noncontrolling interest", "documentation": "Net Increase or Decrease in balance of noncontrolling interest in the subsidiary during the reporting period." } } }, "auth_ref": ["r82"] }, "us-gaap_MinorityInterestTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MinorityInterestTable", "presentation": ["http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureNoncontrollingInterestsSummaryOfNetChangeInNoncontrollingInterestsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Minority Interest [Table]", "label": "Noncontrolling Interest [Table]", "documentation": "Disclosure of information about noncontrolling interest, including, but not limited to, name of subsidiary, ownership percentage held by parent, ownership percentage held by noncontrolling owner, amount of noncontrolling interest and its location in statement of financial position, explanation of increase (decrease) in noncontrolling interest, noncontrolling interest share of net income (loss) of subsidiary and its location in statement of income, amount of noncontrolling interest represented by preferred stock, description and dividend requirement of preferred stock, and nature of noncontrolling interest." } } }, "auth_ref": ["r82", "r84", "r139", "r154"] }, "ecd_MnpiDiscTimedForCompValFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MnpiDiscTimedForCompValFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "MNPI Disclosure Timed for Compensation Value", "documentation": "MNPI Disclosure Timed for Compensation Value [Flag]", "terseLabel": "MNPI Disclosure Timed for Compensation Value" } } }, "auth_ref": ["r1242"] }, "ecd_MtrTermsOffRdArrTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MtrTermsOffRdArrTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Material Terms of Trading Arrangement [Text Block]", "terseLabel": "Material Terms of Trading Arrangement" } } }, "auth_ref": ["r1250"] }, "ecd_NamedExecutiveOfficersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NamedExecutiveOfficersFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Named Executive Officers, Footnote [Text Block]", "terseLabel": "Named Executive Officers, Footnote" } } }, "auth_ref": ["r1224"] }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInFinancingActivities", "crdr": "debit", "presentation": ["http://www.canopygrowth.com/20241231/taxonomy/role/Role_StatementCondensedInterimConsolidatedStatementsOfCashFlowsUnaudited"], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net cash provided by (used in) financing activities", "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit." } } }, "auth_ref": ["r290"] }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "presentation": ["http://www.canopygrowth.com/20241231/taxonomy/role/Role_StatementCondensedInterimConsolidatedStatementsOfCashFlowsUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "Cash flows from financing activities", "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInInvestingActivities", "crdr": "debit", "presentation": ["http://www.canopygrowth.com/20241231/taxonomy/role/Role_StatementCondensedInterimConsolidatedStatementsOfCashFlowsUnaudited"], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "Net cash (used in) provided by investing activities", "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets." } } }, "auth_ref": ["r290"] }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "presentation": ["http://www.canopygrowth.com/20241231/taxonomy/role/Role_StatementCondensedInterimConsolidatedStatementsOfCashFlowsUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "Cash flows from investing activities", "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInOperatingActivities", "crdr": "debit", "presentation": ["http://www.canopygrowth.com/20241231/taxonomy/role/Role_StatementCondensedInterimConsolidatedStatementsOfCashFlowsUnaudited"], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities, Continuing Operations", "totalLabel": "Net cash (used in) provided by investing activities - continuing operations", "documentation": "Amount of cash inflow (outflow) of investing activities, excluding discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets." } } }, "auth_ref": ["r1297"] }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": ["http://www.canopygrowth.com/20241231/taxonomy/role/Role_StatementCondensedInterimConsolidatedStatementsOfCashFlowsUnaudited"], "lang": { "en-us": { "role": { "label": "Net cash used in operating activities", "label": "Net Cash Provided by (Used in) Operating Activities", "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities." } } }, "auth_ref": ["r165", "r166", "r168"] }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": ["http://www.canopygrowth.com/20241231/taxonomy/role/Role_StatementCondensedInterimConsolidatedStatementsOfCashFlowsUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "Cash flows from operating activities", "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "crdr": "debit", "presentation": ["http://www.canopygrowth.com/20241231/taxonomy/role/Role_StatementCondensedInterimConsolidatedStatementsOfCashFlowsUnaudited"], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities, Continuing Operations", "totalLabel": "Net cash used in operating activities - continuing operations", "documentation": "Amount of cash inflow (outflow) from operating activities, excluding discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities." } } }, "auth_ref": ["r165", "r166", "r168"] }, "us-gaap_NetIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetIncomeLoss", "crdr": "credit", "presentation": ["http://www.canopygrowth.com/20241231/taxonomy/role/StatementCondensedInterimConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited", "http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Net Income (Loss)", "terseLabel": "Net Income (Loss)", "verboseLabel": "Net loss attributable to Canopy Growth Corporation", "totalLabel": "Net loss attributable to Canopy Growth Corporation", "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent." } } }, "auth_ref": ["r158", "r168", "r218", "r249", "r275", "r278", "r282", "r296", "r303", "r306", "r307", "r308", "r309", "r310", "r313", "r314", "r321", "r409", "r496", "r497", "r498", "r499", "r500", "r501", "r502", "r503", "r504", "r640", "r653", "r686", "r713", "r844", "r953", "r972", "r973", "r1172", "r1366"] }, "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetIncomeLossAttributableToNoncontrollingInterest", "crdr": "debit", "presentation": ["http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureNoncontrollingInterestsSummaryOfNetChangeInNoncontrollingInterestsDetails"], "lang": { "en-us": { "role": { "label": "Net Income (Loss) Attributable to Noncontrolling Interest, Total", "label": "Net Income (Loss) Attributable to Noncontrolling Interest", "verboseLabel": "Net loss from continuing operations attributable to noncontrolling interests and redeemable noncontrolling interest", "terseLabel": "Comprehensive income (loss)", "documentation": "Amount of Net Income (Loss) attributable to noncontrolling interest." } } }, "auth_ref": ["r89", "r201", "r275", "r278", "r310", "r313", "r314", "r843", "r1290"] }, "us-gaap_NetIncomeLossAttributableToNonredeemableNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetIncomeLossAttributableToNonredeemableNoncontrollingInterest", "crdr": "debit", "presentation": ["http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureRedeemableNoncontrollingInterestSummaryOfNetChangesInRedeemableNoncontrollingInterestsDetails"], "lang": { "en-us": { "role": { "label": "Redemption of redeemable noncontrolling interest", "label": "Net Income (Loss) Attributable to Nonredeemable Noncontrolling Interest", "totalLabel": "Net Income (Loss) Attributable to Nonredeemable Noncontrolling Interest, Total", "documentation": "Portion of net income (loss) attributable to nonredeemable noncontrolling interest." } } }, "auth_ref": ["r154"] }, "us-gaap_NetIncomeLossAttributableToRedeemableNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetIncomeLossAttributableToRedeemableNoncontrollingInterest", "crdr": "debit", "presentation": ["http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureNoncontrollingInterestsSummaryOfNetChangeInNoncontrollingInterestsDetails"] }

```

http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureRedeemableNoncontrollingInterestSummaryOfNetChangesInRedeemableNoncontrollingInterestsDetails%1"lang":{ "en-us":{ "role":{ "negatedLabel": "Net income (loss) attributable to redeemable noncontrolling interest", "totalLabel": "Net Income (Loss) Attributable to Redeemable Noncontrolling Interest, Total", "terseLabel": "Net income (loss) attributable to redeemable noncontrolling interest", "label": "Net Income (Loss) Attributable to Redeemable Noncontrolling Interest", "negatedTerseLabel": "Net loss attributable to redeemable noncontrolling interest", "documentation": "Amount of Net Income (Loss) attributable to redeemable noncontrolling interest." } } }, "auth_ref":{ "r154" } }, "us-gaap_NonAccountingPronouncementsPolicyPolicyTextBlock":{ "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "presentation":{ "http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" } }, "lang":{ "en-us":{ "role":{ "terseLabel": "New accounting policies", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact." } } }, "auth_ref":{ "r1" }, "cgc_NewTerrascendSecuritiesMember":{ "xbrltype": "domainItemType", "nsuri": "http://www.canopygrowth.com/20241231", "localname": "NewTerrascendSecuritiesMember", "presentation":{ "http://www.canopygrowth.com/20241231/taxonomy/role/DisclosureCanopyUsaAdditionalInformationDetails" } }, "lang":{ "en-us":{ "role":{ "terseLabel": "New TerrAscend Securities", "label": "New TerrAscend Securities [Member]", "documentation": "New TerrAscend Securities." } } }, "auth_ref":{ "r1" }, "cgc_NonCashFairValueAdjustmentsAndChargesRelatedToSettlementOfLongTermDebt":{ "xbrltype": "monetaryItemType", "nsuri": "http://www.canopygrowth.com/20241231", "localname": "NonCashFairValueAdjustmentsAndChargesRelatedToSettlementOfLongTermDebt", "crdr": "debit", "presentation":{ "http://www.canopygrowth.com/20241231/taxonomy/role/Role_StatementCondensedInterimConsolidatedStatementsOfCashFlowsUnaudited" } }, "lang":{ "en-us":{ "role":{ "label": "Non-cash fair value adjustments and charges related to settlement of long-term debt", "terseLabel": "Non-cash fair value adjustments and charges related to settlement of long-term debt", "documentation": "Non-cash fair value adjustments and charges related to settlement of long-term debt." } } }, "auth_ref":{ "r1" }, "ecd_NonGaapMeasureDescriptionTextBlock":{ "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonGaapMeasureDescriptionTextBlock", "presentation":{ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" } }, "lang":{ "en-us":{ "role":{ "label": "Non-GAAP Measure Description [Text Block]", "terseLabel": "Non-GAAP Measure Description" } } }, "auth_ref":{ "r1223" } }, "ecd_NonNeosMember":{ "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonNeosMember", "presentation":{ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" } }, "lang":{ "en-us":{ "role":{ "label": "Non-NEOs [Member]", "terseLabel": "Non-NEOs" } } }, "auth_ref":{ "r1187", "r1197", "r1207", "r1231", "r1239" } }, "ecd_NonPeoNeoAvgCompActuallyPaidAmt":{ "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoAvgCompActuallyPaidAmt", "presentation":{ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" } }, "lang":{ "en-us":{ "role":{ "label": "Non-PEO-NEO Average Compensation Actually Paid Amount", "terseLabel": "Non-PEO-NEO Average Compensation Actually Paid Amount" } } }, "auth_ref":{ "r1214" } }, "ecd_NonPeoNeoAvgTotalCompAmt":{ "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoAvgTotalCompAmt", "presentation":{ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" } }, "lang":{ "en-us":{ "role":{ "label": "Non-PEO-NEO Average Total Compensation Amount", "terseLabel": "Non-PEO-NEO Average Total Compensation Amount" } } }, "auth_ref":{ "r1213" } }, "ecd_NonPeoNeoMember":{ "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoMember", "presentation":{ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" } }, "lang":{ "en-us":{ "role":{ "label": "Non-PEO-NEO [Member]", "terseLabel": "Non-PEO-NEO" } } }, "auth_ref":{ "r1231" } }, "ecd_NonRule10b51ArrAdoptedFlag":{ "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonRule10b51ArrAdoptedFlag", "presentation":{ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" } }, "lang":{ "en-us":{ "role":{ "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]", "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted" } } }, "auth_ref":{ "r1250" } }, "ecd_NonRule10b51ArrTrmtdFlag":{ "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonRule10b51ArrTrmtdFlag", "presentation":{ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" } }, "lang":{ "en-us":{ "role":{ "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]", "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated" } } }, "auth_ref":{ "r1250" } }, "cgc_NonVotingSharesValue":{ "xbrltype": "monetaryItemType", "nsuri": "http://www.canopygrowth.com/20241231", "localname": "NonVotingSharesValue", "crdr": "credit", "presentation":{ "http://www.canopygrowth.com/20241231/taxonomy/role/DisclosureCanopyUsaAdditionalInformationDetails" } }, "lang":{ "en-us":{ "role":{ "label": "Non Voting Shares Value", "documentation": "Non voting shares value.", "terseLabel": "Non voting shares value" } } }, "auth_ref":{ "r1" }, "us-gaap_NoncashInvestingAndFinancingItemsAbstract":{ "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NoncashInvestingAndFinancingItemsAbstract", "presentation":{ "http://www.canopygrowth.com/20241231/taxonomy/role/Role_StatementCondensedInterimConsolidatedStatementsOfCashFlowsUnaudited" } }, "lang":{ "en-us":{ "role":{ "terseLabel": "Noncash investing and financing activities", "label": "Noncash Investing and Financing Items [Abstract]" } } }, "auth_ref":{ "r1" }, "us-gaap_NoncontrollingInterestAbstract":{ "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NoncontrollingInterestAbstract", "lang":{ "en-us":{ "role":{ "label": "Noncontrolling Interest [Abstract]" } } }, "auth_ref":{ "r1" }, "us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance":{ "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance", "crdr": "credit", "presentation":{ "http://www.canopygrowth.com/20241231/taxonomy/role/Role_StatementCondensedInterimConsolidatedStatementsOfShareholderSEquityUnaudited" } }, "lang":{ "en-us":{ "role":{ "label": "Noncontrolling Interest, Increase from Subsidiary Equity Issuance", "terseLabel": "Ownership changes relating to noncontrolling interests, net", "documentation": "Amount of increase in noncontrolling interest from subsidiary issuance of equity interests to noncontrolling interest holders." } } }, "auth_ref":{ "r16", "r64", "r200" } }, "us-gaap_NoncontrollingInterestMember":{ "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NoncontrollingInterestMember", "presentation":{ "http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureNoncontrollingInterestsSummaryOfNetChangeInNoncontrollingInterestsDetails" } }, "http://www.canopygrowth.com/20241231/taxonomy/role/Role_StatementCondensedInterimConsolidatedStatementsOfShareholderSEquityUnaudited" } }, "lang":{ "en-us":{ "role":{ "terseLabel": "Noncontrolling Interests", "label": "Noncontrolling Interest [Member]", "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest." } } }, "auth_ref":{ "r81", "r550", "r1305", "r1306", "r1307", "r1310", "r1479" } }, "us-gaap_NoncurrentAssets":{ "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NoncurrentAssets", "crdr": "debit", "presentation":{ "http://www.canopygrowth.com/20241231/taxonomy/role/DisclosureSegmentInformationSummaryOfDisaggregationOfPropertyPlantAndEquipmentByGeographicAreaDetails" } }, "lang":{ "en-us":{ "role":{ "terseLabel": "Net revenue", "label": "Long-Lived Assets", "documentation": "Long-lived assets other than financial instruments, long-term customer relationships of a financial institution, mortgage and other servicing rights, deferred policy acquisition costs, and deferred tax assets." } } }, "auth_ref":{ "r366" } }, "us-gaap_NontradeReceivables":{ "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NontradeReceivables", "crdr": "debit", "presentation":{ "http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureAmountsReceivableNetAdditionalInformationDetails" } }, "lang":{ "en-us":{ "role":{ "terseLabel": "Amount due relating to facility sale", "label": "Nontrade Receivables", "totalLabel": "Nontrade Receivables, Total", "documentation": "Carrying amounts due as of the balance sheet date of the sum of amounts receivable other than from customers." } } }, "auth_ref":{ "r1282" } }, "cgc_NumberOfCanopySharesExchanged":{ "xbrltype": "sharesItemType", "nsuri": "http://www.canopygrowth.com/20241231", "localname": "NumberOfCanopySharesExchanged", "presentation":{ "http://www.canopygrowth.com/20241231/taxonomy/role/DisclosureCanopyUsaAcreageAgreementsAdditionalInformationDetails" } }, "http://www.canopygrowth.com/20241231/taxonomy/role/DisclosureCanopyUsaAdditionalInformationDetails", "http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails" } }, "lang":{ "en-us":{ "role":{ "verboseLabel": "Number of shares exchanged", "terseLabel": "Number of canopy shares exchanged", "label": "Number Of Canopy Shares Exchanged", "documentation": "Number of canopy shares exchanged." } } }, "auth_ref":{ "r1" }, "cgc_NumberOfCommonSharesIssuedRelatingToCompletionOfAcquisitionMilestones":{ "xbrltype": "sharesItemType", "nsuri": "http://www.canopygrowth.com/20241231", "localname": "NumberOfCommonSharesIssuedRelatingToCompletionOfAcquisitionMilestones", "presentation":{ "http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureShareBasedCompensationAdditionalInformationDetails" } }, "lang":{ "en-us":{ "role":{ "terseLabel": "Number of common shares released on completion of acquisition milestones", "label": "Number Of Common Shares Issued Relating To Completion Of Acquisition Milestones", "documentation": "Number of common shares issued relating to completion of acquisition milestones." } } }, "auth_ref":{ "r1" }, "cgc_NumberOfEquityFinancing":{ "xbrltype": "integerItemType", "nsuri": "http://www.canopygrowth.com/20241231", "localname": "NumberOfEquityFinancing", "presentation":{ "http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureShareCapitalAdditionalInformationDetails" } }, "lang":{ "en-us":{ "role":{ "terseLabel": "Number of equity financings", "label": "Number Of Equity Financing", "documentation": "Number of equity financings." } } }, "auth_ref":{ "r1" }, "cgc_NumberOfFixedAndFloatingSharesIssued":{ "xbrltype": "sharesItemType", "nsuri": "http://www.canopygrowth.com/20241231", "localname": "NumberOfFixedAndFloatingSharesIssued", "presentation":{ "http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureAcreageArrangementAdditionalInformationDetails" } }, "lang":{ "en-us":{ "role":{ "terseLabel": "Number Of Fixed And Floating Shares Issued", "label": "Number Of Fixed And Floating Shares Issued", "documentation": "Number of fixed and floating shares issued." } } }, "auth_ref":{ "r1" }, "cgc_NumberOfFloatingSharesIssuedInFirstInstallment":{ "xbrltype": "sharesItemType", "nsuri": "http://www.canopygrowth.com/20241231", "localname": "NumberOfFloatingSharesIssuedInFirstInstallment", "presentation":{ "http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureCanopyUsaAcreageAgreementsAdditionalInformationDetails" } }, "lang":{ "en-us":{ "role":{ "terseLabel": "Number of floating shares issued in first installment", "label": "Number Of Floating Shares Issued In First Installment", "documentation": "Number of floating shares issued in first installment." } } }, "auth_ref":{ "r1" }, "us-gaap_NumberOfOperatingSegments":{ "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2
```

```

http://www.canopygrowth.com/20241231/,"localname":"NumberOfWholeWarrantsOnIssuanceOfWarrantsFromPrivatePlacement"},"presentation":f
http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureShareCapitalSummaryOfWarrantsDetails"}-,"lang":{"en-us":{"role":{"terseLabel":"Number of whole warrants. Issuance of warrants from private placement."},"label":"Number Of Whole Warrants On Issuance Of Warrants From Private Placement"},"documentation":"Number of whole warrants on issuance of warrants from private placement."}}-,"auth_ref":{"us-gaap_OfficeEquipmentMember":{"xbrltype":"domainItemType","nsuri":"http://fasb.org/us-gaap/2024"},"localname":"OfficeEquipmentMember"},"presentation":f}
http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosurePropertyPlantAndEquipmentScheduleOfComponentsOfPropertyPlantAndEquipmentDetails"}-,"lang":{"en-us":{"role":{"terseLabel":"Office and Lab Equipment."},"label":"Office Equipment [Member]"},"documentation":"Tangible personal property used in an office setting. Examples include, but are not limited to, computers, copiers and fax machine."}}-,"auth_ref":{"cgc_OmnibusEquityIncentivePlanMember":{"xbrltype":"domainItemType","nsuri":"http://www.canopygrowth.com/20241231"},"localname":"OmnibusEquityIncentivePlanMember"},"presentation":f}
http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureShareBasedCompensationAdditionalInformationDetails"}-,"lang":{"en-us":{"role":{"documentation":"Omnibus equity incentive plan."},"label":"Omnibus Equity Incentive Plan [Member]"},"terseLabel":"Omnibus Equity Incentive Plan"}}-,"auth_ref":{"cgc_OmnibusIncentivePlanMember":{"xbrltype":"domainItemType","nsuri":"http://www.canopygrowth.com/20241231"},"localname":"OmnibusIncentivePlanMember"},"presentation":f}
http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureShareBasedCompensationAdditionalInformationDetails"}-,"lang":{"en-us":{"role":{"terseLabel":"Omnibus Incentive Plan."},"label":"Omnibus Incentive Plan [Member]"},"documentation":"Omnibus incentive plan."}}-,"auth_ref":{"cgc_OperatingAndFinanceLeaseLiability":{"xbrltype":"monetaryItemType","nsuri":"http://www.canopygrowth.com/20241231"},"localname":"OperatingAndFinanceLeaseLiability"},"crdr":"credit","presentation":f}
http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureOtherLiabilitiesComponentsOfOtherLiabilitiesDetails"}-,"lang":{"en-us":{"role":{"terseLabel":"Lease Liabilities."},"label":"Operating And Finance Lease Liability"},"documentation":"Operating and finance lease liability."}}-,"auth_ref":{"cgc_OperatingAndFinanceLeaseLiabilityCurrent":{"xbrltype":"monetaryItemType","nsuri":"http://www.canopygrowth.com/20241231"},"localname":"OperatingAndFinanceLeaseLiabilityCurrent"},"crdr":"credit","presentation":f}
http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureOtherLiabilitiesComponentsOfOtherLiabilitiesDetails"}-,"lang":{"en-us":{"role":{"terseLabel":"Lease Liabilities, current."},"label":"Operating And Finance Lease Liability Current"},"documentation":"Operating and finance lease liability, current."}}-,"auth_ref":{"cgc_OperatingAndFinanceLeaseLiabilityNoncurrent":{"xbrltype":"monetaryItemType","nsuri":"http://www.canopygrowth.com/20241231"},"localname":"OperatingAndFinanceLeaseLiabilityNoncurrent"},"crdr":"credit","presentation":f}
http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureOtherLiabilitiesComponentsOfOtherLiabilitiesDetails"}-,"lang":{"en-us":{"role":{"terseLabel":"Lease Liabilities, long-term."},"label":"Operating And Finance Lease Liability Noncurrent"},"documentation":"Operating and finance lease liability, noncurrent."}}-,"auth_ref":{"us-gaap_OperatingExpenses":{"xbrltype":"monetaryItemType","nsuri":"http://fasb.org/us-gaap/2024"},"localname":"OperatingExpenses"},"crdr":"debit","presentation":f}
http://www.canopygrowth.com/20241231/taxonomy/role/StatementCondensedInterimConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited"}-,"lang":{"en-us":{"role":{"totalLabel":"Total operating expenses."},"label":"Operating Expenses"},"documentation":"Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense."}}-,"auth_ref":{"us-gaap_OperatingExpensesAbstract":{"xbrltype":"stringItemType","nsuri":"http://fasb.org/us-gaap/2024"},"localname":"OperatingExpensesAbstract"},"presentation":f}
http://www.canopygrowth.com/20241231/taxonomy/role/StatementCondensedInterimConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited"}-,"lang":{"en-us":{"role":{"terseLabel":"Operating expenses."},"label":"Operating Expenses [Abstract]"},"auth_ref":{"us-gaap_OperatingIncomeLoss":{"xbrltype":"monetaryItemType","nsuri":"http://fasb.org/us-gaap/2024"},"localname":"OperatingIncomeLoss"},"crdr":"credit","presentation":f}
http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureSegmentInformationSummaryOfReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedDe"}-,"lang":{"en-us":{"role":{"documentation":"Operating income (loss)."},"label":"Operating Income (Loss)"},"totalLabel":"TotalLabel","documentation":"The net result for the period of deducting operating expenses from operating revenues."}}-,"auth_ref":{"r223","r1095","r1313","r1315","r1316","r1317","r1318"},"cgc_OperatingLicensesMember":{"xbrltype":"domainItemType","nsuri":"http://www.canopygrowth.com/20241231"},"localname":"OperatingLicensesMember"},"presentation":f}
http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureIntangibleAssetsSummaryOfComponentsOfIntangibleAssetsDetails"}-,"lang":{"en-us":{"role":{"terseLabel":"Operating Licenses."},"label":"Operating Licenses [Member]"},"documentation":"Operating licenses."}}-,"auth_ref":{"us-gaap_OptionIndexedToIssuersEquityTypeAxis":{"xbrltype":"stringItemType","nsuri":"http://fasb.org/us-gaap/2024"},"localname":"OptionIndexedToIssuersEquityTypeAxis"},"presentation":f}
http://www.canopygrowth.com/20241231/taxonomy/role/DisclosureAcreegeArrangementAdditionalInformationDetails"}-,"lang":{"en-us":{"role":{"terseLabel":"Option Indexed to Issuer's Equity Type."},"label":"Option Indexed to Issuer's Equity Type [Axis]"},"documentation":"Information by type of freestanding contracts issued by an entity that are indexed to, and potentially settled in, an entity's own stock."}}-,"auth_ref":{"r55","r94","r95","r204"},"us-gaap_OptionIndexedToIssuersEquityTypeDomain":{"xbrltype":"domainItemType","nsuri":"http://fasb.org/us-gaap/2024"},"localname":"OptionIndexedToIssuersEquityTypeDomain"},"presentation":f}
http://www.canopygrowth.com/20241231/taxonomy/role/DisclosureAcreegeArrangementAdditionalInformationDetails"}-,"lang":{"en-us":{"role":{"terseLabel":"Option Indexed to Issuer's Equity Type."},"label":"Option Indexed to Issuer's Equity Type [Domain]"},"documentation":"Description of the type of freestanding contract issued by a company that is indexed to, and potentially settled in, a company's own stock. Specifically, the pertinent rights and privileges of the securities outstanding."}}-,"auth_ref":{"cgc_OptionPremiumPayment":{"xbrltype":"monetaryItemType","nsuri":"http://www.canopygrowth.com/20241231"},"localname":"OptionPremiumPayment"},"crdr":"credit","presentation":f}
http://www.canopygrowth.com/20241231/taxonomy/role/DisclosureAcreegeArrangementAdditionalInformationDetails"}-,"lang":{"en-us":{"role":{"terseLabel":"Option premium payment."},"label":"Option Premium Payment"},"documentation":"Option premium payment."}}-,"auth_ref":{"cgc_OptionsGrantedToAcquireAdditionalVotingSharesValue":{"xbrltype":"monetaryItemType","nsuri":"http://www.canopygrowth.com/20241231"},"localname":"OptionsGrantedToAcquireAdditionalVotingSharesValue"},"crdr":"credit","presentation":f}
http://www.canopygrowth.com/20241231/taxonomy/role/DisclosureCanopyUsaAdditionalInformationDetails"}-,"lang":{"en-us":{"role":{"terseLabel":"Options granted to acquire additional voting shares, value."},"label":"Options Granted To Acquire Additional Voting Shares, Value"},"documentation":"Options granted to acquire additional voting shares, value."}}-,"auth_ref":{"us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract":{"xbrltype":"stringItemType","nsuri":"http://fasb.org/us-gaap/2024"},"localname":"OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"},"lang":{"en-us":{"role":{"label":"Organization Consolidation and Presentation of Financial Statements [Abstract]"},"auth_ref":{"us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock":{"xbrltype":"textBlockItemType","nsuri":"http://fasb.org/us-gaap/2024"},"localname":"OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"},"presentation":f}
http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureDescriptionOfBusiness"}-,"lang":{"en-us":{"role":{"terseLabel":"Description of Business."},"label":"Organization Consolidation and Presentation of Financial Statements Disclosure [Text Block]"},"documentation":"The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure."}}-,"auth_ref":{"r101","r198","r897","r888"},"us-gaap_OtherAccruedLiabilitiesCurrent":{"xbrltype":"monetaryItemType","nsuri":"http://fasb.org/us-gaap/2024"},"localname":"OtherAccruedLiabilitiesCurrent"},"crdr":"credit","presentation":f}
http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureOtherAccruedExpensesAndLiabilitiesComponentsOfOtherAccruedExpensesAndLiabilitiesDetails"}-,"lang":{"en-us":{"role":{"terseLabel":"Other."},"label":"Other Accrued Liabilities, Current"},"documentation":"Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer."}}-,"auth_ref":{"r125"},"us-gaap_OtherAssetsCurrent":{"xbrltype":"monetaryItemType","nsuri":"http://fasb.org/us-gaap/2024"},"localname":"OtherAssetsCurrent"},"crdr":"debit","presentation":f}
http://www.canopygrowth.com/20241231/taxonomy/role/DisclosurePrepaidExpensesAndOtherAssetsComponentsOfPrepaidExpensesAndOtherAssetsDetails"}-,"lang":{"en-us":{"role":{"terseLabel":"Other assets."},"label":"Other Assets, Current"},"documentation":"Amount of current assets classified as other."}}-,"auth_ref":{"r268","r1147"},"us-gaap_OtherAssetsFairValueDisclosure":{"xbrltype":"monetaryItemType","nsuri":"http://fasb.org/us-gaap/2024"},"localname":"OtherAssetsFairValueDisclosure"},"crdr":"debit","presentation":f}
http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtEstimatedFairVa"}-,"lang":{"en-us":{"role":{"terseLabel":"Other financial assets."},"label":"Other Assets, Fair Value Disclosure"},"documentation":"Fair value portion of other assets."}}-,"auth_ref":{"r1412","r1413","r1417"},"us-gaap_OtherAssetsNoncurrent":{"xbrltype":"monetaryItemType","nsuri":"http://fasb.org/us-gaap/2024"},"localname":"OtherAssetsNoncurrent"},"crdr":"debit","presentation":f}
http://www.canopygrowth.com/20241231/taxonomy/role/Role_StatementCondensedInterimConsolidatedBalanceSheetsUnaudited"}-,"lang":{"en-us":{"role":{"terseLabel":"Other assets."},"label":"Other Assets, Noncurrent"},"documentation":"Amount of noncurrent assets classified as other."}}-,"auth_ref":{"r256"},"cgc_OtherAtFairValueThroughNetIncomeLossMember":{"xbrltype":"domainItemType","nsuri":"http://www.canopygrowth.com/20241231"},"localname":"OtherAtFairValueThroughNetIncomeLossMember"},"presentation":f}
http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureOtherFinancialAssetsSummaryOfChangesInOtherFinancialAssetsDetails"}-,"lang":{"en-us":{"role":{"terseLabel":"Other At Fair Value Through Net Income (Loss)."},"label":"Other At Fair Value Through Net Income Loss [Member]"},"documentation":"Other - at fair value through net income (loss)"},"auth_ref":{"cgc_OtherClassifiedAsHeldForInvestmentMember":{"xbrltype":"domainItemType","nsuri":"http://www.canopygrowth.com/20241231"},"localname":"OtherClassifiedAsHeldForInvestmentMember"},"presentation":f}
http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureOtherFinancialAssetsSummaryOfChangesInOtherFinancialAssetsDetails"}-,"lang":{"en-us":{"role":{"terseLabel":"Other - Classified as Held for Investment."},"label":"Other Classified As Held For Investment [Member]"},"documentation":"Other classified as held for investment."}}-,"auth_ref":{"us-gaap_OtherComprehensiveIncomeLossBeforeTax":{"xbrltype":"monetaryItemType","nsuri":"http://fasb.org/us-gaap/2024"},"localname":"OtherComprehensiveIncomeLossBeforeTax"},"crdr":"credit","presentation":f}
http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureAccumulatedOtherComprehensiveIncomeLossAccumulatedOtherComprehensiveIncomeDetails"}-,"lang":{"en-us":{"role":{"totalLabel":"Other Comprehensive Income (Loss), before Tax, Total."},"label":"Other Comprehensive Income (Loss), before Tax"},"terseLabel":"Other comprehensive income (loss)"},"documentation":"Amount before tax, after reclassification adjustments of other comprehensive income (loss)."}}-,"auth_ref":{"r284","r715","r716","r721","r817","r845","r1288","r1289"},"us-gaap_OtherComprehensiveIncomeLossFinancialLiabilityFairValueOptionAfterTaxAndReclassificationAdjustmentAttributableToParent":{"xbrltype":"monetaryItemType","nsuri":"http://fasb.org/us-gaap/2024"},"localname":"OtherComprehensiveIncomeLossFinancialLiabilityFairValueOptionAfterTaxAndReclassificationAdjustmentAttributableToParent"},"crdr":"credit","presentation":f}
http://www.canopygrowth.com/20241231/taxonomy/role/StatementCondensedInterimConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited"}-,"lang":{"en-us":{"role":{"totalLabel":"Other Comprehensive Income (Loss), Financial Liability, Fair Value Option, after Tax and Reclassification Adjustment, Attributable to Parent, Total."},"terseLabel":"Fair value changes of own credit risk of financial liabilities."},"label":"Other Comprehensive Income (Loss), Financial Liability, Fair Value Option, after Tax and Reclassification Adjustment, Attributable to Parent"},"negatedLabel":"Fair value changes of own credit risk of financial liabilities"},"documentation":"Amount, after tax and reclassification adjustment, of gain (loss) from increase (decrease) in instrument-specific credit risk of financial liability measured under fair value option, attributable to parent."}}-,"auth_ref":{"r655","r660"},"us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax":{"xbrltype":"monetaryItemType","nsuri":"http://fasb.org/us-gaap/2024"},"localname":"OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"},"crdr":"credit","presentation":f}
http://www.canopygrowth.com/20241231/taxonomy/role/StatementCondensedInterimConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited"}-,"lang":{"en-us":{"role":{"totalLabel":"Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Total."},"terseLabel":"Foreign currency translation."},"label":"Other Comprehensive Income (
```



```

OtherComprehensiveIncomeLossNetOfTax, "crdr", "credit", "presentation":-
http://www.canopygrowth.com/20241231/taxonomy/role/StatementCondensedInterimConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited", "lang": "en-us", "role": "label", "OtherComprehensiveIncome (Loss), Net of Tax", "totalLabel": "Total other comprehensive income (loss), net of income tax", "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss).", "auth_ref": "r19", "r27", "r276", "r279", "r284", "r310", "r715", "r716", "r721", "r817", "r845", "r1288", "r1289", "us-gaap-OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract", "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract", "presentation":-
http://www.canopygrowth.com/20241231/taxonomy/role/StatementCondensedInterimConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited", "lang": "en-us", "role": "label", "OtherComprehensiveIncome (Loss), Net of Tax [Abstract]", "terseLabel": "Other comprehensive income (loss), net of income tax", "auth_ref": "cgc-OtherFinancialAssets", "xbrltype": "monetaryItemType", "nsuri": "http://www.canopygrowth.com/20241231", "localname": "OtherFinancialAssets", "crdr", "debit", "presentation":-
presentation": "http://www.canopygrowth.com/20241231/taxonomy/role/DisclosureOtherIncomeExpenseNetScheduleOfOtherIncomeExpenseNetParenteticalDetails", "http://www.canopygrowth.com/20241231/taxonomy/role/Role_StatementCondensedInterimConsolidatedBalanceSheetsUnaudited", "lang": "en-us", "role": "terseLabel", "Other financial assets", "label": "Other Financial Assets", "documentation": "Other financial assets.", "auth_ref": "cgc-OtherFinancialAssetsAdditions", "xbrltype": "monetaryItemType", "nsuri": "http://www.canopygrowth.com/20241231", "localname": "OtherFinancialAssetsAdditions", "crdr", "debit", "presentation":-
http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureOtherFinancialAssetsSummaryOfChangesInOtherFinancialAssetsDetails", "lang": "en-us", "role": "terseLabel", "Additions", "label": "Other Financial Assets Additions", "documentation": "Other financial assets additions.", "auth_ref": "cgc-OtherFinancialAssetsFairValueAdjustment", "xbrltype": "monetaryItemType", "nsuri": "http://www.canopygrowth.com/20241231", "localname": "OtherFinancialAssetsFairValueAdjustment", "crdr", "debit", "presentation":-
http://www.canopygrowth.com/20241231/taxonomy/role/DisclosureOtherIncomeExpenseNetScheduleOfOtherIncomeExpenseNetParenteticalDetails", "http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureOtherIncomeExpenseNetScheduleOfOtherIncomeExpenseNetDetails", "lang": "en-us", "role": "label", "Other Financial Assets Fair Value Adjustment", "documentation": "Amount of expense (income) related to adjustment to fair value of other financial assets.", "negatedLabel": "Fair value changes on other financial assets", "terseLabel": "Fair value changes on other financial assets", "auth_ref": "cgc-OtherFinancialAssetsOther", "xbrltype": "monetaryItemType", "nsuri": "http://www.canopygrowth.com/20241231", "localname": "OtherFinancialAssetsOther", "crdr", "credit", "presentation": "http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureOtherFinancialAssetsSummaryOfChangesInOtherFinancialAssetsDetails", "lang": "en-us", "role": "negatedLabel", "Other", "label": "Other Financial Assets Other", "documentation": "Other financial assets other.", "auth_ref": "cgc-OtherFinancialAssetsTextBlock", "xbrltype": "textBlockItemType", "nsuri": "http://www.canopygrowth.com/20241231", "localname": "OtherFinancialAssetsTextBlock", "presentation": "http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureOtherFinancialAssets", "lang": "en-us", "role": "terseLabel", "Other Financial Assets", "label": "Other Financial Assets [Text Block]", "documentation": "Other financial assets.", "auth_ref": "cgc-OtherGeographicalAreaMember", "xbrltype": "domainItemType", "nsuri": "http://www.canopygrowth.com/20241231", "localname": "OtherGeographicalAreaMember", "presentation":-
http://www.canopygrowth.com/20241231/taxonomy/role/DisclosureSegmentInformationSummaryOfDisaggregationOfPropertyPlantAndEquipmentByGeographicAreaDetails", "http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureSegmentInformationSummaryOfDisaggregationOfNetRevenueByGeographicAreaDetails", "lang": "en-us", "role": "terseLabel", "Other", "label": "Other Geographical Area [Member]", "documentation": "Other geographical area member.", "auth_ref": "us-gaap-OtherIncomeAndExpensesAbstract", "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherIncomeAndExpensesAbstract", "lang": "en-us", "role": "label", "Other Income and Expenses [Abstract]", "auth_ref": "cgc-OtherIncomeAndExpensesLineItems", "xbrltype": "stringItemType", "nsuri": "http://www.canopygrowth.com/20241231", "localname": "OtherIncomeAndExpensesLineItems", "presentation":-
http://www.canopygrowth.com/20241231/taxonomy/role/DisclosureOtherIncomeExpenseNetScheduleOfOtherIncomeExpenseNetParenteticalDetails", "lang": "en-us", "role": "label", "Other Income and Expenses [Line Items]", "documentation": "Other income and expenses line items.", "auth_ref": "cgc-OtherIncomeAndExpensesTable", "xbrltype": "stringItemType", "nsuri": "http://www.canopygrowth.com/20241231", "localname": "OtherIncomeAndExpensesTable", "presentation": "http://www.canopygrowth.com/20241231/taxonomy/role/DisclosureOtherIncomeExpenseNetScheduleOfOtherIncomeExpenseNetParenteticalDetails", "lang": "en-us", "role": "label", "Other Income And Expenses [Table]", "documentation": "Other income and expenses table.", "auth_ref": "us-gaap-OtherIncomeAndOtherExpenseDisclosureTextBlock", "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherIncomeAndOtherExpenseDisclosureTextBlock", "presentation": "http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureOtherIncomeExpenseNet", "lang": "en-us", "role": "terseLabel", "Other Income (Expense), Net", "label": "Other Income and Other Expense Disclosure [Text Block]", "documentation": "The entire disclosure for other income or other expense items (both operating and nonoperating). Sources of nonoperating income or nonoperating expense that may be disclosed, include amounts earned from dividends, interest on securities, profits (losses) on securities, net and miscellaneous other income or income deductions.", "auth_ref": "r1271", "r1401", "cgc-OtherIssuancesAndShareIssueCostsMember", "xbrltype": "domainItemType", "nsuri": "http://www.canopygrowth.com/20241231", "localname": "OtherIssuancesAndShareIssueCostsMember", "presentation":-
http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureShareCapitalSummaryOfIssuancesOfStockOtherDetails", "lang": "en-us", "role": "label", "Other Issuances and Share Issue Costs [Member]", "documentation": "Other issuances and share issue costs.", "auth_ref": "cgc-OtherIssuancesOfCommonSharesNetOfShareIssuanceCost", "xbrltype": "monetaryItemType", "nsuri": "http://www.canopygrowth.com/20241231", "localname": "OtherIssuancesOfCommonSharesNetOfShareIssuanceCost", "crdr", "credit", "presentation":-
http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureShareCapitalSummaryOfIssuancesOfStockOtherDetails", "lang": "en-us", "role": "terseLabel", "Share capital", "label": "Other Issuances Of Common Shares Net Of Share Issuance Cost", "documentation": "Other issuances of common shares net of share issuance cost.", "auth_ref": "cgc-OtherLenderMember", "xbrltype": "domainItemType", "nsuri": "http://www.canopygrowth.com/20241231", "localname": "OtherLenderMember", "presentation": "http://www.canopygrowth.com/20241231/taxonomy/role/DisclosureCanopyUsaAcceageAgreementsAdditionalInformationDetails", "http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureOtherFinancialAssetsAdditionalInformationDetails", "lang": "en-us", "role": "terseLabel", "Other Lender", "label": "Other Lender [Member]", "documentation": "Other Lender.", "auth_ref": "us-gaap-OtherLiabilities", "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherLiabilities", "crdr", "credit", "presentation":-
http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureOtherLiabilitiesComponentsOfOtherLiabilitiesDetails", "lang": "en-us", "role": "totalLabel", "Other liabilities", "label": "Other Liabilities", "documentation": "Amount of liabilities classified as other.", "auth_ref": "r208", "r827", "r925", "r926", "r1174", "r1439", "r1476", "us-gaap-OtherLiabilitiesAbstract", "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherLiabilitiesAbstract", "presentation": "http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureOtherLiabilitiesComponentsOfOtherLiabilitiesDetails", "lang": "en-us", "role": "terseLabel", "Total", "label": "Other Liabilities [Abstract]", "auth_ref": "us-gaap-OtherLiabilitiesCurrent", "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherLiabilitiesCurrent", "crdr", "credit", "presentation":-
http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureOtherLiabilitiesComponentsOfOtherLiabilitiesDetails", "http://www.canopygrowth.com/20241231/taxonomy/role/Role_StatementCondensedInterimConsolidatedBalanceSheetsUnaudited", "lang": "en-us", "role": "totalLabel", "Other Liabilities Current", "terseLabel": "Other liabilities", "label": "Other Liabilities, Current", "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.", "auth_ref": "r125", "r147", "us-gaap-OtherLiabilitiesCurrentAbstract", "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherLiabilitiesCurrentAbstract", "presentation":-
http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureOtherLiabilitiesComponentsOfOtherLiabilitiesDetails", "lang": "en-us", "role": "terseLabel", "Current", "label": "Other Liabilities, Current [Abstract]", "auth_ref": "us-gaap-OtherLiabilitiesDisclosureAbstract", "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherLiabilitiesDisclosureAbstract", "lang": "en-us", "role": "label", "Other Liabilities Disclosure [Abstract]", "auth_ref": "us-gaap-OtherLiabilitiesDisclosureTextBlock", "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherLiabilitiesDisclosureTextBlock", "presentation": "http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureOtherLiabilities", "lang": "en-us", "role": "terseLabel", "Other Liabilities", "label": "Other Liabilities Disclosure [Text Block]", "documentation": "The entire disclosure for other liabilities.", "auth_ref": "r125", "r130", "r1353", "us-gaap-OtherLiabilitiesFairValueDisclosure", "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherLiabilitiesFairValueDisclosure", "crdr", "credit", "presentation":-
http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureFairValueOffFinancialInstrumentsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtEstimatedFairVa", "lang": "en-us", "role": "terseLabel", "Other liabilities", "label": "Other Liabilities, Fair Value Disclosure", "documentation": "Fair value portion of other liabilities.", "auth_ref": "r1412", "r1413", "r1417", "us-gaap-OtherLiabilitiesNoncurrent", "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherLiabilitiesNoncurrent", "crdr", "credit", "presentation":-
http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureOtherLiabilitiesComponentsOfOtherLiabilitiesDetails", "http://www.canopygrowth.com/20241231/taxonomy/role/Role_StatementCondensedInterimConsolidatedBalanceSheetsUnaudited", "lang": "en-us", "role": "totalLabel", "Other liabilities long-term", "terseLabel": "Other liabilities", "label": "Other Liabilities, Noncurrent", "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.", "auth_ref": "r130", "us-gaap-OtherLiabilitiesNoncurrentAbstract", "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherLiabilitiesNoncurrentAbstract", "presentation":-
http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureOtherLiabilitiesComponentsOfOtherLiabilitiesDetails", "lang": "en-us", "role": "terseLabel", "Long-term", "label": "Other Liabilities, Noncurrent [Abstract]", "auth_ref": "us-gaap-OtherLiabilitiesTableTextBlock", "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherLiabilitiesTableTextBlock", "presentation":-
http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureOtherLiabilitiesTables", "lang": "en-us", "role": "terseLabel", "Components of Other Liabilities", "label": "Other Liabilities [Table Text Block]", "documentation": "Tabular disclosure of other liabilities.", "auth_ref": "us-gaap-OtherLongTermDebt", "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherLongTermDebt", "crdr", "credit", "presentation":-
http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureDebtSummaryOfComponentsOfDebtDetails",
```


"http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureOtherIncomeExpenseNetScheduleOfOtherIncomeExpenseNetDetails" |
"http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureSegmentInformationSummaryOfReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedDel
"http://www.canopygrowth.com/20241231/taxonomy/role/StatementCondensedInterimConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited" |, "lang": {
"en-us": { "role": { "totalLabel": "Other income (expense), net", "terseLabel": "Other income (expense), net", "label": "Other Nonoperating Income (Expense)", "negatedLabel":
"Other income (expense), net", "documentation": "Amount of income (expense) related to nonoperating activities, classified as other." } } }, "auth_ref": { "r160" } }, "us-
gaap_OtherOperatingIncomeExpenseNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherOperatingIncomeExpenseNet",
"crdr": "credit", "presentation": { "http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails" |, "lang": { "en-us": { "role": {
"terseLabel": "Other income (expense), net", "label": "Other Operating Income (Expense), Net", "documentation": "The net amount of other operating income and expenses,
the components of which are not separately disclosed on the income statement, from items that are associated with the entity's normal revenue producing operations." } } },
"auth_ref": { } }, "ecd_OtherPerfMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OtherPerfMeasureAmt", "presentation": {
"http://xbrl.sec.gov/ecd/role/PvpDisclosure" |, "lang": { "en-us": { "role": { "label": "Other Performance Measure, Amount", "terseLabel": "Other Performance Measure,
Amount" } } }, "auth_ref": { "r1223" } }, "us-gaap_OtherReceivablesNetCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"OtherReceivablesNetCurrent", "crdr": "debit", "presentation": {
"http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureAmountsReceivableNetComponentsOfAmountsReceivableNetDetails" |, "lang": { "en-us": { "role": {
"totalLabel": "Other Receivables, Net, Current, Total", "terseLabel": "Other receivables", "label": "Other Receivables, Net, Current", "documentation": "Amount, after
allowance, of receivables classified as other, due within one year or the operating cycle, if longer." } } }, "auth_ref": { } }, "cgc_OtherRestOfWorldCannabisMember": {
"xbrltype": "domainItemType", "nsuri": "http://www.canopygrowth.com/20241231", "localname": "OtherRestOfWorldCannabisMember", "presentation": {
"http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureRevenueSummaryOfDisaggregationOfRevenueDetails" |, "lang": { "en-us": { "role": { "terseLabel":
"Other rest of world cannabis", "label": "Other rest of world cannabis [Member]", "documentation": "Other rest of world cannabis." } } }, "auth_ref": { } },
"cgc_OtherRevenueMember": { "xbrltype": "domainItemType", "nsuri": "http://www.canopygrowth.com/20241231", "localname": "OtherRevenueMember", "presentation": {
"http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureRevenueSummaryOfDisaggregationOfRevenueDetails" |, "lang": { "en-us": { "role": { "terseLabel":
"Other", "label": "Other Revenue [Member]", "documentation": "Other revenue." } } }, "auth_ref": { } }, "ecd_OutstandingAggtErrCompAmt": { "xbrltype": "monetaryItemType",
"nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingAggtErrCompAmt", "presentation": { "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" |, "lang": { "en-us": {
"role": { "label": "Outstanding Aggregate Erroneous Compensation Amount", "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount" } } }, "auth_ref": {
"r1185", "r1195", "r1205", "r1237" } }, "cgc_OutstandingPrincipalOfAcreagesDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://www.canopygrowth.com/20241231",
"localname": "OutstandingPrincipalOfAcreagesDebt", "crdr": "credit", "presentation": {
"http://www.canopygrowth.com/20241231/taxonomy/role/DisclosureCanopyUsaAcreageAgreementsAdditionalInformationDetails" |, "lang": { "en-us": { "role": { "terseLabel":
"http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureOtherFinancialAssetsAdditionalInformationDetails" |, "lang": { "en-us": { "role": { "terseLabel":
"Outstanding principal of acreage's debt", "label": "Outstanding Principal Of Acreage's Debt", "documentation": "Outstanding principal of acreage's debt." } } }, "auth_ref": { } },
"ecd_OutstandingRecoveryCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingRecoveryCompAmt",
"presentation": { "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" |, "lang": { "en-us": { "role": { "label": "Outstanding Recovery Compensation Amount", "terseLabel":
"Compensation Amount" } } }, "auth_ref": { "r1188", "r1198", "r1208", "r1240" } }, "ecd_OutstandingRecoveryIndName": { "xbrltype": "stringItemType", "nsuri":
"http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingRecoveryIndName", "presentation": { "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" |, "lang": { "en-us": { "role": {
"label": "Outstanding Recovery, Individual Name", "terseLabel": "Name" } } }, "auth_ref": { "r1188", "r1198", "r1208", "r1240" } }, "cgc_OwnershipChangesMember": {
"xbrltype": "domainItemType", "nsuri": "http://www.canopygrowth.com/20241231", "localname": "OwnershipChangesMember", "presentation": {
"http://www.canopygrowth.com/20241231/taxonomy/role/Role_StatementCondensedInterimConsolidatedStatementsOfShareholderSEquityUnaudited" |, "lang": { "en-us": {
"role": { "terseLabel": "Ownership Changes", "label": "Ownership Changes [Member]", "documentation": "Ownership changes." } } }, "auth_ref": { } },
"cgc_OwnershipPercentageExercised": { "xbrltype": "percentItemType", "nsuri": "http://www.canopygrowth.com/20241231", "localname": "OwnershipPercentageExercised",
"presentation": { "http://www.canopygrowth.com/20241231/taxonomy/role/DisclosureCanopyUsaAdditionalInformationDetails" |, "lang": { "en-us": { "role": { "documentation":
"Ownership percentage exercised.", "label": "Ownership Percentage Exercised", "terseLabel": "Ownership percentage exercised" } } }, "auth_ref": { } },
"ecd_PayVsPerformanceDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PayVsPerformanceDisclosureLineItems",
"lang": { "en-us": { "role": { "label": "Pay vs Performance Disclosure [Line Items]", "terseLabel": "Pay vs Performance Disclosure" } } }, "auth_ref": { "r1212" } },
"cgc_PaydownAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.canopygrowth.com/20241231", "localname": "PaydownAgreementMember",
"presentation": { "http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails" |, "lang": { "en-us": { "role": { "label": "Paydown
Agreement [Member]", "documentation": "Paydown agreement." } } }, "auth_ref": { } },
"cgc_PaymentsForProceedsFromDivestitureOfInterestInDeconsolidationOfSubsidiariesAndAffiliates": { "xbrltype": "monetaryItemType", "nsuri":
"http://www.canopygrowth.com/20241231", "localname": "PaymentsForProceedsFromDivestitureOfInterestInDeconsolidationOfSubsidiariesAndAffiliates", "crdr": "credit",
"presentation": { "http://www.canopygrowth.com/20241231/taxonomy/role/Role_StatementCondensedInterimConsolidatedStatementsOfCashFlowsUnaudited" |, "lang": { "en-us": {
"role": { "role": { "documentation": "Payments For Proceeds From Divestiture Of Interest In deconsolidation of subsidiaries And Affiliates", "terseLabel": "Net cash outflow on sale or deconsolidation of subsidiaries", "negatedLabel": "Net cash
outflow on sale or deconsolidation of subsidiaries" } } }, "auth_ref": { } }, "cgc_PaymentsForProceedsFromOtherFinancialAssets": { "xbrltype": "monetaryItemType", "nsuri":
"http://www.canopygrowth.com/20241231", "localname": "PaymentsForProceedsFromOtherFinancialAssets", "crdr": "credit", "presentation": {
"http://www.canopygrowth.com/20241231/taxonomy/role/Role_StatementCondensedInterimConsolidatedStatementsOfCashFlowsUnaudited" |, "lang": { "en-us": { "role": {
"label": "Payments For Proceeds From Other Financial Assets", "documentation": "Payments for proceeds from other financial assets.", "negatedLabel": "Investment in other
financial assets" } } }, "auth_ref": { } }, "us-gaap_PaymentsForProceedsFromOtherInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "PaymentsForProceedsFromOtherInvestingActivities", "crdr": "credit", "presentation": {
"http://www.canopygrowth.com/20241231/taxonomy/role/Role_StatementCondensedInterimConsolidatedStatementsOfCashFlowsUnaudited" |, "lang": { "en-us": { "role": {
"negatedLabel": "Other investing activities", "label": "Payments for (Proceeds from) Other Investing Activities", "documentation": "Amount of cash (inflow) outflow from
investing activities classified as other." } } }, "auth_ref": { "r1267", "r1292" } }, "us-gaap_PaymentsForProceedsFromShortTermInvestments": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsForProceedsFromShortTermInvestments", "crdr": "credit", "presentation": {
"http://www.canopygrowth.com/20241231/taxonomy/role/Role_StatementCondensedInterimConsolidatedStatementsOfCashFlowsUnaudited" |, "lang": { "en-us": { "role": {
"label": "(Investment in) sale of other financial assets", "totalLabel": "Payments for (Proceeds from) Short-Term Investments, Total", "negatedLabel": "Redemption of short-
term investments", "documentation": "The net amount paid (received) by the reporting entity through acquisition or sale and maturities of short-term investments with an
original maturity that is three months or less which qualify for treatment as an investing activity based on management's intention and intended by management to be
liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale
in the short-term." } } }, "auth_ref": { "r1291", "r1293", "r1300" } }, "us-gaap_PaymentsToAcquireBusinessesAndInterestInAffiliates": { "xbrltype": "monetaryItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsToAcquireBusinessesAndInterestInAffiliates", "crdr": "credit", "presentation": {
"http://www.canopygrowth.com/20241231/taxonomy/role/DisclosureAcreageArrangementAdditionalInformationDetails" |, "lang": { "en-us": { "role": { "totalLabel": "Payments
to Acquire Businesses and Interest in Affiliates, Total", "terseLabel": "Aggregate payment", "label": "Payments to Acquire Businesses and Interest in Affiliates",
"documentation": "The cash outflow associated with the acquisition of a controlling interest in another entity or an entity that is related to it but not strictly controlled (for
example, an unconsolidated subsidiary, affiliate, joint venture or equity method investment)." } } }, "auth_ref": { "r37" } }, "us-gaap_PaymentsToAcquireBusinessesGross": {
"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsToAcquireBusinessesGross", "crdr": "credit", "presentation": {
"http://www.canopygrowth.com/20241231/taxonomy/role/DisclosureAcquisitionAdditionalInformationDetails" |, "lang": { "en-us": { "role": { "totalLabel": "Payments
to Acquire Businesses, Gross", "terseLabel": "Consideration paid in cash", "documentation": "The cash outflow associated
with the acquisition of business during the period. The cash portion only of the acquisition price." } } }, "auth_ref": { "r37", "r647" } }, "us-
gaap_PaymentsToAcquireBusinessesNetOfCashAcquired": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"PaymentsToAcquireBusinessesNetOfCashAcquired", "crdr": "credit", "presentation": {
"http://www.canopygrowth.com/20241231/taxonomy/role/DisclosureAcquisitionSummaryOfConsolidatedBalanceSheetImpactAtAcquisitionOfCompanyBusinessCombinationDetail
" |, "lang": { "en-us": { "role": { "label": "Payments to Acquire Businesses, Net of Cash Acquired", "totalLabel": "Net cash outflow (inflow)", "terseLabel": "Net cash outflow",
"documentation": "The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase." } } }, "auth_ref": { "r37" } }, "us-
gaap_PaymentsToAcquireIntangibleAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsToAcquireIntangibleAssets",
"crdr": "credit", "presentation": { "http://www.canopygrowth.com/20241231/taxonomy/role/Role_StatementCondensedInterimConsolidatedStatementsOfCashFlowsUnaudited" |, "lang": { "en-us": { "role": {
"label": "Payments to Acquire Intangible Assets", "documentation": "The cash outflow to acquire
asset without physical form usually arising from contractual or other legal rights, excluding goodwill." } } }, "auth_ref": { "r163" } }, "us-
gaap_PaymentsToAcquireInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsToAcquireInvestments", "crdr":
"credit", "presentation": { "http://www.canopygrowth.com/20241231/taxonomy/role/DisclosureAcreageArrangementAdditionalInformationDetails" |, "lang": { "en-us": { "role": {
"totalLabel": "Payments to Acquire Investments, Total", "terseLabel": "Payments to acquire investments", "label": "Payments to Acquire Investments", "documentation": "The
cash outflow associated with the purchase of all investments (debt, security, other) during the period." } } }, "auth_ref": { "r162" } }, "us-
gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"PaymentsToAcquirePropertyPlantAndEquipment", "crdr": "credit", "presentation": {
"http://www.canopygrowth.com/20241231/taxonomy/role/Role_StatementCondensedInterimConsolidatedStatementsOfCashFlowsUnaudited" |, "lang": { "en-us": { "role": {
"totalLabel": "Payments to Acquire Property, Plant, and Equipment, Total", "negatedLabel": "Purchases of and deposits on property, plant and equipment", "label": "Payments
to Acquire Property, Plant, and Equipment", "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal
conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets." } } }, "auth_ref": {
"r163" } }, "ecd_PeerGroupIssuersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeerGroupIssuersFnTextBlock",
"presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure" |, "lang": { "en-us": { "role": { "label": "Peer Group Issuers, Footnote [Text Block]", "terseLabel": "Peer Group
Issuers, Footnote" } } }, "auth_ref": { "r1222" } }, "ecd_PeerGroupTotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024",
"localname": "PeerGroupTotalShareholderRtnAmt", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure" |, "lang": { "en-us": { "role": { "label": "Peer Group Total
Shareholder Return Amount", "terseLabel": "Peer Group Total Shareholder Return Amount" } } }, "auth_ref": { "r1222" } }, "ecd_PeoActuallyPaidCompAmt": { "xbrltype":
"monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoActuallyPaidCompAmt", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure" |, "lang": {
"en-us": { "role": { "label": "PEO Actually Paid Compensation Amount", "terseLabel": "PEO Actually Paid Compensation Amount" } } }, "auth_ref": { "r1214" } },
"ecd_PeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoMember", "presentation": {
"http://xbrl.sec.gov/ecd/role/PvpDisclosure" |, "lang": { "en-us": { "role": { "label": "PEO [Member]", "terseLabel": "PEO" } } }, "auth_ref": { "r1231" } }, "ecd_PeoName": {
"xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoName", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure" |, "lang": {
"en-us": { "role": { "label": "PEO Name", "terseLabel": "PEO Name" } } }, "auth_ref": { "r1224" } }, "ecd_PeoTotalCompAmt": { "xbrltype": "monetaryItemType",
"nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoTotalCompAmt", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure" |, "lang": { "en-us": { "role": { "label":
"PEO Total Compensation Amount", "terseLabel": "PEO Total Compensation Amount" } } }, "auth_ref": { "r1213" } }, "cgc_PercentageNonVotingSharesInCapital": { "xbrltype":
"percentItemType", "nsuri": "http://www.canopygrowth.com/20241231", "localname": "PercentageNonVotingSharesInCapital", "presentation": {
"http://www.canopygrowth.com/20241231/taxonomy/role/DisclosureCanopyUsaAdditionalInformationDetails" |, "lang": { "en-us": { "role": { "documentation": "Percentage non
voting shares in capital", "label": "Percentage Non-Voting Shares in Capital", "terseLabel": "Percentage non-voting shares in capital" } } }, "auth_ref": { } },
"cgc_PercentageOfCommonSharesToBeIssuedToFormerHolders": { "xbrltype": "percentItemType", "nsuri": "http://www.canopygrowth.com/20241231", "localname":
"PercentageOfCommonSharesToBeIssuedToFormerHolders", "presentation": {
"http://www.canopygrowth.com/20241231/taxonomy/role/DisclosureCanopyUsaAdditionalInformationDetails" |, "lang": { "en-us": { "role": { "terseLabel": "Percentage of

common shares to be issued to former holders." } } }, "auth_ref": "I", "cgc_PercentageOfIssuedAndOutstandingShares": { "xbrltype": "percentItem", "nsuri": "http://www.canopygrowth.com/20241231", "localname": "PercentageOfIssuedAndOutstandingShares", "presentation": { "http://www.canopygrowth.com/20241231/taxonomy/role/DisclosureCanopyUsaAdditionalInformationDetails": { "lang": { "en-us": { "role": { "documentation": "Percentage of issued and outstanding shares.", "label": "Percentage of issued and outstanding shares", "terseLabel": "Percentage of issued and outstanding shares" } } }, "auth_ref": "I", "cgc_PercentageOfOptionsExercisableOnEachAnniversariesFromDateOfGrant": { "xbrltype": "percentItem", "nsuri": "http://www.canopygrowth.com/20241231", "localname": "PercentageOfOptionsExercisableOnEachAnniversariesFromDateOfGrant", "presentation": { "http://www.canopygrowth.com/20241231/taxonomy/role/DisclosureShareBasedCompensationAdditionalInformationDetails": { "lang": { "en-us": { "role": { "terseLabel": "Percentage of number of shares issuable from treasury pursuant to awards", "label": "Percentage of Options Exercisable On Each Anniversaries From Date Of Grant", "documentation": "Percentage of options exercisable on each anniversaries from date of grant." } } }, "auth_ref": "I", "cgc_PercentageOfPurchasePriceForRollingInterest": { "xbrltype": "percentItem", "nsuri": "http://www.canopygrowth.com/20241231", "localname": "PercentageOfPurchasePriceForRollingInterest", "presentation": { "http://www.canopygrowth.com/20241231/taxonomy/role/DisclosureCanopyUsaAcreageAgreementsAdditionalInformationDetails": { "lang": { "en-us": { "role": { "documentation": "Percentage of purchase price for Rolling Interest.", "label": "Percentage of Purchase Price for Rolling Interest", "terseLabel": "Percentage of purchase price for Rolling Interest" } } }, "auth_ref": "I", "cgc_PercentageOfSharesOwnedAtConversion": { "xbrltype": "percentItem", "nsuri": "http://www.canopygrowth.com/20241231", "localname": "PercentageOfSharesOwnedAtConversion", "presentation": { "http://www.canopygrowth.com/20241231/taxonomy/role/DisclosureCanopyUsaAdditionalInformationDetails": { "lang": { "en-us": { "role": { "terseLabel": "Percentage of shares owned", "label": "Percentage Of Shares Owned At Conversion", "documentation": "Percentage of shares owned at conversion." } } }, "auth_ref": "I", "cgc_PercentageOwnershipOfWhollyOwnedSubsidiaries": { "xbrltype": "percentItem", "nsuri": "http://www.canopygrowth.com/20241231", "localname": "PercentageOwnershipOfWhollyOwnedSubsidiaries", "presentation": { "http://www.canopygrowth.com/20241231/taxonomy/role/DisclosureAcreageArrangementAdditionalInformationDetails": { "http://www.canopygrowth.com/20241231/taxonomy/role/DisclosureCanopyUsaAcreageAgreementsAdditionalInformationDetails": { "lang": { "en-us": { "role": { "documentation": "Percentage ownership of wholly owned subsidiaries.", "label": "Percentage Ownership Of Wholly Owned Subsidiaries", "terseLabel": "Percentage ownership of wholly owned subsidiaries" } } }, "auth_ref": "I", "us-gaap_PlanNameAxis": { "xbrltype": "stringItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PlanNameAxis", "presentation": { "http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureShareBasedCompensationAdditionalInformationDetails": { "lang": { "en-us": { "role": { "terseLabel": "Plan Name", "label": "Plan Name [Axis]", "documentation": "Information by plan name for share-based payment arrangement." } } }, "auth_ref": "I", "r1375", "r1376", "r1377", "r1378", "r1379", "r1380", "r1381", "r1382", "r1383", "r1384", "r1385", "r1386", "r1387", "r1388", "r1389", "r1390", "r1391", "r1392", "r1393", "r1394", "r1395", "r1396", "r1397", "r1398", "r1399", "r1400": { "us-gaap_PlanNameDomain": { "xbrltype": "domainItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PlanNameDomain", "presentation": { "http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureShareBasedCompensationAdditionalInformationDetails": { "lang": { "en-us": { "role": { "terseLabel": "Plan Name", "label": "Plan Name [Domain]", "documentation": "Plan name for share-based payment arrangement." } } }, "auth_ref": "I", "r1375", "r1376", "r1377", "r1378", "r1379", "r1380", "r1381", "r1382", "r1383", "r1384", "r1385", "r1386", "r1387", "r1388", "r1389", "r1390", "r1391", "r1392", "r1393", "r1394", "r1395", "r1396", "r1397", "r1398", "r1399", "r1400": { "ecd_PnsnAdjsPrvSvcCstMember": { "xbrltype": "domainItem", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PnsnAdjsPrvSvcCstMember", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure": { "lang": { "en-us": { "role": { "label": "Pension Adjustments Prior Service Cost [Member]", "terseLabel": "Pension Adjustments Prior Service Cost", "documentation": "Information by plan name for share-based payment arrangement." } } }, "auth_ref": "I", "r1215": { "ecd_PnsnAdjsSvcCstMember": { "xbrltype": "domainItem", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PnsnAdjsSvcCstMember", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure": { "lang": { "en-us": { "role": { "label": "Pension Adjustments Service Cost [Member]", "terseLabel": "Pension Adjustments Service Cost", "documentation": "Information by plan name for share-based payment arrangement." } } }, "auth_ref": "I", "r1259": { "ecd_PnsnBnftsAdjFnTextBlock": { "xbrltype": "textBlockItem", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PnsnBnftsAdjFnTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure": { "lang": { "en-us": { "role": { "label": "Pension Benefits Adjustments, Footnote [Text Block]", "terseLabel": "Pension Benefits Adjustments, Footnote", "documentation": "Information by plan name for share-based payment arrangement." } } }, "auth_ref": "I", "r1214": { "cgc_PrepaidDepositsCurrent": { "xbrltype": "monetaryItem", "nsuri": "http://www.canopygrowth.com/20241231", "localname": "PrepaidDepositsCurrent", "crdr": "debit", "presentation": { "http://www.canopygrowth.com/20241231/taxonomy/role/DisclosurePrepaidExpensesAndOtherAssetsComponentsOfPrepaidExpensesAndOtherAssetsDetails": { "lang": { "en-us": { "role": { "terseLabel": "Deposits", "label": "Prepaid Deposits Current", "documentation": "Prepaid deposits current." } } }, "auth_ref": "I", "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "xbrltype": "monetaryItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PrepaidExpenseAndOtherAssetsCurrent", "crdr": "debit", "presentation": { "http://www.canopygrowth.com/20241231/taxonomy/role/DisclosurePrepaidExpensesAndOtherAssetsComponentsOfPrepaidExpensesAndOtherAssetsDetails": { "http://www.canopygrowth.com/20241231/taxonomy/role/Role_StatementCondensedInterimConsolidatedBalanceSheetsUnaudited": { "lang": { "en-us": { "role": { "totalLabel": "Prepaid and other assets", "terseLabel": "Prepaid expenses and other assets", "label": "Prepaid Expense and Other Assets, Current", "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer." } } }, "auth_ref": "I", "r1287": { "us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract": { "xbrltype": "stringItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PrepaidExpenseAndOtherAssetsCurrentAbstract", "lang": { "en-us": { "role": { "label": "Prepaid Expense and Other Assets, Current [Abstract]", "documentation": "Information by plan name for share-based payment arrangement." } } }, "auth_ref": "I", "cgc_PrepaidExpenseAndOtherAssetsDisclosureTextBlock": { "xbrltype": "textBlockItem", "nsuri": "http://www.canopygrowth.com/20241231", "localname": "PrepaidExpenseAndOtherAssetsDisclosureTextBlock", "presentation": { "http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherAssets": { "lang": { "en-us": { "role": { "terseLabel": "Prepaid Expenses and Other Assets", "label": "Prepaid Expense and Other Assets Disclosure [Text Block]", "documentation": "Prepaid expense and other assets disclosure." } } }, "auth_ref": "I", "us-gaap_PrepaidExpenseCurrent": { "xbrltype": "monetaryItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PrepaidExpenseCurrent", "crdr": "debit", "presentation": { "http://www.canopygrowth.com/20241231/taxonomy/role/DisclosurePrepaidExpensesAndOtherAssetsComponentsOfPrepaidExpensesAndOtherAssetsDetails": { "lang": { "en-us": { "role": { "totalLabel": "Prepaid Expense, Current, Total", "terseLabel": "Prepaid expenses", "label": "Prepaid Expense, Current", "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer." } } }, "auth_ref": "I", "r267", "r434", "r435", "r1090": { "cgc_PrepaidInventoryCurrent": { "xbrltype": "monetaryItem", "nsuri": "http://www.canopygrowth.com/20241231", "localname": "PrepaidInventoryCurrent", "crdr": "debit", "presentation": { "http://www.canopygrowth.com/20241231/taxonomy/role/DisclosurePrepaidExpensesAndOtherAssetsComponentsOfPrepaidExpensesAndOtherAssetsDetails": { "lang": { "en-us": { "role": { "terseLabel": "Prepaid inventory", "label": "Prepaid Inventory Current", "documentation": "Prepaid inventory current." } } }, "auth_ref": "I", "cgc_PrimeRateFloorMember": { "xbrltype": "domainItem", "nsuri": "http://www.canopygrowth.com/20241231", "localname": "PrimeRateFloorMember", "presentation": { "http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails": { "lang": { "en-us": { "role": { "documentation": "Prime rate floor", "label": "Prime Rate Floor [Member]", "terseLabel": "Prime Rate Floor", "documentation": "Information by plan name for share-based payment arrangement." } } }, "auth_ref": "I", "us-gaap_PrimeRateMember": { "xbrltype": "domainItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PrimeRateMember", "presentation": { "http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails": { "lang": { "en-us": { "role": { "label": "Prime Rate [Member]", "terseLabel": "Prime Rate", "documentation": "Interest rate charged by financial institutions to their most creditworthy borrowers." } } }, "auth_ref": "I", "cgc_PrincipalAmountOfAccretionDebentures": { "xbrltype": "monetaryItem", "nsuri": "http://www.canopygrowth.com/20241231", "localname": "PrincipalAmountOfAccretionDebentures", "crdr": "credit", "presentation": { "http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails": { "lang": { "en-us": { "role": { "terseLabel": "Principal amount of accretion debentures", "label": "Principal Amount Of Accretion Debentures", "documentation": "Principal amount of accretion debentures." } } }, "auth_ref": "I", "cgc_PrincipalAmountOfNewlyIssuedUnsecuredNonInterestBearingConvertibleDebentures": { "xbrltype": "monetaryItem", "nsuri": "http://www.canopygrowth.com/20241231", "localname": "PrincipalAmountOfNewlyIssuedUnsecuredNonInterestBearingConvertibleDebentures", "crdr": "credit", "presentation": { "http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails": { "lang": { "en-us": { "role": { "terseLabel": "Principal amount of newly issued unsecured non-interest bearing convertible debentures", "label": "Principal Amount Of Newly Issued Unsecured Non-Interest Bearing Convertible Debentures", "documentation": "Principal amount of newly issued unsecured non-interest bearing convertible debentures." } } }, "auth_ref": "I", "cgc_PrincipalPaymentsOfAccretionDebentures": { "xbrltype": "monetaryItem", "nsuri": "http://www.canopygrowth.com/20241231", "localname": "PrincipalPaymentsOfAccretionDebentures", "crdr": "credit", "presentation": { "http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails": { "lang": { "en-us": { "role": { "terseLabel": "Principal payments of accretion debentures", "label": "Principal Payments Of Accretion Debentures", "documentation": "Principal payments of accretion debentures." } } }, "auth_ref": "I", "us-gaap_PrivatePlacementMember": { "xbrltype": "domainItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PrivatePlacementMember", "presentation": { "http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureShareCapitalAdditionalInformationDetails": { "lang": { "en-us": { "role": { "label": "Private Placement [Member]", "terseLabel": "Private Placement Unit Offering", "documentation": "A private placement is a direct offering of securities to a limited number of sophisticated investors such as insurance companies, pension funds, mezzanine funds, stock funds and trusts." } } }, "auth_ref": "I", "cgc_PrivatePlacementUnitOfferingCompleted": { "xbrltype": "monetaryItem", "nsuri": "http://www.canopygrowth.com/20241231", "localname": "PrivatePlacementUnitOfferingCompleted", "crdr": "credit", "presentation": { "http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureBasisOfPresentationAdditionalInformationDetails": { "lang": { "en-us": { "role": { "documentation": "Private placement unit offering completed.", "label": "Private Placement Unit Offering Completed", "terseLabel": "Private placement unit offering completed" } } }, "auth_ref": "I", "cgc_ProceedsFromCreditFacility": { "xbrltype": "monetaryItem", "nsuri": "http://www.canopygrowth.com/20241231", "localname": "ProceedsFromCreditFacility", "crdr": "debit", "presentation": { "http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails": { "lang": { "en-us": { "role": { "terseLabel": "Proceeds from the Credit Facility", "label": "Proceeds From Credit Facility", "documentation": "Proceeds from the Credit Facility." } } }, "auth_ref": "I", "us-gaap_ProceedsFromDivestitureOfBusinesses": { "xbrltype": "monetaryItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromDivestitureOfBusinesses", "crdr": "debit", "presentation": { "http://www.canopygrowth.com/20241231/taxonomy/role/DisclosureCanopyUsaSummaryOfDerecognizedAssetsAndLiabilitiesTransferredDetails": { "lang": { "en-us": { "role": { "label": "Proceeds from Divestiture of Businesses", "terseLabel": "Proceeds from divestiture of businesses", "documentation": "The cash inflow associated with the amount received from the sale of a portion of the company's business, for example a segment, division, branch or other business, during the period." } } }, "auth_ref": "I", "r36": { "us-gaap_ProceedsFromInterestReceived": { "xbrltype": "monetaryItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromInterestReceived", "crdr": "debit", "presentation": { "http://www.canopygrowth.com/20241231/taxonomy/role/Role_StatementCondensedInterimConsolidatedStatementsOfCashFlowsUnaudited": { "lang": { "en-us": { "role": { "terseLabel": "Interest", "label": "Proceeds from Interest Received", "documentation": "Interest received on loans and other debt instruments during the current period." } } }, "auth_ref": "I", "r1296": { "cgc_ProceedsFromIssuanceOfCommonSharesAndWarrants": { "xbrltype": "monetaryItem", "nsuri": "http://www.canopygrowth.com/20241231", "localname": "ProceedsFromIssuanceOfCommonSharesAndWarrants", "crdr": "debit", "presentation": { "http://www.canopygrowth.com/20241231/taxonomy/role/Role_StatementCondensedInterimConsolidatedStatementsOfCashFlowsUnaudited": { "lang": { "en-us": { "role": { "documentation": "Proceeds from issuance of common shares and warrants.", "label": "Proceeds From Issuance Of Common Shares And Warrants", "terseLabel": "Proceeds from issuance of common shares and warrants" } } }, "auth_ref": "I", "us-gaap_ProceedsFromIssuanceOfCommonStock": { "xbrltype": "monetaryItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromIssuanceOfCommonStock", "crdr": "debit", "presentation": { "http://www.canopygrowth.com/20241231/taxonomy/role/DisclosureCanopyUsaAdditionalInformationDetails": { "http://www.canopygrowth.com/20241231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails": { "http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureBasisOfPresentationAdditionalInformationDetails": { "http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureShareCapitalAdditionalInformationDetails": { "lang": { "en-us": { "role": { "label": "Proceeds from Issuance of Common Stock", "terseLabel": "Gross proceeds from common shares", "documentation": "The cash inflow from the additional capital contribution to the entity." } } }, "auth_ref": "I", "r8": { "us-gaap_ProceedsFromIssuanceOfLongTermDebt": { "xbrltype": "monetaryItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromIssuanceOfLongTermDebt", "crdr": "debit", "presentation": { "http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails": { "http://www.canopygrowth.com/20241231/taxonomy/role/Role_StatementCondensedInterimConsolidatedStatementsOfCashFlowsUnaudited": { "lang": { "en-us": { "role": {

"totalLabel": "Proceeds from Issuance of Long-Term Debt, Total", "terseLabel": "Issuance of long-term debt", "label": "Proceeds from Issuance of Long-Term Debt", "verboseLabel": "Issuance of long-term debt and convertible debentures", "documentation": "The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer." } } }, "auth_ref": { "r38", "r890" } }, "us-gaap_ProceedsFromIssuanceOfPrivatePlacement": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromIssuanceOfPrivatePlacement", "crdr": "debit", "presentation": { "http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureBasisOfPresentationAdditionalInformationDetails", "lang": { "en-us": { "role": { "label": "Proceeds from Issuance of Private Placement", "terseLabel": "Proceeds from private placement unit offering", "documentation": "The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement." } } }, "auth_ref": { "r8" } }, "us-gaap_ProceedsFromPaymentsForOtherFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromPaymentsForOtherFinancingActivities", "crdr": "debit", "presentation": { "http://www.canopygrowth.com/20241231/taxonomy/role/Role_StatementCondensedInterimConsolidatedStatementsOfCashFlowsUnaudited", "lang": { "en-us": { "role": { "terseLabel": "Other financing activities", "label": "Proceeds from (Payments for) Other Financing Activities", "documentation": "Amount of cash inflow (outflow) from financing activities classified as other." } } }, "auth_ref": { "r1268", "r1294" } }, "us-gaap_ProceedsFromSaleAndCollectionOfLoansReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromSaleAndCollectionOfLoansReceivable", "crdr": "debit", "presentation": { "http://www.canopygrowth.com/20241231/taxonomy/role/Role_StatementCondensedInterimConsolidatedStatementsOfCashFlowsUnaudited", "lang": { "en-us": { "role": { "totalLabel": "Proceeds from Sale and Collection of Loans Receivable, Total", "label": "Proceeds from Sale and Collection of Loans Receivable", "terseLabel": "Net cash inflow on loan receivable", "documentation": "The cash inflow associated with the sale and collection of loans receivables arising from the financing of goods and services." } } }, "auth_ref": { "r35" } }, "us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromSaleOfPropertyPlantAndEquipment", "crdr": "debit", "presentation": { "http://www.canopygrowth.com/20241231/taxonomy/role/Role_StatementCondensedInterimConsolidatedStatementsOfCashFlowsUnaudited", "lang": { "en-us": { "role": { "terseLabel": "Proceeds on sale of property, plant and equipment", "label": "Proceeds from Sale of Property, Plant, and Equipment", "totalLabel": "Proceeds from Sale of Property, Plant, and Equipment, Total", "documentation": "The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale." } } }, "auth_ref": { "r161" } }, "us-gaap_ProceedsFromSaleOfTreasuryStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromSaleOfTreasuryStock", "crdr": "debit", "presentation": { "http://www.canopygrowth.com/20241231/taxonomy/role/DisclosureCanopyUsaAdditionalInformationDetails", "http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureBasisOfPresentationAdditionalInformationDetails", "http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureShareCapitalAdditionalInformationDetails", "lang": { "en-us": { "role": { "label": "Proceeds from Sale of Treasury Stock", "terseLabel": "Gross proceed from sale of common stock", "documentation": "The cash inflow from the issuance of an equity stock that has been previously reacquired by the entity." } } }, "auth_ref": { "r8" } }, "us-gaap_ProceedsFromStockOptionsExercised": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromStockOptionsExercised", "crdr": "debit", "presentation": { "http://www.canopygrowth.com/20241231/taxonomy/role/Role_StatementCondensedInterimConsolidatedStatementsOfCashFlowsUnaudited", "lang": { "en-us": { "role": { "terseLabel": "Proceeds from exercise of stock options", "label": "Proceeds from Stock Options Exercised", "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement." } } }, "auth_ref": { "r8", "r24" } }, "us-gaap_ProceedsFromWarrantExercises": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromWarrantExercises", "crdr": "debit", "presentation": { "http://www.canopygrowth.com/20241231/taxonomy/role/Role_StatementCondensedInterimConsolidatedStatementsOfCashFlowsUnaudited", "lang": { "en-us": { "role": { "terseLabel": "Proceeds from exercise of warrants", "label": "Proceeds from Warrant Exercises", "documentation": "The cash inflow associated with the amount received from holders exercising their stock warrants." } } }, "auth_ref": { "r1295" } }, "srt_ProductOrServiceAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ProductOrServiceAxis", "presentation": { "http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureBasisOfPresentationAdditionalInformationDetails", "http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureRevenueSummaryOfDisaggregationOfRevenueDetails", "http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureRevenueSummaryOfDisaggregationOfRevenueParenteticalDetails", "lang": { "en-us": { "role": { "terseLabel": "Product and Service", "label": "Product and Service [Axis]", "auth_ref": { "r363", "r782", "r862", "r863", "r864", "r865", "r866", "r867", "r868", "r1086", "r1116", "r1157", "r1158", "r1159", "r1162", "r1163", "r1363", "r1364", "r1373", "r1442", "r1446", "r1447", "r1448", "r1449", "r1450", "r1451", "r1452", "r1453", "r1454", "r1455", "r1456", "r1457", "r1458", "r1459", "r1460", "r1461", "r1462", "r1463", "r1464", "r1465", "r1466", "r1467", "r1468", "r1469", "r1470", "r1471", "r1472", "r1473" } } }, "cgc_ProductionAndWarehouseEquipmentMember": { "xbrltype": "domainItemType", "nsuri": "http://www.canopygrowth.com/20241231", "localname": "ProductionAndWarehouseEquipmentMember", "presentation": { "http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosurePropertyPlantAndEquipmentScheduleOfComponentsOfPropertyPlantAndEquipmentDetails", "lang": { "en-us": { "role": { "terseLabel": "Production and Warehouse Equipment", "label": "Production and Warehouse Equipment [Member]", "documentation": "Production and warehouse equipment." } } }, "auth_ref": { "1" }, "srt_ProductsAndServicesDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ProductsAndServicesDomain", "presentation": { "http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureBasisOfPresentationAdditionalInformationDetails", "http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureRevenueSummaryOfDisaggregationOfRevenueDetails", "http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureRevenueSummaryOfDisaggregationOfRevenueParenteticalDetails", "lang": { "en-us": { "role": { "terseLabel": "Product and Service", "label": "Product and Service [Domain]", "auth_ref": { "r363", "r782", "r862", "r863", "r864", "r865", "r866", "r867", "r868", "r1086", "r1116", "r1157", "r1158", "r1159", "r1162", "r1163", "r1363", "r1364", "r1373", "r1442", "r1446", "r1447", "r1448", "r1449", "r1450", "r1451", "r1452", "r1453", "r1454", "r1455", "r1456", "r1457", "r1458", "r1459", "r1460", "r1461", "r1462", "r1463", "r1464", "r1465", "r1466", "r1467", "r1468", "r1469", "r1470", "r1471", "r1472", "r1473" } } }, "us-gaap_ProfitLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProfitLoss", "crdr": "credit", "presentation": { "http://www.canopygrowth.com/20241231/taxonomy/role/Role_StatementCondensedInterimConsolidatedStatementsOfCashFlowsUnaudited", "http://www.canopygrowth.com/20241231/taxonomy/role/StatementCondensedInterimConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited", "lang": { "en-us": { "role": { "totalLabel": "Net loss", "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest", "terseLabel": "Net loss from continuing operations", "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest." } } }, "auth_ref": { "r249", "r275", "r278", "r289", "r296", "r303", "r310", "r313", "r314", "r409", "r496", "r497", "r498", "r499", "r500", "r501", "r502", "r503", "r504", "r640", "r653", "r655", "r658", "r659", "r686", "r713", "r821", "r842", "r898", "r953", "r972", "r973", "r1133", "r1134", "r1173", "r1290", "r1366" } } }, "cgc_PromissoryNote": { "xbrltype": "monetaryItemType", "nsuri": "http://www.canopygrowth.com/20241231", "localname": "PromissoryNote", "crdr": "credit", "presentation": { "http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureBasisOfPresentationAdditionalInformationDetails", "http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureDebtSummaryOfComponentsOfDebtDetails", "lang": { "en-us": { "role": { "terseLabel": "Promissory note", "label": "Promissory Note", "documentation": "Promissory note." } } }, "auth_ref": { "1" }, "cgc_PromissoryNoteMember": { "xbrltype": "domainItemType", "nsuri": "http://www.canopygrowth.com/20241231", "localname": "PromissoryNoteMember", "presentation": { "http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureDebtSummaryOfComponentsOfDebtDetails", "lang": { "en-us": { "role": { "terseLabel": "Promissory Note", "label": "Promissory Note [Member]", "documentation": "Promissory note." } } }, "auth_ref": { "1" }, "us-gaap_PropertyPlantAndEquipmentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentAbstract", "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment [Abstract]", "auth_ref": { "1" }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentByTypeAxis", "presentation": { "http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosurePropertyPlantAndEquipmentScheduleOfComponentsOfPropertyPlantAndEquipmentDetails", "lang": { "en-us": { "role": { "terseLabel": "Long-Lived Tangible Asset", "label": "Long-Lived Tangible Asset [Axis]", "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale." } } }, "auth_ref": { "r12", "r729" } }, "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentDisclosureTextBlock", "presentation": { "http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosurePropertyPlantAndEquipment", "lang": { "en-us": { "role": { "terseLabel": "Property, Plant and Equipment", "label": "Property, Plant and Equipment Disclosure [Text Block]", "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections." } } }, "auth_ref": { "r175", "r229", "r232", "r233" } }, "us-gaap_PropertyPlantAndEquipmentGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentGross", "crdr": "debit", "presentation": { "http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosurePropertyPlantAndEquipmentScheduleOfComponentsOfPropertyPlantAndEquipmentDetails", "lang": { "en-us": { "role": { "periodEndLabel": "Property, Plant and Equipment, Gross, Ending Balance", "periodStartLabel": "Property, Plant and Equipment, Gross, Beginning Balance", "totalLabel": "Property, Plant and Equipment, Gross, Total", "terseLabel": "Property, plant and equipment, gross", "label": "Property, Plant and Equipment, Gross", "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": { "r177", "r253", "r838" } }, "us-gaap_PropertyPlantAndEquipmentLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentLineItems", "presentation": { "http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosurePropertyPlantAndEquipmentAdditionalInformationDetails", "http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosurePropertyPlantAndEquipmentScheduleOfComponentsOfPropertyPlantAndEquipmentDetails", "lang": { "en-us": { "role": { "terseLabel": "Property Plant and Equipment [Line Items]", "label": "Property, Plant and Equipment [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": { "r729" } }, "us-gaap_PropertyPlantAndEquipmentNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentNet", "crdr": "debit", "presentation": { "http://www.canopygrowth.com/20241231/taxonomy/role/DisclosureSegmentInformationSummaryOfDisaggregationOfPropertyPlantAndEquipmentByGeographicAreaDetails", "http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosurePropertyPlantAndEquipmentScheduleOfComponentsOfPropertyPlantAndEquipmentDetails", "http://www.canopygrowth.com/20241231/taxonomy/role/Role_StatementCondensedInterimConsolidatedBalanceSheetsUnaudited", "lang": { "en-us": { "role": { "totalLabel": "Property, plant and equipment, net", "terseLabel": "Property, plant and equipment", "label": "Property, Plant and Equipment, Net", "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": { "r12", "r729", "r822", "r838", "r1147" } }, "us-gaap_PropertyPlantAndEquipmentTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentTextBlock", "presentation": { "http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosurePropertyPlantAndEquipmentTables", "lang": { "en-us": { "role": { "terseLabel": "Summary of Expected Useful Life of Property, Plant and Equipment", "label": "Property, Plant and Equipment [Table Text Block]", "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated depreciation." } } }, "auth_ref": { "r12" } }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentTypeDomain", "presentation": { "http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosurePropertyPlantAndEquipmentScheduleOfComponentsOfPropertyPlantAndEquipmentDetails", "lang": { "en-us": { "role": { "terseLabel": "Long-Lived Tangible Asset", "label": "Long-Lived Tangible Asset [Domain]", "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software." } } }, "auth_ref": { "r177", "r729" } }, "cgc_PurchaseAndSaleOfAggregatePrincipalAmountOfSeniorUnsecuredConvertibleDebentures": { "xbrltype": "monetaryItemType", "nsuri": "http://www.canopygrowth.com/20241231", "localname": "PurchaseAndSaleOfAggregatePrincipalAmountOfSeniorUnsecuredConvertibleDebentures", "crdr": "credit", "presentation": { "http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails", "lang": { "en-us": { "role": { "terseLabel": "Purchase and sale of aggregate principal amount of senior unsecured convertible debentures", "label": "Purchase and sale of aggregate principal amount of senior unsecured convertible debentures", "documentation": "Purchase and sale of aggregate principal amount of senior unsecured convertible debentures." } } }, "auth_ref": { "1" } }

"cgc_PurchasedInitialAmountOfConvertibleDebentures": { "xbrltype": "monetaryItemType", "nsuri": "http://www.canopygrowth.com/20241231", "localname": "PurchasedInitialAmountOfConvertibleDebentures", "crdr": "credit", "presentation": { "http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails": { "lang": { "en-us": { "role": { "terseLabel": "Purchased initial amount of convertible debentures." } } }, "documentation": "Purchased initial amount of convertible debentures." } } }, "auth_ref": { } }, "ecd_PvpTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PvpTable", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosureTable": { "lang": { "en-us": { "role": { "label": "Pay vs Performance Disclosure [Table]", "terseLabel": "Pay vs Performance Disclosure" } } } }, "auth_ref": { "r1212" } }, "ecd_PvpTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PvpTableTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure": { "lang": { "en-us": { "role": { "label": "Pay vs Performance [Table Text Block]", "terseLabel": "Pay vs Performance Disclosure Table" } } } }, "auth_ref": { "r1212" } }, "srt_RangeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RangeAxis", "presentation": { "http://www.canopygrowth.com/20241231/taxonomy/role/DisclosureAcreegeArrangementAdditionalInformationDetails": { "http://www.canopygrowth.com/20241231/taxonomy/role/DisclosureCanopyUsaAdditionalInformationDetails": { "http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureBasisOfPresentationAdditionalInformationDetails": { "http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails": { "http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureShareBasedCompensationAdditionalInformationDetails": { "http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureShareBasedCompensationSummaryOfAssumptionsAppliedToEstablishFairValueOfOptionsGrantedUsing": { "lang": { "en-us": { "role": { "terseLabel": "Statistical Measurement", "label": "Statistical Measurement [Axis]" } } } }, "auth_ref": { "r489", "r490", "r491", "r492", "r562", "r570", "r599", "r600", "r601", "r608", "r692", "r756", "r765", "r781", "r869", "r871", "r885", "r921", "r922", "r983", "r1002", "r1007", "r1008", "r1044", "r1082", "r1083", "r1105", "r1115", "r1128", "r1139", "r1140", "r1144", "r1145", "r1158", "r1166", "r1358", "r1370", "r1415", "r1432", "r1433", "r1434", "r1435", "r1436" } } }, "srt_RangeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RangeMember", "presentation": { "http://www.canopygrowth.com/20241231/taxonomy/role/DisclosureAcreegeArrangementAdditionalInformationDetails": { "http://www.canopygrowth.com/20241231/taxonomy/role/DisclosureCanopyUsaAdditionalInformationDetails": { "http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureBasisOfPresentationAdditionalInformationDetails": { "http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails": { "http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureShareBasedCompensationAdditionalInformationDetails": { "http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureShareBasedCompensationSummaryOfAssumptionsAppliedToEstablishFairValueOfOptionsGrantedUsing": { "lang": { "en-us": { "role": { "terseLabel": "Statistical Measurement", "label": "Statistical Measurement [Domain]" } } } }, "auth_ref": { "r489", "r490", "r491", "r492", "r562", "r570", "r599", "r600", "r601", "r608", "r692", "r756", "r765", "r781", "r869", "r871", "r885", "r921", "r922", "r983", "r1002", "r1007", "r1008", "r1044", "r1082", "r1083", "r1105", "r1115", "r1128", "r1139", "r1140", "r1144", "r1145", "r1158", "r1166", "r1358", "r1370", "r1415", "r1432", "r1433", "r1434", "r1435", "r1436" } } }, "cgc_RangeOneMember": { "xbrltype": "domainItemType", "nsuri": "http://www.canopygrowth.com/20241231", "localname": "RangeOneMember", "presentation": { "http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureShareBasedCompensationSummaryOfOptionsOutstandingDetails": { "lang": { "en-us": { "role": { "terseLabel": "Range One", "label": "Range One [Member]", "documentation": "RangeOne200b one." } } } }, "auth_ref": { "cgc_RangeThreeMember": { "xbrltype": "domainItemType", "nsuri": "http://www.canopygrowth.com/20241231", "localname": "RangeThreeMember", "presentation": { "http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureShareBasedCompensationSummaryOfOptionsOutstandingDetails": { "lang": { "en-us": { "role": { "terseLabel": "Range Three", "label": "Range Three [Member]", "documentation": "RangeOne200b three." } } } }, "auth_ref": { "cgc_RangeTwoMember": { "xbrltype": "domainItemType", "nsuri": "http://www.canopygrowth.com/20241231", "localname": "RangeTwoMember", "presentation": { "http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureShareBasedCompensationSummaryOfOptionsOutstandingDetails": { "lang": { "en-us": { "role": { "terseLabel": "Range Two", "label": "Range Two [Member]", "documentation": "RangeOne200b two." } } } }, "auth_ref": { "us-gaap_ReceivablesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ReceivablesAbstract", "lang": { "en-us": { "role": { "label": "Receivables [Abstract]" } } } }, "auth_ref": { "us-gaap_ReconciliationOfOtherSignificantReconcilingItemsFromSegmentsToConsolidatedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ReconciliationOfOtherSignificantReconcilingItemsFromSegmentsToConsolidatedTextBlock", "presentation": { "http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureSegmentInformationTables": { "lang": { "en-us": { "role": { "terseLabel": "Summary of Reconciliation of Operating Profit (Loss) from Segments to Consolidated", "label": "Segment, Reconciliation of Other Items from Segments to Consolidated [Table Text Block]", "documentation": "Tabular disclosure of reconciliation of other items from reportable segments to their consolidated amount. Excludes reconciliation of revenue, profit (loss), and assets." } } } }, "auth_ref": { "r49", "r50" } }, "ecd_RecoveryOfErrCompDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RecoveryOfErrCompDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]", "terseLabel": "Recovery of Erroneously Awarded Compensation Disclosure" } } } }, "auth_ref": { "r1180", "r1190", "r1200", "r1232" } }, "cgc_RecreationalRevenueMember": { "xbrltype": "domainItemType", "nsuri": "http://www.canopygrowth.com/20241231", "localname": "RecreationalRevenueMember", "presentation": { "http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureRevenueSummaryOfDisaggregationOfRevenueParenteticalDetails": { "lang": { "en-us": { "role": { "terseLabel": "Recreational Cannabis Revenue", "label": "Recreational Revenue [Member]", "documentation": "Recreational revenue." } } } }, "auth_ref": { "cgc_RedeemableNonControllingInterestsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.canopygrowth.com/20241231", "localname": "RedeemableNonControllingInterestsMember", "presentation": { "http://www.canopygrowth.com/20241231/taxonomy/role/Role_StatementCondensedInterimConsolidatedStatementsOfShareholderSEquityUnaudited": { "lang": { "en-us": { "role": { "documentation": "Redeemable non controlling interests.", "label": "Redeemable Non Controlling Interests [Member]", "terseLabel": "Redeemable Noncontrolling Interest" } } } }, "auth_ref": { "us-gaap_RedeemableNoncontrollingInterestByLegalEntityTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RedeemableNoncontrollingInterestByLegalEntityTable", "presentation": { "http://www.canopygrowth.com/20241231/taxonomy/role/DisclosureRedeemableNoncontrollingInterestAdditionalInformationDetails": { "http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureRedeemableNoncontrollingInterestSummaryOfNetChangesInRedeemableNoncontrollingInterestsDetail": { "lang": { "en-us": { "role": { "terseLabel": "Redeemable Noncontrolling Interest By Legal Entity [Table]", "label": "Redeemable Noncontrolling Interest [Table]", "documentation": "Disclosure of information about redeemable noncontrolling interest included in statement of financial position outside of permanent equity." } } } }, "auth_ref": { "cgc_RedeemableNoncontrollingInterestChangeInRedemptionValue": { "xbrltype": "monetaryItemType", "nsuri": "http://www.canopygrowth.com/20241231", "localname": "RedeemableNoncontrollingInterestChangeInRedemptionValue", "crdr": "credit", "presentation": { "http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureRedeemableNoncontrollingInterestSummaryOfNetChangesInRedeemableNoncontrollingInterestsDetail": { "lang": { "en-us": { "role": { "terseLabel": "Adjustments to redemption amount", "label": "Redeemable Noncontrolling Interest Change In Redemption Value", "documentation": "Redeemable noncontrolling interest change in redemption value." } } } }, "auth_ref": { "us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RedeemableNoncontrollingInterestEquityCarryingAmount", "crdr": "credit", "presentation": { "http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureRedeemableNoncontrollingInterestSummaryOfNetChangesInRedeemableNoncontrollingInterestsDetail": { "lang": { "en-us": { "role": { "totalLabel": "Redeemable Noncontrolling Interest, Equity, Carrying Amount, Total", "terseLabel": "Redeemable noncontrolling interest", "periodStartLabel": "Beginning balance", "periodEndLabel": "Ending balance", "label": "Redeemable Noncontrolling Interest, Equity, Carrying Amount", "documentation": "As of the reporting date, the aggregate carrying amount of all noncontrolling interests which are redeemable by the (parent) entity (1) at a fixed or determinable price on a fixed or determinable date, (2) at the option of the holder of the noncontrolling interest, or (3) upon occurrence of an event that is not solely within the control of the (parent) entity. This item includes noncontrolling interest holder's ownership (or holders' ownership) regardless of the type of equity interest (common, preferred, other) including all potential organizational (legal) forms of the investee entity." } } } }, "auth_ref": { "r56", "r57", "r186", "r187" } }, "us-gaap_RedeemableNoncontrollingInterestLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RedeemableNoncontrollingInterestLineItems", "presentation": { "http://www.canopygrowth.com/20241231/taxonomy/role/DisclosureRedeemableNoncontrollingInterestAdditionalInformationDetails": { "http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureRedeemableNoncontrollingInterestSummaryOfNetChangesInRedeemableNoncontrollingInterestsDetail": { "lang": { "en-us": { "role": { "terseLabel": "Redeemable Noncontrolling Interest [Line Items]", "label": "Redeemable Noncontrolling Interest [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } } }, "auth_ref": { "cgc_RedeemableNoncontrollingInterestMember": { "xbrltype": "domainItemType", "nsuri": "http://www.canopygrowth.com/20241231", "localname": "RedeemableNoncontrollingInterestMember", "presentation": { "http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureRedeemableNoncontrollingInterestSummaryOfNetChangesInRedeemableNoncontrollingInterestsDetail": { "lang": { "en-us": { "role": { "terseLabel": "Redeemable Noncontrolling Interest [Member]", "label": "Redeemable Noncontrolling Interest [Member]", "documentation": "Redeemable noncontrolling interest." } } } }, "auth_ref": { "us-gaap_RedeemableNoncontrollingInterestTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RedeemableNoncontrollingInterestTableTextBlock", "presentation": { "http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureRedeemableNoncontrollingInterestTables": { "lang": { "en-us": { "role": { "terseLabel": "Summary of Net Changes in Redeemable Noncontrolling Interests", "label": "Redeemable Noncontrolling Interest [Table Text Block]", "documentation": "Tabular disclosure of redeemable noncontrolling interest (as defined) included in the statement of financial position as either a liability or temporary equity. As of the date of the statement of financial position, such redeemable noncontrolling interest is currently redeemable, as defined, for cash or other assets of the entity at (1) at a fixed or determinable price on a fixed or determinable date, (2) at the option of the holder of the noncontrolling interest, or (3) upon occurrence of an event that is not solely within the control of the entity." } } } }, "auth_ref": { "cgc_RedeemableNoncontrollingInterestTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.canopygrowth.com/20241231", "localname": "RedeemableNoncontrollingInterestTextBlock", "presentation": { "http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureRedeemableNoncontrollingInterest": { "lang": { "en-us": { "role": { "terseLabel": "Redeemable Noncontrolling Interest", "label": "Redeemable Noncontrolling Interest [Text Block]", "documentation": "Redeemable noncontrolling interest." } } } }, "auth_ref": { "cgc_RedeemptionAgreementsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.canopygrowth.com/20241231", "localname": "RedemptionAgreementsMember", "presentation": { "http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails": { "lang": { "en-us": { "role": { "terseLabel": "Redemption Agreements", "label": "Redemption Agreements [Member]", "documentation": "Redemption Agreements." } } } }, "auth_ref": { "cgc_RedemptionOfNotesAggregateCashPayment": { "xbrltype": "monetaryItemType", "nsuri": "http://www.canopygrowth.com/20241231", "localname": "RedemptionOfNotesAggregateCashPayment", "crdr": "credit", "presentation": { "http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails": { "lang": { "en-us": { "role": { "terseLabel": "Aggregate cash payment", "label": "Redemption of Notes, Aggregate Cash Payment", "documentation": "Redemption of notes, aggregate cash payment." } } } }, "auth_ref": { "cgc_ReducedLiquidityRequirement": { "xbrltype": "monetaryItemType", "nsuri": "http://www.canopygrowth.com/20241231", "localname": "ReducedLiquidityRequirement", "crdr": "debit", "presentation": { "http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails": { "lang": { "en-us": { "role": { "terseLabel": "Reduced liquidity requirement", "label": "Reduced liquidity requirement", "documentation": "Reduced liquidity requirement." } } } }, "auth_ref": { "cgc_RefundLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://www.canopygrowth.com/20241231", "localname": "RefundLiability", "crdr": "credit", "presentation": { "http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureOtherLiabilitiesComponentsOfOtherLiabilitiesDetails": { "lang": { "en-us": { "role": { "terseLabel": "Refund liability", "label": "Refund Liability", "documentation": "Refund liability." } } } }, "auth_ref": { "cgc_RefundLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.canopygrowth.com/20241231", "localname": "RefundLiabilityCurrent", "crdr": "credit", "presentation": { "http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureOtherLiabilitiesComponentsOfOtherLiabilitiesDetails": { "lang": { "en-us": { "role": { "terseLabel": "Refund liability, current", "label": "Refund Liability Current", "documentation": "Refund liability current." } } } }, "auth_ref": { "cgc_RefundLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.canopygrowth.com/20241231", "localname": "RefundLiabilityNoncurrent", "crdr": "credit", "presentation": { "http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureOtherLiabilitiesComponentsOfOtherLiabilitiesDetails": { "lang": { "en-us": { "role": { "terseLabel": "Refund liability, long-term", "label": "Refund Liability Noncurrent", "documentation": "Refund liability noncurrent." } } } }, "auth_ref": { "us-gaap_RelatedPartyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyDomain", "presentation": { "http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureGoodwillChangesInCarryingAmountOfGoodwillDetails": { "lang": { "en-us": { "role": { "terseLabel":

```

Related Party", "label": "Related and Nonrelated Parties [Domain]", "documentation": "Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest." } } }, "auth_ref": { "r370", "r569", "r736", "r737", "r828", "r836", "r924", "r925", "r926", "r927", "r928", "r949", "r951", "r979" } }, "us-gaap-RelatedPartyTransactionsByRelatedPartyAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "presentation": { "http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureGoodwillChangesInCarryingAmountOfGoodwillDetails": { "lang": { "en-us": { "role": { "terseLabel": "Related Party", "label": "Related and Nonrelated Parties [Axis]", "documentation": "Information by related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest." } } }, "auth_ref": { "r370", "r569", "r736", "r737", "r828", "r836", "r924", "r925", "r926", "r927", "r928", "r949", "r951", "r979", "r1428" } }, "cgc_RelationshipOfUnobservableInputsToFairValueDescription": { "xbrltype": "stringItemType", "nsuri": "http://www.canopygrowth.com/20241231", "localname": "RelationshipOfUnobservableInputsToFairValueDescription", "presentation": { "http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsSummaryOfValuationTechniquesAndSignificantUnobservableInputs": { "lang": { "en-us": { "role": { "terseLabel": "Relationship of Unobservable Inputs to Fair Value", "label": "Relationship of Unobservable Inputs To Fair Value Description", "documentation": "Relationship of unobservable inputs to fair value description." } } }, "auth_ref": { "cgc_RemainingInterestInAcreeagesDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://www.canopygrowth.com/20241231", "localname": "RemainingInterestInAcreeagesDebt", "credit": "presentation": { "http://www.canopygrowth.com/20241231/taxonomy/role/DisclosureCanopyUsaAcreeageAgreementsAdditionalInformationDetails": { "lang": { "en-us": { "role": { "documentation": "Remaining interest in Acreeage's 2019s debt.", "label": "Remaining Interest in Acreeage's debt", "terseLabel": "Remaining interest in Acreeage's debt" } } }, "auth_ref": { "cgc_ReorganizationAmendmentsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.canopygrowth.com/20241231", "localname": "ReorganizationAmendmentsMember", "presentation": { "http://www.canopygrowth.com/20241231/taxonomy/role/DisclosureCanopyUsaAdditionalInformationDetails": { "lang": { "en-us": { "role": { "terseLabel": "Reorganization Amendments", "label": "Reorganization Amendments [Member]", "documentation": "Reorganization Amendments." } } }, "auth_ref": { "cgc_ReorganizationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.canopygrowth.com/20241231", "localname": "ReorganizationLineItems", "presentation": { "http://www.canopygrowth.com/20241231/taxonomy/role/DisclosureCanopyUsaAcreeageAgreementsAdditionalInformationDetails": { "http://www.canopygrowth.com/20241231/taxonomy/role/DisclosureCanopyUsaAdditionalInformationDetails": { "lang": { "en-us": { "role": { "documentation": "Reorganization", "label": "Reorganization [Line Items]", "auth_ref": { "cgc_ReorganizationTable": { "xbrltype": "stringItemType", "nsuri": "http://www.canopygrowth.com/20241231", "localname": "ReorganizationTable", "presentation": { "http://www.canopygrowth.com/20241231/taxonomy/role/DisclosureCanopyUsaAcreeageAgreementsAdditionalInformationDetails": { "http://www.canopygrowth.com/20241231/taxonomy/role/DisclosureCanopyUsaAdditionalInformationDetails": { "lang": { "en-us": { "role": { "documentation": "Reorganization", "label": "Reorganization [Table]", "auth_ref": { "us-gaap-ReorganizationUnderChapter11OfUSBankruptcyCodeDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ReorganizationUnderChapter11OfUSBankruptcyCodeDisclosureTextBlock", "presentation": { "http://www.canopygrowth.com/20241231/taxonomy/role/DisclosureCanopyUsa": { "lang": { "en-us": { "role": { "label": "Reorganization under Chapter 11 of US Bankruptcy Code Disclosure [Text Block]", "terseLabel": "Canopy USA", "documentation": "The entire disclosure for the description and amounts of reorganization under Chapter 11 of the US Bankruptcy Code." } } }, "auth_ref": { "r738", "r740", "r743", "r744", "r745", "r746" } }, "us-gaap-ReorganizationsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ReorganizationsAbstract", "lang": { "en-us": { "role": { "label": "Reorganizations [Abstract]", "auth_ref": { "us-gaap-RepaymentsOfLongTermDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RepaymentsOfLongTermDebt", "credit": "presentation": { "http://www.canopygrowth.com/20241231/taxonomy/role/DisclosureCanopyUsaAdditionalInformationDetails": { "http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureBasisOfPresentationAdditionalInformationDetails": { "http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails": { "http://www.canopygrowth.com/20241231/taxonomy/role/Role_StatementCondensedInterimConsolidatedStatementsOfCashFlowsUnaudited": { "lang": { "en-us": { "role": { "totalLabel": "Repayments of Long-Term Debt, Total", "negatedLabel": "Repayment of long-term debt", "label": "Repayments of Long-Term Debt", "verboseLabel": "Repayment of debt", "terseLabel": "Mandatory prepayment of senior secured term loan facility", "documentation": "The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer." } } }, "auth_ref": { "r164", "r893" } }, "cgc-ReplacementEquityInstruments": { "xbrltype": "monetaryItemType", "nsuri": "http://www.canopygrowth.com/20241231", "localname": "ReplacementEquityInstruments", "credit": "presentation": { "http://www.canopygrowth.com/20241231/taxonomy/role/Role_StatementCondensedInterimConsolidatedStatementsOfShareholderSEquityUnaudited": { "lang": { "en-us": { "role": { "label": "Replacement equity instruments from the acquisition of Supreme Cannabis", "label": "Replacement Equity Instruments", "documentation": "Replacement equity instruments." } } }, "auth_ref": { "cgc_RestOfWorldCannabisMember": { "xbrltype": "domainItemType", "nsuri": "http://www.canopygrowth.com/20241231", "localname": "RestOfWorldCannabisMember", "presentation": { "http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureRevenueSummaryOfDisaggregationOfRevenueDetails": { "lang": { "en-us": { "role": { "terseLabel": "Rest of world Cannabis", "label": "Rest of world Cannabis [Member]", "documentation": "Rest of world Cannabis." } } }, "auth_ref": { "ecd-RestatementDateAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDateAxis", "presentation": { "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure": { "lang": { "en-us": { "role": { "label": "Restatement Determination Date [Axis]", "terseLabel": "Restatement Determination Date", "auth_ref": { "r1191", "r1191", "r1201", "r1233" } }, "ecd-RestatementDeterminationDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDeterminationDate", "presentation": { "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure": { "lang": { "en-us": { "role": { "label": "Restatement Determination Date", "terseLabel": "Restatement Determination Date", "auth_ref": { "r1192", "r1192", "r1202", "r1234" } }, "ecd-RestatementDoesNotRequireRecoveryTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDoesNotRequireRecoveryTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure": { "lang": { "en-us": { "role": { "label": "Restatement Does Not Require Recovery [Text Block]", "terseLabel": "Restatement does not require Recovery", "auth_ref": { "r1189", "r1199", "r1209", "r1241" } }, "us-gaap-RestrictedInvestmentsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestrictedInvestmentsCurrent", "credit": "debit", "presentation": { "http://www.canopygrowth.com/20241231/taxonomy/role/Role_StatementCondensedInterimConsolidatedBalanceSheetsUnaudited": { "lang": { "en-us": { "role": { "terseLabel": "Restricted short-term investments", "label": "Restricted Investments Current", "documentation": "This element represents the current portion of investments which are not defined as or included in marketable (debt, equity, or other) securities that are pledged or subject to withdrawal restrictions." } } }, "auth_ref": { "r823", "r1068", "r1069" } }, "cgc-RestrictedShortTermInvestmentsFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://www.canopygrowth.com/20241231", "localname": "RestrictedShortTermInvestmentsFairValueDisclosure", "credit": "debit", "presentation": { "http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtEstimatedFairVa": { "lang": { "en-us": { "role": { "terseLabel": "Restricted short-term investments", "label": "Restricted Short-Term Investments Fair Value Disclosure", "documentation": "Restricted Short-Term Investments Fair Value Disclosure." } } }, "auth_ref": { "us-gaap-RestrictedStockUnitsRSUMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestrictedStockUnitsRSUMember", "presentation": { "http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureShareBasedCompensationAdditionalInformationDetails": { "http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureShareBasedCompensationSummaryOfChangesInRsusAndPsusDetails": { "lang": { "en-us": { "role": { "terseLabel": "RSUs", "label": "Restricted Stock Units (RSUs) [Member]", "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met." } } }, "auth_ref": { "us-gaap-RestructuringAndRelatedActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestructuringAndRelatedActivitiesAbstract", "lang": { "en-us": { "role": { "label": "Restructuring and Related Activities [Abstract]", "auth_ref": { "us-gaap-RestructuringCostAndReserveLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestructuringCostAndReserveLineItems", "presentation": { "http://www.canopygrowth.com/20241231/taxonomy/role/DisclosureLossOnAssetImpairmentAndRestructuringAdditionalInformationDetails": { "lang": { "en-us": { "role": { "terseLabel": "Restructuring Cost And Reserve [Line Items]", "label": "Restructuring Cost and Reserve [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": { "r479", "r480", "r481", "r482", "r483", "r484", "r485" } }, "us-gaap-RetainedEarningsAccumulatedDeficit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetainedEarningsAccumulatedDeficit", "credit": "credit", "presentation": { "http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureBasisOfPresentationAdditionalInformationDetails": { "http://www.canopygrowth.com/20241231/taxonomy/role/Role_StatementCondensedInterimConsolidatedBalanceSheetsUnaudited": { "lang": { "en-us": { "role": { "totalLabel": "Retained Earnings (Accumulated Deficit), Total", "verboseLabel": "Accumulated deficit", "terseLabel": "Deficit", "label": "Retained Earnings (Accumulated Deficit)", "documentation": "Amount of accumulated undistributed earnings (deficit)." } } }, "auth_ref": { "r137", "r191", "r833", "r879", "r884", "r894", "r932", "r1147" } }, "us-gaap-RetainedEarningsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetainedEarningsMember", "presentation": { "http://www.canopygrowth.com/20241231/taxonomy/role/Role_StatementCondensedInterimConsolidatedStatementsOfShareholderSEquityUnaudited": { "lang": { "en-us": { "role": { "terseLabel": "Deficit", "label": "Retained Earnings [Member]", "documentation": "Accumulated undistributed earnings (deficit)." } } }, "auth_ref": { "r240", "r299", "r300", "r301",
```

"http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureSegmentInformationAdditionalInformationDetails"},"lang":{"en-us":{"role":{"terseLabel":"Revenue from Contract with Customer Benchmark","label":"Revenue from Contract with Customer Benchmark [Member]","documentation":"Revenue from satisfaction of performance obligation by transferring promised product and service to customer, when it serves as benchmark in concentration of risk calculation."}}},"auth_ref":{"r367","r1269"}},"us-gaap_RevenueFromContractWithCustomerTextBlock":{"xbrltype":"textBlockItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":"RevenueFromContractWithCustomerTextBlock"},"presentation":{"http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureRevenue"},"lang":{"en-us":{"role":{"terseLabel":"Revenue","label":"Revenue from Contract with Customer [Text Block]","documentation":"The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts."}}},"auth_ref":{"r236","r551","r552","r553","r554","r555","r556","r557","r558","r561"}},"us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock":{"xbrltype":"textBlockItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":"RevenueFromExternalCustomersByGeographicAreasTableTextBlock"},"presentation":{"http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureSegmentInformationTables"},"lang":{"en-us":{"role":{"terseLabel":"Summary of Disaggregation of Net Revenue by Geographic Area","label":"Revenue from External Customers by Geographic Areas [Table Text Block]","documentation":"Tabular disclosure of revenue from external customers by geographic areas attributed to the entity's country of domicile and to foreign countries from which the entity derives revenue."}}},"auth_ref":{"r172"}},"us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems":{"xbrltype":"stringItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":"RevenuesFromExternalCustomersAndLongLivedAssetsLineItems"},"presentation":{"http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureSegmentInformationSummaryOfDisaggregationOfPropertyPlantAndEquipmentByGeographicAreaDetails"},"http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureSegmentInformationSummaryOfDisaggregationOfNetRevenueByGeographicAreaDetails"},"lang":{"en-us":{"role":{"terseLabel":"Revenues From External Customers And Long Lived Assets [Line Items]","label":"Revenues from External Customers and Long Lived Assets [Line Items]","documentation":"Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."}}},"auth_ref":{"us-gaap_RevolvingCreditFacilityMember":{"xbrltype":"domainItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":"RevolvingCreditFacilityMember"},"presentation":{"http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureDebtSummaryOfComponentsOfDebtDetails"},"lang":{"en-us":{"role":{"terseLabel":"Revolving Credit Facility","label":"Revolving Credit Facility [Member]","documentation":"Arrangement in which loan proceeds can continuously be obtained following repayments, but the total amount borrowed cannot exceed a specified maximum amount."}}},"auth_ref":{"cgc_RightOfUseAssetsMember":{"xbrltype":"domainItemType","nsuri":"http://www.canopygrowth.com/20241231","localname":"RightOfUseAssetsMember"},"presentation":{"http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosurePropertyPlantAndEquipmentScheduleOfComponentsOfPropertyPlantAndEquipmentDetails"},"lang":{"en-us":{"role":{"terseLabel":"Right of Use Assets","label":"Right of Use Assets [Member]","documentation":"Right of use assets."}}},"auth_ref":{"cgc_RollingInterestPurchasePricePercentage":{"xbrltype":"percentItemType","nsuri":"http://www.canopygrowth.com/20241231","localname":"RollingInterestPurchasePricePercentage"},"presentation":{"http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureOtherFinancialAssetsAdditionalInformationDetails"},"lang":{"en-us":{"role":{"documentation":"Percentage price of rolling interest amount at which debt can be purchased."},"label":"Rolling Interest, Purchase Price, Percentage"},"terseLabel":"Purchase price of rolling interest"}}},"auth_ref":{"cgc_RollingLenderMember":{"xbrltype":"domainItemType","nsuri":"http://www.canopygrowth.com/20241231","localname":"RollingLenderMember"},"presentation":{"http://www.canopygrowth.com/20241231/taxonomy/role/DisclosureCanopyUsaAdditionalInformationDetails"},"lang":{"en-us":{"role":{"verboseLabel":"Other Lender","documentation":"Rolling Lender."},"label":"Rolling Lender [Member]"},"terseLabel":"Rolling Lender"}}},"auth_ref":{"ecd_Rule10b51ArrAdoptedFlag":{"xbrltype":"booleanItemType","nsuri":"http://xbrl.sec.gov/ecd/2024","localname":"Rule10b51ArrAdoptedFlag"},"presentation":{"http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"},"lang":{"en-us":{"role":{"label":"Rule 10b5-1 Arrangement Adopted [Flag]","terseLabel":"Rule 10b5-1 Arrangement Adopted [Flag]"},"auth_ref":{"r1250"},"ecd_Rule10b51ArrTrmndFlag":{"xbrltype":"booleanItemType","nsuri":"http://xbrl.sec.gov/ecd/2024","localname":"Rule10b51ArrTrmndFlag"},"presentation":{"http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"},"lang":{"en-us":{"role":{"label":"Rule 10b5-1 Arrangement Terminated [Flag]","terseLabel":"Rule 10b5-1 Arrangement Terminated [Flag]"},"auth_ref":{"r1250"},"us-gaap_SaleOfStockNameOfTransactionDomain":{"xbrltype":"domainItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":"SaleOfStockNameOfTransactionDomain"},"presentation":{"http://www.canopygrowth.com/20241231/taxonomy/role/DisclosureCanopyUsaAdditionalInformationDetails"},"http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureSubsequentEventsAdditionalInformationDetails"},"http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureBasisOfPresentationAdditionalInformationDetails"},"http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureShareCapitalAdditionalInformationDetails"},"http://www.canopygrowth.com/20241231/taxonomy/role/Role_StatementCondensedInterimConsolidatedStatementsOfShareholderSEquityUnaudited"},"lang":{"en-us":{"role":{"label":"Sale of Stock [Domain]","documentation":"Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement."}}},"auth_ref":{"us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction":{"xbrltype":"sharesItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":"SaleOfStockNumberOfSharesIssuedInTransaction"},"presentation":{"http://www.canopygrowth.com/20241231/taxonomy/role/DisclosureCanopyUsaAdditionalInformationDetails"},"http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureBasisOfPresentationAdditionalInformationDetails"},"http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureShareCapitalAdditionalInformationDetails"},"lang":{"en-us":{"role":{"terseLabel":"Number of common shares issued and sold","label":"Sale of Stock, Number of Shares Issued in Transaction"},"verboseLabel":"Number of units sold","documentation":"The number of shares issued or sold by the subsidiary or equity method investee per stock transaction."}}},"auth_ref":{"srt_ScenarioForecastMember":{"xbrltype":"domainItemType","nsuri":"http://fasb.org/srt/2024","localname":"ScenarioForecastMember"},"presentation":{"http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureOtherFinancialAssetsAdditionalInformationDetails"},"lang":{"en-us":{"role":{"label":"Forecast [Member]","terseLabel":"Scenario Forecast"}}},"auth_ref":{"r771","r1309"},"srt_ScenarioUnspecifiedDomain":{"xbrltype":"domainItemType","nsuri":"http://fasb.org/srt/2024","localname":"ScenarioUnspecifiedDomain"},"presentation":{"http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureOtherFinancialAssetsAdditionalInformationDetails"},"lang":{"en-us":{"role":{"label":"Scenario [Domain]"},"auth_ref":{"r315","r571","r1262","r1309"},"us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable":{"xbrltype":"stringItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":"ScheduleOfAccountsNotesLoansAndFinancingReceivableTable"},"presentation":{"http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureAmountsReceivableNetAdditionalInformationDetails"},"lang":{"en-us":{"role":{"label":"Accounts and Financing Receivables [Table]","documentation":"Disclosure of information about accounts and financing receivables. Includes, but is not limited to, amount of receivable and allowance for credit loss."}}},"auth_ref":{"r135","r141","r371","r1321"},"us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock":{"xbrltype":"textBlockItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":"ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock"},"presentation":{"http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureAmountsReceivableNetTables"},"lang":{"en-us":{"role":{"terseLabel":"Components of Amounts Receivable, Net","label":"Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block]","documentation":"Tabular disclosure of the various types of trade accounts and notes receivable and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables."}}},"auth_ref":{"r135","r141"},"us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock":{"xbrltype":"textBlockItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":"ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock"},"presentation":{"http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureOtherAccruedExpensesAndLiabilitiesTables"},"lang":{"en-us":{"role":{"terseLabel":"Components of Other Accrued Expenses and Liabilities","label":"Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]","documentation":"Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses."}}},"auth_ref":{"us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock":{"xbrltype":"textBlockItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":"ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock"},"presentation":{"http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureAccumulatedOtherComprehensiveIncomeLossTables"},"lang":{"en-us":{"role":{"terseLabel":"Accumulated Other Comprehensive Income","label":"Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]","documentation":"Tabular disclosure of the components of accumulated other comprehensive income (loss)."},"auth_ref":{"r33","r1423","r1424"},"us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionEquityInterestIssuedOrIssuableTextBlock":{"xbrltype":"textBlockItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":"ScheduleOfBusinessAcquisitionsByAcquisitionEquityInterestIssuedOrIssuableTextBlock"},"presentation":{"http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureShareCapitalTables"},"lang":{"en-us":{"role":{"terseLabel":"Summary of Issuances of Stock Other","label":"Schedule of Business Acquisitions by Acquisition, Equity Interest Issued or Issuable [Table Text Block]","documentation":"Tabular disclosure of the equity interest issued or issuable in a business acquisition (or series of individually immaterial business acquisitions) planned, initiated, or completed during the period."}}},"auth_ref":{"r197"},"us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable":{"xbrltype":"stringItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":"ScheduleOfBusinessAcquisitionsByAcquisitionTable"},"presentation":{"http://www.canopygrowth.com/20241231/taxonomy/role/DisclosureAcquisitionAdditionalInformationDetails"},"http://www.canopygrowth.com/20241231/taxonomy/role/DisclosureAcquirementAdditionalInformationDetails"},"http://www.canopygrowth.com/20241231/taxonomy/role/DisclosureAcquisitionSummaryOfConsolidatedBalanceSheetImpactAtAcquisitionOfCompanysBusinessCombinationDetail"},"lang":{"en-us":{"role":{"terseLabel":"Schedule Of Business Acquisitions By Acquisition [Table]","label":"Schedule of Business Acquisitions, by Acquisition [Table]","documentation":"Disclosure of information about business combination. Includes, but is not limited to, recognized asset and liability."}}},"auth_ref":{"r75","r77","r642"},"us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock":{"xbrltype":"textBlockItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":"ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock"},"presentation":{"http://www.canopygrowth.com/20241231/taxonomy/role/DisclosureAcquisitionTables"},"lang":{"en-us":{"role":{"label":"Schedule of Business Acquisitions, by Acquisition [Table Text Block]","terseLabel":"Summary of Consolidated Balance Sheet Impact at Acquisition of Company's Business Combination","documentation":"Tabular disclosure of a material business combination completed during the period, including background, timing, and recognized assets and liabilities. This table does not include leveraged buyouts."}}},"auth_ref":{"r75","r77"},"us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock":{"xbrltype":"textBlockItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":"ScheduleOfCashAndCashEquivalentsTableTextBlock"},"presentation":{"http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureCashAndCashEquivalentsTables"},"lang":{"en-us":{"role":{"terseLabel":"Components of Cash and Cash Equivalents","label":"Schedule of Cash and Cash Equivalents [Table Text Block]","documentation":"Tabular disclosure of the components of cash and cash equivalents."}}},"auth_ref":{"us-gaap_ScheduleOfDebtTableTextBlock":{"xbrltype":"textBlockItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":"ScheduleOfDebtTableTextBlock"},"presentation":{"http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureDebtTables"},"lang":{"en-us":{"role":{"terseLabel":"Summary of Components of Debt","label":"Schedule of Debt [Table Text Block]","documentation":"Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation."}}},"auth_ref":{"us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock":{"xbrltype":"textBlockItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":"ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock"},"presentation":{"http://www.canopygrowth.com/20241231/taxonomy/role/DisclosureBiosteelTables"},"http://www.canopygrowth.com/20241231/taxonomy/role/DisclosureCanopyUsaTables"},"lang":{"en-us":{"role":{"label":"Disposal Groups, Including Discontinued Operations [Table Text Block]","terseLabel":"Summary of Derecognized Assets and Liabilities Transferred"},"verboseLabel":"Summary of Discontinued Operations","documentation":"Tabular disclosure of information related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component."}}}}}

"auth_ref": "r13", "r25", "r30", "r103", "r109", "r110", "r111", "r112", "r113", "r118", "r120", "r121", "r181", "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "presentation": "http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureEarningsLossPerShareTables", "lang": "en-us", "role": "terseLabel": "Earnings (Loss) Per Share", "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]", "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations." }, {"auth_ref": "r1312", "srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis", "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis", "presentation": "http://www.canopygrowth.com/20241231/taxonomy/role/DisclosureBiosteelAdditionalInformationDetails", "lang": "en-us", "role": "terseLabel": "Investment, Name", "label": "Investment, Name [Axis]", "auth_ref": "r405", "r406", "r408", "r632", "r1263", "r1264", "r1265", "r1405", "r1406", "r1407", "r1408", "us-gaap_ScheduleOfEquityMethodInvestmentsLineItems", "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfEquityMethodInvestmentsLineItems", "presentation": "http://www.canopygrowth.com/20241231/taxonomy/role/DisclosureEquityMethodInvestmentsComponentsOfEquityMethodInvestmentsDetails", "lang": "en-us", "role": "label": "Schedule of Equity Method Investments [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "auth_ref": "r296", "r405", "r406", "r408", "r409", "r713", "us-gaap_ScheduleOfEquityMethodInvestmentsTable", "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfEquityMethodInvestmentsTable", "presentation": "http://www.canopygrowth.com/20241231/taxonomy/role/DisclosureEquityMethodInvestmentsComponentsOfEquityMethodInvestmentsDetails", "lang": "en-us", "role": "label": "Equity Method Investment [Table]", "documentation": "Disclosure of information about equity method investment. Includes, but is not limited to, name of investee or group of investees, percentage ownership, difference between investment and value of underlying equity in net assets.", "auth_ref": "r249", "r296", "r405", "r406", "r408", "r409", "r713", "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "presentation": "http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsTables", "lang": "en-us", "role": "terseLabel": "Summary of Financial Assets and Liabilities Measured at Estimated Fair Value on a Recurring Basis", "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]", "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).", "auth_ref": "r1412", "r1413", "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable", "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable", "presentation": "http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureIntangibleAssetsAdditionalInformationDetails", "lang": "en-us", "role": "terseLabel": "Schedule Of Finite Lived Intangible Assets [Table]", "label": "Intangible Asset, Finite-Lived [Table]", "documentation": "Disclosure of information about finite-lived intangible asset. Excludes indefinite-lived intangible asset.", "auth_ref": "r453", "r460", "r463", "r464", "r466", "r783", "r1085", "r1108", "us-gaap_ScheduleOfGoodwillTable", "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfGoodwillTable", "presentation": "http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureGoodwillAdditionalInformationDetails", "lang": "en-us", "role": "terseLabel": "Schedule Of Goodwill [Table]", "label": "Goodwill [Table]", "documentation": "Disclosure of information about goodwill, including, but not limited to, change from acquisition, sale, impairment, and other reason.", "auth_ref": "r440", "r441", "r442", "r443", "r444", "r445", "r446", "r447", "r448", "r449", "r451", "r1107", "us-gaap_ScheduleOfGoodwillTextBlock", "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfGoodwillTextBlock", "presentation": "http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureGoodwillTables", "lang": "en-us", "role": "terseLabel": "Changes in Carrying Amount of Goodwill", "label": "Schedule of Goodwill [Table Text Block]", "documentation": "Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.", "auth_ref": "r1107", "r1332", "r1333", "r1334", "r1335", "r1336", "r1337", "r1338", "r1339", "r1340", "r1341", "r1342", "us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock", "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock", "presentation": "http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureIntangibleAssetsTables", "lang": "en-us", "role": "terseLabel": "Summary of Components of Intangible Assets", "label": "Schedule of Intangible Assets and Goodwill [Table Text Block]", "documentation": "Tabular disclosure of goodwill and intangible assets, which may be broken down by segment or major class.", "auth_ref": "r1331", "r1343", "us-gaap_ScheduleOfIntangibleAssetsNetExcludingGoodwillTable", "xbrltype": "stringItemType", "nsuri": "http://www.canopygrowth.com/20241231", "localname": "ScheduleOfIntangibleAssetsNetExcludingGoodwillTable", "presentation": "http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureIntangibleAssetsSummaryOfComponentsOfIntangibleAssetsDetails", "lang": "en-us", "role": "terseLabel": "Schedule Of Intangible Assets Net Excluding Goodwill [Table]", "label": "Schedule of Intangible Assets Net Excluding Goodwill [Table]", "documentation": "Schedule of intangible assets net excluding goodwill.", "auth_ref": "r1", "us-gaap_ScheduleOfInventoryCurrentTableTextBlock", "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfInventoryCurrentTableTextBlock", "presentation": "http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureInventoryTables", "lang": "en-us", "role": "terseLabel": "Components of Inventory", "label": "Schedule of Inventory, Current [Table Text Block]", "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.", "auth_ref": "r31", "r142", "r143", "r144", "us-gaap_ScheduleOfInvestmentsAbstract", "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfInvestmentsAbstract", "lang": "en-us", "role": "label": "Schedule of Investments [Abstract]", "auth_ref": "r1", "us-gaap_ScheduleOfInvestmentsLineItems", "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfInvestmentsLineItems", "presentation": "http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureOtherFinancialAssetsAdditionalInformationDetails", "lang": "en-us", "role": "terseLabel": "Schedule Of Investments [Line Items]", "label": "Schedule of Investments [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "auth_ref": "r980", "r981", "r982", "r983", "r984", "r985", "r986", "r987", "r988", "r989", "r990", "r991", "r992", "r993", "r994", "r995", "r996", "r997", "r998", "r999", "r1000", "r1001", "r1004", "r1005", "r1006", "r1007", "r1008", "r1009", "r1010", "r1011", "r1012", "r1013", "r1014", "r1015", "r1016", "r1017", "r1018", "r1019", "r1020", "r1021", "r1022", "r1023", "r1024", "r1025", "r1026", "r1027", "r1035", "r1036", "r1037", "r1038", "r1039", "r1040", "r1041", "r1042", "r1043", "r1044", "r1045", "r1046", "r1047", "r1054", "r1055", "r1056", "r1057", "r1058", "r1059", "us-gaap_ScheduleOfInvestmentsTable", "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfInvestmentsTable", "presentation": "http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureOtherFinancialAssetsAdditionalInformationDetails", "lang": "en-us", "role": "terseLabel": "Schedule Of Investments [Table]", "label": "Schedule of Investments [Table]", "documentation": "Disclosure of information about investments owned by investment company.", "auth_ref": "r980", "r981", "r982", "r983", "r984", "r985", "r986", "r987", "r988", "r989", "r990", "r991", "r992", "r993", "r994", "r995", "r996", "r997", "r998", "r999", "r1000", "r1001", "r1004", "r1005", "r1006", "r1007", "r1008", "r1009", "r1010", "r1011", "r1012", "r1013", "r1014", "r1015", "r1016", "r1017", "r1018", "r1019", "r1020", "r1021", "r1022", "r1023", "r1024", "r1025", "r1026", "r1027", "r1035", "r1036", "r1037", "r1038", "r1039", "r1040", "r1041", "r1042", "r1043", "r1044", "r1045", "r1046", "r1047", "r1054", "r1055", "r1056", "r1057", "r1058", "r1059", "us-gaap_ScheduleOfOtherFinancialAssetsTableTextBlock", "xbrltype": "textBlockItemType", "nsuri": "http://www.canopygrowth.com/20241231", "localname": "ScheduleOfOtherFinancialAssetsTableTextBlock", "presentation": "http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureOtherFinancialAssetsTables", "lang": "en-us", "role": "terseLabel": "Summary of Changes in Other Financial Assets", "label": "Schedule Of Other Financial Assets [Table Text Block]", "documentation": "Schedule of other financial assets.", "auth_ref": "r1", "us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock", "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock", "presentation": "http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureOtherIncomeExpenseNetTables", "lang": "en-us", "role": "terseLabel": "Schedule of Other Income (Expense) Net", "label": "Schedule of Other Nonoperating Income (Expense) [Table Text Block]", "documentation": "Tabular disclosure of the components of non-operating income or non-operating expense that may include amounts earned from dividends, interest on securities, gains (losses) on securities sold, equity earnings of unconsolidated affiliates, net gain (loss) on

```
"http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureShareBasedCompensationSummaryOfAssumptionsAppliedToEstablishFairValueOfOptionsGranted/using",  
"http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureShareBasedCompensationSummaryOfChangesInRusAndPssDetails"}], "lang": {"en-us": {"role": {"terseLabel": "Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]", "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]", "documentation": "Disclosure of information about share-based payment arrangement." } } }, "auth_ref": {"r573": "r575", "r577", "r578", "r579", "r580", "r581", "r582", "r583", "r584", "r585", "r586", "r587", "r588", "r589", "r590", "r591", "r592", "r593", "r594", "r595", "r596", "r597", "r598", "r599", "r600", "r601", "r602"}}, "us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock": {"xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock", "presentation": [{"http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureShareBasedCompensationTables"}, {"lang": {"en-us": {"role": {"terseLabel": "Summary of Changes in RSUs and PSUs", "label": "Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]", "documentation": "Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year." } } } ], "auth_ref": {"r193"}}, {"us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable": {"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable", "presentation": [{"http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureShareBasedCompensationSummaryOfOptionsOutstandingDetails"}, {"lang": {"en-us": {"role": {"terseLabel": "Schedule Of Share Based Compensation Shares Authorized Under Stock Option Plans By Exercise Price Range [Table]", "label": "Share-Based Payment Arrangement, Option, Exercise Price Range [Table]", "documentation": "Disclosure of information about share-based payment arrangement by range of exercise prices." } } } ], "auth_ref": {"r70"}}, {"us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTableTextBlock": {"xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTableTextBlock", "presentation": [{"http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureShareBasedCompensationTables"}, {"lang": {"en-us": {"role": {"terseLabel": "Summary of Options Outstanding", "label": "Share-Based Payment Arrangement, Option, Exercise Price Range [Table Text Block]", "documentation": "Tabular disclosure of option exercise prices, by grouped ranges, including the upper and lower limits of the price range, the number of shares under option, weighted average exercise price and remaining contractual option terms." } } } ], "auth_ref": {"r70"}}, {"us-gaap_ScheduleOfShortTermInvestmentsTableTextBlock": {"xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShortTermInvestmentsTableTextBlock", "presentation": [{"http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureShareBasedCompensationTables"}, {"lang": {"en-us": {"role": {"terseLabel": "Summary of Changes in Options Outstanding", "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]", "documentation": "Tabular disclosure for stock option plans, includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value." } } } ], "auth_ref": {"r21", "r22", "r193"}}, {"us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTableTextBlock": {"xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfStockholdersEquityNoteWarrantsOrRightsTableTextBlock", "presentation": [{"http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureShareBasedCompensationTables"}, {"lang": {"en-us": {"role": {"terseLabel": "Summary of Assumptions Applied to Establish Fair Value of Options Granted Using Black-Scholes Option Pricing Model", "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]", "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions." } } } ], "auth_ref": {"r195"}}, {"cgc_ScheduleOfShortTermInvestmentsTableTextBlock": {"xbrltype": "textBlockItemType", "nsuri": "http://www.canopygrowth.com/20241231", "localname": "ScheduleOfShortTermInvestmentsTableTextBlock", "presentation": [{"http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureShortTermInvestmentsTables"}, {"lang": {"en-us": {"role": {"terseLabel": "Components of Short-term Investments", "label": "Schedule Of Short Term Investments Table [Table Text Block]", "documentation": "Schedule of short term investments." } } } ], "auth_ref": {}}, {"us-gaap_ScheduleOfStockByClassTable": {"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfStockByClassTable", "presentation": [{"http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureShareCapitalAdditionalInformationDetails"}, {"lang": {"en-us": {"role": {"label": "Stock, Class of Stock [Table]", "documentation": "Disclosure of information about stock by class. Includes, but is not limited to, common, convertible, and preferred stocks." } } } ], "auth_ref": {"r58", "r59", "r60", "r61", "r62", "r63", "r185", "r189", "r190", "r191", "r261", "r262", "r263", "r331", "r534", "r535", "r536", "r538", "r541", "r546", "r548", "r890", "r891", "r892", "r893", "r1115", "r1261", "r1302"}}, {"us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTableTextBlock": {"xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfStockholdersEquityNoteWarrantsOrRightsTableTextBlock", "presentation": [{"http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureShareCapitalTables"}, {"lang": {"en-us": {"role": {"terseLabel": "Summary of Warrants", "label": "Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]", "documentation": "Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable." } } } ], "auth_ref": {"r69"}}, {"cgc_SecondAmendedAndRestatedInvestorRightsAgreementAndConsentAgreementMember": {"xbrltype": "domainItemType", "nsuri": "http://www.canopygrowth.com/20241231", "localname": "SecondAmendedAndRestatedInvestorRightsAgreementAndConsentAgreementMember", "presentation": [{"http://www.canopygrowth.com/20241231/taxonomy/role/DisclosureAcreegeArrangementAdditionalInformationDetails"}, {"lang": {"en-us": {"role": {"terseLabel": "Second Amended and Restated Investor Rights Agreement and Consent Agreement", "label": "Second Amended And Restated Investor Rights Agreement And Consent Agreement [Member]", "documentation": "Second amended and restated investor rights agreement and consent agreement." } } } ], "auth_ref": {}}, {"cgc_SecondQuarterTwoThousandAndTwentyFivePaydownsMember": {"xbrltype": "domainItemType", "nsuri": "http://www.canopygrowth.com/20241231", "localname": "SecondQuarterTwoThousandAndTwentyFivePaydownsMember", "presentation": [{"http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails"}, {"lang": {"en-us": {"role": {"terseLabel": "Second Quarter 2025 Paydown", "label": "Second Quarter Two Thousand And Twenty Five Paydowns [Member]", "documentation": "Second quarter two thousand and twenty five paydowns." } } } ], "auth_ref": {}}, {"cgc_SecondQuarterTwoThousandAndTwentyFourPaydownsMember": {"xbrltype": "domainItemType", "nsuri": "http://www.canopygrowth.com/20241231", "localname": "SecondQuarterTwoThousandAndTwentyFourPaydownsMember", "presentation": [{"http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails"}, {"lang": {"en-us": {"role": {"terseLabel": "Second Quarter 2024 Paydowns", "label": "Second Quarter Two Thousand And Twenty Four Paydowns [Member]", "documentation": "Second quarter two thousand and twenty four paydowns." } } } ], "auth_ref": {}}, {"cgc_SecondQuarterTwoThousandAndTwentyThreePaydownsMember": {"xbrltype": "domainItemType", "nsuri": "http://www.canopygrowth.com/20241231", "localname": "SecondQuarterTwoThousandAndTwentyThreePaydownsMember", "presentation": [{"http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails"}, {"lang": {"en-us": {"role": {"documentation": "Second quarter two thousand and twenty three pay downs.", "label": "Second Quarter Two Thousand And Twenty Three Pay Downs [Member]", "terseLabel": "Second Quarter 2023 Paydowns"} } } ], "auth_ref": {}}, {"us-gaap_SecuredOvernightFinancingRateSoftOvernightIndexSwapRateMember": {"xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SecuredOvernightFinancingRateSoftOvernightIndexSwapRateMember", "presentation": [{"http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails"}, {"lang": {"en-us": {"role": {"label": "Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate [Member]", "terseLabel": "SOFR Plus", "documentation": "Fixed rate on U.S. dollar, constant-notional interest rate swap that has its variable-rate leg referenced to Secured Overnight Financing Rate (SOFR) with no additional spread over SOFR on variable-rate leg." } } } ], "auth_ref": {"r1409"}}, {"cgc_SecuredOvernightFinancingRateSoftOvernightindexSwapAdjustedFloorRateMember": {"xbrltype": "domainItemType", "nsuri": "http://www.canopygrowth.com/20241231", "localname": "SecuredOvernightFinancingRateSoftOvernightindexSwapAdjustedFloorRateMember", "presentation": [{"http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails"}, {"lang": {"en-us": {"role": {"documentation": "SOFR Floor", "label": "Secured Overnight Financing Rate Soft Overnight Index Swap Floor Rate [Member]", "terseLabel": "SOFR Adjusted Floor"} } } ], "auth_ref": {}}, {"cgc_SecuredOvernightFinancingRateSoftOvernightindexSwapFloorRateMember": {"xbrltype": "domainItemType", "nsuri": "http://www.canopygrowth.com/20241231", "localname": "SecuredOvernightFinancingRateSoftOvernightindexSwapFloorRateMember", "presentation": [{"http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails"}, {"lang": {"en-us": {"role": {"documentation": "SOFR Prime", "label": "Secured Overnight Financing Rate Soft Overnight Index Swap Prime Rate [Member]", "terseLabel": "SOFR Prime"} } } ], "auth_ref": {}}, {"dei_Security12bTitle": {"xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Security12bTitle", "presentation": [{"http://www.canopygrowth.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"}, {"lang": {"en-us": {"role": {"terseLabel": "Title of 12(b) Security", "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } } ], "auth_ref": {"r1175"}}, {"dei_SecurityExchangeName": {"xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SecurityExchangeName", "presentation": [{"http://www.canopygrowth.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"}, {"lang": {"en-us": {"role": {"terseLabel": "Security Exchange Name", "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } } ], "auth_ref": {"r1177"}}, {"us-gaap_SegmentDomain": {"xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SegmentDomain", "presentation": [{"http://www.canopygrowth.com/20241231/taxonomy/role/DisclosureLossOnAssetImpairmentAndRestructuringAdditionalInformationDetails"}, {"http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureGoodwillAdditionalInformationDetails"}, {"http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureRevenueSummaryOfDisaggregationOfRevenueDetails"}, {"http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureRevenueSummaryOfDisaggregationOfRevenueParenteticalDetails"}, {"http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureSegmentInformationSummaryOfReconciliationOfOperatingProfit/LossFromSegmentsToConsolidatedTotal"}, {"lang": {"en-us": {"role": {"terseLabel": "Segments", "label": "Segments [Domain]", "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other
```

"r1473"}], "us-gaap_SegmentReportingAbstract": {"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SegmentReportingAbstract", "lang": {"en-us": {"role": {"label": "Segment Reporting [Abstract]"}}, "auth_ref": []}, "us-gaap_SegmentReportingDisclosureTextBlock": {"xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SegmentReportingDisclosureTextBlock", "presentation": [{"http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureSegmentInformation"}], "lang": {"en-us": {"role": {"terseLabel": "Segment Information", "label": "Segment Reporting Disclosure [Text Block]"}, "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments."}}, "auth_ref": [{"r224", "r329", "r333", "r334", "r335", "r336", "r337", "r350", "r352", "r353", "r358", "r359", "r360", "r361", "r362", "r363", "r364", "r367", "r1096", "r1098", "r1099", "r1100", "r1102", "r1103", "r1104"}], "us-gaap_SegmentReportingInformationLineItems": {"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SegmentReportingInformationLineItems", "presentation": [{"http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureSegmentInformationAdditionalInformationDetails"}], "lang": {"en-us": {"role": {"terseLabel": "Segment Reporting Information [Line Items]", "label": "Segment Reporting Information [Line Items]"}, "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."}}, "auth_ref": []}, "us-gaap_SellingGeneralAndAdministrativeExpense": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SellingGeneralAndAdministrativeExpense", "crdr": "debit", "presentation": [{"http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureSegmentInformationSummaryOfReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedDel"}, {"http://www.canopygrowth.com/20241231/taxonomy/role/StatementCondensedInterimConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited"}], "lang": {"en-us": {"role": {"totalLabel": "Selling, General and Administrative Expense, Total", "terseLabel": "Selling, general and administrative expenses", "label": "Selling, General and Administrative Expense", "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc."}}, "auth_ref": [{"r159}], "us-gaap_SellingGeneralAndAdministrativeExpensesMember": {"xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SellingGeneralAndAdministrativeExpensesMember", "presentation": [{"http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureIntangibleAssetsAdditionalInformationDetails"}], "lang": {"en-us": {"role": {"terseLabel": "Selling, General and Administrative Expenses", "label": "Selling, General and Administrative Expenses [Member]"}, "documentation": "Primary financial statement caption encompassing selling, general and administrative expense."}}, "auth_ref": []}, "us-gaap_SeniorNotes": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SeniorNotes", "crdr": "credit", "presentation": [{"http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureDebtSummaryOfComponentsOfDebtDetails"}], "lang": {"en-us": {"role": {"label": "Senior Notes", "totalLabel": "Senior Notes, Total", "documentation": "Including the current and noncurrent portions, carrying value as of the balance sheet date of Notes with the highest claim on the assets of the issuer in case of bankruptcy or liquidation (with maturities initially due after one year or beyond the operating cycle if longer). Senior note holders are paid off in full before any payments are made to junior note holders."}}, "auth_ref": [{"r209", "r1438"}], "cgc_SeniorSecuredTermLoanFacilityMember": {"xbrltype": "domainItemType", "nsuri": "http://www.canopygrowth.com/20241231", "localname": "SeniorSecuredTermLoanFacilityMember", "presentation": [{"http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureBasisOfPresentationAdditionalInformationDetails"}], "lang": {"en-us": {"role": {"terseLabel": "Senior Secured Term Loan Facility", "label": "Senior Secured Term Loan Facility [Member]"}, "documentation": "Senior secured term loan facility."}}, "auth_ref": []}, "cgc_SeniorUnsecuredConvertibleDebentureMember": {"xbrltype": "domainItemType", "nsuri": "http://www.canopygrowth.com/20241231", "localname": "SeniorUnsecuredConvertibleDebentureMember", "presentation": [{"http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureBasisOfPresentationAdditionalInformationDetails"}], "lang": {"en-us": {"role": {"documentation": "Senior Unsecured Convertible Debenture", "label": "Senior Unsecured Convertible Debenture [Member]"}}, "auth_ref": []}, "cgc_SettlementLiabilitiesAndOther": {"xbrltype": "monetaryItemType", "nsuri": "http://www.canopygrowth.com/20241231", "localname": "SettlementLiabilitiesAndOther", "crdr": "credit", "presentation": [{"http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureOtherLiabilitiesComponentsOfOtherLiabilitiesDetails"}], "lang": {"en-us": {"role": {"terseLabel": "Settlement liabilities and other", "label": "Settlement Liabilities And Other", "documentation": "Settlement liabilities and other."}}, "auth_ref": []}, "cgc_SettlementLiabilitiesAndOtherCurrent": {"xbrltype": "monetaryItemType", "nsuri": "http://www.canopygrowth.com/20241231", "localname": "SettlementLiabilitiesAndOtherCurrent", "crdr": "credit", "presentation": [{"http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureOtherLiabilitiesComponentsOfOtherLiabilitiesDetails"}], "lang": {"en-us": {"role": {"terseLabel": "Settlement liabilities and other, current", "label": "Settlement Liabilities And Other Current", "documentation": "Settlement liabilities and other current."}}, "auth_ref": [{"r159}], "cgc_SettlementLiabilitiesAndOtherNonCurrent": {"xbrltype": "monetaryItemType", "nsuri": "http://www.canopygrowth.com/20241231", "localname": "SettlementLiabilitiesAndOtherNonCurrent", "crdr": "credit", "presentation": [{"http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureOtherLiabilitiesComponentsOfOtherLiabilitiesDetails"}], "lang": {"en-us": {"role": {"terseLabel": "Settlement liabilities and other, long term", "label": "Settlement Liabilities And Other Non Current", "documentation": "Settlement liabilities and other noncurrent."}}, "auth_ref": []}, "cgc_SettlementOfAcreageAcquisitionMember": {"xbrltype": "domainItemType", "nsuri": "http://www.canopygrowth.com/20241231", "localname": "SettlementOfAcreageAcquisitionMember", "presentation": [{"http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureShareCapitalSummaryOfIssuancesOfStockOtherDetails"}], "lang": {"en-us": {"role": {"label": "Settlement of Acreage Acquisition [Member]"}, "documentation": "Settlement of acreage acquisition."}}, "auth_ref": []}, "cgc_SettlementOfCanopyNotesMember": {"xbrltype": "domainItemType", "nsuri": "http://www.canopygrowth.com/20241231", "localname": "SettlementOfCanopyNotesMember", "presentation": [{"http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureShareCapitalSummaryOfIssuancesOfStockOtherDetails"}], "lang": {"en-us": {"role": {"documentation": "Settlement of canopy notes", "label": "Settlement of Canopy Notes [Member]"}, "terseLabel": "Settlement of Canopy Notes [Member]"}}, "auth_ref": []}, "cgc_SettlementOfConvertibleDebenturesMember": {"xbrltype": "domainItemType", "nsuri": "http://www.canopygrowth.com/20241231", "localname": "SettlementOfConvertibleDebenturesMember", "presentation": [{"http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureShareCapitalSummaryOfIssuancesOfStockOtherDetails"}], "lang": {"en-us": {"role": {"label": "Settlement of convertible debentures [Member]"}, "documentation": "Settlement of convertible debentures."}, "terseLabel": "Settlement of Convertible Debentures [Member]"}}, "auth_ref": []}, "cgc_SettlementOfDebenturesMember": {"xbrltype": "domainItemType", "nsuri": "http://www.canopygrowth.com/20241231", "localname": "SettlementOfDebenturesMember", "presentation": [{"http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureShareCapitalSummaryOfIssuancesOfStockOtherDetails"}], "lang": {"en-us": {"role": {"label": "Settlement of Debentures [Member]"}, "documentation": "Settlement of debentures."}}, "auth_ref": []}, "us-gaap_ShareBasedCompensation": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensation", "crdr": "debit", "presentation": [{"http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureNoncontrollingInterestsSummaryOfNetChangeInNoncontrollingInterestsDetails"}, {"http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureSegmentInformationSummaryOfReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedDel"}, {"http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureShareBasedCompensationAdditionalInformationDetails"}], "lang": {"en-us": {"role": {"totalLabel": "Share-Based Payment Arrangement, Noncash Expense, Total", "terseLabel": "Share-based compensation", "label": "Share-Based Payment Arrangement, Noncash Expense", "documentation": "Amount of noncash expense for share-based payment arrangement."}}, "auth_ref": [{"r10}], "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod": {"xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod", "presentation": [{"http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureShareBasedCompensationAdditionalInformationDetails"}], "lang": {"en-us": {"role": {"terseLabel": "Vesting period", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period", "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition."}}, "auth_ref": [{"r1129}], "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {"xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod", "presentation": [{"http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureShareBasedCompensationSummaryOfChangesInRsusAndPsusDetails"}], "lang": {"en-us": {"role": {"negatedLabel": "RSUs and PSUs cancelled and forfeited", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period", "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period."}}, "auth_ref": [{"r593}], "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {"xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "presentation": [{"http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureShareBasedCompensationSummaryOfChangesInRsusAndPsusDetails"}], "lang": {"en-us": {"role": {"terseLabel": "RSUs and PSUs granted", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period", "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."}}, "auth_ref": [{"r591}], "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {"xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "presentation": [{"http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureShareBasedCompensationSummaryOfChangesInRsusAndPsusDetails"}], "lang": {"en-us": {"role": {"periodStartLabel": "Beginning balance", "periodEndLabel": "Ending balance", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number", "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date."}}, "auth_ref": [{"r588", "r589"}], "cgc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReplacementRSUsIssuedResultingFromTheAcreageAcquisition": {"xbrltype": "sharesItemType", "nsuri": "http://www.canopygrowth.com/20241231", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReplacementRSUsIssuedResultingFromTheAcreageAcquisition", "presentation": [{"http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureShareBasedCompensationSummaryOfChangesInRsusAndPsusDetails"}], "lang": {"en-us": {"role": {"label": "Share-Based Compensation Arrangement By Share-Based Payment Award Equity Instruments Other Than Options Replacement RSUs Issued Resulting From The Acreage Acquisition", "documentation": "Share based compensation arrangement by share based payment award equity instruments other than options replacement RSUs issued resulting from the acreage acquisition."}, "terseLabel": "Replacement RSUs issued resulting from the Acreage Acquisition"}}, "auth_ref": []}, "cgc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReplacementRSUsIssuedResultingFromTheAcreageTransaction": {"xbrltype": "sharesItemType", "nsuri": "http://www.canopygrowth.com/20241231", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReplacementRSUsIssuedResultingFromTheAcreageTransaction", "presentation": [{"http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureShareBasedCompensationSummaryOfChangesInRsusAndPsusDetails"}], "lang": {"en-us": {"role": {"label": "Share-Based Compensation Arrangement By Share-Based Payment Award Equity Instruments Other Than Options Replacement RSUs Issued Resulting From The Acreage Transaction", "documentation": "Share based compensation arrangement by share based payment award equity instruments other than options replacement rsus issued resulting from the acreage transaction."}, "terseLabel": "Replacement RSUs issued resulting from the Acreage Transaction"}}, "auth_ref": []}, "us-

gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"-{"xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"}, {"presentation": {"http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureShareBasedCompensationSummaryOfChangesInRsusAndPsusDetails"}}, {"lang": {"en-us": {"role": {"negatedLabel": "RSUs and PSUs released", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period", "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period."}}}, {"auth_ref": {"r592"}}, {"us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {"xbrltype": {"percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"}, {"presentation": {"http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureShareBasedCompensationSummaryOfAssumptionsAppliedToEstablishFairValueOfOptionsGrantedUsing"}}, {"lang": {"en-us": {"role": {"terseLabel": "Expected dividend yield", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate", "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term."}}}, {"auth_ref": {"r600"}}, {"cgc_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate": {"xbrltype": {"percentItemType", "nsuri": "http://www.canopygrowth.com/20241231", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate"}, {"presentation": {"http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureShareBasedCompensationSummaryOfAssumptionsAppliedToEstablishFairValueOfOptionsGrantedUsing"}}, {"lang": {"en-us": {"role": {"terseLabel": "Expected forfeiture rate", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Forfeiture Rate", "documentation": "Share-based compensation arrangement by share-based payment award fair value assumptions expected forfeiture rate."}}}, {"auth_ref": {"r601"}}, {"us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {"xbrltype": {"percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"}, {"presentation": {"http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureShareBasedCompensationSummaryOfAssumptionsAppliedToEstablishFairValueOfOptionsGrantedUsing"}}, {"lang": {"en-us": {"role": {"terseLabel": "Expected volatility", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate", "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."}}}, {"auth_ref": {"r599"}}, {"us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {"xbrltype": {"percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"}, {"presentation": {"http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureShareBasedCompensationSummaryOfAssumptionsAppliedToEstablishFairValueOfOptionsGrantedUsing"}}, {"lang": {"en-us": {"role": {"terseLabel": "Risk-free interest rate", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate", "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares."}}}, {"auth_ref": {"r601"}}, {"us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {"xbrltype": {"stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"}, {"presentation": {"http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureShareBasedCompensationAdditionalInformationDetails"}, {"http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureShareBasedCompensationSummaryOfAssumptionsAppliedToEstablishFairValueOfOptionsGrantedUsing"}}, {"http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureShareBasedCompensationSummaryOfChangesInRsusAndPsusDetails"}}, {"lang": {"en-us": {"role": {"terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."}}}, {"auth_ref": {"r573", "r575", "r577", "r578", "r579", "r580", "r581", "r582", "r583", "r584", "r585", "r586", "r587", "r588", "r589", "r590", "r591", "r592", "r593", "r594", "r595", "r596", "r597", "r598", "r599", "r600", "r601"}}, {"us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {"xbrltype": {"sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"}, {"presentation": {"http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureShareBasedCompensationAdditionalInformationDetails"}}, {"lang": {"en-us": {"role": {"terseLabel": "Aggregate number of common shares authorized", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized", "documentation": "Number of shares authorized for issuance under share-based payment arrangement."}}}, {"auth_ref": {"r1131"}}, {"us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {"xbrltype": {"sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"}, {"presentation": {"http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureShareBasedCompensationAdditionalInformationDetails"}}, {"lang": {"en-us": {"role": {"label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant", "terseLabel": "Number of common shares reserved for issuance upon exercise or vesting of Awards", "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable."}}}, {"auth_ref": {"r70"}}, {"cgc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionVestingDateDescription": {"xbrltype": {"stringItemType", "nsuri": "http://www.canopygrowth.com/20241231", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionVestingDateDescription"}, {"presentation": {"http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureShareBasedCompensationAdditionalInformationDetails"}}, {"lang": {"en-us": {"role": {"terseLabel": "Vesting date description", "label": "Share-based Compensation Arrangement by Share-based Payment Award Option Vesting Date Description", "documentation": "Share-based Compensation Arrangement by Share-based Payment Award Option Vesting Date Description"}}, {"auth_ref": {"r598"}}, {"us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {"xbrltype": {"sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"}, {"presentation": {"http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureShareBasedCompensationSummaryOfOptionsOutstandingDetails"}}, {"lang": {"en-us": {"role": {"terseLabel": "Options Exercisable", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number", "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan."}}}, {"auth_ref": {"r582"}}, {"us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {"xbrltype": {"perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"}, {"presentation": {"http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureShareBasedCompensationAdditionalInformationDetails"}}, {"lang": {"en-us": {"role": {"verboseLabel": "Weighted average exercise price of options exercisable", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price", "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan."}}}, {"auth_ref": {"r582"}}, {"us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod": {"xbrltype": {"sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"}, {"presentation": {"http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureShareBasedCompensationSummaryOfChangesInOptionsOutstandingDetails"}}, {"lang": {"en-us": {"role": {"negatedLabel": "Options expired/forfeited", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period", "totalLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Total", "documentation": "For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired."}}}, {"auth_ref": {"r1381"}}, {"us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice": {"xbrltype": {"perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"}, {"presentation": {"http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureShareBasedCompensationSummaryOfChangesInOptionsOutstandingDetails"}}, {"lang": {"en-us": {"role": {"terseLabel": "Weighted average exercise price, Options expired/forfeited", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price", "documentation": "Weighted average price of options that were either forfeited or expired."}}}, {"auth_ref": {"r1381"}}, {"us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {"xbrltype": {"sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"}, {"presentation": {"http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureShareBasedCompensationSummaryOfChangesInOptionsOutstandingDetails"}}, {"lang": {"en-us": {"role": {"terseLabel": "Options granted", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross", "documentation": "Gross number of share options (or share units) granted during the period."}}}, {"auth_ref": {"r584"}}, {"us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {"xbrltype": {"perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"}, {"presentation": {"http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureShareBasedCompensationSummaryOfAssumptionsAppliedToEstablishFairValueOfOptionsGrantedUsing"}}, {"lang": {"en-us": {"role": {"terseLabel": "Black-Scholes value of each option", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value", "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology."}}}, {"auth_ref": {"r594"}}, {"us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {"xbrltype": {"sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"}, {"presentation": {"http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureShareBasedCompensationAdditionalInformationDetails"}, {"http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureShareBasedCompensationSummaryOfChangesInOptionsOutstandingDetails"}, {"http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureShareBasedCompensationSummaryOfOptionsOutstandingDetails"}}, {"lang": {"en-us": {"role": {"verboseLabel": "Stock options outstanding", "terseLabel": "Options Outstanding", "periodStartLabel": "Options outstanding, beginning balance", "periodEndLabel": "Options outstanding, ending balance", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number", "documentation": "Number of options outstanding, including both vested and non-vested options."}}}, {"auth_ref": {"r580", "r581"}}, {"us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {"xbrltype": {"perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"}, {"presentation": {"http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureShareBasedCompensationAdditionalInformationDetails"}, {"http://

"nsuri": "http://www.canopygrowth.com/20241231", "localname":
"ShareBasedCompensationArrangementByShareBasedPaymentAwardReplacementOptionsIssuedResultingFromTheAcreageAcquisition", "presentation":-
"http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureShareBasedCompensationSummaryOfChangesInOptionsOutstandingDetails", "lang": { "en-us": {
"role": { "terseLabel": "Replacement options issued resulting from the Acreage Acquisition", "label": "Share Based Compensation Arrangement By Share Based Payment Award
Replacement Options Issued Resulting From The Acreage Acquisition", "documentation": "Share based compensation arrangement by share based payment award
replacement options issued resulting from the acreage acquisition." } } }, "auth_ref": { } },
"cgc_ShareBasedCompensationArrangementByShareBasedPaymentAwardReplacementOptionsIssuedResultingFromTheAcreageAcquisitionWeightedAverageExercisePrice":-
"xbrltype": "perShareItemType", "nsuri": "http://www.canopygrowth.com/20241231", "localname":
"ShareBasedCompensationArrangementByShareBasedPaymentAwardReplacementOptionsIssuedResultingFromTheAcreageAcquisitionWeightedAverageExercisePrice",
"presentation":- "http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureShareBasedCompensationSummaryOfChangesInOptionsOutstandingDetails",
"lang": { "en-us": { "role": { "label": "Share Based Compensation Arrangement By Share Based Payment Award Replacement Options Issued Resulting From The Acreage
Acquisition Weighted Average Exercise Price", "documentation": "Share based compensation arrangement by share based payment award replacement options issued resulting
from the acreage acquisition weighted average exercise price.", "terseLabel": "Weighted average exercise price, Replacement options issued resulting from the Acreage
Acquisition" } } }, "auth_ref": { } },
"cgc_ShareBasedCompensationArrangementByShareBasedPaymentAwardReplacementOptionsIssuedResultingFromTheAcreageTransaction":- { "xbrltype": "sharesItemType",
"nsuri": "http://www.canopygrowth.com/20241231", "localname":
"ShareBasedCompensationArrangementByShareBasedPaymentAwardReplacementOptionsIssuedResultingFromTheAcreageTransaction", "presentation":-
"http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureShareBasedCompensationSummaryOfChangesInOptionsOutstandingDetails", "lang": { "en-us": {
"role": { "terseLabel": "Replacement options issued resulting from the Acreage Transaction", "label": "Share Based Compensation Arrangement By Share Based Payment
Award Replacement Options Issued Resulting From The Acreage Transaction", "documentation": "Share based compensation arrangement by share based payment award
replacement options issued resulting from the acreage transaction." } } }, "auth_ref": { } },
"cgc_ShareBasedCompensationArrangementByShareBasedPaymentAwardReplacementOptionsIssuedResultingFromTheAcreageTransactionWeightedAverageExercisePrice":-
"xbrltype": "perShareItemType", "nsuri": "http://www.canopygrowth.com/20241231", "localname":
"ShareBasedCompensationArrangementByShareBasedPaymentAwardReplacementOptionsIssuedResultingFromTheAcreageTransactionWeightedAverageExercisePrice",
"presentation":- "http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureShareBasedCompensationSummaryOfChangesInOptionsOutstandingDetails",
"lang": { "en-us": { "role": { "label": "Share Based Compensation Arrangement By Share Based Payment Award Replacement Options Issued Resulting From The Acreage
Transaction Weighted Average Exercise Price", "documentation": "Share based compensation arrangement by share based payment award replacement options issued
resulting from the acreage transaction weighted average exercise price.", "terseLabel": "Weighted average exercise price, Replacement options issued resulting from the
Acreage Transaction" } } }, "auth_ref": { } }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod":- { "xbrltype":
"sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod",
"presentation":- "http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureShareBasedCompensationAdditionalInformationDetails", "lang": { "en-us": { "role": {
"terseLabel": "Equity shares issued to shareholders", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Shares Issued in Period",
"documentation": "Number of shares issued under share-based payment arrangement." } } }, "auth_ref": { "r70" } }, "us-
gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain":- { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "presentation":-
"http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureShareBasedCompensationAdditionalInformationDetails",
"http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureShareBasedCompensationSummaryOfChangesInRsusAndPsusDetails",
"http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "lang": { "en-us": { "role": { "label": "All Award Types", "terseLabel": "All Award Types", "documentation": "Award
under share-based payment arrangement." } } }, "auth_ref": { "r577", "r578", "r579", "r580", "r581", "r582", "r583", "r584", "r585", "r586", "r587", "r588", "r589", "r590",
"r591", "r592", "r593", "r594", "r595", "r596", "r597", "r598", "r599", "r600", "r601", "r602" } }, "us-
gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice":- { "xbrltype": "perShareItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "presentation":-
"http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureShareBasedCompensationSummaryOfChangesInOptionsOutstandingDetails", "lang": { "en-us": {
"role": { "verboseLabel": "Exercise price", "terseLabel": "Weighted average exercise price, Options exercised", "label": "Share-Based Compensation Arrangements by Share-
Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price", "documentation": "Weighted average price at which option holders acquired shares
when converting their stock options into shares." } } }, "auth_ref": { "r585" } }, "us-
gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice":- { "xbrltype": "perShareItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
"presentation":- "http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureShareBasedCompensationSummaryOfChangesInOptionsOutstandingDetails",
"lang": { "en-us": { "role": { "terseLabel": "Weighted average exercise price, Options granted", "label": "Share-Based Compensation Arrangements by Share-Based Payment
Award, Options, Grants in Period, Weighted Average Exercise Price", "documentation": "Weighted average per share amount at which grantees can acquire shares of common
stock by exercise of options." } } }, "auth_ref": { "r584" } }, "us-gaap_ShareBasedCompensationAwardTrancheOneMember":- { "xbrltype": "domainItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationAwardTrancheOneMember", "presentation":-
"http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureShareBasedCompensationAdditionalInformationDetails", "lang": { "en-us": { "role": { "terseLabel":
"Share-based Payment Arrangement, Tranche One", "label": "Share-Based Payment Arrangement, Tranche One [Member]", "documentation": "First portion of award under
share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period." } } }, "auth_ref": { } }, "us-
gaap_ShareBasedCompensationAwardTrancheThreeMember":- { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ShareBasedCompensationAwardTrancheThreeMember", "presentation":-
"http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureShareBasedCompensationAdditionalInformationDetails", "lang": { "en-us": { "role": { "terseLabel":
"Share-based Payment Arrangement, Tranche Three", "label": "Share-Based Payment Arrangement, Tranche Three [Member]", "documentation": "Third portion of award
under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period." } } }, "auth_ref": { } }, "us-
gaap_ShareBasedCompensationAwardTrancheTwoMember":- { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ShareBasedCompensationAwardTrancheTwoMember", "presentation":-
"http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureShareBasedCompensationAdditionalInformationDetails", "lang": { "en-us": { "role": { "terseLabel":
"Share-based Payment Arrangement, Tranche Two", "label": "Share-Based Payment Arrangement, Tranche Two [Member]", "documentation": "Second portion of award under
share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period." } } }, "auth_ref": { } },
"cgc_ShareBasedCompensationIncludingAmountsRecordedInSellingGeneralAndAdministrativeExpenses":- { "xbrltype": "monetaryItemType", "nsuri":
"http://www.canopygrowth.com/20241231", "localname": "ShareBasedCompensationIncludingAmountsRecordedInSellingGeneralAndAdministrativeExpenses", "crdr": "debit",
"presentation":- "http://www.canopygrowth.com/20241231/taxonomy/role/Role_StatementCondensedInterimConsolidatedStatementsOfCashFlowsUnaudited", "lang": { "en-
us": { "role": { "terseLabel": "Share-based compensation", "label": "Share Based Compensation Including Amounts Recorded In Selling General And Administrative Expenses",
"documentation": "Share based compensation including amounts recorded in selling, general and administrative expenses." } } }, "auth_ref": { } },
"cgc_ShareBasedCompensationNumberOfSharesToBeIssuedOnCompletionOfAcquisitionAndAssetPurchaseMilestones":- { "xbrltype": "sharesItemType", "nsuri":
"http://www.canopygrowth.com/20241231", "localname": "ShareBasedCompensationNumberOfSharesToBeIssuedOnCompletionOfAcquisitionAndAssetPurchaseMilestones",
"presentation":- "http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureShareBasedCompensationAdditionalInformationDetails", "lang": { "en-us": { "role": {
"terseLabel": "Number of shares to be issued on completion of acquisition and asset purchase milestones", "label": "Share Based Compensation Number Of Shares To Be
Issued On Completion Of Acquisition And Asset Purchase Milestones", "documentation": "Share based compensation number of shares to be issued on completion of
acquisition and asset purchase milestones." } } }, "auth_ref": { } }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis":-
"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis", "presentation":-
"http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureShareBasedCompensationSummaryOfOptionsOutstandingDetails", "lang": { "en-us": { "role": {
"terseLabel": "Exercise Price Range", "label": "Exercise Price Range [Axis]", "documentation": "Information by range of option prices pertaining to options granted." } } },
"auth_ref": { "r71" } }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain":- { "xbrltype": "domainItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain", "presentation":-
"http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureShareBasedCompensationSummaryOfOptionsOutstandingDetails", "lang": { "en-us": { "role": {
"terseLabel": "Exercise Price Range", "label": "Exercise Price Range [Domain]", "documentation": "Supplementary information on outstanding and exercisable share awards as
of the balance sheet date which stratifies outstanding options by ranges of exercise prices." } } }, "auth_ref": { "r72" } }, "us-
gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems":- { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems", "presentation":-
"http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureShareBasedCompensationSummaryOfOptionsOutstandingDetails", "lang": { "en-us": { "role": {
"terseLabel": "Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range [Line Items]", "label": "Share-Based Payment Arrangement
Option, Exercise Price Range [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable
information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": { } }, "us-
gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit":- { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit", "presentation":-
"http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureShareBasedCompensationSummaryOfOptionsOutstandingDetails", "lang": { "en-us": { "role": {
"terseLabel": "Range of Exercise Prices, Lower Range", "label": "Share-Based Payment Arrangement, Option, Exercise Price Range, Lower Range Limit", "documentation": "The
floor of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other
required information pertaining to awards in the customized range." } } }, "auth_ref": { "r72" } }, "us-
gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit":- { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit", "presentation":-
"http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureShareBasedCompensationSummaryOfOptionsOutstandingDetails", "lang": { "en-us": { "role": {
"terseLabel": "Range of Exercise Prices, Upper Range", "label": "Share-Based Payment Arrangement, Option, Exercise Price Range, Upper Range Limit", "documentation": "The
ceiling of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans
and other required information pertaining to awards in the customized range." } } }, "auth_ref": { "r72" } }, "cgc_ShareCapitalMember":- { "xbrltype": "domainItemType",
"nsuri": "http://www.canopygrowth.com/20241231", "localname": "ShareCapitalMember", "presentation":-
"http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureShareCapitalSummaryOfIssuancesOfStockOtherDetails", "lang": { "en-us": { "role": { "terseLabel":
"Share Capital", "label": "Share Capital [Member]", "documentation": "Share capital." } } }, "auth_ref": { } }, "cgc_ShareConsolidationPolicyTextBlock":- { "xbrltype":
"textBlockItemType", "nsuri": "http://www.canopygrowth.com/20241231", "localname": "ShareConsolidationPolicyTextBlock", "presentation":-
"http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies", "lang": { "en-us": { "role": { "terseLabel": "Share
Consolidation", "label": "Share Consolidation [Policy Text Block]", "documentation": "Share consolidation." } } }, "auth_ref": { } }, "us-gaap_SharePrice":- { "xbrltype":
"perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharePrice", "presentation":-
"http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails", "lang": { "en-us": { "role": { "label": "Share Price", "terseLabel":
"Share price", "verboseLabel": "Price per exchangeable share", "documentation": "Price of a single share of a number of saleable stocks of a company." } } }, "auth_ref": { } },

"cgc_SharePurchaseAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.canopygrowth.com/20241231", "localname": "SharePurchaseAgreementMember", "presentation": ["http://www.canopygrowth.com/20241231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails", { "lang": { "en-us": { "role": { "terseLabel": "Share Purchase Agreement", "label": "Share Purchase Agreement [Member]", "documentation": "Share purchase agreement." } } }, "auth_ref": [] }, "srt_ShareRepurchaseProgramAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ShareRepurchaseProgramAxis", "presentation": ["http://www.canopygrowth.com/20241231/taxonomy/role/Role_StatementCondensedInterimConsolidatedStatementsOfShareholderSEquityUnaudited", { "lang": { "en-us": { "role": { "terseLabel": "Share Repurchase Program", "label": "Share Repurchase Program [Axis]", "documentation": "Share repurchase program." } } }, "auth_ref": ["r1372"] }, "srt_ShareRepurchaseProgramDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ShareRepurchaseProgramDomain", "presentation": ["http://www.canopygrowth.com/20241231/taxonomy/role/Role_StatementCondensedInterimConsolidatedStatementsOfShareholderSEquityUnaudited", { "lang": { "en-us": { "role": { "terseLabel": "Share Repurchase Program", "label": "Share Repurchase Program [Domain]", "documentation": "Share repurchase program." } } }, "auth_ref": ["r1372"] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage", "presentation": ["http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureShareBasedCompensationAdditionalInformationDetails", { "lang": { "en-us": { "role": { "terseLabel": "Percentage of options vest on each anniversary from date of grant", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award-Vesting Rights, Percentage", "documentation": "Percentage of vesting of award under share-based payment arrangement." } } }, "auth_ref": ["r1375"] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod", "presentation": ["http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureShareBasedCompensationAdditionalInformationDetails", { "lang": { "en-us": { "role": { "terseLabel": "Options expiration period", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period", "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDnTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": ["r1130"] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "presentation": ["http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureShareBasedCompensationSummaryOfAssumptionsAppliedToEstablishFairValueOfOptionsGrantedUsing", { "lang": { "en-us": { "role": { "terseLabel": "Expected life of options (years)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term", "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDnTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": ["r598"] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1", "presentation": ["http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureShareBasedCompensationSummaryOfOptionsOutstandingDetails", { "lang": { "en-us": { "role": { "terseLabel": "Options Exercisable, Weighted Average Remaining Contractual Life", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term", "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDnTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": ["r70"] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "presentation": ["http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureShareBasedCompensationSummaryOfOptionsOutstandingDetails", { "lang": { "en-us": { "role": { "terseLabel": "Options Outstanding, Weighted Average Remaining Contractual Life", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term", "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDnTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": ["r194"] }, "cgc_SharebasedReserveMember": { "xbrltype": "domainItemType", "nsuri": "http://www.canopygrowth.com/20241231", "localname": "SharebasedReserveMember", "presentation": ["http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureShareCapitalSummaryOfIssuancesOfStockOtherDetails", { "lang": { "en-us": { "role": { "terseLabel": "Share-based Reserve", "label": "Sharebased Reserve [Member]", "documentation": "Share-based reserve." } } }, "auth_ref": [] }, "us-gaap_SharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharesIssued", "presentation": ["http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails", { "lang": { "en-us": { "role": { "terseLabel": "Shares issued", "label": "Shares, Issued", "verboseLabel": "Exchangeable shares in the capital", "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury." } } }, "auth_ref": ["r19"] }, "us-gaap_SharesIssuedPricePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharesIssuedPricePerShare", "presentation": ["http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureCanopyUsaAdditionalInformationDetails", { "lang": { "en-us": { "role": { "terseLabel": "Purchase price of shares", "label": "Aggregate purchase price of stock options", "documentation": "Notional price per share", "documentation": "Per share or per unit amount of equity securities issued." } } }, "auth_ref": [] }, "us-gaap_ShortTermInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShortTermInvestments", "presentation": ["http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureShortTermInvestmentsComponentsOfShortTermInvestmentsDetails", { "lang": { "en-us": { "role": { "totalLabel": "Short-Term Investments, Total", "terseLabel": "Short-term investments", "label": "Short-Term Investments", "documentation": "Amount of investments including trading securities, available for sale securities, held-to-maturity securities, and short-term investments classified as other and current." } } }, "auth_ref": ["r213", "r214", "r1286"] }, "us-gaap_ShortTermInvestmentsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShortTermInvestmentsAbstract", "presentation": ["http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureShortTermInvestmentsDisclosureTextBlock", { "lang": { "en-us": { "role": { "label": "Short-Term Investments [Abstract]", "documentation": "Short-term investments disclosure." } } }, "auth_ref": [] }, "cgc_ShortTermInvestmentsFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://www.canopygrowth.com/20241231", "localname": "ShortTermInvestmentsFairValueDisclosure", "presentation": ["http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureFairValueOffFinancialInstrumentsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtEstimatedFairVa", { "lang": { "en-us": { "role": { "terseLabel": "Short-term investments", "label": "Short-Term Investments Fair Value Disclosure", "documentation": "Short term investments fair value disclosure." } } }, "auth_ref": [] }, "cgc_SoftwareAndDomainNamesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.canopygrowth.com/20241231", "localname": "SoftwareAndDomainNamesMember", "presentation": ["http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureIntangibleAssetsSummaryOfComponentsOfIntangibleAssetsDetails", { "lang": { "en-us": { "role": { "terseLabel": "Software and Domain Names", "label": "Software And Domain Names [Member]", "documentation": "Software and domain names." } } }, "auth_ref": [] }, "us-gaap_StatementBusinessSegmentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementBusinessSegmentsAxis", "presentation": ["http://www.canopygrowth.com/20241231/taxonomy/role/DisclosureLossOnAssetImpairmentAndRestructuringAdditionalInformationDetails", { "lang": { "en-us": { "role": { "terseLabel": "Segments", "label": "Segments [Axis]", "documentation": "Information by business segments." } } }, "auth_ref": ["r221", "r222", "r223", "r224", "r247", "r329", "r334", "r337", "r338", "r339", "r340", "r341", "r342", "r343", "r344", "r345", "r346", "r348", "r349", "r351", "r352", "r353", "r354", "r355", "r356", "r357", "r358", "r360", "r361", "r362", "r367", "r440", "r441", "r442", "r443", "r444", "r445", "r446", "r447", "r448", "r449", "r466", "r471", "r482", "r485", "r851", "r852", "r853", "r854", "r855", "r856", "r857", "r858", "r859", "r860", "r861", "r862", "r863", "r864", "r865", "r866", "r867", "r868", "r869", "r870", "r871", "r872", "r873", "r874", "r875", "r876", "r877", "r878", "r879", "r880", "r881", "r882", "r883", "r884", "r885", "r886", "r887", "r888", "r889", "r890", "r891", "r892", "r893", "r894", "r895", "r896", "r897", "r898", "r899", "r900", "r901", "r902", "r903", "r904", "r905", "r906", "r907", "r908", "r909", "r910", "r911", "r912", "r913", "r914", "r915", "r916", "r917", "r918", "r919", "r920", "r921", "r922", "r923", "r924", "r925", "r926", "r927", "r928", "r929", "r930", "r931", "r932", "r933", "r934", "r935", "r936", "r937", "r938", "r939", "r940", "r941", "r942", "r943", "r944", "r945", "r946", "r947", "r948", "r949", "r950", "r951", "r952", "r953", "r954", "r955", "r956", "r957", "r958", "r959", "r960", "r961", "r962", "r963", "r964", "r965", "r966", "r967", "r968", "r969", "r970", "r971", "r972", "r973", "r974", "r975", "r976", "r977", "r978", "r979", "r980", "r981", "r982", "r983", "r984", "r985", "r986", "r987", "r988", "r989", "r990", "r991", "r992", "r993", "r994", "r995", "r996", "r997", "r998", "r999", "r1000", "r1001", "r1002", "r1003", "r1004", "r1005", "r1006", "r1007", "r1008", "r1009", "r1010", "r1011", "r1012", "r1013", "r1014", "r1015", "r1016", "r1017", "r1018", "r1019", "r1020", "r1021", "r1022", "r1023", "r1024", "r1025", "r1026", "r1027", "r1028", "r1029", "r1030", "r1031", "r1032", "r1033", "r1034", "r1035", "r1036", "r1037", "r1038", "r1039", "r1040", "r1041", "r1042", "r1043", "r1044", "r1045", "r1046", "r1047", "r1048", "r1049", "r1050", "r1051", "r1052", "r1053", "r1054", "r1055", "r1056", "r1057", "r1058", "r1059", "r1060", "r1061", "r1062", "r1063", "r1064", "r1065", "r1066", "r1067", "r1068", "r1069", "r1070", "r1071", "r1072", "r1073", "r1074", "r1075", "r1076", "r1077", "r1078", "r1079", "r1080", "r1081", "r1082", "r1083", "r1084", "r1085", "r1086", "r1087", "r1088", "r1089", "r1090", "r1091", "r1092", "r1093", "r1094", "r1095", "r1096", "r1097", "r1098", "r1099", "r1100", "r1101", "r1102", "r1103", "r1104", "r1105", "r1106", "r1107", "r1108", "r1109", "r1110", "r1111", "r1112", "r1113", "r1114", "r1115", "r1116", "r1117", "r1118", "r1119", "r1120", "r1121", "r1122", "r1123", "r1124", "r1125", "r1126", "r1127", "r1128", "r1129", "r1130", "r1131", "r1132", "r1133", "r1134", "r1135", "r1136", "r1137", "r1138", "r1139", "r1140", "r1141", "r1142", "r1143", "r1144", "r1145", "r1146", "r1147", "r1148", "r1149", "r1150", "r1151", "r1152", "r1153", "r1154", "r1155", "r1156", "r1157", "r1158", "r1159", "r1160", "r1161", "r1162", "r1163", "r1164", "r1165", "r1166", "r1167", "r1168", "r1169", "r1170", "r1171", "r1172", "r1173", "r1174", "r1175", "r1176", "r1177", "r1178", "r1179", "r1180", "r1181", "r1182", "r1183", "r1184", "r1185", "r1186", "r1187", "r1188", "r1189", "r1190", "r1191", "r1192", "r1193", "r1194", "r1195", "r1196", "r1197", "r1198", "r1199", "r1200", "r1201", "r1202", "r1203", "r1204", "r1205", "r1206", "r1207", "r1208", "r1209", "r1210", "r1211", "r1212", "r1213", "r1214", "r1215", "r1216", "r1217", "r1218", "r1219", "r1220", "r1221", "r1222", "r1223", "r1224", "r1225", "r1226", "r1227", "r1228", "r1229", "r1230", "r1231", "r1232", "r1233", "r1234", "r1235", "r1236", "r1237", "r1238", "r1239", "r1240", "r1241", "r1242", "r1243", "r1244", "r1245", "r1246", "r1247", "r1248", "r1249", "r1250", "r1251", "r1252", "r1253", "r1254", "r1255", "r1256", "r1257", "r1258", "r1259", "r1260", "r1261", "r1262", "r1263", "r1264", "r1265", "r1266", "r1267", "r1268", "r1269", "r1270", "r1271", "r1272", "r1273", "r1274", "r1275", "r1276", "r1277", "r1278", "r1279", "r1280", "r1281", "r1282", "r1283", "r1284", "r1285", "r1286", "r1287", "r1288", "r1289", "r1290", "r1291", "r1292", "r1293", "r1294", "r1295", "r1296", "r1297", "r1298", "r1299", "r1300", "r1301", "r1302", "r1303", "r1304", "r1305", "r1306", "r1307", "r1308", "r1309", "r1310", "r1311", "r1312", "r1313", "r1314", "r1315", "r1316", "r1317", "r1318", "r1319", "r1320", "r1321", "r1322", "r1323", "r1324", "r1325", "r1326", "r1327", "r1328", "r1329", "r1330", "r1331", "r1332", "r1333", "r1334", "r1335", "r1336", "r1337", "r1338", "r1339", "r1340", "r1341", "r1342", "r1343", "r1344", "r1345", "r1346", "r1347", "r1348", "r1349", "r1350", "r1351", "r1352", "r1353", "r1354", "r1355", "r1356", "r1357", "r1358", "r1359", "r1360", "r1361", "r1362", "r1363", "r1364", "r1365", "r1366", "r1367", "r1368", "r1369", "r1370", "r1371", "r1372", "r1373", "r1374", "r1375", "r1376", "r1377", "r1378", "r1379", "r1380", "r1381", "r1382", "r1383", "r1384", "r1385", "r1386", "r1387", "r1388", "r1389", "r1390", "r1391", "r1392", "r1393", "r1394", "r1395", "r1396", "r1397", "r1398", "r1399", "r1400", "r1401", "r1402", "r1403", "r1404", "r1405", "r1406", "r1407", "r1408", "r1409", "r1410", "r1411", "r1412", "r1413", "r1414", "r1415", "r1416", "r1417", "r1418", "r1419", "r1420", "r1421", "r1422", "r1423", "r1424", "r1425", "r1426", "r1427", "r1428", "r1429", "r1430", "r1431", "r1432", "r1433", "r1434", "r1435", "r1436", "r1437", "r1438", "r1439", "r1440", "r1441", "r1442", "r1443", "r1444", "r1445", "r1446", "r1447", "r1448", "r1449", "r1450", "r1451", "r1452", "r1453", "r1454", "r1455", "r1456", "r1457", "r1458", "r1459", "r1460", "r1461", "r1462", "r1463", "r1464", "r1465", "r1466", "r1467", "r1468", "r1469", "r1470", "r1471", "r1472", "r1473"] }, "us-gaap_StatementClassOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementClassOfStockAxis", "presentation": ["http://www.canopygrowth.com/20241231/taxonomy/role/DisclosureAcquireeArrangementAdditionalInformationDetails", { "lang": { "en-us": { "role": { "label": "Class of Stock", "label": "Class of Stock [Axis]", "documentation": "Information by the different classes of stock of the entity." } } }, "auth_ref": ["r237", "r261", "r262", "r263", "r296", "r319", "r320", "r322", "r324", "r331", "r332", "r409", "r496", "r498", "r499", "r500", "r503", "r504", "r534", "r535", "r538", "r541", "r548", "r713", "r890", "r891", "r892", "r893", "r894", "r895", "r896", "r897", "r898", "r899", "r900", "r901", "r902", "r903", "r904", "r905", "r906", "r907", "r908", "r909", "r910", "r911", "r912", "r913", "r914", "r915", "r916", "r917", "r918", "r919", "r920", "r921", "r922", "r923", "r924", "r925", "r926", "r927", "r928", "r929", "r930", "r931", "r932", "r933", "r934", "r935", "r936", "r937", "r938", "r939", "r940", "r941", "r942", "r943", "r944", "r945", "r946", "r947", "r948", "r949", "r950", "r951", "r952", "r953", "r954", "r955", "r956", "r957", "r958", "r959", "r960", "r961", "r962", "r963", "r964", "r965", "r966", "r967", "r968", "r969", "r970", "r971", "r972", "r973", "r974", "r975", "r976", "r977", "r978", "r979", "r980", "r981", "r982", "r983", "r984", "r985", "r986", "r987", "r988", "r989", "r990", "r991", "r992", "r993", "r994", "r995", "r996", "r997", "r998", "r999", "r1000", "r1001", "r1002", "r1003", "r1004", "r1005", "r1006", "r1007", "r1008", "r1009", "r1010", "r1011", "r1012", "r1013", "r1014", "r1015", "r1016", "r1017", "r1018", "r1019", "r1020", "r1021", "r1022", "r1023", "r1024", "r1025", "r1026", "r1027", "r1028", "r1029", "r1030", "r1031", "r1032", "r1033", "r1034", "r1035", "r1036", "r1037", "r1038", "r1039", "r1040", "r1041", "r1042", "r1043", "r1044", "r1045", "r1046", "r1047", "r1048", "r1049", "r1050", "r1051", "r1052", "r1053", "r1054", "r1055", "r1056", "r1057", "r1058", "r1059", "r1060", "r1061", "r1062", "r1063", "r1064", "r1065", "r1066", "r1067", "r1068", "r1069", "r1070", "r1071", "r1072", "r1073", "r1074", "r1075", "r1076", "r1077", "r1078", "r1079", "r1080", "r1081", "r1082", "r1083", "r1084", "r1085", "r1086", "r1087", "r1088", "r1089", "r1090", "r1091", "r1092", "r1093", "r1094", "r1095", "r1096", "r1097", "r1098", "r1099", "r1100", "r1101", "r1102", "r1103", "r1104", "r1105", "r1106", "r1107", "r1108", "r1109", "r1110", "r1111", "r1112", "r1113", "r1114", "r1115", "r1116", "r1117", "r1118", "r1119", "r1120", "r1121", "r1122", "r1123", "r1124", "r1125", "r1126", "r1127", "r1128", "r1129", "r1130", "r1131", "r1132", "r1133", "r1134", "r1135", "r1136", "r1137", "r1138", "r1139", "r1140", "r1141", "r1142", "r1143", "r1144", "r1145", "r1146", "r1147", "r1148", "r1149", "r1150", "r1151", "r1152", "r1153", "r1154", "r1155", "r1156", "r1157", "r1158", "r1159", "r1160", "r1161", "r1162", "r1163", "r1164", "r1165", "r1166", "r1167", "r1168", "r1169", "r1170", "r1171", "r1172", "r1173", "r1174", "r1175", "r1176", "r1177", "r1178", "r1179", "r1180", "r1181", "r1182", "r1183", "r1184", "r1185", "r1186", "r1187", "r1188", "r1189", "r1190", "r1191", "r1192", "r1193", "r1194", "r1195", "r1196", "r1197", "r1198", "r1199", "r1200", "r1201", "r1202", "r1203", "r1204", "r1205", "r1206", "r1207", "r1208", "r1209", "r1210", "r1211", "r1212", "r1213", "r1214", "r1215", "r1216", "r1217", "r1218", "r1219", "r1220", "r1221", "r1222", "r1223", "r1224", "r1225", "r1226", "r1227", "r1228", "r1229", "r1230", "r1231", "r1232", "r1233", "r1234", "r1235", "r1236", "r1237", "r1238", "r1239", "r1240", "r1241", "r1242", "r1243", "r1244", "r1245", "r1246", "r1247", "r1248", "r1249", "r1250", "r1251", "r1252", "r1253", "r1254", "r1255", "r1256", "r1257", "r1258", "r1259", "r1260", "r1261", "r1262", "r1263", "r1264", "r1265", "r1266", "r1267", "r1268", "r1269", "r1270", "r1271", "r1272", "r1273", "r1274", "r1275", "r1276", "r1277", "r1278", "r1279", "r1280", "r1281", "r1282", "r1283", "r1284", "r1285", "r1286", "r1287", "r1288", "r1289", "r1290", "r1291", "r1292", "r1293", "r1294", "r1295", "r1296", "r1297", "r1298", "r1299", "r1300", "r1301", "r1302", "r1303", "r1304", "r1305", "r1306", "r1307", "r1308", "r1309", "r1310", "r1311", "r1312", "r1313", "r1314", "r1315", "r1316", "r1317", "r1318", "r1319", "r1320", "r1321", "r1322", "r1323", "r1324", "r1325", "r1326", "r1327", "r1328", "r1329", "r1330", "r1331", "r1332", "r1333", "r1334", "r1335", "r1336", "r1337", "r1338", "r1339", "r1340", "r1341", "r1342", "r1343", "r1344", "r1345", "r1346", "r1347", "r1348", "r1349", "r1350", "r1351", "r1352", "r1353", "r1354", "r1355", "r1356", "r1357", "r1358", "r1359", "r1360", "r1361", "r1362", "r1363", "r1364", "r1365", "r1366", "r1367", "r1368", "r1369", "r1370", "r1371", "r1372", "r1373", "r1374", "r1375", "r1376", "r1377", "r1378", "r1379", "r1380", "r1381", "r1382", "r1383", "r1384", "r1385", "r1386", "r1387", "r1388", "r1389", "r1390", "r1391", "r1392", "r1393", "r1394", "r1395", "r1396", "r1397", "r1398", "r1399", "r1400", "r1401", "r1402", "r1403", "r1404", "r1405", "r1406", "r1407", "r1408", "r1409", "r1410", "r1411", "r1412", "r1413", "r1414", "r1415", "r1416", "r1417", "r1418", "r1419", "r1420", "r1421", "r1422", "r1423", "r1424", "r1425", "r1426", "r1427", "r1428", "r1429", "r1430", "r1431", "r1432", "r1433", "r1434", "r1435", "r1436", "r1437", "r1438", "r1439", "r1440", "r1441", "r1442", "r1443", "r1444", "r1445", "r1446", "r1447", "r1448", "r1449", "r1450", "r1451", "r1452", "r1453", "r1454", "r1455", "r1456", "r1457", "r1458", "r1459", "r1460", "r1461", "r1462", "r1463", "r1464", "r1465", "r1466", "r1467", "r1468", "r1469", "r1470", "r1471", "r1472", "r1473"] }, "us-gaap_StatementEquityComponentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementEquityComponentsAxis", "presentation": ["http://www.canopygrowth.com/20241231/taxonomy/role/DisclosureAcquisitionAdditionalInformationDetails", { "lang": { "en-us": { "role": { "label": "Geographical", "label": "Geographical [Axis]", "documentation": "Information by component of equity." } } }, "auth_ref": ["r19", "r134", "r138", "r139", "r240", "r280", "r281", "r282", "r299", "r300", "r301", "r304", "r310", "r312", "r314", "r330", "r414", "r420", "r469", "r550", "r620", "r621", "r636", "r637", "r638", "r641", "r652", "r653", "r667", "r668", "r669", "r670", "r671", "r673", "r684", "r715", "r717", "r718", "r719", "r720", "r721", "r726", "r728", "r735", "r738", "r745", "r755", "r756", "r757", "r758", "r759", "r760", "r761", "r762", "r763", "r764", "r765", "r766", "r767", "r768", "r769", "r770", "r771", "r772", "r773", "r774", "r775", "r776", "r777", "r778", "r779", "r780", "r781", "r782", "r783", "r784", "r785", "r786

"r1455", "r1456", "r1457", "r1458", "r1459", "r1460", "r1461", "r1462", "r1463", "r1464", "r1465", "r1466", "r1467", "r1468", "r1469", "r1470", "r1471", "r1472", "r1473" }},
"us-gaap-StatementLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementLineItems", "presentation": {
"http://www.canopygrowth.com/20241231/taxonomy/role/Role-StatementFairValueOffinancialInstrumentsTables",
"http://www.canopygrowth.com/20241231/taxonomy/role/Role-StatementCondensedInterimConsolidatedBalanceSheetsParenteticalUnaudited",
"http://www.canopygrowth.com/20241231/taxonomy/role/Role-StatementCondensedInterimConsolidatedStatementsOfShareholderSEquityUnaudited" }}, "lang": { "en-us": {
"role": { "terseLabel": "Statement [Line Items]", "label": "Statement [Line Items]", "documentation": "Line items represent financial concepts included in a table. These
concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } }}, "auth_ref": { "r299", "r300", "r301",
"r330", "r728", "r782", "r889", "r911", "r923", "r924", "r925", "r926", "r927", "r928", "r931", "r934", "r935", "r936", "r937", "r938", "r940", "r941", "r942", "r943", "r945",
"r946", "r947", "r948", "r949", "r951", "r953", "r956", "r961", "r962", "r963", "r964", "r965", "r966", "r967", "r968", "r969", "r970", "r971", "r974", "r1167" }}, "us-
gaap-StatementOfCashFlowsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfCashFlowsAbstract", "lang": { "en-
us": { "role": { "label": "Statement of Cash Flows [Abstract]" } }}, "auth_ref": { } }, "us-gaap-StatementOfFinancialPositionAbstract": { "xbrltype": "stringItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "StatementOfFinancialPositionAbstract", "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]" } }},
"auth_ref": { } }, "us-gaap-StatementOfStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"StatementOfStockholdersEquityAbstract", "lang": { "en-us": { "role": { "label": "Statement of Stockholders' Equity [Abstract]" } }}, "auth_ref": { } },
"srt-StatementScenarioAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "StatementScenarioAxis", "presentation": {
"http://www.canopygrowth.com/20241231/taxonomy/role/Role-DisclosureOtherFinancialAssetsAdditionalInformationDetails" }}, "lang": { "en-us": { "role": { "label": "Scenario
[Axis]" } }}, "auth_ref": { "r315", "r371", "r1262", "r1266", "r1309" } }, "us-gaap-StatementTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "StatementTable", "presentation": { "http://www.canopygrowth.com/20241231/taxonomy/role/Role-DisclosureFairValueOffinancialInstrumentsTables",
"http://www.canopygrowth.com/20241231/taxonomy/role/Role-StatementCondensedInterimConsolidatedBalanceSheetsParenteticalUnaudited",
"http://www.canopygrowth.com/20241231/taxonomy/role/Role-StatementCondensedInterimConsolidatedStatementsOfShareholderSEquityUnaudited" }}, "lang": { "en-us": {
"role": { "terseLabel": "Statement [Table]", "label": "Statement [Table]", "documentation": "Disclosure of information about statement of comprehensive income, income,
other comprehensive income, financial position, cash flows, and shareholders' equity." } }}, "auth_ref": { "r299", "r300", "r301", "r330", "r370", "r728", "r782", "r889", "r911",
"r923", "r924", "r925", "r926", "r927", "r928", "r931", "r934", "r935", "r936", "r937", "r938", "r940", "r941", "r942", "r943", "r945", "r946", "r947", "r948", "r949", "r951",
"r953", "r956", "r960", "r961", "r962", "r963", "r964", "r965", "r966", "r967", "r968", "r969", "r970", "r971", "r974", "r1167" }},
"ecd-StkPrCOrTsrEstimationMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"StkPrCOrTsrEstimationMethodTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" }}, "lang": { "en-us": { "role": { "label": "Stock Price or TSR
Estimation Method [Text Block]", "terseLabel": "Stock Price or TSR Estimation Method" } }}, "auth_ref": { "r1184", "r1194", "r1204", "r1236" } }, "us-
gaap-StockAppreciationRightsSARSMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockAppreciationRightsSARSMember",
"presentation": { "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" }}, "lang": { "en-us": { "role": { "label": "Stock Appreciation Rights (SARs) [Member]", "terseLabel":
"Stock Appreciation Rights (SARs)", "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during
predetermined time period." } }}, "auth_ref": { } }, "cgc-StockIssuedDuringPeriodSharesAcquisitionsAndCancellationOfNotes": { "xbrltype": "sharesItemType", "nsuri":
"http://www.canopygrowth.com/20241231", "localname": "StockIssuedDuringPeriodSharesAcquisitionsAndCancellationOfNotes", "presentation": {
"http://www.canopygrowth.com/20241231/taxonomy/role/Role-DisclosureDebtAdditionalInformationDetails" }}, "lang": { "en-us": { "role": { "label": "Stock Issued During Period
Shares Acquisitions and cancellation of Notes", "documentation": "Stock issued during period shares acquisitions and cancellation of notes." } }}, "auth_ref": { } }, "us-
gaap-StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities", "presentation": {
"http://www.canopygrowth.com/20241231/taxonomy/role/DisclosureCanopyUsaAdditionalInformationDetails",
"http://www.canopygrowth.com/20241231/taxonomy/role/Role-DisclosureDebtAdditionalInformationDetails",
"http://www.canopygrowth.com/20241231/taxonomy/role/Role-DisclosureShareCapitalAdditionalInformationDetails",
"http://www.canopygrowth.com/20241231/taxonomy/role/Role-StatementCondensedInterimConsolidatedStatementsOfShareholderSEquityUnaudited" }}, "lang": { "en-us": {
"role": { "verboseLabel": "Settlement of convertible senior notes, shares", "terseLabel": "Conversion of loans from related company into shares of Common Stock, shares",
"label": "Exchangeable shares", "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities." } }}, "auth_ref": { "r19",
"r60", "r134", "r138", "r191", "r523" } }, "us-gaap-StockIssuedDuringPeriodSharesNewIssues": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "StockIssuedDuringPeriodSharesNewIssues", "presentation": {
"http://www.canopygrowth.com/20241231/taxonomy/role/Role-DisclosureDebtAdditionalInformationDetails",
"http://www.canopygrowth.com/20241231/taxonomy/role/Role-DisclosureShareCapitalAdditionalInformationDetails" }}, "lang": { "en-us": { "role": { "terseLabel": "Issuance of
common shares", "label": "Stock Issued During Period, Shares, New Issues", "documentation": "Number of new stock issued during the period." } }}, "auth_ref": { "r19",
"r133", "r134", "r191", "r890", "r974", "r1061" } }, "us-gaap-StockIssuedDuringPeriodSharesShareBasedCompensation": { "xbrltype": "sharesItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation", "presentation": {
"http://www.canopygrowth.com/20241231/taxonomy/role/Role-DisclosureShareBasedCompensationAdditionalInformationDetails" }}, "lang": { "en-us": { "role": { "totalLabel":
"Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture, Total", "terseLabel": "Share-based compensation expense, options subject to performance
conditions", "label": "Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture", "documentation": "Number, after forfeiture, of shares or units issued under
share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP)."} }}, "auth_ref": { "r19", "r133", "r134", "r191" } }, "us-
gaap-StockIssuedDuringPeriodSharesStockOptionsExercised": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"StockIssuedDuringPeriodSharesStockOptionsExercised", "presentation": {
"http://www.canopygrowth.com/20241231/taxonomy/role/Role-DisclosureShareBasedCompensationSummaryOfChangesInOptionsOutstandingDetails" }}, "lang": { "en-us": {
"role": { "negatedLabel": "Options exercised", "terseLabel": "Options exercised", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options,
Exercises in Period", "documentation": "Number of share options (or share units) exercised during the current period." } }}, "auth_ref": { "r19", "r133", "r134", "r191", "r585"
} }, "us-gaap-StockIssuedDuringPeriodValueConversionOfConvertibleSecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"StockIssuedDuringPeriodValueConversionOfConvertibleSecurities", "crdr": "credit", "presentation": {
"http://www.canopygrowth.com/20241231/taxonomy/role/Role-StatementCondensedInterimConsolidatedStatementsOfShareholderSEquityUnaudited" }}, "lang": { "en-us": {
"role": { "verboseLabel": "Settlement of convertible senior notes", "label": "Stock Issued During Period, Value, Conversion of Convertible Securities", "terseLabel": "Conversion
of loans from related company into shares of Common Stock", "documentation": "The gross value of stock issued during the period upon the conversion of convertible
securities." } }}, "auth_ref": { "r19", "r134", "r138", "r139", "r191" } }, "us-gaap-StockIssuedDuringPeriodValueNewIssues": { "xbrltype": "monetaryItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodValueNewIssues", "crdr": "credit", "presentation": {
"http://www.canopygrowth.com/20241231/taxonomy/role/DisclosureCanopyUsaAdditionalInformationDetails",
"http://www.canopygrowth.com/20241231/taxonomy/role/Role-DisclosureBasisOfPresentationAdditionalInformationDetails",
"http://www.canopygrowth.com/20241231/taxonomy/role/Role-DisclosureShareCapitalAdditionalInformationDetails",
"http://www.canopygrowth.com/20241231/taxonomy/role/Role-StatementCondensedInterimConsolidatedStatementsOfShareholderSEquityUnaudited" }}, "lang": { "en-us": {
"role": { "label": "Stock Issued During Period, Value, New Issues", "terseLabel": "Sale of common stock", "verboseLabel": "Common shares issued from ATM Program",
"documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering." } }},
"auth_ref": { "r19", "r133", "r134", "r191", "r899", "r974", "r1061", "r1173" } }, "cgc-StockIssuedDuringPeriodValueRedemptionOfRedeemableNoncontrollingInterest": {
"xbrltype": "monetaryItemType", "nsuri": "http://www.canopygrowth.com/20241231", "localname":
"StockIssuedDuringPeriodValueRedemptionOfRedeemableNoncontrollingInterest", "crdr": "credit", "presentation": {
"http://www.canopygrowth.com/20241231/taxonomy/role/Role-StatementCondensedInterimConsolidatedStatementsOfShareholderSEquityUnaudited" }}, "lang": { "en-us": {
"role": { "verboseLabel": "Redemption of redeemable noncontrolling interests, net", "documentation": "Stock Issued During Period Value, Redemption of Redeemable
Noncontrolling Interest", "label": "Stock Issued During Period Value Redemption Of Redeemable Noncontrolling Interest", "terseLabel": "Redemption of redeemable
noncontrolling interest" } }}, "auth_ref": { } }, "cgc-StockIssuedDuringPeriodValueSettlementOfUnsecuredSeniorNotes": { "xbrltype": "monetaryItemType", "nsuri":
"http://www.canopygrowth.com/20241231", "localname": "StockIssuedDuringPeriodValueSettlementOfUnsecuredSeniorNotes", "crdr": "credit", "presentation": {
"http://www.canopygrowth.com/20241231/taxonomy/role/Role-StatementCondensedInterimConsolidatedStatementsOfShareholderSEquityUnaudited" }}, "lang": { "en-us": {
"role": { "terseLabel": "Settlement of unsecured senior notes", "label": "Stock issued during period, value, settlement of unsecured senior notes", "documentation": "Stock
issued during period, value, settlement of unsecured senior notes", "verboseLabel": "Settlement of unsecured senior notes, net of tax" } }}, "auth_ref": { } },
"cgc-StockIssuedDuringPeriodValueSettlementOfUnsecuredSeniorNotesNetOfDeferredIncomeTax": { "xbrltype": "monetaryItemType", "nsuri":
"http://www.canopygrowth.com/20241231", "localname": "StockIssuedDuringPeriodValueSettlementOfUnsecuredSeniorNotesNetOfDeferredIncomeTax", "crdr": "credit",
"presentation": {
"http://www.canopygrowth.com/20241231/taxonomy/role/Role-DisclosureAccumulatedOtherComprehensiveIncomeLossAccumulatedOtherComprehensiveIncomeDetails" }},
"lang": { "en-us": { "role": { "terseLabel": "Settlement of unsecured senior notes, net of deferred income tax", "label": "Stock issued during period, value, settlement of
unsecured senior notes, net of deferred income tax", "documentation": "Stock issued during period, value, settlement of unsecured senior notes, net of deferred income tax." } }},
"auth_ref": { } }, "us-gaap-StockIssuedDuringPeriodValueStockOptionsExercised": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"StockIssuedDuringPeriodValueStockOptionsExercised", "crdr": "credit", "presentation": {
"http://www.canopygrowth.com/20241231/taxonomy/role/Role-StatementCondensedInterimConsolidatedStatementsOfShareholderSEquityUnaudited" }}, "lang": { "en-us": {
"role": { "label": "Stock Issued During Period, Value, Stock Options Exercised", "terseLabel": "Exercise of Previous Equity Incentive Plan stock options", "documentation":
"Value of stock issued as a result of the exercise of stock options." } }}, "auth_ref": { "r19", "r134", "r138", "r139", "r191" } }, "us-gaap-StockOptionMember": { "xbrltype":
"domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockOptionMember", "presentation": {
"http://www.canopygrowth.com/20241231/taxonomy/role/DisclosureCanopyUsaAdditionalInformationDetails",
"http://www.canopygrowth.com/20241231/taxonomy/role/Role-DisclosureOtherFinancialAssetsSummaryOfChangesInOtherFinancialAssetsDetails" }}, "lang": { "en-us": { "role": {
"terseLabel": "Equity Option", "label": "Equity Option [Member]", "documentation": "Contracts conveying rights, but not obligations, to buy or sell a specific quantity of
stock at a specified price during a specified period (an American option) or at a specified date (a European option)."} }}, "auth_ref": { "r1166" } },
"cgc-StockOptionSubjectToPerformanceConditionsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.canopygrowth.com/20241231", "localname":
"StockOptionSubjectToPerformanceConditionsMember", "presentation": {
"http://www.canopygrowth.com/20241231/taxonomy/role/Role-DisclosureShareBasedCompensationAdditionalInformationDetails" }}, "lang": { "en-us": { "role": { "terseLabel":
"Stock Option Subject To Performance Conditions", "label": "Stock Option Subject To Performance Conditions [Member]", "documentation": "Stock option subject to
performance conditions." } }}, "auth_ref": { } }, "us-gaap-StockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"StockholdersEquity", "crdr": "credit", "presentation": {
"http://www.canopygrowth.com/20241231/taxonomy/role/Role-StatementCondensedInterimConsolidatedBalanceSheetsUnaudited" }}, "lang": { "en-us": { "role": {
"periodEndLabel": "Stockholders' Equity Attributable to Parent, Ending Balance", "periodStartLabel": "Stockholders' Equity Attributable to Parent, Beginning Balance",
"totalLabel": "Total Canopy Growth Corporation shareholders' equity", "label": "Equity, Attributable to Parent", "documentation": "Amount of equity (deficit) attributable to
parent. Excludes temporary equity and equity attributable to noncontrolling interest." } }}, "auth_ref": { "r134", "r138", "r139", "r174", "r933", "r950", "r975", "r976",
"r1147", "r1174", "r1304", "r1330", "r1419", "r1479" } }, "us-gaap-StockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "StockholdersEquityAbstract", "presentation": {
"http://www.canopygrowth.com/20241231/taxonomy/role/Role-StatementCondensedInterimConsolidatedBalanceSheetsUnaudited" }}, "lang": { "en-us": { "role": { "terseLabel":
"Canopy Growth Corporation shareholders' equity", "label": "Equity, Attributable to Parent [Abstract]" } }}, "auth_ref": { } }, "us-
gaap-StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "crdr": "credit", "presentation": {

"http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureAccumulatedOtherComprehensiveIncomeLossAccumulatedOtherComprehensiveIncomeDetails",
"http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureNoncontrollingInterestsSummaryOfNetChangeInNoncontrollingInterestsDetails",
"http://www.canopygrowth.com/20241231/taxonomy/role/Role_StatementCondensedInterimConsolidatedBalanceSheetsUnaudited",
"http://www.canopygrowth.com/20241231/taxonomy/role/Role_StatementCondensedInterimConsolidatedStatementsOfShareholderSEquityUnaudited"}}, {"lang": {"en-us": {"role": {"totalLabel": "Total shareholders' equity", "periodStartLabel": "Beginning balance", "periodEndLabel": "Ending balance", "label": "Equity, Including Portion Attributable to Noncontrolling Interest", "documentation": "Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity."}}}, {"auth_ref": {"r81": "r82", "r88": "r240", "r241": "r281", "r299": "r300", "r301": "r304", "r310": "r312", "r414": "r420", "r469": "r550", "r620": "r621", "r636": "r637", "r638", "r641": "r652", "r653": "r667", "r668": "r669", "r670": "r671", "r673": "r684", "r715": "r717", "r721": "r727", "r735": "r876", "r877": "r897", "r933": "r950", "r975": "r976", "r1065": "r1172", "r1304": "r1330", "r1419": "r1479"}}, {"us-gaap": "StockholdersEquityNoteDisclosureTextBlock", {"xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityNoteDisclosureTextBlock", "presentation": {}}, {"http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureShareCapital", {"lang": {"en-us": {"role": {"terseLabel": "Share Capital", "label": "Equity (Text Block)", "documentation": "The entire disclosure for equity."}}}, {"auth_ref": {"r188": "r188", "r295": "r333", "r535": "r537", "r538": "r539", "r540": "r541", "r542": "r543", "r544", "r545": "r547", "r550": "r675", "r977": "r978", "r1066"}}, {"us-gaap": "StockholdersEquityNoteDisclosureTextBlock", {"xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityNoteDisclosureTextBlock", "presentation": {}}, {"http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureBasisOfPresentationAdditionalInformationDetails", {"lang": {"en-us": {"role": {"terseLabel": "Share consolidation ratio", "label": "Stockholders' Equity Note, Stock Split, Conversion Ratio", "documentation": "Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one."}}}, {"auth_ref": {"r192": "r192"}}, {"us-gaap": "StockholdersEquityReverseStockSplit", {"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityReverseStockSplit", "presentation": {}}, {"http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureBasisOfPresentationAdditionalInformationDetails", {"lang": {"en-us": {"role": {"terseLabel": "Share consolidation, description", "label": "Stockholders' Equity, Reverse Stock Split", "documentation": "Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements."}}}, {"auth_ref": {"r192": "r192"}}, {"cgc": "StorzAndBickelMember", {"xbrltype": "domainItemType", "nsuri": "http://www.canopygrowth.com/20241231", "localname": "StorzAndBickelMember", "presentation": {}}, {"http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureSegmentInformationSummaryOfReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedDel", {"lang": {"en-us": {"role": {"terseLabel": "Storz & Bickel", "label": "Storz & Bickel [Member]", "documentation": "Storz and Bickel."}}}, {"auth_ref": {}}, {"cgc": "StorzBickelMember", {"xbrltype": "domainItemType", "nsuri": "http://www.canopygrowth.com/20241231", "localname": "StorzBickelMember", "presentation": {}}, {"http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureRevenueSummaryOfDisaggregationOfRevenueDetails", {"lang": {"en-us": {"role": {"label": "Storz Bickel [Member]", "documentation": "Storz & Bickel", "terseLabel": "Storz & Bickel"}}, {"auth_ref": {}}, {"cgc": "StorzBickelReportingUnitMember", {"xbrltype": "domainItemType", "nsuri": "http://www.canopygrowth.com/20241231", "localname": "StorzBickelReportingUnitMember", "presentation": {}}, {"http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureGoodwillAdditionalInformationDetails", {"lang": {"en-us": {"role": {"documentation": "Storz & Bickel reporting unit member", "label": "Storz Bickel Reporting Unit [Member]", "terseLabel": "Storz & Bickel Reporting Unit"}}, {"auth_ref": {}}, {"cgc": "SubscriptionPercentageForProposedFinancing", {"xbrltype": "percentItemType", "nsuri": "http://www.canopygrowth.com/20241231", "localname": "SubscriptionPercentageForProposedFinancing", {"presentation": {}}, {"http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails", {"lang": {"en-us": {"role": {"documentation": "Subscription percentage for proposed financing", "label": "Subscription percentage for proposed financing", "terseLabel": "Subscription percentage for proposed financing"}}, {"auth_ref": {}}, {"cgc": "SubscriptionPercentageForProposedPrivatePlacement", {"xbrltype": "percentItemType", "nsuri": "http://www.canopygrowth.com/20241231", "localname": "SubscriptionPercentageForProposedPrivatePlacement", {"presentation": {}}, {"http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails", {"lang": {"en-us": {"role": {"documentation": "Subscription percentage for proposed private placement", "label": "Subscription percentage for proposed private placement", "terseLabel": "Subscription percentage for proposed financing"}}, {"auth_ref": {}}, {"cgc": "SubscriptionAgreementWithInstitutionalInvestorsMember", {"xbrltype": "domainItemType", "nsuri": "http://www.canopygrowth.com/20241231", "localname": "SubscriptionAgreementWithInstitutionalInvestorsMember", {"presentation": {}}, {"http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureShareCapitalAdditionalInformationDetails", {"lang": {"en-us": {"role": {"terseLabel": "Subscription Agreement with Institutional Investors", "label": "Subscription Agreement With Institutional Investors [Member]", "documentation": "Subscription agreement with institutional investors."}}}, {"auth_ref": {}}, {"us-gaap": "SubsequentEventLineItems", {"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventLineItems", {"presentation": {}}, {"http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureSubsequentEventsAdditionalInformationDetails", {"lang": {"en-us": {"role": {"label": "Subsequent Event [Table]", "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event."}}}, {"auth_ref": {"r722": "r748"}}, {"us-gaap": "SubsequentEventMember", {"xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventMember", {"presentation": {}}, {"http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureAcquirementAdditionalInformationDetails", {"lang": {"en-us": {"role": {"label": "Subsequent Event [Table]", "documentation": "Disclosure of information about significant event or transaction occurring between statement of financial position date and date when financial statements were issued."}}}, {"auth_ref": {"r722": "r748"}}, {"us-gaap": "SubsequentEventTypeAxis", {"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventTypeAxis", {"presentation": {}}, {"http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureAcquirementAdditionalInformationDetails", {"lang": {"en-us": {"role": {"label": "Subsequent Event [Table]", "documentation": "Disclosure of information about significant event or transaction occurring between statement of financial position date and date when financial statements were issued."}}}, {"auth_ref": {"r722": "r748"}}, {"us-gaap": "SubsequentEventTypeDomain", {"xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventTypeDomain", {"presentation": {}}, {"http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureAcquirementAdditionalInformationDetails", {"lang": {"en-us": {"role": {"label": "Subsequent Event [Table]", "documentation": "Disclosure of information about significant event or transaction occurring between statement of financial position date and date when financial statements were issued."}}}, {"auth_ref": {"r722": "r748"}}, {"us-gaap": "SubsequentEventTextBlock", {"xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventTextBlock", {"presentation": {}}, {"http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureSubsequentEventsAdditionalInformationDetails", {"lang": {"en-us": {"role": {"label": "Subsequent Events [Text Block]", "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business."}}}, {"auth_ref": {"r742": "r749"}}, {"us-gaap": "SubsidiarySaleOfStockAxis", {"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsidiarySaleOfStockAxis", {"presentation": {}}, {"http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureSubsequentEventsAdditionalInformationDetails", {"lang": {"en-us": {"role": {"label": "Subsequent Events [Text Block]", "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business."}}}, {"auth_ref": {"r742": "r749"}}, {"us-gaap": "SupplementalCashFlowInformationAbstract", {"xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SupplementalCashFlowInformationAbstract", {"presentation": {}}, {"http://www.canopygrowth.com/20241231/taxonomy/role/Role_StatementCondensedInterimConsolidatedStatementsOfCashFlowsUnaudited", {"lang": {"en-us": {"role": {"terseLabel": "Supplemental disclosure of cash flow information", "label": "Supplemental Cash Flow Information [Abstract]"}}, {"auth_ref": {}}, {"cgc": "SupremeCannabisMember", {"xbrltype": "domainItemType", "nsuri": "http://www.canopygrowth.com/20241231", "localname": "SupremeCannabisMember", {"presentation": {}}, {"http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureShareBasedCompensationAdditionalInformationDetails", {"lang": {"en-us": {"role": {"terseLabel": "Supreme Cannabis", "label": "Supreme Cannabis [Member]", "documentation": "Supreme cannabis member."}}}, {"auth_ref": {}}, {"cgc": "SupremeConvertibleDebenturesMember", {"xbrltype": "domainItemType", "nsuri": "http://www.canopygrowth.com/20241231", "localname": "SupremeConvertibleDebenturesMember", {"presentation": {}}, {"http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureDebtSummaryOfComponentsOfDebtDetails", {"lang": {"en-us": {"role": {"terseLabel": "Supreme Convertible Debentures", "label": "Supreme convertible debentures [Member]", "documentation": "Supreme convertible debentures."}}}, {"auth_ref": {}}, {"cgc": "SupremeDebtExchangeMember", {"xbrltype": "domainItemType", "nsuri": "http://www.canopygrowth.com/20241231", "localname": "SupremeDebtExchangeMember", {"presentation": {}}, {"http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureBasisOfPresentationAdditionalInformationDetails", {"lang": {"en-us": {"role": {"label": "Supreme Debt Exchange [Member]", "documentation": "Supreme Debt Exchange"}}, {"auth_ref": {}}, {"cgc": "TabularListTableTextBlock", {"xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TabularListTableTextBlock", {"presentation": {}}, {"http://xbrl.sec.gov/ecd/role/PyDisclosure", {"lang": {"en-us": {"role": {"label": "Tabular List [Table Text Block]", "terseLabel": "Tabular List, Table"}}, {"auth_ref": {"r1230"}}, {"cgc": "TaxesAndGovernmentFeesPayableCurrent", {"xbrltype": "monetaryItemType", "nsuri": "http://www.canopygrowth.com/20241231", "localname": "TaxesAndGovernmentFeesPayableCurrent", {"presentation": {}}, {"http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureOtherAccruedExpensesAndLiabilitiesComponentsOfOtherAccruedExpensesAndLiabilitiesDetails", {"lang": {"en-us": {"role": {"documentation": "Taxes and government fees payable in 200b current", "label": "Taxes And Government Fees Payable Current", "terseLabel": "Taxes and government fees"}}, {"auth_ref": {}}, {"us-gaap": "TemporaryEquityDisclosureAbstract", {"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TemporaryEquityDisclosureAbstract", {"presentation": {}}, {"cgc": "TerrAscendCanadaTermLoanOctober2019March2020Member", {"xbrltype": "domainItemType", "nsuri": "http://www.canopygrowth.com/20241231", "localname": "TerrAscendCanadaTermLoanOctober2019March2020Member", {"presentation": {}}, {"http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureFairValueOffFinancialInstrumentsSummaryOfValuationTechniquesAndSignificantUnobservableInputsIn", {"lang": {"en-us": {"role": {"terseLabel": "TerrAscend Canada Term Loan - October 2019 March 2020", "label": "Terr Ascend Canada Term Loan October 2019 March 2020 [Member]", "documentation": "TerrAscend Canada Term Loan October 2019, March 2020"}}, {"auth_ref": {}}, {"cgc": "TerrAscendCommonSharesMember", {"xbrltype": "domainItemType", "nsuri": "http://www.canopygrowth.com/20241231", "localname": "TerrAscendCommonSharesMember", {"presentation": {}}, {"http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureCanopyUsaAdditionalInformationDetails", {"lang": {"en-us": {"role": {"terseLabel": "TerrAscend Common

Shares", "label": "TerrAscendCommonShares[Member]", "documentation": "TerrAscend-common shares." } } }, "auth_ref": [] }, "cgc_TerrAscendDecember2022Member": { "xbrltype": "domainItemType", "nsuri": "http://www.canopygrowth.com/20241231", "localname": "TerrAscendDecember2022Member", "presentation": ["http://www.canopygrowth.com/20241231/taxonomy/role/Role-DisclosureOtherFinancialAssetsSummaryOfChangesInOtherFinancialAssetsDetails"], "lang": { "en-us": { "role": { "documentation": "TerrAscendDecember2022", "label": "TerrAscendDecember2022[Member]", "terseLabel": "TerrAscend-December2022" } } }, "auth_ref": [] }, "cgc_TerrAscendExchangeableSharesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.canopygrowth.com/20241231", "localname": "TerrAscendExchangeableSharesMember", "presentation": ["http://www.canopygrowth.com/20241231/taxonomy/role/DisclosureCanopyUsaAdditionalInformationDetails"], "lang": { "en-us": { "role": { "documentation": "TerrAscendExchangeableShares", "label": "TerrAscendExchangeableShares[Member]", "terseLabel": "TerrAscendExchangeableShares" } } }, "auth_ref": [] }, "cgc_TerrAscendExchangeableSharesTerrAscendOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://www.canopygrowth.com/20241231", "localname": "TerrAscendExchangeableSharesTerrAscendOptionMember", "presentation": ["http://www.canopygrowth.com/20241231/taxonomy/role/Role-DisclosureFairValueOffinancialInstrumentsSummaryOfValuationTechniquesAndSignificantUnobservableInputsIn", "lang": { "en-us": { "role": { "terseLabel": "TerrAscendExchangeableSharesTerrAscendOption", "label": "TerrAscendExchangeableSharesTerrAscendOption[Member]", "documentation": "TerrAscendExchangeableSharesTerrAscendOption." } } }, "auth_ref": [] }, "cgc_TerrAscendMember": { "xbrltype": "domainItemType", "nsuri": "http://www.canopygrowth.com/20241231", "localname": "TerrAscendMember", "presentation": ["http://www.canopygrowth.com/20241231/taxonomy/role/Role-DisclosureOtherFinancialAssetsSummaryOfChangesInOtherFinancialAssetsDetails"], "lang": { "en-us": { "role": { "terseLabel": "TerrAscend", "label": "TerrAscend[Member]", "documentation": "TerrAscend." } } }, "auth_ref": [] }, "cgc_TerrAscendOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://www.canopygrowth.com/20241231", "localname": "TerrAscendOptionMember", "presentation": ["http://www.canopygrowth.com/20241231/taxonomy/role/DisclosureCanopyUsaAdditionalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "TerrAscendOption", "label": "TerrAscendOption[Member]", "documentation": "TerrAscendOption." } } }, "auth_ref": [] }, "cgc_TerrAscendWarrantsDecember2020Member": { "xbrltype": "domainItemType", "nsuri": "http://www.canopygrowth.com/20241231", "localname": "TerrAscendWarrantsDecember2020Member", "presentation": ["http://www.canopygrowth.com/20241231/taxonomy/role/Role-DisclosureFairValueOffinancialInstrumentsSummaryOfValuationTechniquesAndSignificantUnobservableInputsIn", "lang": { "en-us": { "role": { "terseLabel": "TerrAscendWarrants-December2020", "label": "TerrAscendWarrantsDecember2020[Member]", "documentation": "TerrAscendwarrantsdecember2020member." } } }, "auth_ref": [] }, "cgc_TerrAscendWarrantsDecember2022Member": { "xbrltype": "domainItemType", "nsuri": "http://www.canopygrowth.com/20241231", "localname": "TerrAscendWarrantsDecember2022Member", "presentation": ["http://www.canopygrowth.com/20241231/taxonomy/role/Role-DisclosureFairValueOffinancialInstrumentsSummaryOfValuationTechniquesAndSignificantUnobservableInputsIn", "lang": { "en-us": { "role": { "documentation": "TerrAscendWarrantsDecember2022", "label": "TerrAscendWarrantsDecember2022[Member]", "terseLabel": "TerrAscendWarrants-December2022" } } }, "auth_ref": [] }, "cgc_TerrAscendWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.canopygrowth.com/20241231", "localname": "TerrAscendWarrantsMember", "presentation": ["http://www.canopygrowth.com/20241231/taxonomy/role/DisclosureCanopyUsaAdditionalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "TerrAscendWarrants", "label": "TerrAscendWarrants[Member]", "documentation": "TerrAscendwarrants." } } }, "auth_ref": [] }, "cgc_TerrAscendArrangementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.canopygrowth.com/20241231", "localname": "TerrAscendArrangementMember", "presentation": ["http://www.canopygrowth.com/20241231/taxonomy/role/DisclosureCanopyUsaAdditionalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "TerrAscendArrangement", "label": "TerrAscendArrangement[Member]", "documentation": "TerrAscendArrangement." } } }, "auth_ref": [] }, "cgc_ThirdQuarterTwoThousandAndTwentyFivePaydownsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.canopygrowth.com/20241231", "localname": "ThirdQuarterTwoThousandAndTwentyFivePaydownsMember", "presentation": ["http://www.canopygrowth.com/20241231/taxonomy/role/Role-DisclosureDebtAdditionalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "ThirdQuarter2025Paydown", "label": "ThirdQuarterTwoThousandAndTwentyFivePaydowns[Member]", "documentation": "Thirdquartertwothousandandtwentyfivepaydowns." } } }, "auth_ref": [] }, "cgc_ThirdQuarterTwoThousandAndTwentyFourPaydownsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.canopygrowth.com/20241231", "localname": "ThirdQuarterTwoThousandAndTwentyFourPaydownsMember", "presentation": ["http://www.canopygrowth.com/20241231/taxonomy/role/Role-DisclosureDebtAdditionalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "ThirdQuarter2024Paydowns", "label": "ThirdQuarterTwoThousandAndTwentyFourPaydowns[Member]", "documentation": "Thirdquartertwothousandandtwentyfourpaydowns." } } }, "auth_ref": [] }, "cgc_ThisWorkMember": { "xbrltype": "domainItemType", "nsuri": "http://www.canopygrowth.com/20241231", "localname": "ThisWorkMember", "presentation": ["http://www.canopygrowth.com/20241231/taxonomy/role/Role-DisclosureRevenueSummaryOfDisaggregationOfRevenueDetails"], "lang": { "en-us": { "role": { "terseLabel": "ThisWork", "label": "ThisWork[Member]", "documentation": "Thiswork." } } }, "auth_ref": [] }, "cgc_ThisWorksMember": { "xbrltype": "domainItemType", "nsuri": "http://www.canopygrowth.com/20241231", "localname": "ThisWorksMember", "presentation": ["http://www.canopygrowth.com/20241231/taxonomy/role/Role-DisclosureSegmentInformationSummaryOfReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedDel", "lang": { "en-us": { "role": { "terseLabel": "ThisWorks", "label": "ThisWorks[Member]", "documentation": "ThisWorks." } } }, "auth_ref": [] }, "cgc_TotalMember": { "xbrltype": "domainItemType", "nsuri": "http://www.canopygrowth.com/20241231", "localname": "TotalMember", "presentation": ["http://www.canopygrowth.com/20241231/taxonomy/role/Role-DisclosureShareCapitalSummaryOfIssuancesOfStockOtherDetails"], "lang": { "en-us": { "role": { "terseLabel": "Total[Member]", "label": "Total[Member]", "documentation": "Total[Member]." } } }, "auth_ref": [] }, "ecd_TotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TotalShareholderRtnAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "r1222" } } }, "ecd_TotalShareholderReturnAmount": { "terseLabel": "TotalShareholderReturnAmount" } } }, "auth_ref": ["r1222"] }, "ecd_TotalShareholderRtnVsPeerGroupTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TotalShareholderRtnVsPeerGroupTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "TotalShareholderReturnVsPeerGroup[TextBlock]", "terseLabel": "TotalShareholderReturnVsPeerGroup" } } }, "auth_ref": ["r1229"] }, "ecd_TradingArrAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TradingArrAxis", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "TradingArrangement[Axis]", "terseLabel": "TradingArrangement" } } }, "auth_ref": ["r1249"] }, "ecd_TradingArrByIndTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TradingArrByIndTable", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "TradingArrangementsbyIndividual[Table]", "terseLabel": "TradingArrangementsbyIndividual" } } }, "auth_ref": ["r1251"] }, "cgc_TradingPeriodToProvideNoticeOfRedemption": { "xbrltype": "durationItemType", "nsuri": "http://www.canopygrowth.com/20241231", "localname": "TradingPeriodToProvideNoticeOfRedemption", "presentation": ["http://www.canopygrowth.com/20241231/taxonomy/role/Role-DisclosureDebtAdditionalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Number of trading days to provide notice of redemption", "label": "TradingPeriodToProvideNoticeOfRedemption", "documentation": "Tradingperiodtoprovidenoticeofredemption." } } }, "auth_ref": [] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "TradingSymbol", "presentation": ["http://www.canopygrowth.com/20241231/taxonomy/role/Role-DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "terseLabel": "TradingSymbol", "label": "TradingSymbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "cgc_TrancheAWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.canopygrowth.com/20241231", "localname": "TrancheAWarrantsMember", "presentation": ["http://www.canopygrowth.com/20241231/taxonomy/role/DisclosureAcreageArrangementAdditionalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "TrancheAWarrants", "label": "TrancheAWarrants[Member]", "documentation": "TrancheAWarrants." } } }, "auth_ref": [] }, "cgc_TrancheBandCWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.canopygrowth.com/20241231", "localname": "TrancheBandCWarrantsMember", "presentation": ["http://www.canopygrowth.com/20241231/taxonomy/role/DisclosureAcreageArrangementAdditionalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "TrancheB and CWarrants", "label": "TrancheBAndCWarrants[Member]", "documentation": "TrancheBAndCWarrants." } } }, "auth_ref": [] }, "cgc_TrancheBWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.canopygrowth.com/20241231", "localname": "TrancheBWarrantsMember", "presentation": ["http://www.canopygrowth.com/20241231/taxonomy/role/DisclosureAcreageArrangementAdditionalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "TrancheBWarrants", "label": "TrancheBWarrants[Member]", "documentation": "TrancheBWarrants." } } }, "auth_ref": [] }, "cgc_TrancheCWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.canopygrowth.com/20241231", "localname": "TrancheCWarrantsMember", "presentation": ["http://www.canopygrowth.com/20241231/taxonomy/role/DisclosureAcreageArrangementAdditionalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "TrancheC Warrants", "label": "TrancheCWarrants[Member]", "documentation": "TrancheCWarrants." } } }, "auth_ref": [] }, "cgc_TransferOfAcquiredDebtToLenders": { "xbrltype": "monetaryItemType", "nsuri": "http://www.canopygrowth.com/20241231", "localname": "TransferOfAcquiredDebtToLenders", "presentation": ["http://www.canopygrowth.com/20241231/taxonomy/role/DisclosureCanopyUsaAcreageAgreementsAdditionalInformationDetails", "http://www.canopygrowth.com/20241231/taxonomy/role/Role-DisclosureOtherFinancialAssetsAdditionalInformationDetails"], "lang": { "en-us": { "role": { "documentation": "Transfer of acquired debt to lenders", "label": "TransferOfAcquiredDebtToLenders", "terseLabel": "Amount of debt transferred" } } }, "auth_ref": [] }, "us-gaap-TransfersAndServicingOffinancialInstrumentsTypesOffinancialInstrumentsDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TransfersAndServicingOffinancialInstrumentsTypesOffinancialInstrumentsDomain", "presentation": ["http://www.canopygrowth.com/20241231/taxonomy/role/DisclosureAcreageArrangementAdditionalInformationDetails", "http://www.canopygrowth.com/20241231/taxonomy/role/DisclosureCanopyUsaAcreageAgreementsAdditionalInformationDetails", "http://www.canopygrowth.com/20241231/taxonomy/role/DisclosureCanopyUsaAdditionalInformationDetails", "http://www.canopygrowth.com/20241231/taxonomy/role/Role-DisclosureFairValueOffinancialInstrumentsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtEstimatedFairVa", "http://www.canopygrowth.com/20241231/taxonomy/role/Role-DisclosureOtherFinancialAssetsAdditionalInformationDetails", "http://www.canopygrowth.com/20241231/taxonomy/role/Role-DisclosureOtherFinancialAssetsSummaryOfChangesInOtherFinancialAssetsDetails", "http://www.canopygrowth.com/20241231/taxonomy/role/Role-DisclosureShortTermInvestmentsComponentsOfShortTermInvestmentsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Financial Instruments", "label": "Financial Instruments [Domain]", "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms." } } }, "auth_ref": ["r373", "r374", "r375", "r376", "r377", "r378", "r379", "r380", "r381", "r382", "r383", "r384", "r385", "r386", "r387", "r388", "r389", "r390", "r391", "r392", "r393", "r394", "r395", "r396", "r397", "r398", "r399", "r400", "r401", "r402", "r530", "r546", "r674", "r709", "r750", "r751", "r752", "r753", "r754", "r755", "r756", "r757", "r758", "r759", "r760", "r761", "r762", "r763", "r764", "r766", "r767", "r768", "r769", "r770", "r771", "r772", "r773", "r774", "r775", "r776", "r777", "r778", "r779", "r780", "r846", "r1135", "r1137", "r1139", "r1140", "r1141", "r1142", "r1143", "r1144", "r1145", "r1148", "r1272", "r1273", "r1274", "r1275", "r1276", "r1277", "r1278", "r1325", "r1326", "r1327", "r1328", "r1411", "r1414", "r1415", "r1416", "r1417", "r1418"] }, "ecd_TrdArrAdoptionDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrAdoptionDate", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "TradingArrangementAdoptionDate", "terseLabel": "AdoptionDate" } } }, "auth_ref": ["r1252"] }, "ecd_TrdArrDuration": { "xbrltype": "durationItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrDuration", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "TradingArrangementDuration", "terseLabel": "ArrangementDuration" } } }, "auth_ref": ["r1253"] }, "ecd_TrdArrExpirationDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrExpirationDate", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "TradingArrangementExpirationDate", "terseLabel": "ExpirationDate" } } }, "auth_ref": ["r1253"] }, "ecd_TrdArrIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrIndName", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "TradingArrangementIndividualName", "terseLabel": "Name" } } }, "auth_ref": ["r1251"] }, "ecd_TrdArrIndTitle": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrIndTitle", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "TradingArrangementIndividualTitle", "terseLabel": "Title" } } }, "auth_ref": ["r1251"] }, "ecd_TrdArrSecuritiesAggAvailAmt": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrSecuritiesAggAvailAmt" } }

"TrdArrSecuritiesAggAvailAmt": {"presentation": {"http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"}, "lang": {"en-us": {"role": {"label": "Trading Arrangement, Securities Aggregate Available Amount": {"terseLabel": "Aggregate Available"} } } }, "auth_ref": {"r1254"}, "ecd_TradingArrangementTerminationDate": {"xbrltype": "stringItemType", "nsuri": {"http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrTerminationDate", "presentation": {"http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"}, "lang": {"en-us": {"role": {"label": "Trading Arrangement Termination Date": {"terseLabel": "Termination Date"} } } }, "auth_ref": {"r1252"}, "us-gaap_TreasuryStockAcquiredAverageCostPerShare": {"xbrltype": "perShareItemType", "nsuri": {"http://fasb.org/us-gaap/2024", "localname": "TreasuryStockAcquiredAverageCostPerShare", "presentation": {"http://www.canopygrowth.com/20241231/taxonomy/role/DisclosureCanopyUsaAdditionalInformationDetails"}, "lang": {"en-us": {"role": {"label": "Shares Acquired, Average Cost Per Share": {"terseLabel": "Shares acquired, price per share", "documentation": "Total cost of shares repurchased divided by the total number of shares repurchased." } } } }, "auth_ref": {"r65"}, "us-gaap_TreasuryStockSharesAcquired": {"xbrltype": "sharesItemType", "nsuri": {"http://fasb.org/us-gaap/2024", "localname": "TreasuryStockSharesAcquired", "presentation": {"http://www.canopygrowth.com/20241231/taxonomy/role/DisclosureCanopyUsaAdditionalInformationDetails"}, "lang": {"en-us": {"role": {"label": "Treasury Stock, Shares Acquired": {"terseLabel": "Aggregate common shares acquired", "documentation": "Number of shares that have been repurchased during the period and are being held in treasury." } } } }, "auth_ref": {"r19", "r134", "r191"}, "cgc_TrustSPAMember": {"xbrltype": "domainItemType", "nsuri": {"http://www.canopygrowth.com/20241231", "localname": "TrustSPAMember", "presentation": {"http://www.canopygrowth.com/20241231/taxonomy/role/DisclosureCanopyUsaAdditionalInformationDetails"}, "lang": {"en-us": {"role": {"label": "Trust SPA": {"terseLabel": "Trust SPA", "documentation": "Trust SPA [Member]"}, "auth_ref": {"us-gaap_TypeOfArrangementAxis": {"xbrltype": "stringItemType", "nsuri": {"http://fasb.org/us-gaap/2024", "localname": "TypeOfArrangementAxis", "presentation": {"http://www.canopygrowth.com/20241231/taxonomy/role/DisclosureAcreageArrangementAdditionalInformationDetails"}, "http://www.canopygrowth.com/20241231/taxonomy/role/DisclosureCanopyUsaAdditionalInformationDetails"}, "http://www.canopygrowth.com/20241231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"}, "http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureBasisOfPresentationAdditionalInformationDetails"}, "http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails"}, "http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureShareCapitalAdditionalInformationDetails"}, "lang": {"en-us": {"role": {"label": "Collaborative Arrangement and Arrangement Other than Collaborative": {"label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]", "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } } }, "auth_ref": {"r654"}, "us-gaap_TypeOfFreshStartAdjustmentDomain": {"xbrltype": "domainItemType", "nsuri": {"http://fasb.org/us-gaap/2024", "localname": "TypeOfFreshStartAdjustmentDomain", "presentation": {"http://www.canopygrowth.com/20241231/taxonomy/role/DisclosureAcreageArrangementAdditionalInformationDetails"}, "http://www.canopygrowth.com/20241231/taxonomy/role/DisclosureCanopyUsaAcreageAgreementsAdditionalInformationDetails"}, "http://www.canopygrowth.com/20241231/taxonomy/role/DisclosureCanopyUsaAdditionalInformationDetails"}, "lang": {"en-us": {"role": {"label": "Reorganization, Chapter 11": {"label": "Reorganization, Chapter 11 [Domain]", "documentation": "Adjustment for effect of reorganization under Chapter 11 of Bankruptcy Code. Includes, but is not limited to, adjustment for reorganization plan effect and adoption of fresh-start reporting." } } } }, "auth_ref": {"r741", "r742", "r1447"}, "country_US": {"xbrltype": "domainItemType", "nsuri": {"http://xbrl.sec.gov/country/2024", "localname": "US", "presentation": {"http://www.canopygrowth.com/20241231/taxonomy/role/DisclosureSegmentInformationSummaryOfDisaggregationOfPropertyPlantAndEquipmentByGeographicAreaDetails"}, "http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureSegmentInformationSummaryOfDisaggregationOfNetRevenueByGeographicAreaDetails"}, "lang": {"en-us": {"role": {"label": "United States": {"label": "UNITED STATES"}, "auth_ref": {"ecd_UndrlygSecurityMktPriceChngPct": {"xbrltype": "pureItemType", "nsuri": {"http://xbrl.sec.gov/ecd/2024", "localname": "UndrlygSecurityMktPriceChngPct", "presentation": {"http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"}, "lang": {"en-us": {"role": {"label": "Underlying Security Market Price Change, Percent": {"terseLabel": "Underlying Security Market Price Change"} } } }, "auth_ref": {"r1248"}, "us-gaap_UseOfEstimates": {"xbrltype": "textBlockItemType", "nsuri": {"http://fasb.org/us-gaap/2024", "localname": "UseOfEstimates", "presentation": {"http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies"}, "lang": {"en-us": {"role": {"label": "Use of estimates": {"label": "Use of Estimates, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles." } } } }, "auth_ref": {"r43", "r44", "r45", "r227", "r228", "r230", "r231"}, "stpr_VA": {"xbrltype": "domainItemType", "nsuri": {"http://xbrl.sec.gov/stpr/2024", "localname": "VA", "presentation": {"http://www.canopygrowth.com/20241231/taxonomy/role/DisclosureAcquisitionAdditionalInformationDetails"}, "lang": {"en-us": {"role": {"label": "VIRGINIA": {"terseLabel": "Verona, Virginia"}, "auth_ref": {"us-gaap_ValuationAllowanceMethodologiesAndAssumptions": {"xbrltype": "stringItemType", "nsuri": {"http://fasb.org/us-gaap/2024", "localname": "ValuationAllowanceMethodologiesAndAssumptions", "presentation": {"http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureFairValueOffFinancialInstrumentsSummaryOfValuationTechniquesAndSignificantUnobservableInputsIn"}, "http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureFairValueOffFinancialInstrumentsSummaryOfValuationTechniquesAndSignificantUnobservableInputsIn"}, "lang": {"en-us": {"role": {"label": "Valuation techniques": {"label": "Valuation Allowance, Methodologies and Assumptions", "documentation": "Describes the methodologies and assumptions on which the valuation allowance is based for deferred tax assets for which it is more likely than not that all or a portion of the deferred tax asset will not be realized." } } } }, "auth_ref": {"r1402"}, "us-gaap_ValueAddedTaxReceivable": {"xbrltype": "monetaryItemType", "nsuri": {"http://fasb.org/us-gaap/2024", "localname": "ValueAddedTaxReceivable", "crdr": "debit", "presentation": {"http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureAmountsReceivableNetComponentsOfAmountsReceivableNetDetails"}, "lang": {"en-us": {"role": {"label": "Indirect taxes receivable": {"label": "Value Added Tax Receivable", "documentation": "Carrying amount as of the balance sheet date of value added taxes due either from customers arising from sales on credit terms, or as previously overpaid to tax authorities." } } } }, "auth_ref": {"r1282"}, "cgc_VariousMember": {"xbrltype": "domainItemType", "nsuri": {"http://www.canopygrowth.com/20241231", "localname": "VariousMember", "presentation": {"http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureOtherFinancialAssetsSummaryOfChangesInOtherFinancialAssetsDetails"}, "lang": {"en-us": {"role": {"label": "Various": {"label": "Various [Member]", "documentation": "Various." } } } }, "auth_ref": {"cgc_VeronaManufacturingFacilityMember": {"xbrltype": "domainItemType", "nsuri": {"http://www.canopygrowth.com/20241231", "localname": "VeronaManufacturingFacilityMember", "presentation": {"http://www.canopygrowth.com/20241231/taxonomy/role/DisclosureAcquisitionAdditionalInformationDetails"}, "http://www.canopygrowth.com/20241231/taxonomy/role/DisclosureAcquisitionSummaryOfConsolidatedBalanceSheetImpactAtAcquisitionOfCompanyBusinessCombinationDetail"}, "lang": {"en-us": {"role": {"label": "Verona Manufacturing Facility": {"label": "Verona Manufacturing Facility [Member]", "documentation": "Verona Manufacturing Facility"}, "auth_ref": {"cgc_VertMirabelMember": {"xbrltype": "domainItemType", "nsuri": {"http://www.canopygrowth.com/20241231", "localname": "VertMirabelMember", "presentation": {"http://www.canopygrowth.com/20241231/taxonomy/role/DisclosureRedeemableNoncontrollingInterestAdditionalInformationDetails"}, "http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureRedeemableNoncontrollingInterestSummaryOfNetChangesInRedeemableNoncontrollingInterestsDetail"}, "lang": {"en-us": {"role": {"label": "Vert Mirabel": {"label": "Vert Mirabel [Member]", "documentation": "Vert Mirabel." } } } }, "auth_ref": {"cgc_VertMirabelRedeemableNoncontrollingInterestFutureWholesalePriceAndProductionLevelsDiscountRateMember": {"xbrltype": "domainItemType", "nsuri": {"http://www.canopygrowth.com/20241231", "localname": "VertMirabelRedeemableNoncontrollingInterestFutureWholesalePriceAndProductionLevelsDiscountRateMember", "presentation": {"http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureFairValueOffFinancialInstrumentsSummaryOfValuationTechniquesAndSignificantUnobservableInputsIn"}, "lang": {"en-us": {"role": {"label": "Vert Mirabel Redeemable Noncontrolling Interest Future Wholesale Price and Production Levels Discount Rate [Member]": {"label": "Vert Mirabel Redeemable Noncontrolling Interest Future Wholesale Price and Production Levels Discount Rate [Member]", "documentation": "Vert Mirabel Redeemable Noncontrolling Interest Future Wholesale Price and Production Levels Discount Rate"}, "auth_ref": {"cgc_VertMirabelRedeemableNoncontrollingInterestFutureWholesalePriceAndProductionLevelsMember": {"xbrltype": "domainItemType", "nsuri": {"http://www.canopygrowth.com/20241231", "localname": "VertMirabelRedeemableNoncontrollingInterestFutureWholesalePriceAndProductionLevelsMember", "presentation": {"http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureFairValueOffFinancialInstrumentsSummaryOfValuationTechniquesAndSignificantUnobservableInputsIn"}, "lang": {"en-us": {"role": {"label": "Vert Mirabel redeemable noncontrolling interest future wholesale price and production levels": {"label": "Vert Mirabel Redeemable Noncontrolling Interest Future Wholesale Price and Production Levels [Member]", "documentation": "Vert Mirabel Redeemable Noncontrolling Interest Future Wholesale Price and Production Levels"}, "auth_ref": {"us-gaap_VestingAxis": {"xbrltype": "stringItemType", "nsuri": {"http://fasb.org/us-gaap/2024", "localname": "VestingAxis", "presentation": {"http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureShareBasedCompensationAdditionalInformationDetails"}, "lang": {"en-us": {"role": {"label": "Vesting": {"label": "Vesting [Axis]", "documentation": "Information by vesting schedule of award under share-based payment arrangement." } } } }, "auth_ref": {"r1375", "r1376", "r1377", "r1378", "r1379", "r1380", "r1381", "r1382", "r1383", "r1384", "r1385", "r1386", "r1387", "r1388", "r1389", "r1390", "r1391", "r1392", "r1393", "r1394", "r1395", "r1396", "r1397", "r1398", "r1399", "r1400"}, "us-gaap_VestingDomain": {"xbrltype": "domainItemType", "nsuri": {"http://fasb.org/us-gaap/2024", "localname": "VestingDomain", "presentation": {"http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureShareBasedCompensationAdditionalInformationDetails"}, "lang": {"en-us": {"role": {"label": "Vesting": {"label": "Vesting [Domain]", "documentation": "Vesting schedule of award under share-based payment arrangement." } } } }, "auth_ref": {"r1375", "r1376", "r1377", "r1378", "r1379", "r1380", "r1381", "r1382", "r1383", "r1384", "r1385", "r1386", "r1387", "r1388", "r1389", "r1390", "r1391", "r1392", "r1393", "r1394", "r1395", "r1396", "r1397", "r1398", "r1399", "r1400"}, "ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstddInCvrdYrMember": {"xbrltype": "domainItemType", "nsuri": {"http://xbrl.sec.gov/ecd/2024", "localname": "VstngDtFrValOfEqtyAwrdsGrntdAndVstddInCvrdYrMember", "presentation": {"http://xbrl.sec.gov/ecd/role/PvpDisclosure"}, "lang": {"en-us": {"role": {"label": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member]": {"terseLabel": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year"}, "auth_ref": {"cgc_WanaFinancialInstrumentCallOptionsDiscountRateMember": {"xbrltype": "domainItemType", "nsuri": {"http://www.canopygrowth.com/20241231", "localname": "WanaFinancialInstrumentCallOptionsDiscountRateMember", "presentation": {"http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureFairValueOffFinancialInstrumentsSummaryOfValuationTechniquesAndSignificantUnobservableInputsIn"}, "lang": {"en-us": {"role": {"label": "Wana Financial Instrument - Call Options, Discount Rate": {"label": "Wana Financial Instrument Call Options Discount Rate [Member]", "documentation": "Wana financial instrument - Call Options, Discount rate." } } } }, "auth_ref": {"cgc_WanaFinancialInstrumentCallOptionsMember": {"xbrltype": "domainItemType", "nsuri": {"http://www.canopygrowth.com/20241231", "localname": "WanaFinancialInstrumentCallOptionsMember", "presentation": {"http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureFairValueOffFinancialInstrumentsSummaryOfValuationTechniquesAndSignificantUnobservableInputsIn"}, "lang": {"en-us": {"role": {"label": "Wana Financial Instrument - Call Options": {"label": "Wana Financial Instrument Call Options [Member]", "documentation": "Wana financial instrument - Call Options." } } } }, "auth_ref": {"cgc_WanaFinancialInstrumentDeferredPaymentsMember": {"xbrltype": "domainItemType", "nsuri": {"http://www.canopygrowth.com/20241231", "localname": "WanaFinancialInstrumentDeferredPaymentsMember", "presentation": {"http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureFairValueOffFinancialInstrumentsSummaryOfValuationTechniquesAndSignificantUnobservableInputsIn"}, "lang": {"en-us": {"role": {"label": "Wana financial instrument - Deferred Payments": {"label": "Wana Financial Instrument Deferred Payments [Member]", "documentation": "Wana Financial Instrument - Deferred Payments"}, "auth_ref": {"cgc_WanaFinancialInstrumentVolatilityOfWanaEquityMember": {"xbrltype": "domainItemType", "nsuri": {"http://www.canopygrowth.com/20241231", "localname": "WanaFinancialInstrumentVolatilityOfWanaEquityMember", "presentation": {"http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureFairValueOffFinancialInstrumentsSummaryOfValuationTechniquesAndSignificantUnobservableInputsIn"}, "lang": {"en-us": {"role": {"label": "Wana Financial Instrument Volatility of Wana Equity": {"label": "Wana Financial Instrument Volatility of Wana Equity [Member]", "documentation": "Wana financial instrument volatility of wana equity." } } } }, "auth_ref": {"cgc_WanaMember": {"xbrltype": "domainItemType", "nsuri": {"http://www.canopygrowth.com/20241231", "localname": "WanaMember", "presentation": {"http://www.canopygrowth.com/20241231/taxonomy/role/DisclosureCanopyUsaAdditionalInformationDetails"}, "http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureOtherFinancialAssetsSummaryOfChangesInOtherFinancialAssetsDetails"}, "lang": {"en-us": {"role": {"label": "Wana": {"label": "Wana [Member]", "documentation": "Wana member." } } } }, "auth_ref": {"cgc_WarrantDerivativeLiabilityVolatilityOfCanopyGrowthSharePriceMember": {"xbrltype": "domainItemType", "nsuri": {"http://www.canopygrowth.com/20241231", "localname": "WarrantDerivativeLiabilityVolatilityOfCanopyGrowthSharePriceMember", "presentation": {"http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureFairValueOffFinancialInstrumentsSummaryOfValuationTechniquesAndSignificantUnobservableInputsIn"}, "lang": {"en-us": {"role": {"label": "Warrant Derivative Liability Volatility of Canopy Growth Share Price": {"label": "Warrant Derivative Liability Volatility Of Canopy Growth Share Price [Member]", "documentation": "Warrant derivative liability volatility of canopy growth share price." } } } }, "auth_ref": {"cgc_WarrantIssued": {"

"xbrltype": "sharesItemtype", "nsuri": "http://www.canopygrowth.com/20241231", "localname": "WarrantIssued", "presentation": f
"http://www.canopygrowth.com/20241231/taxonomy/role/DisclosureCanopyUsaAdditionalInformationDetails",
"http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails", "lang": f "en-us", f "role": f "terseLabel": "Common share
purchase warrants in the capital", "label": "Warrant Issued", "documentation": "Warrant issued", "verboseLabel": "Common share purchase warrants" } } }, "auth_ref": f } }
"us-gaap_WarrantMember": f "xbrltype": "domainItemtype", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WarrantMember", "presentation": f
"http://www.canopygrowth.com/20241231/taxonomy/role/DisclosureAcquireArrangementAdditionalInformationDetails",
"http://www.canopygrowth.com/20241231/taxonomy/role/DisclosureCanopyUsaAdditionalInformationDetails",
"http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureFairValueOffinancialInstrumentsSummaryOffinancialAssetsAndLiabilitiesMeasuredAtEstimatedFairVa
"http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureOtherFinancialAssetsSummaryOfChangesInOtherFinancialAssetsDetails",
"http://www.canopygrowth.com/20241231/taxonomy/role/Role_StatementCondensedInterimConsolidatedStatementsOfShareholderSEquityUnaudited", "lang": f "en-us", f
"role": f "verboseLabel": "Warrant", "terseLabel": "Warrants", "label": "Warrant [Member]", "documentation": "Security that gives the holder the right to purchase shares of
stock in accordance with the terms of the instrument, usually upon payment of a specified amount." } } }, "auth_ref": f "r1164", "r1165", "r1168", "r1169", "r1170", "r1171" }
"cgc_WarrantValue": f "xbrltype": "monetaryItemtype", "nsuri": "http://www.canopygrowth.com/20241231", "localname": "WarrantValue", "crdr": "debit", "presentation": f
"http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureShareCapitalSummaryOfWarrantsDetails", "lang": f "en-us", f "role": f "periodStartLabel": "Warrant
value, Beginning balance", "periodEndLabel": "Warrant value, Ending balance", "label": "Warrant Value", "documentation": "Warrant value." } } }, "auth_ref": f } }
"cgc_WarrantValueExerciseOfWarrants": f "xbrltype": "monetaryItemtype", "nsuri": "http://www.canopygrowth.com/20241231", "localname":
"WarrantValueExerciseOfWarrants", "crdr": "debit", "presentation": f
"http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureShareCapitalSummaryOfWarrantsDetails", "lang": f "en-us", f "role": f "terseLabel": "Warrant value,
Exercise of warrants", "label": "Warrant Value Exercise Of Warrants", "documentation": "Warrant value exercise of warrants." } } }, "auth_ref": f } }
"cgc_WarrantValueExpiryOfWarrants": f "xbrltype": "monetaryItemtype", "nsuri": "http://www.canopygrowth.com/20241231", "localname": "WarrantValueExpiryOfWarrants",
"crdr": "debit", "presentation": f "http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureShareCapitalSummaryOfWarrantsDetails", "lang": f "en-us", f
"role": f "documentation": "Warrant Value Expiry Of Warrants", "label": "Warrant Value Expiry Of Warrants", "terseLabel": "Warrant value, Expiry of warrants" } } }
"auth_ref": f } } "cgc_WarrantValueIssuanceOfWarrants": f "xbrltype": "monetaryItemtype", "nsuri": "http://www.canopygrowth.com/20241231", "localname":
"WarrantValueIssuanceOfWarrants", "crdr": "debit", "presentation": f
"http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureShareCapitalSummaryOfWarrantsDetails",
"http://www.canopygrowth.com/20241231/taxonomy/role/Role_StatementCondensedInterimConsolidatedStatementsOfShareholderSEquityUnaudited", "lang": f "en-us", f
"role": f "verboseLabel": "Supreme debt settlement", "documentation": "Warrant value issuance of warrants", "label": "Warrant Value Issuance Of Warrants", "terseLabel":
"Warrant value, Issuance of warrants" } } }, "auth_ref": f } } "cgc_WarrantValueIssuanceOfWarrantsFromPrivatePlacement": f "xbrltype": "monetaryItemtype", "nsuri":
"http://www.canopygrowth.com/20241231", "localname": "WarrantValueIssuanceOfWarrantsFromPrivatePlacement", "crdr": "debit", "presentation": f
"http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureShareCapitalSummaryOfWarrantsDetails", "lang": f "en-us", f "role": f "terseLabel": "Warrant value,
Issuance of warrants from private placement", "label": "Warrant Value Issuance Of Warrants From Private Placement", "documentation": "Warrant value issuance of warrants
from private placement." } } }, "auth_ref": f } } "us-gaap_WarrantsAndRightsNoteDisclosureAbstract": f "xbrltype": "stringItemtype", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "WarrantsAndRightsNoteDisclosureAbstract", "lang": f "en-us", f "role": f "label": "Warrants and Rights Note Disclosure [Abstract]" } } }, "auth_ref": f } } "us-
gaap_WarrantsAndRightsOutstandingMaturityDate": f "xbrltype": "dateItemtype", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"WarrantsAndRightsOutstandingMaturityDate", "presentation": f "http://www.canopygrowth.com/20241231/taxonomy/role/DisclosureCanopyUsaAdditionalInformationDetails"
"lang": f "en-us", f "role": f "terseLabel": "Warrant expiration date", "label": "Warrants and Rights Outstanding, Maturity Date", "documentation": "Expiration date of
outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to
occur in YYYY-MM-DD format." } } }, "auth_ref": f "r1414", "r1415", "r1416" } } "cgc_WarrantsAverageExercisePrice": f "xbrltype": "perShareItemtype", "nsuri":
"http://www.canopygrowth.com/20241231", "localname": "WarrantsAverageExercisePrice", "presentation": f
"http://www.canopygrowth.com/20241231/taxonomy/role/Role_DisclosureShareCapitalSummaryOfWarrantsDetails", "lang": f "en-us", f "role": f "periodStartLabel": "Average
exercise price, Beginning balance", "periodEndLabel": "Average exercise price, Ending balance", "label": "Warrants Average Exercise Price", "documentation": "Warrant
average exercise price." } } }, "auth_ref": f } } "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": f "xbrltype": "sharesItemtype", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "presentation": f
"http://www.canopygrowth.com/20241231/taxonomy/role/StatementCondensedInterimConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited", "lang": f "en-
us", f "role": f "totalLabel": "Weighted Average Number of Shares Outstanding, Diluted, Total", "terseLabel": "Diluted weighted average common shares outstanding", "label":
"Weighted Average Number of Shares Outstanding, Diluted", "documentation": "The average number of shares or units issued and outstanding that are used in calculating
diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period." } } }, "auth_ref": f "r318", "r324" } } "us-
gaap_WeightedAverageNumberOfSharesOutstandingBasic": f "xbrltype": "sharesItemtype", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"WeightedAverageNumberOfSharesOutstandingBasic", "presentation": f
"http://www.canopygrowth.com/20241231/taxonomy/role/StatementCondensedInterimConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited", "lang": f "en-
us", f "role": f "totalLabel": "Weighted Average Number of Shares Outstanding, Basic, Total", "verboseLabel": "Weighted average number of common shares outstanding",
"terseLabel": "Basic weighted average common shares outstanding", "label": "Weighted Average Number of Shares Outstanding, Basic", "documentation": "Number of [basic]
shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within
a reporting period that common shares or units have been outstanding to the total time in that period." } } }, "auth_ref": f "r317", "r324" } }
"ecd_YrEndFrValOfEqtyAwrdGrntdInCvrdYrOutsdngAndUnvstdMember": f "xbrltype": "domainItemtype", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"YrEndFrValOfEqtyAwrdGrntdInCvrdYrOutsdngAndUnvstdMember", "presentation": f "http://xbrl.sec.gov/ecd/role/PyPDisclosure", "lang": f "en-us", f "role": f "label":
"Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member]", "terseLabel": "Year-end Fair Value of Equity Awards Granted in
Covered Year that are Outstanding and Unvested" } } }, "auth_ref": f "r1216" } } } "std_ref": f "r0", f "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name":
"Accounting Standards Codification", "Section": "25", "Paragraph": "16", "SubTopic": "10", "Topic": "805", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479405/805-10-25-16", "r1": f "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section":
"25", "Paragraph": "16", "SubTopic": "10", "Topic": "805", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479405/805-10-25-16", "r2": f "role":
"http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "16", "SubTopic": "10", "Topic": "805", "Publisher":
"FASB", "URI": "https://asc.fasb.org/1943274/2147479405/805-10-25-16", "r3": f "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards
Codification", "Section": "45", "Paragraph": "1", "SubTopic": "230", "Topic": "830", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/214747401/830-230-45-1",
"r4": f "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10", "SubTopic": "20", "Topic": "205",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483475/205-20-45-10", "r5": f "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting
Standards Codification", "Section": "45", "Paragraph": "10A", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-
45-10A", "r6": f "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(a)",
"SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A", "r7": f "role": "http://fasb.org/us-
gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482130/360-10-45-11", "r8": f "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section":
"45", "Paragraph": "14", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14", "r9":
f "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "21B", "SubTopic": "10", "Topic": "230",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-21D", "r10": f "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting
Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482740/230-10-45-28", "r11": f "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification",
"Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-
28", "r12": f "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic":
"360", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1", "r13": f "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting
Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "20", "Topic": "205", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-
1", "r14": f "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)",
"SubTopic": "30", "Topic": "805", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1", "r15": f "role": "http://fasb.org/us-
gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "SubTopic": "30", "Topic": "805",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1", "r16": f "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting
Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)(2)", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147481203/810-10-50-1A", "r17": f "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification",
"Section": "50", "Paragraph": "1A", "Subparagraph": "(c)(3)", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-
50-1A", "r18": f "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(d)",
"SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A", "r19": f "role": "http://fasb.org/us-
gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic": "505", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147481112/505-10-50-2", "r20": f "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section":
"50", "Paragraph": "2", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "805", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2", "r21": f
"role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "SubTopic": "10",
"Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2", "r22": f "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480429/718-10-50-2", "r23": f "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section":
"50", "Paragraph": "2", "Subparagraph": "(g)", "SubTopic": "10", "Topic": "860", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2", "r24": f
"role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "SubTopic": "10", "Topic": "220",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482739/220-10-55-15", "r28": f "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting
Standards Codification", "Section": "55", "Paragraph": "44", "SubTopic": "20", "Topic": "805", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479876/805-20-
55-44", "r29": f "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX
210.5-02(22))", "SubTopic": "10", "Topic": "210", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-599-1", "r30": f "role": "http://fasb.org/us-
gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "205", "SubTopic": "20", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147483499/205-20-50-3", "r31": f "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic":
"210", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483489/210-10-50-1", "r32": f "role":
"http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "14", "Publisher":
"FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14", "r33": f "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards
Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "14A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14A",
"r34": f "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "5",

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6", "r1459": "f", "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6", "r1460": "f", "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6", "r1461": "f", "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6", "r1462": "f", "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6", "r1463": "f", "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A", "r1464": "f", "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A", "r1465": "f", "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A", "r1466": "f", "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A", "r1467": "f", "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A", "r1468": "f", "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A", "r1469": "f", "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B", "r1470": "f", "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B", "r1471": "f", "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B", "r1472": "f", "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2", "r1473": "f", "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2", "r1474": "f", "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4", "r1475": "f", "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6", "r1476": "f", "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "599", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-599-1", "r1477": "f", "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "599", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-599-1", "r1478": "f", "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "599", "Paragraph": "3", "Subparagraph": "(SX 210.6-07(7)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-599-1", "r1479": "f", "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "599", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-599-3", "r1480": "f", "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "599", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-599-3", "r1481": "f", "role": "IDEA: XBRL DOCUMENT begin 644.0000950170.25.015839-xbrl.zip M4\$!L#10 (C=PU1UFW LO@<\$ %>12P 0.8V=C+3.P.C0Q.C.Q+!EAT.M=RLW369(f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f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

[illegible]

A32ACG25L5L00.59-B00RDBCKJ#AYR91U#1Y1GSDSX0YUJ#-M(C#7QIR2.W5K5QJ#U#1F#&K8.X9#>0#H61->BE6TEI0HGQWT#X1070R6.MX70-L#E#N3E3%F0&.X.9#9#0
 (F#G.1+>WY.H@0PZ).17-F+AMHZPVJ)-B.M&M#.Y%1%8-M5).8NT.L3.1M-M?LCLZ+IS"W#R&P8?Z#8<30.%=>4C.8W-OY.M?LIMN-49I05/E1PYMWG?
 X52PL1INVNRZK#="JQRI3L1.01&=BPQUGB2.M2087A2+14MHJXJ+A* C.OXDQ?U.T.V13N51S-IGW<3CGD12SDIO2G)C)F3)-0.MDDYI&W>.>5J7<5.FY-E?ODA.55HLC&KPYE88&PP-
 Q&0ST.6@QI->AVOJ.M&E.HF#7I25U#E=2RD1210V3HO>J&SR&JVP0R&ZWC96/SBZXWX#X-WG+K1R#
 W52UBK#5QK1.H1+AIRN3)D#?2S# 61Q-UW#V19-GNR6E+LKBO.WQ?712.T2GBGUEV#Q#+#1+SW7E.0JHB+<C7ZRL&KX7#Q@C97.<@.S#N6<.(VWLEF.M6WME+0Z1-
 (DW).05<->20X5U15D01&X)XSWH4V1KX#5.71%1423.M%1=>1S9Q#XYXD1V4I.5="9UIC9A9F.XYK04UDIF0.8CLRF1M.X#7#4AHO425&7V#F4.159V+<^
 M6L3RSIZ7KIOIN-7WZQV+D&G_.JO.MH(M02\$WO->73-K.WIU17KIMLY.X>VS-R>5NNMNVEPKHIO.SMXWRS#F>S.MBI#>SE9UMGUJ-17K8.EUCI*O-
 GHNSKM=GD.8=>1K(ME69%NYSR.0%#EJ06F+J K-8TW9.2MIS.L7.T1.00MR# 16J7F-MF)=GWDYV9FE+7+1JBV1.HFGWY= GUPH1+<S791PZ+MPIVE5)YXN059K%
 H74Y106-UO/<#EK1XW422G?Z.6>H%>(GJH.WN.MO.9WV2387NAAVOJ#)R3)31.U-X<77.MW1>29D17+7Y2GKQ=>OK\$5SIC.8=>A=>10<ZP?Z?70<+<NG+9W1M
 M523U+>E6GUU.UKH1.U+17G5Y.6VW-N=55W1>?GTSZ=>2HURU->WAY.MP+UWLZJ.JS<0?Z0AUVOR3L.OYT3Y871V.MA35FWT+1>G.Y1G.1DDI725M7&8-QDY?
 WTM=IR6Z31&PZV.S2Q7E+>?SIU.WN#<1N20/UFU.H7LKO1+L.F+Q1.15R+<1.0.WM1.6<2.M1>3MAOA#2>E.9SW#E2S.X2K#10R1X1G10+1P1V.OIE77HWP.M?<
 #H&X.VD+OH#<ZU+1B63WGUVR/OCWIRXJ.~%#%.P3.6C+(VK1G7W.ME.S1E+<-67<@=>1=MT.M.J.HS#WZOE66.61910.LRS?7OB+IG>R
 MGDV+GPDFF/UJICOW6>EPX&K?<W/V16W>.<3F&+<#>#X#XNCLMD/MCHT?Y0L7=2+7BMELJ7F1+>JUH8.#5UXPG3V.MU44L#X#K-
 &00YV+>X&WPAF2UYU22.8AAW#C.17M2UFBJS.U+0#MMF->+18-7NUL3MD-MJIT?<Y0L20.X1IT6>[ATC.MUR-01.1+7.3%KH#W8N# 07(1=CW10*18UQU2">#&\$&
 (G#7K\$0C1QZ7.6-MX8>87YQ3B8=>Q10810.AMWCJH#.AU4.M.BOW2U1+VOS1(1.6C.6C.A#KA9.R71W.910+<N&C.%2%#H9OC@M>Z.M#BN6E(1-
 5%#DN0V7.8-3X0?OMJOT5>@.Y<+<+G8.OOLQO7YTZ1+<9?J.EGUCU01M=>Y&U#X#X#X&S3.19HHG95)N)69%)
 M.2.H.UHJGB&S#(KCYUEF02.P+18E2.ESP#6+<16<3C1*QWK.MXZY/E2GZR%26%(M.J#DP5)123BA319&M.WD1WQ(Z=2-2RX9DX(\$D6V+9U05SO+<#%5Y4.RC10
 M1F>S<3-3&KFM+<88V.A)A+1V4V#<0#>DC11.Z(9L5%&6WQ1W343EGMO> MNH1PUA5A+E@0ANR.41Q<S7.FPK(14V4#9.C127.LY+<C.N158K.U)M1E4MHJRY5.
 M149#H#PIZ@XJ3&ECC@FT#2Y2+H4256?DF2E.61MB14W1FO.S+<D33?41MB#(8C91B+131#1A3-V%P3.UYX+YJU.Y#9.MN171PW1+G>#%X%1L4J6
 X164=<55<7+>1>H61519+XTV.HUKVME# MDS3M5<JRS5176CAV4Y2BOK1<S=>5%6216<6.A1+<TDMW197.08\$>9N78G1MG.M7X59.1L5.EC(GFOL+13USC.V3+4=>1)
 PAU)R#A1.#%&.DP802X&C.MPMG.RA"2<-(01<X6SOY1A#&D(H<+<1)SIHPAUG#2.4\$7.5@X?T1MZCA1)<=>#M#DR+<P&C1C.L1J>+<602?Z1D8GR1.
 >K17V2>22NK&D&O.M9ABN@JTGW.415\$M/M11%<@S&K&9.23W.F=79)S=Q&S9KJW14>->?P5)2.M.7J5=>+<G4G64WCWB.X0)
 PN.#<Z(M+11H51Q32\$VA">#<6H#1.YBB#K#M5-Q1JW3F.3M21Y6910Y+Y07HJ/007X+<Q\$6=>GR2.AB8./93DR7661W.M.W22)J)Z0GRIS191+Q.E\$1-1%)N2<+VP1WN/I
 IG*AO1L#1.&4.50X.M?<1ZCA1*.<P.L4J1LQ@.<?2.6).MS?T3B-61Q1Q+Y102G1B6\$+0#31@C#U#.S(=>=>@X?P.L.CC1&S.@+P+<9.MX10QTD#<4\$G%LW4H8Z3IG
 RVK5/OCR5=>424QAD1&W.52312B&K.ME1<=>+<S.2161W3+LQ+<H>+<0.N.03%12NXX&G4V29TU1.9829.M.MK3YV#PK08\$S.SCH1Q1+D2.OBZ1+<4>DZ.T
 <ED>1&LNY4HIEB=<#39W.M.V+<11%#D0V9Y/RK/V00K51\$3SLU7Y>9?PTZ.C1088%#MU7BI0MK.VICKGK8)ON.M67>ZS1O7T2WUZ41YO=>JUXHXIZAP1+P
 Y#K.WGDZ61C1+PG1+<W+X1.M1.DC514B16Q0>22Z9?K.A@1<#<#OF=MMON@202.61%9K+<X.O.KK9?>>+<MZZ375.TFVIOE1Z&Y9L2XMG1&K1D+L
 HRE.P.7.IAW.CY39<1Q.P+<0N29.M5-681B6DJQ.UU+<F=VYV6SVL0Z>UASH.IQ@.\$.85YV&HSRK-CE#VJ=>SRMA(7M.TFVIOE1Z&Y9L2XMG1&K1D+L
 HPI1L1\$D#H#<#403HB810102.M#OY#N#H=I0K5F3A+H9+?#&6(BL.L130FPL#>?3IGPG2*0M9.TC9J+VCM7BDC(MJF17RS30.9.L9KG+LZ%Q>S19IK
 W7G#KGE8BP@P.A)A3+P2.M2@D.H91=<B1@1DE1(8CF@Y2&G.1WYA51.FE#M.AJ5(S1Q.10.9Y2)+<6J+<B16%Z671UUK13<72)JZLSL17.MRX&1S5.E18X?F+4?1F@
 @/82181-<4\$>HX10.A#H"SL"V3+4=>1) PAU)R#A1.#%&.DP80T1W3L+<17.E#1#<213B1G31@HM45WS=>2343.MLVPN+V99(GT8)>(3.28.66\$SL"V3+4=>1) SB>#<OH-
 Z"Q101.9+GM<ZU.M#E5+409)0IDIF2PL61Z7<6&5HE#B.S+KNSA22Q@OAT.MX8162\$N1>0.HX.M35#9#<1K7P.<8/S&S1T331.RD9V26\$BLU3><W&#<7\$1S1Y1E1>RG+7H/A
 M31..>F@07159.OH0+1N\$K>S3=ENSTJW068.HC5.0D=4@=<M.WWZ.LVAT<T+1ZCA1*.<@.PK.MS68.6C0=A<+V3?3T&E@&#H=<0Z.&1.HC4.8@<T=JH.8=>
 <CP1>?7971.L"AT#M#<#<A\$1WZHTH4G731>?Q\$H9U9(981AGC.OFFE#RRZ.Y4OZCA.YGR10M.M1W19.3.T0+X?>=>H+U6C19R717L3+7<2>0.516R>.7UZNR1>59
 M1T09.1=>#>2PDQ.CT1F#S&OX#X26.PE1H1L2K<1Q>4VE.(MEH.MIQ#MR#<6.2JF."LER#42-DYLLC@92)&.E.H#<LCGGD.L1#G67J.CX7P.FE.G.MQ.4D19SC01L14X1Q86?1
 HQD19NM5Y23&#<TL5HY1SYR&L2QD1K.MXWTXZQD+29P5CHT<=<#>Y@#N1.3ANBUVL1=<+>99E)RDA1YUQG.M122<9WYV.5E\$=<6C91J.Z3

[illegible]

[illegible]

[illegible]

RL61. "0Q:1-L8:CVL:59G.WG3UB.GDV>|BJ572UZ<M6*MJ2>XSVUHT.NR<S9DSI>@.2Z*H3E.US#Q:HW>YKWV.WXVF.LVNFRI.HJ<|<M74&X9-Y.67A>.0V*Y<31
(AG32KL>EIGI>+>\$OG.M75=WSH=YWU:=5/10&1724<1T>+.FN:O:JZ<17K<0BW.KD/0Q/VFI.M183.R3YV.5A>2H8<6KINU<#>72+X<
|U>.XV7+>+CHSLYL&GDI7X8LJYFKQJHJ.LHJHPT<SIE&E.M1.B7.07A<29*VRU<1&KJUM<U>EJCBWZ<+DMG.MIKETU<#>2<IHO<0>YU<0.OLO:8UY<|WJ>E66N<
71UHNY.8A49J.P.N66X.M<6%>PIK2.E7D<E+>+8HZ&:UDTLL4#>LQJHJ+8+2<DQSD1.BCG-F8<C&J.M6<|>TL1<#>UYVDA.0M8<9SP750<17YVUL>
=2I7<3WY45NZTLE>+P10J<+H6&AZH9.Q3F7Q4L9Q125*H.M+5BFEM92.F2001<14EM<12.6&S<K:88A9<ASX<PJ>+M.D8V.D4WVY2H<8LN3<((I&YTL2<
M)>SPLM&LH<P%>+B05+>+R<P7C.M4<@.9:30AF<+>#1.W9R.YYB<L:W8&EH.W.557T4J0>M9Y<L7<@>X+>1<6T9&26TIN.4+P21&CC02K0.114P7.9V4IA=9W2O3<314<
MNTW&H&WG<2V+8E+>+P&Y&OWIG:(K/6+WS?>2IN1+>2>E)0%>P2.M<1>+>9:2ZRI>LSIS9QMH<+>P&A8GLWE5H9G9L0.6TKFOJH2X.NTROG.M<7<
|D4H&L7I2D9R<HJ&S24OZ.K<3U0W&34U<#>Y0VGS4U.M.OU7Q.O.NV19<+>P&S+>+1XUOROMH<YR<E7R<D>P7&+>EL7UC7<+>MGGQI&P0U75+RTL<+>
<4<TUBJ0DL01S530.0>H5<D3J2L>+>YX4YLV0A2+>MG892&S<KY&ESV2+>3VYEZ&GZYV0837K<6CSEF>+>KG.AB67MWGEUBIONIK<M>FHYN5<GX.S#>15+>W+>JU<T1+>
|D9K7CBUJHDB<P7Q>46N9J<AL.M%>+>B0531.97.(LFP<C.B6.W9UY.G6G&ABD.15:4VO/SK<|>X?>=>R<S<KIPR.MGS2G.5K7<1+>7ON7N<26%>VYT/4F.W>+>C<KOR<0/K23P<5<
Y<EJDBH0RUU3.MKQ02.NGKR<OL.E4LQNTHBDEWK<6FIEF7<+>WEX.M<UUKKKKEQG+>E.AB5<P.P.M<H0+>C<CP8<AEEBKA.UFHY.Y2>+>Q<R4Y1WIXK14<#7.EVD<KHEBM.AVEY<
MAYOYH7.O1UE.PJ6S7Q7+>7+I97.5L<+>+HWM3E<+>OS7WUZ<+>#<|O<1<M/GMRP<1+>I<QF<M<OCGH1P&K5NU<#>M2N13JBG<+>YE<+>1VMJM7<+>1M7J<Y.VDFNI<8G1<WLO<
>XUFUHL5<P.N.M=>+>K&A<N<+>IB6NIPYS<2JVL.B<TLHXG<|>E+>Y+>3EXVQ<Q1<|>FKW<1+>LO MWZV.O#X<W0<L.V3>+>|>TRW<1B7<+>GIR.MJE<2+>+>OK.E>>3K65<Y#>CNY<#1#<
#8HJ<+>5SPL3<P.B*#>0<70.HOKUUNL<+>7UO<+>P.W/58H14+>U5K<@9DC.M2<+>I0<+>8D7H<#>2<+>Y#>9&Y4E8F9J78Z57QG08<DZX1<@<=<K:1X7.K8<
M.OWB9J.N.X3IAOJ9V9RPI3+>+>B0531.97.(LFP<C.B6.W9UY.G6G&ABD.15:4VO/SK<|>X?>=>R<S<KIPR.MGS2G.5K7<1+>7ON7N<26%>VYT/4F.W>+>C<KOR<0/K23P<5<
M5<NJS<VYL<+>3W3MHV.Y8&E.DHLZ4<T77%>AS)SIA47AFBMMH.YWC<9YRV2<3.MIC%>GONS<AUBGWOUXWR>+>16PBB<Q>HH<#EM.M<S<#>AA&2FFI+>9<
M#>HWMJMSO.R#>1.LSU<C<LYX&68.CRIH7<O.M<+>5%>O<K<AYB2Y<80SND6P>+>W6W6Y1+>D.M.9GZIW<G<Q05<144<125.MS9<ISD<E.F.A+>90H?<
I+>2&S<@<S=62Z.IWB<16M<+>X<Z+>RAVY<#>KN.MI0<G3FW5V.IHU7H1YK&R<7&K92>+>R16<4<+>M.C<#>+>P.D>>3WJ3V1+>Y2P1UJX&BMZFIS=Y<+>U.O>Y>3C<16<VIF5PXN7<
M1YVM<T81JEG<@<C>+>6.HJL.RAY<|>((KZC<+>IDB.N)SVA.BA.H2EHC<R4+>H44&H0.RD/OFNGB<1.F0Z.GI<+>DU.M.EG<+>BH<#HNUU<+>A79J<DV1W6E+>ME.M2<
>AX18ZI<M.M.630<+>J&K<6%>P7.GZJF4O77<6JHN<+>6<12X86Z<LE>+>K<F+>7.MCMHJH<WY>+>27Z7.DDWITL&85A<|>J.M=>+>3925V1.M=>#>D<008L0Q2<+>65PK8YBG<
E<A<6#86HJ3<M.M=0T>A6DNLKBB9B<+>+>373E.M6.O1<OK<+>6U<C87>+>D.BJBNP<94+>9%>6S49BKFE<N8<SOAG<L.A9FF&SNH<6R.MW6>+>ZJB<16V#>UL+>U<00/7>W>+>1X.ZA)M<
I06H&+>#H+>ORH<+>RG<+>CJ)S<B-7.M.L.M40.GHIC<|>Q&K<8B9<S1AXMM<06N1E2.O1A<+>2<WJSV2<R#>+>#>B2<1.MH<S88.210IXWE7<O1<+>IT1N<+>8%>J<
|PH0S<+>Y%>+>31Z.W.BVY<1N<OOC.MYM<M400<RU<+>#>P<+>186KKA1&FZ4A<|>HJH8I2<+>#>96AYE<+>ASR<XZ<2*XY<
M6<PT2M<76A<K1WUK0<+>2<P%>S2<+>S2N<3P<+>53.XC2Y0>+>6&M.O.MHG8D45<+>3<C<@.04C2<C<OZUW<B<+>#YI16Z2Q<6R.TWGSJHL<MK7ZCEPIQ<M56HNR<G=2IV.9+>N13<
U6<+>RY<L7H<BOJK<M<+>0&6Y1<#>C41<#>T&D5139257<+>@>P.M.O1GW<5<+>Q<7&K<M553<+>I&C2&SVWTLQ9X<1YGP&K<1Z&X<1<MP3B3<+>50<+>6JH<
Q8YRV1X<7T#>S1LK<+>2T6.EO.UH.U4&S<+>+>X<#>YI+>2BCU<#>70T14HR.D.P<A.Q.S<R3N019UJCYX00RW<C<+>BJF<5018<SP2<S/>5.2.MOT3BL0.M<
HJF19<X<+>MYORHC403FLEW42YX<+>|>T<HIL.D44A<+>2LT<#>N1.MLB055H<I<7&UX<+>2.OPIH<58<+>O.2P<W<CZ.M#>B4PIB<D216<
I25<+>50A2IC<@>S0ER33EN<#>G287AY0<WCD<P&HICAH<J0<MDSH144.NJ.Y9YQ3<+>W3<7WTO<W<|>N3<V7&8K<+>E16<4H70+>B.P<B<#>M0LXD99<#>X2D1A<87>+>10F<+>VHV<EH+>W<
J00.1+>U1P02UD<7R.PRWIR<M.I5<M.O57<RQTL1<2ICV10RE<Y>HIX<L&HJ+>17+>96S<+>Y14ADG<E.Y.M<#>0<K7<+>9&021<6K<14B<1+>1&T2P1<3ZE+>B8<7>PJ3<A

[illegible]

1.0K06*2A-9+Q0F1QB0X16+DGMCA-MJ2H:G2-1HH:1H6R+*BYVP7V3X+V2Z->P^CQMTW:VHD7J-LM US M5N6INW+FNQIKU+IPMW,BBB^<LE-
IY5+@W6)INT\$W7X6*MEF+84N&15-MST0TH-ALTR+J1JHM-4@-V00%IKG<4F-04*%B+&YJB6&UM-7J1MGY:C5P-32P-U->I8W>X9:9*EXY^0JG&G2+>DD06*XB80)KD
P91)W8H1M*WGA:AS6GEN&Q8)HYRK+31(N#H)0-5T-CY8H+P-OMTFM-JL#M-SF-MQE-@<XEOFI>I26-RG=I24,229/F-?<ZN+&I0U@6+1-0.6&VE+1SS#-M-2
F&F&B-B-N9X2ZZFV-G-1J1%9X/EZZ->=1J?F2YBW&L-@86(B6BIM-MG00L+&1H2-T<\$(B=A-4HPB8-5CWU+@102Y56XN9J@K8UWFBK)U-@<BFHX=1JMM3;KU=V-V
HXPN-OPME-AJB:SZ-1J4H1S-YC)04B:W&+2P=+93 MY3G-=-E-2&1H H2-8-U?JN1-9U?H#-R\$5+53-62(R) M0#M0#W0D3-C@-I-2Z>R/E+MIR-Y&0+>B+<H93+<80
MTV14H9T8-D92\$A+@L\$S-)<9IPE39JAB6&6;DU74-@#K3Q-G%N74Y0.X1+1-9M*1Y:82Y6R1-2MDK+&-NZ(7CJF-WN+8@MLH(C+1C+
16/6A&9015+&10V0CTNP&F&D2H@&M3-(6@)G^>1H-DV&B)H<ZSF=5P.KPS J-MIPPP*TAJ:HIRO4!R0Y:J1+1+3BJS?3V?P+R100373GM@%0617#(4-#91M1:1%PIS;KZ:
<1\$9\$ PP&@F4I02-X49+8J+30@#ZF-1\$LUZ\$H:0-!RM&P)H<C#M0#DIFL+TJ#M3<=>(A@VIMPQ:U-LJ)C)S1548RGJ0J8H> /JHIEY7C
M,ZHLE+UYV8Y:FAHG(93D@<LA00<=>D474(EZBGC)-M=K1AN0&4HC-M(0WF3J-2@W%=>B-LH-@>3D1(GA#2?ND=D-JB:(Z:101UE-Q2P13D)HJ2DHPG
M6E9F@<IWO(0@<1=1&FV3>\$.#D472F/7?LZL+FE3L-YW59H6:W=G-Z-G-M@&SDS0M5@93-1J1V+13C-A%1=>C.GF&N@<9-4X%100G\$F5E81M\$-XD:
(4X)H)USB&.&0DE411GON:5IEZBYUN:1QC2:260:IS+M(=>1D4-M7J3-1@82F2-U4TFH3H371Z5@<@<X3&3G\$B&K(NB)B346&:\$1QYV1+>W9EW-MXD2&C.8J1TCT46#>+?
+FG+C)XOVTBDM:J+HG:VJHD)T/M:7H2%8YIE-M42N+>4U9D4+&SGK5-4LLBYH+PSEOK(4UAN\$P#7V=?\$G#L1)KBZVP-10>-M9H8-LO<@WMMNK@<S.0=>XN/H
<<D?>WGNP>=>G:BI6/BIGF>PAW5PUS\$M:MLU\$S43Y:H.0A56>JHPYKDGPIE@W%2GIDNLE7R(4#3HV%\$E%U@<Q+1M%Y4-YPPT/5>?<?
I3Y48U815B1@62WY:66T\$152>-A2NXP&JIC2P+H5-MW27\$1>?>NLY/8X\$55+<X\$K1+1&JDF-W:M-@U7#K-@HGNJK:HG:H7WTEIN-W&D+1B@S-HH
MEDR(R141:HMMDM)M\$H:VSBWPV-EM\$#M-6R7\$1(2P3BPBP)6V-W@C(1BA)+V-MZJ41M-MU%2&GNIVU5523X%1-3W39-00)G@Q#G633N9-7/NM-J3-W?G-MB-T
->@04HMD13W&B:LN1\$SSWK<ZS-1W2V&ASU\$YB>2E2F/AB<=9TNMYC=1J3T50%Z<#YNN208HIFU+H1=N^U3+&A.KIT19X(H#N)JW0R1ZZZU
MC:FXMHJM\$WZYEJ>7M>#SIZD-7H#S-VH:SOQD7US-B@J-A=>FEIN\$WYV-MNLIM-ZN1:XA1-EDZR\$S19KN-72-N1WTF5<=>AL>VNV(I:X*T5PQ3-1W-MJ<3>ZTK/R1<8I<=
%OHP#R#JDC.8DSFN#4@<S182MU+ICR-1J-2M-MSN+@-P26-8C<=>#86U1Y3B7G&C1318-R8HUB55P1Z5=H#%KKH
MD5=YQB#P#>2-CY29P+1A:1AM>1OM#T:K\$8@WG\$-OUY7+Z#M-SA4613P-MB-U9HTE12&S:03ITG>2VE+14P/BQW-W0#3B7KX353P-3?3EPA#Z%G
MK20A\$3(4EM8B)0-MT-4V04K45P:W.OUYUTTRF62SLJ(9LX1L\$G/R\$5=>A194JXPL@QCH4@(#B#36-M0\$SLCTSNPL635C=>Q.XJ1#XHI(QSR"-7B28K=
0#M2E-#P&S1MBDRQ&#W&W\$N9A(H=+1-X52%K1U58TF-24KWH8#>Z<0D-6%KXHM-M:#\$2\$-NJGTF2WET1W@3-NIEH?KKN@126GTFY\$Y85+>1YTP-MTFYUPT48A
&4N4C(1C)0WRC:EIOI6&I3SAR00#P=1X+OYR\$X5LOY<M1:6 H-Y1+UA9X/IGP+TUG->R-OVM:GU+UBU=JXV:5W\$YR1-L+<G+C&M7-K:G7F1W+PZDM09S017V<+
I24JN56DFHHM12U5\$1J45>+P+HP000\$1:PM\$8A M86B.01)L#M1-6-C6-2C-3ZC3#0OXYG7G:GP:E7@<(KG\$T+QY0\$Y+@&7\$ MA?N90U45#7J>PV+C2=Q-4#952+7E)Q
Q2\$&1C/W-1(1#1-2%LRLM53 M&2+ABV6Q-OR<67=76-G1-L1J-GJ:JLYAGX>V46KZ&S8R2XCM+W&UH:M-J-N+1<2PA0>+Y%YVQ&?P1P1-5.ZBLN2G-80Y2Z8A6=?
Y3R19T9B?M+P+6MGUHN8@<H#S0Z013-PP3-CP=RIXU MS1W&H:R/XENEYYSU:U-#Z2H4WK1X&XOGV83A3A3ARPF#E%V6686-OR=
<DIE0H4UYHS:HUSN:1FIPA:1+1B?Y0(G:L+1Y+KLI=-M:(5R1TNY+>JG>@DQ0&-(PBBRK&E&-&HNR(9A7/H=OCV+NGK:M19WL=V+1=LD-PI20M;
CIS:LRW-8EWY1@Q1FOC00T#6L1NOD2CE5&>+MBC4G=U+IAG\$G-1EWREDPP3-54&ZRC&K\$E0B&CJH?2#W#1JX\$Q/TO83?>O.E:Q1=&IEJ1(8CU-MMQC0?
>)H^<QO:~W=>Z#8M\$Y-58XDQ9XBH35174B*DH:REZKH=OP*Q-MCNDL960X:1440@HH2UB:SHY9)CD+<G(3?13/P#K&@JOB8*CRP9-1G18+
M7L=>4Y5&341WY>+NCP=OC:CE\$E2M<C&URALE<4D)JMWEL-RHHH\$K9&Z-/MS0LR\$N-V4NR\$7=+1QSG6%>S0E:EMD1411#1#%Y6B5M8FN>Y&Z-MN:3PBEH)5971J
44V=1P3J2+>1919XA31P1U&GYS+&S4\$N@/JZU&1P-M98H2BD19DN>6=>EN3EA241P15?>PV&AOYQWR@U=1+2BOU6 M3V16:Q@N@D+JH=Z<+&D2A@1BM
MX=>108PG#M2T&H\$T57J&J1+&DM&2XMAEGL5M-GLV8H714JW@VEGHANM1-LO7X-0=NG5W-217WADLTIE@IAR'H-M4M5:7-FD+8HB01#4KED30&41NS:>8BRI22?
1.EW8:A9+<C80)XS=>UQ6 MCNXLPPV2J=N1-N:HS<B&-RHN=>@F9T93NMF/OEQ&KH=VJY+PU9JKW
MT8S7RM_K0=5605>C*10QR\$YR&F9+P1/#A-915(CKIS:V)JXVEXN(MQ>G=H=>JG/6KGV#<0M/D+1CT1-N?P+RLJL%6GX?MX:VEY8;#D)3?W-MIV6%IYN-@*T;LZJ^<^)?
N.C9=>Z1\$QV1=1XZ:GWZJ918(1+<9G21&15 M5C11TIN4J06<=>#R72U-B#&#6-61XUQ41A)0\$C.U@UHJ2/6-1540X-MB=Z1(FZG:81)Y3NM0M\$N+12.8@:#!
<25\$2FSRFT@JPD13(7F2IEB@X0#W2J MDC>+44161PTEX6D2->R@O?2U-72J1MJLJH&H=YM5KJ2+1KW7\$-S1-C-M-BW&O?YJH1+>1E1GF38J-MC+11.6
JH(OTX0<#PPH850G8HB6\$38J1@HJ?<S\$S2YN8:16@2-M6\$ M\$1W-71F=7CPIXDM2DXH1=D\$TA81W+TC=>5FER:<+>8-W&E6=X1MR15VX<8
?E44YV<1\$@<#662PIU81\$Y234512NQ07<X\$1\$5F1U@<R-M-S=8YJ8-61S-#M1-3A0J-1U7J2JH155.N\$N@1=5ZNRDE1)Y9JH-5MB^<=&=#1=MOW<#X/KT>VEB?
BDIVGMWL:WNAS:JE/Z&URP>8"0"/-H.CQ-M:DUEM1L:R-@MG57P7JSHSW<J^<%-RUJ+ICN:N5VFWK=0&WPO17+RA2?
MA1>9G>BN1+1=B:603:KLNK#COSH77X2(DZGB7934#14PX12+JZ

[illegible]

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d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q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lt

[illegible]

MF5-W01:2CTB2F175KM(X1M1X1Y>NAZ-7/5-H<VKT<M<JQTV+G-6*G9Z05 MGZL:D3M*U3>YF=VL9PIW:5@L@RDI*5W/5GH<F=I8I:\$+X:7*3XN99
TX>:YK.K@MEK<+>=6MP(MSLB*U1IT"=S)=?>S-N017CY410OH5J=KU<IVT M=VPIECF #CJ=2<?<M#DIBA8>@<ANF?0-4N1<?F19@IH3I76-D-G*7 MGR07+6IDR?
TA:\$130AV6K KD+DV?BTS0B+IADMM091<ASW=S00ZNY0N0<M%U8W<?>M7L3@H7U5X&EPP:BCZAOT<@M5L23JHWJRD@T919A+M%U152522*(W=86J7A?
\$UTC) CPTTFL01(01#C#S0PRI->K62.0-Q-X MSUQX47A7@(<R>T(S)<T\$1S0RZYTHY)<@B MBIH<T DYM31WUWVOE<+>K2>?Y1Y2*7L8709BM(K9YBW*MP5-W%B\$B
M)0&N<O1999 BXV12X5:2X?2<4JR>+<IWM+GA129H0U91M=3+<MB67 M W<M@G(E(Q?+>G&I?W.G5C6Q*71W@G=WKX1J9 <CJOY9<1XG5CS7P00#B8112<(<0Y12J7#
(^0) 2N-M,H&5T-OA<A07IT?K0-X17)#<G>E/P@:LDBB*F#7/5 L/69 -B%ZE-YLAN-M+4!<K&5,Y 8WAY!^ -6F)+#70&?ASRCM:~XW6G *0FLD8M+I02)5CC:168~W.DV?H1V
MM30F0KDNH135F5T~73 P*+H-G-KK<H5GN>D@G%V<NMH@4JHWE.P<+>M<A<89IOE?>A6H<@LP2NMH ETVC<MMAH<BYTAE4WEPES03R4N4PFGKB?
1QF054+92++38FSGS&CS M42-4.U.B=1V G<6N<D+1<U&GKBMLR&H0Y6>+>1N26NCY6<6(YR<LH MSQT<@VAHMY*5+>3L:Y4K70?
%Y<+SM32XIT&FAV1K2TQJMI5TF MTQ1 MH0P1 80NP5K*J86K<?>B8T+MH 80~N<H4CS&9+ X@B5f4WS:(f,M-%<GZCJ= N(6DR&R055CY FWP*8#(5\$)
I=>?>G=RP,Y<:IV@:CW-6X"V M-TQ2H<H0P1<IMQJ<IPFBK<+5U>@/B7XM9A1&I<HU<N K<C19IC4,7 MID\$D&KPM>@OPMN?>#=>O.YGPORQOV\$EM2T1?S!<+IP53Q0<
fVt ZLUL7 MF9785F)B=V4P&M-K6=++>H.5:HK1KZ0P>@L.N66%B4M@ZQ9P.N 3HZVP-X M8IWM&GOLK16KN+P+P?JD?>SYSL3J MNNICISMRJ-J#N

[illegible][illegible]

8\$!Q9>B!>E:0XT0>XU>23:W.DX\$-4M:8B!<KXNWB2-P.YM.MLW.FS^@.Z#YK5C-Q!Q(BB)S0!>P*D\$5.7I=D"AQ*0\$*6!J?>V#Z.8XF.M.YBU
6YW"39MAQ<.@V#L5FWR52OE^4ULFAM.N55!A2K-Q.OQ!<M?9\$9H:Q05BCK!92UD0+446>02!>6L!<H4S.FE@79D?P!8^5^C!<fR=-M@-HOO-\$\$.E!>M#I
<^+SU(L=N68?>4!<WOL&N.W.N9N.MJQ^W62.G^VX#M#P;G^VUX:CU.EH\$AFH#-0&8^!SL9H=-.8?N?7C!J9>K.6.M7E.Z6I?>P!>J?03>ISR!B(!fM=>=&5?>)P&UU
!X.M36=NZZP.WF6+X!>P&PU!X.X36=NQ0B!<+V#?Y4!<M=>50!C!<H9F.SHW.MD>5!>2OMZ@QV>Q1!<S!\$S.3PL2MOD5HUIY>J&X!<M=>JYV6.5BINC@.MX#9P
fBM<=QVVPAR0E!H!R36=3R!<5MN2!04.O2LPQ@.H!H!4FES.D!>9!7Y!<L!<2D&EH!4!G5!M>S>18N?>4H!L24&G!>J36Z4VQ\$>X!M.O!>J7P!JMX\$<5ZG4H!>WBBQZ
M.O8P!<+5+Z5Z!<R&G!>P!V!<6H5!99H>G-M9!<CJNMZKVYWW.WIDW7R!>L!M!>2!>P!>Q&N!<R!<X!<QOGDFB!T!H!M^KH&C=N3NBQ>2!>Y!>7H3F!>J!Q7!<C!>H!>M!<GUC
Q7Z!>H!>46G!>5X!<G1>3>CEA6>?>f\$H!<7F!>L>?>U!<B!<W!<J&R!M\$S>Z0.M3!<L!<X!<N!<B!<X!<R!<B!<G!<GW>#ZQ3?000?N.O&D?>H!<TVZ!>M.O!<JVZ3YK?<H!>+O3YK?<E?<A!<B!<Z!<L
!<ZE!<23E!<GKM&G06S2WV!>9\$YX!<M!<+44D!<BUU&N9P!<SW!<N!<P!<P!<M!<Y!<BZ4C!<M!<N!<M!<Y!<BL94422SL!<SQ25P!<FYD!<^4H!<YUQ!<RC!<W!<M
%D!<4KG!<R4M00W5!<JBT!<@<W&T!<SD?<BX7!<X!<YK!<Z!<G>X>X>Z>I.J!<M!<NH!<P!<M!<L!<RWG!<+<M!<YV!<B!<JMS!<D>>L!<P!<L6!<LS!<@!<H#!<45R!<NBF!<U!<K!<C!<M!<XW!<C!<G\$<=
?>W0!<AF!<E!<H?<ZPQ!<O!<85X!<F!<3!<39!<U!<4!<Z!<E!<D?<T!<RU!<M!<79G\$4!<8Y!<N!<K!<Y!<S!<M!<FT!<45!<H9!<HMG!<A!<F0M!<M!<R!<FX!<N!<J!<H!<P!<+!<M8?<+<96M!<X\$<RO!<W3!<@!<W?<
B5D0!<DO!<M!<+!<3S?<D!<P!<D28!<R20Q!<TZ5!<RAO!<4!<M!<M!<A2G!<1!<D2!<C!<S!<K!<P!<I!<D9!<952VQ!<=>>9D0!<J!<W!<P!<D!<P!<D20!<ZG!<1!<Q!<XO!<M!<7!<WX!<OD7!<O!<O!<2!<G&=<
!<5!<S!<TCB9!<B!<R8Y!<FBN.2Q3!<H!<L!<M!<A\$!<M!<A\$!<Q\$!<T\$!<9\$!<F!<A\$!<S!<P!<K!<19!<7!<DG!<R!<+!<73Z!<C9!<P!<T!<TV!<B!<D!<P!<+!<P!<6!<+!<+!<M!<CV!<F!<2!<2!<R!<V!<C!<F!<S!<R!<+!<003!<J!<L!<D5W!<V!<7TC.

W3H\$N2X.2E0H1%RRN.BJX5D.R5CBED.MDZLZ=>S>3G6H14.322GNOV02\$USTNYVUZ+>1%QY7.OKFH<#K9144A\$""4">.\$
M#<#7R.<G4.D&>3JHFO1">9.F.H#MAG<AGN>KGMdIHNF.OGR.BP0=>E(88.WY.VRGF4.VVL)VY\$>WUHHW<ITFDGZT3<+>+8"V">JX.E.&D=S.C.OIF57
M%<G@GU@<I>.<XG>."7AEVLE7E"J3">1+1.<C%355ZD154+98L>YH.FA.SR.O.4%SGMAY.>ZW19.9.N6L4D.<3SPR@I2.DNM>5FH>B8O.W.X1LA.M.<W.G.BF+N(ZCP.OQ3
BL2RK7">8HP1P72C<V1.I1P)PZAA<L+TA52<(6).O+>M9*92OL.YH4/4ASR8*7T@H112<IDLZ>3XEY8/R.HR<5J265+41\$41.CB.MH.U1>7T).NL"MP71CT/R03A<6IM#LW
MQ?>T8\$5%.O.<.>.<O?J7K<ZL.ZHL<C+>R<C>RUUQ.H8WY<V.V. V9?>O.MRO<+41D&P.>#G/1)O6\$6<=<8K5<@QIELD5GND=>+>G4ZW.OSS6<6T/<5L.M#ZUS3-
6)J6C4<+9#>2K<H+1%2MDP).LH.JDYBMGP<.<M.8HO.2%<O.ANTH">MHA8A2">50.15%#&1+NYVC6%UK#G1<+>KYK1/VN)<+>M.Q.DZGG<6J19JREP.O3M\$5.R2
Q9+O9H5N<=>7+JG8R1@<Y399EPQWM10..M.25PHQ<58L.KGDH.YJHM.HDBLHM<RK<E&IGL.M.G7.AXK.8.3DCLV4H1ZDR6<=>YPT1+6HJH@WDMKX**=>OIH.OOQ8?3M<=>
ZL"<M<KX&Z&M.OQ12OY">UHNK4"6X">U">6.BYBPOTCT.U39L.78.NOEI=<+>XJFYJH.U">A26KQ5151R.MVU<I>.0FB7V7M&J#GWJ#<+>3+>+M<I>M<I>
5=56UBD84">A02150Q44L<H@T+I1P)MAB*H890U515W7P1.2=>4T">M<B=A2PUA9NR053I>+>1=850.U:R#>FVU.T.MDIO<K8.DUAL.HV=DP=>B
3%WD%OCR.W6LHGWHKO5V%7IY?>3.8VY/5.X_VD@/I5<H<C.M%TQ754U7.M7VB.<G7WU/5&G<8X.Z755\$A.L2>T341606E@=IJIZR&4HMH"58\$<H.M8#3<@=>501D/>=\$O
6<N&1A+>S08SBI#0.O@=>M+>U7<0MU7L1KX#7P6LUXK070.7473F<XW7T1@<CZM">3H%>Y2">H+>X.8NX<M.WKC.N2EP73ERUVWWSK<L.TL<+>K>+>+N.H#W+>+>R3?>
7PZP>OVR.7MR.M1GJHUKUVA1<.>S1F+>P>REFXLYF10M70TO49GNI6L13T+1+1E7K#<INC#>HEM.MFLL.LH<RH%<K#<Z1B81PVE>+>D<OQ&G+P7.UY&MD3AOH.FH<+>H+>M3.E1<+>
T.91091.F1">O?>Y53.8*9Y2/UU<V3P355#>MR<H0R\$1.3&<ZKYFHV.S=E5+I.GV3PFF<K.2<O&S1VJH1#7<+>G3540.L.M<6Q.YGLUO<D<6V%#<K\$<AOSD..<HK>:
J2H8352..1">D<8>+>EM%<DL9P.MJHEKFI<Q>3.2RZK<D1.QD9<D8A<A3UEI9>.>Q97D0HFF<+>R97<4D.WD20.MB2.(0BHIO=>I.TB<=>57T<+>G5(VY49R1Z"E5W9MF.F>
HHAZ3S212.W"LATF74.M=<34GR@AR9&<"/>V>9.CG9+UHOIGRCSCLH=50+<.<S%NL%<PD7>-I07ZGLN.MP6EQO>B)W.I5<5<E.F29<DBOPTM">+>7U848
U.PWV7I>Z4R5Y7+>GG<+>YKW.M=8H1.4ZZI?>51V.O1FVY<I161V3H1ZMPZP25C1749PD85H0>IAXIGIP7.MJP.L+>NP77K10GXN<74LR.M<DVZ>7H7M\$H.N>:GYOJ>.<O-
UW&WMSQY<HRI2P5..W1.22<1%<PDL.3K<+>M3OX>+>P1%<FQ5+Z1P.F5\$<N">OGD<68NR1ARQD>7OFY5<UW1>5+>U&H9J>+>M04.RK<SX%<9.G&2MD036BLZ5Y1\$<+>82&HW.M?>
A+>CYCE.7D4IR<HRR.M64&4&U.O1QJ1ZBS&RFDG<+>S.MXOHSOI9>.<O&MIGRXPEI<3.7.YVP6I&31%<C.M.#J#<N99<+>+>X"R5">GT<+>T1Z.QQS6U=>M#<ZQP3.N<7Y1?>
**>ES>.<NUFAM.W=>TV536NIOH1.7N3SE&.9WY1+>W1\$<M.2C2D+>OW&5GCMJH<@<ZUT<+>51\$<H19T13UCY.YE2A<ZGR.D5R&M16<+>Y<9X7A1X&N5=>5)EN.D.7<L5
=>A.T:>@<IDE1G7F6EHQ<^>RZDGAU.MWG<4>.<+>HIS<9H.O05BAKDY056<I<^>AN.D%\$<L+>2.HVKKUIV<W9*AW+>+>59.M5..%ZZI%<16K<8>.<RCK7N#>+>GM\$<HA\$<6H&
W\$<N>N.2.WJVT.WN.W.G4<H#8.M.R1WJ3FNIN>T>F.W.<+>PMG<62M#<40C>@<XVM)MVA6I26=>+>N.7<6.16PZ12CN.X%UHI16MV.<+>
M&WZSP.ZP.NBXD<2UR>+>+>G">.<I(L)NPFXYVMPMG<Q-N@D7HFH<1K&H.M96I#7L.HCPGCI.T06M+>Q560SEIUP>F/RK.K/QRSI6<+>3H1<+>7.6B5<16.M5<5%<WKSJ#>+>PKSD\$1
D&EN<5&5J<I>4U4H5IKI.B6CKW.M0SFH<+>VFN.M.YIYB&.IHH<VY\$<+>C%<M#<P<W42Z.W@I.B6M<T77HDUB4.NG#7KH@<I>Z=>5&X%N<HAN>JB\$EYXK<+>
^<XMM<M.YHA\$<3%0<8&DRMH4">..AX1<54.M=8#>205K1<6ZH.%<O<FYK<4%<46N6S5=>LIZ+>O.MB>+>I#I\$<1%MX+>9JEN8.Q&=>6L">I8#VP#<K.MU<+>+>J.W<+>f@<SVQ?>
S2">3>.<G&6%06<102>4QHB873BF19+<K.M=4\$<N.4IV<L.24.G=>2M0Q<OGR/B.M2.K7"/>+>MN<I>.<PL>@=>NVJY&NC\$<RB">+>#1<+>B36+>1Z.4KZ41.SJ<+>N
M66Q1+JMP6K<A+>AMJ.G.SV.U1U+>A1%>CX7%<@>ZUKN<VBX1THQ18ZUS">M.TE<HX1Y+>+>B<+>W-017H<R&H..%>+>UHC<4+>4&SY9D<=>6<+>KZ43+>ODUJ
M&P7ZAN<C>..O3OQE<+>M.TA<6I1Y#B&14W5IPI#A6OM.BAXE<OJBMQ0751Q&I.MF@>5+>TSB14E33D.Y1Z.YXB63/L5W1W>ZMPR0.ZVUNI.Y916+>V1Z34FIJN
M#<SS0>+>BNYG1WYPP<O>.<#GHI\$<+>WXSNO&A.U-3A<CJY<+>5M&K<8YXUQ43Q4+>11.RAK#<PM.PNZ&55174KJUL1)>RC.M0=>ZPU\$>+>((HFFH<+>+>C+>M1.M.3%<7R">4YN
U4W&J\$J<X2I5Q<+>KV1Z.M6I.8>+>VH%<9GBND0?Tf9>X.FH864">2A15C175861760\$>SBT2Z3.PUJE08Q.M9I>O.8H*TM51&NHI<5&K+>MQ7\$<Y.CZ<+>N<+>C7&H*H&H918I2I
M1<0ZES=>VXF8&PXJK+>+>H%<M<N<+>BD%<H>+>U%<C4>.<R19D>+>6<+>J7Z&M.0%>+>PDRF0+>+>5J5D81406&JLVK74>+>U#W3K1Z4UMU>+>V.M1M5F<^>UNFIW<+>X.WH<+>
ZC2C<6>EUK4D&AW)INRAM6RIC7F2G15#<R<+>

!<RZ@<>P89SBIP1E.MH.O.NTN)0B@.1NA56*#<BYV139ML5FHUY?/B3/D170IH7H?7?@&V-W6M19.O@P1.AOOB7?K1.N.P@CVRB.WW9
CIWFAS.N6UQ.ZZKS6E9UWM15YSWKZKQ6@..SDS3.2MCR<5W/OX/F1-AAJ*810^71&.:03MB35FK6/ETFSR.HARICNP>O-QS1.MA-AEJC/G2/HDEM06E15MX9BER=41H1P
P!E.S6G0.LNMO.X3HJGL.SD4L@.MSW(N.No)Y@T4YV-ZUAC3Q.FARQ3DF=HU.WED21?YEPS@<TDYZGG?>.M4RDPGG>BFL+3%3L.HW+1&CZGQV1H2ODN.8.P.
U9RHEH6/C2^273C86).M0.Q10G/ATLVY@.7N^0A2G0?<S-KE1H+HHW4Y3Q5.OB9Y.1DK1%1%WZ>@.0.MFG76B91F.M#N.8B4AK6(6C.X+1+@&C1#)1<1Z2IML>G+BYO.V7M?
M9ER+HW.LJ6JY@S1>+14XTC15TC.MONA8BS.R5^277(AS29.7B218X1168V1+4P.RC&.8ZYZ.6^U2)2AH.M.#N1H15%60T(62?
6TD1>VP22RFGA<Q^G0Y0CTUCWD/+(H5=*YVW4IR-MX.#.#P2E7G2Q.0ZD@IVK>C1<Q=9)GR.I/FHIMV/C=TO2@_DUQ>N\$RHL.\$5\$5M26+(S1BRX2+8.4MT%OX5
Q06.91.N4.15V2D5350.&01^HFG.N(155KL%0D#<631@<(ULWZF9>B4.OAL.MP4.)XXY0FS9K=-196.#)=1095<0.03\$28&7DZ.VR@50NH1UO-8&=OMF?+4
M20E015.O.#PDXD.1%CB80QNY4+?<B.N4Z2H.UO4J3A-5%)(G=WE)FTO-V-MC.N150YNW=-EYTMVR+RZ2@B.M7.W0TFND.13YFTH8C?<X^#?PZ1.Q1
U4QCG6A8Y7Y321P.13BFJ15IG6RE.YO(Q@W.N.D@M87\$<RM=WTY>R&Q3.MUY.Y.HL/FT+@)<P=N.O3M6=Y^6Y10(QD4IS).D11LH8Y5FP9@B-BKBP28
MYTBPX.#1H1@<K^Q^N>E4SL1@A.PSI<8@HFS5D1\$HH@NV=>T&NWBWY-R.M+VFR7H100L2TNHL3%U6N+QM3+V14W6.16EGX@LZ+1C(06K3JM'UW.VM.
M2AJ@<2>IK51CPK>5.141^Q1P32:QLCIAB8^DQC)AH^B4D@.81Z-K1.MI@A1+D44+LNK5Z.VJH%APHE.E91%BUW^UURIU@.F4P+6D)=ZYBK&.MLK.)1HJ#<?
4SR.<7Z1&SDT>5OYV4^>TJSMAM6718&08&M/F:0I>G-MP55SD.U@.(HKT)Z5-J%NMKT=<@>1CXD1^N1=99.V+H3\$ICPOZ.^U.12MR=6%>PSB+B\$)M1HB>LG.01@?<
M&=SL.M7HK&7D7(HW.RM@<1MTF2D1=5.#H1FN.50@OYV+C4.VAXL2ZR)G5H.M.%NDDT^MNEEAG1<C0>+690P3LRLG1C5?>FMQ1YY416^Q1\$.#C^TDV1KJ^75XE
M.Y&C.2%WLKGDH.123R9=WAYTR-32.M91<0.0JF>=<S\$E>R^151Z>.QR10<51/1S6>9.^5M+*K(AVO1+&F7HN.2.M>M.YECA.0212214UQ?<
9L^<S1&H.EY+HQ=>ITGYA>GKGHR>9P.06G1.MLET35%5E3U.VA.6M)5C5Q0>6.509+4.@7%CT1%>^AR1V1.FDQ24-8
M.DRIA5E1R2C5A1>2^J<14K1S1F.L@T00X91BYW(LN&5%3%61%T5D5)MFBF01C&.I&M0=81+1A6S3G16B21BD1DFFE.T(1ZQ9YH^5Q.J3C1D=M^UW3#4.MA-D6B/WJ@/C?<
<5.3%3J1@H9WK67@G6UPAM&KR.C6174P<550^VX5817.MTY1N\$.361FFB1@L\$#<.<3?7D2CLP8&.<6/>=<S1B>A=6V7Y1-8F41+ML5
104016K&@=>D5281F4U>YZ2HHWZMR<15.KK<S<=<E03G)HT^<=<S&M1.O-M41HK+O7&0E.16.16S472C2WNK.<=<V=>=<P^3X01P.TFKY^?<?K2UG7)CE&K5ZCM^0.HPPO3X
M1#<..9821@<NM=L1UFWY1Z1VP1A101Z1>H5M531W5U13Z1D1>51ZL.MS.7%GDY651Z2Z1MA2N(ZF5^K3DBD2P1C.KF&Y9+G+Q+H^GAO21O1
MD61E21>1E3N36103.O.D@<7>1?TRVP1#1@S/AW1A.#88GTZZAX101^W.M1H10=<GW5D7H10=<V1T8+1GDE.P7.P0K#<=<W>vQ^AU.Z+Y1+BW9+1.M.7%3X5V
M1N#G91=<15X51517H3P680M.JXAP15YMP=<02S5G18H@<P<L.RLWY3%MH0P@<=<3.41(213^1^FBY2%<1T13@.00^24.9^N9%1=WW.8#16.M.T^
MHW1.O1_0=<121H1BWX1&RWBTC(U.M.MX^AZP1A)YV@1V1=<0.Z7N1P61815^2A0R^U>15YR8=BZ621THN.M8.S51312^PS1A11+12+0.05T?
F>T20166&1K1M+S1Z.MMD)<)>=>MWFIXRN.M11^L.WAM9W1YFV?>D=><5.53VS&81(G%9^N4>M1.#N1LYOS1LYZ.ORT1W1UOGAX41^JG1B2KUMT:P.M/
CJ1X1XV.M.O-Q1.40.RVJN<9>+91R=1&L1H1G1B10+W7^5Z.W1F.A9^41P6PE.MGF&L19G2W7T1NW.Q45/R1WEI2/10NU519GHL2AR1=8.<X<=<@>M.O2YH.^Z+
Z14106@P16=<5E7.WX%36%0GBVLZR12U21=0=>U^<M421.13P#KIENXJPV71441GZ.ZCM2M1(R1Z1R^M^X14=P2173SWM<=<@M3HU11
(RK1R1K3X(1Y1%V1%>@<1P1PD?F1GE7K#H1#<FRH1.MQ10TD91TEHUV.3H=>8UJ1=>K^41C1H1^@<H3183R.CM.FB.M1P1^1H1P10P1#=>PTXF1#<0&2E7#99
724&6GM1^5ZSR&E1Y1Q0SAZ8X1<>C1J527/1.LSDP<=<CTONCD.N.M8?1^6AT15FJH1U14WM.H1JN>C1@<+A1+1H1N.01=<1&C5S&V1^<1L16^1Z1+>1DR9D4Q99817M.B1
M1.^WP.G1^D>D9TD1Y>S@<91.710.P4^9/<07=H^AP.Z@<9D4Y%1(U?UT&U1SC@XTX0S@R<9G/&GW1^1T1Z17HDW.&H2RTH>R2AYR1;\$FEM.#%\$>1\$UC>(2?MOG#1
(QZB+1^AZ1R1^1XGL<31^U61H1F1R1<09Y1JOEFX&OX<1L7>1W)3Q1=1A1Y4X.M1JB=<=<F0E7Z55G1L9NKZ.70B=WCA1^8T9ZMW^4S>RS.D&1
M06T1Q1XN1.2B3<1^U4.M8#W1<@W01FEU=HE=HF=>522CWGA1K1V1FZ.MJ5<=<1XQ7.C92:1VYVQ&=FC21J1Z+O^<S^M2E21Z13Q&1^<S^XW>B8B1FEW3QER(WC2
61TR^87STFVL1^<661+>07X.MP<8-BN.02^M1P4V&EJ.LN5OCX&A(V1HDWA1X.F1%60SM1^K^X0E.2H>OY1&2KNRH7F.Z2K.X^T1(1631&6UV61<2RVN
M1YV41UOQ<86^W&S>@.QP<F>=<87&1+V166GH1V1@<F.NM^RBYZ+XTX1H.MW21.50^1P1611415YD.M3L.MK16X1H.YW.H1+<QOSH611E61K^<S#W.M1&1\$<@1Q7NU1?
7D1E)<(1T.B1B^M1H1512RRB\$F6.1MJFT3.+L@L.M\$0A8^1CF=(4WG..H.X.X07@1X.L.T.OW1)<=<8.39719LYP1#E.690RZ.Q.MY+<4X1@68D4S#FVN.ED6C^Y08WRA3#B-A
H10211^A&B\$<@RMK7&FATU715@H.ZW.MW1H1Y1P>D=<0^Y06HX1H6C+1T890QTAL\$=54SD1P0K1@J5&P0.MIE<63(G1D1S.M1^<13A0D7Z1P21OV1H+?>1
A.SB1^551HWQ7Z2.M1FEW1R1H1S1P1.12+71P1..IMRK=<1K1.U.O.0E1^1MUH1A1^M1D1213K1^<00B11Z1Z1C161+63.G1Q5&1L15V361+1+72^P21D213K1.M2^00@<
UJ3D6=<78WY+2N^15YD6C1J1U&S>4Z9Z3G7H18H1?>OET1LOXU121V1TR.MMGXZ14W9W9TAO74Y=<6<C1YU1UO>+56S.V5H1\$<1714W.G1K168%PH+<G%UOY
D1M6=<7X1Z1GJ21&1L@<1XB@<=<G8RT1P.C13.S1X2Y2^20CXG8>2.M1VY9FGYX1W1H1MS1<1H1=>1QZC1\$<W101U

0555AVC4(01)TPM01XJB+S+N65"N55:N.B.IB*AE34.L46C8.N1FWGFSH@.M.V21+K0LH1B I*+C7@+3+7IM**M7P%TXN.051.AQ=1IT"KFAI"4X.WW"HV15C0N6E(FH
G1B.M.D.2X1+I=9.552F6JOKK+M'YOATATICE>=>#X=IC7.T1H3O+C+. CZMP01.MPX1FAI*+>5J<+<S.4.0F513FEU@D124X4V95CV3EE"(009@36H".@#X.M6@+R?
#*=XMOFM(BW)BTJHMC1610YU9VOW.U>X.BF.16H54FA+2+>.MP01.A1LA.#1+P*KR4ADJ@M<C*G*M4@X0@G9.M2
IS28*KLH.82N*KL47*2CNZJ*72U3@<@#TF8*W.M*+<1Y32.9B\$X*+1-3.6@TCQG5L7@/T#.#%SDS<+<5QVAH8YK2+COJ8
MMNO>0.F12+1B+BO#Q.DSUEK(#\$ZKNRTI1WOL.V7.GR.1#>Q=07<C#M%UVW#.MHZZ2>04^<ML(\$15ZV4MM8P8Y*HC(T3.ZHLK9.#M@H=E.6HFZFS\$S@NH.JL_M
45N520@F52T=1@HPUWWS1907F*TWI.VY53C"!!&2621=I23=-ZEL.MI*H7#**.*#SKX.Q.2ZKPZ3.N.Y.IWLUW7@17.L4=1"2RVNVH7LFNZ8**MX@#B?
+8@CMLBSX9918+1+V4L.9028UX)*.P'X'UN@S(CY*ZX.XKIG9.O.M&F.T7+U5X9*CM6ZRTMZ7-N3)9-0100F2=2.A95.22RDDAE*FE2HY81V'H.M5MQO>5)HIX@UW'ZJN.
ME57X'JMB0>+5Q+9+2J58?<=IHFF<XOHBZ5M+1S1F-MXPDIO.C.ROJ+>.Y6HSF19>.<@AU6=<03EJLP0A.IANV6+>6KLI+48.M5Y.6-5+>ND?>I#>KOR@18"W.52.
BJD.%)<P>(2%)>0UQ@P@P@R.MQDPL59K*21@C#>ONH.L+>@&A3/SRI7HF8AQOE.(M0DCM)M1@L.7Z\$LOSQ(0#NZDP.PM9U4APZT=ICD.045\$TRG3@DB6Z
<#6NSB#MNH4.1.S\$S.3MQ2+7V4U@.10MOMXYT@K(H420GADJYX*B\$H.H*Q.7JNB01'CN'YL@A@E'IX.TEIAPOH=3+H99%6
M.0R1M.G1P'MRKKA*IEJ2>+1'E&I&L.R'0E'0BQJ@H5M<+H.I.153A&981+>M&F7R189(8E8X*Q/>I#4JFI4'0R.W>+1.9IO#F17JHY&1\$S.7QM.Y<+T.KB.MTSAJHGD\$42
M@AFB702>8G6.&Q6&4Z37?6f3>KKO@#E4.KYSJP500H\$S.MXI100*+<K<D@KD#00V.XW7.N.NX310YTB1-F@0ZRG+M@N3100N21+P1P'8A8.MI9+50V'XG.W.A&I?>
G1H1J60&1E6@H1<7>V6K1' T.GT6M.#K9S7919M2050.IXN1SBN1P8K@G(=NOXR0INC9INFO1.GH100.IKHG.M2Y#M.#%5GY24+TIOQJZ3.9JHNK3J.XNMW@177<+>
0>S>7JBL.DP5.M1SYMZH6*MC0)(O43*#>=7R4M17VIZKH1H+2)J2@E1.N.YV.S+JMB>2>MD@C.Q.1+>#W2Z.M^<1A197<+QOV#F2*ADL5E1X5E+1)ZW.Q.M.KKR(KM.
1KLW@=PK.JI>=S.M.ZPOIKUT@J3DPD3PF(3'MGM'D.OA81-Q.D(S Y4'M+RC9RAVYK7=1A2C.MS9'6K)GR<+R(02TFL6+Q0)BSJH6E1L1H0X1+M6UY1+FXK#>
<#FY7+10B*AJZ.ZZ.91#&R1P.P0016*5U.O+1\$=G&IQY61#MOMZ8180*Y1@=<@L0E6E\$Z#AQ@E9=>2D.D.HK%#0A<2BNS+7M016=JY
ME#X6*5CUY1M55D1.MN.N.D9+1M.HQO&1<7CD.+8DHF1G14MLN(KY3Y3+0.MPS8H6AW+KR@K14BGNGSV+NM<21G16>+<H.IA.7XMI>8G\$A.L1#TJS
M#M#M#M#C&S'F)M0A)0B#1+&49ISO&B.8AX6XE'G+3&GB17+51Y61&1.V@30/M@0XVSK@NH9Y9P1YH1Z/Y=U+1.GABE14I0T'VFLQ<+10.08XU1X#22T.O
MW21@JTF#T+1XT12D40S1.IQT20A0=QZE<1.01F<+>B>#K&S*F2J2+>M.(20@OP3H19HB3827PKO*YL.S3%J914+&IG4@+>HJOO&@+80A19A.
MLH+3*66&C@U.YSDPK1@L.K1X9>D'G=IA2LZGSPKU*F12.AB#=-81.WZ>+>D2.MI@R&41Y1P.4D2V5A@L'QY.L12&17BCSOAQC=>D701@+>E&X&H3F7H1MP4H1&BNKX-0
*G.V@26>L2@H899#8#<+>L.0+>2Y6@NPKY0#M#A1.B0Y7T.M41(I=9.1@J3(0BPZ'P'D24S'AA504DPD&B2*RW7\$66HENH&E8&B06Z3.2\$6.MC42XN'Y@FV87U
MMPG3T2BAD'J#R8.#.B4<12.C&DNS.<@K3'W&31BP.7C21@GKPA7X.M1M35A9142308K925L4A1'X&SC%WJGM)@EK76'TUDJX9.57DD4Y7.9W
M6HJN7P&6N(HW71)Q%QCG.60P2CAJMPG69G.XCO<+>I+>R0IC9A4Z6+7JY.M72A.490.2R8&164RV4>+1J3.M=-.@3F.17K>I2T.EA&WVFM1718X
>VOG&4H.VYM08/SWJ378.WOOHQB.M#JX'AJ-Q10.9LHR10K7'K=BC.SQ5.21N-82XVY1+>09HQ02IR15**H3.MT3B5&N<0'0B'XKN21Q1L>R467+<0D5D1@<E7
7=18010P0CZ5E'N>+U'R.M2P>7H1.#%Q6\$<@>DRS4412T'7+>+RA=90YF05G@5@Q1(W1'>LXY=>M+Y@LP01)@?>+>I>L=K#A+Q.P-744I.ENTB75.L'X'2LS32
M0S01V8NX20&20RC+5+X.PX.54B5+@>IY24R8(CV&X1+5JW1G.O'X<+>L4>I4T.B5.M#>1M80BQ2PFWACW'0G8CB1\$>+>J18+R@>f.ZU'Y'P.U5(N.1)@>86
MH1@E0E+>Q3(HHQF(Q2V14&FGAW5G8<+>A&5.SY=BC.5RDJH2X1@>1MS50<1-1FRX#CX4Y1+>+>HJ'P4<+>4BID4>+>GJ0E6&4-C
M1=3Q7'EL'HPC=>4OCW3#KM)4+>9(3K)6%P(B&GX1H141<@ZXIH2>7.#=>7+M.OD1+>5V101'1.S.M+C.RCE4NM3V14%4'>4BG.G+W+
81<MHN9Y@<C.BHKH14MEK4W1H5C1H#>NPV5.M.2U5.Y4Y1+>DM.H1P'D31J.IZ1&D/RJQ<+>5M1#EAM<0T9N6K1+AM+ABR@K0.Y0Z1H&4.#TMSYIC'E\$)QZV1>0JG2
/L1'254G=M<1>3>312P1.JCN=RSJ<4F1H1.M08.6729.LU5T0Y5+>K@PQ9RA1Q'@#>8B@>9#>UDBLRH1/CMLE0D.M#B.4.17Q16R.V7+25F1510141
<@Z0E016P#HA11INF421(5U0P*W\$M+175*SQ<@L>8.HD&JHXYT6.KOHPY.6@61F9.L17N7&1&SRD57.M#RH15.T0#>914)G8YK6&46LZY**G+W<K\$1=79<
>J0101E818N1Z'L5.M292IB25=S+UW<1(#7XKZO3M8.MMS14N44XD414SK15WC.K4G154.S1*QQUOTI&6.>2=C.J2M&O>XE+7E-Y.MDLUF@>I3>+X%T%1176QK
Z7M+2&P*P'R'V08:JPSBN4U2.M517B)1/I1-R2N6GQ100HU1F41PEK18PK?B)31VB#C(AB)1%Q>
M&M&M1&0Z15D7MCF=1UA21K3YBQBG=>0FJ19YJ'XWR.W41Y=SKNS*1=MP2K6#Q02&S18H165W&4(487F0H1.G#>7FEXZ'6#N4E73BF60DUF.M3TV1YJBSX
H1J2DOK0HJ306.C17M7F#ZS18Y172@1@N1+>W/D.1+1ZC188**DK+>2ZNB6GT.7FG19>YU1061<+>9)H&2&X@<1-1MM#M#QHC@C742.A.S5J2&1@TOY.Q#4="8A1.SJ2C
M101M&71\$XG341Y#<GZB.D.#5>2+12.IHVAJO=9AV7.YB15>JH=D.M@4>25+1UV6\$*#Y1T@P'0UEE\$11TA.G.Y819C&S1TA.X#S.DE?>1/BMX@XHT@>A1UP.S-DLMP?
81C=<U&L&#>YH4&S.Y92533.BOE1&03*121L6UW9%TA4>41)>B&6Y.M41B1651A4.1Q164+>Q.0BL#IAGA51A'H71D2+72H1AGU0X5C.UH@('ESX72U*G.M'9A.
4M>WMS/GNXCQ58P?LEQN2?7TA>0>UAT'V.SQ1.XF8E>6L#<U&=&

[illegible]

XPV5-M*9F8ISHTXVR7&3B2?*-7BYFTL-SS:4W-7#*2-1-076666M7&_VJS"WAG-MJZA"CL#U+Q@RBT"~C=5&CY=PBZ48V\$Y>125U)K\$2J+&B38442>7C59M-18V1<?2
N:~1A)VNZH.O<OZ9X\$8LH%=<O1ZW76BT1WT98D.FL.QO-MF:MMJ-I+FW=CL\$KCL@U+M.F1\$TS:4DDIXD\$V\$>N5,@.G0L%5(M0@%>A.C2 HW8(MT/6*FZ-7M'=97
M7T?I-YER"W=430.7.P52<A.OHZTJ4Z?W"86I"=<>36.97VD=V>A^76EW=>WCS>CJ8O?F4#ON%~.543A6HKKN0<KABM:UWXCM.MOLPRNAT\$H0CJZHEU?F
I/6I4I4LQ-GOY9>#X5RT4L+U>=DUA8Z 7M-L+1W-W5(W)>E3NM.49\$~1+OY.P62V\$S-ZZ@&FLA~#CJ8B8MTJ.5%#W.MHQ.G6E77K~N<~CFEP60808TR5
9>43XJ1.YL3@C)K.<@R13CM4VB/N\$M+1+S.B&5+6.W(9)U"U>=61D(1KJG.Z2J)P.BIRGH5%~1M&+C4583 ME8?7R@N"7\$~>[9-V+16]>S"JH09@ISH03F/
M=2XU1CWCWJH.7-1<3(U>ESB{I(CURF>C&GH0D>~REU.AA8~X+1BU?PVL.MJ?TJ.OH~\$ZL.D+H142H%CB"P.M.NM2V3?7<C7YN?6E@>~#M96YH@9.MW+Q+1@+BM9?
~V13..XXD4C4J>OW\$54>XEBEK(I"RAH53V2<2UHTV"V1+1MTU+JK?~H.-FU+S.VJN9S7FJH9Q(GC&VL32OPANHC"319S(S19+1MOU1~9<KSUT+Q%2B1+0?%AX&
O08C3B1O.E7W&8BDPUXICAD<8K0~>#S56Z2+M.C0?O.P2L@A969K<O9&+S.MM.OQG&919\$G.#L@L1D.6VH.21\$B:8L+Z2O?>~#YJZ.6.2G29-VT0+2+R1=8R.M0L
6.#ZG<E.E90YX1L.PM.N\$3P~N#5A\$7JZB=V.BMWV4JZ&4Y+W+2\$S1~M+L5U5+1D.KO@I7/EP4TU.EVX.OA-HC93SV:U9J4I<~G"BYH@&LFJ~130+8Y.M4.BL.RVOR"76.K(KT\$~A:
3.2\$&JY?7>@NE(%M\$M.P3V~L%5U9.3'S6\$5.MM.CS924JYT<~<@PWH5+19N8.LWK9J.1.W)@I7.0061B+1V6VD4.KOEDXJ~M.W03KQD?9C>A>423+1BTWC4D?T
F(90*0@O:HZ\$40M.V~36=~AIV.MHTY(DA4~W2C~H4Y7)7R?~Y7R~2WY<~1@6WYKOB1.YW+~E7&6W~^5>7B.M1G7D3X?XHG2Z1?PA72R>A>M6:670E?I-
H8D.985G~FWE7T\$M(YX0~)M&K.BG.C8TP&Z.VH&5DD4>+E?8EU=&JL46+19MEWP?~.#UR3.XYQHTV(F>%)Q3D.MY@~Q@HJ5G.V.OHU)Y0BG6N0Q0P?0A?
B42~33O.<S(L1&5BO)Y.N46Z?GHS(R-MF4O)5%~7G\$U?6.U>X.O.G0%NJP.(MHHTL.V6V?H+G@P+AYVC1K.M72E@3A?2B@~33.BROR<CZ3@&N?
~OC~3P.~#E8I\$5=9GOQ1.D&P(SHH33@B.MOI~MW~5N32~2BU5%PDKL2?H2V08XO.>%Q>(OAG)1.C&~M5O2A^F3Y?TWJN?H?C28?>1U+&B02\$
7.9.9CD+CMPEI.NPC187W+A@L+Y.M'KXN'(EJ+H+1~IEM6IME@OUN.6"HA.9~SSO.TGWB~3WF+1H>M4M1\$SCT5@F2.5H.V7LUI~
~S:8U.2+1XJ-8JH=U<K~KVEV68@K\$3&3?M.MOU.XPA0A?~#A5(1.C&@19.OQ.M)B-T.L7SLT3AFSORT4?F7E@MR#3PI.M@ARFACN@T
I6..W.L.TNW~1M9.~<NKG6ZB05Z<~<G&..901J1V\$F\$M~>).XBRP.GA047U1V\$+76JW1BG5Z.PYV.XVIOHT=FN7U+ET7L8@VN.M2KM5VZKA-
L29W~E7FEA4I2RHTEKFV.HH&K&W4YCL0F4EWFOW.WIZCHL5\$M4I\$SL..K4T.UM5.B;D1&T3V2D&6R%<F+H+M#2>~8A0H@L=I&C9Q7\$5&S10R\$Y\$=F.

[illegible]

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||P69_A^F|^@91>0^R1? C^P2^A511;1^P^>YVY^>=>^>C6;DZHQD+^_ML_Q8R^>8U^<F^>L06L10^>A@3^>A60P^6;6^<L8#7^>N95^>TU;LUCI^M^>U2U3^>6>D2ZA3YVY1^AAA4>4HWQ_GL ^31T^FKAJ^URBNIS0_457H_6+^>MBF97T^GBEX8_X1^>1QVJP&6-Z^W^OAB8^>G87P;T6^W(FYBV+^H^MP&^<60^W&280^>DVSD1^>H^>6M^Z^78X0KJ^>UM^>L02P P6^T^>5^>HJH>_M^>MDO^Q0^<WTF>0>8UTU^>8>D1&5SPS50^<@>FTWP^T^<1X;H+>A3C3M1^>Y^>W1^MX2^>5^>6^E^S^>K^>NRS^>T5^>M8;H^>GMX3A=C^V2NM^>L^>H^>219;^>S^>N^>B^>? ^>CAQ^>W=528>T^3f3A02_7id_9_MIAZ^>M/QJ+7MOO^>F@>^>N044NH\$3DW||J^>1^>H<01ZSP(TB)&?&RG^>#U^MXP0J2TXVH8_IG7^>CRL_LH;4S_-C=>^>EC80^>I06;7|VWV^>T4 ^>HCGZ^>MPTM_GZ&C^>N1^>941954>UC6^>^>H^>U^>M^>2^>V2A89AB^>J^>+E2>^>^>H^>16#>+12HV1^>L^>B+>=>^>00P0H^>+^>H^>L^>D^>M49;N2 28;H^>U65>C^>G00>4<0408417>7G08>^>^>42H;1^>108A^>^>1^>7^>C^>M^>_F^>F^>FOT&4_5B7Y5YK^>7>^>RY&^>(<^>DS;^>H^>R^>D^>060U4^>E^>_

[illegible]

TSK>C>V>S.B.HDD;251CQ(P63X668LG;7FX)>M@<QDO19=0B=W*6XEC@<N;157KW)W#15V1*OWS8=&P.D\IDHWQ=-MN^RHHWUTTF=3-X#X1V2-I-GP2-1O1
I2\$HHH/VA M-5YLLY(L@Z12XK3)=JMM^MHLEF<G@I#?2MFS=ISNDQ@;""N6G=FIR85\$ M\$JHX<J7C9;5%3P2NR0233115GS2?EQU MI/5IHM>=N0%140F XA E?7J#FE"
?HK-1Q%4NL@QXRN=Z1235 IL M-32EYU>?G1RDZ?<6 MCDHNR30L3<?%Y3?2I?>ADIBJ<1+1?7J>JFE54X1A02<4BJZBXDN2 M-36569P>=6N0&0166?>QO-?<
JPAG3\$S;8JM5J?<00% (H5+16ULSH6X MN@CJG=6%)/CH?F-KBZCP=2V3B9ZP-RX63F3EWSW"MTXPX V-1ABDS?SRH7
M#=-OFBJL@L81\AYCRKY@>A6LC8HY3YB+&XN7F3.3TYE4 M-3.4TH8N M-(@J(RJRVJ?<?#HJB<@)XLN@)S-P5J3PHX2\$=WX&R8%(<^Y)9LHB*8W NXI3
M<=Z816>J&URIQ(95<9?3WNO)X1&4B676XHC46H?>@O161M>=>=>5D19 MP-OQ15-7C?>TO7?UF9ZJHX 7VM22I)U/HY4X T#JLTSPI. #RY'80ZOX M.Q'M7N
U(C<3YHR9U@I@RT)M\$SXX1<I?>R00JPK1<?>OV06G1OA77<4K1 M.LAWAI<@HUBUP8XDW1:19727FQR->GN->I-AXTZV&ITU+<?>GVVW44
M \$SK85P14<?>HY V=Q?>I>Q@C@G S= BPTF17IE6C:YRUBD<BU M'4@&P2B)>=HJ?ZCR:HXX"WC4<?>+?>CHJG0E4ZYFFRC0>I>I>ZA<M160+BHH0V3
R<5ZG5U15H04 FELP22LQ17Z7Q-YKX&8H9?>0UGC7H1@4L M2<=QS-UGJCWTF#QS:0AFN1A@U+I7H(DUZZ2VY44?IY#>Z->OZL?G?Z MRH12?>S-I/H/6/
Z<1<?>JL D1?>Q MUCQHL3?>9U(PYUAYZ=M4M5X MG&6779 56JGX@X:DM.G8Z 55SMIT?>I-IBWU-LMU M2<=>Z?>3A1@F7-KQI+UWF7W:W?>9 WION0 974
H=>IAXUJ10LQU M25 176 XA#HPP3>=>H+>M'AC+1W9C9AJ#QAL6A<S<*>T9 M'Y@>P|>U?>I>E:Q>S<5 90Q>#AJ&R1:6A(EIN@M>?)7ASIN%>QJ9Z
MG61&X3<I&AGC Q@OU?R3X3BH#<27>D=>=IN3TV@I#?KPOSA= X\$QVK<N.T M'KFDHF47.99ZEL33BEE<NX F#4KB> "WVW=>ZPIHE@87%Q>X<=>6&T9N
M\$%>+WXLMM1#>9?>1&1>V:S4GQ@IL@.8NXGGOZIL<=>+OFWTFXG&M9DR+I/C M<=>JH<X&R0H8C15990@>J5OJ?13@HKO4L I/H@H75FR7GSV9HJHDW6 M?5
ZMDZ12X&SXTX+P1@J1:HQ A772.NDR15JL H&P P-LK-2ODDD+1N60IX M#=#57<=<5E5K1?>F(44;DYDOR@V77AYIDTOFNU52T5.F5CM:SN#G1S44 M.1&S
ZBDNDI 02B@<8&8X;MHU&Q>WPMR<BLJ3Q1TG47W1H1G83?14F2#E M1=>1ZEGHJ.NF=M>Y2<?>X0S21BIN&1V-A5=>5?>QOLIO@VCM>L>?>I M'XQROJHWWU#9Y
INALC33@MTPP/UA/73>Z1?>10 BS<H?>BKR1Y#""M55FREAW8V56GHI@L927K1R<DKK>J9=7?>@C1Q9@440AP+MP.GG<6%&9
MEG6393OPC/09#LIBU>=F2?>H&I542?>I>E&8U?>M&67P>FV.L6P22QHOQ9>WABA ZY91C<?>C?WIC M10C1H62FAST?>3I8<H+OQ=HDIWQ MFHL1?>0P"HW"JPV?>
S"QO%>GH(KDWV.D2XW&ZS">B(HCF<1<?>NU1?OZ MJK"X@4FI<=>@>TH12P A>#?>M->WA/USX%KO06=3.@G.N'GY FZ5M0
M&96CTK1B5AH+6DQ/AMG<C?R77+D9=>ZXT71HE>G&K M2.5#0B2.192.@S@N<+>+>A-JD8H1@>I?>I)TU<U>I.1P?>ZV6&IN
MHV15<.&OXQ2EUKR>KZP.486V?88IZ&5PZOMJ5F5QO VYN<S=>(UN4&@ MO@1491+&1J9U>S>)>#13Q X.M (P18+>NRRN?>S12F4+GM<NMBQ>BX7MR MI\$B8F?>
H.075N<5.>115WV/FIETDR X<P=>D6A&2PX@>@G&Y6SSZ&1JH21 M'Y L'D M@>L9 "INX"X#<2?>E7N+PBNKOWP351G6G5<?>U.D1.MGM M#M MF35UE
2M5.3L4F<1IDZUHGSLDX MKHEHT1>D>S.6<K1 3O1Z<8IF?>PWN7 MY"XY2V1K3<#JFNIS.4?>1=>Q&8RBEF7P/60G MI9TYXG6H1FE JGMBG579MMMK30)RYV0#2UIRDPK
M0-WEQ11<50B\$A2H7P5#9E45KNG/BO<2<5>V<1E-8R=P%>YKQDD)O@P=>EN M>5B1A2RR&@<1<98 17?>8>Z=R1LTF&JL6:8W6>?H83-Z H3GH/GJH8J M<405&Q
XCE61(GH/AJZ<V(N1876ZD@>L?>B=>=>I>P>5 V6A/D@>L M#&E7 -77#CSZ60L IPL 3%R%>S=>H=H5NL&#>WTL87Z/6Q@<C@R HR'M2
M<=>7?>N6H1>L?>H1CHSYENH A0D<6B%>H&JRL3?>4.120S@SYTD<@>D0 M51%W5Y9>=>#1%CFKP14FD9<U M1K1KTF741YET46 M?>D1V1>?>6C8> ">I?>2?>SEL.S.0R/SX?
GASF1 5X M86PPD(G7EP#51EUPN V86G0UPN?>TKA@E9P\$X1XJL@ J2B3HX<W8> M.M+E&F91<95<7CTN@>U+IWB4B1<X1T1#NEZ<?>U4545SZN?F19E0FGMN7 M@?>
VY1+>B?>73#5D1H<45V.OCT60+VH-55UAUW.KDPN.O0#3X<E1EAO.SU?>?>MILU#>1X<2>3I0I?>Y7DH<@H2K1L191X& BG ">JOSTO<23>@>I(SY
MIOP7X1Z:XZ03?>Y/C?>MAARIS-TZ2H+ON)5HCS 0XIKI2@X D?L8R M"ET I2EX0<?>X14H@<+L0?>6G2?>NN4)WO#&1U1="IYK&>??>#6.OQ
MX8 X\$W@>DFWAI:O?>N2<@>OY>=HVNIR1I=I2>I+18YQ@>0.3%>SIW+ MER3?DR M'>Q71?>HJ&BA<=>MFGTOAIPX2 M.MU3Z9F<INGEE52VTV
IAOHJHM7GN@L25Y.253I.GSE09 M.ML9X0651PI.IN/N9Y>=>XTHTB1@P1Y?768X1L>I 0.310.QM>I0%Q MOUHQ< T6?>QOR-2BHF7O.IR0Q?U#H13DIXTBI71?>
R1L2 Z9P1 M'M+P1=>6%>CWNJ#>3+63Z<81W15%>HJWNW\$>TRR634P15.5TX3K1C4C@B0: MGFEM9K 8P9E9K& HDLIBI2Q01LEI<3AUVIUFORXKN@RI7B3H41YZYWW.P9
M18WYJ.HIDN)OXH051E0671.N&S<1-0AW\$>YU.OOM4 M MPI@I UR-D?P MUH1H1H5H7@BMO: MGFEM9K 8P9E9K& HDLIBI2Q01LEI<3AUVIUFORXKN@RI7B3H41YZYWW.P9
IPI(ZL5\$&L41L<J336M@>=IDLHGH&S;SST=C@<I3CQ2.I><65?3P21.TTXB1+N.M.JH56<69-0Q%>R191RLYVDYSP M*L(9M4Y35KML1C=<=>2X412\$>
#3JN7B22AF2?>3.SR2?71?7ZO1(WPI0 MIC@T8DJ4LAY+Q13W1GXDDP+T.WCPS5<X2<1X"56K84X3.2WV7WCP<@I.U MP9H5=7H"PYKMHQS?>S1B1?>O61C+>F8U U-
X=>6BHB?>01X<31>=>SLT M<=>M&UK4F6<?>R1BJH8H4Y<9> I031P@>C66 5#>7=43?>IZR<X"56K84X3.2WV7WCP<@I.U MP9H5=7H"PYKMHQS?>S1B1?>O61C+>F8U U-
&R8F1<=>8 MRE&A0Z<8C8C1<?>#>@D1B1Q@HIT?>7XIV SW=C"/FCG1A1Y.7G6N71

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

[illegible]

[illegible]

!U+G>1!@5A95 MYT+|=8P+NIQRI.1.s)33+Q#1!Y@9GO:7B*CRSU&+YZQIEE*4G M0+J!FZW+NU62(+J8&R+!R79 LVV M# P8I=UJ#C=<^UY8D)*DS@7
J51P9P=0!44*7X7U+P+QV+H+BIG M+5=J=2!81P.8&GXIS90 3GZA0R D.D3D=7?>14+<0K,ZAX14.6/C M5U48M4! LV50BIM*SFN+N?RT.N!&+4QJ3WY!F5X/9&+
(GRVYE+U+NC<MFOZIC15+|H+L.1#=#5S<2>0.FE+CA&NF96 5!KHA+VHX0+)=*R..MUUN5Z.C8V<7?9G10(S-8&+4J7F=AT8U V5+?>9J+Q9+6M#>#1BJCFN+5F3H@+
MW1+>B.5H+R&X(KX=5&:HDSZ312LX!K3FIWMMX3KQ?E6Z+2)2NK6GHW+MHOEEQ7MVA&KAZQ9=V16+8&0JW+K4<:U1M83+2GJS5MT?>VY
M1.0:#105I90B21*HCU0B2(+GS#=-U0G# T1H31+U)E.Y00.Y10.7!M41E GHEH1B05HY+>8N2WYX&13 7X-1B*3QD1HAQ GON?V11WCG0(+& MZHH+8.L1Q1-1G1
f53X&WETH3+6&7B*PR*M.HLK=2LH0&<8T*:@T M@0AMGSI@N3+>6JMV52<5L1+::@27:PMV(F+)*W:F22-MP988CRFD+?WE+*65#IFMYFU+X1.T32+9<A#81 5&+
H+A3+M@J3H+>M=AMK1%=<#)ND;1-L#0A6;NK N:FF2!O2R0?66G7A!WJ331UEU.M-UA+>7+3?FY(+&4&B#P+N.AB5)WUICV 7D*CG?>K^H7?26=.Q7FVH+@<M
MDQ.T(+<9I#&7+2+H7U+>6+JYU73=U#<?275033)0#K13C(50M*250.MDPHF+M=MAY(A16.Q 4JCLF.D-HCK9@.Y02BND0+1B@V+8U8.YB9914A*X2*Y M=-
(ZRAK10K&SRP4=M&N3&37SV44W4M.FVTOE*0H)H5<+0&K5Y1L95&Y1\$+>XKME+JDL5+1B1B(IJ214N+>0FW+*RP/KI-G4&9Y\$+N.9B &S1C&SZ+ZBBS?ME10X9&K9%<+<
3Z1K-1M3K9P7+?+7F=1X1+42WMTDGI\$+E(H652NX@N3@?Q22.D.M#1GL 23MKE*F2F2.1&5+?#T1E1X+V#N31\$+>+44T-15&5^6)15V&K\$NS
M1*VY&2U1H*9BYU+0+>L.TGD8R+@RA75.WEM+*#J.ZNCAGE.G.1H4I:6B.XM4SOIA(CPN?<+<S16.M8ZJQZB*TOH\$H+>#L61+<SFE*2@QG?
>M.JHSF01U7O7F.H7ZOXIRAS8) MIS&2FOH-BP*#B(M=KWR3.K14JL2LBQBL M2?0.P&=BNY2.58!@+PLZ>6.0Z3-5Z3(72)QF7.LUC)H#)
M40.V920.M9W+>OPG<+*F+E&G+IM0Z79P0VYXZK:6@1K1?FW+I&6LPYGL1M2(MDOZZ.\$6)1%0!A.58UE72P%URL7C?F7(FDQBT1+>P:PHD/MK\$F7W?
@>VB97J1BD.#C1=5&S1CD1GKGP1.0.6C4H\$#>2R7Y&MES.(AR+0&2P)9Z<+<FV9YH1L7BL @+4-(O-4&TNI4+<@QNO.DBKHD+<+>A7U01013&MAL:14*N2 M8?>
H(+>UJ+&F.M=R#OR#<(|DE*RYI&4LH\$K4>8UCTC=>#FAWS&CLZ1+>=PH M*BS*IW&TQA?Z#1+M<85%1K0=LZGU?3COCB=>4+>+I(WY7FBW\$)>G BEW9R?M-
YI-M+IEAGND11EIRZOU2.L8*GT3&2L=ZJA+PK.G6=I*G1489UUTY.M@OX521&NRD:KXTCIGU?41Z4AS9*YDR+42TL2(S:OT/8I*9RGZC|>+U4
M#7Q6D&LFPNX#<R0>D>L HT<=5&5?>+>G=H DK80(CSVPT8W1OR8? MD1?XJ51H5Y8YLS5BJBT1+1\$@+3+<MLO>K=61L(Y62UY+>)(U&1ZE+
MD+7%0YTF(3&RY1+>B1AR-A0VP+>L1CWWRV\$S(|<082U.S1%2:1A> M?C3+QEN 1#R.19UKS(B3?C5VJGIEV<+<B-MJH-04H1FZ(3?2+>Y#YUD
M43+4+>ROLTITXIG&F=H#X82G.IMDXU2+L2XJG7B\$SS>>OXID0!1.&TL+XJPM9B31T?QO1.OYD23<+<LXG-0+M.D.9&JQ?>S5YQK*#S4N/08A9L\$JW#*46A%QG6&1
M0S)CVH0TUDG&1@#B#2+>X#C9-FHMTD1N-7&5E6(G3+<K&AN:61MH5FO.F M\$2EA\$+>@83.24+<#NBSW\$&63X1+>M)B1@ON.3+>WU#8H.6JXH80
MIMSEH7&K0#>C?>E4<=>B&LBPXK9C.D(BGLAG&9CN.BP9D.T43+1H7*68X*1\$&P>HUGLJ&S.ML*Y.(H+<0NRN+<0)S6P=EF7ZLW+67MD
MG6P6H1+<K0"N.1%=&9Y59KFZU<6&BUH9->B77ZGYGP>RX-EDSM86UTSTBLJZ+>THT.B+2&OKU46K MM>X9A&FROM@3B7D1L1224=GV9T7:IK5Y?TBIY+<Q
M#S1L+7R6R&KM MTO2?>1N+<K+Z10FM3S21KJ-Z+>Q+V+<G%CI+VN:CG=MM6P*VR1+>U MS36>1&31+L.F+U@U@>X1+<X#8P7*PM@>77%>Y?>
=>XAH9R3)U.FV+>A#>M(GIVSWFOY+>S.SM+W36Q@K0F@>8>+>L58R.AHA6.XME&Q? 19 MB&415C121008LZ1P1?21AC6<+>F3+3V1)5W5ZY+KAI1.VOOO*9F M@%>+<
<2?H&K&DZ=>3#BM+1JB1813?Q.Z+>3BNB&1BH 1YBMH758R" M-C+>+>5&XCG=>MBU/FR5291M+>H66.X06&6(3&6<+<M1AW6UJCVUMXWY1BMM+>)*R-
TB*XINP-PE.T=>202BA3H\$>SKT*W2.M1ZMTU.T4=SEWOW1MIFA1M@PO.9SF4L.P6EN.266DN7?Z MNXT?G0IRK+&IKH2D?>8&JNGYM+>#HH1PKF8-
9R1HTEFC8H&8V=X\$ M\$5W\$M%>M%Y0V31HCY51#1L(H4M0)2=>=AIGR4R1*SW2OX526.ND(H)E9O.MWE+E59RG4UFH=#>W>=>C(W17Z6LV1+@PTL09#5?>
>41%>=19(4+Y\$>D MACN(RF+>JYB9Y0Y+>#P>JZMUUVY+MZU9&KVI*6E=-J2H1@>S1&M@+1V MT14W8@93>U+>O91*TL(G1MPD%V6V-
POXY.1QO)4&+>DP>+<LQ+<IK6 M+>2PTF*YV4&54Z79X&3BO.RVJOQ+>3NG9QA(C9?9T9?>V+<LQOK=>#M.M+>P+>HBM+L+LT7?0(BID.6ZLL+<+<M19R\$1VM.97QR0*H4-
0?>DUF 16P1.M1K&S (HUB0P3?>6J&E2K5G+>7.M.OTD9+>T*U+>SC+34+>G#1F+>V%ZFRV) M&5Z+>197VSPM GU41P1M76C=J(BH+H&S+N?716=>3RNL6VUMR&6N5Y+>+<Q
M7D12L1*WAS1!>76=>=&YAIL.C1J+>F=1\$ 2SG(-O.M1BY1H1*3A5&@>S.KI6@>F*N@>2%36&L?>X2*2+>QOI>KR.8YA@ROX L.PRWX MZ<@>Z.L4JBYX&C.M3ID451?>
f8(N8U@>+>OVR N.MY BVM)MIV@>4&+>VVDK@>G1U@PXT?>B.J+>3JM51XZ7RLN*DW7H1*MP5B7D MO=>#>SX9OCR+>IF+>EL1+>WTV=>#>DY7Q*40C6+>61+4GD1.3T14E>FJH&73
MT=701N)P.DR5.5OU1+>?>1WVN#C@>C1HC.HHAWK.Z7OSV1N1NBRH&XPG M6DNC&AUE&#>JH&K3(YK1+>UL1FJN0)3+>091@>10&9G.VJ?>SZWITBX
MJA.E4JKC+>3H4E>WAL+>V&C?2PH+>W5.0F2+>1P2N/B1.R7ZUY1Y2 M2 BD1U@JUNU=4.5*#J2?6*OILE#>RJT?>4\$+>CLMO:Q9S># M7UEYQTS(C
Q9D?>061*FJB+W6H(GD1@>NL\$5+>14+>PLK (+<16.9+>12.MYB1F7-EE.Y15YU2810GL1419IK8&1EEN:JFS&=>R.NS?>RWT4?5+>7B>8"H
MAR3E1F+>F1=7.T8&UG1+>49P/MG1K*MA6?>RUU4.O429@>G6 M.H&amp

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

[illegible]

[illegible]

2024-06-30-0001737927-us-gaap:AllOtherSegmentsMember 2023-04-012023-12-31-0001737927-us-gaap:AccumulatedGainLossFinancialLiabilityFairValueOptionAttributableToParentMember 2024-03-31-0001737927-cgc:AcquireAcquisitionMember 2024-06-04-0001737927-cgc:OtherNoncontrollingInterestMember 2023-04-012023-12-31-0001737927-cgc:FixedSharesOptionAndFloatingSharesAgreementMembercgc:AcquireOneMember 2024-04-012024-12-31-0001737927-cgc:CanopyRiversMembercgc:WanaMember 2024-04-30-0001737927-cgc:StockOptionSubjectToPerformanceConditionsMember 2023-04-012023-12-31-0001737927-us-gaap:StockOptionMembercgc:TerrAscendMember 2024-04-012024-12-31-0001737927-2024-09-30-0001737927-us-gaap:RetainedEarningsMember 2023-09-30-0001737927-cgc:CanopyUSAAssetsMember 2024-10-012024-12-31-0001737927-cgc:SharebasedReserveMemberus-gaap:AdditionalPaidInCapitalMember 2023-04-012023-06-30-0001737927-cgc:JettlyMember 2024-06-04-0001737927-cgc:BioSteelMember 2023-04-012023-12-31-0001737927-cgc:SettlementOfConvertibleDebenturesMember 2024-03-04-012023-12-31-0001737927-us-gaap:CostOfSalesMember 2024-04-012024-12-31-0001737927-cgc:LoanReceivableMembercgc:AcquireDebtMember 2024-04-012024-12-31-0001737927-cgc:WanaMemberus-gaap:SubsequentEventMember 2025-02-06-0001737927-us-gaap:StockOptionMembercgc:TerrAscendMember 2024-03-31-0001737927-cgc:OperatingLicensesMember 2024-03-31-0001737927-us-gaap:AllOtherSegmentsMember 2023-10-012023-12-31-0001737927-srt:MinimumMembercgc:OmnibusEquityIncentivePlanMember 2023-09-252023-09-25-0001737927-us-gaap:CommonStockMember 2024-07-012024-09-30-0001737927-us-gaap:PrivatePlacementMembercgc:SubscriptionAgreementWithInstitutionalInvestorsMember 2024-10-012024-12-31-0001737927-cgc:AcquireHoldingsIncMemberus-gaap:CommonStockMember 2024-12-092024-12-09-0001737927-cgc:CbiExchangeAgreementMember 2024-04-18-0001737927-us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-12-31-0001737927-cgc:LoanReceivableMembercgc:ElevateLoanReceivableMember 2024-12-31-0001737927-us-gaap:FairValueInputsLevelHMemberus-gaap:FairValueMeasurementsRecurringMember 2024-12-31-0001737927-us-gaap:CommonStockMember 2024-12-31-0001737927-us-gaap:FairValueInputsLevelHMemberus-gaap:FairValueMeasurementsRecurringMember 2024-03-31-0001737927-us-gaap:NoncontrollingInterestMember 2024-04-012024-12-31-0001737927-cgc:AcquiredBrandsMember 2024-03-31-0001737927-2023-06-30-0001737927-cgc:OtherGeographicalAreaMember 2024-10-012024-12-31-0001737927-cgc:SecondQuarterTwoThousandAndTwentyFourPaydownsMembercgc:CreditFacilityMember 2023-07-012023-09-30-0001737927-cgc:FourPointTwoFivePercentUnsecuredSeniorNotesMember 2023-04-012023-12-31-0001737927-srt:MinimumMembercgc:SupremeDebtExchangeMember 2024-05-022024-05-02-0001737927-cgc:OtherGeographicalAreaMember 2024-12-31-0001737927-us-gaap:SellingGeneralAndAdministrativeExpensesMember 2024-04-012024-12-31-0001737927-us-gaap:CostOfSalesMember 2024-10-012024-12-31-0001737927-cgc:ThisWorkMember 2023-04-012023-12-31-0001737927-cgc:SupremeDebtExchangeMember 2024-04-012024-12-31-0001737927-cgc:PrimeRateFloorMember 2023-12-272023-12-27-0001737927-cgc:CanadianAdultUseCannabisMembercgc:CanadianMedicalCannabisNetRevenueMember 2023-04-012023-12-31-0001737927-cgc:SharebasedReserveMemberus-gaap:AdditionalPaidInCapitalMember 2024-03-31-0001737927-cgc:CanadianCannabisNetRevenueMember 2023-04-012023-12-31-0001737927-us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-10-012024-12-31-0001737927-us-gaap:WarrantMemberus-gaap:AdditionalPaidInCapitalMember 2024-10-012024-12-31-0001737927-cgc:AccelerationOfShareBasedCompensationExpenseRelatedToAcquisitionMilestonesMembercgc:TerrAscendExchangeableSharesMember 2024-04-012024-12-31-0001737927-cgc:InternationalMarketsCannabisMember 2024-04-012024-12-31-0001737927-cgc:OwnershipChangesMemberus-gaap:AdditionalPaidInCapitalMember 2024-12-31-0001737927-us-gaap:WarrantMemberus-gaap:AdditionalPaidInCapitalMember 2024-06-30-0001737927-cgc:StorzBickelReportingUnitMember 2024-12-31-0001737927-cgc:CanadianAdultUseCannabisMembercountry:CA 2023-04-012023-12-31-0001737927-cgc:CanadianAdultUseCannabisMembercgc:CanadianMedicalCannabisNetRevenueMember 2023-10-012023-12-31-0001737927-cgc:PaydownAgreementMembercgc:CreditFacilityMember 2021-03-18-0001737927-cgc:CanadianMedicalCannabisMembercgc:CanadianMedicalCannabisNetRevenueMember 2023-04-012023-12-31-0001737927-cgc:AtTheMarketEquityProgramMember 2024-06-062024-06-06-0001737927-us-gaap:NoncontrollingInterestMember 2023-06-30-0001737927-us-gaap:RevolvingCreditFacilityMember 2024-03-31-0001737927-us-gaap:SellingGeneralAndAdministrativeExpensesMember 2024-10-012024-12-31-0001737927-us-gaap:ComputerEquipmentMember 2024-12-31-0001737927-cgc:AcquireHoldingsIncMemberus-gaap:CommonStockMember 2022-10-24-0001737927-cgc:OwnershipChangesMemberus-gaap:AdditionalPaidInCapitalMember 2023-09-30-0001737927-srt:MaximumMembercgc:TrustSPAMember 2023-05-19-0001737927-cgc:SharebasedReserveMemberus-gaap:AdditionalPaidInCapitalMember 2023-10-012023-12-31-0001737927-us-gaap:AccumulatedTranslationAdjustmentMember 2023-04-012023-12-31-0001737927-cgc:InternationalMarketsCannabisMember 2024-04-012024-12-31-0001737927-2023-09-09-0001737927-us-gaap:SubsequentEventMember 2025-02-06-0001737927-us-gaap:CommonStockMember 2024-06-30-0001737927-cgc:CanopyUSAAssetsMember 2023-10-012023-12-31-0001737927-srt:MinimumMembercgc:PaydownAgreementMember 2021-03-18-0001737927-cgc:BioSteelCanadaMember 2024-04-012024-12-31-0001737927-cgc:ThirdQuarterTwoThousandAndTwentyFivePaydownsMembercgc:CreditFacilityMember 2024-07-012024-09-30-0001737927-cgc:CreditFacilityMember 2024-10-16-0001737927-us-gaap:NoncontrollingInterestMember 2024-04-012024-06-30-0001737927-cgc:LIBORPlusMember 2024-12-31-0001737927-us-gaap:CommonStockMember 2024-03-31-0001737927-2023-07-012023-09-30-0001737927-cgc:SupremeDebtExchangeMember 2024-05-022024-05-02-0001737927-cgc:JulyTwoThousandAndTwentyThreePaydownMembercgc:CreditFacilityMember 2023-07-13-0001737927-cgc:AcquireHoldingsIncMembercgc:FixedSharesMember 2024-12-092024-12-09-0001737927-us-gaap:AccumulatedGainLossFinancialLiabilityFairValueOptionAttributableToParentMember 2023-04-012023-12-31-0001737927-srt:MaximumMember 2018-10-19-0001737927-us-gaap:CommonStockMember 2024-04-012024-06-30-0001737927-us-gaap:FairValueInputsLevel3Membercgc:CanopyUsaEquityMethodInvestmentDiscountRateMember 2024-04-012024-12-31-0001737927-cgc:SharebasedReserveMemberus-gaap:AdditionalPaidInCapitalMember 2023-09-30-0001737927-cgc:ThisWorksMember 2023-10-012023-12-31-0001737927-cgc:OtherIssuancesAndShareIssueCostsMember 2023-04-012023-12-31-0001737927-country:CA 2023-10-012023-12-31-0001737927-cgc:OtherNoncontrollingInterestMember 2024-03-01-0001737927-srt:MinimumMember 2023-04-012023-12-31-0001737927-cgc:CanadianMedicalCannabisMembercgc:CanadianMedicalCannabisNetRevenueMember 2023-10-012023-12-31-0001737927-cgc:CanadaCannabisMember 2024-04-012024-12-31-0001737927-cgc:DebtentureMembercgc:AcquireHempcoMember 2024-03-31-0001737927-country:CA 2023-04-012023-12-31-0001737927-cgc:AtTheMarketEquityProgramMember 2024-10-012024-12-31-0001737927-us-gaap:RestrictedStockUnitsRSUMember 2024-12-31-0001737927-us-gaap:RestrictedStockUnitsRSUMember 2023-04-012023-12-31-0001737927-cgc:FirstQuarterTwoThousandAndTwentyFivePaydownsMembercgc:CreditFacilityMember 2024-06-3

cgc:FairValueMeasurementsRecurringMember 2024-12-31-0001737927 cgc:CbiExchangeMember 2024-04-18-0001737927 2023-04-012023-06-30-0001737927
cgc:BuildingsAndGreenhousesMember 2024-12-31-0001737927 country:CA 2024-10-012024-12-31-0001737927 us-gaap:WarrantMember
gaap:AdditionalPaidInCapitalMember 2024-03-31-0001737927 us-gaap:RevenueFromContractWithCustomerMemberus-gaap:CustomerConcentrationRiskMember 2024-04-012024-12-31-0001737927 cgc:SettlementOfAcquireAcquisitionMember 2024-04-012024-12-31-0001737927
cgc:SecuredOvernightFinancingRateSoftOvernightIndexSwapAdjustedFloorRateMember 2023-12-272023-12-27-0001737927 us-gaap:
gaap:AccumulatedOtherComprehensiveIncomeMember 2023-04-012023-06-30-0001737927 us-gaap:RestrictedStockUnitsRSUMember 2024-04-012024-12-31-0001737927 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2023-10-012023-12-31-0001737927 2023-12-31-0001737927 2018-10-19-0001737927 us-gaap:RetainedEarningsMember 2024-10-012024-12-31-0001737927 country:US 2023-10-012023-12-31-0001737927 cgc:BrandsMember 2024-03-31-0001737927 us-gaap:NoncontrollingInterestMember 2023-03-31-0001737927 us-gaap:FairValueInputsLevel3Membercgc:CanopyUsaEquityMethodInvestmentVolatilityOfWanaAndJettyEquityMember 2024-04-012024-12-31-0001737927
cgc:RightOfUseAssetsMembercgc:BuildingsAndGreenhousesMember 2024-03-31-0001737927 us-gaap:StockOptionMembercgc:AcquireDebtOptionPremiumMember 2024-03-31-0001737927 cgc:SharebasedReserveMemberus-gaap:AdditionalPaidInCapitalMember 2023-07-012023-09-30-0001737927 cgc:SupremeConvertibleDebenturesMember 2024-03-31-0001737927 cgc:HSCPHoldersPursuantToAmendedTRAMemberus-gaap:CommonStockMember 2024-12-092024-12-09-0001737927 us-gaap:CommonStockMember 2024-09-30-0001737927 us-gaap:RetainedEarningsMember 2023-04-012023-06-30-0001737927 cgc:OmnibusEquityIncentivePlanMember 2024-12-31-0001737927 us-gaap:StockOptionMembercgc:AcquireDebtOptionPremiumMember 2024-04-012024-12-31-0001737927 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-07-012023-09-30-0001737927 us-gaap:CommonStockMember 2023-06-30-0001737927 cgc:StorzAndBickelMember 2023-04-012023-12-31-0001737927
cgc:CanadianMedicalCannabisMembercountry:CA 2024-04-012024-12-31-0001737927 us-gaap:EmployeeStockOptionMember 2024-04-012024-12-31-0001737927
cgc:BioSteelMember 2024-04-012024-12-31-0001737927 cgc:SoftwareAndDomainNamesMember 2024-03-31-0001737927 cgc:CreditFacilityMember 2021-03-182021-03-18-0001737927 cgc:VariousMemberscgc:EntityOtherMember 2024-03-31-0001737927 us-gaap:DepositsMember 2024-03-31-0001737927 cgc:RangeThreeMember 2024-12-31-0001737927 cgc:SharebasedReserveMemberus-gaap:AdditionalPaidInCapitalMember 2024-04-012024-06-30-0001737927 cgc:OwnershipChangesMemberus-gaap:AdditionalPaidInCapitalMember 2023-06-30-0001737927 cgc:RedeemableNonControllingInterestsMemberus-gaap:AdditionalPaidInCapitalMember 2023-04-012023-06-30-0001737927 us-gaap:PrimeRateMember 2023-12-272023-12-27-0001737927 us-gaap:FairValueInputsLevel3Membercgc:CanopyUsaEquityMethodInvestmentProbabilityOfEachAcquireScenarioMember 2024-04-012024-12-31-0001737927 us-gaap:RestrictedStockUnitsRSUMember 2024-03-31-0001737927 us-gaap:LandMember 2024-03-31-0001737927 country:DE 2024-04-012024-12-31-0001737927 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-03-31-0001737927 2023-04-012023-12-31-0001737927
cgc:AcquireDebtOptionAgreementMembercgc:OtherLenderMember 2024-09-13-0001737927 us-gaap:RetainedEarningsMember 2024-07-012024-09-30-0001737927 us-gaap:CommonStockMember 2024-10-012024-12-31-0001737927 cgc:CanadianCannabisNetRevenueMember 2024-10-012024-12-31-0001737927
cgc:SecondQuarterTwoThousandAndTwentyFourPaydownsMembercgc:CreditFacilityMember 2023-09-30-0001737927 cgc:RedeemableNonControllingInterestsMemberus-gaap:AdditionalPaidInCapitalMember 2023-07-012023-09-30-0001737927 us-gaap:RevenueFromContractWithCustomerMemberus-gaap:CustomerConcentrationRiskMember 2024-10-012024-12-31-0001737927 cgc:BioSteelMember 2024-12-31-0001737927 cgc:CanopyUSAAssetsMember 2024-04-012024-12-31-0001737927
cgc:CanadianMedicalCannabisMembercgc:CanadianMedicalCannabisNetRevenueMember 2024-04-012024-12-31-0001737927
cgc:CanadianMedicalCannabisMembercountry:CA 2024-10-012024-12-31-0001737927 2020-09-09-0001737927 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-04-012023-12-31-0001737927 cgc:RangeOneMember 2024-12-31-0001737927
cgc:CanadianAdultUseCannabisMembercgc:CanadianMedicalCannabisNetRevenueMember 2024-04-012024-12-31-0001737927 2024-07-012024-09-30-0001737927 2024-06-30-0001737927 us-gaap:CommonStockMember 2023-09-30-0001737927 cgc:ExchangeableSharesMember 2024-12-31-0001737927 us-gaap:PrivatePlacementMembercgc:SubscriptionAgreementWithInstitutionalInvestorsMember 2024-04-012024-12-31-0001737927 country:DE 2024-10-012024-12-31-0001737927 us-gaap:RetainedEarningsMember 2024-12-31-0001737927 cgc:DistributionChannelMember 2024-12-31-0001737927 cgc:AcquireDebtOptionAgreementMember 2024-09-13-0001737927 cgc:CanadianMedicalCannabisMembercountry:CA 2023-10-012023-12-31-0001737927 cgc:AmortizableIntangiblesInProcessMember 2024-03-31-0001737927 us-gaap:RetainedEarningsMember 2024-06-30-0001737927 country:US 2023-04-012023-12-31-0001737927 cgc:BioSteelUSAAndBioSteelManufacturingMember 2024-04-012024-12-31-0001737927 cgc:OtherRevenueMember 2023-04-012023-12-31-0001737927 cgc:RightOfUseAssetsMembercgc:BuildingsAndGreenhousesMember 2024-12-31-0001737927 country:US 2024-10-012024-12-31-0001737927 us-gaap:SubsequentEventMembercgc:TrustSPAMember 2023-02-06-0001737927 us-gaap:NoncontrollingInterestMember 2023-07-012023-09-30-0001737927 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-12-31-0001737927
cgc:RangeTwoMember 2024-04-012024-12-31-0001737927 cgc:ThisWorksMember 2023-04-012023-12-31-0001737927 us-gaap:WarrantMemberus-gaap:AdditionalPaidInCapitalMember 2023-03-31-0001737927 cgc:CanadianMedicalCannabisMembercgc:CanadianMedicalCannabisNetRevenueMember 2024-10-012024-12-31-0001737927 cgc:VariousMemberscgc:EntityOtherMember 2024-12-31-0001737927 us-gaap:FairValueInputsLevel3Membercgc:AcquireDebtMember 2024-04-012024-12-31-0001737927 cgc:StorzBickelMember 2023-10-012023-12-31-0001737927 cgc:CanopyUsaMember 2024-12-31-0001737927 us-gaap:OfficeEquipmentMember 2024-03-31-0001737927 cgc:CbiExchangeAgreementMember 2024-04-18-0001737927 us-gaap:AccumulatedGainLossFinancialLiabilityFairValueOptionAttributableToParentMember 2024-04-012024-12-31-0001737927 us-gaap:RetainedEarningsMember 2023-07-012023-09-30-0001737927 cgc:PaydownAgreementMembercgc:CreditFacilityMember 2023-04-17-0001737927 us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember 2024-03-31-0001737927 us-gaap:WarrantMemberus-gaap:AdditionalPaidInCapitalMember 2023-06-30-0001737927
cgc:LoanReceivableMembercgc:AcquireDebtMember 2024-12-31-0001737927 us-gaap:AssetUnderConstructionMember 2024-12-31-0001737927 us-gaap:AccumulatedTranslationAdjustmentMember 2024-03-31-0001737927 2024-12-31-0001737927 cgc:TotalMember 2023-04-012023-12-31-0001737927 country:CA 2024-12-31-0001737927 us-gaap:CostOfSalesMember 2023-04-012023-12-31-000

align:left;">These condensed interim consolidated financial statements are unaudited and reflect adjustments (consisting of normal recurring adjustments) that are, in the opinion of management, necessary to provide a fair statement of results for the interim periods in accordance with U.S. GAAP.</p><p style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none,min-width:fit-content;"></p><p style="text-indent:4.52%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">The results reported in these condensed interim consolidated financial statements should not be regarded as necessarily indicative of results that may be expected for an entire fiscal year. The policies set out below are consistently applied to all periods presented, unless otherwise noted.</p><p style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none,min-width:fit-content;"></p><p style="text-indent:4.52%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;">Going Concern</p><div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;">These condensed interim consolidated financial statements have been prepared in accordance with U.S. GAAP on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business.</p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;">In the Company's condensed interim consolidated financial statements for the period ended December 31, 2023, the Company raised substantial doubt about the Company's ability to continue as a going concern for at least twelve months from the issuance of those condensed interim consolidated financial statements, due to certain material debt obligations coming due in the short-term, recurring losses from operations and additional required financing to fund its business and operations.</p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;">As of the filing of the Annual Report, the Company had been able to successfully mitigate the substantial doubt by completing several balance sheet actions as further described in the Annual Report. During the nine months ended December 31, 2024, the Company completed additional actions and established the ATM Program (as defined below), issued and sold an aggregate of39,519,029 common shares for gross proceeds of \$255,989 under the ATM Program (see Note 19), amended the terms of the Credit Facility (as defined below) thereby extending the maturity date of the Credit Facility, made a mandatory US\$100,000 prepayment of the Credit Facility, which significantly reduced the Company's short-term debt obligation, received additional proceeds from the liquidation and sale of assets of BioSteel Canada (as defined below), and entered into an amended facility lease, which is expected to reduce the Company's potential lease payment obligation.</p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;">TheCompany continues to evaluate different strategies and may pursue additional actions that are expected to further increase its liquidity position, including, but not limited to, pursuing additional actions to find cost savings and seeking additional financing from both the public and private markets through the issuance of equity and/or debt securities. As a result of management's plans</p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;">above and the financial results of the Company at December 31, 2024, management concludes that the substantial doubt about the Company's ability to continue as a going concern continues to be alleviated.</p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.52%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">Principles of consolidation</p><p style="text-indent:4.52%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">These condensed interim consolidated financial statements include the accounts of the Company and all entities in which the Company either has a controlling voting interest or is the primary beneficiary of a variable interest entity. All intercompany accounts and transactions have been eliminated on consolidation.</p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.52%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;">Variable interest entities</p><p style="text-indent:4.52%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;">A variable interest entity ("VIE") is an entity that does not have sufficient equity at risk to finance its activities without additional subordinated financial support or is structured such that equity investors lack the ability to control the entity's activities or do not substantially participate in the gains and losses of the entity. Upon inception of a contractual agreement, and thereafter, if a reconsideration event occurs, the Company performs an assessment to determine whether the arrangement contains a variable interest in an entity and whether that entity is a VIE. The primary beneficiary of a VIE is the party that has both the power to direct the activities that most significantly impact the VIE's economic performance and the obligation to absorb losses or the right to receive benefits from the VIE that could potentially be significant to the VIE. Under ASC 610 -Consolidations, where the Company concludes that it is the primary beneficiary of a VIE, the Company consolidates the accounts of that VIE.</p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.52%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;">Equity method investments</p><p style="text-indent:4.52%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;">Equity method investments include those investments where the Company: (i) can exercise significant influence over the other entity and (ii) holds common stock and/or in-substance common stock of the other entity. Unless the fair value method is elected, equity method investments are accounted for under the equity method. Under the equity method, investments are carried at cost, and subsequently adjusted for the Company's share of net income (loss), comprehensive income (loss) and distributions received from the investee. If the current fair value of an investment falls below its carrying amount, this may indicate that an impairment loss should be recorded. Any impairment losses recognized are not reversed in subsequent periods.</p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.52%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;font-style:italic;font-kerning:none,min-width:fit-content;">Use of estimates</p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">The preparation of these condensed interim consolidated financial statements and accompanying notes in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported. Actual results could differ from those estimates. Financial statement areas that require significant judgements and estimates are as follows:</p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">Allowance for credit lossesThe assessment involves judgement and incorporates estimates of loss based on available information relevant to considering the collectability and includes consideration of economic and business conditions, default trends and other internal and external factors. The amount is subject to change based on experience and new information which could result in outcomes that require adjustment to the carrying amounts affecting future periods.</p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">Inventory reservesThe Company records inventory reserves based on the Company's estimated forecast of product demand, production requirements, market conditions and regulatory environment. Actual losses may differ from management's estimates.</p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">Estimated useful lives, impairment considerations, and amortization of property, plant and equipment and intangible assetsAmortization of capital and intangible assets is dependent upon estimates of useful lives based on management's judgment.</p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">Impairment of long-lived assets is influenced by judgment in defining an asset group and determining the indicators of impairment, and estimates used to measure impairment losses.</p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">Legal proceedingsJudgement is used in determining the probability of incurring a loss in addition to determining the estimated amount. Amounts recorded are based on management's judgement and actual amounts recorded may not be realized.</p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">Fair value measurement of financial instrumentsThe use of various valuation approaches described in Note 23 may involve uncertainties and determinations based on the Company's judgment and any value estimated from these techniques may not be realized or realizable.</p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">Share Consolidation</p><p style="text-indent:4.52%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">The determination of whether the Company is the primary beneficiary of a variable interest entity requires significant judgement. The assessment requires a qualitative analysis of power and benefits of the variable interest entity.</p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.52%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">Share Consolidation</p><p style="text-indent:4.52%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">On December 13, 2023, the Company announced that the Company's board of directors (the "Board") had approved the consolidation of the Company's issued and outstanding common shares on the basis ofone post-consolidation

common share for every 10 pre-consolidation common shares (the "Share Consolidation").The Share Consolidation was implemented to ensure that the Company continues to comply with the listing requirements of the Nasdaq Global Select Market.</p><p style="text-indent:4.52%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">The Share Consolidation was approved by the Company's shareholders at the annual general and special meeting of shareholders held on September 25, 2023. The Share Consolidation became effective on December 15, 2023. No fractional common shares were issued in connection with the Share Consolidation. Any fractional common shares arising from the Share Consolidation were deemed to have been tendered by its registered owner to the Company for cancellation for no consideration. In addition, the exercise or conversion price and/or the number of common shares issuable under any of the Company's outstanding convertible securities, were proportionately adjusted in connection with the Share Consolidation.</p><p style="text-indent:4.52%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">All issued and outstanding common shares, per share amounts, and outstanding equity instruments and awards exercisable into common shares, as well as the exchange ratios for the Fixed Shares (as defined below) and the Floating Shares (as defined below) in connection with the Acreege Amended Arrangement (as defined below) and the Floating Share Arrangement (as defined below), respectively, contained in these condensed interim consolidated financial statements of the Company and notes thereto have been retroactively adjusted to reflect the Share Consolidation for all prior periods presented.</p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.52%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">New accounting policies</p><p style="text-indent:4.52%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">Accounting Guidance Not Yet Adopted</p><p style="text-indent:4.52%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">Segment Reporting</p><p style="text-indent:4.52%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">In November 2023, the Financial Accounting Standards Board (the "FASB") issued ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures ("ASU 2023-07"), which expands reportable segment disclosure requirements, primarily through enhanced disclosures about significant segment expenses that are regularly provided to the chief operating decision maker and included within each reported measure of segment profit or loss. ASU 2023-07 is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. The Company is evaluating the impact on the consolidated financial statements and expects to implement the provisions of ASU 2023-07 for its fiscal year ending March 31, 2025.</p><p style="text-indent:4.52%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">Income Taxes</p><p style="text-indent:4.52%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures ("ASU 2023-09"), which enhances income tax disclosures, primarily through changes to the rate reconciliation and disaggregation of income taxes paid. ASU 2023-09 is effective for annual periods beginning after December 15, 2024, with early adoption permitted. The Company is evaluating the impact on the consolidated financial statements and expects to implement the provisions of ASU 2023-09 for its fiscal year ending March 31, 2026.</p><p style="text-indent:4.52%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">Disaggregation of Income Statement Expenses</p><p style="text-indent:4.52%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">In November 2024, the FASB issued ASU 2024-03, Income Statement – Reporting Comprehensive Income – Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses ("ASU 2024-03"), which requires the disclosure of additional information related to certain costs and expenses, including amounts of inventory purchases, employee compensation, and depreciation and amortization included in each income statement line item. ASU 2024-03 is effective for annual periods beginning after December 15, 2026, and interim periods within fiscal years beginning after December 15, 2027. The Company is evaluating the impact on the consolidated financial statements and expects to implement the provisions of ASU 2024-03 for its fiscal year ending March 31, 2028.</p></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;">These condensed interim consolidated financial statements have been prepared in accordance with U.S. GAAP on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business.</p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;">In the Company's condensed interim consolidated financial statements for the period ended December 31, 2023, the Company raised substantial doubt about the Company's ability to continue as a going concern for at least twelve months from the issuance of those condensed interim consolidated financial statements, due to certain material debt obligations coming due in the short-term, recurring losses from operations and additional required financing to fund its business and operations.</p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;">As of the filing of the Annual Report, the Company had been able to successfully mitigate the substantial doubt by completing several balance sheet actions as further described in the Annual Report. During the nine months ended December 31, 2024, the Company completed additional actions and established the ATM Program (as defined below), issued and sold an aggregate of 39,519,029 common shares for gross proceeds of \$255,989 under the ATM Program (see Note 19), amended the terms of the Credit Facility (as defined below) thereby extending the maturity date of the Credit Facility, made a mandatory US\$100,000 prepayment of the Credit Facility, which significantly reduced the Company's short-term debt obligation, received additional proceeds from the liquidation and sale of assets of BioSteel Canada (as defined below), and entered into an amended facility lease, which is expected to reduce the Company's potential lease payment obligation.</p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;">The Company continues to evaluate different strategies and may pursue additional actions that are expected to further increase its liquidity position, including, but not limited to, pursuing additional actions to find cost-savings and seeking additional financing from both the public and private markets through the issuance of equity and/or debt securities. As a result of management's plans and the financial results of the Company at December 31, 2024, management concludes that the substantial doubt about the Company's ability to continue as a going concern continues to be alleviated.</p><p style="text-indent:4.52%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">Principles of consolidation</p><p style="text-indent:4.52%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">These condensed interim consolidated financial statements include the accounts of the Company and all entities in which the Company either has a controlling voting interest or is the primary beneficiary of a variable interest entity. All intercompany accounts and transactions have been eliminated on consolidation.</p><p style="text-indent:4.52%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">Use of estimates</p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">The preparation of these condensed interim consolidated financial statements and accompanying notes in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported. Actual results could differ from those estimates. Financial statement areas that require significant judgements and estimates are as follows:</p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">Allowance for credit lossesThe assessment involves judgement and incorporates estimates of loss based on available information relevant to considering the collectability and includes consideration of economic and business conditions, default trends and other internal and external factors. The amount is subject to change based on experience and new information which could result in outcomes that require adjustment to the carrying amounts affecting future periods.</p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">Inventory reservesThe Company records inventory reserves based on the Company's estimated forecast of product demand, production requirements, market conditions and regulatory environment. Actual losses may differ from management's estimates.</p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">Estimated useful lives, impairment considerations, and amortization of property, plant and equipment and intangible assetsThe assessment involves judgement and incorporates estimates of loss based on available information relevant to considering the collectability and includes consideration of economic and business conditions, default trends and other internal and external factors. The amount is subject to change based on experience and new information which could result in outcomes that require adjustment to the carrying amounts affecting future periods.</p></p></div>

none;font-kerning:none;min-width:fit-content;">- Amortization of capital and intangible assets is dependent upon estimates of useful lives based on management's judgment.</p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">Goodwill and indefinite lived intangible asset impairment testing requires management to make estimates in the impairment testing model. On at least an annual basis, the Company tests whether goodwill and indefinite lived intangible assets are impaired. The reporting unit's fair value is determined using a discounted future cash flow model, which incorporate assumptions regarding future events, specifically future cash flows, growth rates and discount rates.</p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">Legal proceedings- Judgement is used in determining the probability of incurring a loss in addition to determining the estimated amount. Amounts recorded are based on management's judgement and actual amounts recorded may not be realized.</p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">Fair value measurement of financial instruments- The use of various valuation approaches described in Note 23 may involve uncertainties and determinations based on the Company's judgment and any value estimated from these techniques may not be realized or realizable.</p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">Consolidation of variable interest entities- The determination of whether the Company is the primary beneficiary of a variable interest entity requires significant judgement. The assessment requires a qualitative analysis of power and benefits of the variable interest entity.</p><p style="text-indent:4.52%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">Share Consolidation</p><p style="text-indent:4.52%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">On December 13, 2023, the Company announced that the Company's board of directors (the "Board") had approved the consolidation of the Company's issued and outstanding common shares on the basis ofsec ix hidden: F 089c4b2a-8b45-433d-9b07-d24a2f7bd214;">one</p><p style="text-indent:4.52%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">post-consolidation common share for every 10 pre-consolidation common shares (the "Share Consolidation").</p><p style="text-indent:4.52%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">The Share Consolidation was implemented to ensure that the Company continues to comply with the listing requirements of the Nasdaq Global Select Market.</p><p style="text-indent:4.52%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">The Share Consolidation was approved by the Company's shareholders at the annual general and special meeting of shareholders held on September 25, 2023. The Share Consolidation became effective on December 15, 2023. No fractional common shares were issued in connection with the Share Consolidation. Any fractional common shares arising from the Share Consolidation were deemed to have been tendered by its registered owner to the Company for cancellation for no consideration. In addition, the exercise or conversion price and/or the number of common shares issuable under any of the Company's outstanding convertible securities, were proportionately adjusted in connection with the Share Consolidation.</p><p style="text-indent:4.52%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">All issued and outstanding common shares, per share amounts, and outstanding equity instruments and awards exercisable into common shares, as well as the exchange ratios for the Fixed Shares (as defined below) and the Floating Shares (as defined below) in connection with the Acreage Amended Arrangement (as defined below) and the Floating Share Arrangement (as defined below), respectively, contained in these condensed interim consolidated financial statements of the Company and notes thereto have been retroactively adjusted to reflect the Share Consolidation for all prior periods presented.</p><p>On December 13, 2023, the Company announced that the Company's board of directors (the "Board") had approved the consolidation of the Company's issued and outstanding common shares on the basis of one post-consolidation common share for every 10 pre-consolidation common shares (the "Share Consolidation").</p><p style="text-indent:4.52%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">New accounting policies</p><p style="text-indent:4.52%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">Accounting Guidance Not Yet Adopted</p><p style="text-indent:4.52%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">Segment Reporting</p><p style="text-indent:4.52%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">In November 2023, the Financial Accounting Standards Board (the "FASB") issued ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures ("ASU 2023-07"), which expands reportable segment disclosure requirements, primarily through enhanced disclosures about significant segment expenses that are regularly provided to the chief operating decision maker and included within each reported measure of segment profit or loss. ASU 2023-07 is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. The Company is evaluating the impact on the consolidated financial statements and expects to implement the provisions of ASU 2023-07 for its fiscal year ending March 31, 2025.</p><p style="text-indent:4.52%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">Income Taxes</p><p style="text-indent:4.52%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures ("ASU 2023-09"), which enhances income tax disclosures, primarily through changes to the rate reconciliation and disaggregation of income taxes paid. ASU 2023-09 is effective for annual periods beginning after December 15, 2024, with early adoption permitted. The Company is evaluating the impact on the consolidated financial statements and expects to implement the provisions of ASU 2023-09 for its fiscal year ending March 31, 2026.</p><p style="text-indent:4.52%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">Disaggregation of Income Statement Expenses</p><p style="text-indent:4.52%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">In November 2024, the FASB issued ASU 2024-03, Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses ("ASU 2024-03"), which requires the disclosure of additional information related to certain costs and expenses, including amounts of inventory purchases, employee compensation, and depreciation and amortization included in each income statement line item. ASU 2024-03 is effective for annual periods beginning after December 15, 2026, and interim periods within fiscal years beginning after December 15, 2027. The Company is evaluating the impact on the consolidated financial statements and expects to implement the provisions of ASU 2024-03 for its fiscal year ending March 31, 2028.</p></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">3CANOPY USA</p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;">Canopy USA</p><p style="text-indent:4.52%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;">On October 24, 2022, Canopy Growth completed a number of strategic transactions (the "Reorganization") in connection with the creation of Canopy USA, LLC ("Canopy USA"), a U.S.-domiciled holding company wherein, as of October 24, 2022, Canopy USA holds certain U.S. cannabis investments previously held by Canopy Growth.</p><p style="text-indent:4.52%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;">Followingthe creation of Canopy USA, the Nasdaq Stock Market LLC ("Nasdaq") communicated its position to the Company stating that companies that consolidate "the assets and revenues generated from activities in violation under federal law cannot continue to list on Nasdaq". Since the Company is committed to compliance with the listing requirements of the Nasdaq, the Company and Canopy USA effectuated certain changes to the initial structure of the Company's interest in Canopy USA that were intended to facilitate the deconsolidation of the financial results of Canopy USA within the Company's financial statements. These changes included, among other things, modifying the terms of the Protection Agreement (as defined below) between the Company, its<span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning

terms of the Trust's investment in Canopy USA in the aggregate amount of up to US\$

space:pre-wrap;font-kerning:none;min-width:fit-content;">20

space:pre-wrap;font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">million (the "Trust Transaction").

Agustin Huneeus, Jr. is the trustee of the Trust and is an affiliate of a shareholder of Jetty (as defined below). Pursuant to the terms of the Trust SPA, the Trust was entitled, subject to certain terms and conditions contained in the Trust SPA, to be issued Canopy USA Common Shares in two tranches with an aggregate value of up to US\$

space:pre-wrap;font-kerning:none;min-width:fit-content;">10

space:pre-wrap;font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">million along with warrants of Canopy USA to acquire additional Canopy USA Common Shares. In addition, subject to the terms of the Trust SPA, the Trust has also been granted options to acquire additional Voting Shares (as defined in the A&M;R LLC Agreement) with a value of up to an additional US\$

space:pre-wrap;font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10

space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">million and one such additional option includes the issuance of additional warrants of Canopy USA. On April 26, 2024, Canopy USA completed the first tranche closing of the Trust Transaction in accordance with the Trust SPA and pursuant to the Trust SPA, the timeline to complete the second tranche closing has lapsed. As of February 6, 2025, the Trust holds an aggregate

space:pre-wrap;font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">28,571,429

space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Canopy USA Common Shares and warrants to acquire up to

space:pre-wrap;font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">85,714,284

space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Voting Shares expiring on

space:pre-wrap;font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">April 26, 2031

space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Canopy USA Common Shares and warrants to acquire up to

space:pre-wrap;font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">On November 3, 2023, the Company received a letter from the staff of the SEC (the "Staff") in which the Staff indicated that, despite the Reorganization Amendments, it would object to the deconsolidation of the financial results of Canopy USA from the Company's financial statements in accordance with U.S. GAAP once Canopy USA acquires Wana, Jetty or the Fixed Shares of Acreage Holdings, Inc. ("Acreage"). The Company subsequently had discussions with the Office of Chief Accountant of the SEC (the "OCA") and determined to make certain additional amendments to the structure of Canopy USA (the "Additional Reorganization Amendments") to facilitate the deconsolidation of Canopy USA from the financial results of Canopy Growth in accordance with U.S. GAAP upon Canopy USA's acquisition of Wana, Jetty or Acreage. In connection with the Additional Reorganization Amendments, Canopy USA and its members entered into a second amended and restated limited liability company agreement (the "Second A&M;R LLC Agreement"). In accordance with the terms of the Second A&M;R LLC Agreement, the terms of the Non-Voting Shares have been amended such that the Non-Voting Shares are only convertible into Canopy USA Class B Shares following the date that the NASDAQ Stock Market or The New York Stock Exchange permit the listing of companies that consolidate the financial statements of companies that cultivate, distribute or possess marijuana (as defined in 21 U.S.C. 802) in the United States (the "Stock Exchange Permissibility Date"). Based on the Company's discussions with the OCA, upon effectuating the Additional Reorganization Amendments, the Company believes that the Staff would not object to the deconsolidation of the financial results of Canopy USA from the Company's financial statements in accordance with U.S. GAAP.

space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Following the Reorganization, Reorganization Amendments and Additional Reorganization Amendments, on May 6, 2024, Canopy USA exercised the options (the "Wana Options") to acquire Mountain High Products, LLC, Wana Wellness, LLC and The

space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Cima Group, LLC (collectively, "Wana"), a leading cannabis edibles brand in North America, and subsequently closed the transactions to acquire Wana Wellness, LLC and The Cima Group, LLC. On October 8, 2024, Canopy USA closed the acquisition of Mountain High Products, LLC. In addition, Canopy USA exercised the options (the "Jetty Options") to acquire Lemurian, Inc. ("Jetty") a California-based producer of high-quality cannabis extracts and pioneer of clean vape technology and subsequently completed the first tranche closing to acquire Jetty. On June 4, 2024, the option to acquire the issued and outstanding Class E subordinate voting shares (the "Fixed Shares") of Acreage, a leading vertically-integrated multi-state cannabis operator, with its main operations in densely populated states across the Northeast U.S., including New Jersey and New York (the "Acreage Option") was exercised and on December 9, 2024, Canopy USA completed the acquisition of all of the issued and outstanding Fixed Shares and Class D subordinate voting shares (the "Floating Shares") of Acreage (the "Acreage Acquisition"). Canopy USA also holds direct and indirect interests in the capital of TerrAscend Corp. ("TerrAscend"), a leading North American cannabis operator with vertically integrated operations and a presence in Pennsylvania, New Jersey, Michigan and California as well as licensed cultivation and processing operations in Maryland.

space:pre-wrap;font-size:10pt;margin-top:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Canopy USA currently holds an ownership interest in the following assets, among others:

space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">margin-left:2.63%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:2.62%;text-align:left;">Acreage

space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Wana

space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">100

space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of the membership interests of Wana Wellness, LLC, The Cima Group, LLC, and Mountain High Products, LLC.

space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">margin-left:2.63%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:2.62%;text-align:left;">Jetty

space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">margin-left:2.63%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:2.62%;text-align:left;">approximately

space:pre-wrap;font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">77

space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of the shares of Jetty.

space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">margin-left:2.63%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:2.62%;text-align:left;">TerrAscend

space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Canopy USA beneficially holds an aggregate of

space:pre-wrap;font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">64,564,487

space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">TerrAscend common shares (the "TerrAscend Common Shares") on an as-converted basis and

space:pre-wrap;font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">22,474,130

space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of the issued and outstanding shares of Acreage

space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">margin-left:2.62%;text-align:left;">Acreage

space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">margin-left:2.62%;text-align:left;">Wana

space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">margin-left:2.62%;text-align:left;">TerrAscend

space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Canopy USA beneficially holds an aggregate of

space:pre-wrap;font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">87,038,617

space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">TerrAscend Common Shares on an as-converted basis assuming conversion of the TerrAscend exchangeable shares (the "TerrAscend Exchangeable Shares") beneficially held by Canopy USA.

space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">text-indent:4.52%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Following the implementation of the Reorganization, Canopy USA was determined to be a variable interest entity pursuant to ASC 810

space:pre-wrap;font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Consolidations

space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">("ASC 810") and prior to the completion of the Reorganization Amendments and the Additional Reorganization Amendments, Canopy Growth was determined to be the primary beneficiary of Canopy USA. As a result of such determination and in accordance with ASC 810, Canopy Growth consolidated the financial results of Canopy USA up to April 30, 2024.

space:pre-wrap;font-size:10pt;margin-top:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Ownership of U.S. Cannabis Investments

space:pre-wrap;font-size:10pt;margin-top:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">text-indent:4.52%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Following the implementation of the Reorganization, the shares and interests in Acreage, Wana, Jetty and TerrAscend are held, directly or indirectly, by Canopy USA, and Canopy Growth no longer holds a direct interest in any shares or interests in such entities. Canopy Growth holds non-voting and non-participating shares (the "Non-Voting Shares") in the capital of Canopy USA. The Non-Voting Shares do not carry voting rights, rights to receive dividends or other rights upon dissolution of Canopy USA. Following the Reorganization Amendments, the Non-Voting Shares are convertible into Class B shares of Canopy USA (the "Canopy USA Class B Shares"), provided that such conversion shall only be permitted following the Stock Exchange Permissibility Date. The Company also has the right (regardless of the fact that its Non-Voting Shares are non-voting and non-participating) to appoint one member to the Canopy USA board of managers (the "Canopy USA Board").

space:pre-wrap;font-size:10pt;margin-top:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On October 24, 2022, Canopy USA and the Company also entered into an agreement with, among others, Nancy Whiteman, the controlling shareholder of Wana, which was amended and restated on May 19, 2023 and on April 30, 2024, whereby subsidiaries of Canopy USA agreed to pay additional consideration in order to acquire the Wana Options and the future payments owed in connection with the exercise of the Wana Options were reduced to US\$

space:pre-wrap;font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.00

space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">in

exchange for the issuance of Canopy USA Common Shares and Canopy Growth common shares (the “Wana Amending Agreement”). In accordance with the terms of the Wana Amending Agreement, on April 30, 2024, (i) Canopy USA issued 60,955,929 Canopy USA Common Shares and (ii) Canopy Growth issued 1,086,279 Canopy Growth common shares to the shareholders of Wana. The Canopy USA Common Shares issued to Ms. Whiteman, or entities controlled by Ms. Whiteman, are subject to a repurchase right exercisable at any time after April 30, 2027, being the 36 month anniversary of the closing of the transaction contemplated by the Wana Amending Agreement (the “Wana Repurchase Right”) to repurchase all Canopy USA Common Shares that have been issued at a price per Canopy USA Common Share equal to the fair market value as determined by an appraiser. As part of this agreement, Canopy USA has granted Ms. Whiteman the right to appoint one member to the Canopy USA Board and a put right on the same terms and conditions as the Wana Repurchase Right.</p><p style="text-indent:4.52%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">As of February 6, 2025, the Trust holds 28,571,429 Canopy USA Common Shares, the shareholders of Wana collectively hold 60,955,929 Canopy USA Common Shares and a wholly-owned subsidiary of the Company holds all of the issued and outstanding Non-Voting Shares in the capital of Canopy USA, representing approximately 84.4 % of the issued and outstanding shares in Canopy USA on an as-converted basis.</p><p style="text-indent:4.52%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">Canopy Growth and Canopy USA are also party to a protection agreement (the “Protection Agreement”) to provide for certain covenants in order to preserve the value of the Non-Voting Shares held by Canopy Growth until such time as the Non-Voting Shares are converted in accordance with their terms, provided that, such conversion shall only be permitted following the Stock Exchange Permissibility Date, but does not provide Canopy Growth with the ability to direct the business, operations or activities of Canopy USA. The Protection Agreement was amended and restated in connection with: (a) the Reorganization Amendments (the “First A&R Protection Agreement”); and (b) the Additional Reorganization Amendments (the “Second A&R Protection Agreement”) and together with the First A&R Protection Agreement, the “A&R Protection Agreement”).</p><p style="text-indent:4.52%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">Until such time as Canopy Growth converts the Non-Voting Shares into Canopy USA Class B Shares following the Stock Exchange Permissibility Date, Canopy Growth will have no economic or voting interest in Canopy USA, Wana, Jetty, TerrAscend, or Acreage. Canopy USA, Wana, Jetty, TerrAscend, and Acreage will continue to operate independently of Canopy Growth.</p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;">Acreage Agreements</p><p style="text-indent:4.52%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">On October 24, 2022, Canopy Growth entered into an arrangement agreement with Canopy USA and Acreage, as amended (the “Floating Share Arrangement Agreement”), pursuant to which Canopy USA acquired all of the issued and outstanding Floating Shares by way of a court-approved plan of arrangement (the “Floating Share Arrangement”) in exchange for 0.045 % of a Company common share for each Floating Share held. In connection with the Floating Share Arrangement Agreement, Canopy Growth irrevocably waived the Acreage Floating Option (as defined below) existing under the Existing Acreage Arrangement Agreement.</p><p style="text-indent:4.52%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">On October 24, 2022, the Company and Canopy USA entered into a third amendment to tax receivable agreement (the “Amended TRA”) with, among others, certain current or former unitholders (the “Holders”) of High Street Capital Partners, LLC, a subsidiary of Acreage (“HSCP”), pursuant to HSCP’s amended tax receivable agreement (the “TRA”) and related tax receivable bonus plans with Acreage. Pursuant to the Amended TRA, the Company, on behalf of Canopy USA, agreed to issue common shares of the Company with a value of US\$ 30.4 million to certain Holders as consideration for the assignment of such Holder’s rights under the TRA to Canopy USA. As a result of the Amended TRA, Canopy USA is the sole member and beneficiary under the TRA. In connection with the foregoing, the Company issued: (i) 564,893 common shares with a value of \$ 20.6 million (US\$ 20.6 million (US\$ 15.2 million) to certain Holders on November 4, 2022 as the first installment under the Amended TRA; and (ii) 710,208 common shares with a value of \$ 20.6 million (US\$ 15.2 million) to certain Holders on March 17, 2023, as the second installment under the Amended TRA. In connection with the Acreage Acquisition, the Company, on behalf of Canopy USA, issued 5,118,426 common shares of the Company to an eligible participant pursuant to HSCP’s existing tax receivable bonus plans.</p><p style="text-indent:4.52%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">In addition to shareholder and court approvals, completion of the Floating Share Arrangement was subject to applicable regulatory approvals including, but not limited to, Toronto Stock Exchange (“TSX”) approval and the satisfaction of certain other closing conditions, including the conditions set forth in the Acreage Amended Arrangement. The Floating Share Arrangement received the requisite approval from the holders of Floating Shares at the special meeting of Acreage shareholders held on March 15, 2023 and on March 20, 2023 Acreage obtained a final order from the Supreme Court of British Columbia approving the Floating Share Arrangement. The Floating Share Arrangement was implemented on December 9, 2024 in connection with the closing of the Acreage Acquisition.</p><p style="text-indent:4.52%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">On June 4, 2024, the Acreage Option was exercised in accordance with the terms of the arrangement agreement dated April 18, 2019, as amended on May 15, 2019, September 23, 2020 and November 17, 2020 (the “Existing Acreage Arrangement Agreement”). Concurrently with the closing of the acquisition of the Fixed Shares pursuant to the exercise of the Acreage Option, on December 9, 2024, the Fixed Shares were issued to Canopy USA upon closing of the Acreage Acquisition. Accordingly, Canopy Growth does not hold any Fixed Shares or Floating Shares. The acquisition of the Floating Shares pursuant to the Floating Share Arrangement occurred immediately prior to the acquisition of the Fixed Shares pursuant to the Existing Acreage Arrangement Agreement such that 100 % of the issued and outstanding shares of Acreage are owned by Canopy USA. For additional details, see “Acreage Acquisition” below.</p><p style="text-indent:4.52%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">On June 3, 2024, the Company exercised its option to acquire certain outstanding debt of Acreage (the “Debt Acquisition”) in connection with the option agreement dated November 15, 2022 (the “Option Agreement”) among a wholly-owned subsidiary of Canopy Growth (the “Optionor”) and the lenders (the “Lenders”) party to Acreage’s credit agreement dated as of December 16, 2021, as amended by the first amendment to credit agreement dated as of October 24, 2022 and the second amendment to credit agreement dated as of April 28, 2023.</p><p style="text-indent:4.52%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">The Optionor entered into various agreements in connection with the Debt Acquisition in order to acquire approximately 136,567 (US\$ 99,837 of Acreage’s outstanding debt (the “Acquired Debt”) from certain Lenders in exchange for \$ 95,460 (US\$ 69,786 in cash and the release of approximately 41,107 (US\$ 30,051 (the “Option Premium”) that was held in escrow pursuant to the Option Agreement. As reported in the Annual Report, the Option Premium was not included in Canopy Growth’s cash and cash equivalents as of March 31, 2024.</p><p style="text-indent:4.52%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">The Optionor subsequently transferred approximately 2,972 (US\$ 2,173 of the Acquired Debt to the other Lender (the “Rolling Lender”) and entered into a series of agreements with the Rolling Lender and Acreage, among others, including an amended and restated credit agreement (the “First ARCA”), which provided for, among other things, the Acquired Debt, certain interest payments to be paid-in-kind, revisions to certain financial covenants and, following certain events, an extension to the maturity date.</p><p style="text-indent:4.52%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">On September 13, 2024, the Optionor entered into a series of transactions with, among others, Acreage, the Rolling Lender and an arm’s length third-party lender (the “Other Lender”). Pursuant to such transactions, all of Acreage’s indebtedness held by the Rolling Lender was acquired by the Other Lender. Following the acquisition by the Other Lender, the Optionor, the Other Lender and Acreage, among others, amended and restated the First ARCA pursuant to a second amended and restated credit agreement dated as of September 13, 2024 (the “Second ARCA”). Pursuant to the Second ARCA and an agreement among lenders entered into on September 13, 2024 between, among others, the Optionor and the Other Lender, all interest owing to the Optionor under the Second ARCA is, subject to the consent of the Other Lender, to be paid-in-kind and not in cash. Under the Second ARCA, as of September 13, 2024, the Optionor was owed an aggregate principal amount equal to approximately </p></div>

known:none,min-width:fit-content;">137,955 (US\$102,000), which is subordinate to approximately \$87,913 (US\$65,000 owed to the Other Lender.</p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;">Deconsolidation of Canopy USA</p><p style="text-indent:4.52%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;">As of April 30, 2024, as a result of the series of transactions related to the Additional Reorganization Amendments described above (the "Canopy USA Transactions"), Canopy Growth has deconsolidated the financial results of Canopy USA and has a non-controlling interest in Canopy USA as of such date. The deconsolidation of Canopy USA occurred after completion of the following structural amendments: (i) execution of the Second A&P;R LLC Agreement, (ii) execution of the Second A&P;R Protection Agreement and (iii) completion of the initial tranche closing of the Trust Transaction, which included the election of a third member to the Canopy USA Board such that the Canopy USA Board is comprised of an appointee of the Trust, Ms. Whiteman, and the Company.</p><p style="text-indent:4.52%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;">Canopy Growth's deconsolidation of Canopy USA resulted in recognition of an equity method investment (see Note 11) and a loan receivable recorded at fair value (see Note 12).</p><div style="font-size:10pt;font-family:Times New Roman;"><table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"><tr style="visibility:collapse;"><td style="width:86.863%;box-sizing:content-box;"></td><td style="width:1.1%;box-sizing:content-box;"></td><td style="width:1.1%;box-sizing:content-box;"></td><td style="width:10.038%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><tr style="height:10pt;background-color:#ffffff;word-break:break-word;"><td style="padding-top:0.01in:white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;">Cash</p></td><td style="padding-top:0.01in:white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"></p></td><td style="padding-top:0.01in:white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;">6,968</p></td><td style="padding-top:0.01in:white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"></p></td><tr style="height:10pt;background-color:#ffffff;word-break:break-word;"><td style="padding-top:0.01in:white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;">Other financial assets</p></td><td style="padding-top:0.01in;text-indent:10pt:white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"></p></td><td style="padding-top:0.01in:white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"></p></td><td style="padding-top:0.01in:white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;">386,045</p></td><td style="padding-top:0.01in:white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"></p></td><tr style="height:10pt;background-color:#ffffff;word-break:break-word;"><td style="padding-top:0.01in:white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;">1,315</p></td><td style="padding-top:0.01in:white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"></p></td><tr style="height:10pt;background-color:#ffffff;word-break:break-word;"><td style="padding-top:0.01in:white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;">2,067</p></td><td style="padding-top:0.01in:white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"></p></td><tr style="height:10pt;background-color:#ffffff;word-break:break-word;"><td style="padding-top:0.01in:white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;">10,398</p></td><td style="padding-top:0.01in:white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"></p></td><tr style="height:10pt;background-color:#ffffff;word-break:break-word;"><td style="padding-top:0.01in:white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;">2,25pt double #000000;padding-right:0.01in;"></p></td><td style="padding-top:0.01in:white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;">2,25pt double #ffffff;padding-right:0.01in;">&lt

[illegible]

#####padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><p></td></tr></table></div><p style="text-indent:4.52%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;">The gain on derecognition of Canopy USA is the differences between the carrying amounts of the derecognized assets, liabilities and non-controlling interest, value of common shares issued, and the fair value of the retained non-controlling interest in Canopy USA, being the equity method investment and the Canopy Elevate I LLC, Canopy Elevate II LLC and Canopy Elevate III LLC (collectively, "Elevate") loan receivable. The gain on derecognition is reflected in other income (expense), net.</p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;">On December 9, 2024, Canopy USA completed the Acreage Acquisition and now owns 100% of the issued and outstanding shares of Acreage. In connection with: (i) the Existing Acreage Arrangement Agreement and the Acreage Amended Arrangement; and (ii) the Floating Share Arrangement Agreement, Canopy USA acquired all of the issued and outstanding Floating Shares of Acreage on the terms and conditions set forth in Floating Share Arrangement. Immediately following the implementation of the Floating Share Arrangement, Canopy USA acquired all of the issued and outstanding Fixed Shares of Acreage (the "Fixed Share Acquisition"). In accordance with the Floating Share Arrangement, registered holders of Floating Shares received 0.045 of a common share of Canopy Growth for each Floating Share (the "Floating Share Exchange Ratio"). In connection with the Fixed Share Acquisition, each of the outstanding Fixed Shares was exchanged for 0.00000000617 of a common share of Canopy Growth for each Fixed Share, as adjusted pursuant to the terms and conditions set forth in the Existing Acreage Arrangement Agreement (the "Fixed Share Exchange Ratio"). In aggregate, Canopy Growth issued 5,888,291 common shares to former shareholders of Acreage.</p><p style="text-indent:4.52%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;">Pursuant to the Floating Share Arrangement, (i) each outstanding stock option to acquire Floating Shares was exchanged for a replacement option exercisable for Canopy Growth common shares, with the number of underlying Canopy Growth common shares and exercise price of such options adjusted by the Floating Share Exchange Ratio; (ii) each outstanding warrant to acquire Floating Shares was exchanged for a replacement warrant to acquire Canopy Growth common shares, with the number of underlying Canopy Growth common shares and exercise price of such warrants adjusted by the Floating Share Exchange Ratio; and (iii) each outstanding restricted share unit, performance share and performance unit, as applicable, that vested into Floating Shares was exchanged for a replacement restricted share unit, performance share or performance unit, as applicable, that vests into Canopy Growth common shares, with the number of underlying Canopy Growth common shares adjusted by the Floating Share Exchange Ratio.</p><p style="text-indent:4.52%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;">In connection with the Fixed Share Acquisition, (i) each outstanding stock option to acquire Fixed Shares was exchanged for a replacement option exercisable for Canopy Growth common shares, with the number of underlying Canopy Growth common shares and exercise price of such options adjusted by the Fixed Share Exchange Ratio; (ii) each outstanding warrant to acquire Fixed Shares was exchanged for a replacement warrant to acquire Canopy Growth common shares, with the number of underlying Canopy Growth common shares and exercise price of such warrants adjusted by the Fixed Share Exchange Ratio; and (iii) each restricted share unit and performance share unit, as applicable, that vested into Fixed Shares was exchanged for a replacement restricted share unit or performance share unit, as applicable, that vests into Canopy Growth common shares, with the number of underlying Canopy Growth common shares adjusted by the Fixed Share Exchange Ratio.</p><p style="text-indent:4.52%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;">In addition, Canopy Growth: (i) issued 5,118,426 common shares of the Company to an eligible participant pursuant to HSCP's existing tax receivable bonus plans; and (ii) 306,151 common shares of the Company were issuable in connection with Canopy USA's acquisition of the minority interests of certain subsidiaries of Acreage, of which 236,960 common shares of the Company have been issued.</p><p style="text-indent:4.52%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;">Immediately following the closing of the Acreage Acquisition, Canopy Growth issued an aggregate of 1,315,553 common shares and 1,197,658 common share purchase warrants to certain securityholders of Acreage in order to satisfy an outstanding liability. Each common share purchase warrant entitles the holder thereof to acquire one common share of Canopy Growth at an exercise price of US\$ 3.66 until June 6, 2029.</p><p style="text-indent:4.52%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;">In exchange for the issuances of Canopy Growth common shares, warrants and other replacement securities in connection with the Acreage Acquisition, Canopy Growth received additional Non-Voting Share S with a value of \$ 50,786 and Canopy USA delivered guarantees in respect of the obligations owing pursuant to the Elevate loan receivable. Refer to Note 11 and 12 for more information on Canopy USA investment balances and refer to Note 19 for more information on the debt and warrant issuances as part of the Acreage Acquisition.</p><p>0.100.9020000000100000001000000028571429857142842031-04-2610.7746456448724741306.072032-12.3187038617360955929108627928571429609559290.8440.00045304000005648932060000015200000710208206000001520000051184261136567000998370009546000069780The deconsolidation of Canopy USA from the financial results of Canopy Growth resulted in the derecognition of the following assets and liabilities:<table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"><tr><tr style="visibility:collapse;"><td style="width:86.863%;box-sizing:content-box;"></td><td style="width:1.1%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:10.038%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><tr><tr style="height:10pt;background-color:#ff0fc;word-break:break-word;"><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;">Cash</p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;">Other financial assets</p></td><td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;">Other liabilities</p></td><td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in

[illegible]

BIOSTEEL SPORTS NUTRITION INC.

On September 14, 2023, following a review of the strategic options for the BioSteel business unit, Canopy Growth ceased funding the operations of BioSteel Sports Nutrition Inc. ("BioSteel Canada"). BioSteel Canada commenced proceedings (the "CCAA Proceedings") under the Companies' Creditors Arrangement Act ("CCAA") in the Ontario Superior Court of Justice (Commercial List) (the "CCAA Court") and sought and obtained recognition of that proceeding under Chapter 15 of the United States Bankruptcy Code. To assist with the sale process, the CCAA Court approved the appointment of a monitor as required under the CCAA.

The strategic decisions made encompassed all operations of the BioSteel business unit, including those of BioSteel Canada. For this reason, the BioSteel segment results for all periods prior to the September 14, 2023 deconsolidation of BioSteel Canada, including costs to exit, were classified as discontinued operations.

On November 16, 2023, BioSteel Sports Nutrition USA LLC ("BioSteel US") and BioSteel Manufacturing LLC ("BioSteel Manufacturing") and collectively with BioSteel Canada and BioSteel US, the "BioSteel Entities" were added as additional applicants in the CCAA Proceedings. As a result, the most relevant activity of both entities became the liquidation and sale of assets and distribution of cash and proceeds to their respective stakeholders and management concluded that Canopy Growth ceased to have the power to direct the relevant activities of BioSteel US and BioSteel Manufacturing because those activities required approval from the CCAA Court. As a result of the conclusion of the sale of assets and distribution of the cash and proceeds of the BioSteel Entities, on July 31, 2024, the CCAA Court granted an order which provided, among other things, for the termination of the CCAA Proceedings upon service of a certificate (the "CCAA Termination Certificate") and authorization for the BioSteel Entities to file assignments in bankruptcy pursuant to the Insolvency Act.

As a result of the foregoing, Canopy Growth no longer has a controlling interest in BioSteel US and BioSteel Manufacturing and has deconsolidated both entities effective November 16, 2023. The deconsolidation of BioSteel US and BioSteel Manufacturing and related impairment charges were classified under losses from discontinued operations.

Three months ended:

	September 14, 2023	October 22, 2024
Revenue	\$100.0%	\$100.0%
Gross profit	\$100.0%	\$100.0%
Operating income	\$100.0%	\$100.0%
Net income	\$100.0%	\$100.0%

Nine months ended:

	September 14, 2023	October 22, 2024
Revenue	\$100.0%	\$100.0%
Gross profit	\$100.0%	\$100.0%
Operating income	\$100.0%	\$100.0%
Net income	\$100.0%	\$100.0%

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

```
<pre><pre>pre-wrap;font-kerning:none,min-width:fit-content;">
```


[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

134,267
(US\$
97,500
)
<p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;">Promissory Note
<p style="text-indent:4.52%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">On April 13, 2023, the Company entered into an exchange agreement (the "April 2023 Exchange Agreement") with Greenstar Canada Investment Limited Partnership ("Greenstar"), an affiliate of Constellation Brands, Inc. ("CBI"), in order to acquire and cancel \$
100,000
 to aggregate principal amount of the
4.25
)% unsecured senior notes due in 2023 (the "Canopy Notes"). Pursuant to the April 2023 Exchange Agreement, the Company agreed to acquire and cancel \$
100,000
 to aggregate principal amount of the Canopy Notes held by Greenstar in exchange for: (i) a cash payment to Greenstar in the amount of the unpaid and accrued interest owing under the Canopy Notes held by Greenstar; and (ii) a promissory note (the "CBI Note") issuable to Greenstar in the aggregate amount of \$
100,000
 payable on December 31, 2024. The CBI Note bears interest at a rate of
4.25
)% per year, payable on maturity of the CBI Note.
<p style="text-indent:4.52%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">On April 18, 2024, the Company entered into an exchange agreement (the "April 2024 Exchange Agreement") with Greenstar, pursuant to which Greenstar converted approximately \$
81,220
 of the principal amount of the
100,000
 principal amount of the CBI Note into
9,111,549
 exchangeable shares of the Company (the "Exchangeable Shares"), calculated based on a price per Exchangeable Share equal to \$
8.91
 (the "Note Exchange"). Pursuant to the terms of the April 2024 Exchange Agreement, all accrued but unpaid interest on the CBI Note together with the remaining principal amount of the CBI Note was cancelled and forgiven for no additional consideration by Greenstar. Following the closing of the Note Exchange, there is no outstanding balance owing under the CBI Note and the CBI Note has been cancelled.
<p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">Supreme Cannabis Convertible Debentures and Accretion Debentures
<p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">On October 19, 2018, The Supreme Cannabis Company, Inc. ("Supreme Cannabis") entered into an indenture with Computershare Trust Company of Canada (the "Trustee") pursuant to which Supreme Cannabis issued
6.0
 senior unsecured convertible debentures (the "Supreme Debentures") for gross proceeds of \$
100,000
 of principal amount of the Supreme Debentures; (ii) an increase in the interest rate to
8
 per annum; (iii) the extension of the maturity date to
September 10, 2025
 and (iv) a reduction in the conversion price to \$
2.85
 per share. The principal amount began at \$nil and accreted at a rate of
11.06
 per annum based on the remaining principal amount of the Supreme Debentures of \$
36,500
 to a maximum of \$
13,500
 per annum, compounded on a semi-annual basis commencing on September 9, 2020, and ending on September 9, 2023. As of September 9, 2023, the principal amount of the Accretion Debentures was finalized as \$
10,434
 The Accretion Debentures are payable in cash, but do not bear cash interest and are not convertible into the common shares of Supreme Cannabis (the "Supreme Shares"). The principal amount of the Accretion Debentures will amortize, or be paid, at
1.0
 per month over the 24 months prior to maturity.
<p style="text-indent:4.52%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">As a result of the completion of an arrangement on June 22, 2021 by the Company and Supreme Cannabis, pursuant to which the Company acquired
100
 of the issued and outstanding Supreme Shares (the "Supreme Arrangement"), the Supreme Debentures remain outstanding as securities of Supreme Cannabis, which, upon conversion will entitle the holder thereof to receive, in lieu of the number of Supreme Shares to which such holder was theretofore entitled, the consideration payable under the Supreme Arrangement that such holder would have been entitled to be issued and receive if, immediately prior to the effective time of the Supreme Arrangement, such holder had been the registered holder of the number of Supreme Shares to which such holder was theretofore entitled.
<p style="text-indent:4.52%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">In connection with the Supreme Arrangement, the Company, Supreme Cannabis and the Trustee entered into a supplemental indenture whereby the Company agreed to issue common shares upon conversion of any Supreme Debenture.
530
 and \$
1,207
 nil
 and \$
30,227
 respectively, of
100,000
 aggregate principal amount of outstanding Supreme Debentures and Accretion Debentures were settled through the August 2024 Supreme Convertible Debt Exchange (as defined below) and the Exchange and Subscription Agreement (as defined below).
<p style="text-indent:4.52%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">On August 20, 2024, the Company entered into an exchange and subscription agreement (the "August 2024 Supreme Convertible Debt Exchange")
1
 with a single institutional investor (the "August 2024 Investor") pursuant to which, among other things, the August 2024 Investor delivered to the Company approximately \$
2,664
 of
100,000
 aggregate principal amount of outstanding Supreme
100,000
 Debentures
100,000
 held by the August 2024 Investor in

exchange for (i) a new senior unsecured convertible debenture of the Company (the "May 2024 Convertible Debenture") with an aggregate principal amount of \$29,351,351 and (ii) common share purchase warrants (the "May 2024 Investor Warrants") of the Company. Each May 2024 Investor Warrant entitles the holder to acquire one Canopy Growth common share at an exercise price equal to \$16.18 per share. The May 2024 Convertible Debenture bears interest at a rate of 7.50% per annum, payable in semi-annual payments in cash or, at the option of the Company, in Canopy Growth common shares for the first four semi-annual interest payments after the Closing Date, subject to satisfaction of certain conditions, including the prior approval of the TSX. The May 2024 Convertible Debenture is convertible into Canopy Growth common shares at the option of the May 2024 Investor at a conversion price equal to \$14.38 per share. The May 2024 Convertible Debenture is subject to a forced conversion feature upon notice from the Company in the event that the average closing trading price of the Canopy Growth common shares on the TSX exceeds \$21.57 per share. The May 2024 Convertible Debenture remains outstanding (the "Debenture ROFR Term"), the Company granted the May 2024 Investor a right of first refusal to subscribe for, and to be issued, as an investor in any debt or equity financing that the Company wishes to complete during the Debenture ROFR Term (the "Proposed Financing"); provided, however, that the May 2024 Investor shall subscribe for 25% of the Proposed Financing on the same terms and conditions contemplated in the Proposed Financing. The components of debt are as follows:

Instrument	Principal Amount	Interest Rate	Term	Conversion Price	Conversion Feature
May 2024 Convertible Debenture	\$29,351,351	7.50%	5 years	\$14.38	Yes
May 2024 Investor Warrants	\$29,351,351	N/A	5 years	\$16.18	Yes

The May 2024 Convertible Debenture is convertible into Canopy Growth common shares at the option of the May 2024 Investor at a conversion price equal to \$14.38 per share. The May 2024 Convertible Debenture is subject to a forced conversion feature upon notice from the Company in the event that the average closing trading price of the Canopy Growth common shares on the TSX exceeds \$21.57 per share. The May 2024 Convertible Debenture remains outstanding (the "Debenture ROFR Term"), the Company granted the May 2024 Investor a right of first refusal to subscribe for, and to be issued, as an investor in any debt or equity financing that the Company wishes to complete during the Debenture ROFR Term (the "Proposed Financing"); provided, however, that the May 2024 Investor shall subscribe for 25% of the Proposed Financing on the same terms and conditions contemplated in the Proposed Financing.

[illegible]

```


0.0097222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none,min-width:fit-content;"></span></p></td><td style="padding-top:0in:white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;"><span><span style="color:#000000:white-space:pre-wrap;font-f


```

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

kerneling:none,min-width:fit-content;"></p></td><td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"></p></td><td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">\$(span><p></td><td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">119.882</p></td><td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #fffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td></tr><tr><td style="padding-top:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">19</td><td style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none,min-width:fit-content;">SHARE CAPITAL</td><td style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">CANOPY GROWTH</td><td style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">Authorized</td><td style="text-indent:4.52;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">An unlimited number of common shares.</td><td style="text-indent:4.52;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">(i) Equity financings</td><td style="text-indent:4.52;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">On June 6, 2024, the Company established an at-the-market equity program that allows it to sell up to US\$</td><td style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none,min-width:fit-content;">250,000</td><td style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none,min-width:fit-content;">of common shares of the Company from treasury to the public from time to time at the Company's discretion (the "ATM Program"). The ATM Program will be effective until the earlier of (i) the issuance and sale of all of the common shares issuable pursuant to the ATM Program (ii) the date on which the Company receives notice from a securities regulatory authority that the Company's Canadian short form base shelf prospectus dated June 5, 2024 and/or the Company's registration statement on Form S-3ASR has ceased to be effective and (iii) July 5, 2026, unless terminated earlier in accordance with the terms of the equity distribution agreement entered into between the Company and BMO Nesbitt Burns Inc., as Canadian agent, and BMO Capital Markets Corp., as U.S. agent. As part of the ATM Program, during the</td><td style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none,min-width:fit-content;">three and nine months ended December 31, 2024</td><td style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none,min-width:fit-content;">the Company sold</td><td style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none,min-width:fit-content;">22,713,177</td><td style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none,min-width:fit-content;">and</td><td style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none,min-width:fit-content;">39,519,029</td><td style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none,min-width:fit-content;">common</td><td style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none,min-width:fit-content;">common</td><td style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">shares,</td><td style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none,min-width:fit-content;">respectively, for gross proceeds of</td><td style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none,min-width:fit-content;">117,513</td><td style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none,min-width:fit-content;">and</td><td style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none,min-width:fit-content;">255,989</td><td style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none,min-width:fit-content;">respectively,</td><td style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none,min-width:fit-content;">Refer to Note 30 for additional information on common shares sold after December 31, 2024 as part of the ATM Program.</td><td style="text-indent:4.52;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">For the three and nine months ended December 31, 2023,</td><td style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none,min-width:fit-content;">the Company issued</td><td style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none,min-width:fit-content;">nil</td><td style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none,min-width:fit-content;">and</td><td style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none,min-width:fit-content;">2,292,947</td><td style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none,min-width:fit-content;">common shares, respectively, for aggregate gross proceeds of</td><td style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none,min-width:fit-content;">nil</td><td style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none,min-width:fit-content;">and</td><td style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none,min-width:fit-content;">33,745</td><td style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none,min-width:fit-content;">respectively, relating to the private placement unit offering completed by the Company pursuant to the terms of the subscription agreements entered into between the Company and certain institutional investors on September 18, 2023.</td><td style="text-indent:4.53;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">(ii) Other issuances of common shares and share capital transactions</td><td style="font-size:10pt;font-family:Times New Roman;"></td><td style="text-indent:4.53;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;">During the</td><td style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none,min-width:fit-content;">nine months ended December 31, 2024,</td><td colspan="2"><table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"><tr style="visibility:collapse;"><td style="width:60.02%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:10.5%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:10.040000000000001%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:1.2%;box-sizing:content-box;"></td><td style="width:10.040000000000001%;box-sizing:content-box;"></td><td style="width:1.2%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:10.040000000000001%;box-sizing:content-box;"></td><td style="width:1.2%;box-sizing:content-box;"></td></tr><tr style="height:8pt;background-color:#fffff0;word-break:break-word;white-space:pre-wrap;text-align:left;"><td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:center;"></p></td><td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:center;"></p></td><td colspan="2"><td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

```
<div><p>size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></div>
```

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

where the majority of the Company's income for tax purposes was earned, or where its temporary differences or losses are expected to be realized or settled. Although statutory income tax rates remain stable, the Company's effective income tax rate may fluctuate, arising as a result of the Company's evolving footprint, discrete transactions and other factors that, to the extent material, are disclosed in these financial statements.

Times New Roman; margin-bottom: 6pt; text-align: left;">The Company continues to believe that the amount of unrealized tax benefits appropriately reflects the uncertainty of items that are or may in the future be under discussion, audit, dispute or appeal with a tax authority or which otherwise result in uncertainty in the determination of income for tax purposes. If appropriate, an unrealized tax benefit will be realized in the reporting period in which the Company determines that realization is not in doubt. Where the final determined outcome is different from the Company's estimate, such difference will impact the Company's income taxes in the reporting period during which such determination is made.

Times New Roman; margin-bottom: 6pt; text-align: left;">On December 9, 2024, Canopy USA completed the Acreage Acquisition and now owns 5,888,291 common shares, with the number of underlying Canopy Growth common shares and exercise price of such options adjusted by the Floating Share Exchange Ratio. (ii) each outstanding warrant to acquire Floating Shares was exchanged for a replacement warrant to acquire Canopy Growth common shares, with the number of underlying Canopy Growth common shares and exercise price of such warrants adjusted by the Floating Share Exchange Ratio; and (iii) each outstanding restricted share unit, performance share and performance unit, as applicable, that vested into Floating Shares was exchanged for a replacement restricted share unit, performance share or performance unit, as applicable, that vests into Canopy Growth common shares, with the number of underlying Canopy Growth common shares adjusted by the Floating Share Exchange Ratio.

Times New Roman; margin-bottom: 6pt; text-align: left;">In connection with the Fixed Share Acquisition, (i) each outstanding stock option to acquire Fixed Shares was exchanged for a replacement option exercisable for Canopy Growth common shares, with the number of underlying Canopy Growth common shares and exercise price of such options adjusted by the Fixed Share Exchange Ratio; (ii) each outstanding warrant to acquire Fixed Shares was exchanged for a replacement warrant to acquire Fixed Shares; and (iii) each restricted share unit, performance share unit, as applicable, that vested into Fixed Shares was exchanged for a replacement restricted share unit or performance share unit, as applicable, that vests into Canopy Growth common shares, with the number of underlying Canopy Growth common shares adjusted by the Fixed Share Exchange Ratio.

Times New Roman; margin-bottom: 6pt; text-align: left;">See Note 3 for information regarding the Reorganization. In connection with the Reorganization, Canopy USA, holds certain U.S. cannabis investments previously held by the Company, which enabled Canopy USA to consummate the acquisition of Acreage. See Note 3 for more details related to the Acreage Acquisition.

Times New Roman; margin-bottom: 6pt; text-align: left;">For the three months ended December 31, 2024, there have been no material changes with respect to provisions relating to legal proceedings for the Company.

Times New Roman; margin-bottom: 6pt; text-align: left;">The Company reports its financial results for the following segments:

Times New Roman; margin-bottom: 6pt; text-align: left;">Reportable segments

Times New Roman; margin-bottom: 6pt; text-align: left;">Canada cannabis

Times New Roman; margin-bottom: 6pt; text-align: left;">Cannabis Act

Times New Roman; margin-bottom: 6pt; text-align: left;">and cannabis-related areas such as merchandise and clinics.

Times New Roman; margin-bottom: 6pt; text-align: left;">includes the production, distribution and sale of a diverse range of cannabis, hemp and cannabis-related products in Canada pursuant to the Cannabis Act

Times New Roman; margin-bottom: 6pt; text-align: left;">International markets

Times New Roman; margin-bottom: 6pt; text-align: left;">includes the production, distribution and sale of a diverse range of cannabis and hemp products internationally pursuant to applicable international legislation, regulations and permits. Priority markets include medical cannabis in Australia and Europe where the Company offers branded high-quality flower, oil and extract products under the Company's recognized Spectrum Therapeutics, Canopy Medical and Tweed brands, as well as the Company's Storz & Bickel line of medically approved vaporizers in Australia.

Times New Roman; margin-bottom: 6pt; text-align: left;">This Works

Times New Roman; margin-bottom: 6pt; text-align: left;">includes the production, distribution and sale of vaporizers and accessories; and

Times New Roman; margin-bottom: 6pt; text-align: left;">beauty, skincare, wellness and sleep products, some of which have been blended with hemp-derived CBD isolate. On December 18, 2023, the Company completed the sale of This Works and as of such date, the results of This Works are no longer included in the Company's financial results.

Times New Roman; margin-bottom: 6pt; text-align: left;">These segments reflect how the Company's operations are managed, how the Company's Chief Executive Officer, who is the Chief Operating Decision Maker ("CODM"), allocates resources and evaluates performance, and how the Company's internal management financial reporting is structured. The Company's CODM evaluates the performance of these segments, with a focus on (i) segment net revenue, and (ii) segment gross margin as the measure of segment profit or loss. The remainder of the Company's operations include revenue derived from, and cost of sales associated with, the Company's non-cannabis extraction activities and other ancillary activities; these are included within "other."

Times New Roman; margin-bottom: 6pt; text-align: left;">Storz & Bickel

Times New Roman; margin-bottom: 6pt; text-align: left;">includes the production, distribution and sale of vaporizers and accessories; and

Times New Roman; margin-bottom: 6pt; text-align: left;">beauty, skincare, wellness and sleep products, some of which have been blended with hemp-derived CBD isolate. On December 18, 2023, the Company completed the sale of This Works and as of such date, the results of This Works are no longer included in the Company's financial results.

Times New Roman; margin-bottom: 6pt; text-align: left;">These segments reflect how the Company's operations are managed, how the Company's Chief Executive Officer, who is the Chief Operating Decision Maker ("CODM"), allocates resources and evaluates performance, and how the Company's internal management financial reporting is structured. The Company's CODM evaluates the performance of these segments, with a focus on (i) segment net revenue, and (ii) segment gross margin as the measure of segment profit or loss. The remainder of the Company's operations include revenue derived from, and cost of sales associated with, the Company's non-cannabis extraction activities and other ancillary activities; these are included within "other."

Times New Roman; margin-bottom: 6pt; text-align: left;">Storz & Bickel

Times New Roman; margin-bottom: 6pt; text-align: left;">includes the production, distribution and sale of vaporizers and accessories; and

Times New Roman; margin-bottom: 6pt; text-align: left;">beauty, skincare, wellness and sleep products, some of which have been blended with hemp-derived CBD isolate. On December 18, 2023, the Company completed the sale of This Works and as of such date, the results of This Works are no longer included in the Company's financial results.

Times New Roman; margin-bottom: 6pt; text-align: left;">These segments reflect how the Company's operations are managed, how the Company's Chief Executive Officer, who is the Chief Operating Decision Maker ("CODM"), allocates resources and evaluates performance, and how the Company's internal management financial reporting is structured. The Company's CODM evaluates the performance of these segments, with a focus on (i) segment net revenue, and (ii) segment gross margin as the measure of segment profit or loss. The remainder of the Company's operations include revenue derived from, and cost of sales associated with, the Company's non-cannabis extraction activities and other ancillary activities; these are included within "other."

Times New Roman; margin-bottom: 6pt; text-align: left;">Storz & Bickel

Times New Roman; margin-bottom: 6pt; text-align: left;">includes the production, distribution and sale of vaporizers and accessories; and

Times New Roman; margin-bottom: 6pt; text-align: left;">beauty, skincare, wellness and sleep products, some of which have been blended with hemp-derived CBD isolate. On December 18, 2023, the Company completed the sale of This Works and as of such date, the results of This Works are no longer included in the Company's financial results.

Times New Roman; margin-bottom: 6pt; text-align: left;">These segments reflect how the Company's operations are managed, how the Company's Chief Executive Officer, who is the Chief Operating Decision Maker ("CODM"), allocates resources and evaluates performance, and how the Company's internal management financial reporting is structured. The Company's CODM evaluates the performance of these segments, with a focus on (i) segment net revenue, and (ii) segment gross margin as the measure of segment profit or loss. The remainder of the Company's operations include revenue derived from, and cost of sales associated with, the Company's non-cannabis extraction activities and other ancillary activities; these are included within "other."

Times New Roman; margin-bottom: 6pt; text-align: left;">Storz & Bickel

Times New Roman; margin-bottom: 6pt; text-align: left;">includes the production, distribution and sale of vaporizers and accessories; and

Times New Roman; margin-bottom: 6pt; text-align: left;">beauty, skincare, wellness and sleep products, some of which have been blended with hemp-derived CBD isolate. On December 18, 2023, the Company completed the sale of This Works and as of such date, the results of This Works are no longer included in the Company's financial results.

Times New Roman; margin-bottom: 6pt; text-align: left;">These segments reflect how the Company's operations are managed, how the Company's Chief Executive Officer, who is the Chief Operating Decision Maker ("CODM"), allocates resources and evaluates performance, and how the Company's internal management financial reporting is structured. The Company's CODM evaluates the performance of these segments, with a focus on (i) segment net revenue, and (ii) segment gross margin as the measure of segment profit or loss. The remainder of the Company's operations include revenue derived from, and cost of sales associated with, the Company's non-cannabis extraction activities and other ancillary activities; these are included within "other."

Times New Roman; margin-bottom: 6pt; text-align: left;">Storz & Bickel

Times New Roman; margin-bottom: 6pt; text-align: left;">includes the production, distribution and sale of vaporizers and accessories; and

Times New Roman; margin-bottom: 6pt; text-align: left;">beauty, skincare, wellness and sleep products, some of which have been blended with hemp-derived CBD isolate. On December 18, 2023, the Company completed the sale of This Works and as of such date, the results of This Works are no longer included in the Company's financial results.

Times New Roman; margin-bottom: 6pt; text-align: left;">These segments reflect how the Company's operations are managed, how the Company's Chief Executive Officer, who is the Chief Operating Decision Maker ("CODM"), allocates resources and evaluates performance, and how the Company's internal management financial reporting is structured. The Company's CODM evaluates the performance of these segments, with a focus on (i) segment net revenue, and (ii) segment gross margin as the measure of segment profit or loss. The remainder of the Company's operations include revenue derived from, and cost of sales associated with, the Company's non-cannabis extraction activities and other ancillary activities; these are included within "other."

Times New Roman; margin-bottom: 6pt; text-align: left;">Storz & Bickel

Times New Roman; margin-bottom: 6pt; text-align: left;">includes the production, distribution and sale of vaporizers and accessories; and

Times New Roman; margin-bottom: 6pt; text-align: left;">beauty, skincare, wellness and sleep products, some of which have been blended with hemp-derived CBD isolate. On December 18, 2023, the Company completed the sale of This Works and as of such date, the results of This Works are no longer included in the Company's financial results.

Times New Roman; margin-bottom: 6pt; text-align: left;">These segments reflect how the Company's operations are managed, how the Company's Chief Executive Officer, who is the Chief Operating Decision Maker ("CODM"), allocates resources and evaluates performance, and how the Company's internal management financial reporting is structured. The Company's CODM evaluates the performance of these segments, with a focus on (i) segment net revenue, and (ii) segment gross margin as the measure of segment profit or loss. The remainder of the Company's operations include revenue derived from, and cost of sales associated with, the Company's non-cannabis extraction activities and other ancillary activities; these are included within "other."

Times New Roman; margin-bottom: 6pt; text-align: left;">Storz & Bickel

Times New Roman; margin-bottom: 6pt; text-align: left;">includes the production, distribution and sale of vaporizers and accessories; and

Times New Roman; margin-bottom: 6pt; text-align: left;">beauty, skincare, wellness and sleep products, some of which have been blended with hemp-derived CBD isolate. On December 18, 2023, the Company completed the sale of This Works and as of such date, the results of This Works are no longer included in the Company's financial results.

Times New Roman; margin-bottom: 6pt; text-align: left;">These segments reflect how the Company's operations are managed, how the Company's Chief Executive Officer, who is the Chief Operating Decision Maker ("CODM"), allocates resources and evaluates performance, and how the Company's internal management financial reporting is structured. The Company's CODM evaluates the performance of these segments, with a focus on (i) segment net revenue, and (ii) segment gross margin as the measure of segment profit or loss. The remainder of the Company's operations include revenue derived from, and cost of sales associated with, the Company's non-cannabis extraction activities and other ancillary activities; these are included within "other."

Times New Roman; margin-bottom: 6pt; text-align: left;">Storz & Bickel

Times New Roman; margin-bottom: 6pt; text-align: left;">includes the production, distribution and sale of vaporizers and accessories; and

Times New Roman; margin-bottom: 6pt; text-align: left;">beauty, skincare, wellness and sleep products, some of which have been blended with hemp-derived CBD isolate. On December 18, 2023, the Company completed the sale of This Works and as of such date, the results of This Works are no longer included in the Company's financial results.

Times New Roman; margin-bottom: 6pt; text-align: left;">These segments reflect how the Company's operations are managed, how the Company's Chief Executive Officer, who is the Chief Operating Decision Maker ("CODM"), allocates resources and evaluates performance, and how the Company's internal management financial reporting is structured. The Company's CODM evaluates the performance of these segments, with a focus on (i) segment net revenue, and (ii) segment gross margin as the measure of segment profit or loss. The remainder of the Company's operations include revenue derived from, and cost of sales associated with, the Company's non-cannabis extraction activities and other ancillary activities; these are included within "other."

Times New Roman; margin-bottom: 6pt; text-align: left;">Storz & Bickel

Times New Roman; margin-bottom: 6pt; text-align: left;">includes the production, distribution and sale of vaporizers and accessories; and

Times New Roman; margin-bottom: 6pt; text-align: left;">beauty, skincare, wellness and sleep products, some of which have been blended with hemp-derived CBD isolate. On December 18, 2023, the Company completed the sale of This Works and as of such date, the results of This Works are no longer included in the Company's financial results.

Times New Roman; margin-bottom: 6pt; text-align: left;">These segments reflect how the Company's operations are managed, how the Company's Chief Executive Officer, who is the Chief Operating Decision Maker ("CODM"), allocates resources and evaluates performance, and how the Company's internal management financial reporting is structured. The Company's CODM evaluates the performance of these segments, with a focus on (i) segment net revenue, and (ii) segment gross margin as the measure of segment profit or loss. The remainder of the Company's operations include revenue derived from, and cost of sales associated with, the Company's non-cannabis extraction activities and other ancillary activities; these are included within "other."

Times New Roman; margin-bottom: 6pt; text-align: left;">Storz & Bickel

Times New Roman; margin-bottom: 6pt; text-align: left;">includes the production, distribution and sale of vaporizers and accessories; and

Times New Roman; margin-bottom: 6pt; text-align:

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

#N#0 *2>ZTJH.K-I@GJ?X MOGH%RI9C8UPO#3&C1-TW?4>-O@%/.4SXBXN4#)17Z<@G(18U#^~OEI6!-MLO0CK;HDU(A\$8 L>#0AN3M;I;+%;0W/UUV&00%E+N^G#Q0
MJVH1HT01A\$W BQVYU/7@U+U+@VTIO&2*LF:~61Y-RE<&7F~AB9HMY MIE((A+Q)VWE?E3P\$N\$)N.JXCUC<7<1~<QA!L-TCJ32~KZ;+%;%UAI 8-M?PAA?2AA4!@1S82P?
#MIV18W2&MD;~%#M2M3=2YAUW XLFI+1*U10=;~MFOY<-HYUO0%)UEI\$1%SKH+U>?XV(O;X5Q138PDU=IMZUV-AKT?Q=K+1 2WI-MHQY&@FDF.PW*WZ3Z?
XLI\$1<C~NNDFE0Q?XIAE?U1~IN8B0UHY@>2+K&U4&P%U;~U74<~%6S H O L F D +& #U\$>~2SW3E<@M7-SIX<~LH+L N%21K/UQ9Q?HAC9 Z\$>~1FW#K<~M(H>~>161?2
&G=MAS;45MXR%GBV\$!<~0K.8;0V0~!~!+@+F' XIF~!~!<~>~%6H O L F +W 6L%~MOQ9?7H0E-KIG<@SU!MW=G2D0U~4A~M3AC9#>~FEX0?5U?E87VIS 7%VFY(60+%)T?
P6 MC5TW#P0D X~IY2>~I(YX&A#FFY)~P%1Y(B<~%446 M/61+~.9HV\$5V66E=Y05E2+1 4CY\$T5?5R7BORSN;LH17CKP)N9%AJE+
MK'S ~+V12H3\$6>8R1;GZ~55%19Q(XC)0%~N~KCAIR0J(K#7A+CW 2*OK52 KT3;8E5Z~M+~EIVAWX(CRQNS&C(RJ2+K=U1H~!@VJH>=IKUAS?
M#EOL>SEQ>8XOEFBC1?K2?X!P61?~!H2<IG~<~BK Y@Uj=WB D YBE M&Y U(3?7=15~*FV1TW2L~KROXOMU~<~K47E M~ZC1A~CZZQ5E?O=17ZBDE2S?
~!#H(400HFEZ?Z0P5+5QY9@W*~!Z500+~<~S' 5.Z2+&=3WR194AG9Y+L&S/WZ17<3 1 M76N.OACXI+UVY~>04HPNHVKO<~\$7YA@E24R/ <6.623M4.EHFF5YVB<7?C9%7 MJJ
#P<4?@TG10YJFZJ+EK#~#B~244=WDID?S L O;F G A;I2XR%\$8 M=20?ZKSA(C78~3M)+~OG6(IQ)YB2?YCG<~>H>M!5;BUB;YH6?KV#K~MO~Q05DH+OPLY<~\$D3R\$>
=H.Q0I~IYN&S U.LDH<~@EH>8P4+RH1U2/ M.R2Q4A<~HIE?>RLTIGSTF@<~>H>F>E!~<C%V~>A+~NCZ;&(QE#&IJBHFH MKXSL~B~UO!~W6JZP3)2D~YU;U!L6O=2H?
CIE V=J(K<~9 MJLW~N8E\$=H M3;C#1?Y2CY6V1V~U.OJCB.O 0/2<@W+JOZRR2PH4(I+~3SG9%#I2W2T MJA2D57DDP2(T2+WW6)!~.1J5D9?
@<XAR 00!<~SK7FS9PKW&C@<STRO1 L DPCW~VY-FH 13?2FWH<~I.J6.C0+L M+@EW\$WR<~(I?Q9EHJ4<~ICOG\$K<~A9LZ4C&UBE.UV0?=>4 POODGY(513 MY<8R000L?<
#7JH M462/80B08<2?>SYAK+W@B/!<0>F4<A(NC4S~*E~<19M7VPZ02V<~&U91@J2\$%<(O?M16<0<3P?7O?<~W MTC~16+87.3GT1.QV.L%2BV;W?E4I+~(S12\$83.P~<
(1M(4 M6=&A2.PVF~*~<~2R+<1.GZBV<@C!~R1Q#1ZW<@<7&X(C%VDS!+~!!OP 6M!!\$>+3BGZ4XQ0770HTG5JBYZ=1~0A~TA3K~G6 M!&=ANDEV6~9
N!@Q8/08=4AG(I G!+~) 0159\$~?7QYUW~JN~#~222ZVKC(MP150%CW1;2/!+IQWW?OJCA(\$1\$D X40LJHG<X6~>~!AS;VJP#1(I> ML~>PC<Z=4.8 GHT+4.BU4&~21CJB8X</>
2X X78#8X X>41?E&0 L MV~%K0?>IAKTBK<47VX0~H4TU06S;JY.15 LPIK UH&7~L+FS3D398! M~L<@95C7FE
0?K(Y;~AQH0\$H NG NKD03PFNK&VKN9V?O\$0N0WN;T#E#B&3~>1+6NA0HRWVC77A6.O1Y9J6L<~NC00\$0F+1WR1\$<7Q MX6XP(47Y\$9PSR%1?Z>?>F~FXTNR/2
L~<2D5 IRT(I@LFR~W00@V#21QV~>M590%KZ~#*FEZE*P=4WZ9A(Y2KM8L~J1R1(8?@~U 3IN2+6F#<X~LS~MFH(ZBIA~XZS~>A+&ES<XR+&3/KTW~SHHK<
~<F~D~<5BM@K~A~T~C~IRV M=IX.N!P.M~<U~F4N8MV\$~(QRZ>CJXX4X M~C~UO L H~8~.~0%~>3HTKPI22JIM~F53UICW3V8H%7.R%\$4#1JOONC0~<X?FS1~YRNL1DI<(<?<Q
M!P?VQY@~M~\$E=I67U~<KHKI?>=5/ WJUHMQO<~DUAEI<~>>Y6RS%JRL M5!>LMCO@002FE I OPS=NT~>1A@<~JKHOG(8@P~#BEI8)HV@B?X7X
M@LMD?WBCYIYN>2&~PBPTXW~>2&=1&381L M6\$X15~.O0XPF<@&IKUAI MRC~H~\$8M&VW0811LELR.VL8N@<R+P~
G~NBVAE.KUJHJ0U.YAQ~LUE2~134Z(D?OT~BEM00Q?X2H!>~\$?Y!AWT<~S~CIXK;F~IBRE5Y~MKT ZI.R1#N!S~&3Y@<~<Z2C%G.XHEX*415U?F7L~FZ~L W.M~JU0X=WIS)F
M!66\$2~<U1E+27L~\$H4(FD;R0F=Q1&O4~2S<~C#8NP MEZ>F!+Q(D;~<YXY<~<4 J9N.A.T6.C5E#5@N~IH6\$O HG69T000L&S O~
M~W#7&~3LFA66S.NB8>1D2F4Q1MXC8X%>F@OP1W99XKRCRAE!~L M;KQVM61%IM0?9RFLA!BDF3%E29?7L;DL.OL!L%<G=5LE:TEAWFIX#8~1PH+QIV I R2&F
M2\$#?T@CYMK8UBI3\$>BGP<~<F?#T18\$3F-B ROYKE51L\$~<2R~EEN;KYL7L M9~G1M4UDH\$DZZQ+OOT6@<R(M4~EPB1@~!~T~Q~0NBA=F~
N~!<15H~2T.Y0XKXG&F~<OC10~1H~WTXTXRP?>T7G)=L5 M~ACBP~FV ZQ00UHJ5C7F~2%G~1%<X&V~M&2SJUC 7Z?0@<~7%K7L~<C M~<@~416W B.NJ&~51&3~<M~
M~<G2F5H?2%KLSHSM<IKYD0FF~HJW 2+SBOMTIS\$5%<D~&K~55M9IJM~<~NB+ M~>H~T~H~\$IN6I(G.W.G.%#FOO~?1~C~Q~1ZQ4LCL9UB>HSG.30K4=YA<~
MG 5P(GE.NH\$=+~1AIZ&S~<8%+513?78L9Y42I@/D1~G2?>~>~M8%<=3KDM3W~4DXXK&C~AKO~<ZH@7%#0H~ZX1~2>59P.T\$>9<~MMXTV5~56I!H~
Q\$FUVE08.1C.96\$<H/K=IBXNE~KK337LR.VY4~U~<~!WPF M5&W@<~94~JLA&41!4PXJFH6!AX~>5~F~X~>=XKPS+9IA3#DE~K~<~H MB%?Y?BG~5I G3.Y4~
~Z8RP489~MMEO\$5VH82L+~W<~<~XUA V~<L ZK MCT.GWICNSBHUL0?QK5;T7+94X~%6W>?7 IC<3A~Y8~L7J3SIC0~<DH>~>~M#1~<GRQ3W\$5L5F16?<

[illegible]

<&9=K0;B9T\$C.RSY9+QUPW7EM>/=LHJY/~/KWX1-M:3.\$66%X.YND?WSD<\$IXI64\$PC/X<.:091:NS/PP?^06,201XH7T&8>H4M!7 MRAB012SBY6=@MP=Y^YJH!^I#9B^I^C
M@S LHKYB&INJR-S 8T7@APB&CVP6ZD8-P0->|FE^*B G6KEUY^YI8Q?M>OXA0?&E^?^5@>RQ!&I=IZYI 9HCBFD<^MJQ0?=\$CIG20L84^H(C-DJH
MP2If>YO.P.SSB4\$W(MWX28Z2/20?I25G \$0ZGHAMXV.CE@/4!>BK7Z_HXU^)^>#>EX?<M<@ ^!M2A6:7X@7^H30(%975^K1_B8<4B;<^!JG/7>^TN=,&H1PBMZ7/C
M^*C^T^I^W^C2RI.YV^JFPWY+3@5Y%R:AA@&OPI^WHX_3^AC3K-6W-M(GZ5Z/&DSQ_Q:)!A#^AU.D:IU.%Y22^P^!B^=>IY47D^3=#UOM/\$0GAI?>F
MC+SI50=\$R^?H)^>H\$N-DT:ZB=?TW9.@7MQ\$)8^5SC\$SD&(@ITI3?SI(CM.,U MMM(?8TYHH>.(O.^NXHTU-MCSBX%BP:"IC1@T^#VD#&+I X(6:7B-
JQ9N<I58WT&D.JXITQ(=(LCBYOQ7?P^2^CI-6V-M.^F^I-RC&8G?2%="^5.DHYF#ESZ&JH-N-M+"SNZE410+^%A>.<CR>7)%@A18I0(YD9I^&P?^H^7:1+1^B%82^!_.\$OI.TF9:6 M#?
=I68A<30ISD)WC0:0ROE>P+.^)T3=@TS&P70%FW^!_YX6?5KM54DI^!>3+P^0MYHJE<\$GZ50^K4V^*^!THH<^7ZF^SY\$WT:3^IOSM)BC^IU))UZ=E10W=>
ME+EZR0H4\$ZF9?/H\$^_SI^3^!^C^PUUU9="=U^T=#PIS@GSIB1^I=F.A\$^IJSF.L^&OBSSSY->OXH16ZL9Q30:7NMP.%\$Y^I/J^1^\$J5A-M4.#4L#.#E&^!B^>9W^P#<^&E!^I<^(EHG<:
7I2QFCITMZK<^*6(M%BI8&4#NN)DI3Y6I>3-D>LES02CJ0H29_R^C^MM.M^I7\$1^!02^H^H^F:3(I#D-8FPGM)%GKDRHK39K.M^<^<@:FIHA-0
M1IZ^AVE<=AGIREI9\$B;V.IPX2ZYG7.U-DL0WT-ARK2!BQ>.^IH+YQ-S-T4T9-M)8UXR(S%24F(E^/S_#>1PN,PW?GEBK3,UK1M)P7^9J0X&9ZE-LM151.7A6!-MC?WP">G>.:
NNH/Z.H5TY3OFTFL^0+R+Z^16+944?5^G3U0XYJH1HUMO^0^5% MZY%G-8XF(E0IT^?72P.^074CHP^VH^PH^Y+A%DKY5L5SY%N^X8+#+=YWPB8&U-M5=I^><7.P^>W5I^/R-
>I68A<30ISD)WC0:0ROE>P+.^)T3=@TS&P70%FW^!_YX6?5KM54DI^!>3+P^0MYHJE<\$GZ50^K4V^*^!THH<^7ZF^SY\$WT:3^IOSM)BC^IU))UZ=E10W=>
I#WQI^R^*^NZH1^7F:~2I48!.RWH=-Q^U9XCR12491^!HCV22^H9-M:HP0+I2XF2I^!^VX-PU#?2BIR>^<^@I^KY=IC^OS^J90UFJ6\$!^YHUTM1^*J
MM^H\$PFR:AQ7FN84Y<3%3H29!H)D@:F^I^VP#&FNLZ%77&8/GP9<2/I^J^R-MHN!>AMK=783TCRB>&FF-(PVL9NIA-I-W=Y\$^3HO5WHK8GJC^AC3)!><.:8
M6F%:#6^!4:1^5F%#\$2(W2E2QVYV>>QFR829B658M.PX%ED?N&TPF&^(<.)M>7.I6E(&C8GYQ>.>3B1W<%<7TN%LJ<YUEU=YT-RKU%<^<YP)ES.^?E8E\$6
MHHP^DM^RA(O@I+2.^*D&KOY11-M:IV^T^I@&>CJJA2:5.G1^!F5=W#P?PAIY^I@+Y+RI.S&B>7W13E2FE&8.
MAC)BOG\$+^I#&CMAE.9EA^P+3.^IG3SO4)&YDL&09=O^%&&_@&I3EM^6(U00OH-M!>#<.&WMX3HE#4G!>0R-V-HR\$62JK@6.&5G!^ISM?+?/_.K00K2^759(O^*WYS.C:
\$X.YMP/O1W+&1^!0/I.3AS^!^VPSS7BPJ.Z3KR>P&#IAYNF/I^>0.MH.5BIPU6="SO)UA/L^X5\$8:3CY\$_(@YBI2-T3W/GGF:~5PC7KE?PPDIE.CFF>R9C<.00&M@X^I4JE:
I0%\$>\$L>3P2-W^<@UH+I+Z<@U74I^&#U3D72\$S^*G6RBSJH<^0O1)!E2.&X-M-Q@A0A!>1G!^N01_1Y39L@5T(4-P->&+1-8%Z!>Z!-F-3.OM^I630!CBQ!EF3WGG/6NX-
!=T".SS5L?2^JFC(I#5W2\$D-I(?W0#M-VNJ(MEQM/R/P->^&HIL-2VX4#.#L1=F.H@P^?^N+L7TIOS.S^<M/B-W?Q.^GOH7T^!>^DXYRNW:/0%#B;IX
EG&I&BQW^SI&GVBYDH_YV^<0C<.<I8?W^8^P0N)H0U!8#^!^!M^+VE&4+V#%T%Z!X^1PU2K:5V0P2(GLKNFA%IL&^MJ8C^)(^2L%<%D>PIB:XR-"S55I-H%NJU^"VH:?
&6IYC2MGEZXDS+STZ>XY65ZPLJS@M8\$<BY:16X(BPYZ)H^<4)U^AF&CYUDH(P@DH^YI^>@G8^ZH53Q>BL&E&IY-3 MJM#&
(BIA\$5(6QJFD)OLHGB+<^!EFA^>%17U+1<40%7W^!-C^WPHZ?7@^M^KCUV4L.RY/IH-ZFTQI.;5)!^!#15Z2IM5Y%W:(V+0WD1#JZ+1%GCF"E-@I<IY\$14#H.
I6N1E!>\$C#V3Q?_W2G_O_R^)^_XM^NAX(F-MGQIORB?<4\$^*B7Z-BPM@YI^B^F)F1N>0.8Y3I):H\$9@H3ATIG?43DLR#_MS4.T6FK^F^TX-3.OM^I0L^M^359T7M^IY1N2^!^
\$3^#YF\$9Q%#HEV!MMB-7>HBE:\$0<538)H7SF@T>_F024VO^*IC3#F!=1^QC)2/4I^!_#8#8&6IL9-M(I-P=ISG^Q5^B1IE-M85ID_!SX:AH^!J^OB-ZUT8+OD)2QP>B1MOA='
!%5L\$-C-#=\$IROFR.NI5)_M1GBN.HO@LUH_Z_VK6Q7NT_RD:3&2>HBB#=#A.ID8-MYMUXXE^S?>BP\$&2I-M8\$UF:U!83O7M2%JUIXU5LM49.5:XFOUI9(R)&GJ^BHHIZ&MWO^<^F
HC0-MGIVW^=\$+I#83#^OR^="D2-Z+R^!="#4^4JP.SIH2W^05IC_C!@KY-FMS^T+M.G.L.H2Z(IGI9+G.EZIAHXY9:4LY3D^!A@V^DA:#IA>S^NI#^*GI99I-W3X&WWMM@V-CES
^X!0&XU^SV_KTQ:I7_QJZL1>3-M(C-B.W9K6+Z07^1QIH^!-SGCTD-?%A-BS69Z0I@-Q729.7+A-E>TE.I^!7<-M%I5(Q.6OIQ.M&IC2^!^!TL>M5V25-
PIE!3L3^E>B&Y\$MEC^Q^*I^!W6.5-ML@G>Y44.Y^JXIB@>R?OM09=>Y^MV^C/(&9Y>0^6H1%NSIA&L+U&0Y8GIC-M)PALH.AWO(GO!UYT^N!J/I60C.C0MLB^QIT>L
H5-T2DN5H>(>3^I@%NT^M:2^<@L^Y0%!ML8L@C4MJZVI>^>)QB2...R&+Q^3\$V/Y8O/2P^I7I_OSTF^MNIKU#1<W9IAYK4K2JG^/=W:5?G(=-FRK!W#1U^&.&B(NI-BEPISY=,~%
M+OJ\$-ZFP8=9DU=1_@E^>_2_P#^+<^IR/ACIKV:=U#W%NZ!^>5>SVZ^>IB!MXHC511#E3H20: F%02/B^4Y.HZN+J/A3^O)A.EN6X^<L4L2TLI-
51I7\$HIX(16<^>)D@^".FHQIZ52(960+A8\$@U-MIV4PIUZI4/I-M#^I0RF8&.DC@K^!MAJW=4IW<^>^>ANIP.+?_P\$APQIQ\$LP^T2\$IT6\$<^>^6XWWEFB3720?^E^3)
M91N12?^SR1=6/B0L(NZDI^R=0)TO(8JEB^A^TR^&HULPDP47E3E+&SBW?F%#MFPIUSI^!+^*FOKVHS_ZN)^#@JZ57X^<56.S0^B4HE?P\$>#Y\$(Q_2R05H@.HN
M(I6B7I.N:2U\$Y6Z2H&IK4^?D\$9V^<2I@I^%T(I?*\$Y.#F5ZI^H968U29&<4.MV4XFES0)0M>0<OIP@S>%0IG6&\$^U^2PQI\$S1\$X4W@B8^U&D:&%LK^<6DGU
MZID^LYC(+&WNA4=\$^+^>@)496!_D&VP@J9@^(^EIFV+YV01<7+M=IZ@>FU.ML8G20E-QJFTHM.NI\$QI!^OOZYT=<_T3\$I-
K4^>7FE(U(IU958:P^VHGC5DL5Q4(R:R^FY2^>NVJA@4@5-M\$%420Y2\$U4^>^XJ&^92I^R/Y56@)NX^A>UV^>JIM^XQ^3PJ9WG#<^?9E7I_Z-G.MMI=(^=Z4.FI0^PI50^*L,I4
(I^F+3U>IB^NI2:\$S1(3X@:%KWT>I\$67H_I08-M^&^_IS^<0)B)B/WRN^!4C.N.(854QI0^*DH-1@QAJ.COI^%DCH!UIG=IM-M9\$%3FM_)N2FG(PD37?ZICJK?^YJ(24&IGNVYWB^NM?
9IH&V54O:1^7?2)M><>XF0Q!^<^UV>^6^J0?D5^YI075HR-DY).0&LH95^38C5+TF95<SIHWDE-MEGARIP^\$0RD-T24V=@CFM.M@U/ID@M^I)O?
N.C@#H@N/R4.K0TIQZIOYQ!^M&^>72H@F^?7@_TIG?+H^7E-GJE:1/U^>_0<SM-V^*Q3H^78AI.R-OIZN5B=-L3.A-MR-G1-VYCY:
(S1-LHJVKYC>I7KNE2UDM>E.5IRI9^UH0JG\$B^52IC^0L)=!M^!YAPGY<@KWHBA.9KI20IG6GO^%\$>0N>+O+HB1R\$B+#+EGL^P<JH147:\$
M^HOWTE4J3#IAW^<^I^TI3R^3^0TGDY-I2+95G@=IHOZ&^41.C9-3I=TP>\$M7:U^OVHJX\$%^V<_IHYNCRHH?)^GE?^H7H:&#&3UZFRPT78D(MG:T^31&XJE/T^(3HJ=UA^!KUB8
T+<C%3WZ-W&M1G=TIJZG\$H&7\$8R-W+/00E.XK2TAY2-CSW/LI:L01G/^NV.<R^IHTW^T^XK-M^Y7/A7CZY^/KM/^+E0XW#^:(382I^VP@I&P^IDW4^TNA..A?_QI!>+DAS.KV
MHO.^*(XU^ZI+FR00.^09X-M-7^IA%4#DB-WJHN&ZY06C3U.Y&I%RRYJA3^P^UGCM%:(S(CD.R-MP4A=E.IRFHWWKOU.67925&9R>6@F1C12H(4E-0!\$6+1A50P3^.(P6PK%\$>.\$@
MG!<^<P6UM>:(OK#^0WU4^I6L.Y&+43KS&^6#C^S^3?W154N^!=(P^J.C.DA2W-M^2R5Y5F.WN5\$+AR^<.(GL@3FY^RR)4?6-M^2T\$-BYO^R^IP^<W59E2FI\$#C%N^@G^*CT^
5M^GHD9)^%<CLIP!^D\$%W/3^M.ED4^*S=NM^IZ-(B!&P6^!%789K..B^<0V/0V0?&M1-)3QN&=E-G<<Z^SE^R^N>)>FIJ5\$WP5^OQ\$7^=#N400^AIU^M.J!&M2_4\$47DMW:I
I#^&54>^TGU5\$<B;?@V==8Z(6)^E\$!:#WDA&V&FY;R^V>(R-I^?60ZY-M<^+X3I^89N^/I3)/^<C+&L^I+M3I^MQ^I^@I^92QN!\$-S2ZMJ3UI&+-(ML8W8OLEB4D5_F^<\$.
O^>C+RS\$<^EU/I^A<^<I^KE=3^B^V=4VDL^L.M(^I@RI\$&=@U6=W@/A15XB-CI4H8:0IA:N#)S^!OFF=I.KM.J728E)6ZWQIE9^O!&?5:6-<)D
M%0D^5/60G@6#Z\$IM%KEI5^O^Y96-RRC^HUTL^3E9V^<SS88Q>@L!<M.GI!\$O:#WVN24K&5K6ON&7@84(I+#+%2VF:1)3\$?
2=Z<C^I0IDB^5ITH&+O%_A!7H^DN\$<#&W%I4.&ITSD^MHLG/O^I^!%GA0>&BQ(69I.V5HFF&JXG^AOKIYFMZ.0TM-D@=>+B%3/GLHNDKS^FR&CN#6L-Y!MH@G.5/M\$+>
(H+M^OTL(0)29(I-LLYA-8^A@<3CDG3V>I8IL%NL^R!^M&^I^P45X!\$MLA%)Y286GE9G8P?>?8NW5\$<^JNS%6UJO&^R=OZI^?+^MG:~Y.Y.ZR.^I6<5Y42=\$5IY3H22C1_.D3OEU+
I%F)FI@H@8^IN^MK809S7^3^0#K!<^I(TQ)U^FBW^E^PRB^&C^&XZ^I<^XM7I^T.566&XJF^C-M^!H0.0I0VM^<^0HA.IA-!5=ISP0VM^?CG>BBO;D=IKISDP!5OV^J^@M=68J^!"